<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38996330</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Integrating Clinical Data and Medical Imaging in Lung Cancer: Feasibility Study Using the Observational Medical Outcomes Partnership Common Data Model Extension.</ArticleTitle><Pagination><StartPage>e59187</StartPage><MedlinePgn>e59187</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e59187</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/59187</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Digital transformation, particularly the integration of medical imaging with clinical data, is vital in personalized medicine. The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) standardizes health data. However, integrating medical imaging remains a challenge.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study proposes a method for combining medical imaging data with the OMOP CDM to improve multimodal research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our approach included the analysis and selection of digital imaging and communications in medicine header tags, validation of data formats, and alignment according to the OMOP CDM framework. The Fast Healthcare Interoperability Resources ImagingStudy profile guided our consistency in column naming and definitions. Imaging Common Data Model (I-CDM), constructed using the entity-attribute-value model, facilitates scalable and efficient medical imaging data management. For patients with lung cancer diagnosed between 2010 and 2017, we introduced 4 new tables-IMAGING_STUDY, IMAGING_SERIES, IMAGING_ANNOTATION, and FILEPATH-to standardize various imaging-related data and link to clinical data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This framework underscores the effectiveness of I-CDM in enhancing our understanding of lung cancer diagnostics and treatment strategies. The implementation of the I-CDM tables enabled the structured organization of a comprehensive data set, including 282,098 IMAGING_STUDY, 5,674,425 IMAGING_SERIES, and 48,536 IMAGING_ANNOTATION records, illustrating the extensive scope and depth of the approach. A scenario-based analysis using actual data from patients with lung cancer underscored the feasibility of our approach. A data quality check applying 44 specific rules confirmed the high integrity of the constructed data set, with all checks successfully passed, underscoring the reliability of our findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings indicate that I-CDM can improve the integration and analysis of medical imaging and clinical data. By addressing the challenges in data standardization and management, our approach contributes toward enhancing diagnostics and treatment strategies. Future research should expand the application of I-CDM to diverse disease populations and explore its wide-ranging utility for medical conditions.</AbstractText><CopyrightInformation>&#xa9;Hyerim Ji, Seok Kim, Leonard Sunwoo, Sowon Jang, Ho-Young Lee, Sooyoung Yoo. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 12.07.2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Hyerim</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3878-0244</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4996-8613</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunwoo</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0374-8658</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Sowon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3320-1557</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-6518-0602</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8620-4925</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDM</Keyword><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">DICOM</Keyword><Keyword MajorTopicYN="N">Digital Imaging and Communications in Medicine</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">data integration</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">lung cancer</Keyword><Keyword MajorTopicYN="N">medical imaging</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>12</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>12</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38996330</ArticleId><ArticleId IdType="pmc">PMC11282389</ArticleId><ArticleId IdType="doi">10.2196/59187</ArticleId><ArticleId IdType="pii">v12i1e59187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, Cui C, Corrado G, Thrun S, Dean J. A guide to deep learning in healthcare. Nat Med. 2019 Jan;25(1):24&#x2013;29. doi: 10.1038/s41591-018-0316-z. 
 
10.1038/s41591-018-0316-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0316-z</ArticleId><ArticleId IdType="pubmed">30617335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2(10):719&#x2013;731. doi: 10.1038/s41551-018-0305-z.10.1038/s41551-018-0305-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-018-0305-z</ArticleId><ArticleId IdType="pubmed">31015651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho MJ, Kim SR, Park SH, Jang KS, Park BJ, Hong JY, Choi IY. Common data model for decision support system of adverse drug reaction to extract knowledge from multi-center database. Inf Technol Manag. 2015 Jul 3;17(1):57&#x2013;66. doi: 10.1007/s10799-015-0240-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10799-015-0240-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco FJ, Londhe A, Zhu V, Ryan PB. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;64. doi: 10.1093/jamia/ocu023. 
 
ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li YC, Stang PE, Madigan D, Ryan PB. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim JE, Kim HM, Kim JH, Baek HS, Han MY. Association between dyslipidemia and asthma in children: a systematic review and multicenter cohort study using a common data model. Clin Exp Pediatr. 2023 Aug;66(8):357&#x2013;365. doi: 10.3345/cep.2023.00290. 
 
cep.2023.00290</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/cep.2023.00290</ArticleId><ArticleId IdType="pmc">PMC10397992</ArticleId><ArticleId IdType="pubmed">37321588</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CH, You SC, Jeon H, Jeong CW, Choi JW, Park RW. Development and validation of the radiology common data model (R-CDM) for the international standardization of medical imaging data. Yonsei Med J. 2022 Jan;63(Suppl):S74&#x2013;S83. doi: 10.3349/ymj.2022.63.S74. 
 
63.S74</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2022.63.S74</ArticleId><ArticleId IdType="pmc">PMC8790584</ArticleId><ArticleId IdType="pubmed">35040608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Noh SH, Kim YR, Lee CS, Kim JE, Jeong CW, Yoon KH. Development and validation of a management system and dataset quality assessment tool for the Radiology Common Data Model (R_CDM): a case study in liver disease. Int J Med Inform. 2022;162:104759. doi: 10.1016/j.ijmedinf.2022.104759. 
 
S1386-5056(22)00073-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104759</ArticleId><ArticleId IdType="pubmed">35390589</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik B, Jeon K, Alkasab T, Mallol P, You SC, Nagy P. Development of the medical imaging extension for OMOP-CDM. Observational Health Data Sciences and Informatics. 2022.  [2024-06-28].  
 https://www.ohdsi.org/2022showcase-26/
</Citation></Reference><Reference><Citation>Praeta J, Scherer M, Smeets D. Application of the R-CDM extension to capture metadata and features extracted from quantitative brain MRI and CT data. The Fourth European OHDSI Symposium; July 1-3, 2023; Rotterdam, The Netherlands. 2023.</Citation></Reference><Reference><Citation>Kalokyri V, Kondylakis H, Sfakianakis S, Nikiforaki K, Karatzanis I, Mazzetti S, Tachos N, Regge D, Fotiadis DI, Marias K, Tsiknakis M. MI-common data model: extending observational medical outcomes partnership-common data model (OMOP-CDM) for registering medical imaging metadata and subsequent curation processes. JCO Clin Cancer Inform. 2023 Sep;7:e2300101. doi: 10.1200/CCI.23.00101. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.23.00101?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.23.00101</ArticleId><ArticleId IdType="pmc">PMC10715775</ArticleId><ArticleId IdType="pubmed">38061012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui DCC, Camidge DR, Rusthoven CG. Managing central nervous system spread of lung cancer: the state of the art. J Clin Oncol. 2022;40(6):642&#x2013;660. doi: 10.1200/JCO.21.01715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.01715</ArticleId><ArticleId IdType="pubmed">34985937</ArticleId></ArticleIdList></Reference><Reference><Citation>Eaton K. Lung Cancer: Translational and Emerging Therapies. New York, NY: CRC Press; 2007. 278 pp.</Citation></Reference><Reference><Citation>Mildenberger P, Eichelberg M, Martin E. Introduction to the DICOM standard. Eur Radiol. 2002;12(4):920&#x2013;927. doi: 10.1007/s003300101100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s003300101100</ArticleId><ArticleId IdType="pubmed">11960249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidgood WD, Horii SC, Prior FW, Van Syckle DE. Understanding and using DICOM, the data interchange standard for biomedical imaging. J Am Med Inform Assoc. 1997;4(3):199&#x2013;212. doi: 10.1136/jamia.1997.0040199. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.1997.0040199</ArticleId><ArticleId IdType="pmc">PMC61235</ArticleId><ArticleId IdType="pubmed">9147339</ArticleId></ArticleIdList></Reference><Reference><Citation>Haripriya P, Porkodi R. A survey paper on data mining techniques and challenges in distributed DICOM. Int J Adv Res Comput Commun Eng. 2016:741&#x2013;747. doi: 10.17148/IJARCCE.2016.53179. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.17148/IJARCCE.2016.53179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel P, Nagy P. Patient-centered radiology with FHIR: an introduction to the use of FHIR to offer radiology a clinically integrated platform. J Digit Imaging. 2018;31(3):327&#x2013;333. doi: 10.1007/s10278-018-0087-6. 
 
10.1007/s10278-018-0087-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-018-0087-6</ArticleId><ArticleId IdType="pmc">PMC5959836</ArticleId><ArticleId IdType="pubmed">29725963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tournier J, Smith R, Raffelt D, Tabbara R, Dhollander T, Pietsch M, Christiaens D, Jeurissen B, Yeh CH, Connelly A. MRtrix3: a fast, flexible and open software framework for medical image processing and visualisation. Neuroimage. 2019;202:116137. doi: 10.1016/j.neuroimage.2019.116137.S1053-8119(19)30728-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.116137</ArticleId><ArticleId IdType="pubmed">31473352</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello M, Esposito G, Pagliari G, Borrelli P, Brancato V, Salvatore M. How does DICOM support big data management? investigating its use in medical imaging community. Insights Imaging. 2021;12(1):164. doi: 10.1186/s13244-021-01081-8. 
 
10.1186/s13244-021-01081-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13244-021-01081-8</ArticleId><ArticleId IdType="pmc">PMC8574146</ArticleId><ArticleId IdType="pubmed">34748101</ArticleId></ArticleIdList></Reference><Reference><Citation>Onken M, Riesmeier J, Bennett A. Biomedical Image Processing. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010. Digital imaging and communications in medicine; pp. 427&#x2013;454.</Citation></Reference><Reference><Citation>Lelong R, Soualmia L, Dahamna B, Griffon N, Darmoni SJ. Querying EHRs with a semantic and entity-oriented query language. Stud Health Technol Inform. 2017;235:121&#x2013;125. doi: 10.3233/978-1-61499-753-5-121. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-753-5-121</ArticleId><ArticleId IdType="pubmed">28423767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni P. QAV: querying entity-attribute-value metadata in a biomedical database. Comput Methods Programs Biomed. 1997 Jun;53(2):93&#x2013;103. doi: 10.1016/s0169-2607(97)01815-4. 
 
S0169-2607(97)01815-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0169-2607(97)01815-4</ArticleId><ArticleId IdType="pubmed">9186046</ArticleId></ArticleIdList></Reference><Reference><Citation>Morozov S, Gombolevskiy V, Elizarov A, Gusev M, Novik V, Prokudaylo S, Bardin A, Popov E, Ledikhova N, Chernina V, Blokhin I, Nikolaev A, Reshetnikov R, Vladzymyrskyy A, Kulberg N. A simplified cluster model and a tool adapted for collaborative labeling of lung cancer CT scans. Comput Methods Programs Biomed. 2021;206:106111. doi: 10.1016/j.cmpb.2021.106111.S0169-2607(21)00186-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106111</ArticleId><ArticleId IdType="pubmed">33957377</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Pinto A, Alle S, Nath V, Tang Y, Ihsani A, Asad M, P&#xe9;rez-Garc&#xed;a F, Mehta P, Li W, Flores M, Roth HR, Vercauteren T, Xu D, Dogra P, Ourselin S, Feng A, Cardoso MJ. MONAI label: a framework for AI-assisted interactive labeling of 3D medical images. Med Image Anal. 2024;95:103207. doi: 10.1016/j.media.2024.103207.S1361-8415(24)00132-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2024.103207</ArticleId><ArticleId IdType="pubmed">38776843</ArticleId></ArticleIdList></Reference><Reference><Citation>Philbrick K, Weston A, Akkus Z, Kline TL, Korfiatis P, Sakinis T, Kostandy P, Boonrod A, Zeinoddini A, Takahashi N, Erickson BJ. RIL-Contour: a medical imaging dataset annotation tool for and with deep learning. J Digit Imaging. 2019 Aug;32(4):571&#x2013;581. doi: 10.1007/s10278-019-00232-0. 
 
10.1007/s10278-019-00232-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-019-00232-0</ArticleId><ArticleId IdType="pmc">PMC6646456</ArticleId><ArticleId IdType="pubmed">31089974</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;sel Philipp D, van de Kamp T, Jayme A, Ershov A, Farag&#xf3; Tom&#xe1;&#x161;, Pichler O, Tan Jerome N, Aadepu N, Bremer S, Chilingaryan SA, Heethoff M, Kopmann A, Odar J, Schmelzle S, Zuber M, Wittbrodt J, Baumbach T, Heuveline V. Introducing Biomedisa as an open-source online platform for biomedical image segmentation. Nat Commun. 2020 Nov 04;11(1):5577. doi: 10.1038/s41467-020-19303-w.10.1038/s41467-020-19303-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19303-w</ArticleId><ArticleId IdType="pmc">PMC7642381</ArticleId><ArticleId IdType="pubmed">33149150</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology Common Dada Model (CDM) framework on OMOP CDM. GitHub.  [2024-06-12].  
 https://github.com/HIRC-SNUBH/ImagingCDM
.</Citation></Reference><Reference><Citation>Chu Z, Zhang Y, Li WJ, Li Q, Zheng YN, Lv FJ. Primary solid lung cancerous nodules with different sizes: computed tomography features and their variations. BMC Cancer. 2019;19(1):1060. doi: 10.1186/s12885-019-6274-0. 
 
10.1186/s12885-019-6274-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-6274-0</ArticleId><ArticleId IdType="doi">10.1186/s12885-019-6274-0</ArticleId><ArticleId IdType="pmc">PMC6836448</ArticleId><ArticleId IdType="pubmed">31699047</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan O, Lim Choi Keung SN, Zhao L, Arvanitis TN. A hybrid EAV-relational model for consistent and scalable capture of clinical research data. Stud Health Technol Inform. 2014;202:32&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25000008</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y, Shen M, Yang J, Yang G. Reliable label-efficient learning for biomedical image recognition. IEEE Trans Biomed Eng. 2019;66(9):2423&#x2013;2432. doi: 10.1109/tbme.2018.2889915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/tbme.2018.2889915</ArticleId><ArticleId IdType="pubmed">30596566</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Zhou Z, Wu W. OneSeg: self-learning and one-shot learning based single-slice annotation for 3D medical image segmentation. arXiv. doi: 10.48550/arXiv.2309.13671. Preprint posted online on September 24, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2309.13671</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrovski I, Kocev D, Loskovska S, D&#x17e;eroski S. Hierarchical annotation of medical images. Pattern Recognit. 2011 Oct;44(10-11):2436&#x2013;2449. doi: 10.1016/j.patcog.2011.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patcog.2011.03.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Garc&#xed;a M, Hern&#xe1;ndez-Lemus E. Data integration challenges for machine learning in precision medicine. Front Med (Lausanne) 2021;8:784455. doi: 10.3389/fmed.2021.784455. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.784455</ArticleId><ArticleId IdType="pmc">PMC8821900</ArticleId><ArticleId IdType="pubmed">35145977</ArticleId></ArticleIdList></Reference><Reference><Citation>Parciak M, Suhr M, Schmidt C, B&#xf6;nisch C, L&#xf6;hnhardt B, Keszty&#xfc;s D, Keszty&#xfc;s T. FAIRness through automation: development of an automated medical data integration infrastructure for FAIR health data in a maximum care university hospital. BMC Med Inform Decis Mak. 2023;23(1):94. doi: 10.1186/s12911-023-02195-3. 
 
10.1186/s12911-023-02195-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-023-02195-3</ArticleId><ArticleId IdType="doi">10.1186/s12911-023-02195-3</ArticleId><ArticleId IdType="pmc">PMC10186636</ArticleId><ArticleId IdType="pubmed">37189148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalokyri V, Kondylakis H, Sfakianakis S, Nikiforaki K, Karatzanis I, Mazzetti S, Tachos N, Regge D, Fotiadis DI, Marias K, Tsiknakis M. MI-common data model: extending observational medical outcomes partnership-common data model (OMOP-CDM) for registering medical imaging metadata and subsequent curation processes. JCO Clin Cancer Inform. 2023;7:e2300101. doi: 10.1200/CCI.23.00101. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.23.00101?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed</ArticleId><ArticleId IdType="doi">10.1200/CCI.23.00101</ArticleId><ArticleId IdType="pmc">PMC10715775</ArticleId><ArticleId IdType="pubmed">38061012</ArticleId></ArticleIdList></Reference><Reference><Citation>Park W, Jeon K, Schmidt TS, Kondylakis H, Alkasab T, Dewey BE, You SC, Nagy P. Development of medical imaging data standardization for imaging-based observational research: OMOP common data model extension. J Imaging Inform Med. 2024;37(2):899&#x2013;908. doi: 10.1007/s10278-024-00982-6.10.1007/s10278-024-00982-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-024-00982-6</ArticleId><ArticleId IdType="pmc">PMC11031512</ArticleId><ArticleId IdType="pubmed">38315345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39043402</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>allofus: an R package to facilitate use of the All of Us Researcher Workbench.</ArticleTitle><Pagination><StartPage>3013</StartPage><EndPage>3021</EndPage><MedlinePgn>3013-3021</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocae198</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Despite easy-to-use tools like the Cohort Builder, using All of Us Research Program data for complex research questions requires a relatively high level of technical expertise. We aimed to increase research and training capacity and reduce barriers to entry for the All of Us community through an R package, allofus. In this article, we describe functions that address common challenges we encountered while working with All of Us Research Program data, and we demonstrate this functionality with an example of creating a cohort of All of Us participants by synthesizing electronic health record and survey data with time dependencies.</AbstractText><AbstractText Label="TARGET AUDIENCE" NlmCategory="BACKGROUND">All of Us Research Program data are widely available to health researchers. The allofus R package is aimed at a wide range of researchers who wish to conduct complex analyses using best practices for reproducibility and transparency, and who have a range of experience using R. Because the All of Us data are transformed into the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), researchers familiar with existing OMOP CDM tools or who wish to conduct network studies in conjunction with other OMOP CDM data will also find value in the package.</AbstractText><AbstractText Label="SCOPE" NlmCategory="METHODS">We developed an initial set of functions that solve problems we experienced across survey and electronic health record data in our own research and in mentoring student projects. The package will continue to grow and develop with the All of Us Research Program. The allofus R package can help build community research capacity by increasing access to the All of Us Research Program data, the efficiency of its use, and the rigor and reproducibility of the resulting research.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Louisa H</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0001-9029-4644</Identifier><AffiliationInfo><Affiliation>Roux Institute, Northeastern University, Portland, ME 04101, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Health Sciences, Bouv&#xe9; College of Health Sciences, Northeastern University, Boston, MA 02115, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavanaugh</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2114-6565</Identifier><AffiliationInfo><Affiliation>Roux Institute, Northeastern University, Portland, ME 04101, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Health Sciences, Bouv&#xe9; College of Health Sciences, Northeastern University, Boston, MA 02115, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 OD026556</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U2C OD023196</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025315</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026551</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023121</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026552</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026549</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025337</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025277</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026555</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026550</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026553</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD023205</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD025276</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026557</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026554</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023163</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD023206</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 OD023176</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 OD026548</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012108" MajorTopicYN="N">Research Personnel</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">All of Us</Keyword><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">R package</Keyword></KeywordList><CoiStatement>R.C. received a mentor stipend from the <i>All of Us</i> Research Scholar Program.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>11</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>23</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39043402</ArticleId><ArticleId IdType="pmc">PMC11631081</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocae198</ArticleId><ArticleId IdType="pii">7718788</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The All of Us Research Program Investigators. The &#x201c;All of Us&#x201d; research program. N Engl J Med. 2019;381(7):668-676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. &#xa0;Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, et al. &#xa0;OHDSI Standardized Vocabularies&#x2014;a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31(3):583-590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. 2023. Accessed April 4, 2024. https://www.R-project.org/ </Citation></Reference><Reference><Citation>van Rossum G. &#xa0;Python. CRC Press; 1998. 10.1201/9780849331350.ch23</Citation><ArticleIdList><ArticleId IdType="doi">10.1201/9780849331350.ch23</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kluyver T, Ragan-Kelley B, P&#xe9;rez F, et al.  &#xa0;Jupyter Notebooks: a publishing format for reproducible computational workflows. In: Loizides F, Scmidt B, eds. Positioning and Power in Academic Publishing: Players, Agents and Agendas. IOS Press; 2016:87-90. Accessed April 4, 2024. https://eprints.soton.ac.uk/403913/</Citation></Reference><Reference><Citation>Posit Team. RStudio: Integrated Development Environment for R; 2024. Accessed April 4, 2024. http://www.posit.co/</Citation></Reference><Reference><Citation>SAS Institute Inc. SAS302-2014.pdf. Accessed April 4, 2024. https://support.sas.com/en/software/studio-support.html</Citation></Reference><Reference><Citation>Wickham H, Averick M, Bryan J, et al. &#xa0;Welcome to the Tidyverse. JOSS. 2019;4(43):1686.</Citation></Reference><Reference><Citation>
Wickham H, Fran&#xe7;ois R, Henry L, et al.  dplyr: a grammar of data manipulation. 2023. Accessed April 4, 2024. https://CRAN.R-project.org/package=dplyr</Citation></Reference><Reference><Citation>
BigQuery Enterprise Data Warehouse. Google Cloud. Accessed April 4, 2024. https://cloud.google.com/bigquery</Citation></Reference><Reference><Citation>
Wickham H, Girlich M, Ruiz E. dbplyr: a &#x201c;dplyr&#x201d; back end for databases. 2024. Accessed April 4, 2024. https://CRAN.R-project.org/package=dbplyr</Citation></Reference><Reference><Citation>
Wickham H, M&#xfc;ller K, R Special Interest Group on Databases (R-SIG-DB). DBI: R database interface. 2024. Accessed April 4, 2024. https://CRAN.R-project.org/package=DBI</Citation></Reference><Reference><Citation>Home. OHDSI/Atlas Wiki. Accessed April 4, 2024. https://github.com/OHDSI/Atlas/wiki</Citation></Reference><Reference><Citation>
Wickham H, Bigrquery BJ. An interface to google&#x2019;s &#x201c;BigQuery&#x201d; &#x201c;API.&#x201d; 2024. Accessed April 4, 2024. https://CRAN.R-project.org/package=bigrquery</Citation></Reference><Reference><Citation>The MIT License. Open Source Initiat. 2006. Accessed April 3, 2024. https://opensource.org/license/MIT</Citation></Reference><Reference><Citation>
All of Us Survey Changes Over Time. User Support. 2023. Accessed April 5, 2024. https://support.researchallofus.org/hc/en-us/articles/14935566710804-All-of-Us-Survey-Changes-Over-Time</Citation></Reference><Reference><Citation>&#xc7;etinkaya-Rundel M, Hardin J, Baumer BS, et al. &#xa0;An educator&#x2019;s perspective of the tidyverse. Technol Innov Stat Educ. 2022;14(1). Accessed April 4, 2024. 10.5070/T514154352</Citation><ArticleIdList><ArticleId IdType="doi">10.5070/T514154352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim R, G&#xee;rj&#x103;u M-C, Horton NJ. &#xa0;Fostering better coding practices for data scientists. Harv Data Sci Rev. 2023;5(3). 10.1162/99608f92.97c9f60f</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.97c9f60f</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39049393</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>315</Volume><PubDate><Year>2024</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Building Bridges for Federated Learning in Healthcare: Review on Approaches for Common Data Model Development.</ArticleTitle><Pagination><StartPage>711</StartPage><EndPage>712</EndPage><MedlinePgn>711-712</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240292</ELocationID><Abstract><AbstractText>Common data models provide a standardized way to represent data used in federated learning tasks. The aim of this review was to explore the development and use of common data models to harmonize electronic health record data in health research. The data search yielded 724 records, of which 19 were included for this study. None of the research focused on nursing specific topics. All studies either utilized the Observational Medical Outcomes Partnership (OMOP) common data model, or developed a model partly based on the OMOP. A roadmap to guide research for the development of common data models for federated learning are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Gerich</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nursing Science, University of Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chomutare</LastName><ForeName>Taridzo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Norwegian Centre for E-health Research, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peltonen</LastName><ForeName>Laura-Maria</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Nursing Science, University of Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Turku University Hospital, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Federated learning</Keyword><Keyword MajorTopicYN="N">Healthcare</Keyword><Keyword MajorTopicYN="N">Scoping review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>25</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39049393</ArticleId><ArticleId IdType="doi">10.3233/SHTI240292</ArticleId><ArticleId IdType="pii">SHTI240292</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39075459</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>Creating a health informatics data resource for hearing health research.</ArticleTitle><Pagination><StartPage>209</StartPage><MedlinePgn>209</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-024-02589-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The National Institute of Health and Social Care Research (NIHR) Health Informatics Collaborative (HIC) for Hearing Health has been established in the UK to curate routinely collected hearing health data to address research questions. This study defines priority research areas, outlines its aims, governance structure and demonstrates how hearing health data have been integrated into a common data model using pure tone audiometry (PTA) as a case study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">After identifying key research aims in hearing health, the governance structure for the NIHR HIC for Hearing Health is described. The Observational Medical Outcomes Partnership (OMOP) was chosen as our common data model to provide a case study example.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The NIHR HIC Hearing Health theme have developed a data architecture outlying the flow of data from all of the various siloed electronic patient record systems to allow the effective linkage of data from electronic patient record systems to research systems. Using PTAs as an example, OMOPification of hearing health data successfully collated a rich breadth of datapoints across multiple centres.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study identified priority research areas where routinely collected hearing health data could be useful. It demonstrates integration and standardisation of such data into a common data model from multiple centres. By describing the process of data sharing across the HIC, we hope to invite more centres to contribute and utilise data to address research questions in hearing health. This national initiative has the power to transform UK hearing research and hearing care using routinely collected clinical data.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Nishchay</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal National ENT Hospital, UCLH Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeyre</LastName><ForeName>Baptiste Briot</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrov</LastName><ForeName>Lilia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal National ENT Hospital, UCLH Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>English</LastName><ForeName>Louise J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewart</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NIHR Health Informatics Collaborative Hearing Health, Patient and Public Engagement Group, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinrich</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester Centre for Audiology and Deafness (ManCAD), School of Health Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal National ENT Hospital, UCLH Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manchester Centre for Audiology and Deafness (ManCAD), School of Health Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roadknight</LastName><ForeName>Gail</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust: Oxford, Oxfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romao</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilder</LastName><ForeName>Anne Gm</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal National ENT Hospital, UCLH Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spriggs</LastName><ForeName>Ruth V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>NIHR Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norris</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Health Informatics, School of Health Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Talisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>NIHR University College London Hospitals Biomedical Research Centre, London, UK. Talisaross@doctors.org.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal National ENT Hospital, UCLH Trust, London, UK. Talisaross@doctors.org.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nottingham Audiology Services, Nottingham University Hospitals, Nottingham, UK. Talisaross@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilston</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Health Informatics, School of Health Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>BMC Med Inform Decis Mak. 2024 Aug 19;24(1):230. doi: 10.1186/s12911-024-02632-x.</RefSource><PMID Version="1">39160523</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001301" MajorTopicYN="N">Audiometry, Pure-Tone</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data sharing</Keyword><Keyword MajorTopicYN="N">Database</Keyword><Keyword MajorTopicYN="N">Hearing health</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39075459</ArticleId><ArticleId IdType="pmc">PMC11285202</ArticleId><ArticleId IdType="doi">10.1186/s12911-024-02589-x</ArticleId><ArticleId IdType="pii">10.1186/s12911-024-02589-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Royal National Institute for the Deaf. Facts and figures - RNID. https://rnid.org.uk/about-us/research-and-policy/facts-and-figures/ (accessed 12 Apr 2023).</Citation></Reference><Reference><Citation>Office of National Statistics. 2011 censuses UK comparability report. https://www.ons.gov.uk/census/planningforcensus2021/ukcensusdata (accessed 12 Apr 2023).</Citation></Reference><Reference><Citation>Shield B. Hearing Loss-Numbers and Costs EVALUATION OF THE SOCIAL AND ECONOMIC COSTS OF HEARING IMPAIRMENT A report for Hear-It AISBL. 2019.</Citation></Reference><Reference><Citation>Demorest ME, Erdman SA. Relationships among behavioral, environmental, and affective communication variables: a canonical analysis of the CPHI. J Speech Hear Disorders. 1989;54:180&#x2013;8. 10.1044/jshd.5402.180. 10.1044/jshd.5402.180</Citation><ArticleIdList><ArticleId IdType="doi">10.1044/jshd.5402.180</ArticleId><ArticleId IdType="pubmed">2709836</ArticleId></ArticleIdList></Reference><Reference><Citation>Meadow-Orlans KP. Social and psychological effects of hearing loss in adulthood: a literature review. Adjustment Adult Hear loss 1985;:35&#x2013;57.</Citation></Reference><Reference><Citation>Shan A, Ting JS, Price C, et al. Hearing loss and employment: a systematic review of the association between hearing loss and employment among adults. J Laryngol Otol. 2020;134:387&#x2013;97. 10.1017/S0022215120001012. 10.1017/S0022215120001012</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022215120001012</ArticleId><ArticleId IdType="pubmed">32468973</ArticleId></ArticleIdList></Reference><Reference><Citation>Haile L, Orji A, Briant P, et al. Updates on hearing from the global burden of Disease Study. Innov Aging. 2020;4:808&#x2013;808. 10.1093/geroni/igaa057.2934. 10.1093/geroni/igaa057.2934</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geroni/igaa057.2934</ArticleId></ArticleIdList></Reference><Reference><Citation>Raviv D, Dror AA, Avraham KB. Hearing loss: a common disorder caused by many rare alleles. Ann N Y Acad Sci. 2010;1214:168&#x2013;79. 10.1111/j.1749-6632.2010.05868.x. 10.1111/j.1749-6632.2010.05868.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2010.05868.x</ArticleId><ArticleId IdType="pmc">PMC3689008</ArticleId><ArticleId IdType="pubmed">21175685</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet. Calling for research into deafness. Lancet. 2007;370:1738. 10.1016/S0140-6736(07)61729-2. 10.1016/S0140-6736(07)61729-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61729-2</ArticleId><ArticleId IdType="pubmed">18037070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson BS, Tucci DL, O&#x2019;Donoghue GM, et al. A Lancet Commission to address the global burden of hearing loss. Lancet. 2019;393:2106&#x2013;8. 10.1016/S0140-6736(19)30484-2. 10.1016/S0140-6736(19)30484-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30484-2</ArticleId><ArticleId IdType="pubmed">30827785</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Informatics Collaborative &#x2013; National Institute for Health Research. https://hic.nihr.ac.uk/ (accessed 12 Apr 2023).</Citation></Reference><Reference><Citation>Davis AC. The prevalence of hearing impairment and reported hearing disability among adults in Great Britain. 1389. https://academic.oup.com/ije/article/18/4/911/683421.</Citation><ArticleIdList><ArticleId IdType="pubmed">2621028</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimpida D, Kontopantelis E, Ashcroft DM, et al. Regional patterns and trends of hearing loss in England: evidence from the English longitudinal study of ageing (ELSA) and implications for health policy. BMC Geriatr. 2020;20:536. 10.1186/s12877-020-01945-6. 10.1186/s12877-020-01945-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-020-01945-6</ArticleId><ArticleId IdType="pmc">PMC7737370</ArticleId><ArticleId IdType="pubmed">33319704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer CS, Armitage CJ, Munro KJ, et al. Correlates of hearing Aid Use in UK adults. Ear Hear. 2019;40:1061&#x2013;8. 10.1097/AUD.0000000000000695. 10.1097/AUD.0000000000000695</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AUD.0000000000000695</ArticleId><ArticleId IdType="pubmed">30664127</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin FR, Albert M. Hearing loss and dementia &#x2013; who is listening? Aging Ment Health. 2014;18:671&#x2013;3. 10.1080/13607863.2014.915924. 10.1080/13607863.2014.915924</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607863.2014.915924</ArticleId><ArticleId IdType="pmc">PMC4075051</ArticleId><ArticleId IdType="pubmed">24875093</ArticleId></ArticleIdList></Reference><Reference><Citation>Samocha-Bonet D, Wu B, Ryugo DK. Diabetes mellitus and hearing loss: a review. Ageing Res Rev. 2021;71:101423. 10.1016/j.arr.2021.101423. 10.1016/j.arr.2021.101423</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101423</ArticleId><ArticleId IdType="pubmed">34384902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin FR. Hearing loss and Falls among older adults in the United States. Arch Intern Med. 2012;172:369. 10.1001/archinternmed.2011.728. 10.1001/archinternmed.2011.728</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2011.728</ArticleId><ArticleId IdType="pmc">PMC3518403</ArticleId><ArticleId IdType="pubmed">22371929</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien W. Prevalence of hearing Aid Use among older adults in the United States. Arch Intern Med. 2012;172:292. 10.1001/archinternmed.2011.1408. 10.1001/archinternmed.2011.1408</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2011.1408</ArticleId><ArticleId IdType="pmc">PMC3564585</ArticleId><ArticleId IdType="pubmed">22332170</ArticleId></ArticleIdList></Reference><Reference><Citation>Melgar-Rojas P, Alvarado JC, Fuentes-Santamar&#xed;a V et al. Cellular mechanisms of Age-related hearing loss. 2015. 305&#x2013;33. 10.1007/978-3-319-13473-4_15.</Citation></Reference><Reference><Citation>Schilder AGM, Su MP, Mandavia R, et al. Early phase trials of novel hearing therapeutics: avenues and opportunities. Hear Res. 2019;380:175&#x2013;86. 10.1016/j.heares.2019.07.003. 10.1016/j.heares.2019.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heares.2019.07.003</ArticleId><ArticleId IdType="pubmed">31319285</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai T, Dixon S, Ziebland S. Shifting research culture to address the mismatch between where trials recruit and where populations with the most disease live: a qualitative study. BMC Med Res Methodol. 2021;21:80. 10.1186/s12874-021-01268-z. 10.1186/s12874-021-01268-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01268-z</ArticleId><ArticleId IdType="pmc">PMC8058580</ArticleId><ArticleId IdType="pubmed">33882874</ArticleId></ArticleIdList></Reference><Reference><Citation>Experimental medicine | NIHR. https://www.nihr.ac.uk/explore-nihr/support/experimental-medicine.htm (accessed 12 Apr 2023).</Citation></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C et al. The Usage of OHDSI OMOP &#x2013; A Scoping Review. 2021. 10.3233/SHTI210546.</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>ISO 8253-1. 2010(en), Acoustics &#x2014; Audiometric test methods &#x2014; Part 1: Pure-tone air and bone conduction audiometry. https://www.iso.org/obp/ui/#iso:std:iso:8253:-1:ed-2:v1:en (accessed 12 Apr 2023).</Citation></Reference><Reference><Citation>documentation:cdm:single. -page [Observational Health Data Sciences and Informatics]. https://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:single-page (accessed 12 Apr 2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39075527</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a patient-level model to predict dementia across a network of observational databases.</ArticleTitle><Pagination><StartPage>308</StartPage><MedlinePgn>308</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">308</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-024-03530-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">A prediction model can be a useful tool to quantify the risk of a patient developing dementia in the next years and take risk-factor-targeted intervention. Numerous dementia prediction models have been developed, but few have been externally validated, likely limiting their clinical uptake. In our previous work, we had limited success in externally validating some of these existing models due to inadequate reporting. As a result, we are compelled to develop and externally validate novel models to predict dementia in the general population across a network of observational databases. We assess regularization methods to obtain parsimonious models that are of lower complexity and easier to implement.</AbstractText><AbstractText Label="METHODS">Logistic regression models were developed across a network of five observational databases with electronic health records (EHRs) and claims data to predict 5-year dementia risk in persons aged 55-84. The regularization methods L1 and Broken Adaptive Ridge (BAR) as well as three candidate predictor sets to optimize prediction performance were assessed. The predictor sets include a baseline set using only age and sex, a full set including all available candidate predictors, and a phenotype set which includes a limited number of clinically relevant predictors.</AbstractText><AbstractText Label="RESULTS">BAR can be used for variable selection, outperforming L1 when a parsimonious model is desired. Adding candidate predictors for disease diagnosis and drug exposure generally improves the performance of baseline models using only age and sex. While a model trained on German EHR data saw an increase in AUROC from 0.74 to 0.83 with additional predictors, a model trained on US EHR data showed only minimal improvement from 0.79 to 0.81 AUROC. Nevertheless, the latter model developed using BAR regularization on the clinically relevant predictor set was ultimately chosen as best performing model as it demonstrated more consistent external validation performance and improved calibration.</AbstractText><AbstractText Label="CONCLUSIONS">We developed and externally validated patient-level models to predict dementia. Our results show that although dementia prediction is highly driven by demographic age, adding predictors based on condition diagnoses and drug exposures further improves prediction performance. BAR regularization outperforms L1 regularization to yield the most parsimonious yet still well-performing prediction model for dementia.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>John</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. l.john@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fridgeirsson</LastName><ForeName>Egill A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dementia prediction</Keyword><Keyword MajorTopicYN="N">External validation</Keyword><Keyword MajorTopicYN="N">Logistic regression model</Keyword><Keyword MajorTopicYN="N">Observational data</Keyword></KeywordList><CoiStatement>Jenna M. Reps and Patrick B. Ryan are employees of Janssen Research &amp; Development and shareholder of Johnson &amp; Johnson. Peter R. Rijnbeek, Egill A. Fridgeirsson, Luis H. John, Jan A. Kors, Jenna M. Reps, and Ross D. Williams work for a research group that in the past 3&#xa0;years receives/received unconditional research grants from Chiesi, UCB, Amgen, Johnson and Johnson, Innovative Medicines Initiative, and the European Medicines Agency. None of these grants results in a conflict of interest to the content of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39075527</ArticleId><ArticleId IdType="pmc">PMC11288076</ArticleId><ArticleId IdType="doi">10.1186/s12916-024-03530-9</ArticleId><ArticleId IdType="pii">10.1186/s12916-024-03530-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stephan BC, Kurth T, Matthews FE, Brayne C, Dufouil C. Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol. 2010;6(6):318&#x2013;26. 10.1038/nrneurol.2010.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2010.54</ArticleId><ArticleId IdType="pubmed">20498679</ArticleId></ArticleIdList></Reference><Reference><Citation>Society As. The progression, signs and stages of dementia. 2023. Available from: https://www.alzheimers.org.uk/about-dementia/symptoms-and-diagnosis/how-dementia-progresses/progression-stages-dementia. Updated 24 Feb 2021.</Citation></Reference><Reference><Citation>Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet. 2020;396(10248):413&#x2013;46. 10.1016/S0140-6736(20)30367-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang EY, Harrison SL, Errington L, Gordon MF, Visser PJ, Novak G, et al. Current developments in dementia risk prediction modelling: an updated systematic review. PLoS One. 2015;10(9):e0136181. 10.1371/journal.pone.0136181</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136181</ArticleId><ArticleId IdType="pmc">PMC4559315</ArticleId><ArticleId IdType="pubmed">26334524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou XH, Feng L, Zhang C, Cao XP, Tan L, Yu JT. Models for predicting risk of dementia: a systematic review. J Neurol Neurosurg Psychiatry. 2019;90(4):373&#x2013;9. 10.1136/jnnp-2018-318212</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318212</ArticleId><ArticleId IdType="pubmed">29954871</ArticleId></ArticleIdList></Reference><Reference><Citation>Goerdten J, &#x10c;uki&#x107; I, Danso SO, Carri&#xe8;re I, Muniz-Terrera G. Statistical methods for dementia risk prediction and recommendations for future work: a systematic review. Alzheimers Dement (N Y). 2019;5:563&#x2013;9. 10.1016/j.trci.2019.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2019.08.001</ArticleId><ArticleId IdType="pmc">PMC6804431</ArticleId><ArticleId IdType="pubmed">31646170</ArticleId></ArticleIdList></Reference><Reference><Citation>John LH, Kors JA, Fridgeirsson EA, Reps JM, Rijnbeek PR. External validation of existing dementia prediction models on observational health data. BMC Med Res Methodol. 2022;22(1):1&#x2013;12. 10.1186/s12874-022-01793-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01793-5</ArticleId><ArticleId IdType="pmc">PMC9720950</ArticleId><ArticleId IdType="pubmed">36471238</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;75. 10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Kim C, et al. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed. 2021;211:106394. 10.1016/j.cmpb.2021.106394</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters K, Hardoon S, Petersen I, Iliffe S, Omar RZ, Nazareth I, et al. Predicting dementia risk in primary care: development and validation of the dementia risk score using routinely collected data. BMC Med. 2016;14:6. 10.1186/s12916-016-0549-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-016-0549-y</ArticleId><ArticleId IdType="pmc">PMC4722622</ArticleId><ArticleId IdType="pubmed">26797096</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ridder MA, de Wilde M, de Ben C, Leyba AR, Mosseveld BM, Verhamme KM, et al. Data resource profile: the integrated primary care information (IPCI) database, The Netherlands. Int J Epidemiol. 2022;51(6):e314&#x2013;23. 10.1093/ije/dyac026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac026</ArticleId><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta HB, Mehta V, Tsai C-L, Chen H, Aparasu RR, Johnson ML. Development and validation of the RxDx-Dementia risk index to predict dementia in patients with type 2 diabetes and hypertension. J Alzheimers Dis. 2016;49(2):423&#x2013;32. 10.3233/JAD-150466</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150466</ArticleId><ArticleId IdType="pubmed">26519436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardin J, Reps JM. Evaluating the impact of covariate lookback times on performance of patient-level prediction models. BMC Med Res Methodol. 2021;21(1):1&#x2013;9. 10.1186/s12874-021-01370-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01370-2</ArticleId><ArticleId IdType="pmc">PMC8403343</ArticleId><ArticleId IdType="pubmed">34454423</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Rijnbeek P, Cuthbert A, Ryan PB, Pratt N, Schuemie M. An empirical analysis of dealing with patients who are lost to follow-up when developing prognostic models using a cohort design. BMC Med Inform Decis Mak. 2021;21:1&#x2013;24. 10.1186/s12911-021-01408-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-021-01408-x</ArticleId><ArticleId IdType="pmc">PMC7866757</ArticleId><ArticleId IdType="pubmed">33549087</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto D, Feldman AL, Karlsson IK, Dahl Aslan AK, Gatz M, Pedersen NL. Detection of dementia cases in two Swedish health registers: a validation study. J Alzheimers Dis. 2018;61(4):1301&#x2013;10. 10.3233/JAD-170572</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170572</ArticleId><ArticleId IdType="pmc">PMC6218116</ArticleId><ArticleId IdType="pubmed">29376854</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, Markus AF, Yang C, Duarte-Salles T, DuVall SL, Falconer T, et al. Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network. BMC Med Res Methodol. 2022;22(1):35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="pubmed">35094685</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G. The OHDSI phenotype library 2023 [Available from: https://github.com/OHDSI/PhenotypeLibrary.
</Citation></Reference><Reference><Citation>John LH, Kors JA, Reps JM, Ryan PB, Rijnbeek PR. Logistic regression models for patient-level prediction based on massive observational data: Do we need all data? Int J Med Inform. 2022;163:104762.</Citation><ArticleIdList><ArticleId IdType="pubmed">35429722</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkson J. Application of the logistic function to bio-assay. J Am Stat Assoc. 1944;39(227):357&#x2013;65.</Citation></Reference><Reference><Citation>Yang C, Kors JA, Ioannou S, John LH, Markus AF, Rekkas A, et al. Trends in the conduct and reporting of clinical prediction model development and validation: a systematic review. J Am Med Inform Assoc. 2022;29(5):983&#x2013;9. 10.1093/jamia/ocac002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac002</ArticleId><ArticleId IdType="pmc">PMC9006694</ArticleId><ArticleId IdType="pubmed">35045179</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):10. 10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Chen K, Sun Z, Liu Z, Li G. Broken adaptive ridge regression and its asymptotic properties. J Multivar Anal. 2018;168:334&#x2013;51. 10.1016/j.jmva.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmva.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6430210</ArticleId><ArticleId IdType="pubmed">30911202</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Peng X, Kawaguchi E, Suchard MA, Li G. A scalable surrogate L0 sparse regression method for generalized linear models with applications to large scale data. J Stat Plan Inference. 2021;213:262&#x2013;81. 10.1016/j.jspi.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jspi.2020.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: springer; 2001.</Citation></Reference><Reference><Citation>Austin PC, Steyerberg EW. The Integrated Calibration Index (ICI) and related metrics for quantifying the calibration of logistic regression models. Stat Med. 2019;38(21):4051&#x2013;65. 10.1002/sim.8281</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8281</ArticleId><ArticleId IdType="pmc">PMC6771733</ArticleId><ArticleId IdType="pubmed">31270850</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. Circulation. 2015;131(2):211&#x2013;9. 10.1161/CIRCULATIONAHA.114.014508</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.014508</ArticleId><ArticleId IdType="pmc">PMC4297220</ArticleId><ArticleId IdType="pubmed">25561516</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. The book of OHDSI 2020. Available from: https://ohdsi.github.io/TheBookOfOhdsi/.</Citation></Reference><Reference><Citation>Nori VS, Hane CA, Martin DC, Kravetz AD, Sanghavi DM. Identifying incident dementia by applying machine learning to a very large administrative claims dataset. PLoS One. 2019;14(7):e0203246. 10.1371/journal.pone.0203246</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203246</ArticleId><ArticleId IdType="pmc">PMC6611655</ArticleId><ArticleId IdType="pubmed">31276468</ArticleId></ArticleIdList></Reference><Reference><Citation>White N, Parsons R, Collins G, Barnett A. Evidence of questionable research practices in clinical prediction models. BMC Med. 2023;21(1):339. 10.1186/s12916-023-03048-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03048-6</ArticleId><ArticleId IdType="pmc">PMC10478406</ArticleId><ArticleId IdType="pubmed">37667344</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hond AA, Steyerberg EW, van Calster B. Interpreting area under the receiver operating characteristic curve. Lancet Digit Health. 2022;4(12):e853&#x2013;5. 10.1016/S2589-7500(22)00188-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00188-1</ArticleId><ArticleId IdType="pubmed">36270955</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ, Logan JR, Payne PR, Bernstam EV, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care. 2013;51(8 0 3):S30. 10.1097/MLR.0b013e31829b1dbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31829b1dbd</ArticleId><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Korolev IO, Symonds LL, Bozoki AC, Initiative AsDN. Predicting progression from mild cognitive impairment to Alzheimer&#x2019;s dementia using clinical, MRI, and plasma biomarkers via probabilistic pattern classification. PLoS One. 2016;11(2):e0138866. 10.1371/journal.pone.0138866</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138866</ArticleId><ArticleId IdType="pmc">PMC4762666</ArticleId><ArticleId IdType="pubmed">26901338</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Habes M, Wolk DA, Fan Y, Initiative AsDN. A deep learning model for early prediction of Alzheimer&#x2019;s disease dementia based on hippocampal magnetic resonance imaging data. Alzheimers Dement. 2019;15(8):1059&#x2013;70. 10.1016/j.jalz.2019.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.02.007</ArticleId><ArticleId IdType="pmc">PMC6719787</ArticleId><ArticleId IdType="pubmed">31201098</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Latouche A, Fine JP. A review of the use of time-varying covariates in the fine-gray subdistribution hazard competing risk regression model. Stat Med. 2020;39(2):103&#x2013;13. 10.1002/sim.8399</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8399</ArticleId><ArticleId IdType="pmc">PMC6916372</ArticleId><ArticleId IdType="pubmed">31660633</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubachev I, Alekberov A, Gorishniy Y, Babenko A. Revisiting pretraining objectives for tabular deep learning. arXiv preprint arXiv:220703208. 2022.</Citation></Reference><Reference><Citation>Arik S&#xd6;, Pfister T. Tabnet: Attentive interpretable tabular learning. InProceedings of the AAAI conference on artificial intelligence 2021;35(8):6679-87.</Citation></Reference><Reference><Citation>Gorishniy Y, Rubachev I, Khrulkov V, Babenko A. Revisiting deep learning models for tabular data. Adv Neural Inf Process Syst. 2021;34:18932&#x2013;43.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39088253</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1947-2579</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Online journal of public health informatics</Title><ISOAbbreviation>Online J Public Health Inform</ISOAbbreviation></Journal><ArticleTitle>Making Metadata Machine-Readable as the First Step to Providing Findable, Accessible, Interoperable, and Reusable Population Health Data: Framework Development and Implementation Study.</ArticleTitle><Pagination><StartPage>e56237</StartPage><MedlinePgn>e56237</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e56237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/56237</ELocationID><Abstract><AbstractText Label="BACKGROUND">Metadata describe and provide context for other data, playing a pivotal role in enabling findability, accessibility, interoperability, and reusability (FAIR) data principles. By providing comprehensive and machine-readable descriptions of digital resources, metadata empower both machines and human users to seamlessly discover, access, integrate, and reuse data or content across diverse platforms and applications. However, the limited accessibility and machine-interpretability of existing metadata for population health data hinder effective data discovery and reuse.</AbstractText><AbstractText Label="OBJECTIVE">To address these challenges, we propose a comprehensive framework using standardized formats, vocabularies, and protocols to render population health data machine-readable, significantly enhancing their FAIRness and enabling seamless discovery, access, and integration across diverse platforms and research applications.</AbstractText><AbstractText Label="METHODS">The framework implements a 3-stage approach. The first stage is Data Documentation Initiative (DDI) integration, which involves leveraging the DDI Codebook metadata and documentation of detailed information for data and associated assets, while ensuring transparency and comprehensiveness. The second stage is Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) standardization. In this stage, the data are harmonized and standardized into the OMOP CDM, facilitating unified analysis across heterogeneous data sets. The third stage involves the integration of Schema.org and JavaScript Object Notation for Linked Data (JSON-LD), in which machine-readable metadata are generated using Schema.org entities and embedded within the data using JSON-LD, boosting discoverability and comprehension for both machines and human users. We demonstrated the implementation of these 3 stages using the Integrated Disease Surveillance and Response (IDSR) data from Malawi and Kenya.</AbstractText><AbstractText Label="RESULTS">The implementation of our framework significantly enhanced the FAIRness of population health data, resulting in improved discoverability through seamless integration with platforms such as Google Dataset Search. The adoption of standardized formats and protocols streamlined data accessibility and integration across various research environments, fostering collaboration and knowledge sharing. Additionally, the use of machine-interpretable metadata empowered researchers to efficiently reuse data for targeted analyses and insights, thereby maximizing the overall value of population health resources. The JSON-LD codes are accessible via a GitHub repository and the HTML code integrated with JSON-LD is available on the Implementation Network for Sharing Population Information from Research Entities website.</AbstractText><AbstractText Label="CONCLUSIONS">The adoption of machine-readable metadata standards is essential for ensuring the FAIRness of population health data. By embracing these standards, organizations can enhance diverse resource visibility, accessibility, and utility, leading to a broader impact, particularly in low- and middle-income countries. Machine-readable metadata can accelerate research, improve health care decision-making, and ultimately promote better health outcomes for populations worldwide.</AbstractText><CopyrightInformation>&#xa9;David Amadi, Sylvia Kiwuwa-Muyingo, Tathagata Bhattacharjee, Amelia Taylor, Agnes Kiragga, Michael Ochola, Chifundo Kanjala, Arofan Gregory, Keith Tomlin, Jim Todd, Jay Greenfield. Originally published in the Online Journal of Public Health Informatics (https://ojphi.jmir.org/), 01.08.2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6814-4439</Identifier><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiwuwa-Muyingo</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9978-5690</Identifier><AffiliationInfo><Affiliation>African Population and Health Research Center, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Tathagata</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9437-0894</Identifier><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1485-8721</Identifier><AffiliationInfo><Affiliation>Malawi University of Business and Applied Science, Blantyre, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiragga</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0969-0699</Identifier><AffiliationInfo><Affiliation>African Population and Health Research Center, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochola</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9081-3360</Identifier><AffiliationInfo><Affiliation>African Population and Health Research Center, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanjala</LastName><ForeName>Chifundo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0540-8374</Identifier><AffiliationInfo><Affiliation>Independent researcher, Lilongwe, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Arofan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1067-7659</Identifier><AffiliationInfo><Affiliation>Committee on Data (CODATA), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlin</LastName><ForeName>Keith</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0870-5147</Identifier><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Jim</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5918-4914</Identifier><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>Jay</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2773-5317</Identifier><AffiliationInfo><Affiliation>Committee on Data (CODATA), Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Online J Public Health Inform</MedlineTA><NlmUniqueID>101536954</NlmUniqueID><ISSNLinking>1947-2579</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Online J Public Health Inform. 2024 Aug 14;16:e65249. doi: 10.2196/65249.</RefSource><PMID Version="1">39141912</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DDI</Keyword><Keyword MajorTopicYN="N">Data Documentation Initiative</Keyword><Keyword MajorTopicYN="N">FAIR data principles</Keyword><Keyword MajorTopicYN="N">JSON-LD</Keyword><Keyword MajorTopicYN="N">JavaScript Object Notation for Linked Data</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership Common Data Model</Keyword><Keyword MajorTopicYN="N">data models</Keyword><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">machine-readable metadata</Keyword><Keyword MajorTopicYN="N">metadata</Keyword><Keyword MajorTopicYN="N">standardization</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39088253</ArticleId><ArticleId IdType="pmc">PMC11327634</ArticleId><ArticleId IdType="doi">10.2196/56237</ArticleId><ArticleId IdType="pii">v16i1e56237</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brownson RC, Chriqui JF, Stamatakis KA. Understanding evidence-based public health policy. Am J Public Health. 2009 Sep;99(9):1576&#x2013;1583. doi: 10.2105/AJPH.2008.156224.AJPH.2008.156224</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2008.156224</ArticleId><ArticleId IdType="pmc">PMC2724448</ArticleId><ArticleId IdType="pubmed">19608941</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall IS, Rajatonirina S, Yahaya AA, Zabulon Y, Nsubuga P, Nanyunja M, Wamala J, Njuguna C, Lukoya CO, Alemu W, Kasolo FC, Talisuna AO. Integrated Disease Surveillance and Response (IDSR) strategy: current status, challenges and perspectives for the future in Africa. BMJ Glob Health. 2019 Jul 03;4(4):e001427. doi: 10.1136/bmjgh-2019-001427. 
 
bmjgh-2019-001427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2019-001427</ArticleId><ArticleId IdType="pmc">PMC6615866</ArticleId><ArticleId IdType="pubmed">31354972</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankoh O, Byass P. The INDEPTH Network: filling vital gaps in global epidemiology. Int J Epidemiol. 2012 Jun;41(3):579&#x2013;588. doi: 10.1093/ije/dys081. 
 
dys081</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dys081</ArticleId><ArticleId IdType="pmc">PMC3396316</ArticleId><ArticleId IdType="pubmed">22798690</ArticleId></ArticleIdList></Reference><Reference><Citation>van Panhuis WG, Paul P, Emerson C, Grefenstette J, Wilder R, Herbst AJ, Heymann D, Burke DS. A systematic review of barriers to data sharing in public health. BMC Public Health. 2014 Nov 05;14:1144. doi: 10.1186/1471-2458-14-1144. 
 
1471-2458-14-1144</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-1144</ArticleId><ArticleId IdType="doi">10.1186/1471-2458-14-1144</ArticleId><ArticleId IdType="pmc">PMC4239377</ArticleId><ArticleId IdType="pubmed">25377061</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettengill JB, Beal J, Balkey M, Allard M, Rand H, Timme R. Interpretative labor and the bane of nonstandardized metadata in public health surveillance and food safety. Clin Infect Dis. 2021 Oct 20;73(8):1537&#x2013;1539. doi: 10.1093/cid/ciab615.6317707</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab615</ArticleId><ArticleId IdType="pubmed">34240118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen PAC, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3(1):160018. doi: 10.1038/sdata.2016.18.sdata201618</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mons B, Neylon C, Velterop J, Dumontier M, da Silva Santos LOB, Wilkinson MD. Cloudy, increasingly FAIR; revisiting the FAIR Data guiding principles for the European Open Science Cloud. Inf Serv Use. 2017 Mar 07;37(1):49&#x2013;56. doi: 10.3233/ISU-170824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/ISU-170824</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley J. Understanding Metadata: What is Metadata and What is it For? NISO.  [2024-09-07].  
 https://www.fidgeo.de/fileadmin/user_upload/2016/07/2017_01-NISO-understanding-metadata.pdf
.</Citation></Reference><Reference><Citation>Devaraju A, Huber R. An automated solution for measuring the progress toward FAIR research data. Patterns. 2021 Nov 12;2(11):100370. doi: 10.1016/j.patter.2021.100370. 
 
S2666-3899(21)00232-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patter.2021.100370</ArticleId><ArticleId IdType="pmc">PMC8600246</ArticleId><ArticleId IdType="pubmed">34820651</ArticleId></ArticleIdList></Reference><Reference><Citation>Green AE, Humphrey C. Building the DDI. IQ. 2014 May 26;37(1-4):36. doi: 10.29173/iq500.</Citation><ArticleIdList><ArticleId IdType="doi">10.29173/iq500</ArticleId></ArticleIdList></Reference><Reference><Citation>iSHARE repository.  [2024-08-17].  
 https://www.indepth-ishare.org/index.php/catalog/central
.</Citation></Reference><Reference><Citation>Central Data Catalog.  [2024-08-17].  
 https://saprindata.samrc.ac.za/index.php/catalog
.</Citation></Reference><Reference><Citation>Microdata portal. African Population and Health Research Center.  [2024-08-17].  
 https://aphrc.org/microdata-portal/
</Citation></Reference><Reference><Citation>Chapter 4. The common data model. The Book of OHDSI: Observational Health Data Sciences and Informatics. GitHub.  [2024-04-17].  
 https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html
.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012 Jan 01;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376. 
 
amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkthrough of the OMOP CDM (Part 1) Michael Wornrow.  [2024-04-17].  
 https://michaelwornow.net/2022/12/30/omop-cdm-part-1
.</Citation></Reference><Reference><Citation>Chapter 5. Standardized vocabularies. The Book of OHDSI. Observational Health Data Sciences and Informatics. GitHub.  [2024-04-17].  
 https://ohdsi.github.io/TheBookOfOhdsi/StandardizedVocabularies.html
.</Citation></Reference><Reference><Citation>Hallinan CM, Ward R, Hart GK, Sullivan C, Pratt N, Ng AP, Capurro D, Van Der Vegt A, Liaw S, Daly O, Luxan BG, Bunker D, Boyle D. Seamless EMR data access: integrated governance, digital health and the OMOP-CDM. BMJ Health Care Inform. 2024 Feb 21;31(1):e100953. doi: 10.1136/bmjhci-2023-100953. 
 
bmjhci-2023-100953</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjhci-2023-100953</ArticleId><ArticleId IdType="pmc">PMC10882353</ArticleId><ArticleId IdType="pubmed">38387992</ArticleId></ArticleIdList></Reference><Reference><Citation>Schema.org.  [2024-02-17].  
 https://schema.org/docs/schemas.html
.</Citation></Reference><Reference><Citation>JSON for Linking Data.  [2024-09-17].  
 https://json-ld.org/
</Citation></Reference><Reference><Citation>Guerrero CU, Vivas Romero M, Dolman M, Dumontier M. FAIR begins at home: implementing FAIR via the community data driven insights. arXiv Preprint posted online on March 13, 2023. doi: 10.3897/rio.8.e96082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3897/rio.8.e96082</ArticleId></ArticleIdList></Reference><Reference><Citation>FAIR principles. GO FAIR.  [2023-05-23].  
 https://www.go-fair.org/fair-principles/
</Citation></Reference><Reference><Citation>WorldFAIR. CODATA, The Committee on Data for Science and Technology.  [2024-09-17].  
 https://codata.org/initiatives/decadal-programme2/worldfair/
</Citation></Reference><Reference><Citation>Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur J Hum Genet. 2018 Jul 17;26(7):931&#x2013;936. doi: 10.1038/s41431-018-0160-0. 
 
10.1038/s41431-018-0160-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0160-0</ArticleId><ArticleId IdType="pmc">PMC6018669</ArticleId><ArticleId IdType="pubmed">29777206</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng G. The state of assessing data stewardship maturity &#x2013; an overview. Data Sci J. 2018;17:7. doi: 10.5334/dsj-2018-007.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/dsj-2018-007</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine. Board on Health Sciences Policy. Board on Health Care Services. Committee on Health Research and the Privacy of Health Information. The HIPAA Privacy Rule. Nass SJ, Levit LA, Gostin LO. Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research. Washington, DC: National Academies Press; 2009.</Citation><ArticleIdList><ArticleId IdType="pubmed">20662116</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston G, Pakenham-Walsh N, Zielinski C. Universal access to essential health information: accelerating progress towards universal health coverage and other SDG health targets. BMJ Glob Health. 2020 May 17;5(5):e002475. doi: 10.1136/bmjgh-2020-002475. 
 
bmjgh-2020-002475</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2020-002475</ArticleId><ArticleId IdType="pmc">PMC7245367</ArticleId><ArticleId IdType="pubmed">32424012</ArticleId></ArticleIdList></Reference><Reference><Citation>Welter D, Juty N, Rocca-Serra P, Xu F, Henderson D, Gu W, Strubel J, Giessmann RT, Emam I, Gadiya Y, Abbassi-Daloii T, Alharbi E, Gray AJG, Courtot M, Gribbon P, Ioannidis V, Reilly DS, Lynch N, Boiten J, Satagopam V, Goble C, Sansone S, Burdett T. FAIR in action - a flexible framework to guide FAIRification. Sci Data. 2023 May 19;10(1):291. doi: 10.1038/s41597-023-02167-2.10.1038/s41597-023-02167-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02167-2</ArticleId><ArticleId IdType="pmc">PMC10199076</ArticleId><ArticleId IdType="pubmed">37208349</ArticleId></ArticleIdList></Reference><Reference><Citation>NADA microdata cataloging tool.  [2024-06-17].  
 https://nada.ihsn.org/
</Citation></Reference><Reference><Citation>NADA Documentation. Overview.  [2024-09-17].  
 https://ihsn.github.io/nada-documentation/intro/#why-nada
.</Citation></Reference><Reference><Citation>DDI Metadata Editor (Nesstar Publisher 4.0.10) International Household Survey Network (IHSN)  [2024-09-17].  
 http://www.ihsn.org/software/ddi-metadata-editor
.</Citation></Reference><Reference><Citation>Quick reference guide for data archivists. International Household Survey Network (IHSN)  [2024-09-17].  
 https://guide-for-data-archivists.readthedocs.io/en/latest/
</Citation></Reference><Reference><Citation>DDI-Codebook 2.5. Data Documentation Initiative.  [2024-08-17].  
 https://ddialliance.org/Specification/DDI-Codebook/2.5/
</Citation></Reference><Reference><Citation>Barkow I, Block W, Greenfield J, Gregory A, Hebing M, Hoyle L, Zenk-M&#xf6;ltgen W. Generic longitudinal business process model. DDI Working Paper Series (Longitudinal Best Practice) 2013.  [2024-08-17].  
 https://ddialliance.org/sites/default/files/GenericLongitudinalBusinessProcessModel.pdf
.</Citation></Reference><Reference><Citation>Kanjala C, Todd J, Beckles D, Castillo T, Knight G, Mtenga B, Urassa M, Zaba B. Open-access for existing LMIC demographic surveillance data using DDI. IQ. 2017 Feb 24;40(2):18. doi: 10.29173/iq783.</Citation><ArticleIdList><ArticleId IdType="doi">10.29173/iq783</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee T, Kiwuwa-Muyingo S, Kanjala C, Maoyi ML, Amadi D, Ochola M, Kadengye D, Gregory A, Kiragga A, Taylor A, Greenfield J, Slaymaker E, Todd J, INSPIRE Network  INSPIRE datahub: a pan-African integrated suite of services for harmonising longitudinal population health data using OHDSI tools. Front Digit Health. 2024;6:1329630. doi: 10.3389/fdgth.2024.1329630. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fdgth.2024.1329630</ArticleId><ArticleId IdType="pmc">PMC10859396</ArticleId><ArticleId IdType="pubmed">38347885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiwuwa-Muyingo S, Todd J, Bhattacharjee T, Taylor A, Greenfield J. Enabling data sharing and utilization for African population health data using OHDSI tools with an OMOP-common data model. Front Public Health. 2023;11:1116682. doi: 10.3389/fpubh.2023.1116682. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1116682</ArticleId><ArticleId IdType="pmc">PMC10287979</ArticleId><ArticleId IdType="pubmed">37361151</ArticleId></ArticleIdList></Reference><Reference><Citation>5. FAIRification of observational studies and databases: the EHDEN and OHDSI use case. FAIR Cookbook.  [2024-02-17].  
 https://fairplus.github.io/the-fair-cookbook/content/recipes/applied-examples/ehden-ohdsi.html
.</Citation></Reference><Reference><Citation>Google Dataset Search.  [2024-02-17].  
 https://datasetsearch.research.google.com/
</Citation></Reference><Reference><Citation>OHDSI/ATLAS. GitHub.  [2024-04-17].  
 https://github.com/OHDSI/Atlas
.</Citation></Reference><Reference><Citation>INSPIRE domain model for network cohort studies. GitHub.  [2024-07-17].  
 https://github.com/jaygee-on-github/INSPIRE-Domain-Model-for-Network-Cohort-Studies
.</Citation></Reference><Reference><Citation>Inspire PEACH data network.  [2024-05-06].  
 https://inspiredata.network/ext/fairomop
.</Citation></Reference><Reference><Citation>Columbia International eHealth Laboratory.  [2024-05-06].  
 https://app.openconceptlab.org/#/orgs/CIEL/
</Citation></Reference><Reference><Citation>OHDSI GIS Work Group  OHDSI/GIS. GitHub.  [2024-07-17].  
 https://github.com/OHDSI/GIS
.</Citation></Reference><Reference><Citation>DDI-Cross Domain Integration (DDI-CDI) CODATA, The Committee on Data for Science and Technology.  [2023-05-12].  
 https://codata.org/initiatives/decadal-programme2/ddi-cross-domain-integration/
</Citation></Reference><Reference><Citation>Kellerman M, David E. Implementation of the SDMX International Standard in statistical data specification. SDMX.  [2023-05-12].  
 https://sdmx.org/?page_id=5008
.</Citation></Reference><Reference><Citation>HL7 International and OHDSI announce collaboration to provide single common data model for sharing information in clinical care and observational research. OHDSI. Observational Health Data Sciences and Informatics.  [2024-04-17].  
 https://www.ohdsi.org/ohdsi-hl7-collaboration/
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39140273</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Transforming Primary Care Data Into the Observational Medical Outcomes Partnership Common Data Model: Development and Usability Study.</ArticleTitle><Pagination><StartPage>e49542</StartPage><MedlinePgn>e49542</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e49542</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/49542</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Patient-monitoring software generates a large amount of data that can be reused for clinical audits and scientific research. The Observational Health Data Sciences and Informatics (OHDSI) consortium developed the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) to standardize electronic health record data and promote large-scale observational and longitudinal research.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to transform primary care data into the OMOP CDM format.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We extracted primary care data from electronic health records at a multidisciplinary health center in Wattrelos, France. We performed structural mapping between the design of our local primary care database and the OMOP CDM tables and fields. Local French vocabularies concepts were mapped to OHDSI standard vocabularies. To validate the implementation of primary care data into the OMOP CDM format, we applied a set of queries. A practical application was achieved through the development of a dashboard.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Data from 18,395 patients were implemented into the OMOP CDM, corresponding to 592,226 consultations over a period of 20 years. A total of 18 OMOP CDM tables were implemented. A total of 17 local vocabularies were identified as being related to primary care and corresponded to patient characteristics (sex, location, year of birth, and race), units of measurement, biometric measures, laboratory test results, medical histories, and drug prescriptions. During semantic mapping, 10,221 primary care concepts were mapped to standard OHDSI concepts. Five queries were used to validate the OMOP CDM by comparing the results obtained after the completion of the transformations with the results obtained in the source software. Lastly, a prototype dashboard was developed to visualize the activity of the health center, the laboratory test results, and the drug prescription data.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Primary care data from a French health care facility have been implemented into the OMOP CDM format. Data concerning demographics, units, measurements, and primary care consultation steps were already available in OHDSI vocabularies. Laboratory test results and drug prescription data were mapped to available vocabularies and structured in the final model. A dashboard application provided health care professionals with feedback on their practice.</AbstractText><CopyrightInformation>&#xa9; Mathilde Fruchart, Paul Quindroit, Chlo&#xe9; Jacquemont, Jean-Baptiste Beuscart, Matthieu Calafiore, Antoine Lamer. Originally published in JMIR Medical Informatics (https://medinform.jmir.org).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fruchart</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7826-0713</Identifier><AffiliationInfo><Affiliation>Univ Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des, Pratiques m&#xe9;dicales, 2 Place de Verdun, Lille, F-59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quindroit</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0387-2413</Identifier><AffiliationInfo><Affiliation>Univ Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des, Pratiques m&#xe9;dicales, 2 Place de Verdun, Lille, F-59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquemont</LastName><ForeName>Chlo&#xe9;</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0007-7413-6057</Identifier><AffiliationInfo><Affiliation>D&#xe9;partement de M&#xe9;decine G&#xe9;n&#xe9;rale, University of Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuscart</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-0734-8371</Identifier><AffiliationInfo><Affiliation>Univ Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des, Pratiques m&#xe9;dicales, 2 Place de Verdun, Lille, F-59000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calafiore</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4755-5172</Identifier><AffiliationInfo><Affiliation>Univ Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des, Pratiques m&#xe9;dicales, 2 Place de Verdun, Lille, F-59000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>D&#xe9;partement de M&#xe9;decine G&#xe9;n&#xe9;rale, University of Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9546-1808</Identifier><AffiliationInfo><Affiliation>Univ Lille, CHU Lille, ULR 2694 - METRICS: &#xc9;valuation des Technologies de sant&#xe9; et des, Pratiques m&#xe9;dicales, 2 Place de Verdun, Lille, F-59000, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F2RSM Psy - F&#xe9;d&#xe9;ration r&#xe9;gionale de recherche en psychiatrie et sant&#xe9; mentale Hauts-de-France, Saint-Andr&#xe9;-Lez-Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">dashboard</Keyword><Keyword MajorTopicYN="N">data reuse</Keyword><Keyword MajorTopicYN="N">data warehouse</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">patient monitoring</Keyword><Keyword MajorTopicYN="N">patient tracking system</Keyword><Keyword MajorTopicYN="N">primary care</Keyword><Keyword MajorTopicYN="N">primary care data</Keyword><Keyword MajorTopicYN="N">reproducible research</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39140273</ArticleId><ArticleId IdType="pmc">PMC11337138</ArticleId><ArticleId IdType="doi">10.2196/49542</ArticleId><ArticleId IdType="pii">v12i1e49542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schoen C, Osborn R, Squires D, et al. A survey of primary care doctors in ten countries shows progress in use of health information technology, less in other areas. Health Aff (Millwood) 2012 Dec;31(12):2805&#x2013;2816. doi: 10.1377/hlthaff.2012.0884. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2012.0884</ArticleId><ArticleId IdType="pubmed">23154997</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre SM, Lovis C, B&#xfc;rkle T, Tognola G, Budrionis A, Lehmann CU. Clinical data reuse or secondary use: current status and potential future progress. Yearb Med Inform. 2017 Aug;26(1):38&#x2013;52. doi: 10.15265/IY-2017-007. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2017-007</ArticleId><ArticleId IdType="pmc">PMC6239225</ArticleId><ArticleId IdType="pubmed">28480475</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannot AS, Zapletal E, Avillach P, Mamzer MF, Burgun A, Degoulet P. The Georges Pompidou University Hospital clinical data warehouse: a 8-years follow-up experience. Int J Med Inform. 2017 Jun;102:21&#x2013;28. doi: 10.1016/j.ijmedinf.2017.02.006. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2017.02.006</ArticleId><ArticleId IdType="pubmed">28495345</ArticleId></ArticleIdList></Reference><Reference><Citation>Men&#xe9;ndez Torre EL, Ares Blanco J, Conde Barreiro S, Rojo Mart&#xed;nez G, Delgado Alvarez E, en representaci&#xf3;n del Grupo de Epidemiolog&#xed;a de la Sociedad Espa&#xf1;ola de Diabetes (SED) Prevalence of diabetes mellitus in Spain in 2016 according to the Primary Care Clinical Database (BDCAP) Endocrinol Diabetes Nutr (Engl Ed) 2021 Feb;68(2):109&#x2013;115. doi: 10.1016/j.endinu.2019.12.004. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.endinu.2019.12.004</ArticleId><ArticleId IdType="pubmed">32988801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Moussa MD, Marcilly R, Logier R, Vallet B, Tavernier B. Development and usage of an anesthesia data warehouse: lessons learnt from a 10-year project. J Clin Monit Comput. 2023 Apr;37(2):461&#x2013;472. doi: 10.1007/s10877-022-00898-y. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10877-022-00898-y</ArticleId><ArticleId IdType="pmc">PMC10068662</ArticleId><ArticleId IdType="pubmed">35933465</ArticleId></ArticleIdList></Reference><Reference><Citation>Primary care. NHS Digital.  [31-07-2023]. https://digital.nhs.uk/data-and-information/areas-of-interest/primary-care URL. Accessed.</Citation></Reference><Reference><Citation>Institute of Medicine (US) Committee on the Future of Primary Care  . In: Primary Care: America&#x2019;s Health in a New Era. Donaldson MS, Yordy KD, Lohr KN, et al., editors. National Academies Press (US); 1996.  [31-07-2023]. Defining primary care.https://www.ncbi.nlm.nih.gov/books/NBK232631/ URL. Accessed.</Citation><ArticleIdList><ArticleId IdType="pubmed">25121221</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentil ML, Cuggia M, Fiquet L, et al. Factors influencing the development of primary care data collection projects from electronic health records: a systematic review of the literature. BMC Med Inform Decis Mak. 2017 Sep 25;17(1):139. doi: 10.1186/s12911-017-0538-x. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-017-0538-x</ArticleId><ArticleId IdType="pmc">PMC5613384</ArticleId><ArticleId IdType="pubmed">28946908</ArticleId></ArticleIdList></Reference><Reference><Citation>Danciu I, Cowan JD, Basford M, et al. Secondary use of clinical data: the Vanderbilt approach. J Biomed Inform. 2014 Dec;52:28&#x2013;35. doi: 10.1016/j.jbi.2014.02.003. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2014.02.003</ArticleId><ArticleId IdType="pmc">PMC4133331</ArticleId><ArticleId IdType="pubmed">24534443</ArticleId></ArticleIdList></Reference><Reference><Citation>Coorevits P, Sundgren M, Klein GO, et al. Electronic health records: new opportunities for clinical research. J Intern Med. 2013 Dec;274(6):547&#x2013;560. doi: 10.1111/joim.12119. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12119</ArticleId><ArticleId IdType="pubmed">23952476</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller S. Electronic medical records: the way forward for primary care research? Fam Pract. 2014 Apr;31(2):127&#x2013;129. doi: 10.1093/fampra/cmu009. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmu009</ArticleId><ArticleId IdType="pmc">PMC3969524</ArticleId><ArticleId IdType="pubmed">24627543</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey IM, Banchoff E, Nirmalananthan N, et al. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS One. 2021 Dec 31;16(12):e0261983. doi: 10.1371/journal.pone.0261983. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261983</ArticleId><ArticleId IdType="pmc">PMC8719665</ArticleId><ArticleId IdType="pubmed">34972157</ArticleId></ArticleIdList></Reference><Reference><Citation>Boullenger L, Quindroit P, Legrand B, et al. Type 2 diabetics followed up by family physicians: treatment sequences and changes over time in weight and glycated hemoglobin, prim. Prim Care Diabetes. 2022 Oct;16(5):670&#x2013;676. doi: 10.1016/j.pcd.2022.07.002. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2022.07.002</ArticleId><ArticleId IdType="pubmed">35864077</ArticleId></ArticleIdList></Reference><Reference><Citation>Loadsman MEN, Verheij TJM, van der Velden AW. Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. Fam Pract. 2019 Jul 31;36(4):410&#x2013;416. doi: 10.1093/fampra/cmy104. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmy104</ArticleId><ArticleId IdType="pubmed">30346521</ArticleId></ArticleIdList></Reference><Reference><Citation>Marwaha S, Dusendang JR, Alexeeff SE, et al. Comanagement of rashes by primary care providers and dermatologists: a retrospective study. Perm J. 2021 Dec 13;25:20.320. doi: 10.7812/TPP/20.320. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.7812/TPP/20.320</ArticleId><ArticleId IdType="pmc">PMC8784066</ArticleId><ArticleId IdType="pubmed">35348083</ArticleId></ArticleIdList></Reference><Reference><Citation>Milea D, Yeo SH, Nam Y, et al. Long-acting bronchodilator use in chronic obstructive pulmonary disease in primary care in New Zealand: a retrospective study of treatment patterns and evolution using the HealthStat database. Int J Chron Obstruct Pulmon Dis. 2021 Apr 20;16:1075&#x2013;1091. doi: 10.2147/COPD.S290887. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S290887</ArticleId><ArticleId IdType="pmc">PMC8068498</ArticleId><ArticleId IdType="pubmed">33907394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollie A, Sijmons RH, Helsper C, Numans ME. Reusability of coded data in the primary care electronic medical record: a dynamic cohort study concerning cancer diagnoses. Int J Med Inform. 2017 Mar;99:45&#x2013;52. doi: 10.1016/j.ijmedinf.2016.08.004. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2016.08.004</ArticleId><ArticleId IdType="pubmed">28118921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornf&#xe4;lt Isberg H, Hedin K, Melander E, M&#xf6;lstad S, Beckman A. Increased adherence to treatment guidelines in patients with urinary tract infection in primary care: a retrospective study. PLoS One. 2019 Mar 28;14(3):e0214572. doi: 10.1371/journal.pone.0214572. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0214572</ArticleId><ArticleId IdType="pmc">PMC6438509</ArticleId><ArticleId IdType="pubmed">30921411</ArticleId></ArticleIdList></Reference><Reference><Citation>Fruchart M, Quindroit P, Patel H, Beuscart JB, Calafiore M, Lamer A. Implementation of a data warehouse in primary care: first analyses with elderly patients. Stud Health Technol Inform. 2022 May 25;294:505&#x2013;509. doi: 10.3233/SHTI220510. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220510</ArticleId><ArticleId IdType="pubmed">35612131</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Practice Research Datalink (CPRD)  [04-05-2023]. https://www.cprd.com/node/120 URL. Accessed.</Citation></Reference><Reference><Citation>The Health Improvement Network (THIN)  [04-05-2023]. https://www.the-health-improvement-network.com URL. Accessed.</Citation></Reference><Reference><Citation>Corporate Data Warehouse (CDW) US Department of Veterans Affairs.  [04-05-2023]. https://www.hsrd.research.va.gov/for_researchers/cdw.cfm URL. Accessed.</Citation></Reference><Reference><Citation>Canadian Primary Care Sentinel Surveillance Network (CPCSSN)  [04-05-2023]. https://cpcssn.ca/ URL. Accessed.</Citation></Reference><Reference><Citation>Safran C. Reuse of clinical data. Yearb Med Inform. 2014 Aug 15;9(1):52&#x2013;54. doi: 10.15265/IY-2014-0013. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2014-0013</ArticleId><ArticleId IdType="pmc">PMC4287069</ArticleId><ArticleId IdType="pubmed">25123722</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc. 2013 Jan 1;20(1):144&#x2013;151. doi: 10.1136/amiajnl-2011-000681. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000681</ArticleId><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascoe SW, Neal RD, Heywood PL, Allgar VL, Miles JN, Stefoski-Mikeljevic J. Identifying patients with a cancer diagnosis using general practice medical records and cancer registry data. Fam Pract. 2008 Aug;25(4):215&#x2013;220. doi: 10.1093/fampra/cmn023. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmn023</ArticleId><ArticleId IdType="pubmed">18550895</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry AL, Stewart M, Cejic S, et al. A basic model for assessing primary health care electronic medical record data quality. BMC Med Inform Decis Mak. 2019 Feb 12;19(1):30. doi: 10.1186/s12911-019-0740-0. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0740-0</ArticleId><ArticleId IdType="pmc">PMC6373085</ArticleId><ArticleId IdType="pubmed">30755205</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V, Moinat M, Voss EA, et al. Transforming and evaluating the UK Biobank to the OMOP common data model for COVID-19 research and beyond. J Am Med Inform Assoc. 2022 Dec 13;30(1):103&#x2013;111. doi: 10.1093/jamia/ocac203. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac203</ArticleId><ArticleId IdType="pmc">PMC9619789</ArticleId><ArticleId IdType="pubmed">36227072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578. Medline.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI)  [13-02-2023]. https://www.ohdsi.org/ URL. Accessed.</Citation></Reference><Reference><Citation>OMOP CDM v5.4. OHDSI GitHub.  [13-02-2023]. https://ohdsi.github.io/CommonDataModel/cdm54.html URL. Accessed.</Citation></Reference><Reference><Citation>OMOP Standardized Vocabulary V5.0. Observational Health Data Sciences and Informatics (OHDSI)  [13-07-2022]. https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary URL. Accessed.</Citation></Reference><Reference><Citation>Lamer A, Abou-Arab O, Bourgeois A, et al. Transforming anesthesia data into the Observational Medical Outcomes Partnership common data model: development and usability study. J Med Internet Res. 2021 Oct 29;23(10):e29259. doi: 10.2196/29259. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29259</ArticleId><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="pubmed">34714250</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris N, Lamer A, Parrot A. Transformation and evaluation of the MIMIC database in the OMOP common data model: development and usability study. JMIR Med Inform. 2021 Dec 14;9(12):e30970. doi: 10.2196/30970. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30970</ArticleId><ArticleId IdType="pmc">PMC8715361</ArticleId><ArticleId IdType="pubmed">34904958</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl A, Gall W. Feasibility of mapping Austrian health claims data to the OMOP common data model. J Med Syst. 2019 Sep 7;43(10):314. doi: 10.1007/s10916-019-1436-9. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Weda.  [14-09-2023]. https://weda.fr/ URL. Accessed.</Citation></Reference><Reference><Citation>White Rabbit. OHDSI GitHub.  [13-02-2023]. http://ohdsi.github.io/WhiteRabbit/WhiteRabbit.html URL. Accessed.</Citation></Reference><Reference><Citation>Rabbit in a Hat. OHDSI GitHub.  [13-02-2023]. http://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html URL. Accessed.</Citation></Reference><Reference><Citation>Lemaire F. The Jard&#xe9; law: what does change [Article in French] Presse Med. 2019 Mar;48(3 Pt 1):238&#x2013;242. doi: 10.1016/j.lpm.2019.01.006. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2019.01.006</ArticleId><ArticleId IdType="pubmed">30853280</ArticleId></ArticleIdList></Reference><Reference><Citation>Athena. Observational Health Data Sciences and Informatics (OHDSI)  [13-02-2023]. https://athena.ohdsi.org/search-terms/start URL. Accessed.</Citation></Reference><Reference><Citation>Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960 Apr;20(1):37&#x2013;46. doi: 10.1177/001316446002000104. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/001316446002000104</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLAS. Observational Health Data Sciences and Informatics (OHDSI)  [13-02-2023]. https://atlas-demo.ohdsi.org/ URL. Accessed.</Citation></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC) 2016 Sep 11;4(1):1244. doi: 10.13063/2327-9214.1244. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1244</ArticleId><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinydashboard. Rstudio GitHub.  [13-02-2023]. https://rstudio.github.io/shinydashboard/ URL. Accessed.</Citation></Reference><Reference><Citation>Yoo S, Yoon E, Boo D, et al. Transforming thyroid cancer diagnosis and staging information from unstructured reports to the Observational Medical Outcome Partnership Common Data Model. Appl Clin Inform. 2022 May;13(3):521&#x2013;531. Medline.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200482</ArticleId><ArticleId IdType="pubmed">35705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Delanerolle G, Williams R, Stipancic A, et al. Methodological issues in using a common data model of COVID-19 vaccine uptake and important adverse events of interest: feasibility study of data and connectivity COVID-19 vaccines pharmacovigilance in the United Kingdom. JMIR Form Res. 2022 Aug 22;6(8):e37821. doi: 10.2196/37821. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/37821</ArticleId><ArticleId IdType="pmc">PMC9400842</ArticleId><ArticleId IdType="pubmed">35786634</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39143600</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1172</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Orphanet journal of rare diseases</Title><ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation></Journal><ArticleTitle>How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned.</ArticleTitle><Pagination><StartPage>298</StartPage><MedlinePgn>298</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">298</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-024-03312-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given the geographical sparsity of Rare Diseases (RDs), assembling a cohort is often a challenging task. Common data models (CDM) can harmonize disparate sources of data that can be the basis of decision support systems and artificial intelligence-based studies, leading to new insights in the field. This work is sought to support the design of large-scale multi-center studies for rare diseases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In an interdisciplinary group, we derived a list of elements of RDs in three medical domains (endocrinology, gastroenterology, and pneumonology) according to specialist knowledge and clinical guidelines in an iterative process. We then defined a RDs data structure that matched all our data elements and built Extract, Transform, Load (ETL) processes to transfer the structure to a joint CDM. To ensure interoperability of our developed CDM and its subsequent usage for further RDs domains, we ultimately mapped it to Observational Medical Outcomes Partnership (OMOP) CDM. We then included a fourth domain, hematology, as a proof-of-concept and mapped an acute myeloid leukemia (AML) dataset to the developed CDM.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We have developed an OMOP-based rare diseases common data model (RD-CDM) using data elements from the three domains (endocrinology, gastroenterology, and pneumonology) and tested the CDM using data from the hematology domain. The total study cohort included 61,697 patients. After aligning our modules with those of Medical Informatics Initiative (MII) Core Dataset (CDS) modules, we leveraged its ETL process. This facilitated the seamless transfer of demographic information, diagnoses, procedures, laboratory results, and medication modules from our RD-CDM to the OMOP. For the phenotypes and genotypes, we developed a second ETL process. We finally derived lessons learned for customizing our RD-CDM for different RDs.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This work can serve as a blueprint for other domains as its modularized structure could be extended towards novel data types. An interdisciplinary group of stakeholders that are actively supporting the project's progress is necessary to reach a comprehensive CDM.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The customized data structure related to&#xa0;our RD-CDM can be used to perform multi-center studies to test data-driven hypotheses on a larger scale and take advantage of the analytical tools offered by the OHDSI community.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Najia</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9769-5109</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany. najia.ahmadi@tu-dresden.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guengoeze</LastName><ForeName>Oya</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Facchinello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mondorf</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratmann</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musleh</LastName><ForeName>Khader</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erasmus</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchertov</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebler</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaaf</LastName><ForeName>Jannik</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Goethe University Frankfurt, University Hospital, Institute of Medical Informatics, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frischen</LastName><ForeName>Lena S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University Hospital Frankfurt, Goethe University, Executive Department for Medical IT-Systems and Digitalization, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasirian</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center of Medical Informatics, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Jiabin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremblay</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srisuwananukorn</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ohio State Comprehensive Cancer Center, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornh&#xe4;user</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;llig</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Jan-Niklas</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Else-Kroener-Fresenius-Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middeke</LastName><ForeName>Jan Moritz</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Else-Kroener-Fresenius-Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfien</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI) Dresden/Leipzig, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, TUD Dresden University of Technology, Fetscherstra&#xdf;e 74, 01307, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FKZ: ZMI1-2520DAT02C</GrantID><Agency>Bundesministerium f&#xfc;r Gesundheit (BMG)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Orphanet J Rare Dis</MedlineTA><NlmUniqueID>101266602</NlmUniqueID><ISSNLinking>1750-1172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="Y">Rare Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Data standardization</Keyword><Keyword MajorTopicYN="N">Genotypes and phenotypes</Keyword><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">Multi-center studies</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Rare disease</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39143600</ArticleId><ArticleId IdType="pmc">PMC11325822</ArticleId><ArticleId IdType="doi">10.1186/s13023-024-03312-9</ArticleId><ArticleId IdType="pii">10.1186/s13023-024-03312-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Commissioner O of the. FDA. FDA; 2022 [cited 2023 Nov 27]. Rare Diseases at FDA. Available from: https://www.fda.gov/patients/rare-diseases-fda</Citation></Reference><Reference><Citation>Wakap S, Lambert D, Olry A, Rodwell C, Gueydan C, Val&#xe9;rie L, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2019;16:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6974615</ArticleId><ArticleId IdType="pubmed">31527858</ArticleId></ArticleIdList></Reference><Reference><Citation>Aym&#xe9; S, Schmidtke J. Networking for rare diseases: a necessity for Europe. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(12):1477&#x2013;83. 10.1007/s00103-007-0381-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00103-007-0381-9</ArticleId><ArticleId IdType="pubmed">18026888</ArticleId></ArticleIdList></Reference><Reference><Citation>Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J Med Genet. 2019;56(12):783&#x2013;91. 10.1136/jmedgenet-2019-106111</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2019-106111</ArticleId><ArticleId IdType="pmc">PMC6929710</ArticleId><ArticleId IdType="pubmed">31023718</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnosing rare disease in children. Nat Rev Genet. 2018;19(5):253&#x2013;68. 10.1038/nrg.2017.116</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2017.116</ArticleId><ArticleId IdType="pubmed">29398702</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu SY, Weng CY. Introduction to genetic/rare disease and the application of genetic counseling. Hu Li Za Zhi. 2017;64(5):11&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28948586</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoller JK. The challenge of rare diseases. Chest. 2018;153(6):1309&#x2013;14. 10.1016/j.chest.2017.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.12.018</ArticleId><ArticleId IdType="pubmed">29325986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, Miller Needleman KI, et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat Rev Drug Discov. 2020;19(2):93&#x2013;111. 10.1038/s41573-019-0049-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0049-9</ArticleId><ArticleId IdType="pubmed">31836861</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani AA, Haneuse S. Small data challenges of studying rare diseases. JAMA Netw Open. 2020;3(3):e201965. 10.1001/jamanetworkopen.2020.1965. 10.1001/jamanetworkopen.2020.1965</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.1965</ArticleId><ArticleId IdType="pubmed">32202640</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu L, Maroilley T, Tarailo-Graovac M. The Power of Clinical Diagnosis for Deciphering Complex Genetic Mechanisms in Rare Diseases. Genes. 2023;14(1):196. 10.3390/genes14010196</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14010196</ArticleId><ArticleId IdType="pmc">PMC9858967</ArticleId><ArticleId IdType="pubmed">36672937</ArticleId></ArticleIdList></Reference><Reference><Citation>Personalised medicine [Internet]. 2023 [cited 2023 Nov 27]. Available from: https://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en</Citation></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;15(3): 160018.10.1038/sdata.2016.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos VB, Bernab&#xe9; CH, Zhang S, Abaza H, Benis N, C&#xe1;mara A, et al. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries. Orphanet J Rare Dis. 2022;17(1):436. 10.1186/s13023-022-02558-5. 10.1186/s13023-022-02558-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-022-02558-5</ArticleId><ArticleId IdType="pmc">PMC9749345</ArticleId><ArticleId IdType="pubmed">36517834</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman IC, van Rooij IALM, de Blaauw I, Trajanovska M, King SK. A systematic overview of rare disease patient registries: challenges in design, quality management, and maintenance. Orphanet J Rare Dis. 2023;18(1):106. 10.1186/s13023-023-02719-0. 10.1186/s13023-023-02719-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-023-02719-0</ArticleId><ArticleId IdType="pmc">PMC10163740</ArticleId><ArticleId IdType="pubmed">37147718</ArticleId></ArticleIdList></Reference><Reference><Citation>Torab-Miandoab A, Samad-Soltani T, Jodati A, Rezaei-Hachesu P. Interoperability of heterogeneous health information systems: a systematic literature review. BMC Med Inform Decis Mak. 2023;23:18. 10.1186/s12911-023-02115-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-023-02115-5</ArticleId><ArticleId IdType="pmc">PMC9875417</ArticleId><ArticleId IdType="pubmed">36694161</ArticleId></ArticleIdList></Reference><Reference><Citation>A review of interoperability standards in E-health and imperatives for their adoption in Africa. S Afr Comput J. 2013;50. https://sacj.cs.uct.ac.za/index.php/sacj/article/view/176</Citation></Reference><Reference><Citation>Olaronke I, Soriyan A, Gambo I, Olaleke J. Interoperability in healthcare: benefits, challenges and resolutions. Int J Innov Appl Stud. 2013;1(3):2028&#x2013;9324.</Citation></Reference><Reference><Citation>Overview&#x2014;FHIR v5.0.0. [cited 2023 Nov 27]. Available from: https://www.hl7.org/fhir/overview.html</Citation></Reference><Reference><Citation>The Medical Informatics Initiative&#x2019;s core data set | Medical Informatics Initiative [Internet]. [cited 2023 Nov 27]. Available from: https://www.medizininformatik-initiative.de/en/medical-informatics-initiatives-core-data-set</Citation></Reference><Reference><Citation>Kaliyaperumal R, Wilkinson MD, Moreno PA, Benis N, Cornet R, dos SantosVieira B, et al. Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data. J Biomed Semant. 2022;13(1):9. 10.1186/s13326-022-00264-6.10.1186/s13326-022-00264-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-022-00264-6</ArticleId><ArticleId IdType="pmc">PMC8922780</ArticleId><ArticleId IdType="pubmed">35292119</ArticleId></ArticleIdList></Reference><Reference><Citation>European Platform on Rare Disease Registration. [cited 2023 Nov 27]. Available from: https://eu-rd-platform.jrc.ec.europa.eu</Citation></Reference><Reference><Citation>Choquet R, Maaroufi M, de Carrara A, Messiaen C, Luigi E, Landais P. A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research. J Am Med Inf Assoc. 2015;22(1):76&#x2013;85. 10.1136/amiajnl-2014-002794.10.1136/amiajnl-2014-002794</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002794</ArticleId><ArticleId IdType="pmc">PMC4433369</ArticleId><ArticleId IdType="pubmed">25038198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardi FA, Mello de Oliveira B, Bettiol Yamada D, Artifon M, Schmidt AM, Machado Scheibe V, et al. The minimum data set for rare diseases: systematic review. J Med Internet Res. 2023;25:e44641. 10.2196/44641</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/44641</ArticleId><ArticleId IdType="pmc">PMC10415943</ArticleId><ArticleId IdType="pubmed">37498666</ArticleId></ArticleIdList></Reference><Reference><Citation>Abaza H, Kadioglu D, Martin S, Papadopoulou A, Dos Santos VB, Schaefer F, et al. Domain-specific common data elements for rare disease registration: conceptual approach of a european joint initiative toward semantic interoperability in rare disease research. JMIR Med Inform. 2022;10(5): e32158. 10.2196/32158</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/32158</ArticleId><ArticleId IdType="pmc">PMC9166638</ArticleId><ArticleId IdType="pubmed">35594066</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin AP, Corey D, Turner EC, Liwski R, Olson D, Burton J, et al. Standardized data structures in rare diseases: CDISC user guides for duchenne muscular dystrophy and Huntington&#x2019;s disease. Clin Transl Sci. 2021;14(1):214&#x2013;21. 10.1111/cts.12845</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12845</ArticleId><ArticleId IdType="pmc">PMC7877853</ArticleId><ArticleId IdType="pubmed">32702147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HH, Park YR, Lee S, Kim JH. Composite CDE: modeling composite relationships between common data elements for representing complex clinical data. BMC Med Inform Decis Mak. 2020;20(1):147. 10.1186/s12911-020-01168-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01168-0</ArticleId><ArticleId IdType="pmc">PMC7333279</ArticleId><ArticleId IdType="pubmed">32620117</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;09(01):054&#x2013;61. 10.1055/s-0037-1617452.10.1055/s-0037-1617452</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Peng Y, Wolfien M, Zoch M, Sedlmayr M. OMOP CDM can facilitate data-driven studies for cancer prediction: a systematic review. Int J Mol Sci. 2022;23(19):11834. 10.3390/ijms231911834</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911834</ArticleId><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Peng Y, Wolfien M, Zoch M, Sedlmayr M. Cancer prediction on OMOP CDM&#x2014;a rapid review. In German Medical Science GMS Publishing House;2022. p. DocAbstr. 23.</Citation></Reference><Reference><Citation>Ahmadi N, Zoch M, Sedlmayr B, Schuler K, Hahn W, Sedlmayr M, et al. Context-sensitive common data models for genetic rare diseases&#x2014;a concept. In: Healthcare transformation with informatics and artificial intelligence. IOS Press; 2023 [cited 2023 Oct 23]. p. 139&#x2013;40. 10.3233/SHTI230443</Citation><ArticleIdList><ArticleId IdType="pubmed">37386977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagholikar KB, Dessai P, Sanz J, Mendis ME, Bell DS, Murphy SN. Implementation of informatics for integrating biology and the bedside (i2b2) platform as Docker containers. BMC Med Inf Decis Mak. 2018;18(1):66. 10.1186/s12911-018-0646-2.10.1186/s12911-018-0646-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0646-2</ArticleId><ArticleId IdType="pmc">PMC6048900</ArticleId><ArticleId IdType="pubmed">30012140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfien M, Ahmadi N, Fitzer K, Grummt S, Heine KL, Jung IC, et al. Ten topics to get started in medical informatics research. J Med Internet Res. 2023;25(1):e45948. 10.2196/45948</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/45948</ArticleId><ArticleId IdType="pmc">PMC10407648</ArticleId><ArticleId IdType="pubmed">37486754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoch M, Gierschner C, Peng Y, Gruhl M, Leutner LA, Sedlmayr M, et al. Adaption of the OMOP CDM for rare diseases. Stud Health Technol Inform. 2021;27(281):138&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">34042721</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomic Data Harmonization through the OMOP Standardized Vocabularies&#x2014;OHDSI. [cited 2023 Nov 27]. Available from: https://www.ohdsi.org/2020-global-symposium-showcase-13/</Citation></Reference><Reference><Citation>Buy M, Digan W, Chen X, Husson J, M&#xe9;nager M, Rieux-Laucat F, et al. A multi-omics common data model for primary immunodeficiencies. Stud Health Technol Inform. 2022;6(290):56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">35672970</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson PN, K&#xf6;hler S, Bauer S, Seelow D, Horn D, Mundlos S. The human phenotype ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008;83(5):610&#x2013;5. 10.1016/j.ajhg.2008.09.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.09.017</ArticleId><ArticleId IdType="pmc">PMC2668030</ArticleId><ArticleId IdType="pubmed">18950739</ArticleId></ArticleIdList></Reference><Reference><Citation>BfArM&#x2014;ORPHAcodes [Internet]. [cited 2023 Aug 7]. Available from: https://www.bfarm.de/DE/Kodiersysteme/Kooperationen-und-Projekte/Orphanet/Orphanet-International/Orphacodes/_node.html</Citation></Reference><Reference><Citation>Zhang XA, Yates A, Vasilevsky N, Gourdine JP, Callahan TJ, Carmody LC, et al. Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery. Digit Med. 2019;2(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527418</ArticleId><ArticleId IdType="pubmed">31119199</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87: 104413. 10.1016/j.ebiom.2022.104413</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104413</ArticleId><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Zoch M, Kelbert P, Noll R, Schaaf J, Wolfien M, et al. Methods used in the development of common data models for health data: scoping review. JMIR Med Inf. 2023;11(1):e45116.10.2196/45116</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/45116</ArticleId><ArticleId IdType="pmc">PMC10436118</ArticleId><ArticleId IdType="pubmed">37535410</ArticleId></ArticleIdList></Reference><Reference><Citation>SATURN Projekt. [cited 2023 Nov 27]. Available from: https://www.saturn-projekt.de/</Citation></Reference><Reference><Citation>Chen PPS. The entity-relationship model&#x2014;toward a unified view of data. ACM Trans Database Syst. 1976;1(1):9&#x2013;36. 10.1145/320434.320440.10.1145/320434.320440</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/320434.320440</ArticleId></ArticleIdList></Reference><Reference><Citation>fhir-to-omop. Observational Health Data Sciences and Informatics; 2023 [cited 2023 Nov 27]. Available from: https://github.com/OHDSI/ETL-German-FHIR-Core</Citation></Reference><Reference><Citation>Informatics OHDS and Chapter 13 Patient-Level Prediction | The Book of OHDSI [Internet]. [cited 2023 Nov 27]. Available from: https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>HADES. [cited 2023 Aug 4]. Available from: https://ohdsi.github.io/Hades/</Citation></Reference><Reference><Citation>Ahmadi N. NajiaAhmadi/ETL-genotype-phenotype-to-OMOP: extract transform load (ETL) processes to write gene mutation data and phenotype data to OMOP CDM. [cited 2023 Nov 27]. Available from: https://github.com/NajiaAhmadi/ETL-Genotype-Phenotype-to-OMOP</Citation></Reference><Reference><Citation>Hitachi Vantara Lumada and Pentaho Documentation. 2020 [cited 2023 Nov 27]. Pentaho Data Integration. Available from: https://help.hitachivantara.com/Documentation/Pentaho/Data_Integration_and_Analytics/9.1/Products/Pentaho_Data_Integration</Citation></Reference><Reference><Citation>VORBEHALTEN IUAR. Orphanet: Suche /Krankheit. [cited 2023 Nov 27]. Available from: https://www.orpha.net/consor/cgi-bin/Disease_Search_Simple.php?lng=DE</Citation></Reference><Reference><Citation>Athena. [cited 2023 Nov 27]. Available from: https://athena.ohdsi.org/search-terms/start</Citation></Reference><Reference><Citation>BfArM&#x2014;OPS. [cited 2023 Nov 27]. Available from: https://www.bfarm.de/EN/Code-systems/Classifications/OPS-ICHI/OPS/_node.html</Citation></Reference><Reference><Citation>BfArM&#x2014;LOINC. [cited 2023 Nov 27]. Available from: https://www.bfarm.de/EN/Code-systems/Terminologies/LOINC-UCUM/LOINC-and-RELMA/_node.html</Citation></Reference><Reference><Citation>RxNorm Overview. U.S. National Library of Medicine; [cited 2023 Nov 27]. https://www.nlm.nih.gov/research/umls/rxnorm/overview.html</Citation></Reference><Reference><Citation>Anatomical Therapeutic Chemical (ATC) Classification. [cited 2023 Nov 27]. https://www.who.int/tools/atc-ddd-toolkit/atc-classification</Citation></Reference><Reference><Citation>Diagnosis-related group (DRG). [cited 2023 Nov 27]. https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:drg</Citation></Reference><Reference><Citation>Schee Genannt Halfmann S, M&#xe4;hlmann L, Leyens L, Reumann M, Brand A. Personalized medicine: What&#x2019;s in it for rare diseases? Adv Exp Med Biol. 2017;1031:387&#x2013;404. 10.1007/978-3-319-67144-4_22</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-67144-4_22</ArticleId><ArticleId IdType="pubmed">29214584</ArticleId></ArticleIdList></Reference><Reference><Citation>Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, et al. An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe. PHG. 2014;17(5&#x2013;6):287&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">25401385</ArticleId></ArticleIdList></Reference><Reference><Citation>Raycheva R, Kostadinov K, Mitova E, Bogoeva N, Iskrov G, Stefanov G, et al. Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review. Front Public Health. 2023;11:1214766. 10.3389/fpubh.2023.1214766</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1214766</ArticleId><ArticleId IdType="pmc">PMC10540868</ArticleId><ArticleId IdType="pubmed">37780450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequence Variant Nomenclature [Internet]. [cited 2023 Nov 27]. Available from: https://varnomen.hgvs.org/</Citation></Reference><Reference><Citation>D&#xf6;hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345&#x2013;77. 10.1182/blood.2022016867. 10.1182/blood.2022016867</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022016867</ArticleId><ArticleId IdType="pubmed">35797463</ArticleId></ArticleIdList></Reference><Reference><Citation>Asche CV, Seal B, Kahler KH, Oehrlein EM, Baumgartner MG. Evaluation of healthcare interventions and big data: review of associated data issues. Pharmacoeconomics. 2017;35(8):759&#x2013;65. 10.1007/s40273-017-0513-5. 10.1007/s40273-017-0513-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-017-0513-5</ArticleId><ArticleId IdType="pubmed">28474299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, Jonsson P, &#xd8;stby JT, Hughes N, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021;39(3):275&#x2013;85. 10.1007/s40273-020-00981-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckardt JN, Hahn W, R&#xf6;llig C, Stasik S, Platzbecker U, M&#xfc;ller-Tidow C, et al. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. npj Digit Med. 2024;7(1):1&#x2013;11. 10.1038/s41746-024-01076-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-024-01076-x</ArticleId><ArticleId IdType="pmc">PMC10954666</ArticleId><ArticleId IdType="pubmed">38509224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39153282</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research.</ArticleTitle><Pagination><StartPage>105602</StartPage><MedlinePgn>105602</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2024.105602</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(24)00265-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Norwegian health registries covering entire population are used for administration, research, and emergency preparedness. We harmonized these data onto the Observational Medical Outcomes Partnership common data model (OMOP CDM) and enrich real-world data in OMOP format with COVID-19 related data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data from six registries (2018-2021) covering birth registrations, selected primary and secondary care events, vaccinations, and communicable disease notifications were mapped onto the OMOP CDM v5.3. An Extract-Transform-Load (ETL) pipeline was developed on simulated data using data characterization documents and scanning tools. We ran dashboard quality checks, cohort generations, investigated differences between source and mapped data, and refined the ETL accordingly.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We mapped 1.5 billion rows of data of 5,673,845 individuals. Among these, there were 804,277 pregnancies, 483,585 mothers together with 792,477 children, and 472,948 fathers. We identified 382,516 positive tests for COVID-19 in 380,794 patients. These figures are consistent with results from source data. In addition to 11 million source codes mapped automatically, we mapped 237 non-standard codes to standard concepts and introduced 38 custom concepts to accommodate pregnancy-related terminologies that were not supported by OMOP CDM vocabularies. A total of 3,700/3,705 (99.8%) checks passed. The 5 failed checks could be explained by the nature of the data and only represent a small number of records.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="CONCLUSIONS">Norwegian registry data were successfully harmonized onto OMOP CDM with high level of concordance and provides valuable source for federated COVID-19 related research. Our mapping experience is highly valuable for data partners with Nordic health registries.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung Th</ForeName><Initials>NT</Initials><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. Electronic address: nhung.trinh@farmasi.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghtaling</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>EdenceHealth NV, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernal</LastName><ForeName>Fabian Lm</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Division for Research, Dissemination and Education, IT-department, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayati</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maglanoc</LastName><ForeName>Luigi A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division for Research, Dissemination and Education, IT-department, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lupattelli</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halvorsen</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>EdenceHealth NV, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordeng</LastName><ForeName>Hedvig Me</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Health registries</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Phenotyping</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Nhung TH Trinh reports was provided by European Health Data &amp; Evidence Network. Jared Houghtaling reports financial support was provided by European Health Data &amp; Evidence Network. Jared Houghtaling reports a relationship with EdenceHealth that includes: employment. Fabian Bernal reports was provided by European Health Data &amp; Evidence Network. Saeed Hayati reports was provided by European Health Data &amp; Evidence Network. Luigi Maglanoc reports was provided by European Health Data &amp; Evidence Network. Angela Lupattelli reports was provided by European Health Data &amp; Evidence Network. Lars Halvorsen reports financial support was provided by European Health Data &amp; Evidence Network. Lars Halvorsen reports a relationship with EdenceHealth that includes: employment. Hedvig ME Nordeng reports financial support was provided by European Health Data &amp; Evidence Network].</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>17</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39153282</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2024.105602</ArticleId><ArticleId IdType="pii">S1386-5056(24)00265-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39153995</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021.</ArticleTitle><Pagination><StartPage>19069</StartPage><MedlinePgn>19069</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">19069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-69006-1</ELocationID><Abstract><AbstractText>Breast cancer is the most frequently diagnosed cancer in females globally. However, we know relatively little about trends in males. This study describes United Kingdom (UK) secular trends in breast cancer from 2000 to 2021 for both sexes. We describe a population-based cohort study using UK primary care Clinical Practice Research Datalink (CPRD) GOLD and Aurum databases. There were 5,848,436 eligible females and 5,539,681 males aged 18+&#x2009;years, with&#x2009;&#x2265;&#x2009;one year of prior data availability in the study period. We estimated&#xa0;crude breast cancer incidence rates (IR), prevalence and survival probability at one-, five- and 10-years after diagnosis using the Kaplan-Meier method. Analyses were further stratified by age. Crude&#xa0;IR of breast cancer from 2000 to 2021 was 194.4 per 100,000 person-years for females and 1.16 for males. Crude&#xa0;prevalence in 2021 was 2.1% for females and 0.009% for males. Both sexes have seen around a 2.5-fold increase in prevalence across time. Incidence increased with age for both sexes, peaking in females aged 60-69&#xa0;years and males 90+&#x2009;. There was a drop in incidence for females aged 70-79&#xa0;years. From 2003-2019, incidence increased&#x2009;&gt;&#x2009;twofold in younger females (aged 18-29: IR 2.12 in 2003 vs. 4.58 in 2018); decreased in females aged 50-69&#xa0;years; and further declined from 2015 onwards in females aged 70-89&#xa0;years. Survival probability for females after one-, five-, and ten-years after diagnosis was 95.1%, 80.2%, and 68.4%, and for males 92.9%, 69.0%, and 51.3%. Survival probability at one-year increased by 2.08% points, and survival at five years increased by 5.39% from 2000-2004 to 2015-2019 for females, particularly those aged 50-70&#xa0;years. For males, there were no clear time-trends for short-term and long-term survival probability. Changes in incidence of breast cancer in females largely reflect the success of screening programmes, as rates rise and fall in synchronicity with ages of eligibility for such programmes. Overall survival from breast cancer for females has improved from 2000 to 2021, again reflecting the success of screening programmes, early diagnosis, and improvements in treatments. Male breast cancer patients have worse survival outcomes compared to females, highlighting the need to develop male-specific diagnosis and treatment strategies to improve long-term survival in line with females.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barclay</LastName><ForeName>Nicola L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a La Recerca a L'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol I Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Service, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at the Roux Institute, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Wai Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tietzova</LastName><ForeName>Ilona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>First Department of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University, Katerinska 1660/32, 121 08, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OPTIMA Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newby</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>806968</GrantID><Agency>Innovative Medicines Initiative 2 (IMI2) Joint Undertaking</Agency><Country/></Grant><Grant><GrantID>806968</GrantID><Agency>Innovative Medicines Initiative 2 (IMI2) Joint Undertaking</Agency><Country/></Grant><Grant><GrantID>806968</GrantID><Agency>Innovative Medicines Initiative 2 (IMI2) Joint Undertaking</Agency><Country/></Grant><Grant><GrantID>101034347</GrantID><Agency>OPTIMA</Agency><Country/></Grant><Grant><GrantID>101034347</GrantID><Agency>OPTIMA</Agency><Country/></Grant><Grant><GrantID>101034347</GrantID><Agency>OPTIMA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018567" MajorTopicYN="N">Breast Neoplasms, Male</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Professor Daniel Prieto-Alhambra&#x2019;s research group has received research grants from the European Medicines Agency from the Innovative Medicines Initiative from Amgen Chiesi and from UCB Biopharma; and consultancy or speaker fees (paid to his department) from Astellas Amgen Astra Zeneca and UCB Biopharma. NLB is Director of Sleep Universal Limited (though this work is in no way connected to the present manuscript). All other authors declare no conflicts of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>N'Dow</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witjes</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Emma Jane</ForeName><Initials>EJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bezuidenhout</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plass</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blum</LastName><ForeName>Torsten Gerriet</ForeName><Initials>TG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borkowetz</LastName><ForeName>Angelika</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willemse</LastName><ForeName>Peter-Paul</ForeName><Initials>PP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornford</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dabestani</LastName><ForeName>Saeed</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlief</LastName><ForeName>Maurice</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>Juan G&#xf3;mez</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bjartell</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roobol</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beyer</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venderbos</LastName><ForeName>Lionne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remmers</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieboer</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boomsma</LastName><ForeName>Raoul</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Meulder</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auffray</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taibi</LastName><ForeName>Nesrine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hijazy</LastName><ForeName>Ayman</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saporta</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pellet</LastName><ForeName>Johann</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Omar</LastName><ForeName>Imran</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacLennan</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacLennan</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Speirs</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zibaite</LastName><ForeName>Solveiga</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyle</LastName><ForeName>Moragh</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Dianne</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>Demi</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metspalu</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vilo</LastName><ForeName>Jaak</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Sulev</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>S&#xfc;gis</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oja</LastName><ForeName>Marek</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Objartel</LastName><ForeName>Telver</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Briganti</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandaglia</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faticoni</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matteuzzi</LastName><ForeName>Greta</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chelala</LastName><ForeName>Claude</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abdollahyan</LastName><ForeName>Maryam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gadaleta</LastName><ForeName>Emanuela</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juckeland</LastName><ForeName>Guido</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bussmann</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kotik</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yakimovich</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kollmeier</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werchan</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blum</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graebig-Rancourt</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sj&#xf6;blom</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larsson</LastName><ForeName>Chatarina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nordmark</LastName><ForeName>Arvid Widenlou</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mafi</LastName><ForeName>Mahkameh</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newby</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tan</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forg&#xf3;</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Napieralski</LastName><ForeName>Antoni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wimmer</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haimbuchner</LastName><ForeName>Katharina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaltenbrunner</LastName><ForeName>Saskia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartl</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guliaeva</LastName><ForeName>Kseniia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curigliano</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Criscitiello</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morganti</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corti</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zotto</LastName><ForeName>Elena Dal</ForeName><Initials>ED</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harbeck</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koch</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Navani</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janes</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhamani</LastName><ForeName>Amyn</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lejeune</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campone</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frenel</LastName><ForeName>Jean-Sebastien</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joubel</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bocquet</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berneur</LastName><ForeName>Camille</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laloue</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutot</LastName><ForeName>Malvina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacob</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macle</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thauvin</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seguin</LastName><ForeName>Fanny</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Manach</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lambin</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ankolekar</LastName><ForeName>Anshu</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaccaro</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonia</LastName><ForeName>Thomy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genton</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Geffen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tietzova</LastName><ForeName>Ilona</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frille</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fallet</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costantini</LastName><ForeName>Adrien</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wesselmann</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sibert</LastName><ForeName>Nora Tabea</ForeName><Initials>NT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griesshammer</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>Pippa</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dorp</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honing</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>T&#xe9;llez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrido</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gal&#xe1;n</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villoria</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez</LastName><ForeName>Inmaculada Perea</ForeName><Initials>IP</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Arenosa Barbeito</LastName><ForeName>Paloma L&#xf3;pez</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrull</LastName><ForeName>Enric Bouso&#xf1;o</ForeName><Initials>EB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gim&#xe9;nez</LastName><ForeName>Laura Tur</ForeName><Initials>LT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Soralys</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuente</LastName><ForeName>Pablo Gonzalez</ForeName><Initials>PG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Juan Miguel Au&#xf1;&#xf3;n</ForeName><Initials>JMA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Jos&#xe9; Carlos Barrios</ForeName><Initials>JCB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galban</LastName><ForeName>Alvaro Morandeira</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kremer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quaranta</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>La Ferla</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marc</LastName><ForeName>Loic</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christian</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pina</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auweter</LastName><ForeName>Sigrid</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reichwald</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonsen-Thomas</LastName><ForeName>Corinna Zur</ForeName><Initials>CZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tschetsch</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinto</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesuffleur</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blotti&#xe8;re</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duflot</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vallas</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaud&#xe9;</LastName><ForeName>Pierre-Olivier</ForeName><Initials>PO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumier</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cremonini</LastName><ForeName>Daniele</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torremante</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fromm</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Scharfenberg</LastName><ForeName>Verena</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenits</LastName><ForeName>Karin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Nuno</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartig</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kantz</LastName><ForeName>Waltraud</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kube</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arondekar</LastName><ForeName>Bhakti</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gori</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kr&#xfc;ger</LastName><ForeName>Hagen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ilinares</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilner</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serfass</LastName><ForeName>Lucile</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McRoy</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Sofia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papanastasiou</LastName><ForeName>Georgios</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godbold</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cahill</LastName><ForeName>Edwina</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langhammer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boie</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reis</LastName><ForeName>Florian</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Axelsson</LastName><ForeName>Susan Evans</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butler-Ransohoff</LastName><ForeName>John-Edward</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>Imke</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saatci</LastName><ForeName>Selmin Ulusu</ForeName><Initials>SU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurki</LastName><ForeName>Samu</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostojic</LastName><ForeName>Helene</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majdi</LastName><ForeName>Abdelali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villalba</LastName><ForeName>Santiago</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jasti</LastName><ForeName>Sai</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolny</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rousset</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleuren</LastName><ForeName>Ivo</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylvan</LastName><ForeName>Sandra Eketorp</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paintin</LastName><ForeName>Ellie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pokrzepa</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pourbaix</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorber</LastName><ForeName>Carolin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mouta</LastName><ForeName>Joao</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Meyenn</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shivhare</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metcalfe</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andre</LastName><ForeName>Camille</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baeumen</LastName><ForeName>Tobias Schulte In den</ForeName><Initials>TSID</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannon</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hochberg</LastName><ForeName>Alan Mark</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sukumaran</LastName><ForeName>Kartick</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katta</LastName><ForeName>Nareen</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Yilin</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ossyra</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dellamonica</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moses</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yiduo</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufour</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campos</LastName><ForeName>Maria Teresa</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naqvi</LastName><ForeName>Hassan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceder</LastName><ForeName>Jens</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alekseeva</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mueller</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flosdorf</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koch</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goette</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedstr&#xf6;m</LastName><ForeName>Gustaf</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edqvist</LastName><ForeName>Per-Henrik</ForeName><Initials>PH</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>17</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39153995</ArticleId><ArticleId IdType="pmc">PMC11330450</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-69006-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-69006-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.71, 209&#x2013;249 (2021).10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano, S. H. Breast cancer in men. N. Engl. J. Med.378, 2311&#x2013;2320 (2018). 10.1056/NEJMra1707939</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1707939</ArticleId><ArticleId IdType="pubmed">29897847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Research UK. Breast cancer incidence (invasive) statistics, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence-invasive#heading-Zero (2021).</Citation></Reference><Reference><Citation>Speirs, V. &amp; Shaaban, A. M. The rising incidence of male breast cancer. Breast Cancer Res. Treat.115, 429&#x2013;430 (2009). 10.1007/s10549-008-0053-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-008-0053-y</ArticleId><ArticleId IdType="pubmed">18478326</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G. &amp; Hortobagyi, G. N. Breast carcinoma in men: a population-based study. Cancer101, 51&#x2013;57 (2004). 10.1002/cncr.20312</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.20312</ArticleId><ArticleId IdType="pubmed">15221988</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton, L. A. et al. Prospective evaluation of risk factors for male breast cancer. J. Natl. Cancer Inst.100, 1477&#x2013;1481 (2008). 10.1093/jnci/djn329</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djn329</ArticleId><ArticleId IdType="pmc">PMC2720728</ArticleId><ArticleId IdType="pubmed">18840816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding, Y. C., Steele, L., Kuan, C.-J., Greilac, S. &amp; Neuhausen, S. L. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res. Treat.126, 771&#x2013;778 (2011). 10.1007/s10549-010-1195-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-010-1195-2</ArticleId><ArticleId IdType="pmc">PMC3059396</ArticleId><ArticleId IdType="pubmed">20927582</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton, L. A. et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J. Clin. Oncol.33, 2041 (2015). 10.1200/JCO.2014.59.1602</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.59.1602</ArticleId><ArticleId IdType="pmc">PMC4461805</ArticleId><ArticleId IdType="pubmed">25964249</ArticleId></ArticleIdList></Reference><Reference><Citation>Macke, A. J. &amp; Petrosyan, A. Alcohol and prostate cancer: Time to draw conclusions. Biomolecules12, 375 (2022). 10.3390/biom12030375</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12030375</ArticleId><ArticleId IdType="pmc">PMC8945566</ArticleId><ArticleId IdType="pubmed">35327568</ArticleId></ArticleIdList></Reference><Reference><Citation>Shield, K. D., Soerjomataram, I. &amp; Rehm, J. Alcohol use and breast cancer: a critical review. Alcohol. Clin. Exp. Res.40, 1166&#x2013;1181 (2016). 10.1111/acer.13071</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acer.13071</ArticleId><ArticleId IdType="pubmed">27130687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pati, S., Irfan, W., Jameel, A., Ahmed, S. &amp; Shahid, R. K. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers15, 485 (2023). 10.3390/cancers15020485</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15020485</ArticleId><ArticleId IdType="pmc">PMC9857053</ArticleId><ArticleId IdType="pubmed">36672434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ron, E., Ikeda, T., Preston, D. L. &amp; Tokuoka, S. Male breast cancer incidence among atomic bomb survivors. J. Natl. Cancer Inst.97, 603&#x2013;605 (2005). 10.1093/jnci/dji097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dji097</ArticleId><ArticleId IdType="pubmed">15840883</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, C. et al. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993&#x2013;2015: Population based observational cohort study. BMJ381, 1 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10261971</ArticleId><ArticleId IdType="pubmed">37311588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzato, M. et al. Trends in male breast cancer mortality: A global overview. Eur. J. Cancer30, 472&#x2013;479 (2021).10.1097/CEJ.0000000000000651</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CEJ.0000000000000651</ArticleId><ArticleId IdType="pubmed">33470692</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggemann, H. et al. Survival benefit of tamoxifen in male breast cancer: Prospective cohort analysis. Br. J. Cancer123, 33&#x2013;37 (2020). 10.1038/s41416-020-0857-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-020-0857-z</ArticleId><ArticleId IdType="pmc">PMC7341811</ArticleId><ArticleId IdType="pubmed">32367072</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfati, D., Blakely, T. &amp; Pearce, N. Measuring cancer survival in populations: Relative survival vs cancer-specific survival. Int. J. Epidemiol.39, 598&#x2013;610 (2010). 10.1093/ije/dyp392</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyp392</ArticleId><ArticleId IdType="pubmed">20142331</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow, A. Cancer registration in England and Wales: Some aspects relevant to interpretation of the data. J. R. Stat. Soc.149, 146&#x2013;160 (1986).</Citation></Reference><Reference><Citation>Cancer Research UK. Breast Screening, https://www.cancerresearchuk.org/about-cancer/breast-cancer/getting-diagnosed/screening-breast#:~:text=Who%20has%20breast%20screening%3F,are%2052%20or%2053%20years. (2023).</Citation></Reference><Reference><Citation>Woolcott, O. O. &amp; Seuring, T. Temporal trends in obesity defined by the relative fat mass (RFM) index among adults in the United States from 1999 to 2020: A population-based study. BMJ open13, e071295 (2023). 10.1136/bmjopen-2022-071295</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-071295</ArticleId><ArticleId IdType="pmc">PMC10441088</ArticleId><ArticleId IdType="pubmed">37591649</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik, V. S., Willet, W. C. &amp; Hu, F. B. Nearly a decade on&#x2014;Trends, risk factors and policy implications in global obesity. Nature Reviews Endocrinology16, 615&#x2013;616 (2020). 10.1038/s41574-020-00411-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-020-00411-y</ArticleId><ArticleId IdType="pmc">PMC7461756</ArticleId><ArticleId IdType="pubmed">32873971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett, R., Blanks, R. &amp; Moss, S. Evaluation of extension of breast screening to women aged 65&#x2013;70 in England using screening performance measures. Br. J. Cancer100, 1043&#x2013;1047 (2009). 10.1038/sj.bjc.6604981</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6604981</ArticleId><ArticleId IdType="pmc">PMC2669999</ArticleId><ArticleId IdType="pubmed">19277039</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckert-Lind, C. et al. Worldwide secular trends in age at pubertal onset assessed by breast development among girls: A systematic review and meta-analysis. JAMA Pediat.174, e195881&#x2013;e195881 (2020).10.1001/jamapediatrics.2019.5881</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2019.5881</ArticleId><ArticleId IdType="pmc">PMC7042934</ArticleId><ArticleId IdType="pubmed">32040143</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, D. H., Jones, M. E., Schoemaker, M. J., Ashworth, A. &amp; Swerdlow, A. J. Secular trends in age at menarche in women in the UK born 1908&#x2013;93: Results from the Breakthrough Generations Study. Paediatr. Perinat. Epidemiol.25, 394&#x2013;400 (2011). 10.1111/j.1365-3016.2011.01202.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3016.2011.01202.x</ArticleId><ArticleId IdType="pubmed">21649682</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick, D., Pirie, K., Reeves, G., Green, J. &amp; Beral, V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case&#x2013;control study and meta-analysis. Plos Medicine20, e1004188 (2023). 10.1371/journal.pmed.1004188</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004188</ArticleId><ArticleId IdType="pmc">PMC10030023</ArticleId><ArticleId IdType="pubmed">36943819</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. Public Health England launches nationwide breast cancer campaign, https://www.gov.uk/government/news/public-health-england-launches-nationwide-breast-cancer-campaign#:~:text=The%20Be%20Clear%20on%20Cancer%20campaign%20is%20part%20of%20the,us%20to%20improve%20cancer%20survival. (2015).</Citation></Reference><Reference><Citation>Arnold, M. et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995&#x2013;2014 (ICBP SURVMARK-2): A population-based study. Lancet Oncol20, 1493&#x2013;1505 (2019). 10.1016/S1470-2045(19)30456-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30456-5</ArticleId><ArticleId IdType="pmc">PMC6838671</ArticleId><ArticleId IdType="pubmed">31521509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Research UK. Cancer mortality statistics, https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality#heading-Zero (2023).</Citation></Reference><Reference><Citation>Benz, C. C. Impact of aging on the biology of breast cancer. Crit. Rev. Oncol./Hematol.66, 65&#x2013;74 (2008). 10.1016/j.critrevonc.2007.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2007.09.001</ArticleId><ArticleId IdType="pmc">PMC2626623</ArticleId><ArticleId IdType="pubmed">17949989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, N., Johnson, K. J. &amp; Ma, C. X. Male breast cancer: An updated surveillance, epidemiology, and end results data analysis. Clin. Breast Cancer18, e997&#x2013;e1002 (2018). 10.1016/j.clbc.2018.06.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2018.06.013</ArticleId><ArticleId IdType="pubmed">30007834</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao, H. et al. Incidence and outcome of male breast cancer: an international population-based study. J. Clin. Oncol.29, 4381&#x2013;4386 (2011). 10.1200/JCO.2011.36.8902</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2011.36.8902</ArticleId><ArticleId IdType="pubmed">21969512</ArticleId></ArticleIdList></Reference><Reference><Citation>Korde, L. A. et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J. Clin. Oncol.28, 2114 (2010). 10.1200/JCO.2009.25.5729</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2009.25.5729</ArticleId><ArticleId IdType="pmc">PMC2860409</ArticleId><ArticleId IdType="pubmed">20308661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Research UK. Breast cancer survival statistics, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Zero (2014).</Citation></Reference><Reference><Citation>NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">33406487</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay, N. L. et al. The impact of the COVID-19 pandemic on incidence and short-term survival for common solid tumours in the United Kingdom: A cohort analysis. Clin. Epidemiol.1, 417&#x2013;429 (2024).10.2147/CLEP.S463160</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S463160</ArticleId><ArticleId IdType="pmc">PMC11179647</ArticleId><ArticleId IdType="pubmed">38882578</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay, N. L. et al. Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: A cohort study. Ther. Adv. Med. Oncol.16, 17588359241253116 (2024). 10.1177/17588359241253115</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17588359241253115</ArticleId><ArticleId IdType="pmc">PMC11146008</ArticleId><ArticleId IdType="pubmed">38832300</ArticleId></ArticleIdList></Reference><Reference><Citation>Barclay, N. L. et al. The impact of the UK COVID-19 lockdown on the screening, diagnostics and incidence of breast, colorectal, lung and prostate cancer in the UK: A population-based cohort study. Front. Oncol.14, 1370862 (2024). 10.3389/fonc.2024.1370862</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2024.1370862</ArticleId><ArticleId IdType="pmc">PMC11004443</ArticleId><ArticleId IdType="pubmed">38601756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher, A. M., Dedman, D., Padmanabhan, S., Leufkens, H. G. &amp; de Vries, F. The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations. Pharmacoepidemiol. Drug Saf.28, 563&#x2013;569 (2019). 10.1002/pds.4747</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4747</ArticleId><ArticleId IdType="pmc">PMC6593793</ArticleId><ArticleId IdType="pubmed">30908785</ArticleId></ArticleIdList></Reference><Reference><Citation>Strongman, H., Williams, R. &amp; Bhaskaran, K. What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? A concordance and validation study using linked English electronic health records data. BMJ Open10, e037719 (2020). 10.1136/bmjopen-2020-037719</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037719</ArticleId><ArticleId IdType="pmc">PMC7443310</ArticleId><ArticleId IdType="pubmed">32819994</ArticleId></ArticleIdList></Reference><Reference><Citation>Huszno, J., Ko&#x142;osza, Z. &amp; Grzybowska, E. BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival. Oncol. Lett.17, 1986&#x2013;1995 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341769</ArticleId><ArticleId IdType="pubmed">30675265</ArticleId></ArticleIdList></Reference><Reference><Citation>Denu, R. A. et al. Racial and socioeconomic disparities are more pronounced in inflammatory breast cancer than other breast cancers. J. Cancer Epidemiol.2017, 1 (2017).10.1155/2017/7574946</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7574946</ArticleId><ArticleId IdType="pmc">PMC5574219</ArticleId><ArticleId IdType="pubmed">28894467</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheri, M., Tavakol, M., Akbari, M. E., Almasi-Hashiani, A. &amp; Abbasi, M. Relationship of socio economic status, income, and education with the survival rate of breast cancer: a meta-analysis. Iran. J. Public Health48, 1428 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145923</ArticleId><ArticleId IdType="pubmed">32292725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, J.-Y. &amp; Qin, L.-Q. Education level and breast cancer incidence: a meta-analysis of cohort studies. Menopause27, 113&#x2013;118 (2020). 10.1097/GME.0000000000001425</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GME.0000000000001425</ArticleId><ArticleId IdType="pubmed">31479033</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett, E. et al. Data resource profile: clinical practice research datalink (CPRD). Int. J. Epidemiol.44, 827&#x2013;836 (2015). 10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf, A. et al. Data resource profile: Clinical practice research datalink (CPRD) aurum. Int. J. Epidemiol.48, 1740&#x2013;1740g (2019). 10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, E. A. et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc.22, 553&#x2013;564 (2015). 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. et al. Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform.216, 574&#x2013;578 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert, J., Rao, G., Schuemie, M., Ryan, P. &amp; Weaver, J. CohortDiagnostics: Diagnostics for OHDSI Cohorts, https://ohdsi.github.io/CohortDiagnostics, https://github.com/OHDSI/CohortDiagnostics (2023).</Citation></Reference><Reference><Citation>National Cancer Institute. Joinpoint Regression Program, Version 5.0.2. Statistical Methodology and Applications Branch, Surveillance Research Program (2023).</Citation></Reference><Reference><Citation>Goel, M. K., Khanna, P. &amp; Kishore, J. Understanding survival analysis: Kaplan-Meier estimate. Int. J. Ayurveda Res.1, 274 (2010). 10.4103/0974-7788.76794</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0974-7788.76794</ArticleId><ArticleId IdType="pmc">PMC3059453</ArticleId><ArticleId IdType="pubmed">21455458</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn, E., Raventos, B., Catala, M., Du, M., Guo, Y., Black, A&gt;, Inberg, G., Lopez, K. IncidencePrevalence: Estimate Incidence and Prevalence using the OMOP Common Data Model. R Package Verion 0.4.0, https://cran.r-project.org/web/packages/IncidencePrevalence/index.html (2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39174009</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Coverage of Physical Therapy Assessments in the Observational Medical Outcomes Partnership Common Data Model.</ArticleTitle><Pagination><StartPage>1003</StartPage><EndPage>1012</EndPage><MedlinePgn>1003-1012</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-2401-3688</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">&#x2003;High-value care aims to enhance meaningful patient outcomes while reducing costs and is accelerated by curating data across health care systems through common data models (CDMs), such as Observational Medical Outcomes Partnership (OMOP). Meaningful patient outcomes, such as physical function, must be included in these CDMs. However, the extent to which physical therapy assessments are covered in the OMOP CDM is unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to examine the extent to which physical therapy assessments used in neurologic and orthopaedic conditions are in the OMOP CDM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;After identifying assessments, two reviewer teams independently mapped the neurologic and orthopaedic assessments into the OMOP CDM. Agreement within the reviewer team was assessed by the number of assessments mapped by both reviewers, one reviewer but not the other, or neither reviewer. The reviewer teams then reconciled disagreements, after which agreement and the average number of concept ID numbers per assessment were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;Of the 81 neurologic assessments, 48.1% (39/81) were initially mapped by both reviewers, 9.9% (8/81) were mapped by one reviewer but not the other, and 42% (34/81) were unmapped. After reconciliation, 46.9% (38/81) were mapped by both reviewers and 53.1% (43/81) were unmapped. Of the 79 orthopaedic assessments, 46.8% (37/79) were initially mapped by both reviewers, 12.7% (10/79) were mapped by one reviewer but not the other, and 48.1% (38/79) were unmapped. After reconciliation, 48.1% (38/79) were mapped by both reviewers and 51.9% (41/79) were unmapped. Most assessments that were mapped had more than one concept ID number (2.2&#x2009;&#xb1;&#x2009;1.3 and 4.3&#x2009;&#xb1;&#x2009;4.4 concept IDs per neurologic and orthopaedic assessment, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;The OMOP CDM includes some physical therapy assessments recommended for use in neurologic and orthopaedic conditions but many have multiple concept IDs. Including more functional assessments in the OMOP CDM and creating guidelines for mapping would improve our ability to include functional data in large datasets.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>French</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Leah</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magel</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thackeray</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy and Athletic Training, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026741" MajorTopicYN="Y">Physical Therapy Modalities</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39174009</ArticleId><ArticleId IdType="pmc">PMC11602249</ArticleId><ArticleId IdType="doi">10.1055/a-2401-3688</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Papanicolas I, Woskie L R, Jha A K. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536101</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunja M Z, Gumas E D, Williams R D. 2023. II.</Citation><ArticleIdList><ArticleId IdType="doi">10.26099/8ejy-yc74</ArticleId></ArticleIdList></Reference><Reference><Citation>Jewell D V, Moore J D, Goldstein M S. Delivering the physical therapy value proposition: a call to action. Phys Ther. 2013;93(01):104&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">23001526</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter M E. What is value in health care? N Engl J Med. 2010;363(26):2477&#x2013;2481.</Citation><ArticleIdList><ArticleId IdType="pubmed">21142528</ArticleId></ArticleIdList></Reference><Reference><Citation>Teisberg E, Wallace S, O'Hara S. Defining and implementing value-based health care: a strategic framework. Acad Med. 2020;95(05):682&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185050</ArticleId><ArticleId IdType="pubmed">31833857</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumhauer J F, Bozic K J. Value-based healthcare: patient-reported outcomes in clinical decision making. Clin Orthop Relat Res. 2016;474(06):1375&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868147</ArticleId><ArticleId IdType="pubmed">27052020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S, Yoon E, Boo D et al.Transforming thyroid cancer diagnosis and staging information from unstructured reports to the Observational Medical Outcome Partnership Common Data Model. Appl Clin Inform. 2022;13(03):521&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200482</ArticleId><ArticleId IdType="pubmed">35705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks J, Pardee R. Learning to share health care data: a brief timeline of influential common data models and distributed health data networks in U.S. Health Care Research. EGEMS (Wash DC) 2019;7(01):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437693</ArticleId><ArticleId IdType="pubmed">30937326</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E A, Makadia R, Matcho A et al.Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(03):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus M N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D et al.Common problems, common data model solutions: evidence generation for health technology assessment. PharmacoEconomics. 2021;39(03):275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.The Book of OHDSIAccessed February 23, 2024 at:https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>Klann J G, Joss M AH, Embree K, Murphy S N. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS ONE. 2019;14(02):e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D et al.Content coverage evaluation of the OMOP vocabulary on the transplant domain focusing on concepts relevant for kidney transplant outcomes analysis. Appl Clin Inform. 2020;11(04):650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="pubmed">33027834</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan S MK, Jeon Y S, Dang T K et al.Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM Dataset. Appl Clin Inform. 2021;12(04):757&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C, Sedlmayr M, Bathelt F. The usage of OHDSI OMOP - a scoping review. Stud Health Technol Inform. 2021;283:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M et al.Transforming French electronic health records into the Observational Medical Outcome Partnership's Common Data Model: a feasibility study. Appl Clin Inform. 2020;11(01):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H et al.Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C X, Halfpenny W, Boland M V et al.Advancing toward a common data model in ophthalmology: gap analysis of general eye examination concepts to Standard Observational Medical Outcomes Partnership (OMOP) concepts. Ophthalmol Sci. 2023;3(04):100391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10630664</ArticleId><ArticleId IdType="pubmed">38025162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Abou-Arab O, Bourgeois A et al.Transforming anesthesia data into the Observational Medical Outcomes Partnership Common Data Model: development and usability study. J Med Internet Res. 2021;23(10):e29259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="pubmed">34714250</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieleman J L, Cao J, Chapin A et al.US Health Care Spending by Payer and Health Condition, 1996-2016. JAMA. 2020;323(09):863&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054840</ArticleId><ArticleId IdType="pubmed">32125402</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group . Feigin V L, Forouzanfar M H, Krishnamurthi R et al.Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181600</ArticleId><ArticleId IdType="pubmed">24449944</ArticleId></ArticleIdList></Reference><Reference><Citation>French M A, Hartman P, Hayes H Aet al.Examination of the coverage of functional assessments in the OMOP common data model medRxiv 2024; 2024.2005.2003.24306841. Doi:10.1101/2024.05.03.24306841</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.05.03.24306841</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter K, Cohen E T, Allen D D et al.Outcome measures for individuals with multiple sclerosis: recommendations from the American Physical Therapy Association Neurology Section Task Force. Phys Ther. 2014;94(05):593&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">24363338</ArticleId></ArticleIdList></Reference><Reference><Citation>Academy of Neurologic Physical Therapy; Parkinson Evidence Database to Guide Effectiveness 2018. Accessed May 1, 2024 at:https://www.neuropt.org/practice-resources/neurology-section-outcome-measures-recommendations/parkinson-disease</Citation></Reference><Reference><Citation>Kahn J H, Tappan R, Newman C P et al.Outcome measure recommendations from the Spinal Cord Injury EDGE Task Force. Phys Ther. 2016;96(11):1832&#x2013;1842.</Citation><ArticleIdList><ArticleId IdType="pubmed">27231273</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan J E, Crowner B E, Kluding P M et al.Outcome measures for individuals with stroke: process and recommendations from the American Physical Therapy Association neurology section task force. Phys Ther. 2013;93(10):1383&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">23704035</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch K L, de Joya A L, Hays K et al.Outcome measures for persons with moderate to severe traumatic brain injury: recommendations from the American Physical Therapy Association Academy of Neurologic Physical Therapy TBI EDGE Task Force. J Neurol Phys Ther. 2016;40(04):269&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">27576089</ArticleId></ArticleIdList></Reference><Reference><Citation>Academy of Neurologic Physical Therapy; Vestibular EDGE 2018. Accessed May 1, 2024 at:https://www.neuropt.org/practice-resources/neurology-section-outcome-measures-recommendations/vestibular-disorders</Citation></Reference><Reference><Citation>Martin R L, Chimenti R, Cuddeford T et al.Achilles pain, stiffness, and muscle power deficits: Midportion Achilles Tendinopathy Revision 2018. J Orthop Sports Phys Ther. 2018;48(05):A1&#x2013;A38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29712543</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R L, Davenport T E, Fraser J J et al.Ankle stability and movement coordination impairments: Lateral Ankle Ligament Sprains Revision 2021. J Orthop Sports Phys Ther. 2021;51(04):CPG1&#x2013;CPG80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33789434</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson M, Lawrence M, Jansen C WS, Coker D, Amadio P, Cleary C. Hand pain and sensory deficits: Carpal Tunnel Syndrome. J Orthop Sports Phys Ther. 2019;49(05):CPG1&#x2013;CPG85.</Citation><ArticleIdList><ArticleId IdType="pubmed">31039690</ArticleId></ArticleIdList></Reference><Reference><Citation>Koc T A, Jr, Bise C G, Neville C, Carreira D, Martin R L, McDonough C M. Heel pain - plantar fasciitis: Revision 2023. J Orthop Sports Phys Ther. 2023;53(12):CPG1&#x2013;CPG39.</Citation><ArticleIdList><ArticleId IdType="pubmed">38037331</ArticleId></ArticleIdList></Reference><Reference><Citation>Arundale A JH, Bizzini M, Dix C et al.Exercise-based knee and anterior cruciate ligament injury prevention. J Orthop Sports Phys Ther. 2023;53(01):CPG1&#x2013;CPG34.</Citation><ArticleIdList><ArticleId IdType="pubmed">36587265</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopaedic Section of the American Physical Therapist Association . Logerstedt D S, Snyder-Mackler L, Ritter R C, Axe M J, Godges J J. Knee stability and movement coordination impairments: knee ligament sprain. J Orthop Sports Phys Ther. 2010;40(04):A1&#x2013;A37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158982</ArticleId><ArticleId IdType="pubmed">20357420</ArticleId></ArticleIdList></Reference><Reference><Citation>Logerstedt D S, Scalzitti D A, Bennell K L et al.Knee pain and mobility impairments: Meniscal and Articular Cartilage Lesions Revision 2018. J Orthop Sports Phys Ther. 2018;48(02):A1&#x2013;A50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29385940</ArticleId></ArticleIdList></Reference><Reference><Citation>Willy R W, Hoglund L T, Barton C J et al.Patellofemoral pain. J Orthop Sports Phys Ther. 2019;49(09):CPG1&#x2013;CPG95.</Citation><ArticleIdList><ArticleId IdType="pubmed">31475628</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin R L, Cibulka M T, Bolgla L A et al.Hamstring strain injury in athletes. J Orthop Sports Phys Ther. 2022;52(03):CPG1&#x2013;CPG44.</Citation><ArticleIdList><ArticleId IdType="pubmed">35164536</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonough C M, Harris-Hayes M, Kristensen M T et al.Physical therapy management of older adults with hip fracture. J Orthop Sports Phys Ther. 2021;51(02):CPG1&#x2013;CPG81.</Citation><ArticleIdList><ArticleId IdType="pubmed">33522384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cibulka M T, Bloom N J, Enseki K R, Macdonald C W, Woehrle J, McDonough C M. Hip pain and mobility deficits-hip osteoarthritis: Revision 2017. J Orthop Sports Phys Ther. 2017;47(06):A1&#x2013;A37.</Citation><ArticleIdList><ArticleId IdType="pubmed">28566053</ArticleId></ArticleIdList></Reference><Reference><Citation>Enseki K R, Bloom N J, Harris-Hayes M et al.Hip pain and movement dysfunction associated with nonarthritic hip joint pain: a revision. J Orthop Sports Phys Ther. 2023;53(07):CPG1&#x2013;CPG70.</Citation><ArticleIdList><ArticleId IdType="pubmed">37383013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucado A M, Day J M, Vincent J I et al.Lateral elbow pain and muscle function impairments. J Orthop Sports Phys Ther. 2022;52(12):CPG1&#x2013;CPG111.</Citation><ArticleIdList><ArticleId IdType="pubmed">36453071</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopaedic Section of the American Physical Therapy Association . Delitto A, George S Z, Van Dillen L et al.Low back pain. J Orthop Sports Phys Ther. 2012;42(04):A1&#x2013;A57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893951</ArticleId><ArticleId IdType="pubmed">22466247</ArticleId></ArticleIdList></Reference><Reference><Citation>George S Z, Fritz J M, Silfies S P et al.Interventions for the management of acute and chronic low back pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1&#x2013;CPG60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10508241</ArticleId><ArticleId IdType="pubmed">34719942</ArticleId></ArticleIdList></Reference><Reference><Citation>Quatman-Yates C C, Hunter-Giordano A, Shimamura K K et al.Physical therapy evaluation and treatment after concussion/mild traumatic brain injury. J Orthop Sports Phys Ther. 2020;50(04):CPG1&#x2013;CPG73.</Citation><ArticleIdList><ArticleId IdType="pubmed">32241234</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanpied P R, Gross A R, Elliott J M et al.Neck pain: Revision 2017. J Orthop Sports Phys Ther. 2017;47(07):A1&#x2013;A83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28666405</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley D, Payne L P, Galper J et al.Clinical guidance to optimize work participation after injury or illness: the role of physical therapists. J Orthop Sports Phys Ther. 2021;51(08):CPG1&#x2013;CPG102.</Citation><ArticleIdList><ArticleId IdType="pubmed">34338006</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton S, Newell A, Downey P et al.Pelvic girdle pain in the antepartum population: Physical Therapy Clinical Practice Guidelines Linked to the International Classification of Functioning, Disability, and Health From the Section on Women's Health and the Orthopaedic Section of the American Physical Therapy Association. J Womens Health Phys Therap. 2017;41:102&#x2013;125.</Citation></Reference><Reference><Citation>Kelley M J, Shaffer M A, Kuhn J E et al.Shoulder pain and mobility deficits: adhesive capsulitis. J Orthop Sports Phys Ther. 2013;43(05):A1&#x2013;A31.</Citation><ArticleIdList><ArticleId IdType="pubmed">23636125</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI Usagi.USAGIAccessed February 23, 2024 at:https://ohdsi.github.io/Usagi/</Citation></Reference><Reference><Citation>R Core Team . R Foundation for Statistical Computing; Vienna, Austria: 2022. A language and environment for statistical computing.</Citation></Reference><Reference><Citation>McHugh M L. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22(03):276&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900052</ArticleId><ArticleId IdType="pubmed">23092060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettori J R, Norvell D C. Kappa and beyond: is there agreement? Global Spine J. 2020;10(04):499&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222679</ArticleId><ArticleId IdType="pubmed">32435572</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwet K L.Computing inter-rater reliability and its variance in the presence of high agreement Br J Math Stat Psychol 200861(Pt 1):29&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18482474</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti D V, Feinstein A R. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990;43(06):551&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">2189948</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinstein A R, Cicchetti D V. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990;43(06):543&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">2348207</ArticleId></ArticleIdList></Reference><Reference><Citation>Viera A J, Garrett J M. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(05):360&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Lin K C, Liing R J, Wu C Y, Chen C L, Chang K C. Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation. Qual Life Res. 2016;25(06):1585&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">26714699</ArticleId></ArticleIdList></Reference><Reference><Citation>van Agt H M, Essink-Bot M L, Krabbe P F, Bonsel G J. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc Sci Med. 1994;39(11):1537&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pubmed">7817218</ArticleId></ArticleIdList></Reference><Reference><Citation>Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993;2(03):169&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz S, Lusardi M. White paper: &#x201c;walking speed: the sixth vital sign&#x201d;. J Geriatr Phys Ther. 2009;32(02):46&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">20039582</ArticleId></ArticleIdList></Reference><Reference><Citation>Foreman K B, Addison O, Kim H S, Dibble L E. Testing balance and fall risk in persons with Parkinson disease, an argument for ecologically valid testing. Parkinsonism Relat Disord. 2011;17(03):166&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042054</ArticleId><ArticleId IdType="pubmed">21215674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J H, Hsu M J, Hsu H W, Wu H C, Hsieh C L. Psychometric comparisons of 3 functional ambulation measures for patients with stroke. Stroke. 2010;41(09):2021&#x2013;2025.</Citation><ArticleIdList><ArticleId IdType="pubmed">20671244</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti G F, Lin C C, Alghadir A, Whitney S L. Responsiveness and minimal detectable change of the dynamic gait index and functional gait index in persons with balance and vestibular disorders. J Neurol Phys Ther. 2014;38(02):119&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">24637931</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J L, Potter K, Blankshain K, Kaplan S L, O&#x2bc;Dwyer L C, Sullivan J E. A core set of outcome measures for adults with neurologic conditions undergoing rehabilitation: a clinical practice guideline. J Neurol Phys Ther. 2018;42(03):174&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023606</ArticleId><ArticleId IdType="pubmed">29901487</ArticleId></ArticleIdList></Reference><Reference><Citation>Beninato M, Fernandes A, Plummer L S. Minimal clinically important difference of the functional gait assessment in older adults. Phys Ther. 2014;94(11):1594&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">24947198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrisley D M, Kumar N A. Functional gait assessment: concurrent, discriminative, and predictive validity in community-dwelling older adults. Phys Ther. 2010;90(05):761&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20360052</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonds A H, Abraham K, Spitznagle T. Clinical practice guidelines for pelvic girdle pain in the postpartum population. J Womens Pelvic Health Phys Ther. 2022;46:E1&#x2013;E38.</Citation></Reference><Reference><Citation>Baez S E, Hoch M C, Hoch J M. Psychological factors are associated with return to pre-injury levels of sport and physical activity after ACL reconstruction. Knee Surg Sports Traumatol Arthrosc. 2020;28(02):495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">31486916</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess R, Mansell G, Bishop A, Lewis M, Hill J. Predictors of functional outcome in musculoskeletal healthcare: an umbrella review. Eur J Pain. 2020;24(01):51&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31509625</ArticleId></ArticleIdList></Reference><Reference><Citation>Philofsky M, Olakpe U.Implementing and adopting a customized OMOP Common Data ModelPaper presented at: OHDSI Global Symposium. Virtual;2021</Citation></Reference><Reference><Citation>Zhuk O, Klebanov G, Reich Cet al.Source vocabulary mapping, typical pitfalls, solutions and quality assurance. OHDSI SymposiumVirtual;2020</Citation></Reference><Reference><Citation>GitHub . OHDSI Vocabulary-v5.0. 2024.</Citation></Reference><Reference><Citation>OHDSI . OHDSI Forums</Citation></Reference><Reference><Citation>Choi S, Joo H J, Kim Y, Kim J H, Seok J. Conversion of automated 12-lead electrocardiogram interpretations to OMOP CDM vocabulary. Appl Clin Inform. 2022;13(04):880&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9492322</ArticleId><ArticleId IdType="pubmed">36130711</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176482</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Synthetic Data Generation in Hematology - Paving the Way for OMOP and FHIR Integration.</ArticleTitle><Pagination><StartPage>1472</StartPage><EndPage>1476</EndPage><MedlinePgn>1472-1476</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240692</ELocationID><Abstract><AbstractText>This study advances the utility of synthetic study data in hematology, particularly for Acute Myeloid Leukemia (AML), by facilitating its integration into healthcare systems and research platforms through standardization into the Observational Medical Outcomes Partnership (OMOP) and Fast Healthcare Interoperability Resources (FHIR) formats. In our previous work, we addressed the need for high-quality patient data and used CTAB-GAN+ and Normalizing Flow (NFlow) to synthesize data from 1606 patients across four multicenter AML clinical trials. We published the generated synthetic cohorts, that accurately replicate the distributions of key demographic, laboratory, molecular, and cytogenetic variables, alongside patient outcomes, demonstrating high fidelity and usability. The conversion to the OMOP format opens avenues for comparative observational multi-center research by enabling seamless combination with related OMOP datasets, thereby broadening the scope of AML research. Similarly, standardization into FHIR facilitates further developments of applications, e.g. via the SMART-on-FHIR platform, offering realistic test data. This effort aims to foster a more collaborative research environment and facilitate the development of innovative tools and applications in AML care and research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Waldemar</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Scalable Data Analytics and Artificial Intelligence, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadi</LastName><ForeName>Najia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eckardt</LastName><ForeName>Jan-Niklas</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universit&#xe4;t, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Else Kr&#xf6;ner Fresenius Center for Digital Health, Technische Universit&#xe4;t Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfien</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Scalable Data Analytics and Artificial Intelligence, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015470" MajorTopicYN="Y">Leukemia, Myeloid, Acute</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006405" MajorTopicYN="N">Hematology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AML</Keyword><Keyword MajorTopicYN="N">Data Sharing</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Hematology</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Synthetic patient data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176482</ArticleId><ArticleId IdType="doi">10.3233/SHTI240692</ArticleId><ArticleId IdType="pii">SHTI240692</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176503</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Towards Efficient Resource Utilization Forecasting in Acute Heat Events Using OMOP.</ArticleTitle><Pagination><StartPage>1555</StartPage><EndPage>1559</EndPage><MedlinePgn>1555-1559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240715</ELocationID><Abstract><AbstractText>Predicting resource utilization can help to optimize the distribution of limited resources in the healthcare system. This requires different climatic and medical data from different sources, which can lead to problems with interoperability. In the paper we describe which data is needed for the prediction and how the data can be made interoperable using OMOP CDM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thiel</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesterow</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidner</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="Y">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">heat events</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">resource utilization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176503</ArticleId><ArticleId IdType="doi">10.3233/SHTI240715</ArticleId><ArticleId IdType="pii">SHTI240715</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176511</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>How to Accurately Detect Renal Replacement Therapy Weaning in Intensive Care: Data Quality and Standardization Considerations for the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1584</StartPage><EndPage>1588</EndPage><MedlinePgn>1584-1588</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240724</ELocationID><Abstract><AbstractText>This study assesses the effectiveness of the Observational Medical Outcomes Partnership common data model (OMOP CDM) in standardising Continuous Renal Replacement Therapy (CRRT) data from intensive care units (ICU) of two French university hospitals. Our objective was to extract and standardise data from various sources, enabling the development of predictive models for CRRT weaning that are agnostic to the data's origin. Data for 1,696 ICU stays from the two data sources were extracted, transformed, and loaded into the OMOP format after semantic alignment of 46 CRRT standard concepts. Although the OMOP CDM demonstrated potential in harmonising CRRT data, we encountered challenges related to data variability and the lack of standard concepts. Despite these challenges, our study supports the promise of the OMOP CDM for ICU data standardization, suggesting that further refinement and adaptation could significantly improve clinical decision making and patient outcomes in critical care settings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Popoff</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Rouen, Department of Anaesthesiology and Critical Care, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delange</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallout</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHU Rouen, Department of Anaesthesiology and Critical Care, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuggia</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clavier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CHU Rouen, Department of Anaesthesiology and Critical Care, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzille</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079664" MajorTopicYN="N">Continuous Renal Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="N">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017582" MajorTopicYN="N">Renal Replacement Therapy</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data standardisation</Keyword><Keyword MajorTopicYN="N">intensive care unit</Keyword><Keyword MajorTopicYN="N">renal replacement therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176511</ArticleId><ArticleId IdType="doi">10.3233/SHTI240724</ArticleId><ArticleId IdType="pii">SHTI240724</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176517</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Intensive Care Quality Indicators Dashboard Using Observational Medical Outcomes Partnership Common Data Model.</ArticleTitle><Pagination><StartPage>1605</StartPage><EndPage>1606</EndPage><MedlinePgn>1605-1606</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240730</ELocationID><Abstract><AbstractText>This paper presents the development of a visualization dashboard for quality indicators in intensive care units (ICUs), using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The dashboard enables the user to visualize quality indicator data using histograms, pie charts and tables. Our project uses the OMOP CDM, ensuring a seamless implementation of our dashboard across various hospitals. Future directions for our research include expanding the dashboard to incorporate additional quality indicators and evaluating clinicians' feedback on its effectiveness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delange</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Maladies Infectieuses et R&#xe9;animation M&#xe9;dicale, H&#xf4;pital Pontchaillou, Universit&#xe9; de Rennes, 2, rue Henri Le Guilloux, 35033 Rennes cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzille</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popoff</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierre-Jean</LastName><ForeName>Morgane</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maamar</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de Maladies Infectieuses et R&#xe9;animation M&#xe9;dicale, H&#xf4;pital Pontchaillou, Universit&#xe9; de Rennes, 2, rue Henri Le Guilloux, 35033 Rennes cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuggia</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Rennes, INSERM, LTSI-UMR 1099, Univ Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019984" MajorTopicYN="Y">Quality Indicators, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019985" MajorTopicYN="N">Benchmarking</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">dashboard</Keyword><Keyword MajorTopicYN="N">data visualization</Keyword><Keyword MajorTopicYN="N">quality indicators</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176517</ArticleId><ArticleId IdType="doi">10.3233/SHTI240730</ArticleId><ArticleId IdType="pii">SHTI240730</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176535</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>A Chatbot-Like Platform to Enhance the Discovery of OMOP CDM Databases.</ArticleTitle><Pagination><StartPage>1689</StartPage><EndPage>1693</EndPage><MedlinePgn>1689-1693</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240748</ELocationID><Abstract><AbstractText>Multicentre studies become possible with the current strategies to solve the interoperability problems between databases. With the great adoption of those strategies, new problems regarding data discovery were raised. Some were solved using database catalogues and graphical dashboards for data analysis and comparison. However, when these communities grow, these strategies become obsolete. In this work, we addressed those challenges by proposing a platform with a chatbot-like mechanism to help medical researchers identify databases of interest. The tool was developed using the metadata extracted from OMOP CDM databases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Jo&#xe3;o A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>DETI/IEETA, LASI, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Jo&#xe3;o R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>DETI/IEETA, LASI, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Tiago M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>DETI/IEETA, LASI, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>DETI/IEETA, LASI, University of Aveiro, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071253" MajorTopicYN="N">Metadata</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHDEN Portal</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">biomedical data discovery</Keyword><Keyword MajorTopicYN="N">data sharing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176535</ArticleId><ArticleId IdType="doi">10.3233/SHTI240748</ArticleId><ArticleId IdType="pii">SHTI240748</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176618</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Synergies Among Health Data Projects with Cancer Use Cases Based on Health Standards.</ArticleTitle><Pagination><StartPage>1292</StartPage><EndPage>1296</EndPage><MedlinePgn>1292-1296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240649</ELocationID><Abstract><AbstractText>We are creating a synergy among European Health Data Space projects (e.g., IDERHA, EUCAIM, ASCAPE, iHELP, Bigpicture, and HealthData@EU pilot project) via health standards usage thanks to the HSBOOSTER EU Project since they are involved or using standards, and/or designing health ontologies. We compare health-standardized models/ontologies/terminologies such as HL7 FHIR, DICOM, OMOP, ISO TC 215 Health Informatics, W3C DCAT, etc. used in those projects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyrard</LastName><ForeName>Amelie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Trialog, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gribbon</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fraunhofer, ITMP, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abedian</LastName><ForeName>Somayeh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonmati</LastName><ForeName>Luis Marti</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>La Fe University Hospital Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabornero</LastName><ForeName>Gibi Luisa</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>La Fe University Hospital Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manias</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Piraeus Research Centre (UPRC), Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danciu</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Siemens, Brasov, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalmiani</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Monasterio Research Hospital (FTGM), Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Autexier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DFKI, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Nuland</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Lygature, Utrecht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jendrossek</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Data Hub, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avramidis</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Ubitech, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Eva Garcia</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>BBMRI ERIC, Graz, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Health Data Space</Keyword><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">Standards</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176618</ArticleId><ArticleId IdType="doi">10.3233/SHTI240649</ArticleId><ArticleId IdType="pii">SHTI240649</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176625</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Real-World Data in Greece: Mapping the Papageorgiou General Hospital Data to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1324</StartPage><EndPage>1325</EndPage><MedlinePgn>1324-1325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240656</ELocationID><Abstract><AbstractText>This paper showcases the results of the Extract-Transform-Load process mapping the Electronic Health Record of Papageorgiou General Hospital in Thessaloniki, Greece, to the Observational Medical Outcomes Partnership Common Data Model. We describe the staged process utilized to account for the intricate structure of the database, along with some general findings from the mapping. Finally, we investigate potential directions for future research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papapostolou</LastName><ForeName>Grigoris</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Research and Technology-Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chytas</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Research and Technology-Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rekkas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Research and Technology-Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigaki</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Papageorgiou General Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeimpekis</LastName><ForeName>Demetrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Papageorgiou General Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dermentzoglou</LastName><ForeName>Lampros</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Papageorgiou General Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortopidis</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Papageorgiou General Hospital, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natsiavas</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Research and Technology-Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006769" MajorTopicYN="Y">Hospitals, General</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">mapping</Keyword><Keyword MajorTopicYN="N">observational data</Keyword><Keyword MajorTopicYN="N">real world data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176625</ArticleId><ArticleId IdType="doi">10.3233/SHTI240656</ArticleId><ArticleId IdType="pii">SHTI240656</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176639</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>From Syntactic to Semantic Interoperability Using a Hyperontology in the Oncology Domain.</ArticleTitle><Pagination><StartPage>1385</StartPage><EndPage>1389</EndPage><MedlinePgn>1385-1389</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240670</ELocationID><Abstract><AbstractText>Interoperability is crucial to overcoming various challenges of data integration in the healthcare domain. While OMOP and FHIR data standards handle syntactic heterogeneity among heterogeneous data sources, ontologies support semantic interoperability to overcome the complexity and disparity of healthcare data. This study proposes an ontological approach in the context of the EUCAIM project to support semantic interoperability among distributed big data repositories that have applied heterogeneous cancer image data models using a semantically well-founded Hyperontology for the oncology domain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El Ghosh</LastName><ForeName>Mirna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalokyri</LastName><ForeName>Varvara</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, Foundation of Research and Technology Hellas, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sambres</LastName><ForeName>M&#xe9;lanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaterkowski</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duclos</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris-Nord, Inserm, Sorbonne Universit&#xe9;, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tannier</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsakou</LastName><ForeName>Gianna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MAGGIOLI S.P.A., Research and Development Lab, Marousi, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsiknakis</LastName><ForeName>Manolis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, Foundation of Research and Technology Hellas, Heraklion, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhombres</LastName><ForeName>Ferdinand</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Inserm, Universit&#xe9; Sorbonne Paris-Nord, LIMICS, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, GRC26 &amp; Fetal Medicine Center, A. Trousseau Hospital, Paris, 75012, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="Y">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="N">Biological Ontologies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077558" MajorTopicYN="N">Big Data</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer image data</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Heterogeneous data models</Keyword><Keyword MajorTopicYN="N">Hyperontology</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Semantic interoperability</Keyword><Keyword MajorTopicYN="N">Syntactic interoperability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176639</ArticleId><ArticleId IdType="doi">10.3233/SHTI240670</ArticleId><ArticleId IdType="pii">SHTI240670</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176643</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Mapping OMOP-CDM to RDF: Bringing Real-World-Data to the Semantic Web Realm.</ArticleTitle><Pagination><StartPage>1406</StartPage><EndPage>1410</EndPage><MedlinePgn>1406-1410</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240674</ELocationID><Abstract><AbstractText>Real-world data (RWD) (i.e., data from Electronic Healthcare Records - EHRs, ePrescription systems, patient registries, etc.) gain increasing attention as they could support observational studies on a large scale. OHDSI is one of the most prominent initiatives regarding the harmonization of RWD and the development of relevant tools via the use of a common data model, OMOP-CDM. OMOP-CDM is a crucial step towards syntactic and semantic data interoperability. Still, OMOP-CDM is based on a typical relational database format, and thus, the vision of a fully connected semantically enriched model is not fully realized. This work presents an open-source effort to map the OMOP-CDM model and the data it hosts, to an ontological model using RDF to support the FAIRness of RWD and their interlinking with Linked Open Data (LOD) towards the vision of the Semantic Web.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chytas</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Informatics, Aristotle University of Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassileiades</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Informatics, Aristotle University of Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natsiavas</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075403" MajorTopicYN="Y">Semantic Web</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Knowledge Graphs</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">Real-World Data</Keyword><Keyword MajorTopicYN="N">Semantic Web</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176643</ArticleId><ArticleId IdType="doi">10.3233/SHTI240674</ArticleId><ArticleId IdType="pii">SHTI240674</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176649</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Enhancing Healthcare Informatics: Integrating Category Theory Reasoning into OMOP-CDM Ontology Model.</ArticleTitle><Pagination><StartPage>1427</StartPage><EndPage>1431</EndPage><MedlinePgn>1427-1431</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240680</ELocationID><Abstract><AbstractText>The task of managing diverse electronic health records requires the consolidation of data from different sources to facilitate clinical research and decision-making support, with the emergence of the Observational Medical Outcomes Partnership - Common Data Model (OMOP-CDM) as a standard relational database schema for structuring health records from different sources. Working with ontologies is strongly associated with reasoners. Implementing them over expansive and intricate Ontologies can pose computational challenges, potentially resulting in slow performance. In this paper, we propose the implementation of a new reasoner based on categorical logic over a translation of OMOP-CDM into an ontology model. This enables enhancements to the efficiency and scalability of implementing such models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albarran</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris Nord, LIMICS, Sorbonne Universit&#xe9;, INSERM, UMR 1142, F-93000, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamy</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Sorbonne Paris Nord, LIMICS, Sorbonne Universit&#xe9;, INSERM, UMR 1142, F-93000, Bobigny, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="N">Biological Ontologies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">Ontologies</Keyword><Keyword MajorTopicYN="N">Reasoning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176649</ArticleId><ArticleId IdType="doi">10.3233/SHTI240680</ArticleId><ArticleId IdType="pii">SHTI240680</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176650</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>OntoBridge Versus Traditional ETL: Enhancing Data Standardization into CDM Formats Using Ontologies Within the DATOS-CAT Project.</ArticleTitle><Pagination><StartPage>1432</StartPage><EndPage>1436</EndPage><MedlinePgn>1432-1436</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240681</ELocationID><Abstract><AbstractText>Common Data Models (CDMs) enhance data exchange and integration across diverse sources, preserving semantics and context. Transforming local data into CDMs is typically cumbersome and resource-intensive, with limited reusability. This article compares OntoBridge, an ontology-based tool designed to streamline the conversion of local datasets into CDMs, with traditional ETL methods in adopting the OMOP CDM. We examine flexibility and scalability in the management of new data sources, CDM updates, and the adoption of new CDMs. OntoBridge showed greater flexibility in integrating new data sources and adapting to CDM updates. It was also more scalable, facilitating the adoption of various CDMs like i2b2, unlike traditional methods reliant on OMOP-specific tools developed by OHDSI. In summary, while traditional ETL provides a structured approach to data integration, OntoBridge offers a more flexible, scalable, and maintenance-efficient alternative.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bracons Cuc&#xf3;</LastName><ForeName>Guillem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Informatics Service, Hospital Cl&#xed;nic de Barcelona. 08036 - Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, 08028 - Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil Rojas</LastName><ForeName>Jessyca</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Informatics Service, Hospital Cl&#xed;nic de Barcelona. 08036 - Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;afiel Macias</LastName><ForeName>Petter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; de Recerca Cl&#xed;nic Barcelona-Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer (FRCB-IDIBAPS), 08036 - Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrat Frigola</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Informatics Service, Hospital Cl&#xed;nic de Barcelona. 08036 - Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lymperidou</LastName><ForeName>Aikaterini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, 08028 - Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomes for Life-GCAT lab-Germans Trias i Pujol Research Institute, 08916, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Gonz&#xe1;lez</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, 08028 - Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Supercomputing Center (BSC), 08034, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labarga</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona Supercomputing Center (BSC), 08034, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frid</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Informatics Service, Hospital Cl&#xed;nic de Barcelona. 08036 - Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="Y">Biological Ontologies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Ontologies</Keyword><Keyword MajorTopicYN="N">common data models</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176650</ArticleId><ArticleId IdType="doi">10.3233/SHTI240681</ArticleId><ArticleId IdType="pii">SHTI240681</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176696</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>OMOP-on-FHIR: A FHIR Server Development to Facilitate Data Interaction with the OMOP-CDM and FHIR for PGHD.</ArticleTitle><Pagination><StartPage>157</StartPage><EndPage>158</EndPage><MedlinePgn>157-158</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240367</ELocationID><Abstract><AbstractText>This paper introduces the concept of the implementation of a FHIR server for bidirectional data exchange with the OMOP-CDM. Leveraging FHIR as a metamodel, the implementation aims to promote a more interconnected and patient-centric healthcare ecosystem. The methodology involves utilizing the Java HAPI FHIR API for server architecture and validating the solution through patient data exchange with a FHIR reference implementation server. This initiative signifies a significant advancement in healthcare data interoperability, promising improved patient care quality and clinical research vigor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jathissa</LastName><ForeName>Prabath</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohatsch</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Applied Sciences Technikum Wien, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauermann</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Applied Sciences Technikum Wien, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">FHIR-API</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">OMOP-on-FHIR.HAPI-FHIR Server</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176696</ArticleId><ArticleId IdType="doi">10.3233/SHTI240367</ArticleId><ArticleId IdType="pii">SHTI240367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39176707</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>DATOS-CAT: OMOP-Common Data Model for the Standardization, Integration and Analysis of Population-Based Biomedical Data in Catalonia.</ArticleTitle><Pagination><StartPage>200</StartPage><EndPage>201</EndPage><MedlinePgn>200-201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240378</ELocationID><Abstract><AbstractText>Transforming the population based biomedical cohort into the Common Data Model (OMOP-CDM) empowers researchers to access direct sources of information, enabling a deeper understanding of how genetic profiles relate to clinical outcomes and providing new knowledge that can significantly influence health care practices around the world.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lymperidou</LastName><ForeName>Aikaterini</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomes for Life-GCAT-Germans Trias i Pujol Research Institute, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Gonzalez</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona Supercomputing Center, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracons Cuc&#xf3;</LastName><ForeName>Guillem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Bioengineering of Catalonia, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Clinic de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frid</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital Clinic de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Cid</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genomes for Life-GCAT-Germans Trias i Pujol Research Institute, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labarga</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Barcelona Supercomputing Center, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DATOS-CAT</Keyword><Keyword MajorTopicYN="N">FAIR principles</Keyword><Keyword MajorTopicYN="N">GCAT</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176707</ArticleId><ArticleId IdType="doi">10.3233/SHTI240378</ArticleId><ArticleId IdType="pii">SHTI240378</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176716</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Improving Healthcare Quality with a LHS: From Patient-Generated Health Data to Evidence-Based Recommendations.</ArticleTitle><Pagination><StartPage>230</StartPage><EndPage>234</EndPage><MedlinePgn>230-234</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240387</ELocationID><Abstract><AbstractText>One approach to enriching the Learning Health System (LHS) is leveraging vital signs and data from wearable technologies. Blood oxygen, heart rate, respiration rates, and other data collected by wearables (like sleep and exercise patterns) can be used to monitor and predict health conditions. This data is already being collected and could be used to improve healthcare in several ways. Our approach will be health data interoperability with HL7 FHIR (for data exchange between different systems), openEHR (to store researchable data separated from software but connected to ontologies, external terminologies and code sets) and maintain the semantics of data. OpenEHR is a standard that has an important role in modelling processes and clinical decisions. The six pillars of Lifestyle Medicine can be a first attempt to change how patients see their daily decisions, affecting the mid to long-term evolution of their health. Our objective is to develop the first stage of the LHS based on a co-produced personal health recording (CoPHR) built on top of a local LLM that interoperates health data through HL7 FHIR, openEHR, OHDSI and terminologies that can ingest external evidence and produces clinical and personal decision support and, when combined with many other patients, can produce or confirm evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Ricardo L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>PhD student Health Data Science, Faculdade de Medicina da Universidade do Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Correia</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Associate Professor, Faculdade de Medicina da Universidade do Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080891" MajorTopicYN="Y">Learning Health System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076206" MajorTopicYN="N">Patient Generated Health Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076251" MajorTopicYN="N">Wearable Electronic Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="N">Health Information Interoperability</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HL7 FHIR</Keyword><Keyword MajorTopicYN="N">Health data interoperability</Keyword><Keyword MajorTopicYN="N">Learning Health System</Keyword><Keyword MajorTopicYN="N">clinical decision</Keyword><Keyword MajorTopicYN="N">openEHR</Keyword><Keyword MajorTopicYN="N">patient-generated health data</Keyword><Keyword MajorTopicYN="N">personal health recording</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176716</ArticleId><ArticleId IdType="doi">10.3233/SHTI240387</ArticleId><ArticleId IdType="pii">SHTI240387</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176723</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Dementia and Alzheimer's Disease Prevalence in Bulgaria During 2018: Nationally Representative Study.</ArticleTitle><Pagination><StartPage>262</StartPage><EndPage>266</EndPage><MedlinePgn>262-266</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240394</ELocationID><Abstract><AbstractText>This paper presents data analysis of a large dataset of outpatient records for the purpose of establishing accurate prevalence rates of dementia and Alzheimer's disease in Bulgaria. The research is motivated by the lack of accurate prevalence data as well as statistics about the actual number of people affected by dementia at national level. Health data from pseudonymized outpatient records (1,378,355) of 642,013 unique patients (Male 39.88%, Female 61.67%) with visits to neurologists and psychiatrists in 2018 was mapped to an OMOP CDM relational database. The size of this dataset is one of largest in the EU context. Prevalence of dementia for all age groups [30,100+] years is 1.61% (Male 0.62%, Female 0.99%) and Alzheimer' disease prevalence is 0.39% (Male 0.15%, Female 0.24%), where 24.34% of all the patients with dementia suffer Alzheimer's disease. The mean prevalence rates of dementia and Alzheimer's disease for ages above 64 are 9.52% (CI 95%, [6.98%, 12.04%]) and 1.04 % (CI 95%, [0.84%, 1.27%,]). A comparison with EU statistics yields 0.07% difference for dementia prevalence, while data visualization confirms the known patterns of prevalence with aging and gender specifics These results stimulate further research and support the development of a national strategy for dementia and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krastev</LastName><ForeName>Evgeniy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Mathematics and Informatics, Sofia University St. Kliment Ohridski, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasteva</LastName><ForeName>Ralitsa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Specialized Hospital for Active Treatment of Children's Diseases, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fazli</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Mathematics and Informatics, Sofia University St. Kliment Ohridski, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tcharaktchiev</LastName><ForeName>Dimitar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Medical University, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002031" MajorTopicYN="N" Type="Geographic">Bulgaria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">nationally representative study</Keyword><Keyword MajorTopicYN="N">outpatient records</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176723</ArticleId><ArticleId IdType="doi">10.3233/SHTI240394</ArticleId><ArticleId IdType="pii">SHTI240394</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39176749</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>316</Volume><PubDate><Year>2024</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Converting Entity-Attribute-Value Data Sources to OMOP's CDM: Lessons Learned.</ArticleTitle><Pagination><StartPage>356</StartPage><EndPage>357</EndPage><MedlinePgn>356-357</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI240419</ELocationID><Abstract><AbstractText>Clinical data repositories often use entity-attribute-value (EAV) data models. To be valuable for secondary use, these health data can be transformed to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The present paper describes the lessons learned from such an endeavour based on the concept of registering transformation functions on source data elements. We further provide future work directions for follow-up projects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsch</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duftschmid</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093983" MajorTopicYN="N">Information Sources</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDM</Keyword><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">EAV</Keyword><Keyword MajorTopicYN="N">Entity Attribute Value</Keyword><Keyword MajorTopicYN="N">Health Information Interoperability</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">RDA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39176749</ArticleId><ArticleId IdType="doi">10.3233/SHTI240419</ArticleId><ArticleId IdType="pii">SHTI240419</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39178364</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the <i>All of Us</i> Research Program.</ArticleTitle><Pagination><StartPage>e2400052</StartPage><MedlinePgn>e2400052</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI.24.00052</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The specific aims of this paper are to (1) develop and operationalize an electronic health record (EHR) data quality framework, (2) apply the dimensions of the framework to the phenotype and treatment pathways of ductal carcinoma in situ (DCIS) using <i>All of Us</i> Research Program data, and (3) propose and apply a checklist to evaluate the application of the framework.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed a framework of five data quality dimensions (DQD; completeness, concordance, conformance, plausibility, and temporality). Participants signed a consent and Health Insurance Portability and Accountability Act authorization to share EHR data and responded to demographic questions in the Basics questionnaire. We evaluated the internal characteristics of the data and compared data with external benchmarks with descriptive and inferential statistics. We developed a DQD checklist to evaluate concept selection, internal verification, and external validity for each DQD. The Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) concept ID codes for DCIS were used to select a cohort of 2,209 females 18 years and older.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using the proposed DQD checklist criteria, (1) concepts were selected and internally verified for conformance; (2) concepts were selected and internally verified for completeness; (3) concepts were selected, internally verified, and externally validated for concordance; (4) concepts were selected, internally verified, and externally validated for plausibility; and (5) concepts were selected, internally verified, and externally validated for temporality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This assessment and evaluation provided insights into data quality for the DCIS phenotype using EHR data from the <i>All of Us</i> Research Program. The review demonstrates that salient clinical measures can be selected, applied, and operationalized within a conceptual framework and evaluated for fitness for use by applying a proposed checklist.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Lew</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3025-6990</Identifier><AffiliationInfo><Affiliation>National Institutes of Health, All of Us Research Program, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostchega</LastName><ForeName>Yechiam</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0001-8054-9727</Identifier><AffiliationInfo><Affiliation>National Institutes of Health, All of Us Research Program, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7626-6540</Identifier><AffiliationInfo><Affiliation>National Institutes of Health, All of Us Research Program, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anandan</LastName><ForeName>Lakshmi Priya</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0009-0006-5541-0287</Identifier><AffiliationInfo><Affiliation>Leidos, Frederick, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0039-0470</Identifier><AffiliationInfo><Affiliation>Leidos, Frederick, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>National Institutes of Health, All of Us Research Program, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sulieman</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volynski</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>InfoPro Systems, Rockville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6460-0182</Identifier><AffiliationInfo><Affiliation>National Institutes of Health, All of Us Research Program, Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002285" MajorTopicYN="Y">Carcinoma, Intraductal, Noninfiltrating</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>23</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39178364</ArticleId><ArticleId IdType="doi">10.1200/CCI.24.00052</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39185338</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-5121</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Open research Europe</Title><ISOAbbreviation>Open Res Eur</ISOAbbreviation></Journal><ArticleTitle>Getting ready for the European Health Data Space (EHDS): IDERHA's plan to align with the latest EHDS requirements for the secondary use of health data.</ArticleTitle><Pagination><StartPage>160</StartPage><MedlinePgn>160</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">160</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12688/openreseurope.18179.1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The European Health Data Space (EHDS) shapes the digital transformation of healthcare in Europe. The EHDS regulation will also accelerate the use of health data for research, innovation, policy-making, and regulatory activities for secondary use of data (known as EHDS2). The Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance (IDERHA) project builds one of the first pan-European health data spaces in alignment with the EHDS2 requirements, addressing lung cancer as a pilot.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, we conducted a comprehensive review of the EHDS regulation, technical requirements for EHDS2, and related projects. We also explored the results of the Joint Action Towards the European Health Data Space (TEHDAS) to identify the framework of IDERHA's alignment with EHDS2. We also conducted an internal webinar and an external workshop with EHDS experts to share expertise on the EHDS requirements and challenges.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified the lessons learned from the existing projects and the minimum-set of requirements for aligning IDERHA infrastructure with EHDS2, including user journey, concepts, terminologies, and standards. The IDERHA framework (i.e., platform architecture, standardization approaches, documentation, etc.) is being developed accordingly.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The IDERHA's alignment plan with EHDS2 necessitates the implementation of three categories of standardization for: data discoverability: Data Catalog Vocabulary (DCAT-AP), enabling semantics interoperability: Observational Medical Outcomes Partnership (OMOP), and health data exchange (DICOM and FHIR). The main challenge is that some standards are still being refined, e.g., the extension of the DCAT-AP (HealthDCAT-AP). Additionally, extensions to the Observational Health Data Sciences and Informatics (OHDSI) OMOP Common Data Model (CDM) to represent the patient-generated health data are still needed. Finally, proper mapping between standards (FHIR/OMOP) is a prerequisite for proper data exchange.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The IDERHA's plan and our collaboration with other EHDS initiatives/projects are critical in advancing the implementation of EHDS2.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Hussein R et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3056-503X</Identifier><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balaur</LastName><ForeName>Irina</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3671-895X</Identifier><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biology, University of Luxembourg, Luxembourg, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burmann</LastName><ForeName>Anja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6989-1230</Identifier><AffiliationInfo><Affiliation>Fraunhofer Institute for Software and Systems Engineering, Dortmund, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x106;wiek-Kupczy&#x144;ska</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9113-567X</Identifier><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biology, University of Luxembourg, Luxembourg, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gadiya</LastName><ForeName>Yojana</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7683-0452</Identifier><AffiliationInfo><Affiliation>Discovery Research ScreeningPort, Fraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Frankfurt, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bonn-Aachen International Center for Information Technology, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Soumyabrata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biology, University of Luxembourg, Luxembourg, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayathissa</LastName><ForeName>Prabath</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsch</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7952-9326</Identifier><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Outcomes Research, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kremer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ITTM S.A, Luxembourg, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xe4;hteenm&#xe4;ki</LastName><ForeName>Jaakko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>VTT Technical Research Centre of Finland Ltd, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Zhaoling</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Modeling and Evidence Integration, Sanofi, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morasek</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0001-0037-5051</Identifier><AffiliationInfo><Affiliation>Institute of Outcomes Research, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>C Rancourt</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2696-7220</Identifier><AffiliationInfo><Affiliation>Medical School Berlin, Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satagopam</LastName><ForeName>Venkata</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Luxembourg Centre for Systems Biology, University of Luxembourg, Luxembourg, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauermann</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty Life Science Engineering, FH Technikum Wien, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheider</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fraunhofer Institute for Software and Systems Engineering, Dortmund, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chair for Industrial Information Management, TU Dortmund, Dortmund, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Outcomes Research, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muehlendyck</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Medical GmbH, Norderstedt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gribbon</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Discovery Research ScreeningPort, Fraunhofer Institute for Translational Medicine and Pharmacology, Hamburg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Frankfurt, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Belgium</Country><MedlineTA>Open Res Eur</MedlineTA><NlmUniqueID>9918230081006676</NlmUniqueID><ISSNLinking>2732-5121</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial Intelligence; European health data space; cancer</Keyword><Keyword MajorTopicYN="N">digital health; healthcare standards; interoperability; secondary use of data.</Keyword></KeywordList><CoiStatement>No competing interests were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39185338</ArticleId><ArticleId IdType="pmc">PMC11342032</ArticleId><ArticleId IdType="doi">10.12688/openreseurope.18179.1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
European Commission:
European Health Data Space.
Reference Source
</Citation></Reference><Reference><Citation>
Hogervorst MA, M&#xf8;lleb&#xe6;k M, Vreman RA, et al. :
Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts.

<i>BMJ Open.</i>

2023;13(8):
e072309.
10.1136/bmjopen-2023-072309


</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-072309</ArticleId><ArticleId IdType="pmc">PMC10462958</ArticleId><ArticleId IdType="pubmed">37640462</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hallock H, Marshall SE, &#x2019;t Hoen PAC, et al. :
Federated networks for distributed analysis of health data.

<i>Front Public Health.</i>

2021;9:
712569.
10.3389/fpubh.2021.712569


</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.712569</ArticleId><ArticleId IdType="pmc">PMC8514765</ArticleId><ArticleId IdType="pubmed">34660512</ArticleId></ArticleIdList></Reference><Reference><Citation>
Otto B, Jarke M:
Designing a multi-sided data platform: findings from the international data spaces case.

<i>Electron Markets.</i>

2019;29(4):561&#x2013;80.
10.1007/s12525-019-00362-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12525-019-00362-x</ArticleId></ArticleIdList></Reference><Reference><Citation>
Dasaradharami Reddy K, Gadekallu TR:
A comprehensive survey on federated learning techniques for healthcare informatics.Doulamis AD, editor.

<i>Comput Intell Neurosci.</i>

2023;2023:
8393990.
10.1155/2023/8393990


</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/8393990</ArticleId><ArticleId IdType="pmc">PMC9995203</ArticleId><ArticleId IdType="pubmed">36909974</ArticleId></ArticleIdList></Reference><Reference><Citation>
Di Maio M, Basch E, Denis F, et al. :
The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline.

<i>Ann Oncol.</i>

2022;33(9):878&#x2013;92.
10.1016/j.annonc.2022.04.007

</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2022.04.007</ArticleId><ArticleId IdType="pubmed">35462007</ArticleId></ArticleIdList></Reference><Reference><Citation>
Churruca K, Pomare C, Ellis LA, et al. :
Patient-Reported Outcome Measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues.

<i>Health Expect.</i>

2021;24(4):1015&#x2013;24.
10.1111/hex.13254


</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hex.13254</ArticleId><ArticleId IdType="pmc">PMC8369118</ArticleId><ArticleId IdType="pubmed">33949755</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Commission:
Regulation of the European Parliament and of the Council on the European Health Data Space.[cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Mart&#xed;nez-Garc&#xed;a A, Alvarez-Romero C, Rom&#xe1;n-Villar&#xe1;n E, et al. :
FAIR principles to improve the impact on health research management outcomes.

<i>Heliyon.</i>

2023;9(5):
e15733.
10.1016/j.heliyon.2023.e15733


</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e15733</ArticleId><ArticleId IdType="pmc">PMC10189186</ArticleId><ArticleId IdType="pubmed">37205991</ArticleId></ArticleIdList></Reference><Reference><Citation>
Rocca-Serra P, Gu W, Ioannidis V, et al. :
The FAIR cookbook - the essential resource for and by FAIR doers.

<i>Sci Data.</i>

2023;10(1): 292.
10.1038/s41597-023-02166-3


</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02166-3</ArticleId><ArticleId IdType="pmc">PMC10198982</ArticleId><ArticleId IdType="pubmed">37208467</ArticleId></ArticleIdList></Reference><Reference><Citation>
Torab-Miandoab A, Samad-Soltani T, Jodati A, et al. :
Interoperability of heterogeneous health information systems: a systematic literature review.

<i>BMC Med Inform Decis Mak.</i>

2023;23(1): 18.
10.1186/s12911-023-02115-5


</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-023-02115-5</ArticleId><ArticleId IdType="pmc">PMC9875417</ArticleId><ArticleId IdType="pubmed">36694161</ArticleId></ArticleIdList></Reference><Reference><Citation>
Declerck J, Kalra D, Vander Stichele R, et al. :
Frameworks, dimensions, definitions of aspects and assessment methods for the appraisal of quality of health data in secondary use: a review of reviews.

<i>JMIR Med Inform.</i>

2024;12:
e51560.
10.2196/51560


</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/51560</ArticleId><ArticleId IdType="pmc">PMC10955383</ArticleId><ArticleId IdType="pubmed">38446534</ArticleId></ArticleIdList></Reference><Reference><Citation>
Christopoulos P, Schlenk R, Kazdal D, et al. :
Real-world data for precision cancer medicine&#x2014;A European perspective.

<i>Genes Chromosomes Cancer.</i>

2023;62(9):557&#x2013;63.
10.1002/gcc.23135

</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gcc.23135</ArticleId><ArticleId IdType="pubmed">36852573</ArticleId></ArticleIdList></Reference><Reference><Citation>
Marcus JS, Martens B, Carugati C, et al. :
The European Health Data Space. Rochester, NY;2022; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
European Commission:
Electronic cross-border health services. European Commission,2024; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
European Commission:
Data sharing through eDelivery in the HealthData@EU. [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Raab R, K&#xfc;derle A, Zakreuskaya A, et al. :
Federated electronic health records for the European Health Data Space.

<i>Lancet Digit Health.</i>

2023;5(11):e840&#x2013;e847.
10.1016/S2589-7500(23)00156-5

</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(23)00156-5</ArticleId><ArticleId IdType="pubmed">37741765</ArticleId></ArticleIdList></Reference><Reference><Citation>
Digital Implementation Investment Guide (DIIG): integrating digital interventions into health programmes. Geneva: World Health Organization;2020; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Pyper E, McKeown S, Hartmann-Boyce J, et al. :
Digital health technology for real-world clinical outcome measurement using patient-generated data: systematic scoping review.

<i>J Med Internet Res.</i>

2023;25:
e46992.
10.2196/46992


</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/46992</ArticleId><ArticleId IdType="pmc">PMC10600647</ArticleId><ArticleId IdType="pubmed">37819698</ArticleId></ArticleIdList></Reference><Reference><Citation>
Dinh-Le C, Chuang R, Chokshi S, et al. :
Wearable health technology and electronic health record integration: scoping review and future directions.

<i>JMIR Mhealth Uhealth.</i>

2019;7(9):
e12861.
10.2196/12861


</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/12861</ArticleId><ArticleId IdType="pmc">PMC6746089</ArticleId><ArticleId IdType="pubmed">31512582</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gallos P, Aso S, Autexier S, et al. :
CrowdHEALTH: big data analytics and holistic health records.

<i>Stud Health Technol Inform.</i>

2019;258:255&#x2013;256.

</Citation><ArticleIdList><ArticleId IdType="pubmed">30942764</ArticleId></ArticleIdList></Reference><Reference><Citation>
Stellmach C, Muzoora MR, Thun S:
Digitalization of health data: interoperability of the proposed European Health Data Space. In: Scott P, Mantas J, Benis A, Ognjanovic I, Saranto K, Ware A.,
<i>et al.</i>, editors.
<i>Stud Health Technol Inform</i>. IOS Press;2022;298:132&#x2013;136.
10.3233/SHTI220922

</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220922</ArticleId><ArticleId IdType="pubmed">36073471</ArticleId></ArticleIdList></Reference><Reference><Citation>
X-eHealth Project:
D7.1- X-eHealth architecture definition to implement and deploy EEHRxF services. [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Martins H, Carmo A, Asamoah L:
Towards the European electronic health record exchange format: XpanDH project support and risks of a delayed regulation on the EHDS.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
HealthData@EU Pilot:
Launch of the proof Of concept.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
HealthData@EU Pilot identifies common elements for health data access and data use within the legal frameworks of the participating nodes.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Abboud L, Cosgrove S, Kessissoglou I:
Country factsheets.

<i>Zenodo.</i>

2023; [cited 2024 Feb 8].
10.5281/zenodo.8329552
</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8329552</ArticleId></ArticleIdList></Reference><Reference><Citation>
Spalding D, Marquez JA, Capella-Gutierez S, et al. :
Data standards and the European genomic data infrastructure.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
EUCAIM Project:
D5.1. early release of the data federation framework.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Rambla J, Beltran S, D&#x2019;Altri T:
European Genomic Data Infrastructure project (GDI) D8.4 report on federated data access scenarios.2023; [cited 2024 Feb 8].
Reference Source
</Citation></Reference><Reference><Citation>
Claire R, Elvidge J, Hanif S, et al. :
Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop.

<i>Front Pharmacol.</i>

2024;14:
1289365.
10.3389/fphar.2023.1289365


</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1289365</ArticleId><ArticleId IdType="pmc">PMC10811058</ArticleId><ArticleId IdType="pubmed">38283835</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gravitate health FHIR implementation guide v0.1.0. [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>Bihari B, Dallos D, Ferencz L, et al. : D3.1 VA architecture (application and technical).2024; [cited 2024 Feb 9]. 10.5281/zenodo.10593465</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.10593465</ArticleId></ArticleIdList></Reference><Reference><Citation>
Savic M, Kurbalija V, Ilic M, et al. :
The application of machine learning techniques in prediction of quality of life features for cancer patients.

<i>Comput Sci Inf Syst.</i>

2023;20(1):381&#x2013;404.
10.2298/CSIS220227061S
</Citation><ArticleIdList><ArticleId IdType="doi">10.2298/CSIS220227061S</ArticleId></ArticleIdList></Reference><Reference><Citation>
Frid S, Fuentes Exp&#xf3;sito MA, Grau-Corral I, et al. :
Successful integration of EN/ISO 13606-standardized extracts from a patient mobile app Into an electronic health record: description of a methodology.

<i>JMIR Med Inform.</i>

2022;10(10):
e40344.
10.2196/40344


</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/40344</ArticleId><ArticleId IdType="pmc">PMC9607921</ArticleId><ArticleId IdType="pubmed">36222792</ArticleId></ArticleIdList></Reference><Reference><Citation>
Manias G, Op Den Akker H, Azqueta A, et al. :
iHELP: personalised health Monitoring and decision support based on artificial intelligence and holistic health records. In:
<i>2021 IEEE Symposium on Computers and Communications (ISCC)</i>. Athens, Greece: IEEE,2021;1&#x2013;8.
10.1109/ISCC53001.2021.9631475
</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ISCC53001.2021.9631475</ArticleId></ArticleIdList></Reference><Reference><Citation>
Oyen W, Catalano C:
The European Health Data Space and cancer. applying lessons learnt for successful implementation. European Cancer Organisation,2022; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
Boutros M, Baumann M, Bigas A:
UNCAN.eu: toward a European federated cancer research data hub.

<i>Cancer Discov.</i>

2024;14(1):30&#x2013;35.
10.1158/2159-8290.CD-23-1111


</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-23-1111</ArticleId><ArticleId IdType="pmc">PMC10784740</ArticleId><ArticleId IdType="pubmed">38213296</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lazic I, Agullo F, Ausso S, et al. :
The Holistic perspective of the INCISIVE project&#x2014;artificial intelligence in screening mammography.

<i>Appl Sci.</i>

2022;12(17):8755.
10.3390/app12178755
</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app12178755</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mart&#xed;nez-Garc&#xed;a A, Cangioli G, Chronaki C, et al. :
FAIRness for FHIR: towards making health datasets FAIR using HL7 FHIR. In: Otero P, Scott P, Martin SZ, Huesing E, editors.
<i>Studies in Health Technology and Informatics</i>. IOS Press,2022;290:22&#x2013;26.
10.3233/SHTI220024
</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220024</ArticleId><ArticleId IdType="pubmed">35672963</ArticleId></ArticleIdList></Reference><Reference><Citation>
Martins H, Cangioli G, Chronaki C:
Hospitals-on-FHIR: preparing hospitals for European Health Data Space.

<i>Health Management.</i>

2022;22(3).
Reference Source
</Citation></Reference><Reference><Citation>
Data Spaces Support Centre:
Starter kit for data space designers, Version 1.0.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
GAIA-X European Association for Data and Cloud:
Gaia-X architecture document - 23.1O release. [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
Nagel L, Lycklama D:
Design principles for data spaces - position paper.

<i>Zenodo.</i>

2021; [cited 2024 Feb 9].
10.5281/zenodo.5105744
</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.5105744</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lynch N, Williams-Jones B:
D3.8 FAIRplus sustainability white paper.2022; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
Bochove KV, Vos E, Moinat M, et al. :
EHDEN - D4.5 - roadmap for interoperability solutions.2020; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
De Ligt KM, De Rooij BH, Hedayati E, et al. :
International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients.

<i>Breast Cancer Res Treat.</i>

2023;198(2):265&#x2013;81.
10.1007/s10549-022-06827-6


</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-022-06827-6</ArticleId><ArticleId IdType="pmc">PMC10020292</ArticleId><ArticleId IdType="pubmed">36662394</ArticleId></ArticleIdList></Reference><Reference><Citation>
David R, Rybina A, Burel JM, et al. :
&#x201c;Be sustainable&#x201d;: EOSC&#x2010;Life recommendations for implementation of FAIR principles in life science data handling.

<i>EMBO J.</i>

2023;42(23):
e115008.
10.15252/embj.2023115008


</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2023115008</ArticleId><ArticleId IdType="pmc">PMC10690449</ArticleId><ArticleId IdType="pubmed">37964598</ArticleId></ArticleIdList></Reference><Reference><Citation>
Canham S, Ohman C, Demotes-Mainard J, et al. :
Final healthycloud strategic agenda for the health research innovation cloud.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
Alvarez-Romero C, Rodr&#xed;guez-Mejias S, Parra-Calder&#xf3;n CL:
Desiderata for the data governance and FAIR principles adoption in health data hubs. In: Mantas J, Gallos P, Zoulias E, Hasman A, Househ MS, Charalampidou M,
<i>et al.</i>, editors.
<i>Studies in Health Technology and Informatics</i>. IOS Press,2023.
10.3233/SHTI230452
</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI230452</ArticleId><ArticleId IdType="pubmed">37386986</ArticleId></ArticleIdList></Reference><Reference><Citation>
Beyan O, Choudhury A, Van Soest J, et al. :
Distributed analytics on sensitive medical data: the personal health train.

<i>Data Intell.</i>

2020;2(1&#x2013;2):96&#x2013;107.
10.1162/dint_a_00032
</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00032</ArticleId></ArticleIdList></Reference><Reference><Citation>
da Silva Santos LOB, Ferreira Pires L, Graciano Martinez V, et al. :
Personal health train architecture with dynamic cloud staging.

<i>SN Comput Sci.</i>

2022;4(1):
14.
10.1007/s42979-022-01422-4


</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42979-022-01422-4</ArticleId><ArticleId IdType="pmc">PMC9574821</ArticleId><ArticleId IdType="pubmed">36274815</ArticleId></ArticleIdList></Reference><Reference><Citation>
Schultes E, Magagna B, Hettne KM, et al. :
Reusable FAIR implementation profiles as accelerators of FAIR convergence. In: Grossmann G, Ram S. editors.
<i>Advances in Conceptual Modeling</i>. Cham: Springer International Publishing,2020;138&#x2013;47.
10.1007/978-3-030-65847-2_13
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-65847-2_13</ArticleId></ArticleIdList></Reference><Reference><Citation>
HEALTH-X dataLOFT - legitimate, open and federated health data space in GAIA-X. Fraunhofer Institute for Software and Systems Engineering, [cited 2023 Sep 5].
Reference Source
</Citation></Reference><Reference><Citation>
Kiourtis A, Mavrogiorgou A, Mavrogiorgos K, et al. :
Electronic health records at people&#x2019;s hands across Europe: the interopEHRate protocols. In: Blobel B, Yang B, Giacomini M, editors.
<i>Stud Health Technol Inform</i>. IOS Press;2022;299:145&#x2013;150.
10.3233/SHTI220973

</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220973</ArticleId><ArticleId IdType="pubmed">36325855</ArticleId></ArticleIdList></Reference><Reference><Citation>
European commission and WHO/Europe sign &#x20ac;12 million agreement to strengthen health information systems and boost health data governance and interoperability in Europe.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Advancing data sharing to improve health for all in Europe.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Deliverable 5.4: options for governance models for the European Health Data Space.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Deliverable 7.2: options for the services and services architecture and infrastructure for secondary use of data in the EHDS.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Deliverable 6.2: EHDS semantic interoperability framework- recommendations to enhance interoperability within HealthData@EU- a framework for semantic, technical and organisational interoperability.2022; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Deliverable 6.3: recommendations on a data quality framework for the European Health Data Space for secondary use.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
TEHDAS project:
Deliverable 5.3: guidelines document for multicounty data access applications, including mutual recognition and cross-border applications.2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
EIT Health&#x2019;s Think Tank:
Implementing the European Health Data Space across Europe.2024; [cited 2024 May 10].
Reference Source
</Citation></Reference><Reference><Citation>
The ongoing journey to commitment and transformation: digital health in the WHO European region. Copenhagen: WHO Regional Office for Europe,2023; [cited 2024 Feb 9].
Reference Source
</Citation></Reference><Reference><Citation>
:
Privacy&#x2010;preserving data mining and machine learning in healthcare: Applications, challenges, and solutions.

<i>WIREs Data Mining and Knowledge Discovery</i>
.2023;13(2) :
10.1002/widm.1490
10.1002/widm.1490
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/widm.1490</ArticleId></ArticleIdList></Reference><Reference><Citation>
:
Data Quality in Health Research: Integrative Literature Review.

<i>J Med Internet Res</i>
.2023;25:
10.2196/41446
e41446
10.2196/41446

</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/41446</ArticleId><ArticleId IdType="pmc">PMC10646672</ArticleId><ArticleId IdType="pubmed">37906223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39197980</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1558-3597</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of the American College of Cardiology</Title><ISOAbbreviation>J Am Coll Cardiol</ISOAbbreviation></Journal><ArticleTitle>Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.</ArticleTitle><Pagination><StartPage>904</StartPage><EndPage>917</EndPage><MedlinePgn>904-917</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacc.2024.05.069</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-1097(24)07779-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head clinical trials.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to compare the cardiovascular effectiveness of SGLT2is, GLP-1 RAs, dipeptidyl peptidase-4 inhibitors (DPP4is), and clinical sulfonylureas (SUs) as second-line antihyperglycemic agents in T2DM.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Across the LEGEND-T2DM (Large-Scale Evidence Generation and Evaluation Across a Network of Databases for Type 2 Diabetes Mellitus) network, 10 federated international data sources were included, spanning 1992 to 2021. In total, 1,492,855 patients with T2DM and cardiovascular disease (CVD) on metformin monotherapy were identified who initiated 1 of 4 second-line agents (SGLT2is, GLP-1 RAs, DPP4is, or SUs). Large-scale propensity score models were used to conduct an active-comparator target trial emulation for pairwise comparisons. After evaluating empirical equipoise and population generalizability, on-treatment Cox proportional hazards models were fit for 3-point MACE (myocardial infarction, stroke, and death) and 4-point MACE (3-point MACE plus heart failure hospitalization) risk and HR estimates were combined using random-effects meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over 5.2 million patient-years of follow-up and 489 million patient-days of time at risk, patients experienced 25,982 3-point MACE and 41,447 4-point MACE. SGLT2is and GLP-1 RAs were associated with lower 3-point MACE risk than DPP4is (HR: 0.89 [95%&#xa0;CI: 0.79-1.00] and 0.83 [95%&#xa0;CI: 0.70-0.98]) and SUs (HR: 0.76 [95%&#xa0;CI: 0.65-0.89] and 0.72 [95%&#xa0;CI: 0.58-0.88]). DPP4is were associated with lower 3-point MACE risk than SUs (HR: 0.87; 95%&#xa0;CI: 0.79-0.95). The pattern for 3-point MACE was also observed for the 4-point MACE outcome. There were no significant differences between SGLT2is and GLP-1 RAs for 3-point or 4-point MACE (HR: 1.06 [95%&#xa0;CI: 0.96-1.17] and 1.05 [95%&#xa0;CI: 0.97-1.13]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with T2DM and CVD, comparable cardiovascular risk reduction was found with SGLT2is and GLP-1 RAs, with both agents more effective than DPP4is, which in turn were more effective than SUs. These findings suggest that the use of SGLT2is and GLP-1 RAs should be prioritized as second-line agents in those with established CVD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 American College of Cardiology Foundation. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA; Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA. Electronic address: rohan.khera@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminorroaya</LastName><ForeName>Arya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Lovedeep Singh</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thangaraj</LastName><ForeName>Phyllis M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedroso Camargos</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xiyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Tara V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Faaizah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattopadhyay</LastName><ForeName>Shounak</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, U.S. Department of Veterans Affairs, Salt Lake City, Utah, USA; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>French</LastName><ForeName>Tina E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanchrow</LastName><ForeName>Elizabeth E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Guneet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wallis C Y</ForeName><Initials>WCY</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom; Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuntian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom; Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathioudakis</LastName><ForeName>Nestoras</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLeggon</LastName><ForeName>Jody-Ann</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLemore</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Thanh-Phuc</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA; Section of General Medicine and National Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Elise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, Tennessee, USA; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure, U.S. Department of Veterans Affairs, Salt Lake City, Utah, USA; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jianxiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Computational Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea; Institute for Innovation in Digital Healthcare, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jin J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California, USA; Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology, Office of the Chief Medical Officer, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA; Section of Cardiovascular Medicine, Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, California, USA; Veterans Affairs Informatics and Computing Infrastructure, U.S. Department of Veterans Affairs, Salt Lake City, Utah, USA; Department of Biomathematics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA; Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. Electronic address: msuchard@ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL144644</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS022882</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL169954</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 FD005938</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HS025164</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K23 HL153775</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL155000</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL167858</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Cardiol</MedlineTA><NlmUniqueID>8301365</NlmUniqueID><ISSNLinking>0735-1097</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Feb 08:2024.02.05.24302354. doi: 10.1101/2024.02.05.24302354.</RefSource><PMID Version="1">38370787</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">comparative effectiveness research</Keyword><Keyword MajorTopicYN="N">glucagon-like peptide-1 receptor agonists</Keyword><Keyword MajorTopicYN="N">hypoglycemic agents</Keyword><Keyword MajorTopicYN="N">sodium-glucose transporter 2 inhibitors</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This study was partially funded through National Institutes of Health grants R01 HL167858, K23 HL153775, R01 LM006910, R01 HG006139, and R01 HL169954 and the U.S. Department of Veterans Affairs under the research priority to &#x201c;Put VA Data to Work for Veterans&#x201d; (VA ORD 22-D4V). The funders had no role in the design and conduct of the protocol; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr Khera is an associate editor at JAMA; and has received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (awards R01 HL167858 and K23 HL153775) and the Doris Duke Charitable Foundation (award 2022060); has received research support, through Yale University, from Bristol Myers Squibb, Novo Nordisk, and BridgeBio; is a coinventor of U.S. provisional patent applications WO2023230345A1, US20220336048A1, 63/346,610, 63/428,569, 63/484,426, 63/508,315, 63/580,137, 63/606,203, 63/619,241, and 63/562,335, unrelated to the present work; and is a cofounder of Evidence2Health and Ensight-AI, precision health platforms to improve evidence-based cardiovascular care and cardiovascular diagnostics. Dr DuVall has received grants from Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, Biodesix, Celgene, Cerner Enviza, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis International, and Parexel International through the University of Utah or the Western Institute for Veteran Research (outside the submitted work). Dr Man has received support from the C.W. Maplethorpe Fellowship, the National Institute of Health Research, European Commission Framework Horizon 2020, the Hong Kong Research Grant Council, and the Innovation and Technology Commission of the Hong Kong Special Administration Region Government outside the submitted work). Dr Morales is supported by a Wellcome Trust Clinical Research Fellowship (214588/Z/18/Z). In the past 3 years, Dr Krumholz has received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, the Arnold and Porter Law Firm, and the Martin/Baughman Law Firm; is a cofounder of Refactor Health, HugoHealth, and Ensight-AI; and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare and Medicaid Services and, through Yale University, from Johnson &amp; Johnson. Dr You is chief technology officer of PHI Digital Healthcare. Dr Ross has received research support through Yale University from Johnson &amp; Johnson to develop methods of clinical trial data sharing, from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation program (grant U01 FD005938), from the Agency for Healthcare Research and Quality (grant R01 HS022882), and from Arnold Ventures; has received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology and from the National Heart, Lung, and Blood Institute of the National Institutes of Health (grants R01 HS025164 and R01 HL144644); and was an expert witness at the request of the relator&#x2019;s attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen that was settled September 2022. Dr Thangaraj is a coinventor on provisional patent 63/606,203, unrelated to the present work, and is funded by grant 5T32 HL155000-03. Ms Blacketer, Dr Ostropolets, and Dr Ryan are employees of Johnson &amp; Johnson. Dr Schuemie is an employee and shareholder of Johnson &amp; Johnson. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>20</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39197980</ArticleId><ArticleId IdType="mid">NIHMS2077495</ArticleId><ArticleId IdType="pmc">PMC12045554</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2024.05.069</ArticleId><ArticleId IdType="pii">S0735-1097(24)07779-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prattichizzo F, La Sala L, Ryd&#xe9;n L, et al. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol. 2019;26:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">31766918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">30291013</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387:1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">36027570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pubmed">26630143</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985288</ArticleId><ArticleId IdType="pubmed">27295427</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9792409</ArticleId><ArticleId IdType="pubmed">28910237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">31189511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">30833170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40:706&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">28428321</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">28917544</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322:1155&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763993</ArticleId><ArticleId IdType="pubmed">31536101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19:329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">27862902</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47:S158&#x2013;S178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">31497854</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Dhingra LS, Aminorroaya A, et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med. 2023;2:e000651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565313</ArticleId><ArticleId IdType="pubmed">37829182</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm &#x2013; 2020 Executive Summary. Endocr Pract. 2020;26:107&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">32022600</ArticleId></ArticleIdList></Reference><Reference><Citation>Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28:923&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10200071</ArticleId><ArticleId IdType="pubmed">35963508</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobias DK, Merino J, Ahmad A, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023;29:2438&#x2013;2457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10735053</ArticleId><ArticleId IdType="pubmed">37794253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu EL, Clase CM, Janse RJ, et al. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. Int J Cardiol. 2022;352:172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">35074492</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano D, Longo M, Signoriello S, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol. 2022;21:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8925229</ArticleId><ArticleId IdType="pubmed">35296336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol. 2020;11:178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145895</ArticleId><ArticleId IdType="pubmed">32308645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. J Am Heart Assoc. 2021;10:e021084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403287</ArticleId><ArticleId IdType="pubmed">33998258</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Schuemie MJ, Lu Y, et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open. 2022;12:e057977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman BA, Garc&#xed;a-Alb&#xe9;niz X, Logan RW, Denaxas S, Hern&#xe1;n MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25:1601&#x2013;1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7076561</ArticleId><ArticleId IdType="pubmed">31591592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183:758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20:2585&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220807</ArticleId><ArticleId IdType="pubmed">29938883</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Rho Y, Bikdeli B, et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020;324:1640&#x2013;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7592033</ArticleId><ArticleId IdType="pubmed">33107944</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Desai M, Ryan PB, et al. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract. 2017;128:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28448895</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan PB, Berlin JA, Schuemie MJ, Swerdel J, Fife D. Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. Drug Saf. 2020;43:927&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7434801</ArticleId><ArticleId IdType="pubmed">32500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab. 2018;20:582&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836890</ArticleId><ArticleId IdType="pubmed">28898514</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). J Am Med Inform Assoc. 2020;27:1331&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115:2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35:3883&#x2013;3888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, et al. How confident are we about observational findings in healthcare: A benchmark study. Harv Data Sci Rev. 2020;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>LEGEND-T2DM Investigators. Large-scale Evidence Generation and Evaluation across a Network of Database for Type 2 Diabetes Mellitus (LEGEND-T2DM). Observational Health Data Sciences and Informatics
Accessed May 3, 2024. https://data.ohdsi.org/LegendT2dmClassEvidenceExplorer/.</Citation></Reference><Reference><Citation>LEGEND-T2DM Investigators. LegendT2dm GitHub Repository. GitHub
Accessed May 3, 2024. https://github.com/ohdsi-studies/LegendT2dm.</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41&#x2013;55.</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#x2013;3107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MJ, D&#x2019;Alessio DA, Fradkin J, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669&#x2013;2701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6245208</ArticleId><ArticleId IdType="pubmed">30291106</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357214</ArticleId><ArticleId IdType="pubmed">22517736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19:329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">27862902</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson TL Jr, Halvorson AE, Hackstadt AJ, et al. Primary occurrence of cardiovascular events after adding sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists compared with dipeptidyl peptidase-4 inhibitors: A cohort study in veterans with diabetes. Ann Intern Med. 2023;176:751&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10367222</ArticleId><ArticleId IdType="pubmed">37155984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutz A, Kim DH, Wexler DJ, et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care. 2023;46:2004&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620535</ArticleId><ArticleId IdType="pubmed">37677118</ArticleId></ArticleIdList></Reference><Reference><Citation>Thein D, Christiansen MN, Mogensen UM, et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7339487</ArticleId><ArticleId IdType="pubmed">32631337</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Patel A, Dahm L, et al. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes. JAMA Netw Open. 2023;6:e2336613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10546239</ArticleId><ArticleId IdType="pubmed">37782497</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023;11:644&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">37499675</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Cordiner RLM, Huang Y, et al. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. Diabetes Care. 2023;46:967&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10154665</ArticleId><ArticleId IdType="pubmed">36944118</ArticleId></ArticleIdList></Reference><Reference><Citation>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29:305&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">37150579</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Dhingra LS, Aminorroaya A, et al. Multinational patterns of second-line antihyperglycemic drug initiation across cardiovascular risk groups: A federated pharmacoepidemiologic evaluation in LEGEND-T2DM. bioRxiv. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565313</ArticleId><ArticleId IdType="pubmed">37829182</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019;139:351&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43:48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27745828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei Y, Tsoi M-F, Kumana CR, Cheung TT, Cheung BMY. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Int J Cardiol. 2018;254:291&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">29277321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod MN, Abildstr&#xf8;m SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389:1069&#x2013;1084.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622681</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020;142:1205&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pubmed">32955939</ArticleId></ArticleIdList></Reference><Reference><Citation>Anon. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). Clinicaltrials.gov
Accessed January 12, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT04847557.</Citation></Reference><Reference><Citation>Anon. Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction. Clinicaltrials.gov
Accessed January 12, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT05371496.</Citation></Reference><Reference><Citation>Rubbo B, Fitzpatrick NK, Denaxas S, et al. Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: A systematic review and recommendations. Int J Cardiol. 2015;187:705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">25966015</ArticleId></ArticleIdList></Reference><Reference><Citation>Floyd JS, Blondon M, Moore KP, Boyko EJ, Smith NL. Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes. Pharmacoepidemiol Drug Saf. 2016;25:467&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826840</ArticleId><ArticleId IdType="pubmed">26555025</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Fouayzi H, Anzuoni K, et al. Diagnostic Algorithms for Cardiovascular Death in Administrative Claims Databases: A Systematic Review. Drug Saf. 2019;42:515&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliklich RE, Dreyer NA, Leavy MB eds. Registries for Evaluating Patient Outcomes: A User&#x2019;s Guide. Rockville (MD): Agency for Healthcare Research and Quality (US)</Citation><ArticleIdList><ArticleId IdType="pubmed">24945055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gliklich RE, Leavy MB, Dreyer NA. Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User&#x2019;s Guide, 3rd Edition, Addendum 2. Agency for Healthcare Research and Quality (US), 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31891455</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39251861</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Limitations of NHIC claim code-based surveillance and the necessity of UDI implementation in Korea.</ArticleTitle><Pagination><StartPage>21014</StartPage><MedlinePgn>21014</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">21014</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-72063-1</ELocationID><Abstract><AbstractText>The E-Health Big Data Evidence Innovation Network (FeederNet) in Korea, based on the observational medical outcomes partnership (OMOP) common data model (CDM), had 72.3% participation from tertiary hospitals handling severe diseases as of October 2022. While this contributes to the activation of multi-institutional research, concerns about the comprehensiveness of device data persist due to the adoption of national health insurance corporation (NHIC) claim codes as device identifiers in the medical device field. This study critically evaluated the effectiveness and compatibility of NHIC claim codes and unique device identifier (UDI) within FeederNet to identify the optimal identifier for efficient Post-market surveillance (PMS). Specifically, this study addressed three main questions: (1) the number of UDIs classified as NHIC-covered items, (2) the number of UDIs included in each NHIC claim code, and (3) the number of NHIC claim codes each UDI covers. Among the 1,979,655 UDIs registered domestically, only 36.02% (712,983) were classified as covered by National Health Insurance. NHIC-covered medical devices were limited to categories (A) medical devices, (B) medical supplies, and (C) dental materials, excluding most software and in vitro diagnostics (IVD). Multiple UDIs could be registered under a single NHIC claim code, and a single UDI could be registered under multiple NHIC claim codes. Only 32.62% (13,756/42,171) of NHIC claim codes had registered UDIs, with an average of 53 UDIs per claim code. Of the UDIs listed as NHIC covered, 92.39% (659,046/713,341) had one claim code, while 7.25% (51,652) had multiple claim codes. Additionally, 2643 UDIs were listed as NHIC covered but had no registered claim codes. Due to this complex relationship, NHIC claim code-based PMS may pool safe and unsafe models or disperse problematic models across multiple claim codes, leading to a lower problem rate or insignificant differences between claim codes, thus reducing signal detection sensitivity compared to UDI-based PMS. In conclusion, NHIC claim code-based PMS has limitations in granularity and signal detection sensitivity, necessitating the adoption of UDI-based PMS to address these issues. The UDI system can enhance the accuracy of medical device identification and tracking, playing a crucial role in generating real-world evidence (RWE) by integrating data from various sources. Future research should explore specific strategies for integrating and utilizing UDI with NHIC claim codes, contributing to the implementation of a more reliable and comprehensive PMS in Korea's healthcare system.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sooin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Kuk</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinhyoung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Engineering, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Soo Jeong</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Medical Device Safety Monitoring, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea. crystal@schmc.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>You Kyoung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Genetics, Center for Medical Device Safety Monitoring, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Bucheon, 14584, Republic of Korea. cecilia@schmc.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21173-MFDS-245</GrantID><Agency>Ministry of Food and Drug Safety, Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="Y">National Health Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004864" MajorTopicYN="N">Equipment and Supplies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>10</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39251861</ArticleId><ArticleId IdType="pmc">PMC11383859</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-72063-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-72063-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pane, J. <i>et al.</i> EU postmarket surveillance plans for medical devices. <i>Pharmacoepidemiol. Drug Saf.</i><b>28</b>, 1155&#x2013;1165 (2019).
10.1002/pds.4859</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4859</ArticleId><ArticleId IdType="pmc">PMC6771951</ArticleId><ArticleId IdType="pubmed">31318470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser, A. G. <i>et al.</i> Implementing the new European regulations on medical devices&#x2014;Clinical responsibilities for evidence-based practice: A report from the regulatory affairs committee of the European Society of Cardiology. <i>Eur. Heart J.</i><b>41</b>, 2589&#x2013;2596 (2020).
10.1093/eurheartj/ehaa382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa382</ArticleId><ArticleId IdType="pubmed">32484542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. <i>et al.</i> Endovascular aneurysm repair devices as a use case for postmarketing surveillance of medical devices. <i>JAMA Intern. Med.</i><b>183</b>, 1090&#x2013;1097 (2023).
10.1001/jamainternmed.2023.3562</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.3562</ArticleId><ArticleId IdType="pmc">PMC10442779</ArticleId><ArticleId IdType="pubmed">37603326</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S., Choi, S. J., Kim, J. K., Lee, Y.-W. &amp; Lee, Y. K. Real-world evidence of point-of-care glucometers: Enhanced passive surveillance and adverse event reporting status in Korea and the United States. <i>Ann. Lab. Med.</i><b>43</b>, 515&#x2013;519 (2023).
10.3343/alm.2023.43.5.515</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2023.43.5.515</ArticleId><ArticleId IdType="pmc">PMC10151275</ArticleId><ArticleId IdType="pubmed">37080755</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S., Choi, S. J., Kim, J. K., Lee, J. &amp; Lee, Y. K. adverse events associated with the use of leukocyte reduction filters and blood transfusion sets: Experience of a single institute in Korea and status of adverse event reporting in Korea and the United States. <i>Korean J. Blood Transfus.</i><b>33</b>, 161&#x2013;170 (2022). 10.17945/kjbt.2022.33.3.161</Citation><ArticleIdList><ArticleId IdType="doi">10.17945/kjbt.2022.33.3.161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, Y., Bertoldi, M., Fraser, A. G. &amp; Caiani, E. G. Validation of CORE-MD PMS support tool: A novel strategy for aggregating information from notices of failures to support medical devices&#x2019; post-market surveillance. <i>Ther. Innov. Regul. Sci.</i><b>57</b>, 589&#x2013;602 (2023).
10.1007/s43441-022-00493-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-022-00493-y</ArticleId><ArticleId IdType="pmc">PMC10133046</ArticleId><ArticleId IdType="pubmed">36652105</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. <i>et al.</i> Which health impacts of medical device adverse event should be reported immediately in Korea?. <i>J. Patient Saf.</i><b>18</b>, e591 (2022).
10.1097/PTS.0000000000000877</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PTS.0000000000000877</ArticleId><ArticleId IdType="pmc">PMC8855950</ArticleId><ArticleId IdType="pubmed">34091493</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. J. <i>et al.</i> The establishment of the Korean medical device safety information monitoring center: Reviewing ten years of experience. <i>Health Policy</i><b>125</b>, 941&#x2013;946 (2021).
10.1016/j.healthpol.2021.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2021.04.017</ArticleId><ArticleId IdType="pubmed">33994214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, G., Etter, K. &amp; Yoo, A. Medical device active surveillance of spontaneous reports: A literature review of signal detection methods. <i>Pharmacoepidemiol. Drug Saf.</i><b>29</b>, 369&#x2013;379 (2020).
10.1002/pds.4980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4980</ArticleId><ArticleId IdType="pubmed">32128936</ArticleId></ArticleIdList></Reference><Reference><Citation>Drozda, J. P. Jr. <i>et al.</i> Testing a cloud-based model for active surveillance of medical devices with analyses of coronary stent safety using the data extraction and longitudinal trend analysis (DELTA) system. <i>Med. Devices Evid. Res.</i><b>17</b>, 97&#x2013;105 (2024). 10.2147/MDER.S445160</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/MDER.S445160</ArticleId><ArticleId IdType="pmc">PMC10908332</ArticleId><ArticleId IdType="pubmed">38434149</ArticleId></ArticleIdList></Reference><Reference><Citation>Pane, J., Coloma, P. M., Verhamme, K. M. C., Sturkenboom, M. C. J. M. &amp; Rebollo, I. Evaluating the safety profile of non-active implantable medical devices compared with medicines. <i>Drug Saf.</i><b>40</b>, 37&#x2013;47 (2017).
10.1007/s40264-016-0474-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-016-0474-1</ArticleId><ArticleId IdType="pmc">PMC5209416</ArticleId><ArticleId IdType="pubmed">27928726</ArticleId></ArticleIdList></Reference><Reference><Citation>Mofid, S., Bolislis, W. R. &amp; K&#xfc;hler, T. C. Real-world data in the postapproval setting as applied by the EMA and the US FDA. <i>Clin. Ther.</i><b>44</b>, 306&#x2013;322 (2022).
10.1016/j.clinthera.2021.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2021.12.010</ArticleId><ArticleId IdType="pubmed">35074209</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence, R. L. &amp; Shuren, J. Advances in the use of real-world evidence for medical devices: An update from the national evaluation system for health technology. <i>Clin. Pharmacol. Ther.</i><b>106</b>, 30 (2019).
10.1002/cpt.1380</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1380</ArticleId><ArticleId IdType="pmc">PMC6617981</ArticleId><ArticleId IdType="pubmed">30888048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani, A. <i>et al.</i> Generating comparative evidence on new drugs and devices after approval. <i>Lancet</i><b>395</b>, 998&#x2013;1010 (2020).
10.1016/S0140-6736(19)33177-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)33177-0</ArticleId><ArticleId IdType="pubmed">32199487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva, S. S., Ridgeway, J. L., Ross, J. S., Drozda, J. P. &amp; Wilson, N. A. Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators. <i>BMJ Surg. Intervent. Health Technol.</i><b>5</b>. e000167 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9872505</ArticleId><ArticleId IdType="pubmed">36704544</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva, S. S. <i>et al.</i> Safety and effectiveness of a catheter with contact force and 6-hole irrigation for ablation of persistent atrial fibrillation in routine clinical practice. <i>JAMA Netw. Open</i><b>5</b>, e2227134&#x2013;e2227134 (2022).
10.1001/jamanetworkopen.2022.27134</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.27134</ArticleId><ArticleId IdType="pmc">PMC9386540</ArticleId><ArticleId IdType="pubmed">35976649</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S., Choi, S. J., Shin, J. W. &amp; Yoon, Y. A. Common data model-based analysis of selective leukoreduction protocol compliance at three hospitals. <i>Ann. Lab. Med.</i><b>43</b>, 187&#x2013;195 (2023).
10.3343/alm.2023.43.2.187</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2023.43.2.187</ArticleId><ArticleId IdType="pmc">PMC9618907</ArticleId><ArticleId IdType="pubmed">36281513</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke, E. <i>et al.</i> Conceptual design of a generic data harmonization process for OMOP common data model. <i>BMC Med. Inform. Decis. Mak.</i><b>24</b>, 58 (2024).
10.1186/s12911-024-02458-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-024-02458-7</ArticleId><ArticleId IdType="pmc">PMC10895818</ArticleId><ArticleId IdType="pubmed">38408983</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, Y. <i>et al.</i> Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: Implementation and evaluation. <i>JAMIA Open</i>10.1093/jamiaopen/ooac108 (2023).
10.1093/jamiaopen/ooac108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooac108</ArticleId><ArticleId IdType="pmc">PMC9831049</ArticleId><ArticleId IdType="pubmed">36632328</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, Y. <i>et al.</i> Development of a mobile personal health record application designed for emergency care in Korea; integrated information from multicenter electronic medical records. <i>Appl. Sci.</i><b>10</b>, 6711 (2020). 10.3390/app10196711</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app10196711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, S., Jeong, H. &amp; Kwon, B.-J. Strategy for linking data between the health insurance review &amp; assessment service and the ministry of food and drug safety using the integrated medical device information system. <i>Health Insur. Rev. Assess. Serv. Res.</i><b>4</b>, 34&#x2013;48 (2024).</Citation></Reference><Reference><Citation>Kim, D.-S. &amp; Song, I. A review on the post-market surveillance of medical devices in the United States and its Implication: A focus on real-world data using unique device identification of medical devices. <i>Health Insur. Rev. Assess. Serv. Res.</i><b>3</b>, 22&#x2013;36 (2023).</Citation></Reference><Reference><Citation>Lee, G. H. <i>et al.</i> Feasibility study of federated learning on the distributed research network of OMOP common data model. <i>Healthc. Inform. Res.</i><b>29</b>, 168&#x2013;173 (2023).
10.4258/hir.2023.29.2.168</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2023.29.2.168</ArticleId><ArticleId IdType="pmc">PMC10209729</ArticleId><ArticleId IdType="pubmed">37190741</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;nnapuu, K. <i>et al.</i> Trajectories: A framework for detecting temporal clinical event sequences from health data standardized to the observational medical outcomes partnership (OMOP) common data model. <i>JAMIA Open</i>10.1093/jamiaopen/ooac021 (2022).
10.1093/jamiaopen/ooac021</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooac021</ArticleId><ArticleId IdType="pmc">PMC9097714</ArticleId><ArticleId IdType="pubmed">35571357</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. E. <i>et al.</i> The effect of statins on mortality of patients with chronic kidney disease based on data of the observational medical outcomes partnership common data model (OMOP-CDM) and Korea National Health Insurance Claims Database. <i>Front. Nephrol.</i><b>1</b>, 821585 (2022).
10.3389/fneph.2021.821585</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneph.2021.821585</ArticleId><ArticleId IdType="pmc">PMC10479676</ArticleId><ArticleId IdType="pubmed">37674813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, C. <i>et al.</i> Data resource profile: Health insurance review and assessment service Covid-19 observational medical outcomes partnership (HIRA Covid-19 OMOP) database in South Korea. <i>Int. J. Epidemiol.</i>10.1093/ije/dyae062 (2024).
10.1093/ije/dyae062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyae062</ArticleId><ArticleId IdType="pubmed">38658170</ArticleId></ArticleIdList></Reference><Reference><Citation>You, S. C., Lee, S., Choi, B. &amp; Park, R. W. Establishment of an international evidence sharing network through common data model for cardiovascular research. <i>Korean Circ. J.</i><b>52</b>, 853&#x2013;864 (2022).
10.4070/kcj.2022.0294</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2022.0294</ArticleId><ArticleId IdType="pmc">PMC9742390</ArticleId><ArticleId IdType="pubmed">36478647</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Insurance Review &amp; Assessment Service, HIRA bigdata open portal. https://opendata.hira.or.kr/op/opc/olapYadmStatInfoTab1.do. Accessed 2 Jul 2024. (2023).</Citation></Reference><Reference><Citation>Evidnet. FeederNet. https://feedernet.com/. Accessed 14 Mar 2023. (2022).</Citation></Reference><Reference><Citation>Choi, S. <i>et al.</i> Preliminary feasibility assessment of CDM-based active surveillance using current status of medical device data in medical records and OMOP-CDM. <i>Sci. Rep.</i><b>11</b>, 1&#x2013;13 (2021).
10.1038/s41598-021-03332-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03332-6</ArticleId><ArticleId IdType="pmc">PMC8674329</ArticleId><ArticleId IdType="pubmed">34911976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of the Interior and Safety. Therapeutic material master file. Public data portal https://www.data.go.kr/data/15067463. Accessed 2 Apr 2023. (2022).</Citation></Reference><Reference><Citation>Chandran, B. V., Venkatesh, M. P. &amp; Krishna, P. D. Comparison of medical device regulations in India, Japan and South Korea. <i>J. Pharm. Res. Int.</i><b>33</b>, 8&#x2013;23 (2021).</Citation></Reference><Reference><Citation>Ministry of Food and Drug Safety. Medical device standard code notification. UDI system http://udiportal.mfds.go.kr. Accessed 14 Mar 2023. (2023).</Citation></Reference><Reference><Citation>Byun, J. <i>et al.</i> Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer&#x2019;s dementia using OMOP CDM. <i>Sci. Rep.</i><b>12</b>, 4451 (2022).
10.1038/s41598-022-08595-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08595-1</ArticleId><ArticleId IdType="pmc">PMC8924152</ArticleId><ArticleId IdType="pubmed">35292697</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, Y. <i>et al.</i> Comparison of postmarket surveillance strategies of implantable medical devices in the United States, European Union, and South Korea. <i>J. Pharmacoepidemiol. Risk Manag.</i><b>13</b>, 45&#x2013;54 (2021). 10.56142/2021.13.2.45</Citation><ArticleIdList><ArticleId IdType="doi">10.56142/2021.13.2.45</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, Y. A. &amp; Kim, Y. J. Comparative study of ISO standards for an effective implementation of the domestic medical device GMP system. <i>J. Korean Soc. Qual. Manag.</i><b>46</b>, 211&#x2013;224 (2018).</Citation></Reference><Reference><Citation>Cioeta, R., Cossu, A., Giovagnoni, E., Rigoni, M. &amp; Muti, P. A new platform for post-marketing surveillance and real-world evidence data collection for substance-based medical devices. <i>Front. Drug Saf. Regul.</i><b>2</b>, 992359 (2022). 10.3389/fdsfr.2022.992359</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fdsfr.2022.992359</ArticleId></ArticleIdList></Reference><Reference><Citation>White, J. &amp; Carolan-Rees, G. Current state of medical device nomenclature and taxonomy systems in the UK: Spotlight on GMDN and SNOMED CT. <i>JRSM Short Rep.</i><b>4</b>, 1&#x2013;7 (2013).
10.1177/2042533313483719</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042533313483719</ArticleId><ArticleId IdType="pmc">PMC3704061</ArticleId><ArticleId IdType="pubmed">23885299</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, G. <i>et al.</i> Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report. <i>J. Am. Med. Inform. Assoc.</i><b>28</b>, 2241&#x2013;2250 (2021).
10.1093/jamia/ocab117</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab117</ArticleId><ArticleId IdType="pmc">PMC8449615</ArticleId><ArticleId IdType="pubmed">34313748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, N. A. &amp; Drozda, J. Value of unique device identification in the digital health infrastructure. <i>JAMA</i><b>309</b>, 2107&#x2013;2108 (2013).
10.1001/jama.2013.5514</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.5514</ArticleId><ArticleId IdType="pubmed">23695480</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva, S. S. <i>et al.</i> Using real-world data from health systems to evaluate the safety and effectiveness of a catheter to treat ischemic ventricular tachycardia. <i>J. Interv. Card. Electrophysiol.</i><b>66</b>, 1817&#x2013;1825 (2023).
10.1007/s10840-023-01496-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10840-023-01496-x</ArticleId><ArticleId IdType="pmc">PMC12306424</ArticleId><ArticleId IdType="pubmed">36738387</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, W. J., Kang, S. G., Seo, B. M. F., Choi, N. K. &amp; Lee, J. H. Pilot study of the Korean national breast implant registry: Experiences and lessons learned. <i>J. Plast. Reconstr. Aesth. Surg.</i><b>75</b>, 1833&#x2013;1841 (2022). 10.1016/j.bjps.2022.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2022.01.024</ArticleId><ArticleId IdType="pubmed">35151594</ArticleId></ArticleIdList></Reference><Reference><Citation>NEWSIS, Management of Medical Devices for Tracking Made Easier. Guidelines Distributed https://www.akomnews.com/bbs/board.php?bo_table=news&amp;wr_id=53188. Accessed 9 Jul 2024. (2023).</Citation></Reference><Reference><Citation>Campion, T. R. Jr., Johnson, S. B., Paxton, E. W., Mushlin, A. I. &amp; Sedrakyan, A. Implementing unique device identification in electronic health record systems: Organizational, workflow, and technological challenges. <i>Med. Care</i><b>52</b>, 26&#x2013;31 (2014).
10.1097/MLR.0000000000000012</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000012</ArticleId><ArticleId IdType="pubmed">24322986</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39258156</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Association of the protective effect of telmisartan on hearing loss among patients with hypertension.</ArticleTitle><Pagination><StartPage>1410389</StartPage><MedlinePgn>1410389</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1410389</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2024.1410389</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">Hearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor &#x3b3; agonism. Understanding potential protective treatments is crucial for public health. We examine the effect of telmisartan, an antihypertensive drug and partial peroxisome proliferator-activated receptor &#x3b3; agonist, on hearing loss in patients with hypertension.</AbstractText><AbstractText Label="METHOD AND RESULTS" NlmCategory="UNASSIGNED">This retrospective cohort analysis used data from the OMOP Common Data Model database, encompassing information from three tertiary institutions in South Korea. The study included a substantial sample size of 860,103 people diagnosed with hypertension. The study included individuals who had been medically diagnosed with hypertension and had been prescribed antihypertensive drugs, including telmisartan. The study design was established to evaluate the comparative effects of telmisartan and other hypertension medications on hearing loss. We used propensity score matching (PSM) to create a balanced cohort, reducing potential biases between the telmisartan and non-telmisartan groups. From the initial 860,103 patients with hypertension, a propensity score matched cohort was derived from 20,010 patients, with 2,193 in the telmisartan group. After PSM, lower incidence of total hearing loss was observed in the telmisartan group compared to the non-telmisartan group during the 3-year follow-up (0.5% vs. 1.5%, log-rank <i>p</i> = 0.005). In subgroup analysis, this study showed consistent results that lower incidence of total hearing loss was higher in the telmisartan group than in the non-telmisartan group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Telmisartan was associated with reducing certain types of hearing loss in patients with hypertension. Further research is needed to confirm these findings and understand the mechanisms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Cha, Yum, Kim, Kim, Rah, Park, Im, Song, Chae, Choi and Joo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jung-Joon</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yum</LastName><ForeName>Yunjin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong Hyun</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eung Ju</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rah</LastName><ForeName>Yoon Chan</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, College of Medicine, Korea University, Ansan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Euyhyun</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Anam Hospital, College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Gi Jung</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Anam Hospital, College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jae-Jun</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Sung-Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Guro Hospital, College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>June</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, College of Medicine, Korea University, Ansan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Hyung Joon</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Korea University Research Institute for Medical Bigdata Science, College of Medicine, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PPAR &#x3b3; agonist</Keyword><Keyword MajorTopicYN="N">angiotensin II receptor blocker</Keyword><Keyword MajorTopicYN="N">hearing loss</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">telmisartan</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39258156</ArticleId><ArticleId IdType="pmc">PMC11384575</ArticleId><ArticleId IdType="doi">10.3389/fneur.2024.1410389</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olusanya BO, Neumann KJ, Saunders JE. The global burden of disabling hearing impairment: a call to action. Bull World Health Organ. (2014) 92:367&#x2013;73. 10.2471/BLT.13.128728</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.13.128728</ArticleId><ArticleId IdType="pmc">PMC4007124</ArticleId><ArticleId IdType="pubmed">24839326</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (2021) . World Report on Hearing. Geneva: World Health Organization.</Citation></Reference><Reference><Citation>Jun HJ, Hwang SY, Lee SH, Lee JE, Song JJ, Chae S. The prevalence of hearing loss in South Korea: data from a population-based study. Laryngoscope. (2015) 125:690&#x2013;4. 10.1002/lary.24913</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lary.24913</ArticleId><ArticleId IdType="pubmed">25216153</ArticleId></ArticleIdList></Reference><Reference><Citation>Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning, disability and health. Bull World Health Organ. (2019) 97:725&#x2013;8. 10.2471/BLT.19.230367</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.19.230367</ArticleId><ArticleId IdType="pmc">PMC6796665</ArticleId><ArticleId IdType="pubmed">31656340</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad KN, Bondy SC. Increased oxidative stress, inflammation, and glutamate: Potential preventive and therapeutic targets for hearing disorders. Mech Ageing Dev. (2020) 185:111191. 10.1016/j.mad.2019.111191</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2019.111191</ArticleId><ArticleId IdType="pubmed">31765645</ArticleId></ArticleIdList></Reference><Reference><Citation>Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. (2008) 372:1174&#x2013;83. 10.1016/S0140-6736(08)61242-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)61242-8</ArticleId><ArticleId IdType="pubmed">18757085</ArticleId></ArticleIdList></Reference><Reference><Citation>ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. (2008) 358:1547&#x2013;59. 10.1056/NEJMoa0801317</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0801317</ArticleId><ArticleId IdType="pubmed">18378520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekulic-Jablanovic M, Petkovic V, Wright MB, Kucharava K, Huerzeler N, Levano S, et al. Effects of peroxisome proliferator activated receptors (PPAR)-&#x3b3; and -&#x3b1; agonists on cochlear protection from oxidative stress. PLoS ONE. (2017) 12:e0188596. 10.1371/journal.pone.0188596</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0188596</ArticleId><ArticleId IdType="pmc">PMC5705132</ArticleId><ArticleId IdType="pubmed">29182629</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciello F, Fetoni AR, Rolesi R, Wright MB, Grassi C, Troiani D, et al. Pioglitazone represents an effective therapeutic target in preventing oxidative/inflammatory cochlear damage induced by noise exposure. Front Pharmacol. (2018) 9:1103. 10.3389/fphar.2018.01103</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.01103</ArticleId><ArticleId IdType="pmc">PMC6187064</ArticleId><ArticleId IdType="pubmed">30349478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Lee SM, Kim SY. Telmisartan attenuates kanamycin-induced ototoxicity in rats. Int J Mol Sci. (2021) 22:12716. 10.3390/ijms222312716</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222312716</ArticleId><ArticleId IdType="pmc">PMC8657567</ArticleId><ArticleId IdType="pubmed">34884516</ArticleId></ArticleIdList></Reference><Reference><Citation>Yum Y, Kim JH, Joo HJ, Kim YH, Kim EJ. Three-year cardiovascular outcomes of telmisartan in patients with hypertension: an electronic health record-based cohort study. Am J Hypertens. (2024) 37:429&#x2013;37. 10.1093/ajh/hpae012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpae012</ArticleId><ArticleId IdType="pubmed">38285627</ArticleId></ArticleIdList></Reference><Reference><Citation>Suksomboon N, Poolsup N, Prasit T. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther. (2012) 37:319&#x2013;27. 10.1111/j.1365-2710.2011.01295.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2011.01295.x</ArticleId><ArticleId IdType="pubmed">21848583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qiao S, Han DW, Rong XR, Wang YX, Xue JJ, et al. Telmisartan improves insulin resistance: a meta-analysis. Am J Ther. (2018) 25:e642&#x2013;51. 10.1097/MJT.0000000000000733</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0000000000000733</ArticleId><ArticleId IdType="pubmed">29557807</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda S, Tamura K, Wakui H, Kanaoka T, Ohsawa M, Maeda A, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res. (2009) 32:950&#x2013;5. 10.1038/hr.2009.131</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2009.131</ArticleId><ArticleId IdType="pubmed">19713965</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol. (2011) 4:151&#x2013;61. 10.1586/ecp.10.141</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ecp.10.141</ArticleId><ArticleId IdType="pubmed">22115399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res. (2010) 33:695&#x2013;702. 10.1038/hr.2010.67</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2010.67</ArticleId><ArticleId IdType="pubmed">20535115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishi T, Hirooka Y, Sunagawa K. Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure. Am J Hypertens. (2014) 27:260&#x2013;7. 10.1093/ajh/hpt188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpt188</ArticleId><ArticleId IdType="pubmed">24096926</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. (2004) 43:993&#x2013;1002. 10.1161/01.HYP.0000123072.34629.57</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000123072.34629.57</ArticleId><ArticleId IdType="pubmed">15007034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gay RD, Enke YL, Kirk JR, Goldman DR. Therapeutics for hearing preservation and improvement of patient outcomes in cochlear implantation-Progress and possibilities. Hear Res. (2022) 426:108637. 10.1016/j.heares.2022.108637</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heares.2022.108637</ArticleId><ArticleId IdType="pubmed">36306608</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;nfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem. (2004) 279:46065&#x2013;72. 10.1074/jbc.M403046200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M403046200</ArticleId><ArticleId IdType="pubmed">15326186</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciello F, Pisani A, Rolesi R, Escarrat V, Galli J, Paludetti G, et al. Noise-induced cochlear damage involves PPAR down-regulation through the interplay between oxidative stress and inflammation. Antioxidants (Basel). (2021) 10:1188. 10.3390/antiox10081188</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10081188</ArticleId><ArticleId IdType="pmc">PMC8388985</ArticleId><ArticleId IdType="pubmed">34439436</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. (2013) 65:809&#x2013;48. 10.1124/pr.112.007278</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.112.007278</ArticleId><ArticleId IdType="pubmed">23487168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortada M, Wei E, Jain N, Levano S, Bodmer D. Telmisartan protects auditory hair cells from gentamicin-induced toxicity in vitro. Audiol Neurootol. (2020) 25:297&#x2013;308. 10.1159/000506796</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000506796</ArticleId><ArticleId IdType="pubmed">32369826</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39274317</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13175107</ELocationID><Abstract><AbstractText><b>Background:</b> In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence regarding finerenone use in real-world settings is limited. <b>Methods:</b> A retrospective cohort study (NCT06278207) using two Japanese nationwide hospital-based databases provided by Medical Data Vision (MDV) and Real World Data Co., Ltd. (RWD Co., Kyoto Japan), converted to the OMOP common data model, was conducted. Persons with CKD and T2D initiating finerenone from 1 July 2021, to 30 August 2023, were included. Baseline characteristics were described. The occurrence of hyperkalemia after finerenone initiation was assessed. <b>Results:</b> 1029 new users of finerenone were included (967 from MDV and 62 from RWD Co.). Mean age was 69.5 and 72.4 years with 27.3% and 27.4% being female in the MDV and RWD Co. databases, respectively. Hypertension (92 and 95%), hyperlipidemia (59 and 71%), and congestive heart failure (60 and 66%) were commonly observed comorbidities. At baseline, 80% of persons were prescribed angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers. Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists were prescribed in 72% and 30% of the study population, respectively. The incidence proportions of hyperkalemia were 2.16 and 2.70 per 100 persons in the MDV and RWD Co. databases, respectively. There were no hospitalizations associated with hyperkalemia observed in either of the two datasets. <b>Conclusions:</b> For the first time, we report the largest current evidence on the clinical use of finerenone in real-world settings early after the drug authorization in Japan. This early evidence from clinical practice suggests that finerenone is used across comorbidities and comedications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Atsuhisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, International University of Health and Welfare Shioya Hospital, Yaita 329-2145, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Molina</LastName><ForeName>Daloha</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Integrated Evidence Generation &amp; Business Innovation, Bayer AG, 13342 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshikawa-Ryan</LastName><ForeName>Kanae</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Affairs &amp; Pharmacovigilance, Bayer Yakuhin Ltd., Breeze Tower, 2-4-9 Umeda, Kita-ku, Osaka 530-0001, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0001-6600-4261</Identifier><AffiliationInfo><Affiliation>Medical Affairs &amp; Pharmacovigilance, Bayer Yakuhin Ltd., Breeze Tower, 2-4-9 Umeda, Kita-ku, Osaka 530-0001, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okami</LastName><ForeName>Suguru</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4402-0209</Identifier><AffiliationInfo><Affiliation>Medical Affairs &amp; Pharmacovigilance, Bayer Yakuhin Ltd., Breeze Tower, 2-4-9 Umeda, Kita-ku, Osaka 530-0001, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Integrated Evidence Generation &amp; Business Innovation, Bayer AG, 13342 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farjat</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Integrated Evidence Generation &amp; Business Innovation, Bayer AG, 13342 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberprieler</LastName><ForeName>Nikolaus G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Integrated Evidence Generation &amp; Business Innovation, Bayer AG, 13342 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovesdy</LastName><ForeName>Csaba P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0002-8204-911X</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanasaki</LastName><ForeName>Keizo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9563-502X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine 1, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo 693-8501, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Integrated Kidney Research and Advance, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo 693-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0248-7636</Identifier><AffiliationInfo><Affiliation>Integrated Evidence Generation &amp; Business Innovation, Bayer AG, 13342 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Bayer AG</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FOUNTAIN</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership (OMOP)</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">finerenone</Keyword><Keyword MajorTopicYN="N">real world</Keyword></KeywordList><CoiStatement>A.S. reports speaker&#x2019;s bureau from AstraZeneca and Bayer. S.O. and K.Y.-R., D.R.-M., S.Y., F.L., A.F., N.G.O., D.V. are employees of Bayer. C.P.K. reports consultancy work for Abbott, Akebia, AstraZeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Vifor, GlaxoSmithKline, Prokidney, Pharmacosmos, and Takeda. K.K. reports Scholarship Grants from Japan Boehringer Ingelheim, Ono Pharmaceutical, Tanabe Mitsubishi, Kyowa, Nipro, Abbott, Terumo. This COI is for K.K.; K.K. reports Collaborative Research for Japan Boehringer Ingelheim, Boehringer Ingelheim (Germany), Taisho Pharmaceutical, Kyowa. K.K. reports Lecture Fees from Japan Boehringer Ingelheim, Japan Eli Lilly, Astellas, Tanabe Mitsubishi, MSD, Daiichi Sankyo, Sanofi, Daiichi Sankyo, Kyowa Kirin, Bayer, AstraZeneca, Otsuka, Novartis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39274317</ArticleId><ArticleId IdType="pmc">PMC11396164</ArticleId><ArticleId IdType="doi">10.3390/jcm13175107</ArticleId><ArticleId IdType="pii">jcm13175107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Diabetes Federation . IDF Diabetes Atlas. 10th ed. International Diabetes Federation; Brussels, Belgium: 2021.</Citation></Reference><Reference><Citation>Wu B., Bell K., Stanford A., Kern D.M., Tunceli O., Vupputuri S., Kalsekar I., Willey V. Understanding CKD among patients with T2DM: Prevalence, temporal trends, and treatment patterns&#x2013;NHAINES 2007&#x2013;2012. BMJ Open Diabetes Res. Care. 2016;4:e000154. doi: 10.1136/bmjdrc-2015-000154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2015-000154</ArticleId><ArticleId IdType="pmc">PMC4838667</ArticleId><ArticleId IdType="pubmed">27110365</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook S., Schmedt N., Broughton J., Kalra P.A., Thomlinson L.A., Quint J.K. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: A cohort study using the Clinical Practice Research Datalink. BMJ Open. 2023;13:e065927. doi: 10.1136/bmjopen-2022-065927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-065927</ArticleId><ArticleId IdType="pmc">PMC10008473</ArticleId><ArticleId IdType="pubmed">36882249</ArticleId></ArticleIdList></Reference><Reference><Citation>Afkarian M., Sachs M.C., Kestenbaum B., Hirsch I.B., Tuttle K.R., Himmelfarb J., de Boer I.H. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013;24:302&#x2013;308. doi: 10.1681/ASN.2012070718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012070718</ArticleId><ArticleId IdType="pmc">PMC3559486</ArticleId><ArticleId IdType="pubmed">23362314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawaf H., Thomas G., Taliercio J.J., Nakhoul G., Vachharajani T.J., Mehdi A. Therapeutic advances in diabetic nephropathy. J. Clin. Med. 2022;11:378. doi: 10.3390/jcm11020378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020378</ArticleId><ArticleId IdType="pmc">PMC8781778</ArticleId><ArticleId IdType="pubmed">35054076</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink H.J.L., Stef&#xe1;nsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.-F., Mann J.F.E., McMurray J.J.V., Lindberg M., Rossing P., et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020;383:1436&#x2013;1446. doi: 10.1056/NEJMoa2024816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024816</ArticleId><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>The EMPA-KIDNEY Collaborative Group Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2023;388:117&#x2013;127. doi: 10.1056/NEJMoa2204233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204233</ArticleId><ArticleId IdType="pmc">PMC7614055</ArticleId><ArticleId IdType="pubmed">36331190</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019;380:2295&#x2013;2306. doi: 10.1056/NEJMoa1811744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1811744</ArticleId><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V., Tuttle K.R., Rossing P., Mahaffey K.W., Mann J.F., Bakris G., Baeres F.M., Idorn T., Bosch-Traberg H., Lausvig N.L., et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 2024;391:109&#x2013;121. doi: 10.1056/NEJMoa2403347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403347</ArticleId><ArticleId IdType="pubmed">38785209</ArticleId></ArticleIdList></Reference><Reference><Citation>The American Diabetes Association Professional Practice Committee Standard of care in diabetes&#x2013;2024. Diabetes Care. 2024;47((Suppl. S1)):S295&#x2013;S306. doi: 10.2337/dc24-S016.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S016</ArticleId><ArticleId IdType="pmc">PMC10725815</ArticleId><ArticleId IdType="pubmed">38078585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashihara N., Kanegae H., Okami S., Oberprieler N.G., Pladevall-Vila M., Layton J.B., Yamashita S., Johannes C., Farjat A., Kovesdy C.P., et al. Cardiorenal events in medication-initiator cohorts of patients with chronic kidney disease and type 2 diabetes in Japan. Diabetes Res. Clin. Pract. 2024;209((Suppl. S1)):111136. doi: 10.1016/j.diabres.2024.111136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2024.111136</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima M., Neuen B.L., Li J., Perkovic V., Charytan D.M., de Zeeuw D., Edwards R., Greene T., Levin A., Mahaffey K.W., et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the CREDENCE trial. J. Am. Soc. Nephrol. 2020;31:2925&#x2013;2936. doi: 10.1681/ASN.2020050723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020050723</ArticleId><ArticleId IdType="pmc">PMC7790219</ArticleId><ArticleId IdType="pubmed">32998938</ArticleId></ArticleIdList></Reference><Reference><Citation>Waijer S.W., Xie D., Inzucchi S.E., Zinman B., Koitka-Weber A., Mattheus M., von Eynatten M., Inker L.A., Wanner C., Heerspink H.J.L. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: A post hoc analysis of the EMPA-REG OUTCOME trial. J. Am. Heart Assoc. 2020;9:e016976. doi: 10.1161/JAHA.120.016976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.016976</ArticleId><ArticleId IdType="pmc">PMC7727012</ArticleId><ArticleId IdType="pubmed">32893717</ArticleId></ArticleIdList></Reference><Reference><Citation>Wish J.B., Pergola P. Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus. Mayo Clin. Proc. Innov. Qual. Outcomes. 2022;6:536&#x2013;551. doi: 10.1016/j.mayocpiqo.2022.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocpiqo.2022.09.002</ArticleId><ArticleId IdType="pmc">PMC9578990</ArticleId><ArticleId IdType="pubmed">36277502</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaman S.C., Bakris G.L. Diabetic nephropathy: Update on pillars of therapy slowing progression. Diabetes Care. 2023;46:1574&#x2013;1586. doi: 10.2337/dci23-0030.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci23-0030</ArticleId><ArticleId IdType="pmc">PMC10547606</ArticleId><ArticleId IdType="pubmed">37625003</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama S., Yamada D., Nakayama M., Yamada T., Myoishi M., Kato M., Nowack C., Kolkhof P., Yamasaki Y. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J. Diabetes Complicat. 2017;31:758&#x2013;765. doi: 10.1016/j.jdiacomp.2016.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2016.11.021</ArticleId><ArticleId IdType="pubmed">28025025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris G.L., Agarwal R., Anker S.D., Pitt B., Ruilope L.M., Rossing P., Kolkhof P., Nowack C., Schloemer P., Joseph A., et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020;383:2219&#x2013;2229. doi: 10.1056/NEJMoa2025845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2025845</ArticleId><ArticleId IdType="pubmed">33264825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B., Filippatos G., Agarwal R., Anker S.D., Bakris G.L., Rossing P., Joseph A., Kolkhof P., Nowack C., Schloemer P., et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 2021;385:2252&#x2013;2263. doi: 10.1056/NEJMoa2110956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110956</ArticleId><ArticleId IdType="pubmed">34449181</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA)  Prescribing Information for KERENDIA.  [(accessed on 24 June 2024)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf.</Citation></Reference><Reference><Citation>Pharmaceutical and Medical Devices Agency in Japan  KERENDIA Package Insert.  [(accessed on 24 June 2024)].  Available online:  https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/630004_2190044F1020_1_06.</Citation></Reference><Reference><Citation>Marx N., Federici M., Sch&#xfc;tt K., M&#xfc;ller-Wieland D., A Ajjan R., Antunes M.J., Christodorescu R.M., Crawford C., Di Angelantonio E., Eliasson B., et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 2023;44:4043&#x2013;4140.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G., Kreutz R., Brunstr&#xf6;m M., Burnier M., Grassi G., Januszewicz A., Muiesan M.L., Tsioufis K., Agabiti-Rosei E., Algharably E.A.E., et al. 2023 ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension. J. Hypertens. 2023;41:1874&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pubmed">37345492</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberprieler N.G., Pladevall-Vila M., Johannes C.B., Layton J.B., Golozar A., Lavallee M., Kubin M., Vizcaya D. FOUNTAIN: A modular research platform for integrated real-world evidence generation [Poster 186]; Proceedings of the 39th International Conference on Pharmacoepidemiology &amp; Therapeutic Risk Management; Halifax, NS, Canada. 23&#x2013;27 August 2023.</Citation></Reference><Reference><Citation>Hayashida K., Murakami G., Matsuda S., Fushimi K. History and profile of diagnosis procedure combination (DPC): Development of a real data collection system for acute inpatient care in Japan. J. Epidemiol. 2021;31:1&#x2013;11. doi: 10.2188/jea.JE20200288.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20200288</ArticleId><ArticleId IdType="pmc">PMC7738645</ArticleId><ArticleId IdType="pubmed">33012777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumamaru H., Togo K., Kimura T., Koide D., Iihara N., Tokumasu H., Imai S. Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force. Pharmacoepidemiol. Drug Saf. 2024;33:e5680. doi: 10.1002/pds.5680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5680</ArticleId><ArticleId IdType="pubmed">37650434</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI)  OMOP Common Data Model.  [(accessed on 30 January 2024)].  Available online:  https://ohdsi.github.io/CommonDataModel/index.html.</Citation></Reference><Reference><Citation>The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP); Amsterdam, The Netherlands: 2020. Report No.EMA/95098/2010.</Citation></Reference><Reference><Citation>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)  E2A Clinical Safety Data Management: Definition and Standards for Expedited Reporting.  [(accessed on 30 January 2024)].  Available online:  https://www.ema.europa.eu/en/ich-e2a-clinical-safety-data-management-definitions-and-standards-expedited-reporting-scientific-guideline.</Citation></Reference><Reference><Citation>Charlson M.E., Carrozzino D., Guidi J., Patierno C. Charlson Comorbidity Index: A critical review of clinimetric properties. Psychother. Psychosom. 2022;91:8&#x2013;35. doi: 10.1159/000521288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521288</ArticleId><ArticleId IdType="pubmed">34991091</ArticleId></ArticleIdList></Reference><Reference><Citation>Young B.A., Lin E., Von Korff M., Simon G., Ciechanowski P., Ludman E.J., Everson-Stewart S., Kinder L., Oliver M., Boyko E.J., et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am. J. Manag. Care. 2008;14:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810070</ArticleId><ArticleId IdType="pubmed">18197741</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasheen W.P., Renda A., Dong Y. Diabetes complication severity index (DSCI)&#x2014;Update and ICD-10 translation. J. Diabetes Complicat. 2017;31:1007&#x2013;1013. doi: 10.1016/j.jdiacomp.2017.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2017.02.018</ArticleId><ArticleId IdType="pubmed">28416120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Alvarez P.J., Woods S.D., Dai D. A model to predict risk of hyperkalemia in patients with chronic kidney disease using a large administrative claims database. Clinicoecon Outcomes Res. 2020;12:657&#x2013;667. doi: 10.2147/CEOR.S267063.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEOR.S267063</ArticleId><ArticleId IdType="pmc">PMC7665575</ArticleId><ArticleId IdType="pubmed">33204127</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI)  The Book of OHDSI. 2019.  [(accessed on 31 January 2024)].  Available online:  https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>R Development Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2005.</Citation></Reference><Reference><Citation>Von Elm E., Altman D.G., Egger M., Pocock S.J., G&#xf8;tzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann. Int. Med. 2007;147:573&#x2013;577. doi: 10.7326/0003-4819-147-8-200710160-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Labour, Health and Welfare of Japan  Ethical Guidelines for Medical and Health Research Involving Human Subjects.  [(accessed on 27 December 2023)].  Available online:  https://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf.</Citation></Reference><Reference><Citation>Yanai H., Yamaguchi N., Adachi H. Chronic kidney disease stage G4 in a diabetic patient improved by multi-disciplinary treatments based upon literature search for therapeutic evidence. Cardiol. Res. 2022;13:309&#x2013;314. doi: 10.14740/cr1424.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr1424</ArticleId><ArticleId IdType="pmc">PMC9635773</ArticleId><ArticleId IdType="pubmed">36405227</ArticleId></ArticleIdList></Reference><Reference><Citation>Mima A., Lee R., Murakami A., Gotoda H., Akai R., Kidooka S., Nakamoto T., Kido S., Lee S. Effect of finerenone on diabetic kidney outcomes with estimated glomerular filtration rate below 25 mL/min/1.73m2. Metabol. Open. 2023;19:100251. doi: 10.1016/j.metop.2023.100251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2023.100251</ArticleId><ArticleId IdType="pmc">PMC10366575</ArticleId><ArticleId IdType="pubmed">37497038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mima A., Saito Y., Matsumoto K., Nakamoto T., Lee S. Effect of finerenone on nephrotic syndrome patients with diabetic kidney disease. Metabol. Open. 2024;22:100294. doi: 10.1016/j.metop.2024.100294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2024.100294</ArticleId><ArticleId IdType="pmc">PMC11215105</ArticleId><ArticleId IdType="pubmed">38952893</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R., Filippatos G., Pitt B., Anker S.D., Rossing P., Joseph A., Kolkhof P., Nowack C., Gebel M., Ruilope L.M., et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur. Heart J. 2022;43:474&#x2013;484. doi: 10.1093/eurheartj/ehab777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab777</ArticleId><ArticleId IdType="pmc">PMC8830527</ArticleId><ArticleId IdType="pubmed">35023547</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizcaya D., Kovesdy C.P., Reyes A., Pessina E., Pujol P., James G., Oberprieler N.G. Characteristics of patients with chronic kidney disease and type 2 diabetes initiating Finerenone in the USA: A multi-database, cross-sectional study. J. Comp. Eff. Res. 2023;12:e230076. doi: 10.57264/cer-2023-0076.</Citation><ArticleIdList><ArticleId IdType="doi">10.57264/cer-2023-0076</ArticleId><ArticleId IdType="pmc">PMC10949885</ArticleId><ArticleId IdType="pubmed">37387399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 clinical practice guideline for evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117&#x2013;S314. doi: 10.1016/j.kint.2023.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.10.018</ArticleId><ArticleId IdType="pubmed">38490803</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes A.K., Hinton W., Feher M.D., Elson W., Joy M., Ord&#xf3;&#xf1;ez-Mena J., Fan X., Cole N.I., Banerjee D., Suckling R.J., et al. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: A cross-sectional study. eClinicalMedicine. 2024;68:102426. doi: 10.1016/j.eclinm.2024.102426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102426</ArticleId><ArticleId IdType="pmc">PMC10831804</ArticleId><ArticleId IdType="pubmed">38304744</ArticleId></ArticleIdList></Reference><Reference><Citation>Japanese Diabetes Society . Japanese Clinical Practice Guideline for Diabetes. Japanese Diabetes Society; Tokyo, Japan: 2024.</Citation></Reference><Reference><Citation>Agarwal R., Joseph A., Anker S.D., Filippatos G., Rossing P., Ruilope L.M., Pitt B., Kolkhof P., Scott C., Lawatscheck R., et al. Hyperkalemia risk with finerenone: Results from the FIDELIO-DKD trial. J. Am. Soc. Nephrol. 2022;33:225&#x2013;237. doi: 10.1681/ASN.2021070942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021070942</ArticleId><ArticleId IdType="pmc">PMC8763180</ArticleId><ArticleId IdType="pubmed">34732509</ArticleId></ArticleIdList></Reference><Reference><Citation>Roscioni S.S., de Zeeuw D., Bakker S.J.L., Heerspink H.J.L. Management of hyperkalemia to mineralocorticoid-receptor antagonist therapy. Nat. Rev. Nephrol. 2012;8:691&#x2013;699. doi: 10.1038/nrneph.2012.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2012.217</ArticleId><ArticleId IdType="pubmed">23070570</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey T., Davids M.R., Chothia M.Y., Pecoits-Filho R., Pollock C., James G. How common is hyperkalemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalemia reported in observational studies. Clin. Kidney J. 2022;15:727&#x2013;737. doi: 10.1093/ckj/sfab243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfab243</ArticleId><ArticleId IdType="pmc">PMC8967676</ArticleId><ArticleId IdType="pubmed">35371465</ArticleId></ArticleIdList></Reference><Reference><Citation>Shubrook J.H., Neumiller J.J., Wright E. Management of chronic kidney disease in type 2 diabetes: Screening, diagnosis and treatment goals, and recommendations. Postgrad. Med. 2022;134:376&#x2013;387. doi: 10.1080/00325481.2021.2009726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2021.2009726</ArticleId><ArticleId IdType="pubmed">34817311</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberprieler N.G., Kovesdy C.P., Layton J.B., Thapa B., Curhan G., E Farjat A., Liu F., Johannes C., Vizcaya D. Clinical outcomes in US patients initiating finerenone&#x2014;A report from the FOUNTAIN platform; Proceedings of the Poster presented at the 61st European Renal Association (ERA) Congress; Stockholm, Sweden. 23&#x2013;26 May 2024.</Citation></Reference><Reference><Citation>Ruilope L.M., Agarwal R., Anker S.D., Bakris G.L., Filippatos G., Nowack C., Kolkhof P., Joseph A., Mentenich N., Pitt B., et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am. J. Nephrol. 2019;50:345&#x2013;356. doi: 10.1159/000503712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503712</ArticleId><ArticleId IdType="pmc">PMC6889917</ArticleId><ArticleId IdType="pubmed">31665733</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundb&#xf8;ll J., Adelborg K., Munch T., Fr&#xf8;slev T., S&#xf8;rensen H.T., B&#xf8;tker H.E., Schmidt M. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: A validation study. BMJ Open. 2016;6:e012832. doi: 10.1136/bmjopen-2016-012832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012832</ArticleId><ArticleId IdType="pmc">PMC5129042</ArticleId><ArticleId IdType="pubmed">27864249</ArticleId></ArticleIdList></Reference><Reference><Citation>Maru S., Koch G.G., Stender M., Clark D., Gibowski L., Petri H., White A.D., Simpson R.J. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28:20&#x2013;26. doi: 10.2337/diacare.28.1.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.28.1.20</ArticleId><ArticleId IdType="pubmed">15616228</ArticleId></ArticleIdList></Reference><Reference><Citation>Saczynski J.S., Andrade S.E., Harrold L.R., Tjia J., Cutrona S.L., Dodd K.S., Goldberg R.J., Gurwitz J.H. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol. Drug Saf. 2012;21:129&#x2013;140. doi: 10.1002/pds.2313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2313</ArticleId><ArticleId IdType="pmc">PMC3808171</ArticleId><ArticleId IdType="pubmed">22262599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39300043</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Disproportionality Analysis and Characterisation of Medication Errors in EudraVigilance: Exploring Findings on Sexes and Age Groups.</ArticleTitle><Pagination><StartPage>59</StartPage><EndPage>74</EndPage><MedlinePgn>59-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-024-01478-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While medication errors (MEs) have been studied in the European Medicines Agency's EudraVigilance, extensive characterisation and signal detection based on sexes and age groups have not been attempted.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to characterise all ME-related individual case safety reports in EudraVigilance and explore notable signals of disproportionate reporting (SDRs) among sexes and age groups for the 30 most frequently reported drugs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Individual case safety reports were used from EudraVigilance reported between 2002 and 2021. An ME was defined as any Preferred Term from the narrow Standardised Medical Dictionary for Regulatory Activities<sup>&#xae;</sup> Query. Signals of disproportionate reporting were selected based on a lower boundary of the 95% confidence interval &#x2265;&#xa0;1 of the reporting odds ratio, and at least 3 individual case safety reports. Analysed subgroups were female individuals, male individuals, and age groups 0-1 month, 2 months to 2 years, 3-11 years, 12-17 years, 18-64 years, 65-85 years, and &gt;85 years. Heatmaps were utilised as a visual aid to identify striking SDRs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 9,662,345 EudraVigilance reports, 267,262 (2.8%) contained at least one ME, with a total of 300,324 MEs, for 429,554 drugs. The most reported ME was "Inappropriate schedule of product administration" (52,646; 17.5%), followed by "Incorrect dose administered" (32,379; 10.8%) and "Wrong technique in product usage process" (26,831; 8.9%). Individual case safety reports with MEs were most frequently related to female individuals (148,009; 55.4%), most often submitted by healthcare professionals (155,711; 58.3%), originated predominantly from the USA (98,716; 36.9%), followed by France (26,678; 10.0%), and showed a median reported age of 50 years (interquartile range: 26-68). Most ME individual case safety reports (158,991; 59.5%) were associated with a serious health outcome. A total of 847 SDRs were identified, based on the entire EudraVigilance database; for subgroups, the number of SDRs ranged from 84 for the age group 0-1 month to 749 for female individuals. Signals of disproportionate reporting for female individuals and male individuals were very similar. Most MEs were reported for the vaccine against human papillomavirus (Anatomical Therapeutic Chemical [ATC]: J07BM01; 11,086 MEs, 57% being "inappropriate schedule of product administration"), with reporting odds ratios that range from 1.5 to 47.0 among age groups. The SDR for the live-attenuated vaccine against herpes zoster (ATC: J07BK02) had a reporting odds ratio that ranged from 26.6 to 78.1 among all subgroups. Signals of disproportionate reporting for oxycodone (ATC: N02AA05; 847 cases of "Accidental overdose", 35%), risperidone (ATC: N05AX08; 469 cases "Inappropriate schedule of product administration", 22.3%) and rivaroxaban (ATC: B01AF01; 1,377 cases of "Incorrect dose administered", 34.6%) stood out with higher magnitude SDRs for the age group 2 months to 2 years, with an reporting odds ratio range between 8.2 and 10.7, while for the entire EudraVigilance the reporting odds ratio ranged between 1.3 and 1.6 for the same drugs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This exploratory research provides an overview of characterised ME individual case safety reports and SDRs from the EudraVigilance database. Most conspicuous SDRs were identified in specific age groups. Signals of disproportionate reporting, not described in the literature, were found for vaccines, oxycodone, rivaroxaban and risperidone, and may prompt further examination by stakeholders. Top-reported MEs ("Inappropriate schedule of product administration", "Incorrect dose administered" and "Wrong technique in product usage process") emerged as a general priority focus to perform a further root-cause analysis involving healthcare providers, manufacturers and regulatory bodies, to improve the understanding and prevention of MEs.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pera</LastName><ForeName>Victor</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0786-4712</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands. v.pera@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-4929-026X</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Mulligen</LastName><ForeName>Erik M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0003-1377-9386</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wilde</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia M C</ForeName><Initials>KMC</Initials><Identifier Source="ORCID">0000-0001-8162-4904</Identifier><AffiliationInfo><Affiliation>Department of Bioanalysis, Ghent University, Ghent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>806968</GrantID><Agency>EHDEN</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008508" MajorTopicYN="Y">Medication Errors</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Funding: This work has received support from the European Health Data &amp; Evidence Network (EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 806968. Conflicts of Interest/Competing Interests: The research group from the Department of Medical Informatics received unconditional research grants from Chiesi, UCB, Amgen, Johnson and Johnson, and the European Medicines Agency, none of which relates to the content of this article. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Availability of Data and Material: An agreement has been made with the EMA not to transfer or dispose of the ICSR data set Level 2A for which access is provided under the condition of the Confidentiality Undertaking to any third party. It is agreed not to permit any third party to access, study, analyse, refer to or otherwise use the data or permit any party to reproduce any ICSR data. A publicly available version of this database is available here: https://www.adrreports.eu/en/index.html . Further inquiries can be directed to the corresponding author. Code Availability: Not applicable. Authors&#x2019; Contributions: VP: conceptualisation, formal analysis, visualisation, writing (original draft), writing (review and editing), methodology, visualisation. JK: software, writing (review and editing). EV: software, writing (review and editing). MdW: software, writing (review and editing). PR: supervision, writing (review and editing). KV: conceptualisation, supervision, writing (review and editing).&#xa0;All authors read and approved the final version.&#xa0;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>19</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39300043</ArticleId><ArticleId IdType="pmc">PMC11711134</ArticleId><ArticleId IdType="doi">10.1007/s40264-024-01478-6</ArticleId><ArticleId IdType="pii">10.1007/s40264-024-01478-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>EMA. Medication errors 2021. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medication-errors. Accessed 2 Sep 2024.</Citation></Reference><Reference><Citation>Pera V, van Vaerenbergh F, Kors JA, van Mulligen EM, Parry R, de Wilde M, et al. Descriptive analysis on disproportionate medication errors and associated patient characteristics in the Food and Drug Administration&#x2019;s Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. 10.1002/pds.5743.</Citation><ArticleIdList><ArticleId IdType="pubmed">38158381</ArticleId></ArticleIdList></Reference><Reference><Citation>Newbould V, Le Meur S, Goedecke T, Kurz X. Medication errors: a characterisation of spontaneously reported cases in EudraVigilance. Drug Saf. 2017;40:1241&#x2013;8. 10.1007/s40264-017-0569-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688193</ArticleId><ArticleId IdType="pubmed">28698988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirosevic Skvrce N, Galic I, Pacadi C, Kandzija N, Mucalo I. Adverse drug reactions that arise from the use of medicinal products outside the terms of the marketing authorisation. Res Soc Admin Pharm. 2020;16:928&#x2013;34. 10.1016/j.sapharm.2019.10.003.</Citation><ArticleIdList><ArticleId IdType="pubmed">31630960</ArticleId></ArticleIdList></Reference><Reference><Citation>Assiri GA, Shebl NA, Mahmoud MA, Aloudah N, Grant E, Aljadhey H, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8: e019101. 10.1136/bmjopen-2017-019101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5942474</ArticleId><ArticleId IdType="pubmed">29730617</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates DW. Preventing medication errors: a summary. Am J Health Syst Pharm. 2007;64:S3-9. 10.2146/ajhp070190.</Citation><ArticleIdList><ArticleId IdType="pubmed">17617512</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication errors: new EU good practice guide on risk minimisation and error prevention. Drug Saf. 2016;39:491&#x2013;500. 10.1007/s40264-016-0410-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26940903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutair AA, Alhumaid S, Shamsan A, Zaidi ARZ, Mohaini MA, Al Mutairi A, et al. The effective strategies to avoid medication errors and improving reporting systems. Medicines (Basel). 2021;8:46. 10.3390/medicines8090046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8468915</ArticleId><ArticleId IdType="pubmed">34564088</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabatabaee SS, Ghavami V, Javan-Noughabi J, Kakemam E. Occurrence and types of medication error and its associated factors in a reference teaching hospital in northeastern Iran: a retrospective study of medical records. BMC Health Serv Res. 2022;22:1420. 10.1186/s12913-022-08864-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703779</ArticleId><ArticleId IdType="pubmed">36443775</ArticleId></ArticleIdList></Reference><Reference><Citation>Alandajani A, Khalid B, Ng YG, Banakhar M. Knowledge and attitudes regarding medication errors among nurses: a cross-sectional study in major Jeddah hospitals. Nurs Rep. 2022;12:1023&#x2013;39. 10.3390/nursrep12040098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9783575</ArticleId><ArticleId IdType="pubmed">36548171</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed T, Mahmud S, Gintamo B, Mekuria ZN, Gizaw Z. Medication administration errors and associated factors among nurses in Addis Ababa federal hospitals, Ethiopia: a hospital-based cross-sectional study. BMJ Open. 2022;12: e066531. 10.1136/bmjopen-2022-066531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9730371</ArticleId><ArticleId IdType="pubmed">36600356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulac A, Taxis K, Hagesaether E, Granas AG. Severe and fatal medication errors in hospitals: findings from the Norwegian Incident Reporting System. Eur J Hosp Pharm. 2021;28:e56-61. 10.1136/ejhpharm-2020-002298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8640408</ArticleId><ArticleId IdType="pubmed">32576572</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi TK, Seger AC, Overhage JM, Murray MD, Hope C, Fiskio J, et al. Outpatient adverse drug events identified by screening electronic health records. J Patient Saf. 2010;6:91. 10.1097/PTS.0b013e3181dcae06.</Citation><ArticleIdList><ArticleId IdType="pubmed">22130350</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-lela OQB, Bahari MB, Al-abbassi MG, Salih MRM, Basher AY. Estimation of immunization providers&#x2019; activities cost, medication cost, and immunization dose errors cost in Iraq. Vaccine. 2012;30:3862&#x2013;6. 10.1016/j.vaccine.2012.04.014.</Citation><ArticleIdList><ArticleId IdType="pubmed">22521848</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf. 2017;26:481&#x2013;97. 10.1002/pds.4188.</Citation><ArticleIdList><ArticleId IdType="pubmed">28295821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gates PJ, Baysari MT, Gazarian M, Raban MZ, Meyerson S, Westbrook JI. Prevalence of medication errors among paediatric inpatients: systematic review and meta-analysis. Drug Saf. 2019;42:1329&#x2013;42. 10.1007/s40264-019-00850-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">31290127</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatriz G-C, Mar&#xed;a Jos&#xe9; O, In&#xe9;s J-L, Yolanda H-G, Concha &#xc1;-D-V, Javier T-S, et al. Medication errors in children visiting pediatric emergency departments. Farm Hosp. 2023;47:141&#x2013;7. 10.1016/j.farma.2023.03.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">37164795</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA. EudraVigilance. 2018. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance. Accessed 15 Aug 2023.</Citation></Reference><Reference><Citation>EMA. EudraVigilance: electronic reporting. 2018. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-electronic-reporting. Accessed 15 Aug 2023.</Citation></Reference><Reference><Citation>EMA. Access to EudraVigilance data. 2018. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/access-eudravigilance-data. Accessed 15 Aug 2023.</Citation></Reference><Reference><Citation>European database of suspected adverse drug reaction reports. Available from: https://www.adrreports.eu/. Accessed 15 Aug 2023.</Citation></Reference><Reference><Citation>1.4.1 Narrow and Broad Scope Introductory. Guide for Standardised MedDRA Queries (SMQs) Version 24.1. 2021. https://www.meddra.org/how-to-use/supportdocumentation/english. Accessed 4 Jan 2024.</Citation></Reference><Reference><Citation>Parry R. AIOLI. Available from: https://github.com/mi-erasmusmc/aioli 2021. Accessed 2 Sep 2024.</Citation></Reference><Reference><Citation>Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3: 160026. 10.1038/sdata.2016.26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Anatomical Therapeutic Chemical (ATC) Classification. Available from: https://www.who.int/tools/atc-ddd-toolkit/atc-classification. Accessed 11 Apr 2024.</Citation></Reference><Reference><Citation>Parry R. AEOLUS. 2021. Available from: https://github.com/mi-erasmusmc/faersdbstats. Accessed 2 Sep 2024.</Citation></Reference><Reference><Citation>European Medicines Agency. Screening for adverse reactions in EudraVigilance. 2016. https://www.ema.europa.eu/en/documents/other/screening-adverse-reactionseudravigilance_en.pdf. Accessed 8 July 2021.</Citation></Reference><Reference><Citation>European Medicines Agency. EudraVigilance User Manual. Marketing Authorisation Holders - EudraVigilance access via the EudraVigilance Data Analysis System, version 2.1. 2021. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilanceuser-manual-marketing-authorisation-holders_en.pdf. Accessed 21 Sept 2023.</Citation></Reference><Reference><Citation>Abraham J. International Conference On Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. In: Tietje C, Brouder A, editors. Handbook of transnational economic governance regimes. Leiden: Brill Nijhoff; 2010. p. 1041&#x2013;53. 10.1163/ej.9789004163300.i-1081.897.</Citation></Reference><Reference><Citation>Gehlenborg N, Wong B. Heat maps. Nat Methods. 2012;9:213. 10.1038/nmeth.1902.</Citation><ArticleIdList><ArticleId IdType="pubmed">27974286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Chen L, Zhou H, Liu J, Zhang Y, Feng S, et al. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system. Front Pharmacol. 2023;14:1208456. 10.3389/fphar.2023.1208456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10461182</ArticleId><ArticleId IdType="pubmed">37645441</ArticleId></ArticleIdList></Reference><Reference><Citation>Galili T, O&#x2019;Callaghan A, Sidi J, Sievert C. heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics. 2018;34:1600&#x2013;2. 10.1093/bioinformatics/btx657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5925766</ArticleId><ArticleId IdType="pubmed">29069305</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani N. Reducing potential errors associated with insulin administration: an integrative review. J Eval Clin Pract. 2022;28:1037&#x2013;49. 10.1111/jep.13668.</Citation><ArticleIdList><ArticleId IdType="pubmed">35179287</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Rowily A, Jalal Z, Price MJ, Abutaleb MH, Almodiaemgh H, Al Ammari M, et al. Prevalence, contributory factors and severity of medication errors associated with direct-acting oral anticoagulants in adult patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78:623&#x2013;45. 10.1007/s00228-021-03212-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926953</ArticleId><ArticleId IdType="pubmed">34935068</ArticleId></ArticleIdList></Reference><Reference><Citation>Dy SM, Shore AD, Hicks RW, Morlock LL. Medication errors with opioids: results from a national reporting system. J Opioid Manag. 2007;3:189&#x2013;94. 10.5055/jom.2007.0004.</Citation><ArticleIdList><ArticleId IdType="pubmed">17957978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc DC. Opioid medication errors in pediatric practice: four years&#x2019; experience of voluntary safety reporting. Pain Res Manag. 2011;16:93&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084410</ArticleId><ArticleId IdType="pubmed">21499584</ArticleId></ArticleIdList></Reference><Reference><Citation>Motooka Y, Matsui T, Slaton RM, Umetsu R, Fukuda A, Naganuma M, et al. Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004&#x2013;2016. SAGE Open Med. 2018;6:2050312118777953. 10.1177/2050312118777953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5966839</ArticleId><ArticleId IdType="pubmed">29844912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779434</ArticleId><ArticleId IdType="pubmed">25144544</ArticleId></ArticleIdList></Reference><Reference><Citation>Varicella zoster virus vaccines: medication errors. Available from: https://www.medsafe.govt.nz/profs/PUArticles/Sep2015/VaricellaVaccines.htm. Accessed 28 Sep 2023.</Citation></Reference><Reference><Citation>United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC)/Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 09/15/2023, CDC WONDER on-line database. Available from: http://wonder.cdc.gov/vaers.html. Accessed 29 Sep 2023.</Citation></Reference><Reference><Citation>Shimabukuro TT, Miller ER, Strikas RA, Hibbs BF, Dooling K, Goud R, et al. Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine &#x2014; United States, 2017&#x2013;2018. MMWR Morb Mortal Wkly Rep. 2018;67:585&#x2013;6. 10.15585/mmwr.mm6720a4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433334</ArticleId><ArticleId IdType="pubmed">29795075</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax&#xae;) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006&#x2013;2015. Hum Vaccin Immunother. 2018;14:1963&#x2013;9. 10.1080/21645515.2018.1456598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6150039</ArticleId><ArticleId IdType="pubmed">29580194</ArticleId></ArticleIdList></Reference><Reference><Citation>Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006&#x2013;2017. Perspect Clin Res. 2020;11:24&#x2013;30. 10.4103/picr.PICR_140_18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7034135</ArticleId><ArticleId IdType="pubmed">32154146</ArticleId></ArticleIdList></Reference><Reference><Citation>Haber P, Tate J, Marquez PL, Moro PL, Parashar U. Safety profile of rotavirus vaccines among individuals aged &#x2265;8 months of age, United States, vaccine adverse event reporting system (VAERS), 2006&#x2013;2019. Vaccine. 2021;39:746&#x2013;50. 10.1016/j.vaccine.2020.11.026.</Citation><ArticleIdList><ArticleId IdType="pubmed">33267969</ArticleId></ArticleIdList></Reference><Reference><Citation>Vial T, Patat A-M, Paret N, Boels D, Torrents R, Nisse P, et al. Risperidone medication errors in children: an analysis of French poison centres data. Clin Toxicol. 2019;57:362&#x2013;7. 10.1080/15563650.2018.1523424.</Citation><ArticleIdList><ArticleId IdType="pubmed">30449187</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil SE, Gibbons JR, Cogburn M. Risperidone. Treasure Island: StatPearls Publishing; 2023.</Citation></Reference><Reference><Citation>Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonz&#xe1;lez-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15:11&#x2013;34. 10.1080/14740338.2016.1240783.</Citation><ArticleIdList><ArticleId IdType="pubmed">27924643</ArticleId></ArticleIdList></Reference><Reference><Citation>Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: executive summary. Rheumatology. 2019;58:220&#x2013;6. 10.1093/rheumatology/key207.</Citation><ArticleIdList><ArticleId IdType="pubmed">30137623</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellan M, Scotti L, Ferrante D, Calzaducca E, Manfredi GF, Sainaghi PP, et al. Risk of severe infection among rheumatoid arthritis patients on biological DMARDs: a population-based cohort study. J Clin Med. 2022;11:2955. 10.3390/jcm11112955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181346</ArticleId><ArticleId IdType="pubmed">35683344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P, Padhan P, Bhargava N, Behera PK, Tripathy KP, Panda SS. Spectrum of infections occurring in patients of autoimmune rheumatic diseases on treatment with biological versus conventional disease-modifying antirheumatic drugs: a comparative study. J Family Med Prim Care. 2022;11:3575&#x2013;83. 10.4103/jfmpc.jfmpc_2147_21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648259</ArticleId><ArticleId IdType="pubmed">36387744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924&#x2013;39. 10.1002/acr.24596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9273041</ArticleId><ArticleId IdType="pubmed">34101387</ArticleId></ArticleIdList></Reference><Reference><Citation>Faillie J-L. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225&#x2013;32. 10.1016/j.therap.2019.01.006.</Citation><ArticleIdList><ArticleId IdType="pubmed">30773344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385&#x2013;96. 10.2165/00002018-200629050-00003.</Citation><ArticleIdList><ArticleId IdType="pubmed">16689555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331952</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2291-9694</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Implementation of the Observational Medical Outcomes Partnership Model in Electronic Medical Record Systems: Evaluation Study Using Factor Analysis and Decision-Making Trial and Evaluation Laboratory-Best-Worst Methods.</ArticleTitle><Pagination><StartPage>e58498</StartPage><MedlinePgn>e58498</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e58498</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/58498</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Electronic medical record (EMR) systems are essential in health care for collecting and storing patient medical data. They provide critical information to doctors and caregivers, facilitating improved decision-making and patient care. Despite their significance, optimizing EMR systems is crucial for enhancing health care quality. Implementing the Observational Medical Outcomes Partnership (OMOP) shared data model represents a promising approach to improve EMR performance and overall health care outcomes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to evaluate the effects of implementing the OMOP shared data model in EMR systems and to assess its impact on enhancing health care quality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, 3 distinct methodologies are used to explore various aspects of health care information systems. First, factor analysis is utilized to investigate the correlations between EMR systems and attitudes toward OMOP. Second, the best-worst method (BWM) is applied to determine the weights of criteria and subcriteria. Lastly, the decision-making trial and evaluation laboratory technique is used to illustrate the interactions and interdependencies among the identified criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this research, we evaluated the AliHealth EMR system by surveying 98 users and practitioners to assess its effectiveness and user satisfaction. The study reveals that among all components, "EMR resolution" holds the highest importance with a weight of 0.31007783, highlighting its significant role in the evaluation. Conversely, "EMR ease of use" has the lowest weight of 0.1860467, indicating that stakeholders prioritize the resolution aspect over ease of use in their assessment of EMR systems.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings highlight that stakeholders prioritize certain aspects of EMR systems, with "EMR resolution" being the most valued component.</AbstractText><CopyrightInformation>&#xa9;Ming Luo, Yu Gu, Feilong Zhou, Shaohong Chen. Originally published in JMIR Medical Informatics (https://medinform.jmir.org), 27.09.2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0006-5908-4407</Identifier><AffiliationInfo><Affiliation>Meizhou People's Hospital, Meizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0009-4518-4759</Identifier><AffiliationInfo><Affiliation>Meizhou People's Hospital, Meizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Feilong</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0001-5631-9067</Identifier><AffiliationInfo><Affiliation>Shenzhen Luohu District People's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaohong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-5030-3296</Identifier><AffiliationInfo><Affiliation>Shenzhen Luohu District People's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005163" MajorTopicYN="N">Factor Analysis, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Technology Acceptance Model</Keyword><Keyword MajorTopicYN="N">attitude</Keyword><Keyword MajorTopicYN="N">behavioral inclination</Keyword><Keyword MajorTopicYN="N">electronic medical record</Keyword><Keyword MajorTopicYN="N">external factors</Keyword><Keyword MajorTopicYN="N">perception</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331952</ArticleId><ArticleId IdType="pmc">PMC11470222</ArticleId><ArticleId IdType="doi">10.2196/58498</ArticleId><ArticleId IdType="pii">v12i1e58498</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miller RH, Sim I. Physicians' use of electronic medical records: barriers and solutions. Health Aff (Millwood) 2004 Mar;23(2):116&#x2013;26. doi: 10.1377/hlthaff.23.2.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.23.2.116</ArticleId><ArticleId IdType="pubmed">15046136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Yoo S, Kim S, Heo E, Kim B, Lee H, Hwang H. Patient-level fall risk prediction using the observational medical outcomes partnership's common data model: pilot feasibility study. JMIR Med Inform. 2022 Mar 11;10(3):e35104. doi: 10.2196/35104. 
 
v10i3e35104</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/35104</ArticleId><ArticleId IdType="pmc">PMC8957002</ArticleId><ArticleId IdType="pubmed">35275076</ArticleId></ArticleIdList></Reference><Reference><Citation>Spotnitz M, Ostropolets A, Castano VG, Natarajan K, Waldman GJ, Argenziano M, Ottman R, Hripcsak G, Choi H, Youngerman BE. Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: feasibility and pilot results using the common data model in a single-center electronic medical record database. Epilepsy Behav. 2022 Apr;129:108630. doi: 10.1016/j.yebeh.2022.108630.S1525-5050(22)00079-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2022.108630</ArticleId><ArticleId IdType="pubmed">35276502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong M, Gardner HL, Dieterle N, Rentko V. Optimization of electronic medical records for data mining using a common data model. Top Companion Anim Med. 2019 Dec;37:100364. doi: 10.1016/j.tcam.2019.100364. 
 
S1938-9736(19)30101-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcam.2019.100364</ArticleId><ArticleId IdType="pmc">PMC7874511</ArticleId><ArticleId IdType="pubmed">31837755</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke E, Zoch M, Kallfelz M, Ruhnke T, Leutner LA, Spoden M, G&#xfc;nster Christian, Sedlmayr M, Bathelt F. Assessing the use of German claims data vocabularies for research in the observational medical outcomes partnership common data model: development and evaluation study. JMIR Med Inform. 2023 Nov 07;11:e47959. doi: 10.2196/47959. 
 
v11i1e47959</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/47959</ArticleId><ArticleId IdType="pmc">PMC10653283</ArticleId><ArticleId IdType="pubmed">37942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams N. Building the observational medical outcomes partnership's T-MSIS analytic file common data model. Inform Med Unlocked. 2023;39:101259. doi: 10.1016/j.imu.2023.101259. 
 
101259</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2023.101259</ArticleId><ArticleId IdType="pmc">PMC10249773</ArticleId><ArticleId IdType="pubmed">37305615</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Kapsner LA, Mate S, Prokosch H, Kraus S. Patient cohort identification on time series data using the OMOP common data model. Appl Clin Inform. 2021 Jan 27;12(1):57&#x2013;64. doi: 10.1055/s-0040-1721481. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721481</ArticleId><ArticleId IdType="pmc">PMC7840432</ArticleId><ArticleId IdType="pubmed">33506478</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Kim S, Yi S, Hwang H, Kim J, Yoo S. Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J Biomed Inform. 2020 Jul;107:103459. doi: 10.1016/j.jbi.2020.103459.S1532-0464(20)30087-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103459</ArticleId><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016 Dec;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016. 
 
S1532-0464(16)30153-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Oja M, Tamm Sirli, Mooses Kerli, Pajusalu Maarja, Talvik Harry-Anton, Ott Anne, Laht Marianna, Malk Maria, L&#xf5;o Marcus, Holm Johannes, Haug Markus, &#x160;uvalov Hendrik, S&#xe4;rg Dage, Vilo Jaak, Laur Sven, Kolde Raivo, Reisberg Sulev. Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) common data model: lessons learned. JAMIA Open. 2023 Dec;6(4):ooad100&#x2013;02. doi: 10.1093/jamiaopen/ooad100. 
 
ooad100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad100</ArticleId><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravent&#xf3;s B, Fern&#xe1;ndez-Bertol&#xed;n S, Arag&#xf3;n M, Voss EA, Blacketer C, M&#xe9;ndez-Boo L, Recalde M, Roel E, Pistillo A, Reyes C, van Sandijk S, Halvorsen L, Rijnbeek PR, Burn E, Duarte-Salles T. Transforming the information system for research in primary care (SIDIAP) in Catalonia to the OMOP common data model and its use for COVID-19 research. CLEP. 2023 Sep;Volume 15:969&#x2013;986. doi: 10.2147/clep.s419481.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/clep.s419481</ArticleId><ArticleId IdType="pmc">PMC10505380</ArticleId><ArticleId IdType="pubmed">37724311</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Abou-Arab O, Bourgeois A, Parrot A, Popoff B, Beuscart J, Tavernier B, Moussa MD. Transforming anesthesia data into the observational medical outcomes partnership common data model: development and usability study. J Med Internet Res. 2021 Oct 29;23(10):e29259. doi: 10.2196/29259. 
 
v23i10e29259</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29259</ArticleId><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="pubmed">34714250</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, Shin D, Park H, Park RW. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016 Jan;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V, Moinat Maxim, Payralbe Stefan, Asselbergs Folkert W, Lumbers R Thomas, Hemingway Harry, Dobson Richard, Denaxas Spiros. Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open. 2021 Jul;4(3):ooab001. doi: 10.1093/jamiaopen/ooab001. 
 
ooab001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooab001</ArticleId><ArticleId IdType="pmc">PMC8423424</ArticleId><ArticleId IdType="pubmed">34514354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M, Ficheur G, Chazard E, Beuscart J. Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform. 2020 Jan;11(1):13&#x2013;22. doi: 10.1055/s-0039-3402754. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch KE, Deppen SA, DuVall SL, Viernes B, Cao A, Park D, Hanchrow E, Hewa K, Greaves P, Matheny ME. Incrementally transforming electronic medical records into the observational medical outcomes partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform. 2019 Oct 23;10(5):794&#x2013;803. doi: 10.1055/s-0039-1697598. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1697598</ArticleId><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K, Cho M, Song M, Yoo S, Baek H, Kim S, Kim K. Exploring the potential of OMOP common data model for process mining in healthcare. PLoS One. 2023 Jan 3;18(1):e0279641. doi: 10.1371/journal.pone.0279641. 
 
PONE-D-22-14226</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0279641</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0279641</ArticleId><ArticleId IdType="pmc">PMC9810199</ArticleId><ArticleId IdType="pubmed">36595527</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl Alexander, Gall W. Feasibility of mapping Austrian health claims data to the OMOP common data model. J Med Syst. 2019 Sep 07;43(10):314. doi: 10.1007/s10916-019-1436-9. 
 
10.1007/s10916-019-1436-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E, Makadia Rupa, Matcho Amy, Ma Qianli, Knoll Chris, Schuemie Martijn, DeFalco Frank J, Londhe Ajit, Zhu Vivienne, Ryan Patrick B. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;64. doi: 10.1093/jamia/ocu023.ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris N, Lamer A, Parrot A. Transformation and evaluation of the MIMIC database in the OMOP common data model: development and usability study. JMIR Med Inform. 2021 Dec 14;9(12):e30970. doi: 10.2196/30970. 
 
v9i12e30970</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30970</ArticleId><ArticleId IdType="pmc">PMC8715361</ArticleId><ArticleId IdType="pubmed">34904958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, Jonsson P, &#xd8;stby Jens Torup, Hughes N, Rijnbeek P, Bouvy JC. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021 Mar 18;39(3):275&#x2013;285. doi: 10.1007/s40273-020-00981-9. 
 
10.1007/s40273-020-00981-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang Y, Wen A, Wang L, Hong N, Shen F, Bedrick S, Hersh W, Liu H. Create: cohort retrieval enhanced by analysis of text from electronic health records using OMOP common data model. arXiv. Preprint posted online on January 22, 2019. 2019</Citation></Reference><Reference><Citation>Enaizan O, Zaidan AA, Alwi NHM, Zaidan BB, Alsalem MA, Albahri OS, Albahri AS. Electronic medical record systems: decision support examination framework for individual, security and privacy concerns using multi-perspective analysis. Health Technol. 2018 Nov 28;10(3):795&#x2013;822. doi: 10.1007/s12553-018-0278-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12553-018-0278-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou J, Lu M, Hu S, Cheng C, Chuang Y. A hybrid MCDM model for improving the electronic health record to better serve client needs. Sustainability. 2017 Oct 10;9(10):1819. doi: 10.3390/su9101819.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/su9101819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidan A, Zaidan B, Hussain M, Haiqi A, Mat Kiah M, Abdulnabi M. Multi-criteria analysis for OS-EMR software selection problem: a comparative study. Decision Support Systems. 2015 Oct;78:15&#x2013;27. doi: 10.1016/j.dss.2015.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dss.2015.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Esfahani AA, Ahmadi H, Nilashi M, Alizadeh M, Bashiri A, Abbasi Farajzadeh M, Shahmoradi L, Rasouli HR, Hekmat M. An evaluation model for the implementation of hospital information system in public hospitals using multi-criteria-decision-making (MCDM) approaches. IJET. 2017 Dec 04;7(1):1. doi: 10.14419/ijet.v7i1.8404. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.14419/ijet.v7i1.8404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi H, Salahshour Rad M, Nilashi M, Ibrahim O, Almaee A. Ranking the macro-level critical success factors of electronic medical record adoption using fuzzy AHP method. International Journal of Innovation and Scientific Research. 2014 Sep;8(1):35&#x2013;42. 
 
</Citation></Reference><Reference><Citation>Ahmadi H, Salahshour Rad M, Nilashi M, Ibrahim O, Almaee A. Ranking the micro level critical factors of electronic medical records adoption using TOPSIS method. Health Informatics. 2013 Nov;2(4):19&#x2013;32. doi: 10.5121/hiij.2013.2402. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.5121/hiij.2013.2402</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohammadlou M, Alinejad S. Challenges of blockchain implementation in SMEs&#x2019; supply chains: an integrated IT2F-BWM and IT2F-DEMATEL method. Electron Commer Res. 2023 Apr 18;:1&#x2013;43. doi: 10.1007/s10660-023-09696-3. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10660-023-09696-3</ArticleId><ArticleId IdType="doi">10.1007/s10660-023-09696-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar G, Bhujel RC, Aggarwal A, Gupta D, Yadav A, Asjad M. Analyzing the barriers for aquaponics adoption using integrated BWM and fuzzy DEMATEL approach in Indian context. Environ Sci Pollut Res Int. 2023 Apr 07;30(16):47800&#x2013;47821. doi: 10.1007/s11356-023-25561-0.10.1007/s11356-023-25561-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-023-25561-0</ArticleId><ArticleId IdType="pmc">PMC9902835</ArticleId><ArticleId IdType="pubmed">36749509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdi M, Khan F, Abbassi R, Rusli R. Improved DEMATEL methodology for effective safety management decision-making. Safety Science. 2020 Jul;127:104705. doi: 10.1016/j.ssci.2020.104705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ssci.2020.104705</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#x15f;kaya F, &#x15e;enol EMIR. Evaluation of factors affecting logistics performance in a global crisis environment with DEMATEL and BWM. Ak&#x131;ll&#x131; Ula&#x15f;&#x131;m Sistemleri ve Uygulamalar&#x131; Dergis. 2003;6(2):300&#x2013;325. doi: 10.51513/jitsa.1261018.</Citation><ArticleIdList><ArticleId IdType="doi">10.51513/jitsa.1261018</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimohammadlou M, Sharifian S. Industry 4.0 implementation challenges in small- and medium-sized enterprises: an approach integrating interval type-2 fuzzy BWM and DEMATEL. Soft Comput. 2022 Nov 07;27(1):169&#x2013;186. doi: 10.1007/s00500-022-07569-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00500-022-07569-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Mangla SK, Luthra S, Ishizaka A. Evaluating the human resource related soft dimensions in green supply chain management implementation. Production Planning &amp; Control. 2019 Apr 25;30(9):699&#x2013;715. doi: 10.1080/09537287.2018.1555342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537287.2018.1555342</ArticleId></ArticleIdList></Reference><Reference><Citation>Feller D. An evaluation of computational methods to support the clinical management of chronic disease populations. Doctor of Philosophy Thesis. Columbia University. ProQuest. 2020.  [2020-06-22].  
 https://www.proquest.com/openview/baa72b2b1d16bf89ad6ec1161e708bf5/1?pq-origsite=gscholar&amp;cbl=18750&amp;diss=y
.</Citation></Reference><Reference><Citation>Ahmadi H, Darvishi M, Nilashi M, Almaee A, Ibrahim O, Zolghadri AH, Alizadeh M, Farahmand M. Evaluating the critical factors for electronic medical record adoption using fuzzy approaches. International Journal of Innovation and Scientific Research. 2014 Sep;9(2):268&#x2013;284. 
 
</Citation></Reference><Reference><Citation>Kwong M, Gardner HL, Dieterle N, Rentko V. Optimization of electronic medical records for data mining using a common data model. Top Companion Anim Med. 2019 Dec;37:100364. doi: 10.1016/j.tcam.2019.100364. 
 
S1938-9736(19)30101-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcam.2019.100364</ArticleId><ArticleId IdType="pmc">PMC7874511</ArticleId><ArticleId IdType="pubmed">31837755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim S, Ryu B, Song W, Lee H, Yoo S. Transforming electronic health record polysomnographic data into the Observational Medical Outcome Partnership's common data model: a pilot feasibility study. Sci Rep. 2021 Mar 29;11(1):7013. doi: 10.1038/s41598-021-86564-w. doi: 10.1038/s41598-021-86564-w.10.1038/s41598-021-86564-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-86564-w</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-86564-w</ArticleId><ArticleId IdType="pmc">PMC8007756</ArticleId><ArticleId IdType="pubmed">33782494</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang Y, Wen A, Wang L, Hong N, Shen F, Bedrick S, Hersh W, Liu H. Implementation of a cohort retrieval system for clinical data repositories using the Observational Medical Outcomes Partnership common data model: proof-of-concept system validation. JMIR Med Inform. 2020 Oct 06;8(10):e17376. doi: 10.2196/17376. 
 
v8i10e17376</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/17376</ArticleId><ArticleId IdType="pmc">PMC7576539</ArticleId><ArticleId IdType="pubmed">33021486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan SMK, Jeon YS, Dang TK, Lim SC, Shao Y, Tai ES, Feng M. Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM dataset. Appl Clin Inform. 2021 Aug 11;12(4):757&#x2013;767. doi: 10.1055/s-0041-1732301. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1732301</ArticleId><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Jiang Guoqian, Brandt Eric, Forsyth Tom, Dhruva Sanket S, Zhang Shumin, Chen Jiajing, Noseworthy Peter A, Doshi Amit A, Collison-Farr Kimberly, Kim Dure, Ross Joseph S, Coplan Paul M, Drozda Joseph P. Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: implementation and evaluation. JAMIA Open. 2023 Apr;6(1):ooac108. doi: 10.1093/jamiaopen/ooac108. 
 
ooac108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooac108</ArticleId><ArticleId IdType="pmc">PMC9831049</ArticleId><ArticleId IdType="pubmed">36632328</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksberg B, Oskotsky Boris, Thangaraj Phyllis M, Giangreco Nicholas, Badgeley Marcus A, Johnson Kipp W, Datta Debajyoti, Rudrapatna Vivek A, Rappoport Nadav, Shervey Mark M, Miotto Riccardo, Goldstein Theodore C, Rutenberg Eugenia, Frazier Remi, Lee Nelson, Israni Sharat, Larsen Rick, Percha Bethany, Li Li, Dudley Joel T, Tatonetti Nicholas P, Butte Atul J. PatientExploreR: an extensible application for dynamic visualization of patient clinical history from electronic health records in the OMOP common data model. Bioinformatics. 2019 Nov 01;35(21):4515&#x2013;4518. doi: 10.1093/bioinformatics/btz409. 
 
5520433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz409</ArticleId><ArticleId IdType="pmc">PMC6821222</ArticleId><ArticleId IdType="pubmed">31214700</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, Wetherill G, Brand M, Didden E. Standardizing registry data to the OMOP common data model: experience from three pulmonary hypertension databases. BMC Med Res Methodol. 2021 Nov 02;21(1):238. doi: 10.1186/s12874-021-01434-3. 
 
10.1186/s12874-021-01434-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC) 2014 Nov 11;2(1):1110. doi: 10.13063/2327-9214.1110. 
 
egems1110</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1110</ArticleId><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PCY, Lo H, Liou JJH. A combination of DEMATEL and BWM-based ANP methods for exploring the green building rating system in Taiwan. Sustainability. 2020 Apr 16;12(8):3216. doi: 10.3390/su12083216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/su12083216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhshi M, Karkehabadi A, Razavian S. Revolutionizing medical diagnosis with novel teaching-learning-based optimization. 2024 International Conference on Emerging Smart Computing and Informatics (ESCI); March 5-7, 2024; Pune, India. 2024. pp. 1&#x2013;6. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ESCI59607.2024.10497216</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammad Hassan Hajian, Mina Alvandi, Ghazal Rezaei, Seyed Behnam Razavian. Investigation of the dynamic system of providing medical services in the hospital for Covid-19 disease patients. Acad J Health Sci. 2022;37(3):29&#x2013;34. 
 
</Citation></Reference><Reference><Citation>Kohane IS, Aronow BJ, Avillach P, Beaulieu-Jones BK, Bellazzi R, Bradford RL, Brat GA, Cannataro M, Cimino JJ, Garc&#xed;a-Barrio Noelia, Gehlenborg N, Ghassemi M, Guti&#xe9;rrez-Sacrist&#xe1;n Alba, Hanauer DA, Holmes JH, Hong C, Klann JG, Loh NHW, Luo Y, Mandl KD, Daniar M, Moore JH, Murphy SN, Neuraz A, Ngiam KY, Omenn GS, Palmer N, Patel LP, Pedrera-Jim&#xe9;nez Miguel, Sliz P, South AM, Tan ALM, Taylor DM, Taylor BW, Torti C, Vallejos AK, Wagholikar KB, Consortium For Clinical Characterization Of COVID-19 By EHR (4CE) Weber Griffin M, Cai Tianxi. What every reader should know about studies using electronic health record data but may be afraid to ask. J Med Internet Res. 2021 Mar 02;23(3):e22219. doi: 10.2196/22219. 
 
v23i3e22219</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/22219</ArticleId><ArticleId IdType="pmc">PMC7927948</ArticleId><ArticleId IdType="pubmed">33600347</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;nczky Andr&#xe1;s, Gy&#x151;rffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021 Jul 26;23(7):e27633. doi: 10.2196/27633. 
 
v23i7e27633</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/27633</ArticleId><ArticleId IdType="pmc">PMC8367126</ArticleId><ArticleId IdType="pubmed">34309564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurynski Y, Ellis LA, Tong HL, Laranjo L, Clay-Williams R, Testa L, Meulenbroeks I, Turton C, Sara G. Implementation of electronic medical records in mental health settings: scoping review. JMIR Ment Health. 2021 Sep 07;8(9):e30564. doi: 10.2196/30564. 
 
v8i9e30564</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30564</ArticleId><ArticleId IdType="pmc">PMC8456340</ArticleId><ArticleId IdType="pubmed">34491208</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39379683</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Heparin treatment is associated with a delayed diagnosis of Alzheimer's dementia in electronic health records from two large United States health systems.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1465</EndPage><MedlinePgn>1461-1465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-024-02757-5</ELocationID><Abstract><AbstractText>Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records (EHR) from two different health systems to examine whether heparin therapy was associated with a delayed diagnosis of AD dementia. Longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Center (CUMC) were used in separate survival analyses to compare those who did or did not receive heparin therapy, had a least 5 years of observation, were at least 65 years old by their last visit, and had subsequent diagnostic code or drug treatment evidence of possible AD dementia. Analyses controlled for age, sex, comorbidities, follow-up duration and number of inpatient visits. Heparin therapy was associated with significant delays in age of clinical diagnosis of AD dementia, including +1.0 years in the MSMS cohort (P&#x2009;&lt;&#x2009;0.001) and +1.0 years in the CUMC cohort (P&#x2009;&lt;&#x2009;0.001). While additional studies are needed, this study supports the potential roles of heparin-like drugs and HSPGs in the protection from and prevention of AD dementia.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Readhead</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4353-9965</Identifier><AffiliationInfo><Affiliation>ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, 85281, USA. ben.readhead@asu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Klang</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gisladottir</LastName><ForeName>Undina</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandromme</LastName><ForeName>Maxence</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sema4, Stamford, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Yakeel T</ForeName><Initials>YT</Initials><Identifier Source="ORCID">0000-0001-9714-8244</Identifier><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dudley</LastName><ForeName>Joel T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, 85281, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Glicksberg</LastName><ForeName>Benjamin S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0705-3696</Identifier><AffiliationInfo><Affiliation>ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, 85281, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, 85006, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG072980</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG069453</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG054671</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="Y">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: YTQ reports consulting fees from Biogen. YTQ, JFAV, EMR are listed as co-inventors of a patent application for therapeutics modulating interactions between APOE and HSPG filed by MGB. Ethics approval and consent to participate: This retrospective cohort study received Institutional Review Board (IRB) approval from all participating institutions (MSHS: 19-00951, CUMC: AAAL0601). In both cases, the IRB committee waived informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39379683</ArticleId><ArticleId IdType="pmc">PMC11919696</ArticleId><ArticleId IdType="doi">10.1038/s41380-024-02757-5</ArticleId><ArticleId IdType="pii">10.1038/s41380-024-02757-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saroja SR, Gorbachev K, Julia T, Goate AM, Pereira AC. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. Proc Natl Acad Sci USA 2022;119:e2108870119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9407658</ArticleId><ArticleId IdType="pubmed">35969759</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 2013;110:E3138&#x2013;3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch JN, Chen JJ, Sorum AW, Miller GM, Sharf T, See SK, et al. Tau Internalization is Regulated by 6-O Sulfation on Heparan Sulfate Proteoglycans (HSPGs). Sci Rep. 2018;8:6382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5913225</ArticleId><ArticleId IdType="pubmed">29686391</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Zhu Y, Song X, Xiao Y, Su G, Liu X, et al. 3-O-Sulfation of Heparan Sulfate Enhances Tau Interaction and Cellular Uptake. Angew Chem Int Ed Engl. 2020;59:1818&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6982596</ArticleId><ArticleId IdType="pubmed">31692167</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisova P, Cehlar O, Skrabana R, Zilkova M, Filipcik P, Kovacech B, et al. Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathol Commun. 2019;7:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6685285</ArticleId><ArticleId IdType="pubmed">31391090</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer&#x2019;s disease. Nat Med. 2023;29:1979&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427428</ArticleId><ArticleId IdType="pubmed">37550416</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ECB, Carter EK, Dammer EB, Duong DM, Gerasimov ES, Liu Y, et al. Large-scale deep multi-layer analysis of Alzheimer&#x2019;s disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nat Neurosci. 2022;25:213&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825285</ArticleId><ArticleId IdType="pubmed">35115731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer&#x2019;s Disease Progression. Neuron. 2020;105:975&#x2013;91.e977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318843</ArticleId><ArticleId IdType="pubmed">31926610</ArticleId></ArticleIdList></Reference><Reference><Citation>Witoelar A, Rongve A, Almdahl IS, Ulstein ID, Engvig A, White LR, et al. Meta-analysis of Alzheimer&#x2019;s disease on 9751 samples from Norway and IGAP study identifies four risk loci. Sci Rep. 2018;8:18088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6308232</ArticleId><ArticleId IdType="pubmed">30591712</ArticleId></ArticleIdList></Reference><Reference><Citation>Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P T. 2010;35:95&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827912</ArticleId><ArticleId IdType="pubmed">20221326</ArticleId></ArticleIdList></Reference><Reference><Citation>Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25:5&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohdan N, Espin S, Aguila S, Teruel-Montoya R, Vicente V, Corral J, et al. Heparanase Activates Antithrombin through the Binding to Its Heparin Binding Site. PLoS One. 2016;11:e0157834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913942</ArticleId><ArticleId IdType="pubmed">27322195</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest. 1984;74:341&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC370484</ArticleId><ArticleId IdType="pubmed">6746897</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnock LB, Huang D. Heparin. Treasure Island (FL): StatPearls; 2021.</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Suchard M, Ryan P, Reps J, Sena A, Inberg G. FeatureExtraction: Generating Features for a Cohort. R package version 3.7.1, 2024. https://github.com/OHDSI/FeatureExtraction.</Citation></Reference><Reference><Citation>Arboleda-Velasquez JF, Lopera F, O&#x2019;Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer&#x2019;s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898984</ArticleId><ArticleId IdType="pubmed">31686034</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer&#x2019;s disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc. 2005;53:1101&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16108925</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12660385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76:914&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">21383328</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology. 2006;66:1399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163092</ArticleId><ArticleId IdType="pubmed">16682673</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev. 2002;8:1&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741656</ArticleId><ArticleId IdType="pubmed">12070524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39425718</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-6564</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of hand surgery</Title><ISOAbbreviation>J Hand Surg Am</ISOAbbreviation></Journal><ArticleTitle>Observational Health Data Science and Informatics and Hand Surgery Research: Past, Present, and Future.</ArticleTitle><Pagination><StartPage>363</StartPage><EndPage>367</EndPage><MedlinePgn>363-367</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhsa.2024.09.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0363-5023(24)00433-7</ELocationID><Abstract><AbstractText>Single center studies are limited by bias, lack of generalizability and variability, and inability to study rare conditions. Multicenter observational research could address many of those concerns, especially in hand surgery where multicenter research is currently quite limited; however, there are numerous barriers including regulatory issues, lack of common terminology, and variable data set structures. The Observational Health Data Sciences and Informatics (OHDSI) program aims to surmount these limitations by enabling large-scale, collaborative research across multiple institutions. The OHDSI uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) to standardize health care data into a common language, enabling consistent and reliable analysis. The OMOP CDM has been transformative in converting multiple databases into a standardized code with a single vocabulary, allowing for coherent analysis across multiple data sets. Building upon the OMOP CDM, OHDSI provides an extensive suite of open-source tools for all research stages, from data extraction to statistical modeling. By keeping sensitive data local and only sharing summary statistics, OHDSI ensures compliance with privacy regulations while allowing for large-scale analyses. For hand surgery, OHDSI can enhance research depth, understanding of outcomes, risk factors, complications, and device performance, ultimately leading to better patient care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hum</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Georgetown University School of Medicine, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer Ce</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Barts Bone &amp; Joint Health, Blizard Institute, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gongliang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Curtis National Hand Center, MedStar Union Memorial Hospital, Baltimore, MD; MedStar Health Research Institute, Hyattsville, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selles</LastName><ForeName>Ruud W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Plastic and Reconstructive Surgery and Hand Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Aviram M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Curtis National Hand Center, MedStar Union Memorial Hospital, Baltimore, MD. Electronic address: editor@curtishand.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Hand Surg Am</MedlineTA><NlmUniqueID>7609631</NlmUniqueID><ISSNLinking>0363-5023</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="Y">Data Science</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006225" MajorTopicYN="Y">Hand</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hand surgery</Keyword><Keyword MajorTopicYN="N">observational health data science and informatics</Keyword><Keyword MajorTopicYN="N">patient-reported outcomes</Keyword><Keyword MajorTopicYN="N">research</Keyword></KeywordList><CoiStatement>Conflicts of Interest No benefits in any form have been received or will be received related directly to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>6</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>10</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39425718</ArticleId><ArticleId IdType="doi">10.1016/j.jhsa.2024.09.009</ArticleId><ArticleId IdType="pii">S0363-5023(24)00433-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39430337</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2218-6751</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Translational lung cancer research</Title><ISOAbbreviation>Transl Lung Cancer Res</ISOAbbreviation></Journal><ArticleTitle>Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000-2021: a population-based cohort study.</ArticleTitle><Pagination><StartPage>2187</StartPage><EndPage>2201</EndPage><MedlinePgn>2187-2201</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/tlcr-24-241</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Lung cancer is the leading cause of cancer-associated mortality worldwide. In the United Kingdom (UK), there has been a major reduction in smoking, the leading risk factor for lung cancer. Therefore, an up-to-date assessment of the trends of lung cancer is required in the UK. This study aims to describe lung cancer burden and trends in terms of incidence, prevalence, and survival from 2000-2021, using two UK primary care databases.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a population-based cohort study using the UK primary care Clinical Practice Research Datalink (CPRD) GOLD database, compared with CPRD Aurum. Participants aged 18+ years, with 1-year of prior data availability, were included. We estimated lung cancer incidence rates (IRs), period prevalence (PP), and survival at 1, 5 and 10 years after diagnosis using the Kaplan-Meier (KM) method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 11,388,117 participants, with 45,563 lung cancer cases were studied. The IR of lung cancer was 52.0 [95% confidence interval (CI): 51.5 to 52.5] per 100,000 person-years, with incidence increasing from 2000 to 2021. Females aged over 50 years of age showed increases in incidence over the study period, ranging from increases of 8 to 123 per 100,000 person-years, with the greatest increase in females aged 80-89 years. Alternatively, for males, only cohorts aged over 80 years showed increases in incidence over the study period. The highest IR was observed in people aged 80-89 years. PP in 2021 was 0.18%, with the largest rise seen in participants aged over 60 years. Median survival post-diagnosis increased from 6.6 months in those diagnosed between 2000-2004 to 10.0 months between 2015-2019. Both short and long-term survival was higher in younger cohorts, with 82.7% 1-year survival in those aged 18-29 years, versus 24.2% in the age 90+ years cohort. Throughout the study period, survival was longer in females, with a larger increase in survival over time than in males.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The incidence and prevalence of lung cancer diagnoses in the UK have increased, especially in female and older populations, with a small increase in median survival. This study will enable future comparisons of overall disease burden, so the overall impact may be seen.</AbstractText><CopyrightInformation>2024 AME Publishing Company. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corby</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barclay</LastName><ForeName>Nicola L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at the Roux Institute, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Wai Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tietzova</LastName><ForeName>Ilona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>First Department of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newby</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Institute for Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Transl Lung Cancer Res</MedlineTA><NlmUniqueID>101646875</NlmUniqueID><ISSNLinking>2218-6751</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lung cancer</Keyword><Keyword MajorTopicYN="N">cancer survival</Keyword><Keyword MajorTopicYN="N">incidence</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-241/coif). N.L.B. receives grants/consultancy fees/payments from Theramex, F. Hoffmann-La Roche, Innovate UK, and Sleep Universal Limited. A.G. is the Vice President, and Global Head of Data Sciences, at Odysseus Data Services Inc, since September 2021. D.P.A. research group has received research grants from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and from UCB Biopharma; consultancy fees (paid to his department) from Astra Zeneca and UCB Biopharma; and other financial or non-financial interests from Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by D.P.A. and his department. The other authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39430337</ArticleId><ArticleId IdType="pmc">PMC11484731</ArticleId><ArticleId IdType="doi">10.21037/tlcr-24-241</ArticleId><ArticleId IdType="pii">tlcr-13-09-2187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 2023;20:624-39. 10.1038/s41571-023-00798-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-023-00798-3</ArticleId><ArticleId IdType="pubmed">37479810</ArticleId></ArticleIdList></Reference><Reference><Citation>James J. Smoking, information, and education: The Royal College of Physicians and the new public health movement. Journal of Policy Analysis and Management 2024;43:446-71. 10.1002/pam.22508</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pam.22508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang L, Chan CPY, Yau WP, et al. Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis. Lung Cancer 2020;148:129-37. 10.1016/j.lungcan.2020.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.08.012</ArticleId><ArticleId IdType="pubmed">32892102</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma-Lara I, Mart&#xed;nez-Castillo M, Quintana-P&#xe9;rez JC, et al. Arsenic exposure: A public health problem leading to several cancers. Regul Toxicol Pharmacol 2020;110:104539. 10.1016/j.yrtph.2019.104539</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yrtph.2019.104539</ArticleId><ArticleId IdType="pubmed">31765675</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo-Gonz&#xe1;lez M, Torres-Dur&#xe1;n M, Barbosa-Lorenzo R, et al. Radon exposure: a major cause of lung cancer. Expert Rev Respir Med 2019;13:839-50. 10.1080/17476348.2019.1645599</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2019.1645599</ArticleId><ArticleId IdType="pubmed">31318276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak K, Kang D, Paek D. Environmental exposure to asbestos and the risk of lung cancer: a systematic review and meta-analysis. Occup Environ Med 2022;79:207-14. 10.1136/oemed-2020-107222</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/oemed-2020-107222</ArticleId><ArticleId IdType="pubmed">33972375</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics [Internet]. 2021. Smoking prevalence in the UK and the impact of data collection changes: 2020. Accessed 26 Feb 2024. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/bulletins/smokingprevalenceintheukandtheimpactofdatacollectionchanges/2020</Citation></Reference><Reference><Citation>Martins BNFL, Normando AGC, Rodrigues-Fernandes CI, et al. Global frequency and epidemiological profile of electronic cigarette users: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2022;134:548-61. 10.1016/j.oooo.2022.07.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oooo.2022.07.019</ArticleId><ArticleId IdType="pubmed">36182650</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Service, 2022. Accessed 26 Feb 2024. Available online: https://digital.nhs.uk/news/2022/decrease-in-smoking-and-drug-use-among-school-children-but-increase-in-vaping-new-report-shows#:~:text=The%20number%20of%20young%20people,1%2C%20statistics%20published%20today%20show</Citation></Reference><Reference><Citation>Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer. Transl Lung Cancer Res 2020;9:1690-8. 10.21037/tlcr.2019.11.33</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr.2019.11.33</ArticleId><ArticleId IdType="pmc">PMC7481611</ArticleId><ArticleId IdType="pubmed">32953542</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelotti A, de Scordilli M, Bertoli E, et al. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Int J Mol Sci 2022;23:6748. 10.3390/ijms23126748</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23126748</ArticleId><ArticleId IdType="pmc">PMC9223783</ArticleId><ArticleId IdType="pubmed">35743191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Research UK, [Internet]. 2024. Lung cancer mortality statistics. Accessed 26 Feb 2024. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/mortality#heading-Two</Citation></Reference><Reference><Citation>UK Government, June 2023, Accessed 26 Feb 2024. Available online: https://www.gov.uk/government/news/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner</Citation></Reference><Reference><Citation>O'Dowd EL, Lee RW, Akram AR, et al. Defining the road map to a UK national lung cancer screening programme. Lancet Oncol 2023;24:e207-18. 10.1016/S1470-2045(23)00104-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(23)00104-3</ArticleId><ArticleId IdType="pubmed">37142382</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36. 10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform 2015;216:574-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015;22:553-64. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert J, Rao G, Schuemie M, et al. Cohort diagnostics: diagnostics for OHDSI studies. 2020. Accessed 3 Jun 2024. Available online: https://ohdsi.github.io/CohortDiagnostics</Citation></Reference><Reference><Citation>Gallagher AM, Dedman D, Padmanabhan S, et al. The accuracy of date of death recording in the Clinical Practice Research Datalink GOLD database in England compared with the Office for National Statistics death registrations. Pharmacoepidemiol Drug Saf 2019;28:563-9. 10.1002/pds.4747</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4747</ArticleId><ArticleId IdType="pmc">PMC6593793</ArticleId><ArticleId IdType="pubmed">30908785</ArticleId></ArticleIdList></Reference><Reference><Citation>Eurostat Taskforce. Revision of the European Standard Population - Report of Eurostat's task force. 2013. Available online: https://ec.europa.eu/eurostat/web/products-manuals-and-guidelines/-/ks-ra-13-028 (accessed 2nd August 2023).</Citation></Reference><Reference><Citation>Ravent&#xf3;s B, Catal&#xe0; M, Du M, et al. IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf 2024;33:e5717. 10.1002/pds.5717</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5717</ArticleId><ArticleId IdType="pubmed">37876360</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer, New York. ISBN 0-387-98784-3; 2000.</Citation></Reference><Reference><Citation>NHS England [Internet]. 2023 [cited 2024 Jan 9]. Cancer Prevalence. National Disease Registration Service. Available online: https://www.cancerdata.nhs.uk/incidence_and_mortality</Citation></Reference><Reference><Citation>Cancer Research UK. Lung Cancer Statistics. Accessed 26 Feb 2024. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer</Citation></Reference><Reference><Citation>Gysling S, Morgan H, Ifesemen OS, et al. The Impact of COVID-19 on Lung Cancer Incidence in England: Analysis of the National Lung Cancer Audit 2019 and 2020 Rapid Cancer Registration Datasets. Chest 2023;163:1599-607. 10.1016/j.chest.2023.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2023.01.008</ArticleId><ArticleId IdType="pmc">PMC9833851</ArticleId><ArticleId IdType="pubmed">36640995</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyen-Omofoman B, Hubbard RB, Smith CJ, et al. The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data. BMC Public Health 2011;11:857. 10.1186/1471-2458-11-857</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-11-857</ArticleId><ArticleId IdType="pmc">PMC3282683</ArticleId><ArticleId IdType="pubmed">22074413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganti AK, Klein AB, Cotarla I, et al. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol 2021;7:1824-32. 10.1001/jamaoncol.2021.4932</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.4932</ArticleId><ArticleId IdType="pmc">PMC8532041</ArticleId><ArticleId IdType="pubmed">34673888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2015;1:15009. 10.1038/nrdp.2015.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.9</ArticleId><ArticleId IdType="pubmed">27188576</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarga L, Ameijide A, Marcos-Gragera R, et al. Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain). Sci Rep 2021;11:23274. 10.1038/s41598-021-02582-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02582-8</ArticleId><ArticleId IdType="pmc">PMC8639747</ArticleId><ArticleId IdType="pubmed">34857781</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Liu J, Chen Y, et al. Gender disparities in lung cancer incidence in the United States during 2001-2019. Sci Rep 2023;13:12581. 10.1038/s41598-023-39440-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-39440-8</ArticleId><ArticleId IdType="pmc">PMC10400573</ArticleId><ArticleId IdType="pubmed">37537259</ArticleId></ArticleIdList></Reference><Reference><Citation>DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin 2019;69:452-67. 10.3322/caac.21577</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21577</ArticleId><ArticleId IdType="pubmed">31390062</ArticleId></ArticleIdList></Reference><Reference><Citation>Royal College of Surgeons of England. National Lung Cancer Audit: State of the Nation Report 2023. Accessed 26 Feb 2024. Available online: https://www.lungcanceraudit.org.uk/reports-publications/nlca-state-of-the-nation-report-2023-version-3/</Citation></Reference><Reference><Citation>NHS England. National Disease Registration Service. Cancer Survival in England: adult, stage at diagnosis, childhood and geographical patterns. Available online: https://www.cancerdata.nhs.uk/survival/cancersurvivalengland</Citation></Reference><Reference><Citation>Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019;11:943-53. 10.2147/CMAR.S187317</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMAR.S187317</ArticleId><ArticleId IdType="pmc">PMC6345192</ArticleId><ArticleId IdType="pubmed">30718965</ArticleId></ArticleIdList></Reference><Reference><Citation>Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75. 10.1016/S0140-6736(17)33326-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)33326-3</ArticleId><ArticleId IdType="pmc">PMC5879496</ArticleId><ArticleId IdType="pubmed">29395269</ArticleId></ArticleIdList></Reference><Reference><Citation>Francisci S, Minicozzi P, Pierannunzio D, et al. Survival patterns in lung and pleural cancer in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer 2015;51:2242-53. 10.1016/j.ejca.2015.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2015.07.033</ArticleId><ArticleId IdType="pubmed">26421826</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DR, Behzadnia A, Imawana RA, et al. Exposure-lag response of smoking prevalence on lung cancer incidence using a distributed lag non-linear model. Sci Rep 2021;11:14478. 10.1038/s41598-021-91644-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91644-y</ArticleId><ArticleId IdType="pmc">PMC8280159</ArticleId><ArticleId IdType="pubmed">34262067</ArticleId></ArticleIdList></Reference><Reference><Citation>Feliu A, Filippidis FT, Joossens L, et al. Impact of tobacco control policies on smoking prevalence and quit ratios in 27 European Union countries from 2006 to 2014. Tob Control 2019;28:101-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6317447</ArticleId><ArticleId IdType="pubmed">29472445</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson SE, Beard E, Angus C, et al. Moderators of changes in smoking, drinking and quitting behaviour associated with the first COVID-19 lockdown in England. Addiction 2022;117:772-83. 10.1111/add.15656</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/add.15656</ArticleId><ArticleId IdType="pmc">PMC8652848</ArticleId><ArticleId IdType="pubmed">34431577</ArticleId></ArticleIdList></Reference><Reference><Citation>Tattan-Birch H, Jarvis MJ. Children's exposure to second-hand smoke 10 years on from smoke-free legislation in England: Cotinine data from the Health Survey for England 1998-2018. Lancet Reg Health Eur 2022;15:100315. 10.1016/j.lanepe.2022.100315</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100315</ArticleId><ArticleId IdType="pmc">PMC8819129</ArticleId><ArticleId IdType="pubmed">35146477</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracken-Clarke D, Kapoor D, Baird AM, et al. Vaping and lung cancer - A review of current data and recommendations. Lung Cancer 2021;153:11-20. 10.1016/j.lungcan.2020.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.12.030</ArticleId><ArticleId IdType="pubmed">33429159</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone PW, Osen M, Ellis A, et al. Prevalence of Chronic Obstructive Pulmonary Disease in England from 2000 to 2019. Int J Chron Obstruct Pulmon Dis 2023;18:1565-74. 10.2147/COPD.S411739</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S411739</ArticleId><ArticleId IdType="pmc">PMC10368107</ArticleId><ArticleId IdType="pubmed">37497381</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. UK National Radon Action Plan. 2018 Dec. Accessed 26 Feb 2024. Available online: https://www.gov.uk/government/publications/uk-national-radon-action-plan</Citation></Reference><Reference><Citation>A&#xdf;enmacher M, Kaiser JC, Zaballa I, et al. Exposure-lag-response associations between lung cancer mortality and radon exposure in German uranium miners. Radiat Environ Biophys 2019;58:321-36. 10.1007/s00411-019-00800-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00411-019-00800-6</ArticleId><ArticleId IdType="pubmed">31218403</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MC, Andersen ZJ, Baccarelli A, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA Cancer J Clin 2020. [Epub ahead of print]. doi: .10.3322/caac.21632</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21632</ArticleId><ArticleId IdType="pmc">PMC7904962</ArticleId><ArticleId IdType="pubmed">32964460</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Zhu M, Ji M, et al. Air Pollution, Genetic Factors, and the Risk of Lung Cancer: A Prospective Study in the UK Biobank. Am J Respir Crit Care Med 2021;204:817-25. Erratum in: Am J Respir Crit Care Med 2022;205:1254. 10.1164/rccm.202011-4063OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202011-4063OC</ArticleId><ArticleId IdType="pubmed">34252012</ArticleId></ArticleIdList></Reference><Reference><Citation>May L, Shows K, Nana-Sinkam P, et al. Sex Differences in Lung Cancer. Cancers (Basel) 2023;15:3111. 10.3390/cancers15123111</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15123111</ArticleId><ArticleId IdType="pmc">PMC10296433</ArticleId><ArticleId IdType="pubmed">37370722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragavan M, Patel MI. The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. Eur Respir Rev 2022;31:210100. 10.1183/16000617.0100-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0100-2021</ArticleId><ArticleId IdType="pmc">PMC9488944</ArticleId><ArticleId IdType="pubmed">35022255</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien LH, Jiang HF, Tsai FY, et al. Incidence of Lung Adenocarcinoma by Age, Sex, and Smoking Status in Taiwan. JAMA Netw Open 2023;6:e2340704. 10.1001/jamanetworkopen.2023.40704</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.40704</ArticleId><ArticleId IdType="pmc">PMC10620613</ArticleId><ArticleId IdType="pubmed">37910104</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong WM, Xu QP, Li X, et al. The association between human papillomavirus infection and lung cancer: a system review and meta-analysis. Oncotarget 2017;8:96419-32. 10.18632/oncotarget.21682</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.21682</ArticleId><ArticleId IdType="pmc">PMC5707111</ArticleId><ArticleId IdType="pubmed">29221217</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer (Auckl) 2012;3:79-89. 10.2147/LCTT.S37319</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/LCTT.S37319</ArticleId><ArticleId IdType="pmc">PMC5312492</ArticleId><ArticleId IdType="pubmed">28210127</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 2006;119:741-4. 10.1002/ijc.21891</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.21891</ArticleId><ArticleId IdType="pubmed">16557573</ArticleId></ArticleIdList></Reference><Reference><Citation>Stapelfeld C, Dammann C, Maser E. Sex-specificity in lung cancer risk. Int J Cancer 2020;146:2376-82. 10.1002/ijc.32716</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32716</ArticleId><ArticleId IdType="pubmed">31583690</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton E, Conron M. Improving outcomes in lung cancer: the value of the multidisciplinary health care team. J Multidiscip Healthc 2016;9:137-44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820200</ArticleId><ArticleId IdType="pubmed">27099511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev 2016;42:56-72. 10.1016/j.ctrv.2015.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2015.11.007</ArticleId><ArticleId IdType="pubmed">26643552</ArticleId></ArticleIdList></Reference><Reference><Citation>Navani N, Baldwin DR, Edwards JG, et al. Lung Cancer in the United Kingdom. J Thorac Oncol 2022;17:186-93. 10.1016/j.jtho.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2021.11.002</ArticleId><ArticleId IdType="pubmed">35074225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H, Wang Y, Qin D, et al. Advanced surgical technologies for lung cancer treatment: Current status and perspectives. Engineered Regeneration 2023;4:55-67. 10.1016/j.engreg.2022.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.engreg.2022.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ironmonger L, Ohuma E, Ormiston-Smith N, et al. An evaluation of the impact of large-scale interventions to raise public awareness of a lung cancer symptom. Br J Cancer 2015;112:207-16. 10.1038/bjc.2014.596</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bjc.2014.596</ArticleId><ArticleId IdType="pmc">PMC4453621</ArticleId><ArticleId IdType="pubmed">25461805</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball S, Hyde C, Hamilton W, et al. An evaluation of a national mass media campaign to raise public awareness of possible lung cancer symptoms in England in 2016 and 2017. Br J Cancer 2022;126:187-95. 10.1038/s41416-021-01573-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-021-01573-w</ArticleId><ArticleId IdType="pmc">PMC8770501</ArticleId><ArticleId IdType="pubmed">34718357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Sci Rep 2021;11:12180. 10.1038/s41598-021-91852-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-91852-6</ArticleId><ArticleId IdType="pmc">PMC8190256</ArticleId><ArticleId IdType="pubmed">34108586</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland M. Linking physicians' pay to the quality of care--a major experiment in the United kingdom. N Engl J Med 2004;351:1448-54. 10.1056/NEJMhpr041294</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMhpr041294</ArticleId><ArticleId IdType="pubmed">15459308</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow AJ. Cancer Registration in England and Wales: Some Aspects Relevant to Interpretation of the Data. J R Stat Soc 1986;149:146-60. 10.2307/2981527</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2981527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 2010;39:598-610. 10.1093/ije/dyp392</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyp392</ArticleId><ArticleId IdType="pubmed">20142331</ArticleId></ArticleIdList></Reference><Reference><Citation>Arhi CS, Bottle A, Burns EM, et al. Comparison of cancer diagnosis recording between the Clinical Practice Research Datalink, Cancer Registry and Hospital Episodes Statistics. Cancer Epidemiol 2018;57:148-57. 10.1016/j.canep.2018.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2018.08.009</ArticleId><ArticleId IdType="pubmed">30290998</ArticleId></ArticleIdList></Reference><Reference><Citation>Strongman H, Williams R, Bhaskaran K. What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? a concordance and validation study using linked English electronic health records data. BMJ Open 2020;10:e037719. 10.1136/bmjopen-2020-037719</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037719</ArticleId><ArticleId IdType="pmc">PMC7443310</ArticleId><ArticleId IdType="pubmed">32819994</ArticleId></ArticleIdList></Reference><Reference><Citation>Mincuzzi A, Carone S, Galluzzo C, et al. Gender differences, environmental pressures, tumor characteristics, and death rate in a lung cancer cohort: a seven-years Bayesian survival analysis using cancer registry data from a contaminated area in Italy. Front Public Health 2023;11:1278416. 10.3389/fpubh.2023.1278416</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1278416</ArticleId><ArticleId IdType="pmc">PMC10806087</ArticleId><ArticleId IdType="pubmed">38269375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer. Nat Rev Dis Primers 2021;7:3. 10.1038/s41572-020-00235-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-020-00235-0</ArticleId><ArticleId IdType="pmc">PMC8177722</ArticleId><ArticleId IdType="pubmed">33446664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39459008</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Trends in Antidiabetic Drug Use and Safety of Metformin in Diabetic Patients with Varying Degrees of Chronic Kidney Disease from 2010 to 2021 in Korea: Retrospective Cohort Study Using the Common Data Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1369</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17101369</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to investigate trends in antidiabetic drug use and assess the risk of metformin-associated lactic acidosis (MALA) in patients with chronic kidney disease (CKD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective observational analysis based on the common data model was conducted using electronic medical records from 2010 to 2021. The patients included were aged &#x2265;18, diagnosed with CKD and type 2 diabetes, and had received antidiabetic medications for &#x2265;30 days. MALA was defined as pH &#x2264; 7.35 and arterial lactate &#x2265;4 mmol/L.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 8318 patients were included, with 6185 in CKD stages 1-2 and 2133 in stages 3a-5. Metformin monotherapy was the most prescribed regimen, except in stage 5 CKD. As CKD progressed, metformin use significantly declined; insulin and meglitinides were most frequently prescribed in end-stage renal disease. Over the study period, the use of SGLT2 inhibitors (13.3%) and DPP-4 inhibitors (24.5%) increased significantly, while sulfonylurea use decreased (<i>p</i> &lt; 0.05). Metformin use remained stable in earlier CKD stages but significantly decreased in stage 3b or worse. The incidence rate (IR) of MALA was 1.22 per 1000 patient-years, with a significantly increased IR in stage 4 or worse CKD (<i>p</i> &lt; 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Metformin was the most prescribed antidiabetic drug in CKD patients in Korea with a low risk of MALA. Antidiabetic drug use patterns varied across CKD stages, with a notable decline in metformin use in advanced CKD and a rise in SGLT2 inhibitor prescriptions, underscoring the need for further optimized therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Sung Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Seungwon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suhyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8481-4367</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seok Jun</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0009-0008-7087-4914</Identifier><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Taemin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0003-0119-5818</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jae Myung</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-9403-230X</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhie</LastName><ForeName>Sandy Jeong</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-2554-3370</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hyeon Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yang Gyun</ForeName><Initials>YG</Initials><Identifier Source="ORCID">0000-0002-3497-5514</Identifier><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0001-9200-2799</Identifier><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 20221136U0054101S000100</GrantID><Agency>Korea Institute of Drug Safety and Risk Management</Agency><Country/></Grant><Grant><GrantID>No. 20222396</GrantID><Agency>Kyung Hee University</Agency><Country/></Grant><Grant><GrantID>No. 21153MFDS601-1</GrantID><Agency>Ministry of Food and Drug Safety</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic kid-ney disease</Keyword><Keyword MajorTopicYN="N">common data model (CDM)</Keyword><Keyword MajorTopicYN="N">metformin-associated lactic acidosis</Keyword><Keyword MajorTopicYN="N">observational medical outcomes partnership (OMOP)</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">real-world data (RWD)</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459008</ArticleId><ArticleId IdType="pmc">PMC11510110</ArticleId><ArticleId IdType="doi">10.3390/ph17101369</ArticleId><ArticleId IdType="pii">ph17101369</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Boer I.H., Khunti K., Sadusky T., Tuttle K.R., Neumiller J.J., Rhee C.M., Rosas S.E., Rossing P., Bakris G. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Care. 2022;45:3075&#x2013;3090. doi: 10.2337/dci22-0027.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci22-0027</ArticleId><ArticleId IdType="pmc">PMC9870667</ArticleId><ArticleId IdType="pubmed">36189689</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens P.E., Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Ann. Intern. Med. 2013;158:825&#x2013;830. doi: 10.7326/0003-4819-158-11-201306040-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-11-201306040-00007</ArticleId><ArticleId IdType="pubmed">23732715</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X.S., Farej R., Dean B.B., Xia F., Gaiser A., Kong S.X., Elliott J., Lindemann S., Singh R. CKD Prevalence Among Patients with and without Type 2 Diabetes: Regional Differences in the United States. Kidney Med. 2021;4:100385. doi: 10.1016/j.xkme.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xkme.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8767132</ArticleId><ArticleId IdType="pubmed">35072048</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Diabetes: Fact Sheets.  [(accessed on 15 March 2024)].  Available online:  https://www.who.int/news-room/fact-sheets/detail/diabetes.</Citation></Reference><Reference><Citation>Korean Society of Nephrology  Practical Recommendations for the Management of Diabetic Kidney Disease.  [(accessed on 15 March 2024)].  Available online:  https://ksn.or.kr/bbs/index.php?page=1&amp;code=guideline_k.</Citation></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes&#x2014;2024. Diabetes Care. 2024;47:S219&#x2013;S230. doi: 10.2337/dc24-S011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S011</ArticleId><ArticleId IdType="pmc">PMC10725805</ArticleId><ArticleId IdType="pubmed">38078574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S., Presswala L., Harris Y.T., Romao I., Ross D.W., Paz H.A., Zhang M., Jhaveri K.D., Sakhiya V., Fishbane S. Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Prospective Observational Study. Kidney360. 2020;1:897&#x2013;903. doi: 10.34067/KID.0001272020.</Citation><ArticleIdList><ArticleId IdType="doi">10.34067/KID.0001272020</ArticleId><ArticleId IdType="pmc">PMC8815604</ArticleId><ArticleId IdType="pubmed">35369557</ArticleId></ArticleIdList></Reference><Reference><Citation>Flory J.H., Hennessy S., Bailey C.J., Inzucchi S.E. Reports of Lactic Acidosis Attributed to Metformin, 2015&#x2013;2018. Diabetes Care. 2020;43:244&#x2013;246. doi: 10.2337/dc19-0923.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-0923</ArticleId><ArticleId IdType="pmc">PMC7011199</ArticleId><ArticleId IdType="pubmed">31597667</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes&#x2014;2024. Diabetes Care. 2024;47:S158&#x2013;S178. doi: 10.2337/dc24-S009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi S.E., Lipska K.J., Mayo H., Bailey C.J., McGuire D.K. Metformin in Patients with Type 2 Diabetes and Kidney Disease: A Systematic Review. JAMA. 2014;312:2668&#x2013;2675. doi: 10.1001/jama.2014.15298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.15298</ArticleId><ArticleId IdType="pmc">PMC4427053</ArticleId><ArticleId IdType="pubmed">25536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.C., Ko Y., Chen C.H., Hung Y.J., Wei T.E., Chang T.H., Ke S.S., Kuo K.N., Chen C. Relationship between Metformin Use and Lactic Acidosis in Advanced Chronic Kidney Disease: The REMIND-TMU Study. Am. J. Med. Sci. 2022;364:575&#x2013;582. doi: 10.1016/j.amjms.2022.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2022.01.026</ArticleId><ArticleId IdType="pubmed">35483434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur K.Y., Kim M.K., Ko S.H., Han M., Lee D.W., Kwon H.S., Committee of Clinical Practice Guidelines, Korean Diabetes Association Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes Metab. J. 2020;44:3&#x2013;10. doi: 10.4093/dmj.2020.0004.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2020.0004</ArticleId><ArticleId IdType="pmc">PMC7043977</ArticleId><ArticleId IdType="pubmed">32097995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus B., Wu A., Shin J.I., Sang Y., Alexander G.C., Secora A., Inker L.A., Coresh J., Chang A.R., Grams M.E. Association of Metformin Use with Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Intern. Med. 2018;178:903&#x2013;910. doi: 10.1001/jamainternmed.2018.0292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.0292</ArticleId><ArticleId IdType="pmc">PMC6145716</ArticleId><ArticleId IdType="pubmed">29868840</ArticleId></ArticleIdList></Reference><Reference><Citation>Spallek H., Song M., Polk D.E., Bekhuis T., Frantsve-Hawley J., Aravamudhan K. Barriers to Implementing Evidence-Based Clinical Guidelines: A Survey of Early Adopters. J. Evid. Based Dent. Pract. 2010;10:195&#x2013;206. doi: 10.1016/j.jebdp.2010.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jebdp.2010.05.013</ArticleId><ArticleId IdType="pmc">PMC3011934</ArticleId><ArticleId IdType="pubmed">21093800</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.H., Oh H.J., Kwon S.H., Jeon J.S., Noh H., Han D.C., Kim H., Ryu D.R. Metformin Use and Cardiovascular Outcomes in Patients with Diabetes and Chronic Kidney Disease: A Nationwide Cohort Study. Kidney Res. Clin. Pract. 2021;40:660&#x2013;672. doi: 10.23876/j.krcp.20.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.23876/j.krcp.20.222</ArticleId><ArticleId IdType="pmc">PMC8685353</ArticleId><ArticleId IdType="pubmed">34922433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran M., Loi B., Ariff N.M., Chuan N.O., Sham S.Y.Z., Thambiah S.C., Samsudin I.N. Appropriateness of Metformin Prescription for Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease (Stages 3&#x2013;5) Malays. J. Pathol. 2020;42:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">32342933</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A., Wu X., Orloff J., Min J.Y., Flory J. Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose after FDA Label Change. J. Gen. Intern. Med. 2021;36:3261&#x2013;3263. doi: 10.1007/s11606-020-06380-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-06380-2</ArticleId><ArticleId IdType="pmc">PMC8481432</ArticleId><ArticleId IdType="pubmed">33409883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S.J., Lee S.E., Shin D.H., Park I.B., Lee H.S., Kim K.A. Barriers to Initiating SGLT2 Inhibitors in Diabetic Kidney Disease: A Real-World Study. BMC Nephrol. 2021;22:177. doi: 10.1186/s12882-021-02381-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-021-02381-3</ArticleId><ArticleId IdType="pmc">PMC8122538</ArticleId><ArticleId IdType="pubmed">33990175</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie J., Rajapakshe R., Shen H., Rajapakshe S., Lin A. A Semiautomated Chart Review for Assessing the Development of Radiation Pneumonitis Using Natural Language Processing: Diagnostic Accuracy and Feasibility Study. JMIR Med. Inform. 2021;9:e29241. doi: 10.2196/29241.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29241</ArticleId><ArticleId IdType="pmc">PMC8663661</ArticleId><ArticleId IdType="pubmed">34766919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N., Zoch M., Kelbert P., Noll R., Schaaf J., Wolfien M., Sedlmayr M. Methods Used in the Development of Common Data Models for Health Data: Scoping Review. JMIR Med. Inform. 2023;11:e45116. doi: 10.2196/45116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/45116</ArticleId><ArticleId IdType="pmc">PMC10436118</ArticleId><ArticleId IdType="pubmed">37535410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S., Seo J., Kim S., Lee J., Kim J.-H., Sohn J.W., Moon J., Joo H.J. Proposal and Assessment of a De-Identification Strategy to Enhance Anonymity of the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) in a Public Cloud-Computing Environment: Anonymization of Medical Data Using Privacy Models. J. Med. Internet Res. 2020;22:e19597. doi: 10.2196/19597.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/19597</ArticleId><ArticleId IdType="pmc">PMC7728527</ArticleId><ArticleId IdType="pubmed">33177037</ArticleId></ArticleIdList></Reference><Reference><Citation>Junior E.P.P., Normando P., Flores-Ortiz R., Afzal M.U., Jamil M.A., Bertolin S.F., Oliveira V.A., Martufi V., de Sousa F., Bashir A., et al. Integrating real-world data from Brazil and Pakistan into the OMOP common data model and standardized health analytics framework to characterize COVID-19 in the Global South. J. Am. Med. Inform. Assoc. 2023;30:643&#x2013;655. doi: 10.1093/jamia/ocac180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac180</ArticleId><ArticleId IdType="pmc">PMC9619798</ArticleId><ArticleId IdType="pubmed">36264262</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M., Del Fiol G., Tenenbaum J., Walden A., Zozus M.N. Evaluating Common Data Models for Use with a Longitudinal Community Registry. J. Biomed. Inform. 2016;64:333&#x2013;341. doi: 10.1016/j.jbi.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1&#x2013;S115. doi: 10.1016/j.kint.2020.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.06.019</ArticleId><ArticleId IdType="pubmed">32998798</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw J., Harhay M., Setoguchi S., Gerhard T., Dave C.V. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients with Type 2 Diabetes in the U.K. with and Without Chronic Kidney Disease, 2006&#x2013;2020. Diabetes Care. 2022;45:2316&#x2013;2325. doi: 10.2337/dc22-0224.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-0224</ArticleId><ArticleId IdType="pubmed">35984049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gor D., Gerber B.S., Walton S.M., Lee T.A., Nutescu E.A., Touchette D.R. Antidiabetic Drug Use Trends in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Cross-Sectional Analysis of the National Health and Nutrition Examination Survey. J. Diabetes. 2020;12:385&#x2013;395. doi: 10.1111/1753-0407.13003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.13003</ArticleId><ArticleId IdType="pubmed">31652390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee J.J., Han J., Montez-Rath M.E., Kim S.H., Cullen M.R., Stafford R.S., Winkelmayer W.C., Chertow G.M. Antidiabetic Medication Use in Patients with Type 2 Diabetes and Chronic Kidney Disease. J. Diabetes Its Complicat. 2019;33:107423. doi: 10.1016/j.jdiacomp.2019.107423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2019.107423</ArticleId><ArticleId IdType="pmc">PMC6823164</ArticleId><ArticleId IdType="pubmed">31537413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Food and Drug Safety (MFDS)  Drug Approval by MFDS.  [(accessed on 15 March 2024)].  Available online:  https://nedrug.mfds.go.kr/eng/index.</Citation></Reference><Reference><Citation>Wanner C., Inzucchi S.E., Lachin J.M., Fitchett D., von Eynatten M., Mattheus M., Johansen O.E., Woerle H.J., Broedl U.C., Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016;375:323&#x2013;334. doi: 10.1056/NEJMoa1515920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1515920</ArticleId><ArticleId IdType="pubmed">27299675</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J., Charytan D.M., Edwards R., Agarwal R., Bakris G., Bull S., et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019;380:2295&#x2013;2306. doi: 10.1056/NEJMoa1811744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1811744</ArticleId><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink H.J., Stef&#xe1;nsson B.V., Correa-Rotter R., Chertow G.M., Greene T., Hou F.F., Mann J.F., McMurray J.J., Lindberg M., Rossing P., et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020;383:1436&#x2013;1446. doi: 10.1056/NEJMoa2024816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024816</ArticleId><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117&#x2013;S314. doi: 10.1016/j.kint.2023.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2023.10.018</ArticleId><ArticleId IdType="pubmed">38490803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1&#x2013;S127. doi: 10.1016/j.kint.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.06.008</ArticleId><ArticleId IdType="pubmed">36272764</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado-Duque M.E., Gaviria-Mendoza A., Valladales-Restrepo L.F., Franco J.S., de Rosario Forero M., Vizcaya D., Machado-Alba J.E. Treatment Patterns of Antidiabetic and Kidney Protective Therapies Among Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease in Colombia. The KDICO Descriptive Study. Diabetol. Metab. Syndr. 2023;15:150. doi: 10.1186/s13098-023-01126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-023-01126-6</ArticleId><ArticleId IdType="pmc">PMC10318702</ArticleId><ArticleId IdType="pubmed">37403118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A.S., Khan M., Ortega D., Jaffery S., Lamerato L.E., Budzynska K. Prescription Patterns of Novel Antihyperglycemic Medications. J. Am. Board Fam. Med. 2022;35:255&#x2013;264. doi: 10.3122/jabfm.2022.02.210360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2022.02.210360</ArticleId><ArticleId IdType="pubmed">35379713</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Insurance Review &amp; Assessment Service (HIRA)  Medication Reimbursement History.  [(accessed on 15 March 2024)].  Available online:  https://www.hira.or.kr/</Citation></Reference><Reference><Citation>Cole N.I., Swift P.A., Suckling R.J., Andrews P.A. Metformin in Advanced Chronic Kidney Disease: Are Current Guidelines Overly Restrictive? Br. J. Diabetes. 2016;16:168&#x2013;175. doi: 10.15277/bjd.2016.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.15277/bjd.2016.106</ArticleId></ArticleIdList></Reference><Reference><Citation>Montvida O., Shaw J., Atherton J.J., Stringer F., Paul S.K. Long-Term Trends in Antidiabetes Drug Usage in the U.S.: Real-World Evidence in Patients Newly Diagnosed with Type 2 Diabetes. Diabetes Care. 2018;41:69&#x2013;78. doi: 10.2337/dc17-1414.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc17-1414</ArticleId><ArticleId IdType="pubmed">29109299</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes&#x2014;2019. Diabetes Care. 2019;42:S90&#x2013;S102. doi: 10.2337/dc19-S009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-S009</ArticleId><ArticleId IdType="pubmed">30559235</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Diabetes Association  KDA Treatment Guidelines for Diabetes.  [(accessed on 15 March 2024)].  Available online:  https://diabetes.or.kr/english/</Citation></Reference><Reference><Citation>Mann J.F., &#xd8;rsted D.D., Brown-Frandsen K., Marso S.P., Poulter N.R., Rasmussen S., Torn&#xf8;e K., Zinman B., Buse J.B. Liraglutide and Renal Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2017;377:839&#x2013;848. doi: 10.1056/NEJMoa1616011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1616011</ArticleId><ArticleId IdType="pubmed">28854085</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo R., Fleming G.A., Chen K., Bicsak T.A. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016;65:20&#x2013;29. doi: 10.1016/j.metabol.2015.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2015.10.014</ArticleId><ArticleId IdType="pubmed">26773926</ArticleId></ArticleIdList></Reference><Reference><Citation>Visconti L., Cernaro V., Ferrara D., Costantino G., Aloisi C., Amico L., Chirico V., Santoro D., Noto A., David A., et al. Metformin-Related Lactic Acidosis: Is It a Myth or an Underestimated Reality? Ren. Fail. 2016;38:1560&#x2013;1565. doi: 10.1080/0886022X.2016.1216723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2016.1216723</ArticleId><ArticleId IdType="pubmed">27686366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissanayake A.M., Wheldon M.C., Ahmed J., Hood C.J. Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy. Kidney Int. Rep. 2017;2:705&#x2013;712. doi: 10.1016/j.ekir.2017.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2017.03.005</ArticleId><ArticleId IdType="pmc">PMC5720630</ArticleId><ArticleId IdType="pubmed">29318219</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan S.C., Barr J., Arieff A.I., Pearl R.G. Biguanide-Associated Lactic Acidosis: Case Report and Review of the Literature. Arch. Intern. Med. 1992;152:2333&#x2013;2336. doi: 10.1001/archinte.1992.00400230129023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1992.00400230129023</ArticleId><ArticleId IdType="pubmed">1444694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yendapally R., Sikazwe D., Kim S.S., Ramsinghani S., Fraser-Spears R., Witte A.P., La-Viola B. A Review of Phenformin, Metformin, and Imeglimin. Drug Dev. Res. 2020;81:390&#x2013;401. doi: 10.1002/ddr.21636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21636</ArticleId><ArticleId IdType="pubmed">31916629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q., Nong K., Vandvik P.O., Guyatt G.H., Schnell O., Ryd&#xe9;n L., Marx N., Brosius F.C., 3rd, Mustafa R.A., Agarwal A., et al. Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. doi: 10.1136/bmj-2022-074068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074068</ArticleId><ArticleId IdType="pmc">PMC10077111</ArticleId><ArticleId IdType="pubmed">37024129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodmer M., Meier C., Kr&#xe4;henb&#xfc;hl S., Jick S.S., Meier C.R. Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A Nested Case-Control Analysis. Diabetes Care. 2008;31:2086&#x2013;2091. doi: 10.2337/dc08-1171.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc08-1171</ArticleId><ArticleId IdType="pmc">PMC2571051</ArticleId><ArticleId IdType="pubmed">18782901</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;a Porta J.M., Villafuerte Ledesma H.M., Vicente de Vera Florist&#xe1;n C., Ferrer Dufol A., Salvador G&#xf3;mez T., &#xc1;lvarez Lipe R. Incidence, Factors Related to Presentation, Course and Mortality of Metformin-Associated Lactic Acidosis in the Healthcare Area of a Tertiary Hospital. Nefrologia Engl. Ed. 2019;39:35&#x2013;43. doi: 10.1016/j.nefroe.2018.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nefroe.2018.04.012</ArticleId><ArticleId IdType="pubmed">30060893</ArticleId></ArticleIdList></Reference><Reference><Citation>Blough B., Moreland A., Mora A., Jr. Metformin-Induced Lactic Acidosis with Emphasis on the Anion Gap. Proc. Bayl. Univ. Med. Cent. 2015;28:31&#x2013;33. doi: 10.1080/08998280.2015.11929178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08998280.2015.11929178</ArticleId><ArticleId IdType="pmc">PMC4264704</ArticleId><ArticleId IdType="pubmed">25552792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Sarwal A., Yee X.T., Gandarillas Fraga S.A., Campion V., Gnanasekaran I. Metformin-Associated Lactic Acidosis (MALA): Is It an Underestimated Entity? A Retrospective, Single-Center Case Series. Hemodial. Int. 2024;28:32&#x2013;39. doi: 10.1111/hdi.13113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hdi.13113</ArticleId><ArticleId IdType="pubmed">37776126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan N.N., Brain H.P.S., Feher M.D. Metformin-Associated Lactic Acidosis: A Rare or Very Rare Clinical Entity? Diabet. Med. 1999;16:273&#x2013;281. doi: 10.1046/j.1464-5491.1999.00006.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1464-5491.1999.00006.x</ArticleId><ArticleId IdType="pubmed">10220200</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration (FDA)  Drugs@FDA: FDA-Approved Drugs.  [(accessed on 15 March 2024)]; Available online:  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.</Citation></Reference><Reference><Citation>Observational Health Data Science and Informatics (OHDSI)  Standardized Data: The OMOP Common Data Model.  [(accessed on 15 March 2024)].  Available online:  https://www.ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>Fralick M., Kim S.C., Schneeweiss S., Kim D., Redelmeier D.A., Patorno E. Fracture Risk after Initiation of Use of Canagliflozin: A Cohort Study. Ann. Intern. Med. 2019;170:155&#x2013;163. doi: 10.7326/M18-0567.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0567</ArticleId><ArticleId IdType="pmc">PMC6602870</ArticleId><ArticleId IdType="pubmed">30597484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda P., Svanstr&#xf6;m H., Melbye M., Eliasson B., Svensson A.-M., Franz&#xe9;n S., Gudbj&#xf6;rnsdottir S., Hveem K., Jonasson C., Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register-based cohort study. BMJ. 2018;363:k4365. doi: 10.1136/bmj.k4365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k4365</ArticleId><ArticleId IdType="pmc">PMC6233755</ArticleId><ArticleId IdType="pubmed">30429124</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Ann. Intern. Med. 1999;130:461&#x2013;470. doi: 10.7326/0003-4819-130-6-199903160-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-130-6-199903160-00002</ArticleId><ArticleId IdType="pubmed">10075613</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwandt A., Denkinger M., Fasching P., Pfeifer M., Wagner C., Weiland J., Zeyfang A., Holl R.W. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J. Diabetes Its Complicat. 2017;31:1376&#x2013;1383. doi: 10.1016/j.jdiacomp.2017.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2017.06.016</ArticleId><ArticleId IdType="pubmed">28711195</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann P., Ong R., Davydov A., Orlova A., Solovyev P., Sun H., Wetherill G., Brand M., Didden E.M. Standardizing Registry Data to the OMOP Common Data Model: Experience from Three Pulmonary Hypertension Databases. BMC Med. Res. Methodol. 2021;21:238. doi: 10.1186/s12874-021-01434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Thammavaranucupt K., Phonyangnok B., Parapiboon W., Wongluechai L., Pichitporn W., Sumrittivanicha J., Sungkanuparph S., Nongnuch A., Jayanama K. Metformin-Associated Lactic Acidosis and Factors Associated with 30-Day Mortality. PLoS ONE. 2022;17:e0273678. doi: 10.1371/journal.pone.0273678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273678</ArticleId><ArticleId IdType="pmc">PMC9426915</ArticleId><ArticleId IdType="pubmed">36040976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39463847</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2624-909X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in big data</Title><ISOAbbreviation>Front Big Data</ISOAbbreviation></Journal><ArticleTitle>Integrating longitudinal mental health data into a staging database: harnessing DDI-lifecycle and OMOP vocabularies within the INSPIRE Network Datahub.</ArticleTitle><Pagination><StartPage>1435510</StartPage><MedlinePgn>1435510</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1435510</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fdata.2024.1435510</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Longitudinal studies are essential for understanding the progression of mental health disorders over time, but combining data collected through different methods to assess conditions like depression, anxiety, and psychosis presents significant challenges. This study presents a mapping technique allowing for the conversion of diverse longitudinal data into a standardized staging database, leveraging the Data Documentation Initiative (DDI) Lifecycle and the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) standards to ensure consistency and compatibility across datasets.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The "INSPIRE" project integrates longitudinal data from African studies into a staging database using metadata documentation standards structured with a snowflake schema. This facilitates the development of Extraction, Transformation, and Loading (ETL) scripts for integrating data into OMOP CDM. The staging database schema is designed to capture the dynamic nature of longitudinal studies, including changes in research protocols and the use of different instruments across data collection waves.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Utilizing this mapping method, we streamlined the data migration process to the staging database, enabling subsequent integration into the OMOP CDM. Adherence to metadata standards ensures data quality, promotes interoperability, and expands opportunities for data sharing in mental health research.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The staging database serves as an innovative tool in managing longitudinal mental health data, going beyond simple data hosting to act as a comprehensive study descriptor. It provides detailed insights into each study stage and establishes a data science foundation for standardizing and integrating the data into OMOP CDM.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Mugotitsa, Bhattacharjee, Ochola, Mailosi, Amadi, Andeso, Kuria, Momanyi, Omondi, Kajungu, Todd, Kiragga and Greenfield.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mugotitsa</LastName><ForeName>Bylhah</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Strathmore University Business School, Strathmore University, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Tathagata</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochola</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mailosi</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Artificial Intelligence and Machine Learning (AI and ML), CODATA-Committee on Data of the International Science Council, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andeso</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuria</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Momanyi</LastName><ForeName>Reinpeter</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omondi</LastName><ForeName>Evans</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Mathematical Sciences, Strathmore University, Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajungu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Iganga Mayuge Health and Demographic Surveillance Site (IMHDSS), Makerere University Centre for Health and Population Research (MUCHAP), Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiragga</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Artificial Intelligence and Machine Learning (AI and ML), CODATA-Committee on Data of the International Science Council, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Big Data</MedlineTA><NlmUniqueID>101770603</NlmUniqueID><ISSNLinking>2624-909X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DDI-lifecycle</Keyword><Keyword MajorTopicYN="N">OMOP Common Data Model</Keyword><Keyword MajorTopicYN="N">extract</Keyword><Keyword MajorTopicYN="N">longitudinal mental health</Keyword><Keyword MajorTopicYN="N">staging database</Keyword><Keyword MajorTopicYN="N">transform and load</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39463847</ArticleId><ArticleId IdType="pmc">PMC11502395</ArticleId><ArticleId IdType="doi">10.3389/fdata.2024.1435510</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aghababaie-Babaki P., Malekpour M. R., Mohammadi E., Saeedi Moghaddam S., Rashidi M. M., Ghanbari A., et al. . (2023). Global, regional, and national burden and quality of care index (QCI) of bipolar disorder: a systematic analysis of the Global Burden of Disease Study 1990 to 2019. Int. J. Soc. Psychiatry 69, 1958&#x2013;1970. 10.1177/00207640231182358</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00207640231182358</ArticleId><ArticleId IdType="pubmed">37353952</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N., Peng Y., Wolfien M., Zoch M., Sedlmayr M. (2022). OMOP CDM can facilitate data-driven studies for cancer prediction: a systematic review. Int. J. Mol. Sci. 23:11834. 10.3390/ijms231911834</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911834</ArticleId><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Benzler J., Herbst K., MacLeod B. (1998). A Data Model for Demographic Surveillance Systems. INDEPTH Network.</Citation></Reference><Reference><Citation>Bhattacharjee T., Kiwuwa-Muyingo S., Kanjala C., Maoyi M. L., Amadi D., Ochola M., et al. . (2024). INSPIRE datahub: a pan-African integrated suite of services for harmonising longitudinal population health data using OHDSI tools. Frontiers in Digital Health. 6:1329630. 10.3389/fdgth.2024.1329630</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fdgth.2024.1329630</ArticleId><ArticleId IdType="pmc">PMC10859396</ArticleId><ArticleId IdType="pubmed">38347885</ArticleId></ArticleIdList></Reference><Reference><Citation>Community.i2b2 . Star Schema Introduction. Available at: https://community.i2b2.org/wiki/display/BUN/2.+Quick+Start+Guide (accessed June 27 2024).</Citation></Reference><Reference><Citation>Data Documentation Initiative . DDI Data Documentation 3.3. Available at: https://ddialliance.github.io/ddimodel-web/DDI-L-3.3/ (accessed June 27 2024).</Citation></Reference><Reference><Citation>Data Documentation Initiative-CDI . UML Diagram: Class Datum in Context. Available at: https://ddi-cdi-resources.bitbucket.io/2024-03-12/field-level-documentation/DDICDILibrary/Classes/DataDescription/Datum.html (accessed June 23 2024).</Citation></Reference><Reference><Citation>dbdiagram.io. 
Draw Entity-Relationship Diagrams. Available at: https://dbdiagram.io/home (accessed June 27 2024).</Citation></Reference><Reference><Citation>Deguen S., Amuzu M., Simoncic V., Kihal-Talantikite W. (2022). Exposome and social vulnerability: an overview of the literature review. Int. J. Environ. Res. Public. Health 19:3534. 10.3390/ijerph19063534</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19063534</ArticleId><ArticleId IdType="pmc">PMC8955941</ArticleId><ArticleId IdType="pubmed">35329217</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda S. N., Musick B. S., Davies M. A., Sohn A. H., Ledergerber B., Wools-Kaloustian K., et al. . (2020). The IeDEA data exchange standard: a common data model for global HIV cohort collaboration. MedRxiv [Preprint].</Citation></Reference><Reference><Citation>Essock S. M., Olfson M., Hogan M. F. (2015). Current practices for measuring mental health outcomes in the USA: international overview of routine outcome measures in mental health. Int. Rev. Psychiatry 27, 296&#x2013;305. 10.3109/09540261.2015.1014314</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09540261.2015.1014314</ArticleId><ArticleId IdType="pubmed">25800077</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield J., Carpenter D. (2013). The Paradata Information Model.</Citation></Reference><Reference><Citation>Healthcare P. (2017). Informatics for Integrating Biology and the Bedside.</Citation></Reference><Reference><Citation>Hitachi Vantara . Pentaho Data Integration&#x2014;Community Edition. Available at: https://www.hitachivantara.com/pentaho/pentaho-plus-platform/data-integration-analytics/pentaho-community-edition.html (accessed July 03 2024).</Citation></Reference><Reference><Citation>Holistics. 
Kimball's Dimensional Data Modeling. Available at: https://www.holistics.io/books/setup-analytics/kimball-s-dimensional-data-modeling/ (accessed June 24 2024).</Citation></Reference><Reference><Citation>Kajungu D., Hirose A., Rutebemberwa E., Pariyo G. W., Peterson S., Guwatudde D., et al. . (2020). Cohort profile: the Iganga-Mayuge Health and Demographic Surveillance Site, Uganda (IMHDSS, Uganda). Int. J. Epidemiol. 49, 1082&#x2013;1082. 10.1093/ije/dyaa064</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa064</ArticleId><ArticleId IdType="pubmed">32556335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler R. C., Berglund P., Demler O., Jin R., Merikangas K. R., Walters E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archiv. Gen. Psychiatry 62, 593&#x2013;602. 10.1001/archpsyc.62.6.593</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.62.6.593</ArticleId><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimball R. (1996). The Data Warehouse Toolkit: Practical Techniques For Building Dimensional Data Warehouses-Bom.</Citation></Reference><Reference><Citation>Kiwuwa-Muyingo S., Todd J., Bhattacharjee T., Taylor A., Greenfield J. (2023). Enabling data sharing and utilization for African population health data using OHDSI tools with an OMOP-common data model. Front. Public Health 11:1116682. 10.3389/fpubh.2023.1116682</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1116682</ArticleId><ArticleId IdType="pmc">PMC10287979</ArticleId><ArticleId IdType="pubmed">37361151</ArticleId></ArticleIdList></Reference><Reference><Citation>Levene M., Loizou G. (2003). Why is the snowflake schema a good data warehouse design? Inf. Syst. 28, 225&#x2013;240. 10.1016/S0306-4379(02)00021-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4379(02)00021-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeti M. (2022). World Mental Health Day 2022. Available at: https://www.afro.who.int/regional-director/speeches-messages/world-mental-health-day-2022 (accessed June 23, 2024).</Citation></Reference><Reference><Citation>Murray C. J. (2022). The global burden of disease study at 30 years. Nat. Med. 28, 2019&#x2013;2026. 10.1038/s41591-022-01990-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01990-1</ArticleId><ArticleId IdType="pubmed">36216939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas A., Joshua O., Elizabeth O. (2022). Accessing Mental Health Services in Africa: current state, efforts, challenges and recommendation. Ann. Med. Surg. 81:104421. 10.1016/j.amsu.2022.104421</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.104421</ArticleId><ArticleId IdType="pmc">PMC9387063</ArticleId><ArticleId IdType="pubmed">35996570</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. 
Bridge to Artificial Intelligence (Bridge2AI). Available at: https://commonfund.nih.gov/bridge2ai (accessed June 24 2024).</Citation></Reference><Reference><Citation>OHDSI (a) . Standardized Data: The OMOP Common Data Model. Available at: https://ohdsi.org/data-standardization/ (accessed June 23 2024).</Citation></Reference><Reference><Citation>OHDSI (b) . OMOP CDM Oncology Module at Work. Available at: https://www.ohdsi.org/wp-content/uploads/2019/09/Lightning-Talk-2-Oncology.pdf (accessed June 24 2024).</Citation></Reference><Reference><Citation>Planche V., Manjon J. V., Mansencal B., Lanuza E., Tourdias T., Catheline G., et al. . (2022). Structural progression of Alzheimer's disease over decades: the MRI staging scheme. Brain Commun. 4:fcac109. 10.1093/braincomms/fcac109</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac109</ArticleId><ArticleId IdType="pmc">PMC9113086</ArticleId><ArticleId IdType="pubmed">35592489</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarlou C. W., Jongsma K. R., Vermeulen R., Bredenoord A. L. (2023). The ethical aspects of exposome research: a systematic review. Exposome 3:osad004. 10.1093/exposome/osad004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/exposome/osad004</ArticleId><ArticleId IdType="pmc">PMC7615114</ArticleId><ArticleId IdType="pubmed">37745046</ArticleId></ArticleIdList></Reference><Reference><Citation>The Hyve . Mapping UK Biobank to the OMOP CDM: Development of Two OHDSI Tools. Available at: http://thehyve.nl/articles/mapping-uk-biobank-to-omop-cdm-development-of-ohdsi-tools (accessed June 27 2024).</Citation></Reference><Reference><Citation>Vardigan M., Heus P., Thomas W. (2008). Data documentation initiative: toward a standard for the social sciences. Int. J. Digit. Curat. 3, 107&#x2013;113. 10.2218/ijdc.v3i1.45</Citation><ArticleIdList><ArticleId IdType="doi">10.2218/ijdc.v3i1.45</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E. A., Makadia R., Matcho A., Ma Q., Knoll C., Schuemie M., et al. . (2015). Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. 22, 553&#x2013;564. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Verbal Autopsy Standards: Ascertaining and Attributing Causes of Death Tool. Available at: https://www.who.int/standards/classifications/other-classifications/verbal-autopsy-standards-ascertaining-and-attributing-causes-of-death-tool (accessed June 23 2024).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39484687</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>44</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2400680</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2807/1560-7917.ES.2024.29.44.2400680</ELocationID><Abstract><AbstractText>COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95%&#x202f;CI: -17&#x202f;to&#x202f;48), 49% (95%&#x202f;CI: -8&#x202f;to&#x202f;76) before and -11% (95%&#x202f;CI: -84&#x202f;to&#x202f;34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savulescu</LastName><ForeName>Camelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epiconcept, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These authors contributed equally to this work and share first authorship. The other co-authors are listed in the alphabetical order of their countries.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epiconcept, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These authors contributed equally to this work and share first authorship. The other co-authors are listed in the alphabetical order of their countries.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brolin</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusk&#xfc;la</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Tartu, Institute of Family Medicine and Public Health, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergin</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Saint James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zvirbulis</LastName><ForeName>Viesturs</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zavadska</LastName><ForeName>Dace</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaio</LastName><ForeName>Vania</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>Corneliu P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrisca</LastName><ForeName>Raluca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Military Emergency University Hospital "Dr. Carol Davila", Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisneros</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latorre-Mill&#xe1;n</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohur</LastName><ForeName>Liis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Viljandi Hospital, Viljandi, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Saint James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Gaetano Donati</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abolina</LastName><ForeName>Ilze</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravele</LastName><ForeName>Dagne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Ausenda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florescu</LastName><ForeName>Simin-Aysel</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subirats</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Occupational Risk Prevention, Hospital Sant Joan de Deu, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clusa Cuesta</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Jacklyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Saint James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santangelo</LastName><ForeName>Rosaria</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krievins</LastName><ForeName>Dainis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzdina</LastName><ForeName>Elza Anna</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valadas Henriques</LastName><ForeName>Camila</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosa</LastName><ForeName>Alma Gabriela</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohrib</LastName><ForeName>Saftica-Mariana</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Central Military Emergency University Hospital "Dr. Carol Davila", Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Almagro</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ciber of Epidemiology and Public Health CIBERESP, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milagro</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacci</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardone</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epiconcept, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VEBIS HCW VE study group</CollectiveName><AffiliationInfo><Affiliation>The additional collaborators of the VEBIS HCW VE study group are listed at the end of the article.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaborators in VEBIS HCW study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">Healthcare workers</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine effectiveness</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> APU reported payment under EMA DARWIN EU project outside of the submitted work. MLM, AM, LC reported additional support received from ISIDORe (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. CPP, SAF reported speaker fees from and participation in Advisory board of Pfizer and MSD. SAF reports also participation in Advisory board of Gilead. CMA reported speaker fees from MSD, Pfizer and Sanofi. JS reported support for attending ESID conference 2022 from Takeda Pharmaceutical. RH and SP reported grant attributed to their institution on &#x201c;PSCD Longitudinal evaluation of SARS CoV-2 immune status post-natural infection and post-vaccination&#x201d;. All other authors declare no conflicts of interest related to this work.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Sepp</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Domegan</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donell</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kernan</LastName><ForeName>Maeve</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moriarty</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moran</LastName><ForeName>Conor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamonica</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menchinelli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Recine</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tondinelli</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Falasca</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meisters</LastName><ForeName>Janis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zemite</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snipe</LastName><ForeName>Hilda Darta</ForeName><Initials>HD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ergle</LastName><ForeName>Estere</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palmira Amaral</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Almeida Santos</LastName><ForeName>Jo&#xe3;o</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dias</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomes</LastName><ForeName>Licinia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lan&#xe7;a</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Henrique</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alves</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Codreanu</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;rez-Arguello</LastName><ForeName>Amaresh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jordan</LastName><ForeName>Iolanda</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Garcia</LastName><ForeName>Juan Jose</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rezusta</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tristancho</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ezpeleta</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Due&#xf1;as</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terren</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valero</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Nieves Felisa</ForeName><Initials>NF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gracia</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilaberte</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasco</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Maria Pilar</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Maria Gemma</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Moral</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabio</LastName><ForeName>Ana Maria</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guiomar</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melo</LastName><ForeName>Aryse</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pozo</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulchandani</LastName><ForeName>Ranya</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rojas</LastName><ForeName>Madelyn</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39484687</ArticleId><ArticleId IdType="pmc">PMC11528902</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.44.2400680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. Amsterdam: EMA; Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants
</Citation></Reference><Reference><Citation>World Health Organization (WHO). WHO roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity. Geneva: WHO; 2023. Available from: https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2-eng.pdf?sequence=1
</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). The European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC. [Accessed: 11 Jun 2024]. Available from: https://www.ecdc.europa.eu/en/publications-data/european-respiratory-virus-surveillance-summary-erviss
</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 3.0 . Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/generic-protocol-ecdc-studies-covid-19-vaccine-effectiveness
</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Reinfection-with-SARSCoV2-implementation-of-a-surveillance-case-definition.pdf
</Citation></Reference><Reference><Citation>Shrestha NK, Burke PC, Nowacki AS, Gordon SM. Effectiveness of the 2023-2024 Formulation of the coronavirus disease 2019 messenger RNA vaccine. Clin Infect Dis. 2024;79(2):405-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">38465901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan PD, Foulkes S, Munro K, Sparkes D, Singh J, Henry A, et al. Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024. J Infect. 2024;89(5):106293. 10.1016/j.jinf.2024.106293</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2024.106293</ArticleId><ArticleId IdType="pubmed">39343245</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Ciesla AA, Mak J, Miller JD, Silk BJ, Lambrou AS, et al. Early estimates of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating Omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024;73(4):77-83. 10.15585/mmwr.mm7304a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7304a2</ArticleId><ArticleId IdType="pmc">PMC10843065</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId></ArticleIdList></Reference><Reference><Citation>Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O&#x2019;Donnell J, et al. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. Vaccine. 2024;42(19):3931-7. 10.1016/j.vaccine.2024.05.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.05.067</ArticleId><ArticleId IdType="pmc">PMC11252666</ArticleId><ArticleId IdType="pubmed">38839521</ArticleId></ArticleIdList></Reference><Reference><Citation>Thadani NN, Gurev S, Notin P, Youssef N, Rollins NJ, Ritter D, et al. Learning from prepandemic data to forecast viral escape. Nature. 2023;622(7984):818-25. 10.1038/s41586-023-06617-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06617-0</ArticleId><ArticleId IdType="pmc">PMC10599991</ArticleId><ArticleId IdType="pubmed">37821700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Lou J, Chan SY, Zheng H, Liu C, Zhao S, et al. Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nat Med. 2022;28(8):1715-22. 10.1038/s41591-022-01877-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01877-1</ArticleId><ArticleId IdType="pmc">PMC9388371</ArticleId><ArticleId IdType="pubmed">35710987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39486857</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1499-2752</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis.</ArticleTitle><Pagination><StartPage>344</StartPage><EndPage>351</EndPage><MedlinePgn>344-351</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.2024-0574</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Radiographic axial spondyloarthritis (r-axSpA) has a 7-year average diagnostic delay. Although the effects of sex or gender on time to diagnosis have been evaluated, the role of social determinants of health remains understudied. We assessed whether time from initial clinical documentation of r-axSpA symptoms to r-axSpA diagnosis (diagnostic delay) varies based on sex, race, ethnicity, and/or the presence of social needs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied patients with r-axSpA from a tertiary center from 2000 to 2022. The cohort was built with the Observational Health Data Sciences and Informatics (OHDSI) network. For the primary analysis, we assessed the time from back pain and/or spinal pain to r-axSpA diagnosis and, secondarily, the time to r-axSpA from any other r-axSpA-related condition. To estimate differences in diagnostic delay, we employed an accelerated failure time parametric survival model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 404 patients (mean age 49 years; 38.6% female), with 25.5% identifying as Black, 31.1% as other or unknown race, and 14.1% as Hispanic. Patients with a documented social need had a 21% increase in time from back pain to r-axSpA diagnosis (95% CI 0.93-1.56). In patients with any r-axSpA-related condition, time to diagnosis similarly increased by 21% (95% CI 0.92-1.57). Considering that there is an average time to diagnosis of 34 months, a social need increased time to diagnosis by 7 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study reveals a trend toward diagnostic delay in r-axSpA related to social need, sex, race, and ethnicity. Future studies should focus on referral strategies to enable prompt diagnosis and optimize care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 by the Journal of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrandiz-Espadin</LastName><ForeName>Renato</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6104-2712</Identifier><AffiliationInfo><Affiliation>R. Ferrandiz-Espadin, MD, MHA, Department of Internal Medicine, North Alabama Medical Center, Florence, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabasa</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4446-8129</Identifier><AffiliationInfo><Affiliation>G. Rabasa, MS, J.W. Liew, MD, MS, Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasman</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>S. Gasman, MSc, Department of Pediatrics, Boston Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGinley</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>B. McGinley, BS, BA, S.R. Jafarzadeh, DVM, MPVM, PhD, School of Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stovall</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0355-4020</Identifier><AffiliationInfo><Affiliation>R. Stovall, MD, MAS, Division of Rheumatology, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafarzadeh</LastName><ForeName>S Reza</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-1099-9175</Identifier><AffiliationInfo><Affiliation>B. McGinley, BS, BA, S.R. Jafarzadeh, DVM, MPVM, PhD, School of Public Health, Boston University, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Jean W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-8104-2450</Identifier><AffiliationInfo><Affiliation>G. Rabasa, MS, J.W. Liew, MD, MS, Section of Rheumatology, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubreuil</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6253-1515</Identifier><AffiliationInfo><Affiliation>M. Dubreuil, MD, MSc, Section of Rheumatology, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts, and Division of Rheumatology, University of Washington, Seattle, Washington, USA. mdubreui@bu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR072571</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM140972</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="Y">Delayed Diagnosis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000089183" MajorTopicYN="Y">Axial Spondyloarthritis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001416" MajorTopicYN="N">Back Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054625" MajorTopicYN="Y">Healthcare Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ankylosing spondylitis</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">social disparities</Keyword><Keyword MajorTopicYN="N">spondyloarthropathy</Keyword></KeywordList><CoiStatement>Conflict of interest. The authors declare no conflict of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>2</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39486857</ArticleId><ArticleId IdType="mid">NIHMS2031733</ArticleId><ArticleId IdType="pmc">PMC11961325</ArticleId><ArticleId IdType="doi">10.3899/jrheum.2024-0574</ArticleId><ArticleId IdType="pii">jrheum.2024-0574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hwang MC, Ridley L, Reveille JD. Ankylosing spondylitis risk factors: a systematic literature review. Clin Rheumatol. 2021. Aug;40(8):3079&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044547</ArticleId><ArticleId IdType="pubmed">33754220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. Ankylosing spondylitis: an autoimmune or autoinflammatory disease? Nat Rev Rheumatol. 2021. Jul;17(7):387&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">34113018</ArticleId></ArticleIdList></Reference><Reference><Citation>Taurog JD, Chhabra A, Colbert RA. Ankylosing Spondylitis and Axial Spondyloarthritis. Longo DL, editor. N Engl J Med. 2016. Jun 30;374(26):2563&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">27355535</ArticleId></ArticleIdList></Reference><Reference><Citation>Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, et al. Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain. Arthritis &amp; Rheumatology. 2016. Jul;68(7):1669&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094500</ArticleId><ArticleId IdType="pubmed">26816002</ArticleId></ArticleIdList></Reference><Reference><Citation>Jois RN, Macgregor AJ, Gaffney K. Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatology. 2008. Apr 4;47(9):1364&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18577550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong CY, Hamilton J, Benepal J, Griffiths K, Clark ZE, Rush A, et al. Awareness of axial spondyloarthritis among chiropractors and osteopaths: findings from a UK Web-based survey. Rheumatology Advances in Practice. 2019. Jul 1;3(2):rkz034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785804</ArticleId><ArticleId IdType="pubmed">31616854</ArticleId></ArticleIdList></Reference><Reference><Citation>On behalf of BRITSpA (British Society for Spondyloarthritis), Mathieson HR, Merashli M, Gaffney K, Marzo-Ortega H. Poor awareness of inflammatory back pain and axial spondyloarthritis among secondary care specialists. Clin Rheumatol. 2016. Oct;35(10):2627&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27180070</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido-Cumbrera M, Gratac&#xf3;s J, Collantes-Estevez E, Zarco-Montejo P, Sastre C, Christen L, et al. A Benchmarking Study Evaluating Axial Spondyloarthritis Burden in Spain and Other European Countries. Results from the Spanish Atlas and the European Map of Axial Spondyloarthritis (EMAS) Studies. Int J of Rheum Dis. 2021. Sep;24(9):1127&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">34268889</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulysse SN, Chandler MT, Santacroce L, Cai T, Liao KP, Feldman CH. Social Determinants of Health Documentation Among Individuals With Rheumatic and Musculoskeletal Conditions in an Integrated Care Management Program. Arthritis Care &amp; Research. 2023. Aug 7;acr.25174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725994</ArticleId><ArticleId IdType="pubmed">37331999</ArticleId></ArticleIdList></Reference><Reference><Citation>Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology. 2019. Sep 1;58(9):1634&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30903141</ArticleId></ArticleIdList></Reference><Reference><Citation>Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021. Aug;80(8):1004&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8292568</ArticleId><ArticleId IdType="pubmed">33906853</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Heijde D, Song IH, Pangan AL, Deodhar A, Van Den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. The Lancet. 2019. Dec;394(10214):2108&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">31732180</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JA, Pei S, Burningham Z, Penmetsa G, Cannon GW, Clegg DO, et al. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance. J Rheumatol. 2018. Mar;45(3):430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29142040</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvadorini G, Bandinelli F, Delle Sedie A, Riente L, Candelieri A, Generini S, et al. Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol. 2012;30(4):561&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22510360</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossfield SSR, Marzo-Ortega H, Kingsbury SR, Pujades-Rodriguez M, Conaghan PG. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open. 2021. Dec;7(3):e001888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8663075</ArticleId><ArticleId IdType="pubmed">34887345</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi HJ, Baek HJ, et al. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin Rheumatol. 2015. Aug;34(8):1397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">25185731</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmacharya P, Duarte-Garcia A, Dubreuil M, Murad MH, Shahukhal R, Shrestha P, et al. Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis. Arthritis &amp; Rheumatology. 2020. May;72(5):733&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218689</ArticleId><ArticleId IdType="pubmed">31960614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu MC, Huang KY, Tung CH, Hsu BB, Wu CH, Koo M, et al. Factors associated with disease-specific quality of life in Taiwanese patients with ankylosing spondylitis: a cross-sectional study. BMJ Open. 2019. Jun;9(6):e028966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6561418</ArticleId><ArticleId IdType="pubmed">31182453</ArticleId></ArticleIdList></Reference><Reference><Citation>Elolemy G, Aboughanima A, Ganeb S, Elziat H. Health-Related Quality of Life in Patients with Ankylosing Spondylitis: Relationship with Disease-Related Variables. CRR. 2020. Dec 24;16(4):311&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31656154</ArticleId></ArticleIdList></Reference><Reference><Citation>The burden of non-radiographic axial spondyloarthritis - PubMed [Internet]. [cited 2024 Apr 8]. Available from: https://pubmed.ncbi.nlm.nih.gov/25532945/</Citation></Reference><Reference><Citation>Jamalyaria F, Ward MM, Assassi S, Learch TJ, Lee M, Gensler LS, et al. Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol. 2017. Oct;36(10):2359&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5693696</ArticleId><ArticleId IdType="pubmed">28780639</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani CJ, Rundell SD, Jarvik JG, Friedly J, Heagerty PJ, Avins A, et al. Associations of Race and Ethnicity With Patient-Reported Outcomes and Health Care Utilization Among Older Adults Initiating a New Episode of Care for Back Pain. Spine. 2018. Jul 15;43(14):1007&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972040</ArticleId><ArticleId IdType="pubmed">29189640</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh DK, Magrey MN. Racial Differences in Clinical Features and Comorbidities in Ankylosing Spondylitis in the United States. J Rheumatol. 2020. Jun 1;47(6):835&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31474592</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmacharya P, Balls-Berry JE, Davis JM. True Difference or Detection Bias: Racial Differences in Clinical Features and Comorbidities in Ankylosing Spondylitis in the United States. J Rheumatol. 2020. Jul 1;47(7):1150.1&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly DP. Racial and Ethnic Disparities in the Evaluation and Management of Pain in the Outpatient Setting, 2006&#x2013;2015. Pain Medicine. 2019. Feb 1;20(2):223&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6374136</ArticleId><ArticleId IdType="pubmed">29688509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivesind TE, Runion T, Branda M, Schilling LM, Dellavalle RP. Dermatologic Research Potential of the Observational Health Data Sciences and Informatics (OHDSI) Network. Dermatology. 2022;238(1):44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">33735862</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitron De La Vega P, Losi S, Sprague Martinez L, Bovell-Ammon A, Garg A, James T, et al. Implementing an EHR-based Screening and Referral System to Address Social Determinants of Health in Primary Care. Medical Care. 2019. Jun;57(Suppl 2):S133&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31095052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu HE, Ashe EM, Silverstein M, Hofman M, Lange SJ, Razzaghi H, et al. Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center &#x2014; Boston, Massachusetts, 2020. MMWR Morb Mortal Wkly Rep. 2020. Jul 10;69(27):864&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727597</ArticleId><ArticleId IdType="pubmed">32644981</ArticleId></ArticleIdList></Reference><Reference><Citation>Assoumou SA, Bonilla HV, Vautour L, White C, Read Newcomb A, Kibbe D, et al. Boston Medical Center&#x2019;s Communications Campaign to Build Confidence in Covid-19 Vaccines. NEJM Catal Innov Care Deliv. 2024. Jan 17;5(2):CAT.23.0322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11132119</ArticleId><ArticleId IdType="pubmed">38813133</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Pavesi F, Steiling K, Asokan S, Espinosa C, Cabral HJ, et al. Risk factors for lung cancer in an underrepresented safety-net screening cohort. Clin Lung Cancer. 2022. Mar;23(2):e165&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8766584</ArticleId><ArticleId IdType="pubmed">34393063</ArticleId></ArticleIdList></Reference><Reference><Citation>Boston Medical Center [Internet]. [cited 2024 Aug 24]. Boston Medical Center Named #1 in Nation for Racial Inclusivity by Lown Institute. Available from: https://www.bmc.org/news/boston-medical-center-named-1-nation-racial-inclusivity-lown-institute</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, et al. Association of Hemoglobin A 1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Netw Open. 2018. Aug 24;1(4):e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing Reproducible Conclusions from Observational Clinical Data with OHDSI. Yearb Med Inform. 2021. Aug;30(01):283&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C, Sedlmayr M, Bathelt F. The Usage of OHDSI OMOP &#x2013; A Scoping Review. In: R&#xf6;hrig R, Bei&#x3b2; barth T, K&#xf6;nig J, Ose C, Rauch G, Sax U, et al., editors. Studies in Health Technology and Informatics [Internet]. IOS Press; 2021.  [cited 2023 Dec 2]. Available from: https://ebooks.iospress.nl/doi/10.3233/SHTI210546</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210546</ArticleId><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. Journal of the American Medical Informatics Association. 2018. Aug 1;25(8):969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Stensrud MJ, Hern&#xe1;n MA. Why Test for Proportional Hazards? JAMA. 2020. Apr 14;323(14):1401&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11983487</ArticleId><ArticleId IdType="pubmed">32167523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusman T, Van Bentum RE, Van Der Horst-Bruinsma IE. Sex and gender differences in axial spondyloarthritis: myths and truths. Rheumatology. 2020. Oct 1;59(Supplement_4):iv38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566372</ArticleId><ArticleId IdType="pubmed">33053194</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi E, Ahuja A, Rajput T, George AT, Park Y. Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic Review. Rheumatol Ther. 2020. Mar;7(1):65&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7021861</ArticleId><ArticleId IdType="pubmed">31965538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimenti MS, Alten R, D&#x2019;Agostino MA, Gremese E, Kiltz U, Lubrano E, et al. Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open. 2021. Dec;7(3):e001681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8655606</ArticleId><ArticleId IdType="pubmed">34876490</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Weisman MH. The Epidemiology of Back Pain, Axial Spondyloarthritis and HLA-B27 in the United States. The American Journal of the Medical Sciences. 2013. Jun;345(6):431&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122314</ArticleId><ArticleId IdType="pubmed">23841117</ArticleId></ArticleIdList></Reference><Reference><Citation>Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, Navarro-Comp&#xe1;n V, Bundy C, Makri S, et al.
POS0689 DIAGNOSTIC DELAY IN PATIENTS INCLUDED IN THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRTIS: ASSOCIATIONS WITH GEOGRAPHIC, SOCIO-DEMOGRAPHIC AND DISEASE-RELATED FACTORS. In: Scientific Abstracts [Internet]. BMJ Publishing Group Ltd and European League Against Rheumatism; 2023.  [cited 2023 Dec 2]. p. 628&#x2013;9. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2023-eular.3023</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2023-eular.3023</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen MR, Lemeshow AR, Russo LJ, Barnes DM, Ababio Y, Habtezion A. Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity. Healthcare. 2022. Mar 23;10(4):603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025451</ArticleId><ArticleId IdType="pubmed">35455781</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson RM, Feldman CH. A Critical Look at Race-Based Practices in Rheumatology Guidelines. Arthritis Care &amp; Research. 2022. Oct;74(10):1602&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169247</ArticleId><ArticleId IdType="pubmed">33973416</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanicolas I, Woskie LR, Jha AK. Health Care Spending in the United States and Other High-Income Countries. JAMA. 2018. Mar 13;319(10):1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">29536101</ArticleId></ArticleIdList></Reference><Reference><Citation>Webers C, Vanhoof L, Leue C, Boonen A, K&#xf6;hler S. Depression in ankylosing spondylitis and the role of disease-related and contextual factors: a cross-sectional study. Arthritis Res Ther. 2019. Dec;21(1):215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6805406</ArticleId><ArticleId IdType="pubmed">31639012</ArticleId></ArticleIdList></Reference><Reference><Citation>on behalf of the EMAS Working Group, Garrido-Cumbrera M, Poddubnyy D, Gossec L, G&#xe1;lvez-Ruiz D, Bundy C, et al. The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective&#x2014;an Analysis of 2846 Patients Across 13 Countries. Curr Rheumatol Rep. 2019. May;21(5):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449283</ArticleId><ArticleId IdType="pubmed">30868287</ArticleId></ArticleIdList></Reference><Reference><Citation>Putrik P, Ramiro S, Molt&#xf3; A, Keszei AP, Norton S, Dougados M, et al. Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). Ann Rheum Dis. 2019. Apr;78(4):486&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30674477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariyildiz A, Coskun Benlidayi I, Turk I, Zengin Acemoglu SS, Unal I. Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis. Rheumatol Int. 2023. Mar 26;43(5):923&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10040175</ArticleId><ArticleId IdType="pubmed">36966430</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott GC, Monshizadeh A, Selzer F, Zhao SS, Ermann J, Katz JN. Factors associated with diagnostic delay in axial spondyloarthritis: impact of clinical factors and social vulnerability. Arthritis Care &amp; Research. 2023. Oct 26;acr.25264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10963166</ArticleId><ArticleId IdType="pubmed">37881826</ArticleId></ArticleIdList></Reference><Reference><Citation>de Hooge M, Ramonda R, Lorenzin M, Frallonardo P, Punzi L, Ortolan A, et al. Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther. 2016. Nov 16;18(1):265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5112652</ArticleId><ArticleId IdType="pubmed">27852321</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. [cited 2024 Apr 8]; Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23468</ArticleId><ArticleId IdType="pubmed">29125900</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund E, Bremander A, Bergman S, Jacobsson LTH, Petersson IF. Work productivity in a population-based cohort of patients with spondyloarthritis. Rheumatology. 2013. Sep 1;52(9):1708&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23804223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapane KL, Khan S, Shridharmurthy D, Beccia A, Dub&#xe9; C, Yi E, et al. Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. BMC Fam Pract. 2020. Sep 29;21:204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526414</ArticleId><ArticleId IdType="pubmed">32993510</ArticleId></ArticleIdList></Reference><Reference><Citation>Magrey MN, Danve AS, Ermann J, Walsh JA. Recognizing Axial Spondyloarthritis: A Guide for Primary Care. Mayo Clin Proc. 2020. Nov;95(11):2499&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">32736944</ArticleId></ArticleIdList></Reference><Reference><Citation>Deodhar A, Mittal M, Reilly P, Bao Y, Manthena S, Anderson J, et al. Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol. 2016. Jul;35(7):1769&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4914524</ArticleId><ArticleId IdType="pubmed">26987341</ArticleId></ArticleIdList></Reference><Reference><Citation>Danve A, Deodhar A. Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities. Clin Rheumatol. 2019. Mar;38(3):625&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30588555</ArticleId></ArticleIdList></Reference><Reference><Citation>Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis [Internet]. ACR Meeting Abstracts. [cited 2024 Sep 22]. Available from: https://acrabstracts.org/abstract/spondyloarthritis-research-and-treatment-network-spartan-draft-referral-recommendations-for-axial-spondyloarthritis/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39489875</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>29</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Advancing Interpretable Regression Analysis for Binary Data: A Novel Distributed Algorithm Approach.</ArticleTitle><Pagination><StartPage>5573</StartPage><EndPage>5582</EndPage><MedlinePgn>5573-5582</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.10250</ELocationID><Abstract><AbstractText>Sparse data bias, where there is a lack of sufficient cases, is a common problem in data analysis, particularly when studying rare binary outcomes. Although a two-step meta-analysis approach may be used to lessen the bias by combining the summary statistics to increase the number of cases from multiple studies, this method does not completely eliminate bias in effect estimation. In this paper, we propose a one-shot distributed algorithm for estimating relative risk using a modified Poisson regression for binary data, named ODAP-B. We evaluate the performance of our method through both simulation studies and real-world case analyses of postacute sequelae of SARS-CoV-2 infection in children using data from 184&#x2009;501 children across eight national academic medical centers. Compared with the meta-analysis method, our method provides closer estimates of the relative risk for all outcomes considered including syndromic and systemic outcomes. Our method is communication-efficient and privacy-preserving, requiring only aggregated data to obtain relatively unbiased effect estimates compared with two-step meta-analysis methods. Overall, ODAP-B is an effective distributed learning algorithm for Poisson regression to study rare binary outcomes. The method provides inference on adjusted relative risk with a robust variance estimator.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Statistics in Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1213-6699</Identifier><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna Marie</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorman</LastName><ForeName>Vitaly</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Naimin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, Merck &amp; Co., Inc, Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmondson</LastName><ForeName>Mackenzie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, Merck &amp; Co., Inc, Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Xiwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Health Outcomes &amp; Biomedical informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Kelly J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Center for Child Health Equity and Outcomes Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajor</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Divisions of Pulmonary Medicine | Biomedical Informatics | James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health Outcomes &amp; Biomedical informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Haitao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Statistical Research and Data Science Center, Pfizer Inc., New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG073435</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ME-2018C3-14899</GrantID><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ME-2019C3-18315</GrantID><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AI167418</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG077820</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AG074604</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01LM012607</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG077820</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01LM013519</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK128237</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI130460</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21EY034179</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AG069880</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01LM014344</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24MH136069</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01TR003709</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016012" MajorTopicYN="N">Poisson Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">binary data</Keyword><Keyword MajorTopicYN="N">distributed algorithm</Keyword><Keyword MajorTopicYN="N">modified Poisson regression</Keyword><Keyword MajorTopicYN="N">relative risk</Keyword></KeywordList><CoiStatement>Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, and Dynavax, and receives an editorial stipend from Elsevier. Other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>3</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39489875</ArticleId><ArticleId IdType="pmc">PMC11588971</ArticleId><ArticleId IdType="doi">10.1002/sim.10250</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenland S., &#x201c;Noncollapsibility, Confounding, and Sparse Data Bias. Part 2: What Should Researchers Make of Persistent Controversies About the Odds Ratio?,&#x201d; Journal of Clinical Epidemiology 139 (2021): 264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">34119647</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S., &#x201c;Noncollapsibility, Confounding, and Sparse&#x2010;Data Bias. Part 1: The Oddities of Odds,&#x201d; Journal of Clinical Epidemiology 138 (2021): 178&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">34119646</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson D. B., Cole S. R., Ross R. K., Poole C., Chu H., and Keil A. P., &#x201c;Meta&#x2010;Analysis and Sparse&#x2010;Data Bias,&#x201d; American Journal of Epidemiology 190 (2021): 336&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">32975277</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S., Mansournia M. A., and Altman D. G., &#x201c;Sparse Data Bias: A Problem Hiding in Plain Sight,&#x201d; BMJ 352 (2016): 1981.</Citation><ArticleIdList><ArticleId IdType="pubmed">27121591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju K., Lin L., Chu H., Cheng L.&#x2010;L., and Xu C., &#x201c;Laplace Approximation, Penalized Quasi&#x2010;Likelihood, and Adaptive Gauss&#x2013;Hermite Quadrature for Generalized Linear Mixed Models: Towards Meta&#x2010;Analysis of Binary Outcome With sparse data,&#x201d; BMC Medical Research Methodology 20 (2020): 1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296731</ArticleId><ArticleId IdType="pubmed">32539721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender R., Friede T., Koch A., et al., &#x201c;Methods for Evidence Synthesis in the Case of Very Few Studies,&#x201d; Research Synthesis Methods 9 (2018): 382&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175308</ArticleId><ArticleId IdType="pubmed">29504289</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S., Pearl J., and Robins J. M., &#x201c;Confounding and Collapsibility in Causal Inference,&#x201d; Statistical Science 14 (1999): 29&#x2013;46.</Citation></Reference><Reference><Citation>Doi S. A., Furuya&#x2010;Kanamori L., Xu C., Lin L., Chivese T., and Thalib L., &#x201c;Controversy and Debate: Questionable Utility of the Relative Risk in Clinical Research: Paper 1: A Call for Change to Practice,&#x201d; Journal of Clinical Epidemiology 142 (2022): 271&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">33171273</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M., Chu H., Cole S., et al., &#x201c;Odds Ratios are Far From &#x201c;Portable&#x201d;&#x2014;A Call to Use Realistic Models for Effect Variation in Meta&#x2010;Analysis,&#x201d; Journal of Clinical Epidemiology 142 (2022): 294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8831641</ArticleId><ArticleId IdType="pubmed">34390790</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi S. A., Furuya&#x2010;Kanamori L., Xu C., et al., &#x201c;The Odds Ratio is &#x201c;Portable&#x201d; Across Baseline Risk but not the Relative Risk: Time to Do Away With the Log Link in Binomial Regression,&#x201d; Journal of Clinical Epidemiology 142 (2022): 288&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">34380019</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M., Chen Y., Cole S. R., MacLehose R. F., Richardson D. B., and Chu H., &#x201c;Is OR &#x201c;Portable&#x201d; in Meta&#x2010;Analysis? Time to Consider Bivariate Generalized Linear Mixed Model,&#x201d; Journal of Clinical Epidemiology 142 (2022): 280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842816</ArticleId><ArticleId IdType="pubmed">34384876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H. and Cole S. R., &#x201c;Estimation of Risk Ratios in Cohort Studies With Common Outcomes: A Bayesian Approach,&#x201d; Epidemiology 21 (2010): 855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">20844438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz L. M., Woloshin S., and Welch H. G., &#x201c;Misunderstandings About the Effects of Race and Sex on physicians' Referrals for Cardiac Catheterization,&#x201d; New England Journal of Medicine 341 (1999): 279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">10413743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings P., &#x201c;Early Exposure to Marijuana and Risk of Later Drug UseEarly Exposure to Marijuana and Risk of Later Drug Use,&#x201d; Journal of the American Medical Association 290 (2003): 329.</Citation></Reference><Reference><Citation>Whitcomb B. W. and Naimi A. I., &#x201c;Defining, Quantifying, and Interpreting &#x201c;Noncollapsibility&#x201d; in Epidemiologic Studies of Measures of &#x201c;Effect&#x201d;,&#x201d; American Journal of Epidemiology 190 (2021): 697&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530151</ArticleId><ArticleId IdType="pubmed">33305812</ArticleId></ArticleIdList></Reference><Reference><Citation>McNutt L.&#x2010;A., Wu C., Xue X., and Hafner J. P., &#x201c;Estimating the Relative Risk in Cohort Studies and Clinical Trials of Common Outcomes,&#x201d; American Journal of Epidemiology 157 (2003): 940&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">12746247</ArticleId></ArticleIdList></Reference><Reference><Citation>Zocchetti C., Consonni D., and Bertazzi P. A., &#x201c;Estimation of Prevalence Rate Ratios From Cross&#x2010;Sectional data,&#x201d; International Journal of Epidemiology 24 (1995): 1064&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557441</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot D., M&#xe9;sidor M., Chiu Y., Simard M., and Sirois C., &#x201c;An Alternative Perspective on the Robust Poisson Method for Estimating Risk or Prevalence Ratios,&#x201d; Epidemiology 34 (2023): 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36125349</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G., &#x201c;A Modified Poisson Regression Approach to Prospective Studies With Binary data,&#x201d; American Journal of Epidemiology 159 (2004): 702&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033648</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegelman D. and Hertzmark E., &#x201c;Easy SAS Calculations for Risk or Prevalence Ratios and Differences,&#x201d; American Journal of Epidemiology 162 (2005): 199&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan M. I., Lee J. D., and Yang Y., &#x201c;Communication&#x2010;Efficient Distributed Statistical Inference,&#x201d; Journal of the American Statistical Association 114 (2018): 668&#x2013;681.</Citation></Reference><Reference><Citation>Duan R., Boland M. R., Liu Z., et al., &#x201c;Learning From Electronic Health Records Across Multiple Sites: A Communication&#x2010;Efficient and Privacy&#x2010;Preserving Distributed Algorithm,&#x201d; Journal of the American Medical Informatics Association 27 (2019): 376&#x2013;385, 10.1093/jamia/ocz199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz199</ArticleId><ArticleId IdType="pmc">PMC7025371</ArticleId><ArticleId IdType="pubmed">31816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R., Luo C., Schuemie M. J., et al., &#x201c;Learning From Local to Global: An Efficient Distributed Algorithm for Modeling Time&#x2010;to&#x2010;Event Data,&#x201d; Journal of the American Medical Informatics Association 27, no. 7 (2020): 1028&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R., Luo C., Schuemie M. J., et al., &#x201c;Learning From Local to Global&#x2010;An Efficient Distributed Algorithm for Modeling Time&#x2010;To&#x2010;Event data,&#x201d; Journal of the American Medical Informatics Association 27 (2020): 1028&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C., Duan R., Naj A. C., Kranzler H. R., Bian J., and Chen Y., &#x201c;ODACH: A One&#x2010;Shot Distributed Algorithm for Cox Model With Heterogeneous Multi&#x2010;Center data,&#x201d; Scientific Reports 12, no. 1 (2022): 6627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033863</ArticleId><ArticleId IdType="pubmed">35459767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Tong J., Stein R., et al., &#x201c;One&#x2010;Shot Distributed Algorithms for Addressing Heterogeneity in Competing Risks data Across Clinical Sites,&#x201d; Journal of Biomedical Informatics 150 (2024): 104595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11002871</ArticleId><ArticleId IdType="pubmed">38244958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Tong J., Jing N., et al., &#x201c;Learning Competing Risks Across Multiple Hospitals: One&#x2010;Shot Distributed Algorithms,&#x201d; Journal of the American Medical Informatics Association 31 (2024): 1102&#x2013;1112, 10.1093/JAMIA/OCAE027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/JAMIA/OCAE027</ArticleId><ArticleId IdType="pmc">PMC11031234</ArticleId><ArticleId IdType="pubmed">38456459</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Lee G. M., Razzaghi H., et al., &#x201c;Clinical Features and Burden of Postacute Sequelae of SARS&#x2010;CoV&#x2010;2 Infection in Children and Adolescents,&#x201d; JAMA Pediatrics 176 (2022): 1000&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C. H., Murray B., Varsavsky T., et al., &#x201c;Attributes and Predictors of Long COVID,&#x201d; Nature Medicine 27 (2021): 626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., Buxton M., and Husain L., &#x201c;Management of Post&#x2010;Acute Covid&#x2010;19 in Primary Care,&#x201d; BMJ 370 (2020): 3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., and Landi F., &#x201c;Persistent Symptoms in Patients After Acute COVID&#x2010;19,&#x201d; JAMA 324 (2020): 603&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., et al., &#x201c;6&#x2010;Month Consequences of COVID&#x2010;19 in Patients Discharged From Hospital: A Cohort Study,&#x201d; Lancet 397 (2021): 220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest C. B., Margolis P. A., Bailey L. C., et al., &#x201c;PEDSnet: A National Pediatric Learning Health System,&#x201d; Journal of the American Medical Informatics Association 21 (2014): 602&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Lee G. M., Razzaghi H., et al., &#x201c;Clinical Features and Burden of Post&#x2010;Acute Sequelae of SARS&#x2010;CoV&#x2010;2 Infection in Children and Adolescents: An Exploratory EHR&#x2010;Based Cohort Study From the RECOVER Program,&#x201d; medRxiv 176 (2022): 22275544, 10.1101/2022.05.24.22275544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.24.22275544</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon T. D., Haaland W., Hawley K., Lambka K., and Mangione&#x2010;Smith R., &#x201c;Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0,&#x201d; Academic Pediatrics 18 (2018): 577&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon T. D., Cawthon M. L., Stanford S., et al., &#x201c;Pediatric Medical Complexity Algorithm: A New Method to Stratify Children by Medical Complexity,&#x201d; Pediatrics 133 (2014): e1647&#x2013;e1654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035595</ArticleId><ArticleId IdType="pubmed">24819580</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Gross R. S., Mohandas S., et al., &#x201c;Postacute Sequelae of SARS&#x2010;CoV&#x2010;2 in Children,&#x201d; Pediatrics 153 (2024): e2023062570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10904902</ArticleId><ArticleId IdType="pubmed">38321938</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran W. G., &#x201c;The Combination of Estimates From Different Experiments,&#x201d; Biometrics 10 (1954): 101&#x2013;129.</Citation></Reference><Reference><Citation>Higgins J. P. T. and Thompson S. G., &#x201c;Quantifying Heterogeneity in a Meta&#x2010;Analysis,&#x201d; Statistics in Medicine 21 (2002): 1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R., Ning Y., and Chen Y., &#x201c;Heterogeneity&#x2010;Aware and Communication&#x2010;Efficient Distributed Statistical Inference,&#x201d; Biometrika 109 (2022): 67&#x2013;83.</Citation></Reference><Reference><Citation>Luo C., Islam M. N., Sheils N. E., et al., &#x201c;DLMM as a Lossless One&#x2010;Shot Algorithm for Collaborative Multi&#x2010;Site Distributed Linear Mixed Models,&#x201d; Nature Communications 13 (2022): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967932</ArticleId><ArticleId IdType="pubmed">35354802</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo C., Islam M. N., Sheils N. E., et al., &#x201c;dPQL: A Lossless Distributed Algorithm for Generalized Linear Mixed Model With Application to Privacy&#x2010;Preserving Hospital Profiling,&#x201d; Journal of the American Medical Informatics Association 29 (2022): 1366&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277633</ArticleId><ArticleId IdType="pubmed">35579348</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth D., &#x201c;Bias Reduction of Maximum Likelihood Estimates,&#x201d; Biometrika 80 (1993): 27&#x2013;38.</Citation></Reference><Reference><Citation>Wu Y., Jiang X., Kim J., and Ohno&#x2010;Machado L., &#x201c;Grid Binary LOgistic REgression (GLORE): Building Shared Models Without Sharing data,&#x201d; Journal of the American Medical Informatics Association 19 (2012): 758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R., Boland M. R., Moore J. H., and Chen Y., &#x201c;ODAL: A One&#x2010;Shot Distributed Algorithm to Perform Logistic Regressions on Electronic Health Records data From Multiple Clinical Sites,&#x201d; Pacific Symposium on Biocomputing 24 (2019): 30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J., et al., &#x201c;Robust&#x2010;ODAL: Learning From Heterogeneous Health Systems Without Sharing Patient&#x2010;Level data,&#x201d; Pacific Symposium on Biocomputing 25 (2020): 695&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6905508</ArticleId><ArticleId IdType="pubmed">31797639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J., Luo C., Islam M. N., et al., &#x201c;Distributed Learning for Heterogeneous Clinical Data With Application to Integrating COVID&#x2010;19 data Across 230 Sites,&#x201d; npj Digital Medicine 5, no. 1 (2022): 8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9198031</ArticleId><ArticleId IdType="pubmed">35701668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39532529</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Standardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU).</ArticleTitle><Pagination><StartPage>e70042</StartPage><MedlinePgn>e70042</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70042</ELocationID><Abstract><AbstractText Label="PURPOSE">The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real-World Interrogation Network (DARWIN EU). We illustrate the use of this framework by generating phenotypes for two diseases: pancreatic cancer and systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="METHODS">The phenotyping process involves a 14-steps process based on a standard operating procedure co-created by the DARWIN EU Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model.</AbstractText><AbstractText Label="RESULTS">Codelists were generated for both pancreatic cancer and SLE, and cohorts were generated in six OMOP-mapped databases. Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature, despite significant inter-database variability. Co-occurrent symptoms, conditions, and medication use were in keeping with pre-specified clinical descriptions based on previous knowledge.</AbstractText><AbstractText Label="CONCLUSIONS">Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large-scale exploration of the characteristics of the resulting cohorts. Wider use of structured and reproducible phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dernie</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corby</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Sciences Division, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercade-Besora</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffier</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Public Health Department, Medical Information Service, Medical Informatics and Archiving Unit (IAM), University Hospital of Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verdy</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Public Health Department, Medical Information Service, Medical Informatics and Archiving Unit (IAM), University Hospital of Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leis</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Management and Control Department, Consorci Mar Parc de Salut de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Management and Control Department, Consorci Mar Parc de Salut de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brash</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>Rowan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jodicke</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atencio Primaria de Salut Jordi Gol I Gurina (IDIAPJGol), Universitat Autonoma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacurariu</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Real World Evidence Workstream, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Real World Evidence Workstream, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6253-7175</Identifier><AffiliationInfo><Affiliation>Real World Evidence Workstream, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology, Centre for Statistics in Medicines, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NIHR Oxford Biomedical Research Centre</Agency><Country/></Grant><Grant><Agency>European Medicines Agency</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="Y">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">pancreatic cancer</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>12</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39532529</ArticleId><ArticleId IdType="doi">10.1002/pds.70042</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>G. Hripcsak and D. J. Albers, &#x201c;High&#x2010;Fidelity Phenotyping: Richness and Freedom From Bias,&#x201d; Journal of the American Medical Informatics Association 25, no. 3 (2017): 289&#x2013;294.</Citation></Reference><Reference><Citation>G. Hripcsak, J. D. Duke, N. H. Shah, et&#xa0;al., &#x201c;Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers,&#x201d; Studies in Health Technology and Informatics 216 (2015): 574&#x2013;578.</Citation></Reference><Reference><Citation>J. M. Overhage, P. B. Ryan, C. G. Reich, A. G. Hartzema, and P. E. Stang, &#x201c;Validation of a Common Data Model for Active Safety Surveillance Research,&#x201d; Journal of the American Medical Informatics Association 19, no. 1 (2012): 54&#x2013;60.</Citation></Reference><Reference><Citation>R. A. DeFronzo, E. Ferrannini, L. Groop, et&#xa0;al., &#x201c;Type 2 Diabetes Mellitus,&#x201d; Nature Reviews Disease Primers 1, no. 1 (2015): 15019.</Citation></Reference><Reference><Citation>S. Lanes, J. S. Brown, K. Haynes, M. F. Pollack, and A. M. Walker, &#x201c;Identifying Health Outcomes in Healthcare Databases,&#x201d; Pharmacoepidemiology and Drug Safety 24, no. 10 (2015): 1009&#x2013;1016.</Citation></Reference><Reference><Citation>DARWIN EU, &#x201c;Data Analysis and Real World Interrogation Network,&#x201d; https://www.darwin&#x2010;eu.org/index.php.</Citation></Reference><Reference><Citation>https://cprd.com/primary&#x2010;care&#x2010;data&#x2010;public&#x2010;health&#x2010;research.</Citation></Reference><Reference><Citation>https://www.iqvia.com/locations/united&#x2010;states/library/fact&#x2010;sheets/iqvia&#x2010;pharmetrics&#x2010;plus.</Citation></Reference><Reference><Citation>M. A. J. de Ridder, M. de Wilde, C. de Ben, et&#xa0;al., &#x201c;Data Resource Profile: The Integrated Primary Care Information (IPCI) Database, The Netherlands,&#x201d; International Journal of Epidemiology 51, no. 6 (2022): e314&#x2013;e323.</Citation></Reference><Reference><Citation>G. Rao, &#x201c;PhenotypeLibrary: The OHDSI Phenotype Library,&#x201d; 2024.</Citation></Reference><Reference><Citation>A. Ostropolets, P. Ryan, and G. Hripcsak, &#x201c;Phenotyping in Distributed Data Networks: Selecting the Right Codes for the Right Patients,&#x201d; American Medical Informatics Association Annual Symposium Proceedings 2022 (2022): 826&#x2013;835.</Citation></Reference><Reference><Citation>OHDSI, &#x201c;Software Tools,&#x201d; https://www.ohdsi.org/software&#x2010;tools/.</Citation></Reference><Reference><Citation>OHDSI, &#x201c;Capr package,&#x201d; https://github.com/OHDSI/Capr.</Citation></Reference><Reference><Citation>https://ohdsi.github.io/CohortDiagnostics/.</Citation></Reference><Reference><Citation>https://cran.rstudio.com/web/packages/CodelistGenerator/index.html.</Citation></Reference><Reference><Citation>https://cran.r&#x2010;project.org/web/packages/PatientProfiles/index.html.</Citation></Reference><Reference><Citation>https://cran.r&#x2010;project.org/web/packages/IncidencePrevalence/index.html.</Citation></Reference><Reference><Citation>https://gco.iarc.fr/today/en/dataviz/maps&#x2010;heatmap?mode=population&amp;cancers=13.</Citation></Reference><Reference><Citation>Cancer Research UK, accessed November, 2023, https://www.cancerresearchuk.org/health&#x2010;professional/cancer&#x2010;statistics/statistics&#x2010;by&#x2010;cancer&#x2010;type/pancreatic&#x2010;cancer/incidence#heading&#x2010;One.</Citation></Reference><Reference><Citation>https://seer.cancer.gov/statfacts/html/pancreas.html.</Citation></Reference><Reference><Citation>J. Tian, D. Zhang, X. Yao, Y. Huang, and Q. Lu, &#x201c;Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study,&#x201d; Annals of the Rheumatic Diseases 82, no. 3 (2023): 351&#x2013;356.</Citation></Reference><Reference><Citation>N. Conrad, S. Misra, J. Y. Verbakel, et&#xa0;al., &#x201c;Incidence, Prevalence, and Co&#x2010;Occurrence of Autoimmune Disorders Over Time and by Age, Sex, and Socioeconomic Status: A Population&#x2010;Based Cohort Study of 22 Million Individuals in the UK,&#x201d; Lancet 401, no. 10391 (2023): 1878&#x2013;1890.</Citation></Reference><Reference><Citation>F. Rees, M. Doherty, M. J. Grainge, P. Lanyon, and W. Zhang, &#x201c;The Worldwide Incidence and Prevalence of Systemic Lupus Erythematosus: A Systematic Review of Epidemiological Studies,&#x201d; Rheumatology 56, no. 11 (2017): 1945&#x2013;1961.</Citation></Reference><Reference><Citation>C. Shivade, P. Raghavan, E. Fosler&#x2010;Lussier, et&#xa0;al., &#x201c;A Review of Approaches to Identifying Patient Phenotype Cohorts Using Electronic Health Records,&#x201d; Journal of the American Medical Informatics Association 21, no. 2 (2014): 221&#x2013;230.</Citation></Reference><Reference><Citation>S. J. Price, S. A. Stapley, E. Shephard, K. Barraclough, and W. T. Hamilton, &#x201c;Is Omission of Free Text Records a Possible Source of Data Loss and Bias in Clinical Practice Research Datalink Studies? A Case&#x2013;Control Study,&#x201d; BMJ Open 6, no. 5 (2016): e011664.</Citation></Reference><Reference><Citation>N. U. Din, O. C. Ukoumunne, G. Rubin, et&#xa0;al., &#x201c;Age and Gender Variations in Cancer Diagnostic Intervals in 15 Cancers: Analysis of Data From the UK Clinical Practice Research Datalink,&#x201d; PLoS One 10, no. 5 (2015): e0127717.</Citation></Reference><Reference><Citation>R. D. Neal, N. U. Din, W. Hamilton, et&#xa0;al., &#x201c;Comparison of Cancer Diagnostic Intervals Before and After Implementation of NICE Guidelines: Analysis of Data From the UK General Practice Research Database,&#x201d; British Journal of Cancer 110, no. 3 (2014): 584&#x2013;592.</Citation></Reference><Reference><Citation>M. Swertz, E. van Enckevort, J. L. Oliveira, et&#xa0;al., &#x201c;Towards an Interoperable Ecosystem of Research Cohort and Real&#x2010;World Data Catalogues Enabling Multi&#x2010;Center Studies,&#x201d; Yearbook of Medical Informatics 31, no. 1 (2022): 262&#x2013;272.</Citation></Reference><Reference><Citation>K. Yoshida, T. Cai, L. G. Bessette, et&#xa0;al., &#x201c;Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Electronic Health Records and Linked Medicare Claims Data,&#x201d; Pharmacoepidemiology and Drug Safety 33, no. 1 (2024): e5684.</Citation></Reference><Reference><Citation>N. A. Dreyer, S. R. Tunis, M. Berger, D. Ollendorf, P. Mattox, and R. Gliklich, &#x201c;Why Observational Studies Should Be Among the Tools Used in Comparative Effectiveness Research,&#x201d; Health Affairs 29, no. 10 (2010): 1818&#x2013;1825.</Citation></Reference><Reference><Citation>C. Willame, C. Dodd, C. E. Dur&#xe1;n, et&#xa0;al., &#x201c;Background Rates of 41 Adverse Events of Special Interest for COVID&#x2010;19 Vaccines in 10 European Healthcare Databases &#x2013; An ACCESS Cohort Study,&#x201d; Vaccine 41, no. 1 (2023): 251&#x2013;262.</Citation></Reference><Reference><Citation>R. Gini, R. Pajouheshnia, H. Gardarsdottir, et&#xa0;al., &#x201c;Describing Diversity of Real World Data Sources in Pharmacoepidemiologic Studies: The DIVERSE Scoping Review,&#x201d; Pharmacoepidemiology and Drug Safety 33, no. 5 (2024): e5787.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39538369</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Learning health system linchpins: information exchange and a common data model.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>19</EndPage><MedlinePgn>9-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocae277</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To demonstrate the potential for a centrally managed health information exchange standardized to a common data model (HIE-CDM) to facilitate semantic data flow needed to support a learning health system (LHS).</AbstractText><AbstractText Label="MATERIALS AND METHODS">The Rhode Island Quality Institute operates the Rhode Island (RI) statewide HIE, which aggregates RI health data for more than half of the state's population from 47 data partners. We standardized HIE data to the Observational Medical Outcomes Partnership (OMOP) CDM. Atherosclerotic cardiovascular disease (ASCVD) risk and primary prevention practices were selected to demonstrate LHS semantic data flow from 2013 to 2023.</AbstractText><AbstractText Label="RESULTS">We calculated longitudinal 10-year ASCVD risk on 62,999 individuals. Nearly two-thirds had ASCVD risk factors from more than one data partner. This enabled granular tracking of individual ASCVD risk, primary prevention (ie, statin therapy), and incident disease. The population was on statins for fewer than half of the guideline-recommended days. We also found that individuals receiving care at Federally Qualified Health Centers were more likely to have unfavorable ASCVD risk profiles and more likely to be on statins. CDM transformation reduced data heterogeneity through a unified health record that adheres to defined terminologies per OMOP domain.</AbstractText><AbstractText Label="DISCUSSION">We demonstrated the potential for an HIE-CDM to enable observational population health research. We also showed how to leverage existing health information technology infrastructure and health data best practices to break down LHS barriers.</AbstractText><AbstractText Label="CONCLUSION">HIE-CDM facilitates knowledge curation and health system intervention development at the individual, health system, and population levels.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eisman</LastName><ForeName>Aaron S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-7609-1488</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT 06510, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Elizabeth S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wen-Chih</ForeName><Initials>WC</Initials><Identifier Source="ORCID">0000-0002-2834-2024</Identifier><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, VA Providence Health Care, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>Karen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aluthge</LastName><ForeName>Dilum P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Indra Neil</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Warren Alpert Medical School, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Brown University, Providence, RI 02912, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rhode Island Quality Institute, Providence, RI 02912, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30LM013320</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080891" MajorTopicYN="Y">Learning Health System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="Y">Health Information Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012237" MajorTopicYN="N" Type="Geographic">Rhode Island</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050197" MajorTopicYN="N">Atherosclerosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="N">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atherosclerotic cardiovascular disease</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">health information exchange</Keyword><Keyword MajorTopicYN="N">learning health system</Keyword></KeywordList><CoiStatement>The authors of this work have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>16</Day><Hour>18</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>17</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>14</Day><Hour>0</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39538369</ArticleId><ArticleId IdType="pmc">PMC11648737</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocae277</ArticleId><ArticleId IdType="pii">7900012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Friedman CP. &#xa0;What is unique about learning health systems? &#xa0;Learn Health Syst. 2022;6:e10328. 10.1002/lrh2.10328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lrh2.10328</ArticleId><ArticleId IdType="pmc">PMC9284922</ArticleId><ArticleId IdType="pubmed">35860320</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders R, Smith MD. &#xa0;The path to continuously learning health care. Issues Sci Technol. 2013;29:27-36.</Citation></Reference><Reference><Citation>Nwaru BI, Friedman C, Halamka J, Sheikh A. &#xa0;Can learning health systems help organisations deliver personalised care? &#xa0;BMC Med. 2017;15:177. 10.1186/s12916-017-0935-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-017-0935-0</ArticleId><ArticleId IdType="pmc">PMC5623976</ArticleId><ArticleId IdType="pubmed">28965492</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowley J. &#xa0;The wisdom hierarchy: representations of the DIKW hierarchy. J Inf Sci Eng. 2007;33:163-180. 10.1177/0165551506070706</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0165551506070706</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MJ, McNicholas C, Nicolay C, Darzi A, Bell D, Reed JE. &#xa0;Systematic review of the application of the plan&#x2013;do&#x2013;study&#x2013;act method to improve quality in healthcare. BMJ Qual Saf. 2014;23:290-298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963536</ArticleId><ArticleId IdType="pubmed">24025320</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Rubin JC, Sullivan KJ. &#xa0;Toward an information infrastructure for global health improvement. Yearb Med Inform. 2017;26:16-23. 10.15265/IY-2017-004</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2017-004</ArticleId><ArticleId IdType="pmc">PMC6239237</ArticleId><ArticleId IdType="pubmed">28480469</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi PJ, Payne PRO, Friedman CP. &#xa0;Learning from data: a recurring feature on the science and practice of data-driven learning health systems. Learn Health Syst. 2022;6:e10302. 10.1002/lrh2.10302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lrh2.10302</ArticleId><ArticleId IdType="pmc">PMC8753296</ArticleId><ArticleId IdType="pubmed">35036559</ArticleId></ArticleIdList></Reference><Reference><Citation>Guise JM, Savitz LA, Friedman CP. &#xa0;Mind the gap: putting evidence into practice in the era of learning health systems. J Gen Intern Med. 2018;33:2237-2239. 10.1007/s11606-018-4633-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-018-4633-1</ArticleId><ArticleId IdType="pmc">PMC6258636</ArticleId><ArticleId IdType="pubmed">30155611</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan S, Dube K, Johnson O, et al. &#xa0;A framework for analysing learning health systems: are we removing the most impactful barriers? &#xa0;Learn Health Syst. 2019;3:e10189. 10.1002/lrh2.10189</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lrh2.10189</ArticleId><ArticleId IdType="pmc">PMC6802533</ArticleId><ArticleId IdType="pubmed">31641685</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SM, Reid RJ, Larson EB. &#xa0;Implementing the learning health system: from concept to action. Ann Intern Med. 2012;157:207-210. 10.7326/0003-4819-157-3-201208070-00012</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-157-3-201208070-00012</ArticleId><ArticleId IdType="pubmed">22868839</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachemi N, Rahurkar S, Harle CA, Vest JR. &#xa0;The benefits of health information exchange: an updated systematic review. J Am Med Inform Assoc. 2018;25:1259-1265. 10.1093/jamia/ocy035</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy035</ArticleId><ArticleId IdType="pmc">PMC7646861</ArticleId><ArticleId IdType="pubmed">29718258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern LM, Barr&#xf3;n Y, Dhopeshwarkar RV, Kaushal R. &#xa0;Health information exchange and ambulatory quality of care. Appl Clin Inform. 2012;3:197-209. 10.4338/ACI-2012-02-RA-0005</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2012-02-RA-0005</ArticleId><ArticleId IdType="pmc">PMC3613017</ArticleId><ArticleId IdType="pubmed">23646072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Totten AM, Eden KB, et al. &#xa0;Outcomes from health information exchange: systematic review and future research needs. JMIR Med Inform. 2015;3:e39. 10.2196/medinform.5215</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.5215</ArticleId><ArticleId IdType="pmc">PMC4704923</ArticleId><ArticleId IdType="pubmed">26678413</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman KA, Hanks A, Williams TW, et al. &#xa0;A state health department and health information exchange partnership: an effective collaboration for a data-driven response for COVID-19 contact tracing in Maryland. Sex Transm Dis. 2023;50:S34-S40. 10.1097/OLQ.0000000000001702</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OLQ.0000000000001702</ArticleId><ArticleId IdType="pmc">PMC9992453</ArticleId><ArticleId IdType="pubmed">36098564</ArticleId></ArticleIdList></Reference><Reference><Citation>Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. &#xa0;Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. [Internet]. 2004;117:14-18. 10.1016/j.amjmed.2004.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2004.01.024</ArticleId><ArticleId IdType="pubmed">15210383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane LJ, Olson CA, Murray S, Dupuis M, Tooman T, Hayes S. &#xa0;Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. J Contin Educ Health Prof. 2007;27:94-102. 10.1002/chp.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chp.106</ArticleId><ArticleId IdType="pubmed">17576625</ArticleId></ArticleIdList></Reference><Reference><Citation>Metser G, Bradley C, Moise N, Liyanage-Don N, Kronish I, Ye S. &#xa0;Gaps and disparities in primary prevention statin prescription during outpatient care. Am J Cardiol. 2021;161:36-41. 10.1016/j.amjcard.2021.08.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.08.070</ArticleId><ArticleId IdType="pmc">PMC8607804</ArticleId><ArticleId IdType="pubmed">34794616</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Rutter JL, Goldstein DB, All of Us Research Program Investigators, et al. &#xa0;The &#x201c;All of Us&#x201d; Research Program. N Engl J Med. 2019;381:668-676. 10.1056/NEJMsr1809937</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1809937</ArticleId><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, N3C Consortium, et al. &#xa0;The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28:427-443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. World Health Statistics 2018: Monitoring Health for the SDGs Sustainable Development Goals. World Health Organization; 2018, 100p. https://www.who.int/gho/publications/world_health_statistics/2018/en/</Citation></Reference><Reference><Citation>
Murphy SL, Kochanek KD, Xu J, Arias E. &#xa0;Mortality in the United States, 2020. NCHS Data Brief. 2022;1-8. https://www.ncbi.nlm.nih.gov/pubmed/34978528</Citation><ArticleIdList><ArticleId IdType="pubmed">34978528</ArticleId></ArticleIdList></Reference><Reference><Citation>Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. &#xa0;2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-2959. 10.1016/j.jacc.2013.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.11.005</ArticleId><ArticleId IdType="pmc">PMC4700825</ArticleId><ArticleId IdType="pubmed">24239921</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone NJ, Robinson JG, Lichtenstein AH, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. &#xa0;2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24222016</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, et al. &#xa0;2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139:e1046&#x2013;81-e1081. 10.1161/CIR.0000000000000624</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakhomov SSV, Hemingway H, Weston SA, Jacobsen SJ, Rodeheffer R, Roger VL. &#xa0;Epidemiology of angina pectoris: role of natural language processing of the medical record. Am Heart J. 2007;153:666-673. 10.1016/j.ahj.2006.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2006.12.022</ArticleId><ArticleId IdType="pmc">PMC1929015</ArticleId><ArticleId IdType="pubmed">17383310</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisman AS, Shah NR, Eickhoff C, et al. &#xa0;Extracting angina symptoms from clinical notes using pre-trained transformer architectures. AMIA Annu Symp Proc. 2020;2020:412-421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075440</ArticleId><ArticleId IdType="pubmed">33936414</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CJ, Chang L-S, Hosomura N, et al. &#xa0;Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk. JAMA Netw Open. 2023;6:e231047. 10.1001/jamanetworkopen.2023.1047</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.1047</ArticleId><ArticleId IdType="pmc">PMC9975905</ArticleId><ArticleId IdType="pubmed">36853604</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N, Bhargava A, Kalra R, &#xa0;et al. &#xa0;Trends in lipid, lipoproteins, and statin&#xa0;use among U.S. adults: impact of 2013 cholesterol guidelines. J Am Coll Cardiol. 2019;74:2525-2528. 10.1016/j.jacc.2019.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2019.09.026</ArticleId><ArticleId IdType="pubmed">31727291</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OMOP CDM 5.3.1 [Internet]. OHDSI; 2021. Accessed January 6, 2021. https://github.com/OHDSI/CommonDataModel/releases/tag/v5.3.1</Citation></Reference><Reference><Citation>OHDSI. ATHENA [Internet]. 2022. Accessed April 13, 2022. https://athena.ohdsi.org/search-terms/start</Citation></Reference><Reference><Citation>OHDSI. OMOP CDM SQL Scripts [Internet]. 2022. Accessed April 13, 2022. https://ohdsi.github.io/CommonDataModel/sqlScripts.html</Citation></Reference><Reference><Citation>OHDSI. The Book of OHDSI [Internet]. 2021. Accessed July 26, 2022. https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>Whelton PK, Colantonio LD. &#xa0;Cardiovascular disease risk estimation in China. Ann Intern Med. 2019;170:340-341. 10.7326/M18-3301</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-3301</ArticleId><ArticleId IdType="pmc">PMC6699934</ArticleId><ArticleId IdType="pubmed">30776799</ArticleId></ArticleIdList></Reference><Reference><Citation>
Eisman A. &#xa0;DrugConceptSets: Guidelines Driven Standard Concept Sets for Electronic Health Records Research [Internet]. Github; 2022. Accessed September 8, 2023. https://github.com/aeisman/DrugConceptSets</Citation></Reference><Reference><Citation>Dalli LL, Kilkenny MF, Arnet I, et al. &#xa0;Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: a scoping review and new tool TEN-SPIDERS. Br J Clin Pharmacol. 2022;88:4427-4442. 10.1111/bcp.15391</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15391</ArticleId><ArticleId IdType="pmc">PMC9546055</ArticleId><ArticleId IdType="pubmed">35524398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ. &#xa0;Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension. 2004;44:429-434. 10.1161/01.HYP.0000141439.34834.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000141439.34834.84</ArticleId><ArticleId IdType="pubmed">15326088</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kurian AK, Cardarelli KM. &#xa0;Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17:143-152. https://www.ncbi.nlm.nih.gov/pubmed/17274224
</Citation><ArticleIdList><ArticleId IdType="pubmed">17274224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. &#xa0;State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233-1241. 10.1161/01.CIR.0000158136.76824.04</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000158136.76824.04</ArticleId><ArticleId IdType="pubmed">15769763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. &#xa0;Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75. 10.1161/01.HYP.0000252676.46043.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000252676.46043.18</ArticleId><ArticleId IdType="pubmed">17159087</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond N, Baer HJ, Hicks LS. &#xa0;Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey. Hypertension. 2011;57:383-389. 10.1161/HYPERTENSIONAHA.110.161950</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.110.161950</ArticleId><ArticleId IdType="pmc">PMC3048351</ArticleId><ArticleId IdType="pubmed">21300667</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SS, Coresh J, Pencina MJ, American Heart Association, et al. &#xa0;Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148:1982-2004. 10.1161/CIR.0000000000001191</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001191</ArticleId><ArticleId IdType="pubmed">37947094</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SS, Matsushita K, Sang Y, et al. &#xa0;Development and validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations. Circulation. 2023. 10.1161/CIRCULATIONAHA.123.067626</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.067626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. &#xa0;Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. 10.1378/chest.09-1584</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-1584</ArticleId><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells PS, Anderson DR, Rodger M, et al. &#xa0;Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. Ann Intern Med. 2001;135:98-107. 10.7326/0003-4819-135-2-200107170-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-135-2-200107170-00010</ArticleId><ArticleId IdType="pubmed">11453709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells PS, Hirsh J, Anderson DR, et al. &#xa0;Accuracy of clinical assessment of deep-vein thrombosis. Lancet. 1995;345:1326-1330. 10.1016/s0140-6736(95)92535-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(95)92535-x</ArticleId><ArticleId IdType="pubmed">7752753</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. &#xa0;A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">20299623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39551922</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Mapping Drug Terms via Integration of a Retrieval-Augmented Generation Algorithm with a Large Language Model.</ArticleTitle><Pagination><StartPage>355</StartPage><EndPage>363</EndPage><MedlinePgn>355-363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2024.30.4.355</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study evaluated the efficacy of integrating a retrieval-augmented generation (RAG) model and a large language model (LLM) to improve the accuracy of drug name mapping across international vocabularies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Drug ingredient names were translated into English using the Japanese Accepted Names for Pharmaceuticals. Drug concepts were extracted from the standard vocabulary of OHDSI, and the accuracy of mappings between translated terms and RxNorm was assessed by vector similarity, using the BioBERT-generated embedded vectors as the baseline. Subsequently, we developed LLMs with RAG that distinguished the final candidates from the baseline. We assessed the efficacy of the LLM with RAG in candidate selection by comparing it with conventional methods based on vector similarity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The evaluation metrics demonstrated the superior performance of the combined LLM + RAG over traditional vector similarity methods. Notably, the hit rates of the Mixtral 8x7b and GPT-3.5 models exceeded 90%, significantly outperforming the baseline rate of 64% across stratified groups of PO drugs, injections, and all interventions. Furthermore, the r-precision metric, which measures the alignment between model judgment and human evaluation, revealed a notable improvement in LLM performance, ranging from 41% to 50% compared to the baseline of 23%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Integrating an RAG and an LLM outperformed conventional string comparison and embedding vector similarity techniques, offering a more refined approach to global drug information mapping.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Eizen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Medical School of Ehime University, Toon, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Yukinobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Medical School of Ehime University, Toon, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Yuimedi Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okajima</LastName><ForeName>Ai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yuimedi Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ministry of Education, Culture, Sports, Science, and Technology</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Computer Neural Network</Keyword><Keyword MajorTopicYN="N">Controlled Vocabulary</Keyword><Keyword MajorTopicYN="N">Machine Learning</Keyword><Keyword MajorTopicYN="N">RxNorm</Keyword><Keyword MajorTopicYN="N">Terminology</Keyword></KeywordList><CoiStatement>
<b>Conflict of Interest</b>
. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>17</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39551922</ArticleId><ArticleId IdType="pmc">PMC11570653</ArticleId><ArticleId IdType="doi">10.4258/hir.2024.30.4.355</ArticleId><ArticleId IdType="pii">hir.2024.30.4.355</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;6. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al. OHDSI standardized vocabularies-a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31(3):583&#x2013;90. doi: 10.1093/jamia/ocad247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Zhang Y, Jiang M, Wang J, Dong J, Liu Y, et al. Toward a normalized clinical drug knowledge base in China-applying the RxNorm model to Chinese clinical drugs. J Am Med Inform Assoc. 2018;25(7):809&#x2013;18. doi: 10.1093/jamia/ocy020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy020</ArticleId><ArticleId IdType="pmc">PMC7647010</ArticleId><ArticleId IdType="pubmed">29635469</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke E, Zoch M, Kallfelz M, Ruhnke T, Leutner LA, Spoden M, et al. Assessing the use of German claims data vocabularies for research in the observational medical outcomes partnership common data model: development and evaluation study. JMIR Med Inform. 2023;11:e47959. doi: 10.2196/47959.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/47959</ArticleId><ArticleId IdType="pmc">PMC10653283</ArticleId><ArticleId IdType="pubmed">37942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441&#x2013;8. doi: 10.1136/amiajnl-2011-000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000116</ArticleId><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot R, Puttmann DP, Fleuren LM, Thoral PJ, Elbers PW, de Keizer NF, et al. Determining and assessing characteristics of data element names impacting the performance of annotation using Usagi. Int J Med Inform. 2023 Oct;178:105200. doi: 10.1016/j.ijmedinf.2023.105200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2023.105200</ArticleId><ArticleId IdType="pubmed">37703800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Jin R, Zhou ZH. Understanding bag-of-words model: a statistical framework. Int J Mach Learn Cybern. 2010;1(1):43&#x2013;52. doi: 10.1007/s13042-010-0001-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13042-010-0001-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J, Zand M. Similarity mapping of national drug code formulary systems between nations [Internet] Durham (NC): Research Square; 2022. [cited at 2024 Jun 6]. Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1858694/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Guo L, Du C, Wang Y, Huang D. Extraction of English drug names based on Bert-CNN mode. J Inf Hiding Multimed Signal Process. 2020;11(2):70&#x2013;8.</Citation></Reference><Reference><Citation>Brown T, Mann B, Ryder N, Subbiah M, Kaplan JD, Dhariwal P, et al. Language models are few-shot learners. Adv Neural Inf Process Syst. 2020;33:1877&#x2013;901. doi: 10.48550/arXiv.2005.14165.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2005.14165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Xiong Y, Gao X, Jia K, Pan J, Bi Y, et al.   Retrieval-augmented generation for large language models: a survey [Internet] Ithaca (NY): arXiv.org; 2023.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/2005.14165.</Citation></Reference><Reference><Citation>Izacard G, Lewis P, Lomeli M, Hosseini L, Petroni F, Schick T, et al.   Few-shot learning with retrieval augmented language models [Internet] Ithaca (NY): arXiv.org; 2022.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/2208.03299.</Citation></Reference><Reference><Citation>Ministry of Health, Labour and Welfare  . National Health Insurance (NHI) drug price listing code 2024 [Internet] Tokyo, Japan: Ministry of Health, Labour and Welfare; c2024.  [cited at 2024 Jun 6]. Available from:  https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000078916.html.</Citation></Reference><Reference><Citation>National Institute of Health Sciences  . Japanese accepted names for pharmaceuticals [Internet] Tokyo, Japan: National Institute of Health Sciences; c2024.  [cited at 2024 Jun 6]. Available from:  https://jpdb.nihs.go.jp/jan.</Citation></Reference><Reference><Citation>Odysseus Data Services  . ATHENA: OHDSI Vocabularies Repository [Internet] [place unknown]: OHDSI; c2024.  [cited at 2024 Jun 6]. Available from:  https://athena.ohdsi.org/</Citation></Reference><Reference><Citation>Lee J, Yoon W, Kim S, Kim D, Kim S, So CH, et al. BioB-ERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics. 2020;36(4):1234&#x2013;40. doi: 10.1093/bioinformatics/btz682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz682</ArticleId><ArticleId IdType="pmc">PMC7703786</ArticleId><ArticleId IdType="pubmed">31501885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.  Google&#x2019;s neural machine translation system: bridging the gap between human and machine translation [Internet] Ithaca (NY): arXiv.org; 2016.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/1609.08144.</Citation></Reference><Reference><Citation>Douze M, Guzhva A, Deng C, Johnson J, Szilvasy G, Mazare PE, et al.   The Faiss library [Internet] Ithaca (NY): arXiv.org; 2024.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/2401.08281.</Citation></Reference><Reference><Citation>Lomeli M.  Faiss indexes [Internet] San Francisco (CA): GitHub; 2023.  [cited at 2024 Jun 6]. Available from:  https://github.com/facebookresearch/faiss/wiki/Faissindexes.</Citation></Reference><Reference><Citation>Jiang AQ, Sablayrolles A, Mensch A, Bamford C, Chaplot DS, de las Casas D, et al.   Mistral 7B [Internet] Ithaca (NY): arXiv.org; 2023.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/2310.06825.</Citation></Reference><Reference><Citation>Tunstall L, Schmid P, Sanseviero O, Cuenca P, Dehaene O, von Werra L, et al.   Welcome Mixtral: a SOTA mixture of experts on Hugging Face [Internet] Brooklyn (NY): Hugging Face; 2023.  [cited at 2024 Jun 6]. Available from:  https://huggingface.co/blog/mixtral.</Citation></Reference><Reference><Citation>Ji Z, Wei Q, Xu H. BERT-based ranking for biomedical entity normalization. AMIA Jt Summits Transl Sci Proc. 2020;2020:269&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233044</ArticleId><ArticleId IdType="pubmed">32477646</ArticleId></ArticleIdList></Reference><Reference><Citation>Shazeer N, Mirhoseini A, Maziarz K, Davis A, Le Q, Hinton G, et al.   Outrageously large neural networks: the sparsely-gated mixture-of-experts layer [Internet] Ithaca (NY): arXiv.org; 2017.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/1701.06538.</Citation></Reference><Reference><Citation>Achiam J, Adler S, Agarwal S, Ahmad L, Akkaya I, Aleman FL, et al.   GPT-4 technical report [Internet] Ithaca (NY): arXiv.org; 2023.  [cited at 2024 Jun 6]. Available from:  https://arxiv.org/abs/2303.08774v1.</Citation></Reference><Reference><Citation>Wu T, He S, Liu J, Sun S, Liu K, Han QL, et al. A brief overview of ChatGPT: the history, status quo and potential future development. IEEE/CAA J Automatica Sinica. 2023;10(5):1122&#x2013;36. doi: 10.1109/JAS.2023.123618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JAS.2023.123618</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub  . LangChain [Internet] San Francisco (CA): GitHub; 2022.  [cited at 2024 Jun 6]. Available from:  https://github.com/langchain-ai/langchain.</Citation></Reference><Reference><Citation>Bassani E. European Conference on Information Retrieval. Cham, Switzerland: Springer; 2022. ranx: a blazing-fast python library for ranking evaluation and comparison; pp. 259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-99739-7_30</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvelin K, Kekalainen J. Cumulated gain-based evaluation of IR techniques. ACM Trans Inf Syst. 2002;20(4):422&#x2013;46. doi: 10.1145/582415.582418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/582415.582418</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffat A, Zobel J. Rank-biased precision for measurement of retrieval effectiveness. ACM Trans Inf Syst. 2008;27(1):1&#x2013;27. doi: 10.1145/1416950.1416952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1416950.1416952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hu D, Li M, Duan H, Lu X. Automatic SNOMED CT coding of Chinese clinical terms via attention-based semantic matching. Int J Med Inform. 2022;159:104676. doi: 10.1016/j.ijmedinf.2021.104676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2021.104676</ArticleId><ArticleId IdType="pubmed">34990940</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39552716</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data.</ArticleTitle><Pagination><StartPage>102903</StartPage><MedlinePgn>102903</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102903</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2024.102903</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We conducted an international network cohort study to estimate the burden of these symptoms in North American, European, and Asian populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A federated analysis was conducted including 10 databases from the United Kingdom, Netherlands, Norway, Estonia, Spain, France, South Korea, and the United States, between September 1st 2020 and latest data availability (which varied from December 31st 2021 to February 28th 2023), covering primary and secondary care, nationwide registries, and claims data, all mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). We defined two cohorts for the main analyses: a SARS-CoV-2 infection cohort [positive polymerase chain reaction (PCR) or rapid lateral flow test (LFT) result or clinical COVID-19 diagnosis] and a general population cohort. Individuals with less than 365 days of prior history or 120 days of follow-up were excluded. We estimated incidence rates (IRs) of the 25 WHO-proposed post-acute COVID-19 symptoms, considering symptoms that occurred &#x2265;90 and&#xa0;&#x2264;365 days after index date, excluding individuals&#xa0;with the respective symptoms 180 days prior to the index event. Stratified analyses were conducted by age&#xa0;and sex. Incidence rate ratios (IRRs) were calculated comparing rates in the infected cohort versus the general population. Results from the different databases were combined using random-effects meta-analyses.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">3,019,408 individuals were included in the infection cohort. 1,585,160 of them were female and 1,434,248 of them male. 929,351,505 individuals were included in the general population group. 461,195,036 of them were female and 466,022,004 of them male. The 1-year IR of any post-acute COVID-19 symptom in the COVID-19 infection cohort varied significantly across databases, from 4.4 (95% CI 3.8-5.1) per 100 person-years to 103.9 (95% CI 103.2-104.7). The five most common symptoms were joint pain (from 1.6 (95% CI 1.3-1.9) to 14.3 (95% CI 14.1-14.6)), abdominal pain (from 0.3 (95% CI 0.1-0.5) to 9.9 (95% CI 9.7-10.1)), gastrointestinal issues (from 0.6 (95% CI 0.4-0.9) to 13.3 (95% CI 13.1-13.6)), cough (from 0.3 (95% CI 0.2-0.5) to 9.1 (95% CI 8.9-9.3)), and anxiety (from 0.8 (95% CI 0.6-1.2) to 11.4 (95% CI 11.2-11.6)); whereas muscle spasms (from 0.01 (95% CI 0.008-0.2) to 1.7 (95% CI 1.6-1.8)), pins and needles (from 0.05 (95% CI 0.03-0.0.9) to 1.5 (95% CI 1.4-1.6)), memory issues (from 0.03 (95% CI 0.02-0.06) to 0.8 (95% CI 0.7-0.8)), cognitive dysfunction (from 0.007 (95% CI 0.004-0.01) to 0.6 (95% CI 0.4-0.8)), and altered smell and/or taste (from 0.04 (95% CI 0.03-0.04) to 0.7 (95% CI 0.6-0.8)) were least common. Incidence rates of any post-acute COVID-19 symptoms generally increased with age, with certain symptoms peaking in middle-aged adults (anxiety, depressive disorders, headache, altered smell and taste) and others in pre-school children (gastrointestinal issues and cough). Females had higher incidence rates for most symptoms. Based on the random-effects model, the infected cohort had a higher incidence of any post-acute COVID-19 symptom than the general population, with a meta-analytic incidence rate ratio (meta-IRR) of 1.4 (1-2). A similar pattern was seen for all individual symptoms. The highest meta-IRRs were depressive disorder, 2.6 (1.7-3.9); anxiety, 2.3 (1.4-3.8); allergy, 2.1 (1.7-2.8) and sleep disorders, 2.1 (1.5-2.6). The meta-IRR for altered smell and/or taste was 1.9 (1.3-2.8).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Post-acute COVID-19 symptoms, as listed by the WHO, were commonly observed following COVID-19 infection. However, even after standardising research methods, there was significant heterogeneity in the incidence rates from different healthcare settings and geographical locations. This is the first international study of the epidemiology of post-acute COVID-19 symptoms using the WHO-listed symptoms. Its findings contibute to understand the epidemiology of this condition from a multinational approach. Limitations of this study include the lack of consensus of the post-acute COVID-19 definition, as well as the difficulty to capture the impact on daily life of the post-acute COVID-19 symptoms in the available datasets.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant and by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC).</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-G&#xfc;ell</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Blasco</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Gregoire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IDESP, Universit&#xe9; de Montpellier, INSERM, 34000, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abellan</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arinze</LastName><ForeName>Johnmary T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccu</LastName><ForeName>Zara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delseny</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Big Data Department, Health Insurance Review and Assessment Service, Wonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loste</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP (Red de Investigaci&#xf3;n Covid Persistente), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP (Red de Investigaci&#xf3;n Covid Persistente), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mel&#xe9;ndez-Cardiel</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercad&#xe9;-Besora</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosseveld</LastName><ForeName>Mees</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordeng</LastName><ForeName>Hedvig M E</ForeName><Initials>HME</Initials><AffiliationInfo><Affiliation>Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyinlola</LastName><ForeName>Jessie O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Crespo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda-Moncus&#xed;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung T H</ForeName><Initials>NTH</Initials><AffiliationInfo><Affiliation>Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusk&#xfc;la</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdivieso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University and Polytechnic La Fe Hospital of Valencia, Avenida Fernando Abril Martorell, 106 Torre H 1a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkard</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;dicke</LastName><ForeName>Annika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Incidence of post-acute COVID-19 symptoms</Keyword><Keyword MajorTopicYN="N">International cohort study</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Real world data</Keyword></KeywordList><CoiStatement>D.P.A.&#x2018;s department has received grant/s from Amgen, Chiesi&#x2013;Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA's department. R.P. reports serving on advisory boards for Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, MSD, GSK, ViiV Healthcare, Eli Lilly and Company, PharmaMar, and Atea Pharmaceuticals, Inc; and receiving research grants paid to his institution from MSD, ViiV Healthcare, Gilead Sciences, and PharmaMar. L.M. reports receiving grants from Grifols; receiving honoraria as a speaker from AstraZeneca, Gilead Sciences, GSK, and Pfizer; and participation in advisory boards for Gilead Sciences and Merck. M.M. works for a research group that in the past 3 years received unconditional research grants from Chiesi, UCB, Amgen, Johnson &amp; Johnson, Innovative Medicines Initiative and the European Medicines Agency. D.Ded., Z.C. and J.O. are employees of the Medicines and Healthcare Products Regulatory Agency, which provides the CPRD research service. K.K. is a consortial author in the US National Institutes of Health National COVID Cohort Collaborative (funding expired in 2022 with no renewal or active impact on any current work). G.M. reports receiving consulting fees from Pfizer. A.N. reports grants or contracts from Alfred P. Sloan Foundation, National Institutes of Health and the U.S. Food and Drug Administration. L.P. was supported by a Sara Borrell fellowship awarded by the Spanish Institute of Health Carlos III (CD23/00223). K.L.G is funded through an MRC scholarship with Bayer AG as an industrial partner. All other co-authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39552716</ArticleId><ArticleId IdType="pmc">PMC11564986</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2024.102903</ArticleId><ArticleId IdType="pii">S2589-5370(24)00482-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A., Desai A.D., Wan E.Y. Post-COVID-19 condition. Annu Rev Med. 2023;74:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">35914765</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson C.L., Broadley T. Long COVID&#x2014;unravelling a complex condition. Lancet Respir Med. 2023;11:667&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">37475126</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE); London: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcaillon-Bentata L., Makovski T.T., Alleaume C., et al. Post-Covid-19 condition: a comprehensive analysis of the World Health Organisation definition. J&#xa0;Infect. 2023;87:e83&#x2013;e87.</Citation><ArticleIdList><ArticleId IdType="pubmed">37604211</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A&#xa0;clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., et al. Symptoms, complications and management of long COVID: a review. J&#xa0;R Soc Med. 2021;114:428&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J&#xa0;Infect Dis. 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg M.A., Watson E., Bhatia M., et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat Commun. 2022;13:5822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Nieters A., Kr&#xe4;usslich H.G., et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olds Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806&#x2013;808. doi: 10.1136/bmj.39335.541782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E., Gallagher A.M., Bhaskaran K., et al. Data resource profile: clinical practice research Datalink (CPRD) Int J Epidemiol. 2015;44:827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A., Dedman D., Campbell J., et al. Data resource profile: clinical practice research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740. 1740g.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Data resource profile: the integrated primary care information (IPCI) database, the Netherlands - PubMed. https://pubmed.ncbi.nlm.nih.gov/35182144/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M., Rodr&#xed;guez C., Burn E., et al. Data resource profile: the information system for research in primary care (SIDIAP) Int J Epidemiol. 2022;51:e324&#x2013;e336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer M.A., Furlong L.I., Torre P., et al. Reuse of EHRs to support clinical research in a hospital of reference. Stud Health Technol Inform. 2015;210:224&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991136</ArticleId></ArticleIdList></Reference><Reference><Citation>Montpellier, C. H. U. de Entrep&#xf4;t de Donn&#xe9;es de Sant&#xe9;, eDOL. CHU de Montpellier: Site Internet. https://www.chu-montpellier.fr/fr/plateformes-recherche/eds</Citation></Reference><Reference><Citation>IQVIA PharMetrics&#xae; Plus. https://www.iqvia.com/locations/united-states/library/fact-sheets/iqvia-pharmetrics-plus</Citation></Reference><Reference><Citation>Transforming Estonian health data to the observational medical outcomes partnership (OMOP) common data model: lessons learned - PubMed. https://pubmed.ncbi.nlm.nih.gov/38058679/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken I.J., Ariansen A.M.S., Knudsen G.P., Johansen K.I., Vollset S.E. The Norwegian patient registry and the Norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48:49&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288711</ArticleId></ArticleIdList></Reference><Reference><Citation>Data standardization &#x2013; OHDSI. https://www.ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>Balduzzi S., R&#xfc;cker G., Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. BMJ Ment Health. 2019;22:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231495</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravent&#xf3;s B., Catal&#xe0; M., Du M., et al. IncidencePrevalence: an R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. 2024;33</Citation><ArticleIdList><ArticleId IdType="pubmed">37876360</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney L.L., Routen A., Gillies C., et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.J., MacKenna B., Inglesby P., et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021;71:e806&#x2013;e814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel P., Baum E., Donner-Banzhoff N. Fatigue as the chief complaint. Dtsch &#xc4;rztebl Int. 2021;118:566&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579431</ArticleId><ArticleId IdType="pubmed">34196270</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe M., Patricia B. Fatigue in the acute care and ambulatory setting. J&#xa0;Pediatr Nurs. 2014;29:344&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">24650424</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pel&#xe0; G., Goldoni M., Solinas E., et al. Sex-related differences in long-COVID-19 syndrome. J&#xa0;Womens Health. 2002;31:620&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostka K., et al. &#x201c;The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis&#x201d;. Nat Commun. 2023;14:7449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656441</ArticleId><ArticleId IdType="pubmed">37978296</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T., Pinto Pereira S.M., Nugawela M.D., et al. Long COVID-six months of prospective follow-up of changes in symptom profiles of non-hospitalised children and young people after SARS-CoV-2 testing: a national matched cohort study (The CLoCk) study. PLoS One. 2023;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987792</ArticleId><ArticleId IdType="pubmed">36877677</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39565915</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-4637</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Pain medicine (Malden, Mass.)</Title><ISOAbbreviation>Pain Med</ISOAbbreviation></Journal><ArticleTitle>Identifying factors associated with persistent opioid use after total joint arthroplasty: a retrospective review.</ArticleTitle><Pagination><StartPage>53</StartPage><EndPage>62</EndPage><MedlinePgn>53-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/pm/pnae120</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify predictors of persistent opioid use in opioid-na&#xef;ve individuals undergoing total joint arthroplasty.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Maine Health System.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Opioid-na&#xef;ve patients who underwent at least one total joint arthroplasty (knee, hip, or shoulder) between 2015 and 2020.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression was used to create a predictive model for persistent opioid use after surgery from a US Electronic Health Record dataset in the Observational Medical Outcomes Partnership Common Data Model format. 75% of the data was used to build the LASSO model using 10-fold cross-validation and 25% of the data was used to determine the optimal probability threshold for predicting the binary outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 6432 patients, 12.3% (792) were identified as having persistent opioid use across combined total joint arthroplasties defined as at least one opioid prescription between 90&#x2009;days and 1 year after surgery. Patients with persistent opioid use were more likely to be current smokers (OR 1.65), use antidepressants (OR 1.76), or have a diagnosis of post-traumatic stress disorder (OR 2.07) or a substance-related disorder (OR 1.69). Other factors associated with persistent opioid use included back pain (OR 1.43), dementia (OR 1.65), and body mass index over 40 (OR 2.50). The probability of persistent opioid use was not associated with age, sex, or ethnicity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This predictive model for persistent opioid use after total joint arthroplasty shows promise as an evidence-based, validated, and standardized tool for identifying high-risk patients before surgery in order to target strategies and interventions to reduce the reliance on opioids for postoperative pain control.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quaye</LastName><ForeName>Aurora</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7573-2164</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME 04102, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spectrum Healthcare Partners, Portland, ME 04106, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, MA 02111, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiPalazzo</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Population &amp; Health Research, Maine Health Institute for Research, Scarborough, ME 04074, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>OHDSI Center at the Roux Institute, Northeastern University, Portland, ME 04101, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Janelle M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME 04102, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beers-Mulroy</LastName><ForeName>Blaire</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME 04102, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peck</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Maine Medical Center, Portland, ME 04102, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krulee</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of New England College of Osteopathic Medicine, Portland, ME 04103, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Northern New England Clinical and Translational Research Center's</Agency><Country/></Grant><Grant><GrantID>U54GM115516</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pain Med</MedlineTA><NlmUniqueID>100894201</NlmUniqueID><ISSNLinking>1526-2375</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="Y">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="Y">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009293" MajorTopicYN="Y">Opioid-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019643" MajorTopicYN="Y">Arthroplasty, Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">analgesics</Keyword><Keyword MajorTopicYN="N">logistic models</Keyword><Keyword MajorTopicYN="N">opioid</Keyword><Keyword MajorTopicYN="N">retrospective studies</Keyword><Keyword MajorTopicYN="N">total joint arthroplasty</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>14</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39565915</ArticleId><ArticleId IdType="pmc">PMC11789782</ArticleId><ArticleId IdType="doi">10.1093/pm/pnae120</ArticleId><ArticleId IdType="pii">7905485</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Fingar KR, Stocks C, Weidd AJ, Steiner CA. Most frequent operating room procedures performed in U.S. hospitals, 2003-2012. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville, MD: Agency for Healthcare Research and Quality; 2014. Statistical Brief #186. Accessed September 5, 2024. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb186-Operating-Room-Procedures-United-States-2012.pdf</Citation></Reference><Reference><Citation>Shichman I, Roof M, Askew N, et al. &#xa0;Projections and epidemiology of primary hip and knee arthroplasty in Medicare patients to 2040-2060. JB JS Open Access. 2023;8(1):e22.00112. 10.2106/jbjs.Oa.22.00112</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.Oa.22.00112</ArticleId><ArticleId IdType="pmc">PMC9974080</ArticleId><ArticleId IdType="pubmed">36864906</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey K, Morgan JR, Lin MY, Kain MS, Creevy WR. &#xa0;Patient outcomes following total joint replacement surgery: a comparison of hospitals and ambulatory surgery centers. J Arthroplasty. 2020;35(1):7-11. 10.1016/j.arth.2019.08.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.08.041</ArticleId><ArticleId IdType="pmc">PMC6910922</ArticleId><ArticleId IdType="pubmed">31526700</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr AJ, Robertsson O, Graves S, et al. &#xa0;Knee replacement. Lancet. 2012;379(9823):1331-1340. 10.1016/s0140-6736(11)60752-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(11)60752-6</ArticleId><ArticleId IdType="pubmed">22398175</ArticleId></ArticleIdList></Reference><Reference><Citation>Klug A, Gramlich Y, Rudert M, et al. &#xa0;The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years. Knee Surg Sports Traumatol Arthrosc. 2021;29(10):3287-3298. 10.1007/s00167-020-06154-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00167-020-06154-7</ArticleId><ArticleId IdType="pmc">PMC7362328</ArticleId><ArticleId IdType="pubmed">32671435</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Yu S, Chen L, Cleveland JD. &#xa0;Rates of total joint replacement in the United States: future projections to 2020-2040 using the national inpatient sample. J Rheumatol. 2019;46(9):1134-1140. 10.3899/jrheum.170990</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170990</ArticleId><ArticleId IdType="pubmed">30988126</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh M, Newman S. &#xa0;Trends and developments in hip and knee arthroplasty technology. J Rehabil Assist Technol Eng. 2021;8:2055668320952043. 10.1177/2055668320952043</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2055668320952043</ArticleId><ArticleId IdType="pmc">PMC7874345</ArticleId><ArticleId IdType="pubmed">33614108</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddapati V, Padaki AS, Lehman RA, Lenke LG, Levine WN, Riew KD. &#xa0;Opioid prescriptions by orthopaedic surgeons in a Medicare population: recent trends, potential complications, and characteristics of high prescribers. J Am Acad Orthop Surg. 2021;29(5):e232-e237. 10.5435/jaaos-d-20-00612</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/jaaos-d-20-00612</ArticleId><ArticleId IdType="pubmed">32796374</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JW, Ma YS, Xiao LK. &#xa0;Postoperative pain management in total knee arthroplasty. Orthop Surg. 2019;11(5):755-761. 10.1111/os.12535</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.12535</ArticleId><ArticleId IdType="pmc">PMC6819170</ArticleId><ArticleId IdType="pubmed">31663286</ArticleId></ArticleIdList></Reference><Reference><Citation>Glare P, Aubrey KR, Myles PS. &#xa0;Transition from acute to chronic pain after surgery. Lancet. 2019;393(10180):1537-1546. 10.1016/s0140-6736(19)30352-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)30352-6</ArticleId><ArticleId IdType="pubmed">30983589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. &#xa0;Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth Analg. 2017;125(5):1733-1740. 10.1213/ane.0000000000002458</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000002458</ArticleId><ArticleId IdType="pmc">PMC6119469</ArticleId><ArticleId IdType="pubmed">29049117</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Bateman BT, Wunsch H. &#xa0;Inappropriate opioid prescription after surgery. Lancet. 2019;393(10180):1547-1557. 10.1016/s0140-6736(19)30428-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(19)30428-3</ArticleId><ArticleId IdType="pmc">PMC6556783</ArticleId><ArticleId IdType="pubmed">30983590</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummett CM, England C, Evans-Shields J, et al. &#xa0;Health care burden associated with outpatient opioid use following inpatient or outpatient surgery. J Manag Care Spec Pharm. 2019;25(9):973-983. 10.18553/jmcp.2019.19055</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2019.19055</ArticleId><ArticleId IdType="pmc">PMC10397638</ArticleId><ArticleId IdType="pubmed">31313621</ArticleId></ArticleIdList></Reference><Reference><Citation>Florence CS, Zhou C, Luo F, Xu L. &#xa0;The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901-906. 10.1097/mlr.0000000000000625</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mlr.0000000000000625</ArticleId><ArticleId IdType="pmc">PMC5975355</ArticleId><ArticleId IdType="pubmed">27623005</ArticleId></ArticleIdList></Reference><Reference><Citation>Okoli MU, Rondon AJ, Townsend CB, Sherman MB, Ilyas AM; Opioid Use in Orthopaedic Surgery Study Group. Comprehensive analysis of opioid use after common elective outpatient orthopaedic surgeries. JAAOS Global Res Rev. 2022;6(4):e21.00226. 10.5435/JAAOSGlobal-D-21-00226</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/JAAOSGlobal-D-21-00226</ArticleId><ArticleId IdType="pmc">PMC10566975</ArticleId><ArticleId IdType="pubmed">35412506</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedard NA, DeMik DE, Dowdle SB, Owens JM, Liu SS, Callaghan JJ. &#xa0;Does preoperative opioid use increase the risk of early revision total hip arthroplasty? &#xa0;J Arthroplasty. 2018;33(7):S154&#x2013;S156. 10.1016/j.arth.2018.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.01.018</ArticleId><ArticleId IdType="pubmed">29452972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell KL, Shohat N, Goswami K, Tan TL, Kalbian I, Parvizi J. &#xa0;Preoperative opioids increase the risk of periprosthetic joint infection after total joint arthroplasty. J Arthroplasty. 2018;33(10):3246&#x2013;3251.e3241. 10.1016/j.arth.2018.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.05.027</ArticleId><ArticleId IdType="pubmed">30054211</ArticleId></ArticleIdList></Reference><Reference><Citation>Weick J, Bawa H, Dirschl DR, Luu HH. &#xa0;Preoperative opioid use is associated with higher readmission and revision rates in total knee and total hip arthroplasty. J Bone Joint Surg Am. 2018;100(14):1171-1176. 10.2106/jbjs.17.01414</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.17.01414</ArticleId><ArticleId IdType="pubmed">30020122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah JW, Sing DC, McLaughlin D, Feeley BT, Ma CB, Zhang AL. &#xa0;The perioperative effects of chronic preoperative opioid use on shoulder arthroplasty outcomes. J Shoulder Elbow Surg. 2017;26(11):1908-1914. 10.1016/j.jse.2017.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2017.05.016</ArticleId><ArticleId IdType="pubmed">28735841</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin PD, Karbassi JA, Li W, Yang W, Ayers DC. &#xa0;Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction. J Arthroplasty. 2010;25(6 Suppl):12-16. 10.1016/j.arth.2010.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2010.05.003</ArticleId><ArticleId IdType="pubmed">20580191</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazi ZM, Lu Y, Patel BH, Cancienne JM, Werner B, Forsythe B. &#xa0;Risk factors for opioid use after total shoulder arthroplasty. J Shoulder Elbow Surg. 2020;29(2):235-243. 10.1016/j.jse.2019.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2019.06.020</ArticleId><ArticleId IdType="pubmed">31495704</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, et al. &#xa0;OHDSI standardized vocabularies&#x2014;a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31(3):583-590. 10.1093/jamia/ocad247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent ML, Hurley RW, Oderda GM, et al.; POQI-4 Working Group. American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on persistent postoperative opioid use: definition, incidence, risk factors, and health care system initiatives. Anesth Analg. 2019;129(2):543-552. 10.1213/ane.0000000000003941</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000003941</ArticleId><ArticleId IdType="pmc">PMC6640123</ArticleId><ArticleId IdType="pubmed">30897590</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller KG, Memtsoudis SG, Mariano ER, Baker LC, Mackey S, Sun EC. &#xa0;Lack of association between the use of nerve blockade and the risk of persistent opioid use among patients undergoing shoulder arthroplasty: evidence from the Marketscan Database. Anesth Analg. 2017;125(3):1014-1020. 10.1213/ane.0000000000002031</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000002031</ArticleId><ArticleId IdType="pubmed">28742777</ArticleId></ArticleIdList></Reference><Reference><Citation>
Observational Health Data Sciences. Chapter 8: OHDSI analytics tools. Accessed September 5, 2024. https://ohdsi.github.io/TheBookOfOhdsi/OhdsiAnalyticsTools.html#atlas</Citation></Reference><Reference><Citation>
Economic Research Service. Rural-urban commuting area codes. Accessed April 12, 2024. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/documentation/</Citation></Reference><Reference><Citation>
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Accessed August 22, 2024. https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report</Citation></Reference><Reference><Citation>Dowell DBS, Gyawali S, Hoenig J, et al. &#xa0;Treatment for opioid use disorder: population estimates&#x2014;United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(25):567-574. 10.15585/mmwr.mm7325a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7325a1</ArticleId><ArticleId IdType="pmc">PMC11254342</ArticleId><ArticleId IdType="pubmed">38935567</ArticleId></ArticleIdList></Reference><Reference><Citation>Brummett CM, Waljee JF, Goesling J, et al. &#xa0;New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. 10.1001/jamasurg.2017.0504</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2017.0504</ArticleId><ArticleId IdType="pmc">PMC7050825</ArticleId><ArticleId IdType="pubmed">28403427</ArticleId></ArticleIdList></Reference><Reference><Citation>Armaghani SJ, Lee DS, Bible JE, et al. &#xa0;Preoperative opioid use and its association with perioperative opioid demand and postoperative opioid independence in patients undergoing spine surgery. Spine (Phila Pa 1976). 2014;39(25):E1524&#x2013;E1530. 10.1097/brs.0000000000000622</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/brs.0000000000000622</ArticleId><ArticleId IdType="pubmed">25417827</ArticleId></ArticleIdList></Reference><Reference><Citation>Larach DB, Hah JM, Brummett CM. &#xa0;Perioperative opioids, the opioid crisis, and the anesthesiologist. Anesthesiology. 2022;136(4):594-608. 10.1097/aln.0000000000004109</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/aln.0000000000004109</ArticleId><ArticleId IdType="pmc">PMC8904272</ArticleId><ArticleId IdType="pubmed">35108351</ArticleId></ArticleIdList></Reference><Reference><Citation>Catchpool M, Knight J, Young JT, et al. &#xa0;Opioid use prior to elective surgery is strongly associated with persistent use following surgery: an analysis of 14&#x2009;354 Medicare patients. ANZ J Surg. 2019;89(11):1410-1416. 10.1111/ans.15492</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.15492</ArticleId><ArticleId IdType="pmc">PMC6900005</ArticleId><ArticleId IdType="pubmed">31637832</ArticleId></ArticleIdList></Reference><Reference><Citation>Goesling J, Moser SE, Zaidi B, et al. &#xa0;Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. 2016;157(6):1259-1265. 10.1097/j.pain.0000000000000516</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000000516</ArticleId><ArticleId IdType="pmc">PMC4868627</ArticleId><ArticleId IdType="pubmed">26871536</ArticleId></ArticleIdList></Reference><Reference><Citation>Waljee JF, Zhong L, Hou H, Sears E, Brummett C, Chung KC. &#xa0;The use of opioid analgesics following common upper extremity surgical procedures: a national, population-based study. Plast Reconstr Surg. 2016;137(2):355e-364e. 10.1097/01.prs.0000475788.52446.7b</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.prs.0000475788.52446.7b</ArticleId><ArticleId IdType="pmc">PMC5090259</ArticleId><ArticleId IdType="pubmed">26818326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarling BJ, Yokhana SS, Herzog DT, Markel DC. &#xa0;Preoperative and postoperative opiate use by the arthroplasty patient. J Arthroplasty. 2016;31(10):2081-2084. 10.1016/j.arth.2016.03.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.03.061</ArticleId><ArticleId IdType="pubmed">27161903</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba RS, Inacio MCS, Pratt NL, Graves SE, Roughead EE, Paxton EW. &#xa0;Persistent opioid use following total knee arthroplasty: a signal for close surveillance. J Arthroplasty. 2018;33(2):331-336. 10.1016/j.arth.2017.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2017.09.001</ArticleId><ArticleId IdType="pubmed">28974377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun EC, Darnall BD, Baker LC, Mackey S. &#xa0;incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. JAMA Intern Med. 2016;176(9):1286-1293. 10.1001/jamainternmed.2016.3298</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2016.3298</ArticleId><ArticleId IdType="pmc">PMC6684468</ArticleId><ArticleId IdType="pubmed">27400458</ArticleId></ArticleIdList></Reference><Reference><Citation>Kugelman DN, Mahure SA, Feng JE, Rozell JC, Schwarzkopf R, Long WJ. &#xa0;Total knee arthroplasty is associated with greater immediate post-surgical pain and opioid use than total hip arthroplasty. Arch Orthop Trauma Surg. 2022;142(12):3575-3580. 10.1007/s00402-021-03951-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-021-03951-8</ArticleId><ArticleId IdType="pubmed">33991234</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto PR, McIntyre T, Ara&#xfa;jo-Soares V, Costa P, Ferrero R, Almeida A. &#xa0;A comparison of predictors and intensity of acute postsurgical pain in patients undergoing total hip and knee arthroplasty. J Pain Res. 2017;10:1087-1098. 10.2147/jpr.S126467</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/jpr.S126467</ArticleId><ArticleId IdType="pmc">PMC5431693</ArticleId><ArticleId IdType="pubmed">28533697</ArticleId></ArticleIdList></Reference><Reference><Citation>Wylde V, Rooker J, Halliday L, Blom A. &#xa0;Acute postoperative pain at rest after hip and knee arthroplasty: severity, sensory qualities and impact on sleep. Orthop Traumatol Surg Res. 2011;97(2):139-144. 10.1016/j.otsr.2010.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2010.12.003</ArticleId><ArticleId IdType="pubmed">21388906</ArticleId></ArticleIdList></Reference><Reference><Citation>Wylde V, Hewlett S, Learmonth ID, Dieppe P. &#xa0;Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain. 2011;152(3):566-572. 10.1016/j.pain.2010.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2010.11.023</ArticleId><ArticleId IdType="pubmed">21239114</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YK, Boden KA, Schreiber KL. &#xa0;The role of regional anaesthesia and multimodal analgesia in the prevention of chronic postoperative pain: a narrative review. Anaesthesia. 2021;76 (Suppl 1):8-17. 10.1111/anae.15256</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15256</ArticleId><ArticleId IdType="pmc">PMC8369227</ArticleId><ArticleId IdType="pubmed">33426669</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pacira Pharmaceuticals, Inc. Exparel (Bupivacaine Liposome Injectable Suspension). Accessed October 22, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022496s005lbl.pdf</Citation></Reference><Reference><Citation>Mikhaeil J, Ayoo K, Clarke H, W&#x105;sowicz M, Huang A. &#xa0;Review of the transitional pain service as a method of postoperative opioid weaning and a service aimed at minimizing the risk of chronic post-surgical pain. Anaesthesiol Intensive Ther. 2020;52(2):148-153. 10.5114/ait.2020.96018</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ait.2020.96018</ArticleId><ArticleId IdType="pmc">PMC10176534</ArticleId><ArticleId IdType="pubmed">32702941</ArticleId></ArticleIdList></Reference><Reference><Citation>Aasvang EK, Gmaehle E, Hansen JB, et al. &#xa0;Predictive risk factors for persistent postherniotomy pain. Anesthesiology. 2010;112(4):957-969. 10.1097/ALN.0b013e3181d31ff8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3181d31ff8</ArticleId><ArticleId IdType="pubmed">20234307</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus A, Hinrichs-Rocker A, Chapman R, et al. &#xa0;Development of a risk index for the prediction of chronic post-surgical pain. Eur J Pain. 2012;16(6):901-910. 10.1002/j.1532-2149.2011.00090.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1532-2149.2011.00090.x</ArticleId><ArticleId IdType="pubmed">22337572</ArticleId></ArticleIdList></Reference><Reference><Citation>Meretoja TJ, Andersen KG, Bruce J, et al. &#xa0;Clinical prediction model and tool for assessing risk of persistent pain after breast cancer surgery. J Clin Oncol. 2017;35(15):1660-1667. 10.1200/jco.2016.70.3413</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2016.70.3413</ArticleId><ArticleId IdType="pubmed">28524782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BWY, Carlson SA, Greenlund KJ, et al. &#xa0;National, state-level, and county-level prevalence estimates of adults aged &#x2265;18 years self-reporting a lifetime diagnosis of depression&#x2014;United States, 2020. MMWR Morb Mortal Wkly Rep. 2023;72(24):644-650. 10.15585/mmwr.mm7224a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7224a1</ArticleId><ArticleId IdType="pmc">PMC10328468</ArticleId><ArticleId IdType="pubmed">37318995</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes KM, Cerd&#xe1; M, Brady JE, Havens JR, Galea S. &#xa0;Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health. 2014;104(2):e52-59-e59. 10.2105/ajph.2013.301709</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.2013.301709</ArticleId><ArticleId IdType="pmc">PMC3935688</ArticleId><ArticleId IdType="pubmed">24328642</ArticleId></ArticleIdList></Reference><Reference><Citation>Monnat SM, Rigg KK. &#xa0;Examining rural/urban differences in prescription opioid misuse among US adolescents. J Rural Health. 2016;32(2):204-218. 10.1111/jrh.12141</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jrh.12141</ArticleId><ArticleId IdType="pmc">PMC4779738</ArticleId><ArticleId IdType="pubmed">26344571</ArticleId></ArticleIdList></Reference><Reference><Citation>Prunuske JP, St Hill CA, Hager KD, et al. &#xa0;Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. BMC Health Serv Res. 2014;14:563. 10.1186/s12913-014-0563-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-014-0563-8</ArticleId><ArticleId IdType="pmc">PMC4241226</ArticleId><ArticleId IdType="pubmed">25407745</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigg KK, Monnat SM. &#xa0;Urban vs. rural differences in prescription opioid misuse among adults in the United States: informing region specific drug policies and interventions. Int J Drug Policy. 2015;26(5):484-491. 10.1016/j.drugpo.2014.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2014.10.001</ArticleId><ArticleId IdType="pmc">PMC4397122</ArticleId><ArticleId IdType="pubmed">25458403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39569020</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2674-0109</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in network physiology</Title><ISOAbbreviation>Front Netw Physiol</ISOAbbreviation></Journal><ArticleTitle>Physiological signal analysis and open science using the Julia language and associated software.</ArticleTitle><Pagination><StartPage>1478280</StartPage><MedlinePgn>1478280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1478280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnetp.2024.1478280</ELocationID><Abstract><AbstractText>In this mini review, we propose the use of the Julia programming language and its software as a strong candidate for reproducible, efficient, and sustainable physiological signal analysis. First, we highlight available software and Julia communities that provide top-of-the-class algorithms for all aspects of physiological signal processing despite the language's relatively young age. Julia can significantly accelerate both research and software development due to its high-level interactive language and high-performance code generation. It is also particularly suited for open and reproducible science. Openness is supported and welcomed because the overwhelming majority of Julia software programs are open source and developed openly on public platforms, primarily through individual contributions. Such an environment increases the likelihood that an individual not (originally) associated with a software program would still be willing to contribute their code, further promoting code sharing and reuse. On the other hand, Julia's exceptionally strong package manager and surrounding ecosystem make it easy to create self-contained, reproducible projects that can be instantly installed and run, irrespective of processor architecture or operating system.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Datseris and Zelko.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Datseris</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Exeter, Exeter, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelko</LastName><ForeName>Jacob S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Northeastern University, Boston, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center, Roux Institute, Northeastern University, Portland, ME, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Netw Physiol</MedlineTA><NlmUniqueID>9918334487406676</NlmUniqueID><ISSNLinking>2674-0109</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Julia</Keyword><Keyword MajorTopicYN="N">complexity measures</Keyword><Keyword MajorTopicYN="N">digital signal processing</Keyword><Keyword MajorTopicYN="N">open science</Keyword><Keyword MajorTopicYN="N">physiological signals</Keyword><Keyword MajorTopicYN="N">reproducible</Keyword><Keyword MajorTopicYN="N">time series analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39569020</ArticleId><ArticleId IdType="pmc">PMC11577965</ArticleId><ArticleId IdType="doi">10.3389/fnetp.2024.1478280</ArticleId><ArticleId IdType="pii">1478280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bagge Carlson F., Chitre M. (2020). New metrics between rational spectra and their connection to optimal transport. arXiv e-prints. arXiv&#x2013;2004.</Citation></Reference><Reference><Citation>Bagge Carlson F., Robertsson A., Johansson R. (2017). &#x201c;Linear parameter-varying spectral decomposition,&#x201d; in 2017 American control conference (ACC).</Citation></Reference><Reference><Citation>Bandt C., Pompe B. (2002). Permutation entropy: a natural complexity measure for time series. Phys. Rev. Lett. 88, 174102. 10.1103/PhysRevLett.88.174102</Citation><ArticleIdList><ArticleId IdType="doi">10.1103/PhysRevLett.88.174102</ArticleId><ArticleId IdType="pubmed">12005759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezanson J., Edelman A., Karpinski S., Shah V. B. (2017). Julia: a fresh approach to numerical computing. SIAM Rev. 59, 65&#x2013;98. 10.1137/141000671</Citation><ArticleIdList><ArticleId IdType="doi">10.1137/141000671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezanson J., Karpinski S., Shah V. B., Edelman A. (2012). Julia: a fast dynamic language for technical computing. Corr. abs/1209, 5145.</Citation></Reference><Reference><Citation>Bouchet-Valat M., Kami&#x144;ski B. (2023). Dataframes. jl: flexible and fast tabular data in julia. J. Stat. Softw. 107, 1&#x2013;32. 10.18637/jss.v107.i04</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v107.i04</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Passi C., Coronado R., Varela-Mattatall G., Alberola-L&#xf3;pez C., Botnar R., Irarrazaval P. (2023). Komamri.jl: an open-source framework for general mri simulations with gpu acceleration. Magnetic Reson. Med. 90, 329&#x2013;342. 10.1002/mrm.29635</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.29635</ArticleId><ArticleId IdType="pmc">PMC10952765</ArticleId><ArticleId IdType="pubmed">36877139</ArticleId></ArticleIdList></Reference><Reference><Citation>Datseris G. (2018). Dynamicalsystems.jl: a julia software library for chaos and nonlinear dynamics. J. Open Source Softw. 3, 598. 10.21105/joss.00598</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.00598</ArticleId></ArticleIdList></Reference><Reference><Citation>Datseris G., Haaga K. A. (2024). Complexitymeasures.jl: scalable software to unify and accelerate entropy and complexity time series analysis.</Citation></Reference><Reference><Citation>Datseris G., Isensee J., Pech S., G&#xe1;l T. (2020). Drwatson: the perfect sidekick for your scientific inquiries. J. Open Source Softw. 5, 2673. 10.21105/joss.02673</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.02673</ArticleId></ArticleIdList></Reference><Reference><Citation>Datseris G., Zelko J. S. (2024). Datseris/JuliaOpenPhysiologicalDSP: first submitted version. 10.5281/zenodo.13284209</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.13284209</ArticleId></ArticleIdList></Reference><Reference><Citation>Delorme A., Makeig S. (2004). Eeglab: an open source toolbox for analysis of single-trial eeg dynamics including independent component analysis. J. Neurosci. methods 134, 9&#x2013;21. 10.1016/j.jneumeth.2003.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2003.10.009</ArticleId><ArticleId IdType="pubmed">15102499</ArticleId></ArticleIdList></Reference><Reference><Citation>Eschle J., G&#xe1;l T., Giordano M., Gras P., Hegner B., Heinrich L., et al. (2023). Potential of the julia programming language for high energy physics computing. Comput. Softw. Big Sci. 7, 10. 10.1007/s41781-023-00104-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41781-023-00104-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy W. F., Valero-Lara P., Anderson C., Lee K. W., Gainaru A., Ferreira Da Silva R., et al. (2023). &#x201c;Julia as a unifying end-to-end workflow language on the frontier exascale system,&#x201d; in Proceedings of the SC&#x2019;23 workshops of the international conference on high performance computing, network, storage, and analysis, 1989&#x2013;1999.</Citation></Reference><Reference><Citation>Gramfort A., Luessi M., Larson E., Engemann D. A., Strohmeier D., Brodbeck C., et al. (2013). MEG and EEG data analysis with MNE-Python. Front. Neurosci. 7, 267&#x2013;313. 10.3389/fnins.2013.00267</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2013.00267</ArticleId><ArticleId IdType="pmc">PMC3872725</ArticleId><ArticleId IdType="pubmed">24431986</ArticleId></ArticleIdList></Reference><Reference><Citation>Haaga K. A., Datseris G. (2022). Time seriessurrogates.jl: a julia package for generating surrogate data. J. Open Source Softw. 7, 4414. 10.21105/joss.04414</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.04414</ArticleId></ArticleIdList></Reference><Reference><Citation>Haaga K. A., RomeoV D. G. (2024). Juliadynamics/associations.jl: v4.2.0. 10.5281/zenodo.8409495</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8409495</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpinski S. (2019). The unreasonable effectiveness of multiple dispatch. Accessed: September-2024-16</Citation></Reference><Reference><Citation>Kluyver T., Ragan-Kelley B., P&#xe9;rez F., Granger B., Bussonnier M., Frederic J., et al. (2016). &#x201c;Jupyter notebooks &#x2013; a publishing format for reproducible computational workflows,&#x201d; in Positioning and power in academic publishing: players, agents and agendas. Editors Loizides F., Schmidt B. (IOS Press; ), 87&#x2013;90.</Citation></Reference><Reference><Citation>Knopp T., Boberg M., Grosser M. (2023). NFFT.jl: generic and fast julia implementation of the nonequidistant fast Fourier transform. SIAM J. Sci. Comput. 45, C179&#x2013;C205. 10.1137/22m1510935</Citation><ArticleIdList><ArticleId IdType="doi">10.1137/22m1510935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornblith S., Lynch G., Holters M., Santos J. F., Russell S., Kickliter J., et al. (2023). Juliadsp/dsp.jl: v0.7.9. 10.5281/zenodo.8344531</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8344531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin M., Dowson O., Dias Garcia J., Huchette J., Legat B., Vielma J. P. (2023). JuMP 1.0: recent improvements to a modeling language for mathematical optimization. Math. Program. Comput. 15, 581&#x2013;589. 10.1007/s12532-023-00239-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12532-023-00239-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor D., Panday D., Kandel H. K., Steffert T., Banks D. (2021). Ceps: an open access matlab graphical user interface (gui) for the analysis of complexity and entropy in physiological signals. Entropy 23, 321. 10.3390/e23030321</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/e23030321</ArticleId><ArticleId IdType="pmc">PMC7998823</ArticleId><ArticleId IdType="pubmed">33800469</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor D., Steffert T., Datseris G., Firth A., Panday D., Kandel H., et al. (2023). Complexity and entropy in physiological signals (ceps): resonance breathing rate assessed using measures of fractal dimension, heart rate asymmetry and permutation entropy. Entropy 25, 301. 10.3390/e25020301</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/e25020301</ArticleId><ArticleId IdType="pmc">PMC9955651</ArticleId><ArticleId IdType="pubmed">36832667</ArticleId></ArticleIdList></Reference><Reference><Citation>Parfenov A. (2023). Brainflow.</Citation></Reference><Reference><Citation>Quinn J., Bouchet-Valat M., Robinson N., Kami&#x144;ski B., Newman G., Stukalov A., et al. (2023). Juliadata/csv.jl: 10. 10.5281/zenodo.8004128</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.8004128</ArticleId></ArticleIdList></Reference><Reference><Citation>Richman J. S., Moorman J. R. (2000). Physiological time series analysis using approximate entropy and sample entropy. Am. J. physiology-heart circulatory physiology 278, H2039&#x2013;H2049. 10.1152/ajpheart.2000.278.6.H2039</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.2000.278.6.H2039</ArticleId><ArticleId IdType="pubmed">10843903</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesch E., Greener J. G., MacLean A. L., Nassar H., Rackauckas C., Holy T. E., et al. (2023). Julia for biologists. Nat. methods 20, 655&#x2013;664. 10.1038/s41592-023-01832-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-023-01832-z</ArticleId><ArticleId IdType="pmc">PMC10216852</ArticleId><ArticleId IdType="pubmed">37024649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso O. A., Blanco S., Yordanova J., Kolev V., Figliola A., Sch&#xfc;rmann M., et al. (2001). Wavelet entropy: a new tool for analysis of short duration brain electrical signals. J. Neurosci. Methods 105, 65&#x2013;75. 10.1016/S0165-0270(00)00356-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0270(00)00356-3</ArticleId><ArticleId IdType="pubmed">11166367</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso O. A., Larrondo H., Martin M. T., Plastino A., Fuentes M. A. (2007). Distinguishing noise from chaos. Phys. Rev. Lett. 99, 154102. 10.1103/PhysRevLett.99.154102</Citation><ArticleIdList><ArticleId IdType="doi">10.1103/PhysRevLett.99.154102</ArticleId><ArticleId IdType="pubmed">17995170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Zhang H., Xu W., Zhang H., Yang L., Zheng S., et al. (2017). Spectral entropy can predict changes of working memory performance reduced by short-time training in the delayed-match-to-sample task. Front. Hum. Neurosci. 11, 437. 10.3389/fnhum.2017.00437</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnhum.2017.00437</ArticleId><ArticleId IdType="pmc">PMC5583228</ArticleId><ArticleId IdType="pubmed">28912701</ArticleId></ArticleIdList></Reference><Reference><Citation>Udell M., Mohan K., Zeng D., Hong J., Diamond S., Boyd S. (2014) &#x201c;Convex optimization in julia,&#x201d; in SC14 workshop on high performance technical computing in dynamic languages.</Citation></Reference><Reference><Citation>Vejmelka M., Palu&#x161; M. (2008). Inferring the directionality of coupling with conditional mutual information. Phys. Rev. E 77, 026214. 10.1103/PHYSREVE.77.026214</Citation><ArticleIdList><ArticleId IdType="doi">10.1103/PHYSREVE.77.026214</ArticleId><ArticleId IdType="pubmed">18352110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wes M. K. (2010). &#x201c;Data structures for statistical computing in Python,&#x201d; in Proceedings of the 9th Python in science conference, 56&#x2013;61. 10.25080/Majora-92bf1922-00a</Citation><ArticleIdList><ArticleId IdType="doi">10.25080/Majora-92bf1922-00a</ArticleId></ArticleIdList></Reference><Reference><Citation>White F. C. (2020). Julialang: the ingredients for a composable programming language Accessed : 2024-September-16.</Citation></Reference><Reference><Citation>Wickham H., Averick M., Bryan J., Chang W., McGowan L. D., Fran&#xe7;ois R., et al. (2019). Welcome to the tidyverse. J. Open Source Softw. 4, 1686. 10.21105/joss.01686</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikipedia contributors (2024). Dependency hell &#x2014; Wikipedia, the free encyclopedia.</Citation></Reference><Reference><Citation>Wysoki&#x144;ski A. (2024). Neuroanalyzer. 10.5281/zenodo.7372648</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.7372648</ArticleId></ArticleIdList></Reference><Reference><Citation>[Dataset Xiang C., Fan X., Bai D., Lv K., Lei X. (2024). A resting-state eeg dataset for sleep deprivation. Sci. Data 11, 427. 10.1038/s41597-024-03268-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-024-03268-2</ArticleId><ArticleId IdType="pmc">PMC11043390</ArticleId><ArticleId IdType="pubmed">38658675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanin M., Olivares F. (2021). Ordinal patterns-based methodologies for distinguishing chaos from noise in discrete time series. Commun. Phys. 4, 190. 10.1038/s42005-021-00696-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42005-021-00696-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelko J., Chinta V., Abdelazeez F., Sanjay J. (2024). Omopcdmcohortcreator 0.5.1. 10.5281/zenodo.11662821</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.11662821</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39575802</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Suitability of the OMOP Common Data Model for Mapping Datasets of Medical Research Studies Using the Example of a Multicenter Registry.</ArticleTitle><Pagination><StartPage>170</StartPage><EndPage>174</EndPage><MedlinePgn>170-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI241086</ELocationID><Abstract><AbstractText>Common Data Models (CDM) are developed to solve integration problems that arise in the secondary use of health data. The OMOP CDM is such a model that is mainly used for healthcare data, so this paper examines whether it is also suitable for mapping research data. An exemplary research dataset is mapped to the model and the model is tested for suitability. For this purpose, an ETL process is first designed with the OHDSI tools and finally implemented with Talend Open Studio for Data Integration. The data quality is checked, and the mapping and the model, together with the tools, are evaluated. Overall, all but three data fields from the source dataset could be mapped to the OMOP model, so that the model's suitability for research data can be confirmed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurtz</LastName><ForeName>Milla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;be</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Data Accuracy</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Registry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39575802</ArticleId><ArticleId IdType="doi">10.3233/SHTI241086</ArticleId><ArticleId IdType="pii">SHTI241086</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39576284</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Hospital Length of Stay Prediction for Planned Admissions Using Observational Medical Outcomes Partnership Common Data Model: Retrospective Study.</ArticleTitle><Pagination><StartPage>e59260</StartPage><MedlinePgn>e59260</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e59260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/59260</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Accurate hospital length of stay (LoS) prediction enables efficient resource management. Conventional LoS prediction models with limited covariates and nonstandardized data have limited reproducibility when applied to the general population.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this study, we developed and validated a machine learning (ML)-based LoS prediction model for planned admissions using the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective patient-level prediction models used electronic health record (EHR) data converted to the OMOP CDM (version 5.3) from Seoul National University Bundang Hospital (SNUBH) in South Korea. The study included 137,437 hospital admission episodes between January 2016 and December 2020. Covariates from the patient, condition occurrence, medication, observation, measurement, procedure, and visit occurrence tables were included in the analysis. To perform feature selection, we applied Lasso regularization in the logistic regression. The primary outcome was an LoS of 7 days or longer, while the secondary outcome was an LoS of 3 days or longer. The prediction models were developed using 6 ML algorithms, with the training and test set split in a 7:3 ratio. The performance of each model was evaluated based on the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Shapley Additive Explanations (SHAP) analysis measured feature importance, while calibration plots assessed the reliability of the prediction models. External validation of the developed models occurred at an independent institution, the Seoul National University Hospital.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The final sample included 129,938 patient entry events in the planned admissions. The Extreme Gradient Boosting (XGB) model achieved the best performance in binary classification for predicting an LoS of 7 days or longer, with an AUROC of 0.891 (95% CI 0.887-0.894) and an AUPRC of 0.819 (95% CI 0.813-0.826) on the internal test set. The Light Gradient Boosting (LGB) model performed the best in the multiclassification for predicting an LoS of 3 days or more, with an AUROC of 0.901 (95% CI 0.898-0.904) and an AUPRC of 0.770 (95% CI 0.762-0.779). The most important features contributing to the models were the operation performed, frequency of previous outpatient visits, patient admission department, age, and day of admission. The RF model showed robust performance in the external validation set, achieving an AUROC of 0.804 (95% CI 0.802-0.807).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of the OMOP CDM in predicting hospital LoS for planned admissions demonstrates promising predictive capabilities for stays of varying durations. It underscores the advantage of standardized data in achieving reproducible results. This approach should serve as a model for enhancing operational efficiency and patient care coordination across health care settings.</AbstractText><CopyrightInformation>&#xa9;Haeun Lee, Seok Kim, Hui-Woun Moon, Ho-Young Lee, Kwangsoo Kim, Se Young Jung, Sooyoung Yoo. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 22.11.2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Haeun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9597-9447</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4996-8613</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Hui-Woun</ForeName><Initials>HW</Initials><Identifier Source="ORCID">0000-0002-0405-9216</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-6518-0602</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4586-5062</Identifier><AffiliationInfo><Affiliation>Department of Transdisciplinary Medicine, Seoul National University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jung</LastName><ForeName>Se Young</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0001-9946-8807</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8620-4925</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="Y">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EHR</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership Common Data Model</Keyword><Keyword MajorTopicYN="N">Shapley Additive Explanation</Keyword><Keyword MajorTopicYN="N">South Korea</Keyword><Keyword MajorTopicYN="N">admission</Keyword><Keyword MajorTopicYN="N">algorithm</Keyword><Keyword MajorTopicYN="N">allocation of resources</Keyword><Keyword MajorTopicYN="N">clinical informatics</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">health care</Keyword><Keyword MajorTopicYN="N">hospital</Keyword><Keyword MajorTopicYN="N">length of stay</Keyword><Keyword MajorTopicYN="N">logistic regression</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">prediction model</Keyword><Keyword MajorTopicYN="N">reproducibility of results</Keyword><Keyword MajorTopicYN="N">retrospective study</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39576284</ArticleId><ArticleId IdType="pmc">PMC11624451</ArticleId><ArticleId IdType="doi">10.2196/59260</ArticleId><ArticleId IdType="pii">v26i1e59260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stone K, Zwiggelaar R, Jones P, Mac Parthal&#xe1;in N. A systematic review of the prediction of hospital length of stay: Towards a unified framework. PLOS Digit Health. 2022 Apr 14;1(4):e0000017. doi: 10.1371/journal.pdig.0000017. 
 
PDIG-D-21-00027</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pdig.0000017</ArticleId><ArticleId IdType="pmc">PMC9931263</ArticleId><ArticleId IdType="pubmed">36812502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K, Tseng M, Weng H, Lin Y, Liou C, Tan T. Prediction of length of stay of first-ever ischemic stroke. Stroke. 2002 Nov;33(11):2670&#x2013;4. doi: 10.1161/01.str.0000034396.68980.39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.0000034396.68980.39</ArticleId><ArticleId IdType="pubmed">12411659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno H, Ross JS, Wang Y, Chen J, Vid&#xe1;n MT, Normand S-LT, Curtis JP, Drye EE, Lichtman JH, Keenan PS, Kosiborod M, Krumholz HM. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA. 2010 Jun 02;303(21):2141&#x2013;7. doi: 10.1001/jama.2010.748. 
 
303/21/2141</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.748</ArticleId><ArticleId IdType="pmc">PMC3020983</ArticleId><ArticleId IdType="pubmed">20516414</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddique SM, Tipton K, Leas B, Greysen SR, Mull NK, Lane-Fall M, McShea K, Tsou AY. Interventions to reduce hospital length of stay in high-risk populations: a systematic review. JAMA Netw Open. 2021 Sep 01;4(9):e2125846. doi: 10.1001/jamanetworkopen.2021.25846. 
 
2784338</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.25846</ArticleId><ArticleId IdType="pmc">PMC8453321</ArticleId><ArticleId IdType="pubmed">34542615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaotombo F, Pauly V, Fond G, Orleans V, Auquier P, Ghattas B, Boyer L. Machine-learning prediction for hospital length of stay using a French medico-administrative database. J Mark Access Health Policy. 2023 Nov 26;11(1):2149318. doi: 10.1080/20016689.2022.2149318. 
 
2149318</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20016689.2022.2149318</ArticleId><ArticleId IdType="pmc">PMC9707380</ArticleId><ArticleId IdType="pubmed">36457821</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez JMP, Sicilia M, Sanchez-Alonso S, Garcia-Barriocanal E. Predicting length of stay across hospital departments. IEEE Access. 2021;9:44671&#x2013;44680. doi: 10.1109/access.2021.3066562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/access.2021.3066562</ArticleId></ArticleIdList></Reference><Reference><Citation>Olle A. Predicting patient length of stay at time of admission using machine learning [thesis] KTH Royal Institute of Technology School of Engineering Sciences in Chemistry, Biotechnology and Health. 2019.  [2024-11-14].  
 https://www.diva-portal.org/smash/get/diva2:1338294/FULLTEXT01.pdf
.</Citation></Reference><Reference><Citation>Wu J, Lin Y, Li P, Hu Y, Zhang L, Kong G. Predicting prolonged length of ICU stay through machine learning. Diagnostics (Basel) 2021 Nov 30;11(12):2242. doi: 10.3390/diagnostics11122242. 
 
diagnostics11122242</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11122242</ArticleId><ArticleId IdType="pmc">PMC8700580</ArticleId><ArticleId IdType="pubmed">34943479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Si Y, Wang Z, Wang Y. Length of stay prediction for ICU patients using individualized single classification algorithm. Comput Methods Programs Biomed. 2020 Apr;186:105224. doi: 10.1016/j.cmpb.2019.105224.S0169-2607(19)31652-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2019.105224</ArticleId><ArticleId IdType="pubmed">31765937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Hsieh C, Lin C, Lin Y, Kao C. Prediction of hospitalization using artificial intelligence for urgent patients in the emergency department. Sci Rep. 2021 Sep 30;11(1):19472. doi: 10.1038/s41598-021-98961-2. 
 
10.1038/s41598-021-98961-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-98961-2</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-98961-2</ArticleId><ArticleId IdType="pmc">PMC8484275</ArticleId><ArticleId IdType="pubmed">34593930</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin S, Barnes S, Toerper M, Debraine A, DeAngelo A, Hamrock E, Hinson J, Hoyer E, Dungarani T, Howell E. Machine-learning-based hospital discharge predictions can support multidisciplinary rounds and decrease hospital length-of-stay. BMJ Innov. 2020 Dec 21;7(2):414&#x2013;421. doi: 10.1136/bmjinnov-2020-000420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjinnov-2020-000420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotoodeh M, Ho J. Improving length of stay prediction using a hidden Markov model. AMIA Summits on Translational Science; May 6; Atlanta, GA. 2019. p. 425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568102</ArticleId><ArticleId IdType="pubmed">31258996</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, Liu PJ, Liu X, Marcus J, Sun M, Sundberg P, Yee H, Zhang K, Zhang Y, Flores G, Duggan GE, Irvine J, Le Q, Litsch K, Mossin A, Tansuwan J, Wang D, Wexler J, Wilson J, Ludwig D, Volchenboum SL, Chou K, Pearson M, Madabushi S, Shah NH, Butte AJ, Howell MD, Cui C, Corrado GS, Dean J. Scalable and accurate deep learning with electronic health records. NPJ Digit Med. 2018 May 08;1(1):18. doi: 10.1038/s41746-018-0029-1. 
 
29</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-018-0029-1</ArticleId><ArticleId IdType="doi">10.1038/s41746-018-0029-1</ArticleId><ArticleId IdType="pmc">PMC6550175</ArticleId><ArticleId IdType="pubmed">31304302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Perez-Concha O, Coiera E, Martin-Sanchez F, Day R, Roffe D, Gallego B. Real-time prediction of mortality, readmission, and length of stay using electronic health record data. J Am Med Inform Assoc. 2016 May;23(3):553&#x2013;61. doi: 10.1093/jamia/ocv110. 
 
ocv110</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv110</ArticleId><ArticleId IdType="pmc">PMC7839923</ArticleId><ArticleId IdType="pubmed">26374704</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskandari M, Alizadeh Bahmani AH, Mardani-Fard HA, Karimzadeh I, Omidifar N, Peymani P. Evaluation of factors that influenced the length of hospital stay using data mining techniques. BMC Med Inform Decis Mak. 2022 Oct 29;22(1):280. doi: 10.1186/s12911-022-02027-w. 
 
10.1186/s12911-022-02027-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-022-02027-w</ArticleId><ArticleId IdType="doi">10.1186/s12911-022-02027-w</ArticleId><ArticleId IdType="pmc">PMC9617362</ArticleId><ArticleId IdType="pubmed">36309751</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton K, Leas B, Mull N. Interventions to decrease hospital length of stay. https://www.ncbi.nlm.nih.gov/books/NBK574435/ 2021. Sep,  [2022-12-10].  
 https://www.ncbi.nlm.nih.gov/books/NBK574435/
</Citation><ArticleIdList><ArticleId IdType="pubmed">34644039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrusciel J, Girardon F, Roquette L, Laplanche D, Duclos A, Sanchez S. The prediction of hospital length of stay using unstructured data. BMC Med Inform Decis Mak. 2021 Dec 18;21(1):351. doi: 10.1186/s12911-021-01722-4. 
 
10.1186/s12911-021-01722-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-021-01722-4</ArticleId><ArticleId IdType="doi">10.1186/s12911-021-01722-4</ArticleId><ArticleId IdType="pmc">PMC8684269</ArticleId><ArticleId IdType="pubmed">34922532</ArticleId></ArticleIdList></Reference><Reference><Citation>Abujaber A, Fadlalla A, Nashwan A, El-Menyar A, Al-Thani H. Predicting prolonged length of stay in patients with traumatic brain injury: A machine learning approach. Intell-Based Med. 2022;6:100052. doi: 10.1016/j.ibmed.2022.100052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibmed.2022.100052</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu W, Chan L, Masud JHB, Hong C, Chien Y, Hsu C, Wu C, Wang C, Tan S, Chung C. Identifying risk factors for prolonged length of stay in hospital and developing prediction models for patients with cardiac arrest receiving targeted temperature management. Rev Cardiovasc Med. 2023 Feb;24(2):55. doi: 10.31083/j.rcm2402055. 
 
S1530-6550(23)00853-0</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2402055</ArticleId><ArticleId IdType="doi">10.31083/j.rcm2402055</ArticleId><ArticleId IdType="pmc">PMC11273144</ArticleId><ArticleId IdType="pubmed">39077396</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida JR, Silva LB, Bos I, Visser PJ, Oliveira JL. A methodology for cohort harmonisation in multicentre clinical research. Inform Med Unlocked. 2021;27:100760. doi: 10.1016/j.imu.2021.100760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2021.100760</ArticleId></ArticleIdList></Reference><Reference><Citation>Carus J, Tr&#xfc;be L, Szczepanski P, N&#xfc;rnberg S, Hees H, Bartels S, Nennecke A, &#xdc;ckert F, Gundler C. Mapping the oncological basis dataset to the standardized vocabularies of a common data model: a feasibility study. Cancers (Basel) 2023 Aug 11;15(16):4059. doi: 10.3390/cancers15164059. 
 
cancers15164059</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15164059</ArticleId><ArticleId IdType="pmc">PMC10452256</ArticleId><ArticleId IdType="pubmed">37627087</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018 Aug 01;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032. 
 
4989437</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim C, Kim K, Lee Y, Yu DH, Yun J, Baek H, Park RW, You SC. Scalable infrastructure supporting reproducible nationwide healthcare data analysis toward FAIR stewardship. Sci Data. 2023 Oct 04;10(1):674. doi: 10.1038/s41597-023-02580-7. 
 
10.1038/s41597-023-02580-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-023-02580-7</ArticleId><ArticleId IdType="doi">10.1038/s41597-023-02580-7</ArticleId><ArticleId IdType="pmc">PMC10550904</ArticleId><ArticleId IdType="pubmed">37794003</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Yoo S, Song W, Kim S, Baek H, Lee JS, Yoon Y, Yoon S, Lee H, Kim K. Development and validation of a prognostic classification model predicting postoperative adverse outcomes in older surgical patients using a machine learning algorithm: retrospective observational network study. J Med Internet Res. 2023 Nov 13;25:e42259. doi: 10.2196/42259. 
 
v25i1e42259</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/42259</ArticleId><ArticleId IdType="pmc">PMC10682929</ArticleId><ArticleId IdType="pubmed">37955965</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokhale S, Taylor D, Gill J, Hu Y, Zeps N, Lequertier V, Prado L, Teede H, Enticott J. Hospital length of stay prediction tools for all hospital admissions and general medicine populations: systematic review and meta-analysis. Front Med (Lausanne) 2023 Aug 16;10:1192969. doi: 10.3389/fmed.2023.1192969. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1192969</ArticleId><ArticleId IdType="pmc">PMC10469540</ArticleId><ArticleId IdType="pubmed">37663657</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntley DA, Cho DW, Christman J, Csernansky JG. Predicting length of stay in an acute psychiatric hospital. Psychiatr Serv. 1998 Aug;49(8):1049&#x2013;53. doi: 10.1176/ps.49.8.1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ps.49.8.1049</ArticleId><ArticleId IdType="pubmed">9712211</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee M, Bergasa N. Imputing missing data in clinical pilot studies. Southern Methodist University. 20.  [2022-12-12].  
 https://www.smu.edu/dedman/academics/departments/statistics/research/~/media/b1cf5222f09d4708a6c89b5e5dd15113.ashx
.</Citation></Reference><Reference><Citation>Mekhaldi R, Caulier P, Chaabane S, Chraibi A, Piechowiak S. A comparative study of machine learning models for predicting length of stay in hospitals. J Inf Sci Eng. 2021 Oct 22;37(5):1025&#x2013;38. doi: 10.6688/JISE.202109_37(5).0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.6688/JISE.202109_37(5).0003</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksberg BS, Oskotsky B, Thangaraj PM, Giangreco N, Badgeley MA, Johnson KW, Datta D, Rudrapatna VA, Rappoport N, Shervey MM, Miotto R, Goldstein TC, Rutenberg E, Frazier R, Lee N, Israni S, Larsen R, Percha B, Li L, Dudley JT, Tatonetti Nicholas P, Butte Atul J. PatientExploreR: an extensible application for dynamic visualization of patient clinical history from electronic health records in the OMOP common data model. Bioinformatics. 2019 Nov 01;35(21):4515&#x2013;4518. doi: 10.1093/bioinformatics/btz409. 
 
5520433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz409</ArticleId><ArticleId IdType="pmc">PMC6821222</ArticleId><ArticleId IdType="pubmed">31214700</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K, Cho M, Song M, Yoo S, Baek H, Kim S, Kim K. Exploring the potential of OMOP common data model for process mining in healthcare. PLoS One. 2023 Jan 3;18(1):e0279641. doi: 10.1371/journal.pone.0279641. 
 
PONE-D-22-14226</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0279641</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0279641</ArticleId><ArticleId IdType="pmc">PMC9810199</ArticleId><ArticleId IdType="pubmed">36595527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu B, Yoo S, Kim S, Choi J. Development of prediction models for unplanned hospital readmission within 30 days based on common data model: a feasibility study. Methods Inf Med. 2021 Dec 28;60(S 02):e65&#x2013;e75. doi: 10.1055/s-0041-1735166. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1735166</ArticleId><ArticleId IdType="pmc">PMC8714301</ArticleId><ArticleId IdType="pubmed">34583416</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmani A, Alavi A, Buergel T, Upadhyayula S, Wang Q, Ananthakrishnan SK, Alavi A, Celis D, Gillespie D, Young G, Xing Z, Nguyen MHH, Haque A, Mathur A, Payne J, Mazaheri G, Li JK, Kotipalli P, Liao L, Bhasin R, Cha K, Rolnik B, Celli A, Dagan-Rosenfeld O, Higgs E, Zhou W, Berry CL, Van Winkle KG, Contrepois K, Ray U, Bettinger K, Datta S, Li X, Snyder MP. A scalable, secure, and interoperable platform for deep data-driven health management. Nat Commun. 2021 Oct 01;12(1):5757. doi: 10.1038/s41467-021-26040-1. 
 
10.1038/s41467-021-26040-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26040-1</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-26040-1</ArticleId><ArticleId IdType="pmc">PMC8486823</ArticleId><ArticleId IdType="pubmed">34599181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MM, Kundu D, Suha SA, Siddiqi UR, Dey SK. Hospital patients&#x2019; length of stay prediction: A federated learning approach. J King Saud Univ-Com. 2022 Nov;34(10):7874&#x2013;7884. doi: 10.1016/j.jksuci.2022.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jksuci.2022.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan B, Haqqani U, Ullah S, Hamayun S, Bibi Z, Khanzada K. Duration of in-hospital stay for elective neurosurgical procedures in a tertiary care hospital. Cureus. 2021 Jun;13(6):e15745. doi: 10.7759/cureus.15745. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.15745</ArticleId><ArticleId IdType="pmc">PMC8286779</ArticleId><ArticleId IdType="pubmed">34285851</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain RV, Jain V. Early recovery after surgery in elective obstetrics-gynaecology surgeries: prospective single-center pilot study. Int J Reprod Contracept Obstet Gynecol. 2021 May 27;10(6):2302. doi: 10.18203/2320-1770.ijrcog20212166.</Citation><ArticleIdList><ArticleId IdType="doi">10.18203/2320-1770.ijrcog20212166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamang T, Wangchuk T, Zangmo C, Wangmo T, Tshomo K. The successful implementation of the Enhanced Recovery After Surgery (ERAS) program among caesarean deliveries in Bhutan to reduce the postoperative length of hospital stay. BMC Pregnancy Childbirth. 2021 Sep 18;21(1):637. doi: 10.1186/s12884-021-04105-9. 
 
10.1186/s12884-021-04105-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12884-021-04105-9</ArticleId><ArticleId IdType="doi">10.1186/s12884-021-04105-9</ArticleId><ArticleId IdType="pmc">PMC8449869</ArticleId><ArticleId IdType="pubmed">34537016</ArticleId></ArticleIdList></Reference><Reference><Citation>Matoba M, Suzuki T, Ochiai H, Shirasawa T, Yoshimoto T, Minoura A, Sano H, Ishii M, Kokaze A, Otake H, Kasama T, Kamijo Y. Seven-day services in surgery and the "weekend effect" at a Japanese teaching hospital: a retrospective cohort study. Patient Saf Surg. 2020 Jun 04;14(1):24. doi: 10.1186/s13037-020-00250-w. 
 
250</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13037-020-00250-w</ArticleId><ArticleId IdType="doi">10.1186/s13037-020-00250-w</ArticleId><ArticleId IdType="pmc">PMC7271452</ArticleId><ArticleId IdType="pubmed">32518591</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaliq AA, Broyles RW. Hospital admissions: who is admitted through the emergency department? Health Serv Manage Res. 2006 Feb 01;19(1):13&#x2013;22. doi: 10.1258/095148406775322034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/095148406775322034</ArticleId><ArticleId IdType="pubmed">16438783</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeza FL, da Rocha NS, Fleck MP. Predictors of length of stay in an acute psychiatric inpatient facility in a general hospital: a prospective study. Braz J Psychiatry. 2018 Jul 06;40(1):89&#x2013;96. doi: 10.1590/1516-4446-2016-2155. 
 
S1516-44462017005013103</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-4446-2016-2155</ArticleId><ArticleId IdType="pmc">PMC6899424</ArticleId><ArticleId IdType="pubmed">28700014</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhaldy HY, Yahya AO, Algarni AM, Bakheet OSE, Assiri M, Saboor M. JAK2 mutation assessment in thrombotic events at unusual anatomical sites: insights from a high-altitude cohort. Int J Gen Med. 2024 Oct 09;17:4551&#x2013;4558. doi: 10.2147/IJGM.S480705. 
 
480705</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S480705</ArticleId><ArticleId IdType="doi">10.2147/IJGM.S480705</ArticleId><ArticleId IdType="pmc">PMC11470770</ArticleId><ArticleId IdType="pubmed">39398483</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkens R, Wernly B, Masyuk M, Muessig J, Franz M, Schulze P, Lichtenauer M, Kelm M, Jung C. Admission body temperature in critically ill patients as an independent risk predictor for overall outcome. Med Princ Pract. 2019 Dec 2;29(4):389&#x2013;395. doi: 10.1159/000505126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000505126</ArticleId><ArticleId IdType="pmc">PMC7445663</ArticleId><ArticleId IdType="pubmed">31786567</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Kim C, Park RW, Park J, Schuemie MJ, Sena AG, Suchard MA, You SC, Rijnbeek PR, Reps JM. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed. 2021 Nov;211:106394. doi: 10.1016/j.cmpb.2021.106394. 
 
S0169-2607(21)00468-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Length of stay prediction.  [2024-11-05].  
 https://github.com/hlee110123/OHDSI---Length-of-Stay-Prediction/tree/main
.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39587821</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1601-0825</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Oral diseases</Title><ISOAbbreviation>Oral Dis</ISOAbbreviation></Journal><ArticleTitle>Antinuclear Positivity and Malignant Transformation Potential of Oral Potentially Malignant Disorder.</ArticleTitle><Pagination><StartPage>1107</StartPage><EndPage>1115</EndPage><MedlinePgn>1107-1115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/odi.15208</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This multicenter cohort study aimed to investigate the impact of antinuclear antibody (ANA) positivity on the malignant transformation potential of oral potentially malignant disorders (OPMDs) using the Observational Health Sciences and Informatics network tools for the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Retrospective cohort data from five medical centers were analyzed. Cox regression and 1:4 propensity score matching followed by aggregated meta-analysis were used to evaluate association between ANA positivity and the risk of oral squamous cell carcinoma (OSCC). The index date was defined as the first day of diagnosis of OPMD. The target and comparator cohorts comprised patients who tested positive and negative for ANA within 180&#x2009;days before or after the index date, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 27,984 OPMD patients, 1302 patients (4.65%) confirmed malignant transformation. Among these, 3035 patients had ANA laboratory data. After 1:4 PS matching, 523 and 1598 patients with positive and negative for ANA were analyzed. Meta-analysis of the hazard ratios demonstrated that ANA positivity significantly increased the risk of malignant transformation compared to ANA negativity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ANA positivity is a significant prognostic marker for predicting malignant transformation in patients with OPMD.</AbstractText><CopyrightInformation>&#xa9; 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Seok Woo</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0003-4059-1557</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jeong-Hyun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-7124-8693</Identifier><AffiliationInfo><Affiliation>Samsung Advanced Institute for Health Sciences &amp; Technology, Sungkyunkwan University, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinic of Oral Medicine and Orofacial Pain, Institute of Oral Health Science, Ajou University School of Medicine, Suwon, Gyeonggi-do, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ajou University Medical Center</Agency><Country/></Grant><Grant><Agency>Korean Academy of Laboratory &amp; Diagnostic Dentistry</Agency><Country/></Grant><Grant><Agency>National Research Foundation of Korea (NRF)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Oral Dis</MedlineTA><NlmUniqueID>9508565</NlmUniqueID><ISSNLinking>1354-523X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002471" MajorTopicYN="Y">Cell Transformation, Neoplastic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="Y">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antinuclear antibody</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">malignant transformation</Keyword><Keyword MajorTopicYN="N">oral potentially malignant disorder</Keyword><Keyword MajorTopicYN="N">propensity score matching</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>2</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39587821</ArticleId><ArticleId IdType="doi">10.1111/odi.15208</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Aguirre&#x2010;Urizar, J. M., I. Lafuente&#x2010;Ibanez de Mendoza, and S. Warnakulasuriya. 2021. &#x201c;Malignant Transformation of Oral Leukoplakia: Systematic Review and Meta&#x2010;Analysis of the Last 5&#x2009;Years.&#x201d; Oral Diseases 27, no. 8: 1881&#x2013;1895. https://doi.org/10.1111/odi.13810.</Citation></Reference><Reference><Citation>Bae, E. H., S. Y. Lim, K. D. Han, et&#xa0;al. 2019. &#x201c;Systemic Lupus Erythematosus Is a Risk Factor for Cancer: A Nationwide Population&#x2010;Based Study in Korea.&#x201d; Lupus 28, no. 3: 317&#x2013;323. https://doi.org/10.1177/0961203319826672.</Citation></Reference><Reference><Citation>Bardellini, E., F. Amadori, P. Flocchini, S. Bonadeo, and A. Majorana. 2013. &#x201c;Clinicopathological Features and Malignant Transformation of Oral Lichen Planus: A 12&#x2010;Years Retrospective Study.&#x201d; Acta Odontologica Scandinavica 71, no. 3&#x2013;4: 834&#x2013;840. https://doi.org/10.3109/00016357.2012.734407.</Citation></Reference><Reference><Citation>Batista, N. V. R., R. M. A. Valdez, E. Silva, et&#xa0;al. 2023. &#x201c;Association Between Autoimmune Rheumatic Diseases and Head and Neck Cancer: Systematic Review and Meta&#x2010;Analysis.&#x201d; Journal of Oral Pathology &amp; Medicine 52, no. 5: 357&#x2013;364. https://doi.org/10.1111/jop.13396.</Citation></Reference><Reference><Citation>Bernatsky, S., L. Joseph, J. F. Boivin, et&#xa0;al. 2008. &#x201c;The Relationship Between Cancer and Medication Exposures in Systemic Lupus Erythaematosus: A Case&#x2010;Cohort Study.&#x201d; Annals of the Rheumatic Diseases 67, no. 1: 74&#x2013;79. https://doi.org/10.1136/ard.2006.069039.</Citation></Reference><Reference><Citation>Carbone, M., and J. M. Neuberger. 2014. &#x201c;Autoimmune Liver Disease, Autoimmunity and Liver Transplantation.&#x201d; Journal of Hepatology 60, no. 1: 210&#x2013;223. https://doi.org/10.1016/j.jhep.2013.09.020.</Citation></Reference><Reference><Citation>Chang, J. Y., C. P. Chiang, C. K. Hsiao, and A. Sun. 2009. &#x201c;Significantly Higher Frequencies of Presence of Serum Autoantibodies in Chinese Patients With Oral Lichen Planus.&#x201d; Journal of Oral Pathology &amp; Medicine 38, no. 1: 48&#x2013;54. https://doi.org/10.1111/j.1600&#x2010;0714.2008.00686.x.</Citation></Reference><Reference><Citation>Chiang, C. P., R. P. Hsieh, T. H. Chen, et&#xa0;al. 2002. &#x201c;High Incidence of Autoantibodies in Taiwanese Patients With Oral Submucous Fibrosis.&#x201d; Journal of Oral Pathology &amp; Medicine 31, no. 7: 402&#x2013;409. https://doi.org/10.1034/j.1600&#x2010;0714.2002.00117.x.</Citation></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Madrid, F., P. J. VandeVord, X. Yang, et&#xa0;al. 1999. &#x201c;Antinuclear Antibodies as Potential Markers of Lung Cancer.&#x201d; Clinical Cancer Research 5, no. 6: 1393&#x2013;1400.</Citation></Reference><Reference><Citation>Ferrari, S. M., P. Fallahi, G. Elia, et&#xa0;al. 2020. &#x201c;Thyroid Autoimmune Disorders and Cancer.&#x201d; Seminars in Cancer Biology 64: 135&#x2013;146. https://doi.org/10.1016/j.semcancer.2019.05.019.</Citation></Reference><Reference><Citation>Giuliani, M., G. Troiano, M. Cordaro, et&#xa0;al. 2019. &#x201c;Rate of Malignant Transformation of Oral Lichen Planus: A Systematic Review.&#x201d; Oral Diseases 25, no. 3: 693&#x2013;709. https://doi.org/10.1111/odi.12885.</Citation></Reference><Reference><Citation>Gonzalez&#x2010;Moles, M. A., I. Ruiz&#x2010;Avila, L. Gonzalez&#x2010;Ruiz, A. Ayen, J. A. Gil&#x2010;Montoya, and P. Ramos&#x2010;Garcia. 2019. &#x201c;Malignant Transformation Risk of Oral Lichen Planus: A Systematic Review and Comprehensive Meta&#x2010;Analysis.&#x201d; Oral Oncology 96: 121&#x2013;130. https://doi.org/10.1016/j.oraloncology.2019.07.012.</Citation></Reference><Reference><Citation>Gronhagen, C. M., C. M. Fored, F. Granath, and F. Nyberg. 2012. &#x201c;Increased Risk of Cancer Among 3663 Patients With Cutaneous Lupus Erythematosus: A Swedish Nationwide Cohort Study.&#x201d; British Journal of Dermatology 166, no. 5: 1053&#x2013;1059. https://doi.org/10.1111/j.1365&#x2010;2133.2011.10773.x.</Citation></Reference><Reference><Citation>Hsu, C. Y., M. S. Lin, Y. J. Su, et&#xa0;al. 2017. &#x201c;Cumulative Immunosuppressant Exposure Is Associated With Diversified Cancer Risk Among 14832 Patients With Systemic Lupus Erythematosus: A Nested Case&#x2010;Control Study.&#x201d; Rheumatology 56, no. 4: 620&#x2013;628. https://doi.org/10.1093/rheumatology/kew457.</Citation></Reference><Reference><Citation>Idrees, M., O. Kujan, K. Shearston, and C. S. Farah. 2021. &#x201c;Oral Lichen Planus Has a Very Low Malignant Transformation Rate: A Systematic Review and Meta&#x2010;Analysis Using Strict Diagnostic and Inclusion Criteria.&#x201d; Journal of Oral Pathology &amp; Medicine 50, no. 3: 287&#x2013;298. https://doi.org/10.1111/jop.12996.</Citation></Reference><Reference><Citation>Johnson, N. W., P. Jayasekara, and A. A. Amarasinghe. 2011. &#x201c;Squamous Cell Carcinoma and Precursor Lesions of the Oral Cavity: Epidemiology and Aetiology.&#x201d; Periodontology 57, no. 1: 19&#x2013;37. https://doi.org/10.1111/j.1600&#x2010;0757.2011.00401.x.</Citation></Reference><Reference><Citation>Kang, J. H., and J. E. Kwon. 2024. &#x201c;Autoimmunity and Epithelial Dysplasia in Patients With Oral Lichenoid Diseases.&#x201d; Oral Diseases. https://doi.org/10.1111/odi.14988.</Citation></Reference><Reference><Citation>Kent, S., E. Burn, D. Dawoud, et&#xa0;al. 2021. &#x201c;Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment.&#x201d; PharmacoEconomics 39, no. 3: 275&#x2013;285. https://doi.org/10.1007/s40273&#x2010;020&#x2010;00981&#x2010;9.</Citation></Reference><Reference><Citation>Kiss, E., L. Kovacs, and P. Szodoray. 2010. &#x201c;Malignancies in Systemic Lupus Erythematosus.&#x201d; Autoimmunity Reviews 9, no. 4: 195&#x2013;199. https://doi.org/10.1016/j.autrev.2009.07.004.</Citation></Reference><Reference><Citation>Li, C. M., and Z. Chen. 2021. &#x201c;Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation.&#x201d; Frontiers in Cell and Development Biology 9: 664305. https://doi.org/10.3389/fcell.2021.664305.</Citation></Reference><Reference><Citation>Lo Muzio, L., A. Santarelli, G. Campisi, M. Lacaita, and G. Favia. 2013. &#x201c;Possible Link Between Hashimoto's Thyroiditis and Oral Lichen Planus: A Novel Association Found.&#x201d; Clinical Oral Investigations 17, no. 1: 333&#x2013;336. https://doi.org/10.1007/s00784&#x2010;012&#x2010;0767&#x2010;4.</Citation></Reference><Reference><Citation>Makadia, R., and P. B. Ryan. 2014. &#x201c;Transforming the Premier Perspective Hospital Database Into the Observational Medical Outcomes Partnership (OMOP) Common Data Model.&#x201d; EGEMS 2, no. 1: 1110. https://doi.org/10.13063/2327&#x2010;9214.1110.</Citation></Reference><Reference><Citation>Pillai, A., D. Adilbay, K. Matsoukas, I. Ganly, and S. G. Patel. 2021. &#x201c;Autoimmune Disease and Oral Squamous Cell Carcinoma: A Systematic Review.&#x201d; Journal of Oral Pathology &amp; Medicine 50, no. 9: 855&#x2013;863. https://doi.org/10.1111/jop.13218.</Citation></Reference><Reference><Citation>Pillai, A., C. Valero, D. Zanoni, et&#xa0;al. 2022. &#x201c;Prognostic Impact of Autoimmune Disease in Oral Cavity Squamous Cell Carcinoma.&#x201d; Journal of Surgical Oncology 126, no. 7: 1183&#x2013;1190. https://doi.org/10.1002/jso.27017.</Citation></Reference><Reference><Citation>Pulte, D., and H. Brenner. 2010. &#x201c;Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis.&#x201d; Oncologist 15, no. 9: 994&#x2013;1001. https://doi.org/10.1634/theoncologist.2009&#x2010;0289.</Citation></Reference><Reference><Citation>Romano, P. S., L. L. Roos, and J. G. Jollis. 1993. &#x201c;Adapting a Clinical Comorbidity Index for Use With ICD&#x2010;9&#x2010;CM Administrative Data: Differing Perspectives.&#x201d; Journal of Clinical Epidemiology 46, no. 10: 1075&#x2013;1079. https://doi.org/10.1016/0895&#x2010;4356(93)90103&#x2010;8.</Citation></Reference><Reference><Citation>Singh, G., A. K. Agarwal, J. Prosek, M. S. K. Jayadev, and A. Singh. 2017. &#x201c;Can Killers Be Saviors?&#x201d; Lupus 26, no. 9: 903&#x2013;908. https://doi.org/10.1177/0961203316688783.</Citation></Reference><Reference><Citation>Song, M., G. Latorre, D. Ivanovic&#x2010;Zuvic, M. C. Camargo, and C. S. Rabkin. 2019. &#x201c;Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta&#x2010;Analysis.&#x201d; Cancer Research and Treatment 51, no. 3: 841&#x2013;850. https://doi.org/10.4143/crt.2019.151.</Citation></Reference><Reference><Citation>Speight, P. M., S. A. Khurram, and O. Kujan. 2018. &#x201c;Oral Potentially Malignant Disorders: Risk of Progression to Malignancy.&#x201d; Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology 125, no. 6: 612&#x2013;627. https://doi.org/10.1016/j.oooo.2017.12.011.</Citation></Reference><Reference><Citation>Sung, H., J. Ferlay, R. L. Siegel, et&#xa0;al. 2021. &#x201c;Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.&#x201d; CA: A Cancer Journal for Clinicians 71, no. 3: 209&#x2013;249. https://doi.org/10.3322/caac.21660.</Citation></Reference><Reference><Citation>Torres, J., S. Mehandru, J. F. Colombel, and L. Peyrin&#x2010;Biroulet. 2017. &#x201c;Crohn's Disease.&#x201d; Lancet 389, no. 10080: 1741&#x2013;1755. https://doi.org/10.1016/S0140&#x2010;6736(16)31711&#x2010;1.</Citation></Reference><Reference><Citation>Valero, C., D. K. Zanoni, A. Pillai, et&#xa0;al. 2020. &#x201c;Host Factors Independently Associated With Prognosis in Patients With Oral Cavity Cancer.&#x201d; JAMA Otolaryngology. Head &amp; Neck Surgery 146, no. 8: 699&#x2013;707. https://doi.org/10.1001/jamaoto.2020.1019.</Citation></Reference><Reference><Citation>Vlagea, A., S. Falagan, G. Gutierrez&#x2010;Gutierrez, et&#xa0;al. 2018. &#x201c;Antinuclear Antibodies and Cancer: A Literature Review.&#x201d; Critical Reviews in Oncology/Hematology 127: 42&#x2013;49. https://doi.org/10.1016/j.critrevonc.2018.05.002.</Citation></Reference><Reference><Citation>Warnakulasuriya, S., N. W. Johnson, and I. van der Waal. 2007. &#x201c;Nomenclature and Classification of Potentially Malignant Disorders of the Oral Mucosa.&#x201d; Journal of Oral Pathology &amp; Medicine 36, no. 10: 575&#x2013;580. https://doi.org/10.1111/j.1600&#x2010;0714.2007.00582.x.</Citation></Reference><Reference><Citation>Warnakulasuriya, S., O. Kujan, J. M. Aguirre&#x2010;Urizar, et&#xa0;al. 2021. &#x201c;Oral Potentially Malignant Disorders: A Consensus Report From an International Seminar on Nomenclature and Classification, Convened by the WHO Collaborating Centre for Oral Cancer.&#x201d; Oral Diseases 27, no. 8: 1862&#x2013;1880. https://doi.org/10.1111/odi.13704.</Citation></Reference><Reference><Citation>Westermann, R., K. Zobbe, R. Cordtz, J. H. Haugaard, and L. Dreyer. 2021. &#x201c;Increased Cancer Risk in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Compared With the General Population: A Danish Nationwide Cohort Study.&#x201d; Lupus 30, no. 5: 752&#x2013;761. https://doi.org/10.1177/0961203321990106.</Citation></Reference><Reference><Citation>Wu, Y. H., Y. C. Wu, S. J. Cheng, Y. S. Kuo, A. Sun, and H. M. Chen. 2019. &#x201c;Gastric Parietal Cell and Thyroid Autoantibodies in Oral Precancer Patients.&#x201d; Journal of the Formosan Medical Association 118, no. 10: 1393&#x2013;1400. https://doi.org/10.1016/j.jfma.2019.05.017.</Citation></Reference><Reference><Citation>Yoon, D., E. K. Ahn, M. Y. Park, et&#xa0;al. 2016. &#x201c;Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research.&#x201d; Healthcare Informatics Research 22, no. 1: 54&#x2013;58. https://doi.org/10.4258/hir.2016.22.1.54.</Citation></Reference><Reference><Citation>Zou, H. Y., X. Gu, W. Z. Yu, Z. Wang, and M. Jiao. 2015. &#x201c;Detection of Serum Antinuclear Antibodies in Lymphoma Patients.&#x201d; Genetics and Molecular Research 14, no. 4: 16546&#x2013;16552. https://doi.org/10.4238/2015.December.11.1.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39591197</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>19</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12111295</ELocationID><Abstract><AbstractText><b>Background:</b> European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of COVID-19 vaccines among HCWs against laboratory-confirmed SARS-CoV-2 infection. <b>Methods:</b> HCWs from 19 hospitals in 10 countries participated in a dynamic prospective cohort study, providing samples for SARS-CoV-2 testing at enrolment and during weekly/fortnightly follow-up. We measured the incidence during pre-Delta (2 May-6 September 2021), Delta (7 September-14 December 2021), and Omicron (15 December 2021-2 May 2023) waves. Using Cox regression, we measured the relative vaccine effectiveness (rVE) of the first COVID-19 booster dose versus primary course alone during Delta and Omicron waves. <b>Results:</b> We included a total of 3015 HCWs. Participants were mostly female (2306; 79%), with a clinical role (2047; 68%), and had a median age of 44 years. The overall incidence of SARS-CoV-2 infection was 3.01/10,000 person-days during pre-Delta, 4.21/10,000 during Delta, and 23.20/10,000 during Omicron waves. rVE was 59% (95% CI: -25; 86) during Delta and 22% (1; 39) during Omicron waves. rVE was 51% (30; 65) 7-90 days after the first booster dose during the Omicron wave. <b>Conclusions:</b> The incidence of SARS-CoV-2 infection among HCWs was higher during the Omicron circulation period. The first COVID-19 vaccine booster provided additional protection against SARS-CoV-2 infection compared to primary course vaccination when recently vaccinated &lt;90 days. This multi-country HCW cohort study addressing infection as the main outcome is crucial for informing public health interventions for HCWs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savulescu</LastName><ForeName>Camelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epiconcept, 75011 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Epiconcept, 75011 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brolin</LastName><ForeName>Kim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0000-4353-7922</Identifier><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, 169 73 Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovri&#x107; Makari&#x107;</LastName><ForeName>Zvjezdana</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4285-2116</Identifier><AffiliationInfo><Affiliation>Croatian Institute of Public Health, 10000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusk&#xfc;la</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine and Public Health, University of Tartu, 50090 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panagiotakopoulos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Public Health Organization (EODY), EL-15123 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergin</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, D08 NHY1 Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Trinity College, D02 PN40 Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Galway, H91 YR71 Galway, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Galway, H91 TK33 Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agodi</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4405-8162</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Policlinico AOUP "G. Rodolico-San Marco", 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonfanti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza-University of Milano, Bicocca, 20126 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murri</LastName><ForeName>Rita</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9468-5458</Identifier><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Sicurezza e Bioetica, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zvirbulis</LastName><ForeName>Viesturs</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, 1002 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zavadska</LastName><ForeName>Dace</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4892-3763</Identifier><AffiliationInfo><Affiliation>Children Clinical University Hospital, 1004 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szuldrzynski</LastName><ForeName>Konstanty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute of Medicine of the Ministry of Interior and Administration, 02-106 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Ausenda</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1849-1499</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>Corneliu Petru</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, 030303 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craiu</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6194-6797</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Mother and Child Care Alessandrescu Rusescu, 20382 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisneros</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Internacional de Catalunya, 08195 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latorre-Mill&#xe1;n</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9932-0124</Identifier><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, IIS Aragon, Miguel Servet University Hospital, 50009 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrovi&#x107;</LastName><ForeName>Goranka</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Croatian Institute of Public Health, 10000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohur</LastName><ForeName>Liis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Outpatient Department, Viljandi Hospital, 71024 Viljandi, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tryfinopoulou</LastName><ForeName>Kyriaki</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0009-7066-7453</Identifier><AffiliationInfo><Affiliation>National Public Health Organization (EODY), EL-15123 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, D08 NHY1 Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Galway, H91 YR71 Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barchitta</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0905-5003</Identifier><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spolti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza-University of Milano, Bicocca, 20126 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Gaetano Donati</LastName><ForeName>Katleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Sicurezza e Bioetica, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abolina</LastName><ForeName>Ilze</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0009-0373-9445</Identifier><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, 1002 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravele</LastName><ForeName>Dagne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, 1004 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaio</LastName><ForeName>V&#xe2;nia</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7626-4991</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, 1649-016 Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florescu</LastName><ForeName>Simin Aysel</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-6482-3386</Identifier><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, 030303 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cantacuzino National Military-Medical Institute for Research and Development, 050096 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subirats</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Occupational Risk Prevention, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clusa Cuesta</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3503-2331</Identifier><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, IIS Aragon, Miguel Servet University Hospital, 50009 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarajli&#x107;</LastName><ForeName>Gordan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0000-3722-8795</Identifier><AffiliationInfo><Affiliation>Croatian Institute of Public Health, 10000 Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amerali</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Public Health Organization (EODY), EL-15123 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Jacklyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, D08 NHY1 Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, University Hospital Galway, H91 YR71 Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapisarda</LastName><ForeName>Venerando</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-3482-1136</Identifier><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Policlinico AOUP "G. Rodolico-San Marco", 95124 Catania, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, Occupational Medicine, University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza-University of Milano, Bicocca, 20126 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamonica</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dipartimento di Sicurezza e Bioetica, Universit&#xe0; Cattolica del Sacro Cuore, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krievins</LastName><ForeName>Dainis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, 1002 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzdina</LastName><ForeName>Elza Anna</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, 1004 Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmira Amaral</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro Hospitalar Tondela-Viseu EPE, 3504-509 Viseu, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosa</LastName><ForeName>Alma Gabriela</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, 030303 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miron</LastName><ForeName>Victor Daniel</ForeName><Initials>VD</Initials><Identifier Source="ORCID">0000-0002-2318-5365</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Mother and Child Care Alessandrescu Rusescu, 20382 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Almagro</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5586-404X</Identifier><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu, Hospital Sant Joan de Deu, 08950 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Internacional de Catalunya, 08195 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ciber of Epidemiology and Public Health CIBERESP, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milagro</LastName><ForeName>Ana Mar&#xed;a</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-3888-8952</Identifier><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, IIS Aragon, Miguel Servet University Hospital, 50009 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacci</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, 169 73 Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramarz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, 169 73 Solna, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardone</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epiconcept, 75011 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>The Vebis Hcw Ve Study Group</LastName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Framework contract ECDC/2021/017, Direct Contract ECD.11486, Direct Contract ECD.12175, Direct Contract ECD. 11236 Work Area 2</GrantID><Agency>European Centre for Disease Prevention and Control</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">healthcare workers</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList><CoiStatement>A.P.-U. reports payment under the EMA DARWIN EU project outside of the submitted work. P.B. reports receiving consulting fees from VIIV, MSD, and GILEAD, and speaker fees from VIIV, GILEAD, ASTRAZENECA, and PFIZER outside of the submitted work. M.L.-M., A.M.M. and L.C.C report additional support received from the ISIDORe (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. C.P.P. and S.A.F. report speaker fees from and participation in the advisory board of Pfizer and MSD. S.A.F. also reports participation in the advisory board of Gilead. J.S. reports support from Takeda Pharmaceutical for attending the ESID 2022 conference. C.M.-A. reports speaker fees from MSD, Pfizer, and Sanofi. All other authors declare no conflicts of interest related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39591197</ArticleId><ArticleId IdType="pmc">PMC11598658</ArticleId><ArticleId IdType="doi">10.3390/vaccines12111295</ArticleId><ArticleId IdType="pii">vaccines12111295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Labour Office  . World Employment and Social Outlook 2023: The Value of Essential Work. International Labour Office; Geneva, Switzerland: 2023.  [(accessed on 6 February 2024)].  Available online:  https://www.ilo.org/sites/default/files/wcmsp5/groups/public/%40dgreports/%40dcomm/%40publ/documents/publication/wcms_871016.pdf.</Citation></Reference><Reference><Citation>World Health Organization  Health Workers at Risk, Older Adults and Residents of Long-Term Care Facilities to Be Prioritized for COVID-19 Vaccination 2022.  [(accessed on 16 February 2024)].  Available online:  https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/11/health-workers-at-risk,-older-adults-and-residents-of-long-term-care-facilities-to-be-prioritized-for-covid-19-vaccination.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  . Overview of the Implementation of COVID-19 Vaccination Strategies and Deployment Plans in the EU/EEA. ECDC; Stockholm, Sweden: 2022.  [(accessed on 16 February 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/Overview-of-COVID-19-vaccination-strategies-deployment-plans-in-the-EU-EEA-Jan-2022_1.pdf.</Citation></Reference><Reference><Citation>Nguyen L.H., Drew D.A., Graham M.S., Joshi A.D., Guo C.G., Ma W., Mehta R.S., Warner E.T., Sikavi D.R., Lo C.H., et al. Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. Lancet Public Health. 2020;5:e475&#x2013;e483. doi: 10.1016/S2468-2667(20)30164-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30164-X</ArticleId><ArticleId IdType="pmc">PMC7491202</ArticleId><ArticleId IdType="pubmed">32745512</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Implementation Guide for Vaccination of Health Workers. World Health Organization; Geneva, Switzerland: 2022.</Citation></Reference><Reference><Citation>World Health Organization . The Impact of COVID-19 on Health and Care Workers: A Closer Look at Deaths. World Health Organization; Geneva, Switzerland: 2021. Health Workforce Department&#x2014;Working Paper 1.</Citation></Reference><Reference><Citation>Bandyopadhyay S., Baticulon R.E., Kadhum M., Alser M., Ojuka D.K., Badereddin Y., Kamath A., Parepalli S.A., Brown G., Iharchane S., et al. Infection and mortality of healthcare workers worldwide from COVID-19: A systematic review. BMJ Glob. Health. 2020;5:e003097. doi: 10.1136/bmjgh-2020-003097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2020-003097</ArticleId><ArticleId IdType="pmc">PMC7722361</ArticleId><ArticleId IdType="pubmed">33277297</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.S.V., Wood R., Gribben C., Caldwell D., Bishop J., Weir A., Kennedy S., Reid M., Smith-Palmer A., Goldberg D., et al. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: Nationwide linkage cohort study. BMJ. 2020;371:m3582. doi: 10.1136/bmj.m3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3582</ArticleId><ArticleId IdType="pmc">PMC7591828</ArticleId><ArticleId IdType="pubmed">33115726</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . WHO Roadmap on Uses of COVID-19 Vaccines in the Context of Omicron and High Population Immunity. World Health Organization; Geneva, Switzerland: 2023.  [(accessed on 19 February 2024)].  Available online:  https://iris.who.int/bitstream/handle/10665/373987/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2-eng.pdf?sequence=1.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  . Interim Public Health Considerations for COVID-19 Vaccination Roll-Out During 2023. ECDC; Stockholm, Sweden: 2023.  [(accessed on 19 February 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-interim-public-health-considerations-vaccination-2023.pdf.</Citation></Reference><Reference><Citation>McGlacken T., Codd M. Comparison, by Country, of the Uptake of COVID-19 Vaccination by Health Care Workers in the EU/EEA. Eur. J. Public Health. 2023;33((Suppl. S2)):ckad160.1040. doi: 10.1093/eurpub/ckad160.1040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckad160.1040</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control  . Interim Analysis of COVID-19 Vaccine Effectiveness in Healthcare Workers, an ECDC Multi-Country Study, May 2021&#x2013;July 2022. ECDC; Stockholm, Sweden: 2022.  [(accessed on 9 October 2023)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-analysis-vaccine-effectiveness-healthcare-workers.pdf.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  . Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts, Version 2.0. ECDC; Stockholm, Sweden: 2022.  [(accessed on 9 October 2023)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/generic-protocol-ecdc-studies-covid-19-vaccine-effectiveness.</Citation></Reference><Reference><Citation>Bergeri I., Lewis H.C., Subissi L., Nardone A., Valenciano M., Cheng B., Glonti K., Williams B., Abejirinde I.O.O., Simniceanu A., et al. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir. Viruses. 2022;16:7&#x2013;13. doi: 10.1111/irv.12915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12915</ArticleId><ArticleId IdType="pmc">PMC8652791</ArticleId><ArticleId IdType="pubmed">34611986</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Regional Office for Europe . Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in WHO European Region: Guidance Document. WHO Regional Office for Europe; Copenhagen, Denmark: 2021.</Citation></Reference><Reference><Citation>Thompson M.G., Natarajan K., Irving S.A., Rowley E.A., Griggs E.P., Gaglani M., Klein N.P., Grannis S.J., DeSilva M.B., Stenehjem E., et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19&#x2013;Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance&#x2014;VISION Network, 10 States, August 2021&#x2013;January 2022. Morb. Mortal. Wkly. Rep. 2022;71:139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351525</ArticleId><ArticleId IdType="pubmed">35085224</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi E.K., Britton A., Fleming-Dutra K.E., Smith Z.R., Shang N., Derado G., Miller J., Schrag S.J., Verani J.R. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327:639. doi: 10.1001/jama.2022.0470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferdinands J.M., Rao S., Dixon B.E., Mitchell P.K., DeSilva M.B., Irving S.A., Lewis N., Natarajan K., Stenehjem E., Grannis S.J., et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19&#x2013;Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance&#x2014;VISION Network, 10 States, August 2021&#x2013;January 2022. Morb. Mortal. Wkly. Rep. 2022;71:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., Wellington E., Khawam J., Munro K., Cole M., et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022;386:1207&#x2013;1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose A.M., Nicolay N., Mart&#xed;n V.S., Mazagatos C., Petrovi&#x107; G., Baruch J., Denayer S., Seyler L., Domegan L., Launay O., et al. Vaccine effectiveness against COVID-19 hospitalisation in adults (&#x2265;20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. Euro Surveill. 2023;28:2300187. doi: 10.2807/1560-7917.ES.2023.28.47.2300187.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.47.2300187</ArticleId><ArticleId IdType="pmc">PMC10668256</ArticleId><ArticleId IdType="pubmed">37997665</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S.K., Hegmann K.T., Thiese M.S., Burgess J.L., Ellingson K., Lutrick K., Olsho L.E., Edwards L.J., Sokol B., Caban-Martinez A.J., et al. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N. Engl. J. Med. 2022;386:1855&#x2013;1857. doi: 10.1056/NEJMc2201821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201821</ArticleId><ArticleId IdType="pmc">PMC9006784</ArticleId><ArticleId IdType="pubmed">35385628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2022;28:202&#x2013;221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.T., Kwan A.T., Rodr&#xed;guez-Barraquer I., Singer B.J., Park H.J., Lewnard J.A., Sears D., Lo N.C. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat. Med. 2023;29:358&#x2013;365. doi: 10.1038/s41591-022-02138-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02138-x</ArticleId><ArticleId IdType="pmc">PMC9974584</ArticleId><ArticleId IdType="pubmed">36593393</ArticleId></ArticleIdList></Reference><Reference><Citation>Oordt-Speets A., Spinardi J., Mendoza C., Yang J., Morales G., McLaughlin J.M., Kyaw M.H. Effectiveness of COVID-19 Vaccination on Transmission: A Systematic Review. COVID. 2023;3:1516&#x2013;1527. doi: 10.3390/covid3100103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/covid3100103</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Infection Prevention and Control in the Context of Coronavirus Disease (COVID-19): A Living Guideline. World Health Organization; Geneva, Switzerland: 2023.  [(accessed on 6 February 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-guideline-2023.2.</Citation></Reference><Reference><Citation>Plumb I.D., Mohr N.M., Hagen M., Wiegand R., Dumyati G., Harland K.K., Krishnadasan A., Gist J.J., Abedi G., Fleming-Dutra K.E., et al. Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021&#x2013;July 2022. Open Forum Infect. Dis. 2023;10:ofad457. doi: 10.1093/ofid/ofad457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad457</ArticleId><ArticleId IdType="pmc">PMC10549208</ArticleId><ArticleId IdType="pubmed">37799130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cegolon L., Negro C., Mastrangelo G., Filon F.L. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021&#x2013;31 May 2022. Viruses. 2022;14:2688. doi: 10.3390/v14122688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122688</ArticleId><ArticleId IdType="pmc">PMC9784665</ArticleId><ArticleId IdType="pubmed">36560692</ArticleId></ArticleIdList></Reference><Reference><Citation>Consonni D., Lombardi A., Mangioni D., Bono P., Oggioni M., Renteria S.U., Valzano A., Bordini L., Nava C.D., Tiwana N., et al. Immunogenicity and effectiveness of BNT162b2 COVID-19 vaccine in a cohort of healthcare workers in Milan (Lombardy Region, Northern Italy) Epidemiol. Prev. 2022;46:250&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">36259341</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer A., Angel Y., Marudi O., Zeltser D., Saiag E., Goldshmidt H., Goldiner I., Stark M., Halutz O., Gamzu R., et al. Association of a Third Dose of BNT162b2 Vaccine with Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA. 2022;327:341&#x2013;349. doi: 10.1001/jama.2021.23641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.23641</ArticleId><ArticleId IdType="pmc">PMC8749710</ArticleId><ArticleId IdType="pubmed">35006256</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotons P., Perez-Arg&#xfc;ello A., Launes C., Torrents F., Subirats M.P., Saucedo J., Claverol J., Garcia-Garcia J.J., Rodas G., Fumado V., et al. Validation and implementation of a direct RT-qPCR method for rapid screening of SARS-CoV-2 infection by using non-invasive saliva samples. Int. J. Infect. Dis. 2021;110:363&#x2013;370. doi: 10.1016/j.ijid.2021.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.07.054</ArticleId><ArticleId IdType="pmc">PMC8310572</ArticleId><ArticleId IdType="pubmed">34320412</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39626797</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5832</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Drug discovery today</Title><ISOAbbreviation>Drug Discov Today</ISOAbbreviation></Journal><ArticleTitle>Learning from European regulator-initiated studies for regulatory decision making.</ArticleTitle><Pagination><StartPage>104256</StartPage><MedlinePgn>104256</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drudis.2024.104256</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1359-6446(24)00381-7</ELocationID><Abstract><AbstractText>Drug developers have displayed a growing interest in using real-word evidence (RWE) in the pre-marketing phase. Together with initiatives like DARWIN EU&#xae;, this interest encourages regulators to initiate their own observational clinical studies, which could be included in regulatory decision making. The Regulatory Science Network Netherlands (RSNN) organised an expert meeting in 2022 to discuss scenarios and learnings related to these regulator-initiated studies, of which the main points (e.g., transparency, independency and stakeholder interaction) have been published previously. In this review, the authors add their own views, underlining the importance of reproducibility and stakeholder interaction. Stakeholders should collaborate to embrace regulator-initiated studies in a timely and transparent manner to realise an optimal European framework for generating RWE to be included in the regulatory decision-making process.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verweij</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Unit of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, Groningen University, Groningen, the Netherlands. Electronic address: stefan.verweij@rug.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weemers</LastName><ForeName>Just</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Biologics BV, Leiden, the Netherlands; Regulatory Science Network Netherlands, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonker</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dutch Medicines Evaluation Board, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasmooij</LastName><ForeName>Anna Maria Gerdina</ForeName><Initials>AMG</Initials><AffiliationInfo><Affiliation>Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Regulatory Science Network Netherlands, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Discov Today</MedlineTA><NlmUniqueID>9604391</NlmUniqueID><ISSNLinking>1359-6446</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="Y">Drug Development</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="N">legislation &amp; jurisprudence</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DARWIN EU&#xae;</Keyword><Keyword MajorTopicYN="N">ENCePP</Keyword><Keyword MajorTopicYN="N">Real-world evidence</Keyword><Keyword MajorTopicYN="N">clinical study</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">regulatory decision making</Keyword><Keyword MajorTopicYN="N">reproducibility</Keyword><Keyword MajorTopicYN="N">study protocol</Keyword><Keyword MajorTopicYN="N">transparency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39626797</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2024.104256</ArticleId><ArticleId IdType="pii">S1359-6446(24)00381-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39631779</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Evolution of a Graph Model for the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1056</StartPage><EndPage>1065</EndPage><MedlinePgn>1056-1065</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0044-1791487</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">&#x2003;Graph databases for electronic health record (EHR) data have become a useful tool for clinical research in recent years, but there is a lack of published methods to transform relational databases to a graph database schema. We developed a graph model for the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) that can be reused across research institutions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;We created and evaluated four models, representing two different strategies, for converting the standardized clinical and vocabulary tables of OMOP into a property graph model within the Neo4j graph database. Taking the Successful Clinical Response in Pneumonia Therapy (SCRIPT) and Collaborative Resource for Intensive care Translational science, Informatics, Comprehensive Analytics, and Learning (CRITICAL) cohorts as test datasets with different sizes, we compared two of the resulting graph models with respect to database performance including database building time, query complexity, and runtime for both cohorts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;Utilizing a graph schema that was optimized for storing critical information as topology rather than attributes resulted in a significant improvement in both data creation and querying. The graph database for our larger cohort, CRITICAL, can be built within 1&#x2009;hour for 134,145 patients, with a total of 749,011,396 nodes and 1,703,560,910 edges.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">&#x2003;To our knowledge, this is the first generalized solution to convert the OMOP CDM to a graph-optimized schema. Despite being developed for studies at a single institution, the modeling method can be applied to other OMOP CDM v5.x databases. Our evaluation with the SCRIPT and CRITICAL cohorts and comparison between the current and previous versions show advantages in code simplicity, database building, and query speed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;We developed a method for converting OMOP CDM databases into graph databases. Our experiments revealed that the final model outperformed the initial relational-to-graph transformation in both code simplicity and query efficiency, particularly for complex queries.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Mengjia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado-Guzman</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Neo4j, Inc., San Mateo, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Luke V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starren</LastName><ForeName>Justin B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Health and Biomedical Informatics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona Health Sciences, Tucson, Arizona, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003196" MajorTopicYN="N">Computer Graphics</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>J.A.A.-G. is an employee of Neo4j. J.A.A.-G. joined the project after Neo4j was selected as our graph database engine and did not play a role in that decision. All other authors have no relevant conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39631779</ArticleId><ArticleId IdType="pmc">PMC11617070</ArticleId><ArticleId IdType="doi">10.1055/s-0044-1791487</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kang M, Alvarado-Guzman J A, Rasmussen L, Starren J B.AMIA Summit 2021. abstract: graph model for OMOP CDM.10.18131/G3-4MSB-ST53</Citation><ArticleIdList><ArticleId IdType="doi">10.18131/G3-4MSB-ST53</ArticleId><ArticleId IdType="pubmed">39631779</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham M, Hodler A.Graph algorithmsAccessed February 11, 2022 at:https://learning.oreilly.com/library/view/graph-algorithms/9781492047674/</Citation></Reference><Reference><Citation>Simpson C M, Gnad F. Applying graph database technology for analyzing perturbed co-expression networks in cancer. Database (Oxford) 2020;2020:baaa110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731929</ArticleId><ArticleId IdType="pubmed">33306799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat A, Korninger F, Viteri G et al.Reactome graph database: efficient access to complex pathway data. PLOS Comput Biol. 2018;14(01):e1005968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5805351</ArticleId><ArticleId IdType="pubmed">29377902</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y, Shankar M, Park B H, Ghosh J.Graph databases for large-scale healthcare systems: a framework for efficient data management and data servicesIEEE 30th International Conference on Data Engineering Workshops. Chicago, IL;201412&#x2013;19.</Citation></Reference><Reference><Citation>Xia Y, Sun C.Property graph database modeling and application of electronic medical recordPaper presented at: 2018 Eighth International Conference on Instrumentation &amp; Measurement, Computer, Communication and Control (IMCCC)2018963&#x2013;967.10.1109/IMCCC.2018.00203</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/IMCCC.2018.00203</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell W S, Pedersen J, McClay J C, Rao P, Bastola D, Campbell J R. An alternative database approach for management of SNOMED CT and improved patient data queries. J Biomed Inform. 2015;57:350&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">26305513</ArticleId></ArticleIdList></Reference><Reference><Citation>Neo4j, Inc  Modeling Designs: Developer GuidesNeo4j Graph Database Platform. Accessed February 11, 2022 at:https://neo4j.com/developer/modeling-designs/</Citation></Reference><Reference><Citation>Rasmussen L V, Brandt P S, Jiang G et al.Considerations for improving the portability of electronic health record-based phenotype algorithms. AMIA Annu Symp Proc. 2020;2019:755&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153055</ArticleId><ArticleId IdType="pubmed">32308871</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics . OMOP Common Data Model &#x2013; OHDSI. Accessed February 8, 2022 at:https://www.ohdsi.org/data-standardization/the-common-data-model/</Citation></Reference><Reference><Citation>National Center for Advancing Translational Sciences (NCATS).National COVID Cohort Collaborative (N3C)National Center for Advancing Translational Sciences. May 12,2020. Accessed February 11, 2022 at:https://ncats.nih.gov/n3c</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services.All of Us Research Program | National Institutes of Health (NIH)National Institutes of Health (NIH)&#x2014;All of Us.2020. Accessed February 13, 2022 at:https://allofus.nih.gov/future-health-begins-all-us</Citation></Reference><Reference><Citation>Alvarado-Guzm&#xe1;n J A, Keren I.Relational to Graph Database: MigrationPublished 2017. Accessed September 16, 2024 at:https://www.ohdsi.org/web/wiki/lib/exe/fetch.php?media=resources:jose_alvarado_rd2gd_ohdsi_submission_2017.pdf</Citation></Reference><Reference><Citation>N3C Consortium . Pfaff E R, Girvin A T, Gabriel D L et al.Synergies between centralized and federated approaches to data quality: a report from the national COVID cohort collaborative. J Am Med Inform Assoc. 2022;29(04):609&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500110</ArticleId><ArticleId IdType="pubmed">34590684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan S MK, Jeon Y S, Dang T K et al.Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM dataset. Appl Clin Inform. 2021;12(04):757&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H et al.Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, Depraetere K, De Roo J et al.Semantic processing of EHR data for clinical research. J Biomed Inform. 2015;58:247&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K E, Deppen S A, DuVall S L et al.Incrementally Transforming Electronic Medical Records into the Observational Medical Outcomes Partnership Common Data Model: A Multidimensional Quality Assurance Approach. Appl Clin Inform. 2019;10(05):794&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP to PCORIv2 ETL Mapping Specification Version 0.1 2015. Google Search. Accessed March 12, 2024 at:https://www.google.com/search?q=OMOP+to+PCORIv2+ETL+Mapping+Specification+Version+0.1+15+May+2015&amp;rlz=1C5GCCM_en&amp;oq=OMOP+to+PCORIv2+ETL+Mapping+Specification+Version+0.1+15+May+2015&amp;gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCDEwMjhqMGo0qAIAsAIA&amp;sourceid=chrome&amp;ie=UTF-8</Citation></Reference><Reference><Citation>Klann J G, Phillips L C, Herrick C, Joss M AH, Wagholikar K B, Murphy S N. Web services for data warehouses: OMOP and PCORnet on i2b2. J Am Med Inform Assoc. 2018;25(10):1331&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188504</ArticleId><ArticleId IdType="pubmed">30085008</ArticleId></ArticleIdList></Reference><Reference><Citation>Neo4j, Inc.Neo4j Graph Data Platform. Neo4j Graph Data PlatformAccessed February 13, 2022 at:https://neo4j.com/</Citation></Reference><Reference><Citation>SCRIPT research team.SCRIPT homepageAccessed February 13, 2022 at:https://script.northwestern.edu/</Citation></Reference><Reference><Citation>NU SCRIPT Study Investigators . Grant R A, Morales-Nebreda L, Markov N S et al.Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gannon D.Azure's new CosmosDB Planet-Scale DatabasePublished online 2017.10.13140/RG.2.2.11135.51360</Citation><ArticleIdList><ArticleId IdType="doi">10.13140/RG.2.2.11135.51360</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson I, Webber J, Eifrem E.Graph Databases. 2nd ed. O'Reilly Media, Inc. 2015. ISBN: 9781491930892</Citation></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O et al.Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498&#x2013;2504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastian M, Heymann S, Jacomy M. Gephi: an open source software for exploring and manipulating networks. Proc Int AAAI Conf Web Soc Media. 2009;3(01):361&#x2013;362.</Citation></Reference><Reference><Citation>Starren J B, Winter A Q, Lloyd-Jones D M. Enabling a learning health system through a unified enterprise data warehouse: the experience of the Northwestern University Clinical and Translational Sciences (NUCATS) institute. Clin Transl Sci. 2015;8(04):269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4553136</ArticleId><ArticleId IdType="pubmed">26032246</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI FHIR Work Groups.Workgroups:mappings_between_ohdsi_cdm_and_fhirAccessed February 13, 2022 at:https://www.ohdsi.org/web/wiki/doku.php?id=projects:workgroups:mappings_between_ohdsi_cdm_and_fhir</Citation></Reference><Reference><Citation>i2b2 tranSMART Foundation.i2b2 Community WikiAccessed February 13, 2022 at:https://community.i2b2.org/wiki/display/OMOP</Citation></Reference><Reference><Citation>Katsma B.Benchmarking big observational health dataMedium.2020. Accessed February 13, 2022 at:https://medium.com/@b.katsma/benchmarking-big-observational-health-data-97e148c393f4</Citation></Reference><Reference><Citation>UKIRDC . Mughal S, Moghul I, Yu J, Clark T, Gregory D S, Pontikos N. Pheno4J: a gene to phenotype graph database. Bioinformatics. 2017;33(20):3317&#x2013;3319.</Citation><ArticleIdList><ArticleId IdType="pubmed">28633344</ArticleId></ArticleIdList></Reference><Reference><Citation>Queralt-Rosinach N, Stupp G S, Li T S et al.Structured reviews for data and knowledge-driven research. Database (Oxford) 2020;2020:baaa015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153956</ArticleId><ArticleId IdType="pubmed">32283553</ArticleId></ArticleIdList></Reference><Reference><Citation>Declerck G, Hussain S, Daniel C et al.Bridging data models and terminologies to support adverse drug event reporting using EHR data. Methods Inf Med. 2015;54(01):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487120</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicknair C, Macias M, Zhao Z, Nan X, Chen Y, Wilkins D.A comparison of a graph database and a relational database: a data provenance perspectiveIn: Proceedings of the 48th Annual ACM Southeast Conference. ACMSE'10. Association for Computing Machinery;20101&#x2013;6.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39657951</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1367-4811</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>26</Day></PubDate></JournalIssue><Title>Bioinformatics (Oxford, England)</Title><ISOAbbreviation>Bioinformatics</ISOAbbreviation></Journal><ArticleTitle>PheWAS analysis on large-scale biobank data with PheTK.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">btae719</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bioinformatics/btae719</ELocationID><Abstract><AbstractText Label="SUMMARY">With the rapid growth of genetic data linked to electronic health record (EHR) data in huge cohorts, large-scale phenome-wide association study (PheWAS) have become powerful discovery tools in biomedical research. PheWAS is an analysis method to study phenotype associations utilizing longitudinal EHR data. Previous PheWAS packages were developed mostly with smaller datasets and with earlier PheWAS approaches. PheTK was designed to simplify analysis and efficiently handle biobank-scale data. PheTK uses multithreading and supports a full PheWAS workflow including extraction of data from OMOP databases and Hail matrix tables as well as PheWAS analysis for both phecode version 1.2 and phecodeX. Benchmarking results showed PheTK took 64% less time than the R PheWAS package to complete the same workflow. PheTK can be run locally or on cloud platforms such as the All of Us Researcher Workbench (All of Us) or the UK Biobank (UKB) Research Analysis Platform (RAP).</AbstractText><AbstractText Label="AVAILABILITY AND IMPLEMENTATION">The PheTK package is freely available on the Python Package Index, on GitHub under GNU General Public License (GPL-3) at https://github.com/nhgritctran/PheTK, and on Zenodo, DOI 10.5281/zenodo.14217954, at https://doi.org/10.5281/zenodo.14217954. PheTK is implemented in Python and platform independent.</AbstractText><CopyrightInformation>Published by Oxford University Press 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Tam C</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0009-0007-5343-8822</Identifier><AffiliationInfo><Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlueter</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Toronto, ON, M5S 1A1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Chenjie</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0149-5661</Identifier><AffiliationInfo><Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Vanderbilt University School of Medicine, Nashville, TN, 37240, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denny</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>All of Us Research Program, National Institutes of Health, Bethesda, MD, 20892, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA HG200417</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioinformatics</MedlineTA><NlmUniqueID>9808944</NlmUniqueID><ISSNLinking>1367-4803</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Feb 13:2024.02.12.24302720. doi: 10.1101/2024.02.12.24302720.</RefSource><PMID Version="1">38410487</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="Y">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080444" MajorTopicYN="N">Phenomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>9</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>11</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>10</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39657951</ArticleId><ArticleId IdType="pmc">PMC11709244</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btae719</ArticleId><ArticleId IdType="pii">7919600</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bastarache L, Denny JC, Roden DM. &#xa0;Phenome-wide association studies. JAMA &#xa0;2022;327:75&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8880207</ArticleId><ArticleId IdType="pubmed">34982132</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. &#xa0;World's biggest set of human genome sequences opens to scientists. Nature &#xa0;2023;624:16&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">38036674</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Bastarache L, Denny JC. &#xa0;R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics &#xa0;2014;30:2375&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133579</ArticleId><ArticleId IdType="pubmed">24733291</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels HE. &#xa0;Saddlepoint approximations in statistics. Ann Math Statist &#xa0;1954;25:631&#x2013;50.</Citation></Reference><Reference><Citation>Denny JC, Ritchie MD, Basford MA &#xa0;et al. &#xa0;PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics &#xa0;2010;26:1205&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859132</ArticleId><ArticleId IdType="pubmed">20335276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dofuku S, Sonehara K, Miyawaki S &#xa0;et al. &#xa0;Genome-wide association study of intracranial artery stenosis followed by phenome-wide association study. Transl Stroke Res &#xa0;2023;14:322&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">35701560</ArticleId></ArticleIdList></Reference><Reference><Citation>Firth D. &#xa0;Bias reduction of maximum likelihood estimates. Biometrika &#xa0;1993;80:27&#x2013;38.</Citation></Reference><Reference><Citation>Ginsburg GS, Denny JC, Schully SD. &#xa0;Data-driven science and diversity in the All of Us Research Program. Sci Transl Med &#xa0;2023;15:eade9214.</Citation><ArticleIdList><ArticleId IdType="pubmed">38091411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hail Team. Hail 0.2. 2008. https://github.com/hail-is/hail</Citation></Reference><Reference><Citation>Hunter JD. &#xa0;Matplotlib: a 2D graphics environment. Comput Sci Eng &#xa0;2007;9:90&#x2013;5.</Citation></Reference><Reference><Citation>Kang HM, Zaitlen NA, Wade CM &#xa0;et al. &#xa0;Efficient control of population structure in model organism association mapping. Genetics &#xa0;2008;178:1709&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278096</ArticleId><ArticleId IdType="pubmed">18385116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerley CI, Chaganti S, Nguyen TQ &#xa0;et al. &#xa0;pyPheWAS: a phenome-disease association tool for electronic medical record analysis. Neuroinformatics &#xa0;2022;20:483&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250547</ArticleId><ArticleId IdType="pubmed">34981404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs GL, Verkman AS. &#xa0;CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med &#xa0;2012;18:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643519</ArticleId><ArticleId IdType="pubmed">22138491</ArticleId></ArticleIdList></Reference><Reference><Citation>Millard LAC, Davies NM, Gaunt TR &#xa0;et al. &#xa0;Software application profile: PHESANT: a tool for performing automated phenome scans in UK biobank. Int J Epidemiol &#xa0;2018;47:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837456</ArticleId><ArticleId IdType="pubmed">29040602</ArticleId></ArticleIdList></Reference><Reference><Citation>Millwood IY, Bennett DA, Walters RG &#xa0;et al.; China Kadoorie Biobank Collaborative Group. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults. Int J Epidemiol &#xa0;2016;45:1588&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100610</ArticleId><ArticleId IdType="pubmed">27301456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao AS, Lindholm D, Rivas MA &#xa0;et al. &#xa0;Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke. Circ Genom Precis Med &#xa0;2018;11:e002162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050027</ArticleId><ArticleId IdType="pubmed">29997226</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlueter DJ, Sulieman L, Mo H &#xa0;et al. &#xa0;Systematic replication of smoking disease associations using survey responses and EHR data in the All of Us Research Program. J Am Med Inform Assoc &#xa0;2023;31:139&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746325</ArticleId><ArticleId IdType="pubmed">37885303</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuey MM, Stead WW, Aka I &#xa0;et al. &#xa0;Next-generation phenotyping: introducing phecodeX for enhanced discovery research in medical phenomics. Bioinformatics &#xa0;2023;39:btad655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10627409</ArticleId><ArticleId IdType="pubmed">37930895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39662181</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Refinement of post-COVID condition core symptoms, subtypes, determinants, and health impacts: a cohort study integrating real-world data and patient-reported outcomes.</ArticleTitle><Pagination><StartPage>105493</StartPage><MedlinePgn>105493</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2024.105493</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(24)00529-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-COVID-19 condition (PCC) affects millions of people, and is an essential component of the long-term impact of COVID-19 during the post-pandemic era. Yet, consensus on clinical case definition and core components of PCC remains lacking, affecting our ability to inform research and evidence-based management. Our study aims 1) to identify the most specific symptoms for PCC, and identify clinical subtypes; 2) to evaluate both virus- and host-related determinants of PCC, and 3) assess the impact of PCC on physical and mental health.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied participants from UK Biobank who completed a health and wellbeing survey between June and September 2022. Participants reported the current conditions of the presence, duration, and functional limitations of 45 symptoms, using an online questionnaire designed specifically for COVID-19 research. SARS-CoV-2 infection status and disease history were obtained through linkage to surveillance data and electronic medical records, respectively. Participants reporting symptoms within 30 days after infection (acute phase) were excluded. The most specific PCC symptoms were defined using two criteria: statistical significance (P&#xa0;&lt;&#xa0;0.05 after Bonferroni correction) and clinical relevance (absolute risk increase &gt; 5%). Propensity score weighting was used to control for confounding. Subtypes of PCC were then defined based on the specific symptoms among the COVID-19 infected individuals. A multivariable regression was used to study pathogen- and host-related risk factors for PCC, and its impact on 13 physical and 4 mental health patient-reported functional outcomes.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">172,303 participants (mean age 68.9, 57.4% female) were included in the analysis, of whom 43,395 had PCR-confirmed COVID-19. We identified 10 most specific symptoms and classified four PCC subtypes: ENT subtype (30.1%), characterized by alterations in smell, taste, and hearing loss; cardiopulmonary subtype (10.4%), characterized by shortness of breath, postural tachycardia, chest tightness, and chest pressure; neurological subtype (23.5%), characterized by brain fog and difficulty speaking; and general fatigue subtype (38.0%), characterized by mild fatigue. A higher PCC risk was observed for patients with Wild-type variant, multiple infections, and severe acute COVID-19 illness, consistently across the four PCC subtypes. In addition, a range of factors, including socioeconomic deprivation, higher BMI, unhealthy lifestyle, and multiple chronic health conditions, were associated with increased PCC risk, except for age and sex. Conversely, vaccination was associated with a largely reduced PCC risk, particularly for the cardiopulmonary subtypes. Individuals with PCC experienced a much worse physical and mental health. Specifically, the cardiopulmonary subtype had the most pronounced adverse impact on function impairments, followed by neurological, mild fatigue, and ENT subtype. The most affected functions included the ability to concentrate, participate in day-to-day work, and emotional vulnerability to health problems.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">PCC can be categorized into four distinct subtypes based on ten core symptoms. These subtypes appeared to share a majority of pathogen and host-related risk factors, but their impact on health varied markedly by subtype. Our findings could help refine current guidelines for precise PCC diagnosis and progression, enhance the identification of PCC subgroups for targeted research, and inform evidence-based policy making to tackle this new and debilitating condition.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">NIHR Senior Research Fellowship (grant SRF-2018-11-ST2-004).</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yunhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcalde-Herraiz</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ell</LastName><ForeName>Kim L&#xf3;pez</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK; Institute of Child and Adolescent Health, School of Public Health, Peking University, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases &amp; irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; Chair in Infectious Diseases and Immunity, Center for Health and Social Care Research (CEESS), Faculty of Medicine, University of Vic- Central University of Catalonia (UVic-UCC), Spain; Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain; REICOP (Red de Investigaci&#xf3;n Covid Persistente), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chunxiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Raghib</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wareham</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Chair in Infectious Diseases and Immunity, Center for Health and Social Care Research (CEESS), Faculty of Medicine, University of Vic- Central University of Catalonia (UVic-UCC), Spain; Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and NIHR Biomedical Research Centre Oxford, NDORMS, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Definition</Keyword><Keyword MajorTopicYN="N">Disease subtype</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>Declaration of interests D.P.-A. reported grants from Amgen, UCB Biopharma, Les Laboratoires Servier, Novartis, and Chiesi-Taylor, as well as speaker fees and advisory board membership with AstraZeneca and Johnson and Johnson outside the submitted work, in addition to research support from Janssen. R.P. has participated in advisory boards for Gilead, MSD, ViiV Healthcare, Theratechnologies and Lilly. His institution has received research support from Gilead, MSD, and ViiV Healthcare. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>12</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>11</Day><Hour>18</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39662181</ArticleId><ArticleId IdType="pmc">PMC11697707</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2024.105493</ArticleId><ArticleId IdType="pii">S2352-3964(24)00529-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29:2347&#x2013;2357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz G.M., Bach K., Bobos P., et al. Understanding how post&#x2013;COVID-19 condition affects adults and health care systems. JAMA Health Forum. 2023;2023 American Medical Association.</Citation><ArticleIdList><ArticleId IdType="pubmed">37418268</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney L.L., Routen A., Gillies C., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichana U., Man K.K.C., Chen A., et al. Definition of post-COVID-19 condition among published research studies. JAMA Netw Open. 2023;6(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10077105</ArticleId><ArticleId IdType="pubmed">37017970</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Nicholson T., Akrami A., et al. A&#xa0;core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10(7):715&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., O'Hara M.E., Akrami A., Perego E., Olliaro P., Needham D.M. Long COVID: aiming for a consensus. Lancet Respir Med. 2022;10(7):632&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067938</ArticleId><ArticleId IdType="pubmed">35525253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.G., Honerlaw J.P., Maripuri M., et al. Potential pitfalls in the use of real-world data for studying long COVID. Nat Med. 2023;29(5):1040&#x2013;1043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205658</ArticleId><ArticleId IdType="pubmed">37055567</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas L.S., Molteni E., Deng J., et al. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations. Lancet Digit Health. 2023;5(7):e421&#x2013;e434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187990</ArticleId><ArticleId IdType="pubmed">37202336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zang C., Xu Z., et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2023;29(1):226&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese J.T., Blau H., Casiraghi E., et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Brightling C.E., Evans R.A., Singapuri A., Smith N., Wain L.V. Long COVID research: an update from the PHOSP-COVID scientific summit. Lancet Respir Med. 2023;11(11):e93&#x2013;e94.</Citation><ArticleIdList><ArticleId IdType="pubmed">37858329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan V., Denaxas S., Gonzalez-Izquierdo A., et al. A&#xa0;chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lancet Digital Health. 2019;1(2):e63&#x2013;e77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798263</ArticleId><ArticleId IdType="pubmed">31650125</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S., Gonzalez-Izquierdo A., Direk K., et al. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J&#xa0;Am Med Inf Assoc. 2019;26(12):1545&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857510</ArticleId><ArticleId IdType="pubmed">31329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C., Freeman C., Petkova D., et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Su B., Alcalde-Herraiz M., et al. Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death. Nat Commun. 2024;15(1):6363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11286928</ArticleId><ArticleId IdType="pubmed">39075060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Su B., Xie J., Garcia-Rizo C., Prieto-Alhambra D. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. Nat Human Behav. 2024;8(6):1076&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11199144</ArticleId><ArticleId IdType="pubmed">38514769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland J.M., Altman D.G. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2548561</ArticleId><ArticleId IdType="pubmed">7833759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J.P.A. The importance of predefined rules and prespecified statistical analyses: do not abandon significance. JAMA. 2019;321(21):2067&#x2013;2068.</Citation><ArticleIdList><ArticleId IdType="pubmed">30946431</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Nieters A., Kr&#xe4;usslich H.-G., et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison C.J., Davies B., Cooper E., et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun. 2023;14(1):6588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10598213</ArticleId><ArticleId IdType="pubmed">37875536</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., Elliott J., Chadeau-Hyam M., et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13(1):1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper E., Lound A., Atchison C.J., et al. Awareness and perceptions of Long COVID among people in the REACT programme: early insights from a pilot interview study. PLoS One. 2023;18(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9879384</ArticleId><ArticleId IdType="pubmed">36701357</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Government  . 2022. COVID-19 response: living with COVID-19.https://www.gov.uk/government/publications/covid-19-response-living-with-covid-19</Citation></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., et al. Risk factors associated with Post&#x2212;COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>UK - Office for National Statistics  Self-reported long COVID symptoms. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidsymptomsuk/10july2023</Citation></Reference><Reference><Citation>Magnusson K., Kristoffersen D.T., Dell&#x2019;Isola A., et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat Commun. 2022;13(1):7363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M., Mercad&#xe9;-Besora N., Kolde R., et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatr. 2022;9(10):815&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson R.C., Simons N.W., Wilkins L., et al. Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. Nat Med. 2023;29(1):236&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873574</ArticleId><ArticleId IdType="pubmed">36482101</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F., Efstathiou C., Fontanella S., et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25:607&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11003868</ArticleId><ArticleId IdType="pubmed">38589621</ArticleId></ArticleIdList></Reference><Reference><Citation>Batty G.D., Gale C.R., Kivim&#xe4;ki M., Deary I.J., Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020;368:m131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190071</ArticleId><ArticleId IdType="pubmed">32051121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39702578</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2052-4463</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific data</Title><ISOAbbreviation>Sci Data</ISOAbbreviation></Journal><ArticleTitle>Cross-Standard Health Data Harmonization using Semantics of Data Elements.</ArticleTitle><Pagination><StartPage>1407</StartPage><MedlinePgn>1407</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1407</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41597-024-04168-1</ELocationID><Abstract><AbstractText>Faced with heterogeneity of healthcare data, we propose a novel approach for harmonizing data elements (i.e., attributes) across health data standards. This approach focuses on the implicit concept that is represented by a data element. The process includes the following steps: identifying concepts, clustering similar concepts and constructing mappings between the clusters using the Simple Standard for Sharing Ontological Mappings (SSSOM) and Resource Description Framework (RDF), and enabling the creation of reusable mappings. As proof-of-concept, we applied the approach to five common health data standards - HL7 FHIR, OMOP, CDISC, Phenopackets, and openEHR, across four domains, such as demographics and diagnoses, and nine topics within those domains, such as gender and vital status. These domains and topics are selected to represent the broader range of topics in the health field. For each topic, data elements were found in the health data standards after a thorough search, resulting in the analysis of 64 data elements, identification of their underlying concepts, and development of mappings. Three use cases were implemented to demonstrate the role of data element concepts in data harmonization and data querying at varying levels of granularity. The approach helps overcome the limitations of context-dependent mappings and provides valuable insight for mapping practice within the health domain.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shuxin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4715-9070</Identifier><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, 1105, AZ, The Netherlands. s.x.zhang@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health &amp; Methodology, Amsterdam, 1105, AZ, The Netherlands. s.x.zhang@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornet</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1704-5980</Identifier><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, 1105, AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health &amp; Methodology, Amsterdam, 1105, AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benis</LastName><ForeName>Nirupama</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, 1105, AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health &amp; Methodology, Amsterdam, 1105, AZ, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064886">Dataset</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Data</MedlineTA><NlmUniqueID>101640192</NlmUniqueID><ISSNLinking>2052-4463</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="Y">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063025" MajorTopicYN="Y">Health Information Management</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>20</Day><Hour>0</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39702578</ArticleId><ArticleId IdType="pmc">PMC11659470</ArticleId><ArticleId IdType="doi">10.1038/s41597-024-04168-1</ArticleId><ArticleId IdType="pii">10.1038/s41597-024-04168-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gopal, G., Suter-Crazzolara, C., Toldo, L. &amp; Eberhardt, W. Digital transformation in healthcare&#x2013;architectures of present and future information technologies. Clinical Chemistry and Laboratory Medicine (CCLM)57, 328&#x2013;335 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30530878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeadally, S. &amp; Bello, O. Harnessing the power of internet of things based connectivity to improve healthcare. Internet of Things14, 100074 (2021).</Citation></Reference><Reference><Citation>Nguyen, D. C. et al. Federated learning for smart healthcare: A survey. ACM Computing Surveys (CSUR)55, 1&#x2013;37 (2022).</Citation></Reference><Reference><Citation>Sheller, M. J. et al. Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. Scientific reports10, 12598 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387485</ArticleId><ArticleId IdType="pubmed">32724046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bak, M. et al. Federated learning is not a cure-all for data ethics. Nature Machine Intelligence 1&#x2013;3 (2024).</Citation></Reference><Reference><Citation>Torab-Miandoab, A., Samad-Soltani, T., Jodati, A. &amp; Rezaei-Hachesu, P. Interoperability of heterogeneous health information systems: a systematic literature review. BMC Medical Informatics and Decision Making23, 18 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9875417</ArticleId><ArticleId IdType="pubmed">36694161</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;nisch, C., Keszty&#xfc;s, D. &amp; Keszty&#xfc;s, T. Harvesting metadata in clinical care: a crosswalk between fhir, omop, cdisc and openehr metadata. Scientific Data9, 659 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9616884</ArticleId><ArticleId IdType="pubmed">36307424</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, G. et al. Fhir-ontop-omop: Building clinical knowledge graphs in fhir rdf with the omop common data model. Journal of Biomedical Informatics134, 104201, 10.1016/j.jbi.2022.104201 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561043</ArticleId><ArticleId IdType="pubmed">36089199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacaci, A., Gonul, S., Sinaci, A. A., Yuksel, M. &amp; Laleci Erturkmen, G. B. A semantic transformation methodology for the secondary use of observational healthcare data in postmarketing safety studies. Frontiers in pharmacology9, 435 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5937227</ArticleId><ArticleId IdType="pubmed">29760661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Costa, C. &amp; Schulz, S. Validating ehr clinical models using ontology patterns. Journal of biomedical informatics76, 124&#x2013;137 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29113934</ArticleId></ArticleIdList></Reference><Reference><Citation>Miles, A. &amp; Bechhofer, S. Skos simple knowledge organization system reference. W3C recommendation (2009).</Citation></Reference><Reference><Citation>HL7. Fast Healthcare Interoperability Resources (FHIR). https://hl7.org/fhir/ 19 January 2024.</Citation></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium (CDISC). Study Data Tabulation Model (SDTM)https://www.cdisc.org/ 19 January 2024.</Citation></Reference><Reference><Citation>Udry, J. R. The nature of gender. Demography31, 561&#x2013;573 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7890091</ArticleId></ArticleIdList></Reference><Reference><Citation>Haig, D. The inexorable rise of gender and the decline of sex: Social change in academic titles, 1945&#x2013;2001. Archives of sexual behavior33, 87&#x2013;96 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15146141</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargava, A. et al. Considering sex as a biological variable in basic and clinical studies: an endocrine society scientific statement. Endocrine reviews42, 219&#x2013;258 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8348944</ArticleId><ArticleId IdType="pubmed">33704446</ArticleId></ArticleIdList></Reference><Reference><Citation>ISO/IEC 11179-6:2023, Information technology &#x2013; Metadata registries (MDR) https://www.iso.org/obp/ui/#iso:std:iso-iec:11179:-3:ed-4:v1:en (2023).</Citation></Reference><Reference><Citation>Matentzoglu, N. et al. A simple standard for sharing ontological mappings (sssom). Database2022 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9216545</ArticleId><ArticleId IdType="pubmed">35616100</ArticleId></ArticleIdList></Reference><Reference><Citation>World Wide Web Consortium and others. RDF 1.1 concepts and abstract syntax (2014).</Citation></Reference><Reference><Citation>OHDSI. Observational Medical Outcomes Partnership (OMOP) common data model (CDM). https://github.com/OHDSI/CommonDataModel Accessed: 19 January 2024.</Citation></Reference><Reference><Citation>openEHR Foundation. openEHR. https://www.openehr.org/ 19 January 2024.</Citation></Reference><Reference><Citation>Jacobsen, J. O. et al. The ga4gh phenopacket schema defines a computable representation of clinical data. Nature biotechnology40, 817&#x2013;820 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9363006</ArticleId><ArticleId IdType="pubmed">35705716</ArticleId></ArticleIdList></Reference><Reference><Citation>W3C. OWL2 New Features - F12:Punning, https://www.w3.org/TR/owl2-new-features/#F12:_Punning 31 March 2022.</Citation></Reference><Reference><Citation>Zhang, S. Proof of Concept for Concept-based Mappings, https://github.com/sxzhang1201/concept-based-mapping 27 January 2024.</Citation></Reference><Reference><Citation>Dumontier, M. et al. The semanticscience integrated ontology (sio) for biomedical research and knowledge discovery. Journal of biomedical semantics5, 1&#x2013;11 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015691</ArticleId><ArticleId IdType="pubmed">24602174</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards, C. et al. Non-binary or genderqueer genders. International Review of Psychiatry28, 95&#x2013;102 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26753630</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnebly, R. A. Biological sex and gender in the united states. Embryo Project Encyclopedia (2022).</Citation></Reference><Reference><Citation>FDA. FDA Glossary of Terms, https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms 19 January 2024.</Citation></Reference><Reference><Citation>Zhang, S. The SSSOM Mappings, https://github.com/sxzhang1201/concept-based-mapping/tree/main/sssom-mappings 27 January 2024.</Citation></Reference><Reference><Citation>Bodenreider, O. The unified medical language system (umls): integrating biomedical terminology. Nucleic acids research32, D267&#x2013;D270 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S., Benis, N. &amp; Cornet, R. Automated approach for quality assessment of rdf resources. BMC Medical Informatics and Decision Making23, 90 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10170671</ArticleId><ArticleId IdType="pubmed">37165363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueda, M., Leist, I. C. &amp; Gut, I. G. Convert-pheno: A software toolkit for the interconversion of standard data models for phenotypic data. Journal of Biomedical Informatics149, 104558, 10.1016/j.jbi.2023.104558 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38035971</ArticleId></ArticleIdList></Reference><Reference><Citation>Foer, D. et al. Utilization of electronic health record sex and gender demographic fields: a metadata and mixed methods analysis. Journal of the American Medical Informatics Association ocae016 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10990507</ArticleId><ArticleId IdType="pubmed">38308819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevsky, N. et al. Mondo disease ontology: harmonizing disease concepts across the world. In CEUR Workshop Proceedings, CEUR-WS, vol. 2807 (2020).</Citation></Reference><Reference><Citation>LinkML Project. LinkML, https://linkml.io/ 19 Septmber 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39711680</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2691-3593</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of surgery open : perspectives of surgical history, education, and clinical approaches</Title><ISOAbbreviation>Ann Surg Open</ISOAbbreviation></Journal><ArticleTitle>Mismatch Repair Status and Surgical Outcomes in Localized Colorectal Cancer: A Nationwide Cohort Study.</ArticleTitle><Pagination><StartPage>e499</StartPage><MedlinePgn>e499</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/AS9.0000000000000499</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study examined the association between deficient mismatch repair (dMMR) versus proficient MMR (pMMR) status and overall survival and disease-free survival in patients with localized colorectal cancer.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Several distinctions exist between patients with dMMR and pMMR colorectal cancer. However, the impact on prognosis is yet to be investigated in large-scale cohort studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this cohort study, we included patients who underwent curative-intent surgery for localized colorectal cancer between 2009 and 2020. Patients were identified in the Danish Colorectal Cancer Group database and patient-level data were extracted from 6 registry databases. After inclusion, patients with dMMR status were matched 1:1 to patients with pMMR status using an estimated propensity score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After matching, 5994 patients were included. The patients had a median age of 74 years and a median follow-up of 4.1 years. There was no significant association between mismatch repair (MMR) status and overall survival (hazard ratio, 0.91; 95% confidence interval [CI], 0.81-1.03) or disease-free survival (hazard ratio, 0.89; 95% CI, 0.78-1.01). However, the restricted 5-year mean disease-free survival time, calculated due to violation of the proportional hazards assumption, showed a significant absolute difference of 0.13 years (95% CI, 0.03-0.23; <i>P</i> = 0.01) in favor of the dMMR group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">No significant association with overall survival was found according to MMR status. dMMR status was, however, found to be associated with marginally improved disease-free survival compared to pMMR status in patients with localized colorectal cancer undergoing curative-intent surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Justesen</LastName><ForeName>Tobias Freyberg</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orhan</LastName><ForeName>Adile</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Andreas Weinberger</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Mikail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf6;genur</LastName><ForeName>Ismail</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Surgery, Center for Surgical Science, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg Open</MedlineTA><NlmUniqueID>101769928</NlmUniqueID><ISSNLinking>2691-3593</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">colorectal cancer</Keyword><Keyword MajorTopicYN="N">deficient mismatch repair system</Keyword><Keyword MajorTopicYN="N">proficient mismatch repair system</Keyword></KeywordList><CoiStatement>Disclosure: The authors declare that they have no conflicts of interest to disclose. This study was supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant number: 806968), the Novo Nordisk Foundation with the project title &#x201c;Personalized medicine infrastructure using the open-source OMOP common data model including an Electronic Health Record interface&#x201d; (grant number: NNF21OC0069821), and the Danish Ministry of Higher Education and Science and the Region Zealand (grant number not provided).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>23</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>23</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>23</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39711680</ArticleId><ArticleId IdType="pmc">PMC11661751</ArticleId><ArticleId IdType="doi">10.1097/AS9.0000000000000499</ArticleId><ArticleId IdType="pii">AOSO-D-24-00178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Wagle NS, Cercek A, et al. . Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">36856579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan E, Arnold M, Gini A, et al. . Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">36604116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchins G, Southward K, Handley K, et al. . Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">21383284</ArticleId></ArticleIdList></Reference><Reference><Citation>Baran B, Mert Ozupek N, Yerli Tetik N, et al. . Difference between left-sided and right-sided colorectal cancer: a focused review of literature. Gastroenterol Res. 2018;11:264&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6089587</ArticleId><ArticleId IdType="pubmed">30116425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. . Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">32251400</ArticleId></ArticleIdList></Reference><Reference><Citation>Cercek A, Lumish M, Sinopoli J, et al. . PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363&#x2013;2376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9492301</ArticleId><ArticleId IdType="pubmed">35660797</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludford K, Ho WJ, Thomas JV, et al. . Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41:2181&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10489404</ArticleId><ArticleId IdType="pubmed">36623241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Kang L, Zhang J, et al. . Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">34688374</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh JWT, Phan K, Reza F, et al. . Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis. Int J Colorectal Dis. 2021;36:1573&#x2013;1596.</Citation><ArticleIdList><ArticleId IdType="pubmed">33604737</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, et al. ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingeholm P, G&#xf6;genur I, Iversen LH. Danish colorectal cancer group database. Clin Epidemiol. 2016;8:465&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094575</ArticleId><ArticleId IdType="pubmed">27822086</ArticleId></ArticleIdList></Reference><Reference><Citation>Lash TL, Riis AH, Ostenfeld EB, et al. . A validated algorithm to ascertain colorectal cancer recurrence using registry resources in Denmark. Int J Cancer. 2015;136:2210&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pubmed">25307704</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Erichsen R, Lash TL, Hamilton-dutoit SJ, et al. . Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943174</ArticleId><ArticleId IdType="pubmed">20865103</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(Suppl 7):42&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21775350</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Pedersen L, S&#xf8;rensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">24965263</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt JFH, Hansen AT, Ladefoged SA, et al. . Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7244445</ArticleId><ArticleId IdType="pubmed">32547238</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandegaard JL, Ehrenstein V, Pedersen L. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A, Schmidt SAJ, Wallach-Kildemoes H, et al. . Data resource profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46:798&#x2013;798f.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837522</ArticleId><ArticleId IdType="pubmed">27789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S. Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin Epidemiol. 2018;10:771&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039060</ArticleId><ArticleId IdType="pubmed">30013400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Kim HJ, Lonjon G, et al. ; written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351359</ArticleId><ArticleId IdType="pubmed">30788363</ArticleId></ArticleIdList></Reference><Reference><Citation>Uno H, Claggett B, Tian L, et al. . Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105489</ArticleId><ArticleId IdType="pubmed">24982461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Uno H, Wei L-J. Restricted mean survival time as a measure to interpret clinical trial results. JAMA Cardiol. 2017;2:1179&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6359932</ArticleId><ArticleId IdType="pubmed">28877311</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Shaddox TR, Tian Y, Yang J, Kawaguchi E. Cyclic coordinate descent for logistic, Poisson and survival analysis (Cyclops).
Available at: https://ohdsi.github.io/Cyclops/. Accessed March 27, 2024.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. . Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Luo S, Lai S, et al. . Survival after curative resection for stage I colorectal mucinous adenocarcinoma. BMC Gastroenterol. 2022;22:192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017001</ArticleId><ArticleId IdType="pubmed">35436867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh K, Stadler ZK, Cercek A, et al. . Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295073</ArticleId><ArticleId IdType="pubmed">30886395</ArticleId></ArticleIdList></Reference><Reference><Citation>Idos GE, Kwok J, Bonthala N, et al. . The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: a systematic review and meta-analysis. Sci Rep. 2020;10:3360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042281</ArticleId><ArticleId IdType="pubmed">32099066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wankhede D, Yuan T, Kloor M, et al. . Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2024;9:609&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">38734024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen SE, Qvortrup C, Olesen R, et al. ; Line Schmidt Tarpgaard AR. Adjuvant chemotherapy for stage III colon cancer - Clinical Guidelines - Cancer.
Danish Color Cancer Gr. 2022:1&#x2013;17. Version 2. Available at: https://www.dmcg.dk/siteassets/forside/kliniske-retningslinjer/godkendte-kr/kolorektal/dccg_adjkemocolon-stadiumiii_v2.1_admgodk030122.pdf. Accessed April 4, 2024.</Citation></Reference><Reference><Citation>Des Guetz G, Schischmanoff O, Nicolas P, et al. . Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45:1890&#x2013;1896.</Citation><ArticleIdList><ArticleId IdType="pubmed">19427194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tougeron D, Mouillet G, Trouilloud I, et al. . Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study. J Natl Cancer Inst. 2016;108:djv438.</Citation><ArticleIdList><ArticleId IdType="pubmed">26839356</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; T, De Gramont A, Vernerey D, et al. . Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176&#x2013;4187.</Citation><ArticleIdList><ArticleId IdType="pubmed">26527776</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello G, Ghidini M, Galassi B, et al. . Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Sci Rep. 2022;12:1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8776729</ArticleId><ArticleId IdType="pubmed">35058539</ArticleId></ArticleIdList></Reference><Reference><Citation>Orhan A, Justesen TF, Raskov H, et al. . Introducing neoadjuvant immunotherapy for colorectal cancer: advancing the frontier [published online ahead of print]. Ann Surg. 2024. doi: 10.1097/SLA.0000000000006443.</Citation><ArticleIdList><ArticleId IdType="pubmed">39005208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalabi M, Verschoor YL, Tan PB, et al. . Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med. 2024;390:1949&#x2013;1958.</Citation><ArticleIdList><ArticleId IdType="pubmed">38838311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cercek A, Sinopoli JC, Shia J, et al. . Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. J Clin Oncol. 2024;42:LBA3512.</Citation></Reference><Reference><Citation>Chen G, Jin Y, Guan W, et al. . Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8:422&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">36870360</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer P, Andersen PV, Salomon S, et al. . Short course immunotherapy as curative-intent treatment in stage I-III dMMR rectal. J Clin Oncol. 2024;42(suppl 3):121&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Verschoor YL, van den Berg J, Beets G, et al. . Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. J Clin Oncol. 2022;40(suppl 16):3511&#x2013;3511.</Citation></Reference><Reference><Citation>Klein MF, G&#xf6;genur I, Ingeholm P, et al. ; the DCCG Validation Group. Validation of the Danish Colorectal Cancer Group (DCCG.dk) database &#x2013; on behalf of the Danish Colorectal Cancer Group. Colorectal Dis. 2020;22:2057&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">32894818</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39720603</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents.</ArticleTitle><Pagination><StartPage>102962</StartPage><MedlinePgn>102962</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2024.102962</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. We aim to assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. We further explore if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection using causal mediation analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted real-world vaccine effectiveness study and mediation analysis using data from twenty health systems in the RECOVER PCORnet electronic health record (EHR) Program. Three independent cohorts were constructed including adolescents (12-20 years) during the Delta phase (July 1-November 30, 2021), children (5-11 years) and adolescents (12-20 years) during the Omicron phase (January 1-November 30, 2022). The intervention is first dose of the BNT162b2 vaccine in comparison with no receipt of COVID-19 vaccine. The outcomes of interest include conclusive or probable diagnosis of long COVID following a documented SARS-CoV-2 infection, and body-system-specific condition clusters of post-acute sequelae of SARS-CoV-2 infection (PASC), such as cardiac, gastrointestinal, musculoskeletal, respiratory, and syndromic categories. The effectiveness was reported as (1-relative risk)&#x2217;100 and mediating effects were reported as relative risks.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">112,590 adolescents (88,811 vaccinated) were included in the cohort for the analysis against Delta variant, and 188,894 children (101,277 vaccinated), and 84,735 adolescents (37,724 vaccinated) were included for the analysis against Omicron variant. During the Delta period, the estimated effectiveness of the BNT162b2 vaccine against long COVID among adolescents was 95.4% (95% CI: 90.9%-97.7%). During the Omicron phase, the estimated effectiveness against long COVID among children was 60.2% (95% CI: 40.3%-73.5%) and 75.1% (95% CI: 50.4%-87.5%) among adolescents. The direct effect of vaccination, defined as the effect beyond their impact on SARS-CoV-2 infections, was found to be statistically non-significant in all three study cohorts, with estimated relative risk of 1.08 (95% CI: 0.75-1.55) in the Delta study among adolescents, 1.24 (95% CI: 0.92-1.66) among children and 0.91 (95% CI: 0.69-1.19) among adolescents in the Omicron studies. Meanwhile, the estimated indirect effects, which are effects through protecting SARS-CoV-2 infections, were estimated as 0.04 (95% CI: 0.03-0.05) among adolescents during Delta phase, 0.31 (95% CI: 0.23-0.42) among children and 0.21 (95% CI: 0.16-0.27) among adolescents during the Omicron period.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Our study suggests that BNT162b2 was effective in reducing risk of long COVID outcomes in children and adolescents during the Delta and Omicron periods. The mediation analysis indicates the vaccine's effectiveness is primarily derived from its role in reducing the risk of SARS-CoV-2 infection.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">National Institutes of Health.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>L Charles</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunnell</LastName><ForeName>H Timothy</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Biomedical Research Informatics Center, Nemours Children's Health, Nemours Children's Hospital, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrischilles</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Downs</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Atrium Health Wake Forest Baptist, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirabayashi</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishkin</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosa</LastName><ForeName>Abu S M</ForeName><Initials>ASM</Initials><AffiliationInfo><Affiliation>Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajor</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razzaghi</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwenk</LastName><ForeName>Hayden T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sills</LastName><ForeName>Marion R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research, OCHIN, Inc., Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linbo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Statistical Sciences, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yudong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchetgen Tchetgen</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECOVER Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Causal mediation analysis</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Pediatric research</Keyword><Keyword MajorTopicYN="N">Real-world effectiveness</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Dr. Mosa is a board member of i2b2tranSMART Foundation. Dr. Jhaveri is a consultant for Gilead, AstraZeneca, Sanofi, and Seqiru; receives grants from GSK, CDC, and AHRQ; holds an editorial stipend Editor-in-Chief of the Journal of the Pediatric Infectious Diseases Society (JPIDS); and receives royalties from UpToDate.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>25</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39720603</ArticleId><ArticleId IdType="pmc">PMC11667630</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2024.102962</ArticleId><ArticleId IdType="pii">S2589-5370(24)00541-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S., Lee G.M., Razzaghi H., et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. JAMA Pediatr. 2022;176(10):1000&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck Jr RW., Klein N.P., Kitchin N., et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N&#xa0;Engl J Med. 2021;385(3):239&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter E.B., Talaat K.R., Sabharwal C., et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N&#xa0;Engl J Med. 2022;386(1):35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman S., Whittaker C., Semenova E., et al. Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US. JAMA Netw Open. 2023;6(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9887489</ArticleId><ArticleId IdType="pubmed">36716029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., AlMukdad S., Ayoub H.H., et al. Covid-19 vaccine protection among children and adolescents in Qatar. N&#xa0;Engl J Med. 2022;387(20):1865&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9644642</ArticleId><ArticleId IdType="pubmed">36322837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Stavi C.J., Magen O., Barda N., et al. BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age. N&#xa0;Engl J Med. 2022;387(3):227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258754</ArticleId><ArticleId IdType="pubmed">35767475</ArticleId></ArticleIdList></Reference><Reference><Citation>Florentino P.T.V., Alves F.J.O., Cerqueira-Silva T., et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period. Nat Commun. 2022;13(1):4756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9375192</ArticleId><ArticleId IdType="pubmed">35963844</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson S.M., Newhams M.M., Halasa N.B., et al. Effectiveness of BNT162b2 vaccine against critical Covid-19 in adolescents. N&#xa0;Engl J Med. 2022;386(8):713&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781318</ArticleId><ArticleId IdType="pubmed">35021004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco C., Del Manso M., Mateo-Urdiales A., et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5&#x2013;11 years in Italy: a retrospective analysis of January&#x2013;April, 2022. Lancet. 2022;400(10346):97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9246475</ArticleId><ArticleId IdType="pubmed">35780801</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F.L., Nguyen J.L., Singh T.G., et al. Estimated BNT162b2 vaccine effectiveness against infection with delta and omicron variants among US children 5 to 11 years of age. JAMA Netw Open. 2022;5(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856252</ArticleId><ArticleId IdType="pubmed">36515946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q., Tong J., Zhang B., et al. Real-world effectiveness of BNT162b2 against infection and severe Diseases in children and adolescents. Ann Intern Med. 2024 doi: 10.7326/M23-1754. Published online January 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1754</ArticleId><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock M.D., Chew R.F., Preiss A.J., et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun. 2023;14(1):2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B., et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.T., Perrodeau E., Saldanha J., Pane I., Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. BMJ medicine. 2023;2(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Kaufmann M., et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PLoS One. 2023;18(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P., Gorelik Y., Zayyad H., et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022;7(1):101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., Vetter P., Chappuis F., Kaiser L., Guessous I. Prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status. Clin Infect Dis. 2023;76(9):1567&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Harrison P.J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W.D., Sherwood O., Banerjee A., Van der Togt V., Hishmeh L., Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines (Basel) 2022;10(5):652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Pijnenburg L., Chatelus E., et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study. Vaccines (Basel) 2021;10(1):46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaden T., Mutubuki E.N., de Bruijn S., et al. Prevalence and severity of symptoms 3 months after infection with SARS-CoV-2 compared to test-negative and population controls in The Netherlands. J&#xa0;Infect Dis. 2023;227(9):1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">36477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlert C.R., Strahm C., G&#xfc;sewell S., et al. Post-acute sequelae after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by viral variant and vaccination status: a multicenter cross-sectional study. Clin Infect Dis. 2023;77(2):194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10371307</ArticleId><ArticleId IdType="pubmed">36905145</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun M.C., Singh A.K., Pal D., et al. Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PLoS One. 2022;17(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhiraja S., Indrayan A., Mahajan M. Effect of COVID-19 vaccine on long-COVID: a 2-year follow-up observational study from hospitals in north India. medRxiv. 2022 2022-2027.</Citation></Reference><Reference><Citation>Wynberg E., Han A.X., Boyd A., et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine. 2022;40(32):4424&#x2013;4431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M., Mercad&#xe9;-Besora N., Kolde R., et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225&#x2013;236. doi: 10.1016/S2213-2600(23)00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n M.A., Monge S. Selection bias due to conditioning on a collider. BMJ. 2023 doi: 10.1136/bmj.p1135. p1135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.p1135</ArticleId><ArticleId IdType="pmc">PMC10245143</ArticleId><ArticleId IdType="pubmed">37286200</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVER  RECOVER program. recovercovid.org</Citation></Reference><Reference><Citation>Forrest C.B., Margolis P.A., Bailey L.C., et al. PEDSnet: a national pediatric learning health system. J&#xa0;Am Med Inf Assoc. 2014;21(4):602&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele T.J. Mediation analysis: a practitioner&#x2019;s guide. Annu Rev Public Health. 2016;37(1):17&#x2013;32. doi: 10.1146/annurev-publhealth-032315-021402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032315-021402</ArticleId><ArticleId IdType="pubmed">26653405</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai K., Keele L., Tingley D. A&#xa0;general approach to causal mediation analysis. Psychol Methods. 2010;15(4):309.</Citation><ArticleIdList><ArticleId IdType="pubmed">20954780</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele T. Oxford University Press; 2015. Explanation in causal inference: methods for mediation and interaction.</Citation></Reference><Reference><Citation>Miao W., Geng Z., Tchetgen Tchetgen E.J. Identifying causal effects with proxy variables of an unmeasured confounder. Biometrika. 2018;105(4):987&#x2013;993. doi: 10.1093/biomet/asy038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/asy038</ArticleId><ArticleId IdType="pmc">PMC7746017</ArticleId><ArticleId IdType="pubmed">33343006</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukes O., Shpitser I., Tchetgen E.J.T.  2021. Proximal mediation analysis.http://arxiv.org/abs/2109.11904 Published online September 24.</Citation></Reference><Reference><Citation>Razzaghi H., Forrest C.B., Hirabayashi K., et al. Vaccine effectiveness against long COVID in children. Pediatrics. 2024 doi: 10.1542/peds.2023-064446. Published online January 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2023-064446</ArticleId><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>PCORnet  PCORnet common data model (CDM) https://pcornet.org/wp-content/uploads/2023/04/PCORnet-Common-Data-Model-v61-2023_04_031.pdf</Citation></Reference><Reference><Citation>OHDSI  OHDSI OMOP common data model (CDM) https://ohdsi.github.io/CommonDataModel/</Citation></Reference><Reference><Citation>Lorman V., Rao S., Jhaveri R., et al. Understanding pediatric long COVID using a tree-based scan statistic approach: an EHR-based cohort study from the RECOVER Program. JAMIA Open. 2023;6(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10013630</ArticleId><ArticleId IdType="pubmed">36926600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Schuemie M.J., Suchard M.A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M.A., Schuemie M.J., Krumholz H.M., et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong G., Deutsch J., Hill H.D. Ratio-of-mediator-probability weighting for causal mediation analysis in the presence of treatment-by-mediator interaction. J&#xa0;Educ Behav Stat. 2015;40(3):307&#x2013;340.</Citation></Reference><Reference><Citation>Huber M. Identifying causal mechanisms (primarily) based on inverse probability weighting. J&#xa0;Appl Econom. 2014;29(6):920&#x2013;943.</Citation></Reference><Reference><Citation>Sturmer T., Webster-Clark M., Lund J.L., et al. Propensity score weighting and trimming strategies for reducing variance and bias of treatment effect estimates: a simulation study. Am J Epidemiol. 2021;190(8):1659&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327194</ArticleId><ArticleId IdType="pubmed">33615349</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanski L.A., Boos D.D. The calculus of M-estimation. Am Stat. 2002;56(1):29&#x2013;38.</Citation></Reference><Reference><Citation>Austin P.C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083&#x2013;3107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Araf Y., Akter F., Tang Y., et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J&#xa0;Med Virol. 2022;94(5):1825&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015557</ArticleId><ArticleId IdType="pubmed">35023191</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R., Levy M.E., Natarajan K., et al. Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA. 4 and BA. 5 sublineage periods. JAMA Netw Open. 2023;6(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10018321</ArticleId><ArticleId IdType="pubmed">36920396</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf A.R., Mak J., Gwynn L., et al. vol. 10. Oxford University Press US; 2023. COVID-19 mRNA vaccination reduces the occurrence of post-COVID conditions in US children aged 5-17 Years following omicron SARS-CoV-2 infection, july 2021-September 2022. (Open forum infectious Diseases). 1935. ofad500-2466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10878356</ArticleId><ArticleId IdType="pubmed">38379567</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R., Mariani F., Mastrantoni L., et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. EClinicalMedicine. 2023;59 doi: 10.1016/j.eclinm.2023.101961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101961</ArticleId><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Camporesi A., Morello R., La Rocca A., et al. Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study. EClinicalMedicine. 2024;76 doi: 10.1016/j.eclinm.2024.102815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102815</ArticleId><ArticleId IdType="pmc">PMC11408803</ArticleId><ArticleId IdType="pubmed">39296584</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39724470</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2568</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Digestive diseases and sciences</Title><ISOAbbreviation>Dig Dis Sci</ISOAbbreviation></Journal><ArticleTitle>Characteristics and Outcomes of Over a Million Patients with Inflammatory Bowel Disease in Seven Countries: Multinational Cohort Study and Open Data Resource.</ArticleTitle><Pagination><StartPage>709</StartPage><EndPage>718</EndPage><MedlinePgn>709-718</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-024-08787-x</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Observational healthcare data are an important tool for delineating patients' inflammatory bowel disease (IBD) journey in real-world settings. However, studies that characterize IBD cohorts typically rely on a single resource, apply diverse eligibility criteria, and extract variable sets of attributes, making comparison between cohorts challenging. We aim to longitudinally describe and compare IBD patient cohorts across multiple geographic regions, employing unified data and analysis framework.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a descriptive cohort study, using routinely collected healthcare data, from a federated network of data partners in sixteen databases from seven countries (USA, UK, France, Germany, Japan, Korea, and Australia); and computed the prevalence of thousands of attributes, across multiple baseline and follow-up time windows, for full disease cohorts and various&#xa0;strata.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Characterizing the disease trajectory of 462,502 Crohn's disease (CD) and 589,118 ulcerative colitis (UC) subjects, we observed a decline over time in the average age at CD diagnosis in Europe and North America but less pronounced shifts in Japan and Korea; an uptick in the proportion of patients with anxiety diagnosis prior to CD diagnosis in European and US datasets; and stable rates of segmental colonic and small bowel resections&#xa0;within one and three years following UC and CD diagnosis, respectively, in most US databases.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study provides a comprehensive characterization of IBD patient cohorts from various countries including insights into disease trends, demographics, and pre-diagnosis symptoms. All characteristics and outcomes are publicly available, providing an unprecedented, comprehensive open resource for clinicians and researchers.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yanover</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA. yanover@ohdsi.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KI Research Institute, 11 haZait St., Kfar Malal, Israel. yanover@ohdsi.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magen-Rimon</LastName><ForeName>Ramit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Ruth Children's Hospital of Haifa, Rambam Medical Center, Pediatric Gastroenterology &amp; Nutrition Institute, Technion, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheahan</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kwang Jae</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Sung Jae</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung-Joo</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kangdong Sacred Heart Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowring</LastName><ForeName>Mary Grace</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Hay</LastName><ForeName>Tal</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KI Research Institute, 11 haZait St., Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bivas-Benita</LastName><ForeName>Maytal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KI Research Institute, 11 haZait St., Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiva</LastName><ForeName>Pinchas</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>KI Research Institute, 11 haZait St., Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowers</LastName><ForeName>Yehuda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Rambam Health Care Campus and Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weisshof</LastName><ForeName>Roni</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Rambam Health Care Campus and Bruce Rappaport School of Medicine, Technion Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 HL168842</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL168842</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HR16C0001</GrantID><Agency>Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dig Dis Sci</MedlineTA><NlmUniqueID>7902782</NlmUniqueID><ISSNLinking>0163-2116</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="Y">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort study</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Routinely collected health data</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: EAV, JS, AS, and NH are employees of Janssen Research and Development LLC and shareholders of Johnson &amp; Johnson (J&amp;J) stock; SM previously consulted for Surescripts and now consults for First Databank; YC is employee of CytoReason. Ethical approval: The New England Institutional Review Board determined that studies conducted in CCAE, MDCR, MDCD, OPTUM-EHR, and OPTUM-CDM were exempt from study-specific Institutional Review Board review, as these studies do not qualify as human subject research. For use of IQVIA&#x2122;&#x2019;s FRANCE, GERMANY, AUSTRALIA, AMB-EMR, and PharMetrics+&#x2009;, no patient permission was necessary because all patient data are deidentified for research purposes. Based on Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor and Welfare, ethics approval and informed consent were not applicable for use of JMDC. The use of AUSOM data in this study was approved by the Institutional Review Board of Ajou University Hospital (IRB number: AJOUIRB-MDB-2022&#x2013;263) and the use of KDH data&#x2014;by the Institutional Review Board of Kangdong Sacred Heart Hospital (IRB number: 2022&#x2013;09-021); both committees waived the requirement for informed consent. IQVIA&#x2122; Scientific Review Committee approved the use of IMRD-UK data for this study (SRC Reference Number: 21SRC066). The research was approved by the Columbia University Institutional Review Board, as an OHDSI network study, and by the Johns Hopkins institutional review board.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>26</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>26</Day><Hour>16</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39724470</ArticleId><ArticleId IdType="pmc">PMC11839857</ArticleId><ArticleId IdType="doi">10.1007/s10620-024-08787-x</ArticleId><ArticleId IdType="pii">10.1007/s10620-024-08787-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benchimol EI, Manuel DG, Guttmann A, Nguyen GC, Mojaverian N, Quach P et al. Changing Age Demographics of Inflammatory Bowel Disease in Ontario, Canada: A Population-based Cohort Study of Epidemiology Trends. Inflamm Bowel Dis. 2014;20:1761&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pubmed">25159453</ArticleId></ArticleIdList></Reference><Reference><Citation>Windsor JW, Kaplan GG. Evolving Epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31338613</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman K, Ryan R, Parsons N, Taylor-Phillips S, Willis BH, Clarke A. The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database. BMC Gastroenterol. 2021;21:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004426</ArticleId><ArticleId IdType="pubmed">33771127</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman MY, Leventer-Roberts M, Rosenblum J, Zigman N, Goren I, Mourad V et al. Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study. Clin Epidemiol. 2018;10:671&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5995295</ArticleId><ArticleId IdType="pubmed">29922093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CK, Ha HJ, Oh SJ, Kim J-W, Lee JK, Kim H-S et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol. 2020;35:760&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">31498502</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI; 2019.Available from: https://books.google.co.il/books?id=JxpnzQEACAAJ</Citation></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet. 2019;394:1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas L, Nagy P, Bowring M, Cook M, Magen-Rimon R, Weisshof R et al. Characterizing the Johns Hopkins Inflammatory Bowel Disease Cohort using OMOP CDM. Gastroenterology. 2023;164:S43&#x2013;S44.</Citation></Reference><Reference><Citation>Kim HJ, Hann HJ, Hong SN, Kim KH, Ahn IM, Song JY et al. Incidence and Natural Course of Inflammatory Bowel Disease in Korea, 2006&#x2013;2012: A Nationwide Population-based Study. Inflamm Bowel Dis. 2015;21:623&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">25647154</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SH, Kim Y-J, Rhee KH, Kim Y-H, Hong SN, Kim KH et al. A 30-year Trend Analysis in the Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District of Seoul, Korea in 1986&#x2013;2015. J Crohns Colitis. 2019;13:1410&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">30989166</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaki R, Matsuura M et al. Characteristics of adult patients newly diagnosed with Crohn&#x2019;s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn&#x2019;s disease in Japan (iCREST-CD). J Gastroenterol. 2022;57:867&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">35930087</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftus CG, Loftus EV Jr, Harmsen SW, Zinsmeister AR, Tremaine WJ, Melton JL III et al. Update on the incidence and prevalence of Crohn&#x2019;s disease and ulcerative colitis in Olmsted County, Minnesota, 1940&#x2013;2000. Inflamm Bowel Dis. 2007;13:254&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">17206702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghersin I, Khteeb N, Katz LH, Daher S, Shamir R, Assa A. Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study. Aliment Pharmacol Ther. 2019;49:556&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">30687945</ArticleId></ArticleIdList></Reference><Reference><Citation>Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V et al. Epidemiology of Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2011;53:141&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">21788753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Moran GW, Benchimol EI, Targownik LE, Heitman SJ, Hubbard JN et al. Surgical Rates for Crohn&#x2019;s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. Am J Gastroenterol. 2017;112:1840&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5729339</ArticleId><ArticleId IdType="pubmed">29087396</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;ss C, Berlet M, Reischl S, Nitsche U, Weber M-C, Friess H et al. Crohn&#x2019;s disease: a population-based study of surgery in the age of biological therapy. Int J Colorectal Dis. 2021;36:2419&#x2013;2426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505365</ArticleId><ArticleId IdType="pubmed">33876296</ArticleId></ArticleIdList></Reference><Reference><Citation>Valvano M, Vinci A, Cesaro N, Frassino S, Ingravalle F, Ameli M et al. The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn&#x2019;s disease in real world-data: a retrospective study. BMC Gastroenterol. 2023;23:438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10720171</ArticleId><ArticleId IdType="pubmed">38097975</ArticleId></ArticleIdList></Reference><Reference><Citation>Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V et al. Natural disease course of Crohn&#x2019;s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68:423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29363534</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens TW, Haasnoot ML, D&#x2019;Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn&#x2019;s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5:900&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619413</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai N, Haidar O, Askari A, Segal JP. Colectomy rates in ulcerative colitis: A systematic review and meta-analysis. Dig Liver Dis. 2023;55:13&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">36180365</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:359&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">33721557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fousekis FS, Katsanos AH, Kourtis G, Saridi M, Albani E, Katsanos KH et al. Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know? J Clin Med Res. 2021;13:466&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510650</ArticleId><ArticleId IdType="pubmed">34691320</ArticleId></ArticleIdList></Reference><Reference><Citation>Frolkis AD, Vallerand IA, Shaheen A-A, Lowerison MW, Swain MG, Barnabe C et al. Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut. 2019;68:1606&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">30337374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananthakrishnan AN, Gainer VS, Perez RG, Cai T, Cheng S-C, Savova G et al. Psychiatric co-morbidity is associated with increased risk of surgery in Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2013;37:445&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552092</ArticleId><ArticleId IdType="pubmed">23289600</ArticleId></ArticleIdList></Reference><Reference><Citation>Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA, Ahbabi AA. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30:44.</Citation></Reference><Reference><Citation>Goodwin RD, Weinberger AH, Kim JH, Wu M, Galea S. Trends in anxiety among adults in the United States, 2008&#x2013;2018: Rapid increases among young adults. J Psychiatr Res. 2020;130:441&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7441973</ArticleId><ArticleId IdType="pubmed">32905958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Feng R, Ben-Horin S, Zhuang X, Tian Z, Li X et al. Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022;55:266&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">34820868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39724693</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><PubDate><Year>2025</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).</ArticleTitle><Pagination><StartPage>126615</StartPage><MedlinePgn>126615</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126615</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01297-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs.</AbstractText><AbstractText Label="METHODS">In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition.</AbstractText><AbstractText Label="RESULTS">Among the 979 included HCWs eligible for a second booster vaccination, 392 (40&#xa0;%) received it and 192 (20&#xa0;%) presented an infection during the study period. The rVE of the second versus first booster dose was -5&#xa0;% (95&#xa0;%CI: -46; 25) overall, 3&#xa0;% (-46; 36) in the 7-89&#xa0;days after receiving the second booster dose. The rVE was 11&#xa0;% (-43; 45) when restricted to the use of bivalent vaccines only.</AbstractText><AbstractText Label="CONCLUSION">The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11&#xa0;%. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savulescu</LastName><ForeName>Camelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Epiconcept, Paris, France. Electronic address: c.savulescu@epiconcept.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Epiconcept, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brolin</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusk&#xfc;la</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergin</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, Dublin, Ireland; Department of Clinical Medicine, Trinity College, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland; Department of Medicine, University of Galway, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zvirbulis</LastName><ForeName>Viesturs</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zavadska</LastName><ForeName>Dace</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szu&#x142;drzy&#x144;ski</LastName><ForeName>Konstanty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Institute of Medicine of the Ministry of the Interior and Administration, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaio</LastName><ForeName>V&#xe2;nia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popescu</LastName><ForeName>Corneliu Petru</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craiu</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; National Institute for Mother and Child Care Alessandrescu Rusescu, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cisneros</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu. Hospital Sant Joan de Deu, Barcelona, Spain; Medicine Department, Universitat internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latorre-Mill&#xe1;n</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS, Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lohur</LastName><ForeName>Liis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Viljandi Hospital, Viljandi, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abolina</LastName><ForeName>Ilze</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravele</LastName><ForeName>Dagne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Ausenda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florescu</LastName><ForeName>Simin Aysel</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subirats</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Occupational Risk Prevention, Hospital Sant Joan de Deu, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clusa Cuesta</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS, Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Jacklyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genitourinary Medicine and Infectious Diseases (GUIDe), St. James's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenny</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Galway University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krievins</LastName><ForeName>Dainis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pauls Stradins Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzdina</LastName><ForeName>Elza Anna</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Children Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melo</LastName><ForeName>Aryse</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosa</LastName><ForeName>Alma Gabriela</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miron</LastName><ForeName>Victor Daniel</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; National Institute for Mother and Child Care Alessandrescu Rusescu, Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Almagro</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institut de Recerca Sant Joan de Deu. Hospital Sant Joan de Deu, Barcelona, Spain; Ciber of Epidemiology and Public Health CIBERESP, Madrid,Spain; Medicine Department, Universitat internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milagro</LastName><ForeName>Ana Mar&#xed;a</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Research Group on Difficult to Diagnose and Treat Infections, Miguel Servet University Hospital, IIS, Aragon, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacci</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramarz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardone</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Epiconcept, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VEBIS HCW Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">Healthcare workers</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine effectiveness</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: APU reported payment under EMA DARWIN EU project outside of the submitted work. MLM, AM, LCC reported additional support received from ISIDORe (EATRIS) Network for carrying out the local SARS-CoV-2 sequencing. CPP reported speaker fees from Pfizer and MSD. SAF reported speaker fees from and participation in Advisory board of Pfizer, MSD and Gilead. CMA reported speaker fees from MSD, Pfizer and Sanofi. JS reported support for attending ESID conference 2022 from Takeda Pharmaceutical. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>27</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>26</Day><Hour>18</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39724693</ArticleId><ArticleId IdType="pmc">PMC11790529</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126615</ArticleId><ArticleId IdType="pii">S0264-410X(24)01297-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>European Centre for Disease Prevention and Control . Stockholm; ECDC: 2021. Assessment of the further emergence and potential impact of the SARS-CoV-2 omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 18th update - 15 December 2021; p. 2021.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Contro. Interim public health considerations for COVID-19 vaccination roll-out during 2023 [internet]. ECDC, Stockholm; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-interim-public-health-considerations-vaccination-2023.pdf.</Citation></Reference><Reference><Citation>Tamura T., Ito J., Uriu K., Zahradnik J., Kida I., Anraku Y., et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants. Nat Commun. 2023;14(1):2800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10187524</ArticleId><ArticleId IdType="pubmed">37193706</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 5 January 2024 [Internet] 2024. https://www.ecdc.europa.eu/en/covid-19/variants-concern Available from.</Citation></Reference><Reference><Citation>Yue C., Song W., Wang L., Jian F., Chen X., Gao F., et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis. 2023;23(3):278&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Uriu K., Ito J., Zahradnik J., Fujita S., Kosugi Y., Schreiber G., et al. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis. 2023;23(3):280&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9889095</ArticleId><ArticleId IdType="pubmed">36736338</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Faraone J.N., Evans J.P., Zheng Y.M., Carlin C., Anghelina M., et al. Enhanced evasion of neutralizing antibody response by omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. COVID-19 vaccines: authorised [Internet]. [cited 2022 Feb 18] 2024. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-vaccines-covid-19-authorised-medicines Available from.</Citation></Reference><Reference><Citation>Patel M.M., Jackson M.L., Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA. 2020;324(19):1939.</Citation><ArticleIdList><ArticleId IdType="pubmed">33064144</ArticleId></ArticleIdList></Reference><Reference><Citation>Savulescu C., Prats-Uribe A., Brolin K., Lovri&#x107; Makari&#x107; Z., Uusk&#xfc;la A., Panagiotakopoulos G., et al. Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023. Vaccines (Basel) 2024 Nov 19;12(11):1295. doi: 10.3390/vaccines12111295. PMID: 39591197; PMCID: PMC11598658.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12111295</ArticleId><ArticleId IdType="pmc">PMC11598658</ArticleId><ArticleId IdType="pubmed">39591197</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Health workers at risk, older adults and residents of long-term care facilities to be prioritized for COVID-19 vaccination [Internet]. [cited 2022 Feb 18] https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/11/health-workers-at-risk,-older-adults-and-residents-of-long-term-care-facilities-to-be-prioritized-for-covid-19-vaccination Available from:</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. [Internet]. Stockholm: ECDC. 2022. https://www.ecdc.europa.eu/sites/default/files/documents/Overview-of-COVID-19-vaccination-strategies-deployment-plans-in-the-EU-EEA-Jan-2022_1.pdf [cited 2022 Feb 18]. Available from.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. COVID-19 vaccination and prioritisation strategies in the EU/EEA. [Internet]. Stockholm: ECDC. 2020. https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf [cited 2022 Feb 18]. Available from.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 2.0 [internet]. ECDC, Stockholm. 2022. https://www.ecdc.europa.eu/en/publications-data/generic-protocol-ecdc-studies-covid-19-vaccine-effectiveness [cited 2023 Oct 9]. Available from:</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control. Reinfection with SARS-CoV-2: Implementation of a surveillance case definition within the EU/EEA. Stockholm. 2021. https://www.ecdc.europa.eu/sites/default/files/documents/Reinfection-with-SARSCoV2-implementation-of-a-surveillance-case-definition.pdf [Internet]. ECDC: Stockholm; 2021; 2021. Available from:</Citation></Reference><Reference><Citation>Kirwan P.D., Hall V.J., Foulkes S., Otter A.D., Munro K., Sparkes D., et al. Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort. Lancet Reg Health Eur. 2024;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10727938</ArticleId><ArticleId IdType="pubmed">38111727</ArticleId></ArticleIdList></Reference><Reference><Citation>Canetti M., Barda N., Gilboa M., Indenbaum V., Asraf K., Gonen T., et al. Six-month follow-up after a fourth BNT162b2 vaccine dose. N Engl J Med. 2022;387(22):2092&#x2013;2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9730934</ArticleId><ArticleId IdType="pubmed">36351266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha N.K., Burke P.C., Nowacki A.S., Simon J.F., Hagen A., Gordon S.M. 2022. Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine [Internet] [cited 2024 Apr 12]. Available from: http://medrxiv.org/lookup/doi/10.1101/2022.12.17.22283625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10234376</ArticleId><ArticleId IdType="pubmed">37274183</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants [Internet] 2023. https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants [cited 2024 Aug 19]. Available from.</Citation></Reference><Reference><Citation>Cohen M.J., Oster Y., Moses A.E., Spitzer A., Benenson S., Israeli-Hospitals 4th Vaccine Working Group, et al. Association of Receiving a fourth dose of the BNT162b vaccine with SARS-CoV-2 infection among health Care Workers in Israel. JAMA Netw Open. 2022;5(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9346545</ArticleId><ArticleId IdType="pubmed">35917125</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G., Gonen T., Gilboa M., Mandelboim M., Indenbaum V., Amit S., et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377&#x2013;1380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006792</ArticleId><ArticleId IdType="pubmed">35297591</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Ellebedy A.H. Immunological imprinting: understanding COVID-19. Immunity. 2023;56(5):909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113596</ArticleId><ArticleId IdType="pubmed">37105169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertz T., Levy S., Ostrovsky D., Oppenheimer H., Zismanov S., Kuzmina A., et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat Commun. 2023;14(1):4575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10387073</ArticleId><ArticleId IdType="pubmed">37516771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nealon J., Mefsin Y.M., McMenamin M.E., Ainslie K.E.C., Cowling B.J. Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe omicron disease in adults: a systematic review and meta-regression analysis. Vaccine X. 2024;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10877401</ArticleId><ArticleId IdType="pubmed">38379667</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MdO, Kamigaki T., Thandar M.M., Haruyama R., Yan F., Shibamura-Fujiogi M., et al. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 omicron subvariant: a systematic review and meta-analysis. BMJ Open. 2023;13(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10748972</ArticleId><ArticleId IdType="pubmed">38128943</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39727091</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2368-7959</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2024</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>JMIR mental health</Title><ISOAbbreviation>JMIR Ment Health</ISOAbbreviation></Journal><ArticleTitle>Implementing Findable, Accessible, Interoperable, Reusable (FAIR) Principles in Child and Adolescent Mental Health Research: Mixed Methods Approach.</ArticleTitle><Pagination><StartPage>e59113</StartPage><MedlinePgn>e59113</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e59113</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/59113</ELocationID><Abstract><AbstractText Label="BACKGROUND">The FAIR (Findable, Accessible, Interoperable, Reusable) data principles are a guideline to improve the reusability of data. However, properly implementing these principles is challenging due to a wide range of barriers.</AbstractText><AbstractText Label="OBJECTIVES">To further the field of FAIR data, this study aimed to systematically identify barriers regarding implementing the FAIR principles in the area of child and adolescent mental health research, define the most challenging barriers, and provide recommendations for these barriers.</AbstractText><AbstractText Label="METHODS">Three sources were used as input to identify barriers: (1) evaluation of the implementation process of the Observational Medical Outcomes Partnership Common Data Model by 3 data managers; (2) interviews with experts on mental health research, reusable health data, and data quality; and (3) a rapid literature review. All barriers were categorized according to type as described previously, the affected FAIR principle, a category to add detail about the origin of the barrier, and whether a barrier was mental health specific. The barriers were assessed and ranked on impact with the data managers using the Delphi method.</AbstractText><AbstractText Label="RESULTS">Thirteen barriers were identified by the data managers, 7 were identified by the experts, and 30 barriers were extracted from the literature. This resulted in 45 unique barriers. The characteristics that were most assigned to the barriers were, respectively, external type (n=32/45; eg, organizational policy preventing the use of required software), tooling category (n=19/45; ie, software and databases), all FAIR principles (n=15/45), and not mental health specific (n=43/45). Consensus on ranking the scores of the barriers was reached after 2 rounds of the Delphi method. The most important recommendations to overcome the barriers are adding a FAIR data steward to the research team, accessible step-by-step guides, and ensuring sustainable funding for the implementation and long-term use of FAIR data.</AbstractText><AbstractText Label="CONCLUSIONS">By systematically listing these barriers and providing recommendations, we intend to enhance the awareness of researchers and grant providers that making data FAIR demands specific expertise, available tooling, and proper investments.</AbstractText><CopyrightInformation>&#xa9; Rowdy de Groot, Frank van der Graaff, Dani&#xeb;l van der Doelen, Michiel Luijten, Ronald De Meyer, Hekmat Alrouh, Hedy van Oers, Jacintha Tieskens, Josjan Zijlmans, Meike Bartels, Arne Popma, Nicolette de Keizer, Ronald Cornet, Tinca J C Polderman. Originally published in JMIR Mental Health (https://mental.jmir.org).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Groot</LastName><ForeName>Rowdy</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1248-1986</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands, 31 648499049.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Graaff</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0002-1165-4600</Identifier><AffiliationInfo><Affiliation>Praktikon, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Doelen</LastName><ForeName>Dani&#xeb;l</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9530-1521</Identifier><AffiliationInfo><Affiliation>Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luijten</LastName><ForeName>Michiel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8016-2859</Identifier><AffiliationInfo><Affiliation>Emma Children's Hospital, Child and Adolescent Psychiatry &amp; Psychosocial Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Meyer</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3915-765X</Identifier><AffiliationInfo><Affiliation>Praktikon, Nijmegen, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alrouh</LastName><ForeName>Hekmat</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2224-149X</Identifier><AffiliationInfo><Affiliation>Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Oers</LastName><ForeName>Hedy</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7342-4953</Identifier><AffiliationInfo><Affiliation>Emma Children's Hospital, Child and Adolescent Psychiatry &amp; Psychosocial Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tieskens</LastName><ForeName>Jacintha</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6418-4852</Identifier><AffiliationInfo><Affiliation>Leiden University Medical Center Curium-Child and Adolescent Psychiatry, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zijlmans</LastName><ForeName>Josjan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4057-8440</Identifier><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry &amp; Psychosocial Care, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Meike</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9667-7555</Identifier><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popma</LastName><ForeName>Arne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2170-3023</Identifier><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry &amp; Psychosocial Care, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Levvel, Academic Center for Child and Adolescent Psychiatry, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Keizer</LastName><ForeName>Nicolette</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-6651-1730</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands, 31 648499049.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cornet</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1704-5980</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands, 31 648499049.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Digital Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Polderman</LastName><ForeName>Tinca J C</ForeName><Initials>TJC</Initials><Identifier Source="ORCID">0000-0001-5564-301X</Identifier><AffiliationInfo><Affiliation>Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Mental Health, Amsterdam University Medical Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leiden University Medical Center Curium-Child and Adolescent Psychiatry, Leiden University Medical Center, Leiden, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry &amp; Psychosocial Care, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Levvel, Academic Center for Child and Adolescent Psychiatry, Amsterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Ment Health</MedlineTA><NlmUniqueID>101658926</NlmUniqueID><ISSNLinking>2368-7959</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAIR data</Keyword><Keyword MajorTopicYN="N">FAIR principles</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">data interoperability</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">data standardization</Keyword><Keyword MajorTopicYN="N">health data</Keyword><Keyword MajorTopicYN="N">implementation</Keyword><Keyword MajorTopicYN="N">research data management</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>27</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39727091</ArticleId><ArticleId IdType="pmc">PMC11683739</ArticleId><ArticleId IdType="doi">10.2196/59113</ArticleId><ArticleId IdType="pii">v11i1e59113</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3(1):160018. doi: 10.1038/sdata.2016.18. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair principles.  [23-08-2024]. https://www.go-fair.org/fairprinciples/ URL. Accessed.</Citation></Reference><Reference><Citation>van Reisen M, Stokmans M, Basajja M, Ong&#x2019;ayo AO, Kirkpatrick C, Mons B. Towards the tipping point for FAIR implementation. Data Intelligence. 2020 Jan;2(1-2):264&#x2013;275. doi: 10.1162/dint_a_00049. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kersloot MG, Abu-Hanna A, Cornet R, Arts DL. Perceptions and behavior of clinical researchers and research support staff regarding data FAIRification. Sci Data. 2022 May 27;9(1):241. doi: 10.1038/s41597-022-01325-2. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01325-2</ArticleId><ArticleId IdType="pmc">PMC9142513</ArticleId><ArticleId IdType="pubmed">35624282</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia L, Bolleman J, Gehant S, Redaschi N, Martin M, UniProt Consortium FAIR adoption, assessment and challenges at UniProt. Sci Data. 2019 Sep 20;6(1):175. doi: 10.1038/s41597-019-0180-9. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-019-0180-9</ArticleId><ArticleId IdType="pmc">PMC6754384</ArticleId><ArticleId IdType="pubmed">31541106</ArticleId></ArticleIdList></Reference><Reference><Citation>Queralt-Rosinach N, Kaliyaperumal R, Bernab&#xe9; CH, et al. Applying the FAIR principles to data in a hospital: challenges and opportunities in a pandemic. J Biomed Semantics. 2022 Dec;13(1):1&#x2013;19. doi: 10.1186/s13326-022-00263-7. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-022-00263-7</ArticleId><ArticleId IdType="pmc">PMC9036506</ArticleId><ArticleId IdType="pubmed">35468846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano R, Fullman N, Mumford JE, et al. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990&#x2013;2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct;396(10258):1250&#x2013;1284. doi: 10.1016/S0140-6736(20)30750-9. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30750-9</ArticleId><ArticleId IdType="pmc">PMC7562819</ArticleId><ArticleId IdType="pubmed">32861314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacellar IOL, Morin G, Daniels S, Turecki G, Palaniyappan L, Lepage M. Opening up mental health research. J Psychiatry Neurosci. 2023;48(3):E209&#x2013;E216. doi: 10.1503/jpn.220199. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/jpn.220199</ArticleId><ArticleId IdType="pmc">PMC10234619</ArticleId><ArticleId IdType="pubmed">37253483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeh Y, Denejkina A, Karyotaki E, Lenferink LIM, Kassam-Adams N. Opportunities for improving data sharing and FAIR data practices to advance global mental health&#x2013;Corrigendum. Glob Ment Health (Camb) 2023;10:e14. doi: 10.1017/gmh.2023.14. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/gmh.2023.14</ArticleId><ArticleId IdType="pmc">PMC10581864</ArticleId><ArticleId IdType="pubmed">37860102</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6(6):e20476. doi: 10.1371/journal.pone.0020476. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020476</ArticleId><ArticleId IdType="pmc">PMC3111406</ArticleId><ArticleId IdType="pubmed">21694759</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI  Standardized data: the OMOP common data model.  [16-06-2022]. https://www.ohdsi.org/data-standardization URL. Accessed.</Citation></Reference><Reference><Citation>Haverman L, van Oers HA, Limperg PF, et al. Implementation of electronic patient reported outcomes in pediatric daily clinical practice: the KLIK experience. Clin Pract Pediatr Psychol. 2014;2(1):50&#x2013;67. doi: 10.1037/cpp0000043. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/cpp0000043</ArticleId></ArticleIdList></Reference><Reference><Citation>DE LERENDE DATABANK JEUGD, DE-LERENDE-DATABANK-JEUGD.pdf [The learning database youth] 2020. https://www.praktikon.nl/ uploaded/publicaties/ De-Lerende-Databank-Jeugd.pdf URL.</Citation></Reference><Reference><Citation>Sejn.  [30-08-2022]. https://www.sejn.nl URL. Accessed.</Citation></Reference><Reference><Citation>Zijlmans J, Tieskens JM, van Oers HA, et al. The effects of COVID-19 on child mental health: biannual assessments up to April 2022 in a clinical and two general population samples. JCPP Adv. 2023 Jun;3(2):e12150. doi: 10.1002/jcv2.12150. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcv2.12150</ArticleId><ArticleId IdType="pmc">PMC10519731</ArticleId><ArticleId IdType="pubmed">37753155</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer K, Tieskens JM, Luijten MAJ, et al. Internalizing problems before and during the COVID-19 pandemic in independent samples of Dutch children and adolescents with and without pre-existing mental health problems. Eur Child Adolesc Psychiatry. 2023 Oct;32(10):1873&#x2013;1883. doi: 10.1007/s00787-022-01991-y. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00787-022-01991-y</ArticleId><ArticleId IdType="pmc">PMC9133820</ArticleId><ArticleId IdType="pubmed">35616715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantril H. Pattern of Human Concerns. Rutgers University Press; 1965.</Citation></Reference><Reference><Citation>Vermulst A, Kroes G, De Meyer R, Nguyen L, Veerman JW. Handleiding OBVL, Eburon Uitgeverij BV [Manual PSQ (Parenting Stress Questionnaire)] 2015</Citation></Reference><Reference><Citation>Klaufus LH, Luijten MAJ, Verlinden E, et al. Psychometric properties of the Dutch-Flemish PROMIS&#xae; pediatric item banks anxiety and depressive symptoms in a general population. Qual Life Res. 2021 Sep;30(9):2683&#x2013;2695. doi: 10.1007/s11136-021-02852-y. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-021-02852-y</ArticleId><ArticleId IdType="pubmed">33983618</ArticleId></ArticleIdList></Reference><Reference><Citation>Extract transform load.  [19-07-2023]. https://ohdsi.github.io/TheBookOfOhdsi/ExtractTransformLoad.html URL. Accessed.</Citation></Reference><Reference><Citation>Data quality.  [19-07-2023]. https://ohdsi.github.io/TheBookOfOhdsi/DataQuality.html URL. Accessed.</Citation></Reference><Reference><Citation>OHDSI analytics tools.  [19-07-2023]. https://ohdsi.github.io/TheBookOfOhdsi/OhdsiAnalyticsTools.html URL. Accessed.</Citation></Reference><Reference><Citation>Cabana MD, Rand CS, Powe NR, et al. Why don&#x2019;t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999 Oct 20;282(15):1458&#x2013;1465. doi: 10.1001/jama.282.15.1458. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.15.1458</ArticleId><ArticleId IdType="pubmed">10535437</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;nger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017 Sep;31(8):684&#x2013;706. doi: 10.1177/0269216317690685. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269216317690685</ArticleId><ArticleId IdType="pubmed">28190381</ArticleId></ArticleIdList></Reference><Reference><Citation>Krippendorff K. Computing krippendorff&#x2019;s alpha-reliability.  [21-03-2024];2011  https://citeseerx.ist.psu.edu/document?repid=rep1&amp;amp;type=pdf&amp;amp;doi=de8e2c7b7992028cf035f8d907635de871ed627d URL. Accessed.</Citation></Reference><Reference><Citation>Krippendorff K. Content Analysis: An Introduction to Its Methodology. Sage Publications; 2018. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.4135/9781071878781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wel of niet WMO-plichtig? Amsterdam Universitair Medische Centra.  [11-12-2024]. https://metc.amsterdamumc.org/wel-of-niet-wmo-plichtig/ URL. Accessed.</Citation></Reference><Reference><Citation>Groenen KHJ, Jacobsen A, Kersloot MG, et al. The de novo FAIRification process of a registry for vascular anomalies. Orphanet J Rare Dis. 2021 Sep 4;16(1):376. doi: 10.1186/s13023-021-02004-y. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-02004-y</ArticleId><ArticleId IdType="pmc">PMC8418729</ArticleId><ArticleId IdType="pubmed">34481493</ArticleId></ArticleIdList></Reference><Reference><Citation>Overmars LM, Niemantsverdriet MSA, Groenhof TKJ, et al. A wolf in sheep&#x2019;s clothing: reuse of routinely obtained laboratory data in research. J Med Internet Res. 2022 Nov 18;24(11):e40516. doi: 10.2196/40516. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/40516</ArticleId><ArticleId IdType="pmc">PMC9719056</ArticleId><ArticleId IdType="pubmed">36399373</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J, de Barron AG, Splendiani A, et al. Implementation and relevance of FAIR data principles in biopharmaceutical R&amp;D. Drug Discov Today. 2019 Apr;24(4):933&#x2013;938. doi: 10.1016/j.drudis.2019.01.008. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2019.01.008</ArticleId><ArticleId IdType="pubmed">30690198</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi E, Gadiya Y, Henderson D, et al. Selection of data sets for FAIRification in drug discovery and development: which, why, and how? Drug Discov Today. 2022 Aug;27(8):2080&#x2013;2085. doi: 10.1016/j.drudis.2022.05.010. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.05.010</ArticleId><ArticleId IdType="pmc">PMC9236643</ArticleId><ArticleId IdType="pubmed">35595012</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi E, Skeva R, Juty N, Jay C, Goble C. Exploring the current practices, costs and benefits of FAIR implementation in pharmaceutical research and development: a qualitative interview study. Data Intell. 2021 Oct 25;3(4):507&#x2013;527. doi: 10.1162/dint_a_00109. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00109</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vlijmen H, Mons A, Waalkens A, et al. The need of industry to Go FAIR. Data Intell. 2020 Jan;2(1-2):276&#x2013;284. doi: 10.1162/dint_a_00050. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00050</ArticleId></ArticleIdList></Reference><Reference><Citation>Arefolov A, Adam L, Brown S, et al. Implementation of the FAIR data principles for exploratory biomarker data from clinical trials. Data Intell. 2021 Oct 25;3(4):631&#x2013;662. doi: 10.1162/dint_a_00106. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00106</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen A, de Miranda Azevedo R, Juty N, et al. FAIR principles: interpretations and implementation considerations. Data Intell. 2020 Jan;2(1-2):10&#x2013;29. doi: 10.1162/dint_r_00024. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_r_00024</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburg M, Braukmann R, Mahabier W. Making Qualitative Data Reusable&#x2014; A Short Guidebook for Researchers and Data Stewards Working With Qualitative Data. 2023 doi: 10.5281/zenodo.7777519. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.7777519</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholtens S, Jetten M, B&#xf6;hmer J, et al.  Final report: towards FAIR data steward as profession for the lifesciences. Report of a ZonMw funded collaborative approach built on existing expertise.  [19-07-2023];2022  doi: 10.5281/zenodo.7225070. https://doi.org/10.5281/zenodo.7225070 URL. Accessed. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.7225070</ArticleId><ArticleId IdType="doi">10.5281/zenodo.7225070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendelborn C, Anger M, Schickhardt C. What is data stewardship? Towards a comprehensive understanding. J Biomed Inform. 2023 Apr;140:104337. doi: 10.1016/j.jbi.2023.104337. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2023.104337</ArticleId><ArticleId IdType="pubmed">36935012</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt C, Biernacka K, Coffey A, et al.  D7.4 how to be FAIR with your data. A teaching and training handbook for higher education institutions.  [24-07-2023];Zenodo. 2022  doi: 10.17875/gup2022-1915. https://doi.org/10.5281/zenodo.6674301 URL. Accessed. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.6674301</ArticleId><ArticleId IdType="doi">10.17875/gup2022-1915</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen A, Kaliyaperumal R, da Silva Santos LOB, et al. A generic workflow for the data FAIRification process. Data Intell. 2020 Jan;2(1-2):56&#x2013;65. doi: 10.1162/dint_a_00028. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/dint_a_00028</ArticleId></ArticleIdList></Reference><Reference><Citation>FAIRification Workflow.  [28-08-2024]. https://fairtoolkit.pistoiaalliance.org/methods/fairification-workflow URL. Accessed.</Citation></Reference><Reference><Citation>The FAIR cookbook.  [24-07-2023]. https://faircookbook.elixir-europe.org/content/home.html URL. Accessed.</Citation></Reference><Reference><Citation>Rocca-Serra P, Sansone SA. Experiment design driven FAIRification of omics data matrices, an exemplar. Sci Data. 2019 Dec 12;6(1):271. doi: 10.1038/s41597-019-0286-0. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-019-0286-0</ArticleId><ArticleId IdType="pmc">PMC6908569</ArticleId><ArticleId IdType="pubmed">31831744</ArticleId></ArticleIdList></Reference><Reference><Citation>USCDI+  [21-03-2024]. https://www.healthit.gov/topic/interoperability/uscdi-plus URL. Accessed.</Citation></Reference><Reference><Citation>van Damme P, Moreno PA, Bernab&#xe9; CH, et al. A resource for guiding data stewards to make European rare disease patient registries FAIR. Data Sci J. 2023 Jun 5;22 doi: 10.5334/dsj-2023-012. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/dsj-2023-012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer G, M&#xfc;ller W, Schork K, et al. Implementing FAIR data management within the German Network for Bioinformatics Infrastructure (de.NBI) exemplified by selected use cases. Brief Bioinform. 2021 Sep 2;22(5):bbab010. doi: 10.1093/bib/bbab010. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab010</ArticleId><ArticleId IdType="pmc">PMC8425304</ArticleId><ArticleId IdType="pubmed">33589928</ArticleId></ArticleIdList></Reference><Reference><Citation>FAIR  FAIR implementation profile.  [19-07-2023]. https://www.go-fair.org/how-to-go-fair/fair-implementation-profile/ URL. Accessed.</Citation></Reference><Reference><Citation>Schultes E, Magagna B, Hettne KM, Pergl R, Such&#xb4;anek M, Kuhn T. Reusable FAIR implementation profiles as accelerators of FAIR convergence. International Conference on Conceptual Modeling; 2020; pp. 138&#x2013;147. Presented at. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-65847-2_13</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39732354</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>161</Volume><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Repeatable process for extracting health data from HL7 CDA documents.</ArticleTitle><Pagination><StartPage>104765</StartPage><MedlinePgn>104765</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2024.104765</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(24)00183-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study aims to address the gap in the literature on converting real-world Clinical Document Architecture (CDA) data into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), focusing on the initial steps preceding the mapping phase. We highlight the importance of a repeatable Extract-Transform-Load (ETL) pipeline for health data extraction from HL7 CDA documents in Estonia for research purposes.</AbstractText><AbstractText Label="METHODS">We developed a repeatable ETL pipeline to facilitate the extraction, cleaning, and restructuring of health data from CDA documents to OMOP CDM, ensuring a high-quality and structured data format. This pipeline was designed to adapt to continuously updated data exchange format changes and handle various CDA document subsets for different scientific studies.</AbstractText><AbstractText Label="RESULTS">We demonstrated via selected use cases that our pipeline successfully transformed a significant portion of diagnosis codes, body weight and eGFR measurements, and PAP test results from CDA documents into OMOP CDM, showing the ease of extracting structured data. However, challenges such as harmonising diverse coding systems and extracting lab results from free-text sections were encountered. The iterative development of the pipeline facilitated swift error detection and correction, enhancing the process's efficiency.</AbstractText><AbstractText Label="CONCLUSION">After a decade of focused work, our research has led to the development of an ETL pipeline that effectively transforms HL7 CDA documents into OMOP CDM in Estonia, addressing key data extraction and transformation challenges. The pipeline's repeatability and adaptability to various data subsets make it a valuable resource for researchers dealing with health data. While tested on Estonian data, the principles outlined are broadly applicable, potentially aiding in handling health data standards that vary by country. Despite newer health data standards emerging, the relevance of CDA for retrospective health studies ensures the continuing importance of this work.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talvik</LastName><ForeName>Harry-Anton</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; STACC, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oja</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamm</LastName><ForeName>Sirli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mooses</LastName><ForeName>Kerli</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia. Electronic address: kerli.mooses@ut.ee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe4;rg</LastName><ForeName>Dage</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; Estonian Genome Centre, Institute of Genomics, University of Tartu, 51010 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf5;o</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; Institute of Mathematics and Statistics, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renata Siimon</LastName><ForeName>&#xd5;ie</ForeName><Initials>&#xd5;</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x160;uvalov</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilo</LastName><ForeName>Jaak</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; STACC, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>Sulev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; STACC, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laur</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, 51009 Tartu, Estonia; STACC, 51009 Tartu, Estonia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="Y">Health Level Seven</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004957" MajorTopicYN="N" Type="Geographic">Estonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="Y">Data Mining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">HL7 Clinical Document Architecture</Keyword><Keyword MajorTopicYN="N">NLP</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Pipeline</Keyword><Keyword MajorTopicYN="N">Workflow</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>16</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>29</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>28</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39732354</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2024.104765</ArticleId><ArticleId IdType="pii">S1532-0464(24)00183-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39733180</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>28</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study.</ArticleTitle><Pagination><StartPage>31477</StartPage><MedlinePgn>31477</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">31477</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-83321-7</ELocationID><Abstract><AbstractText>Proton pump inhibitors (PPIs) are among the most widely used drugs worldwide. However, their influence on the progression of end-stage kidney disease (ESKD) in established chronic kidney disease (CKD) cases is unclear. Using the Korean Health Insurance Review and Assessment database encoded by the Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM), patients with stage 3 or 4 CKD initiating PPIs or histamine-2 receptor antagonists (H2RAs) for over 90&#xa0;days were enrolled from 2012 through 2021. Incidence of ESKD events between the groups were compared using a cox proportional hazard model. A total of 34,656 eligible patients were included. Of the patients, 65.1% had CKD stage 3, 44.5% aged&#x2009;&gt;&#x2009;75&#xa0;years, 59.8% were male individuals, and 68.3% had diabetes. After 1:1 propensity score matching, ESKD progression was observed in 2327 out of 19,438 patients and it was more frequent in PPI users (incidence rate, 10.5/100PYs) than that in H2RA users (incidence rate, 9.2/100PYs; IRR, 1.14 [1.07-1.12]). Using the subgroup analysis, IRR was significantly higher in patients with CKD stage 3 (IRR 1.40 [1.21-1.60]), whereas it was not in those with CKD stage 4 (IRR 1.04 [0.94-1.15]). A similar trend was observed in patients with CKD 3 or 4 with and without diabetes. In general, PPI use is associated with a 14% higher risk of ESKD progression in patients with CKD stage 3 or 4. However, the influence of PPIs differed according to the comorbidities and risks of adverse kidney outcomes.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yu Jeong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pusan National University Hospital, Busan, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Pharmacy, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinmi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Clinical Trial Center, Biomedical Research Institute, Busan National University Hospital, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Dong Han</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Health Insurance Review and Assessment Service, W&#x14f;nju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Je</LastName><ForeName>Nam Kyung</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Pusan National University, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Harin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea. rheeharin@pusan.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Biomedical Research Institute, Pusan National University Hospital, 305 Gudeok-Ro, Seo-Gu, Busan, 602-739, South Korea. rheeharin@pusan.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>202400620001</GrantID><Agency>Biomedical Research Institute Grant Pusan National University Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006635">Histamine H2 Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006635" MajorTopicYN="N">Histamine H2 Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">End stage kidney disease</Keyword><Keyword MajorTopicYN="N">Follow-up studies</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Proton pump inhibitors</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Approval to perform the analyses was obtained with a waiver of informed consent from the Pusan National University IRB Committee [PNUH IRB 2308-021-130].</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>29</Day><Hour>0</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39733180</ArticleId><ArticleId IdType="pmc">PMC11682415</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-83321-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-83321-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shanika, L. G. T., Reynolds, A., Pattison, S. &amp; Braund, R. Proton pump inhibitor use: Systematic review of global trends and practices. Eur. J. Clin. Pharmacol.79, 1159&#x2013;1172 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427555</ArticleId><ArticleId IdType="pubmed">37420019</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE Guideline cg184. 2019 Surveillance of Gastro-Oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31935049</ArticleId></ArticleIdList></Reference><Reference><Citation>Statista. Leading chemical substances dispensed in England in 2022. https://www.statista.com/statistics/378445/prescription-cost-analysis-top-twenty-chemicals-by-items-in-england/.</Citation></Reference><Reference><Citation>ClinCalc, L. L. C. Drug usage statistics, United States (2013&#x2013;2021). https://clincalc.com/DrugStats/Drugs/Omeprazole.</Citation></Reference><Reference><Citation>Oh, J.-A., Lee, G.-M., Chung, S.-Y., Cho, Y.-S. &amp; Lee, H.-J. Utilization trends of proton pump inhibitors in South Korea: Analysis using 2016&#x2013;2020 Healthcare Bigdata Hub by Health Insurance Review and Assessment Service. Yakhak Hoeji65, 276&#x2013;283 (2021).</Citation></Reference><Reference><Citation>Koyyada, A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie76, 13&#x2013;21 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32718584</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly, Z., Maddukuri, G. &amp; Xie, Y. Proton pump inhibitors and the kidney: Implications of current evidence for clinical practice and when and how to deprescribe. Am. J. Kidney Dis.75, 497&#x2013;507 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31606235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med.176, 238&#x2013;246 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772730</ArticleId><ArticleId IdType="pubmed">26752337</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora, P. et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol.17, 112 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973085</ArticleId><ArticleId IdType="pubmed">27487959</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y. et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J. Am. Soc. Nephrol.27, 3153&#x2013;3163 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042677</ArticleId><ArticleId IdType="pubmed">27080976</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, Y. C. et al. Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: A population-based, case-control study. Med. (Baltim).95, e3363 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4839840</ArticleId><ArticleId IdType="pubmed">27082596</ArticleId></ArticleIdList></Reference><Reference><Citation>Klatte, D. C. F. et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology153, 702&#x2013;710 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28583827</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.</Citation></Reference><Reference><Citation>Kim, D. H. et al. Kidney Health Plan 2033 in Korea: Bridging the gap between the present and the future. Kidney Res. Clin. Pract.43, 8&#x2013;19 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846987</ArticleId><ArticleId IdType="pubmed">38311359</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, H. J. et al. Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. PLOS One13, e0207561 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231691</ArticleId><ArticleId IdType="pubmed">30419006</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant, C. H. et al. Proton pump inhibitor use and progression to major adverse renal events: A competing risk analysis. Q. J. M.112, 835&#x2013;840 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31251364</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholin, L. et al. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol.22, 264 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8281649</ArticleId><ArticleId IdType="pubmed">34266395</ArticleId></ArticleIdList></Reference><Reference><Citation>Liabeuf, S. et al. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study. Br. J. Clin. Pharmacol.87, 2967&#x2013;2976 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33368448</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. W. et al. Scalable infrastructure supporting reproducible nationwide healthcare data analysis toward FAIR stewardship. Sci. Data10, 674 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10550904</ArticleId><ArticleId IdType="pubmed">37794003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyoung, D. S. &amp; Kim, H. S. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review &amp; Assessment (HIRA) database for research. J. Lipid Atheroscler.11, 103&#x2013;110 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9133780</ArticleId><ArticleId IdType="pubmed">35656154</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. et al. Health-analytics data to evidence suite (HADES): Open-source software for observational research. Stud. Health Technol. Inform.310, 966&#x2013;970 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>Muriithi, A. K. et al. Biopsy-proven acute interstitial nephritis, 1993&#x2013;2011: A case series. Am. J. Kidney Dis.64, 558&#x2013;566 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24927897</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou, T. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open3, E166&#x2013;E171 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4571830</ArticleId><ArticleId IdType="pubmed">26389094</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med.383, 1436&#x2013;1446 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>The EMPA-KIDNEY Collaborative Group et al. Empagliflozin in patients with chronic kidney disease. N. Engl. J. Med.388, 117&#x2013;127 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7614055</ArticleId><ArticleId IdType="pubmed">36331190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39739635</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1752-8062</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical and translational science</Title><ISOAbbreviation>Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine-based approach in diverse healthcare systems.</ArticleTitle><Pagination><StartPage>e70105</StartPage><MedlinePgn>e70105</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.70105</ELocationID><Abstract><AbstractText>Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under-recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at-risk patients accurately. Our work aims to rapidly identify NAFLD patients within large electronic health record (EHR) databases for automated stratification and targeted intervention based on clinically relevant phenotypes. We present a rule-based phenotyping algorithm for efficient identification of NAFLD patients developed using EHRs from 6.4 million patients at Columbia University Irving Medical Center (CUIMC) and validated at two independent healthcare centers. The algorithm uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model and queries structured and unstructured data elements, including diagnosis codes, laboratory measurements, and radiology and pathology modalities. Our approach identified 16,006 CUIMC NAFLD patients, 10,753 (67%) previously unidentifiable by NAFLD diagnosis codes. Fibrosis scoring on patients without histology identified 943 subjects with scores indicative of advanced fibrosis (FIB-4, APRI, NAFLD-FS). The algorithm was validated at two independent healthcare systems, University of Pennsylvania Health System (UPHS) and Vanderbilt Medical Center (VUMC), where 20,779 and 19,575 NAFLD patients were identified, respectively. Clinical chart review identified a high positive predictive value (PPV) across all healthcare systems: 91% at CUIMC, 75% at UPHS, and 85% at VUMC, and a sensitivity of 79.6%. Our rule-based algorithm provides an accurate, automated approach for rapidly identifying, stratifying, and sub-phenotyping NAFLD patients within a large EHR system.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Basile</LastName><ForeName>Anna O</ForeName><Initials>AO</Initials><Identifier Source="ORCID">0000-0001-5112-5880</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computational Biology, New York Genome Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Anurag</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5063-9107</Identifier><AffiliationInfo><Affiliation>Division of Translational Medicine and Human Genetics, Department of Medicine, Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Leigh Anne</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-6431-6069</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serper</LastName><ForeName>Marina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4899-2160</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scanga</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2416-8687</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Ava</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, New York Presbyterian Morgan Stanley Children's Hospital of New York, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Destin</LastName><ForeName>Brittney</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Metabolic and Bariatric Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Rotonya M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anyanwu-Ofili</LastName><ForeName>Anuli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine, Spring House, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopal</LastName><ForeName>Gunaretnam</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-0111-1936</Identifier><AffiliationInfo><Affiliation>Johnson &amp; Johnson Innovative Medicine, Spring House, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Samsara BioCapital, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krikhely</LastName><ForeName>Abraham</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-0809-2999</Identifier><AffiliationInfo><Affiliation>Division of Metabolic and Bariatric Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bessler</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-4291-2222</Identifier><AffiliationInfo><Affiliation>Division of Metabolic and Bariatric Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reilly</LastName><ForeName>Muredach P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-3035-9386</Identifier><AffiliationInfo><Affiliation>Irving Institute for Clinical and Translational Research, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritchie</LastName><ForeName>Marylyn D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-1208-1720</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0002-2700-2597</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wattacheril</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0368-0860</Identifier><AffiliationInfo><Affiliation>Division of Digestive and Liver Diseases, Department of Medicine, Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Janssen Research and Development; National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001873</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001878</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35GM131905</GrantID><Agency>US National Institutes of Health</Agency><Country/></Grant><Grant><GrantID>2R01AA026302</GrantID><Agency>US National Institutes of Health</Agency><Country/></Grant><Grant><GrantID>R01GM138597</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG010067</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HG012670</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK132138</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK131547</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Sci</MedlineTA><NlmUniqueID>101474067</NlmUniqueID><ISSNLinking>1752-8054</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008103" MajorTopicYN="N">Liver Cirrhosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Patent for algorithm to Columbia University Trustees; &#xa9; 2021 The Trustees of Columbia University in the City of New York. The owner has no objection to reproduction of the work for academic non&#x2010;commercial purposes, but otherwise reserves all copyright rights whatsoever. J.W., N.P.T. and A.O.B. are co&#x2010;inventors. J.W. has received research support from Janssen, Galectin, Intercept, Genfit, Shire, Conatus, Zydus, AMRA, and is on advisory boards for GlaxoSmithKline and AstraZeneca. R.M.C. has received research support from Intercept Pharmaceuticals and Merck, Inc., and consulting fees from Intercept and AstraZeneca. M.S. is funded by NIDDK R01DK132138, R01DK131547 and has an unrestricted grant from Grifols, SA. A.K. is a speaker and proctor for Intuitive, a reviewer for surgical videos for Crowd Sourced Assessment of Technical Skills (CSATs), and a consultant for Johnson and Johnson and Surgical Specialties Corporation. G.R. retired from Janssen Pharma R&amp;D as Scientific Fellow and Head of Computational Sciences and is currently a Venture Partner in Samsara BioCapital, Palo Alto, CA. All other authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>1</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>31</Day><Hour>13</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39739635</ArticleId><ArticleId IdType="pmc">PMC11686338</ArticleId><ArticleId IdType="doi">10.1111/cts.70105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Younossi Z, Anstee QM, Marietti M, et&#xa0;al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930295</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi H, Brown RS, Lim JK, et&#xa0;al. Precipitous changes in nomenclature and definitions&#x2010;NAFLD becomes SLD: implications for and expectations of AASLD journals. Hepatology. 2023;78:1680&#x2010;1681.</Citation><ArticleIdList><ArticleId IdType="pubmed">37941421</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M, Loomis AK, Fairburn&#x2010;Beech J, et&#xa0;al. Real&#x2010;world data reveal a diagnostic gap in non&#x2010;alcoholic fatty liver disease. BMC Med. 2018;16:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088429</ArticleId><ArticleId IdType="pubmed">30099968</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SA, Pierre B, Guy CD, et&#xa0;al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497&#x2010;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">38324483</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5767767</ArticleId><ArticleId IdType="pubmed">28802062</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal AJ, Van Natta ML, Clark J, et&#xa0;al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559&#x2010;1569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8881985</ArticleId><ArticleId IdType="pubmed">34670043</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Eyler AE, Denny JC. Intelligent use and clinical benefits of electronic health records in rheumatoid arthritis. Expert Rev Clin Immunol. 2015;11:329&#x2010;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4518025</ArticleId><ArticleId IdType="pubmed">25660652</ArticleId></ArticleIdList></Reference><Reference><Citation>Basile AO, Ritchie MD. Informatics and machine learning to define the phenotype. Expert Rev Mol Diagn. 2018;18:219&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080627</ArticleId><ArticleId IdType="pubmed">29431517</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey KE, Kartoun U, Zheng H, Chung RT, Shaw SY. Using an electronic medical records database to identify non&#x2010;traditional cardiovascular risk factors in nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:671&#x2010;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864030</ArticleId><ArticleId IdType="pubmed">26925881</ArticleId></ArticleIdList></Reference><Reference><Citation>DeRouen TA. Promises and pitfalls in the use of &#x201c;big data&#x201d; for clinical research. J Dent Res. 2015;94:107S&#x2010;109S.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991650</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vleck TT, Chan L, Coca SG, et&#xa0;al. Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non&#x2010;alcoholic fatty liver disease at risk for disease progression. Int J Med Inform. 2019;129:334&#x2010;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717556</ArticleId><ArticleId IdType="pubmed">31445275</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey KE, Kartoun U, Zheng H, Shaw SY. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci. 2016;61:913&#x2010;919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761309</ArticleId><ArticleId IdType="pubmed">26537487</ArticleId></ArticleIdList></Reference><Reference><Citation>Eremi&#x107;&#x2010;Koji&#x107; N, &#x110;eri&#x107; M, Govor&#x10d;in M, Bala&#x107; D, Kresoja M, Koji&#x107;&#x2010;Damjanov S. Assessment of hepatic steatosis algorithms in non&#x2010;alcoholic fatty liver disease. Hippokratia. 2018;22:10&#x2010;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528695</ArticleId><ArticleId IdType="pubmed">31213752</ArticleId></ArticleIdList></Reference><Reference><Citation>
CCHMC
. Non&#x2010;alcoholic fatty liver disease (NAFLD) &amp; alcoholic fatty liver disease (ALD). PheKB; 2016. Accessed September 03, 2021. https://phekb.org/phenotype/588
</Citation></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the all of us research program: transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14:e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et&#xa0;al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et&#xa0;al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA. 2016;113:7329&#x2010;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C, Sedlmayr M, Bathelt F. The usage of OHDSI OMOP &#x2013; a scoping review. Ger Med Data Sci. 2021;2021:95&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chelico JD, Wilcox AB, Vawdrey DK, et&#xa0;al. Designing a clinical data warehouse architecture to support quality improvement initiatives. AMIA Annu Symp Proc. 2017;2016:381&#x2010;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333328</ArticleId><ArticleId IdType="pubmed">28269833</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalasani N, Younossi Z, Lavine JE, et&#xa0;al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328&#x2010;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">28714183</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhdanpaa HT, Tan WK, Rundell SD, et&#xa0;al. Using natural language processing of free&#x2010;text radiology reports to identify type 1 Modic endplate changes. J Digit Imaging. 2018;31:84&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5788819</ArticleId><ArticleId IdType="pubmed">28808792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling RK, Lissen E, Clumeck N, et&#xa0;al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317&#x2010;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16729309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z&#x2010;H, Xin Y&#x2010;N, Dong Q&#x2010;J, et&#xa0;al. Performance of the aspartate aminotransferase&#x2010;to&#x2010;platelet ratio index for the staging of hepatitis C&#x2010;related fibrosis: an updated meta&#x2010;analysis. Hepatology. 2011;53:726&#x2010;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">21319189</ArticleId></ArticleIdList></Reference><Reference><Citation>Angulo P, Hui JM, Marchesini G, et&#xa0;al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846&#x2010;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">17393509</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi ZM, Golabi P, de Avila L, et&#xa0;al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta&#x2010;analysis. J Hepatol. 2019;71:793&#x2010;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">31279902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattacheril J. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gastroenterol Clin North Am. 2020;49:141&#x2010;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033760</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinella ME, Neuschwander&#x2010;Tetri BA, Siddiqui MS, et&#xa0;al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797&#x2010;1835. doi:10.1097/HEP.0000000000000323</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HEP.0000000000000323</ArticleId><ArticleId IdType="pmc">PMC10735173</ArticleId><ArticleId IdType="pubmed">36727674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39753061</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>195</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>ATC-to-RxNorm mappings - A comparison between OHDSI Standardized Vocabularies and UMLS Metathesaurus.</ArticleTitle><Pagination><StartPage>105777</StartPage><MedlinePgn>105777</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2024.105777</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(24)00440-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The World Health Organization global standard for representing drug data is the Anatomical Therapeutic Chemical (ATC) classification. However, it does not represent ingredients and other drug properties required by clinical decision support systems. A mapping to a terminology system that contains this information, like RxNorm, may help fill this gap. This work evaluates and compares the completeness of mappings from the chemical substance level (5th-level) ATC classes to RxNorm ingredient concepts in the OHDSI Standardized Vocabularies (OSV) and the Unified Medical Language System (UMLS) Metathesaurus.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To check the concordance between OSV and UMLS we compared the included contents of ATC and RxNorm not only in OSV and UMLS but also in BioPortal and the National Library of Medicine (NLM) repository. For each repository, we determined the number of 5th-level ATC concepts, RxNorm ingredient concepts, missing classes and concepts, and the ATC categories with the most missing concepts. The mappings from ATC to RxNorm in OSV and UMLS were compared, and we determined the number of mappings in common, and the mapping differences, which we categorized. We applied the mappings from OSV and UMLS on a sample of Electronic Health Record (EHR) data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">NLM contained the most ATC and RxNorm concepts. UMLS contained more missing mappings (null mappings) than OSV, 1949 versus 916. Most mapping differences were in the "unknown ingredient in the ATC label" category, for which UMLS provided no mappings. UMLS had a higher coverage of mappings in the sample EHR data than OSV, 96.5% versus 91%.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In conclusion, opting for OSV rather than UMLS is generally preferable for an ATC to RxNorm mapping since OSV provides more mappings. However, the results of the sample data show that UMLS can have fewer null mappings in concrete applications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Groot</LastName><ForeName>Rowdy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, the Netherlands; Methodology, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands. Electronic address: rowdy.degroot@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaser</LastName><ForeName>Savannah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, the Netherlands; Methodology, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kogan</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Information Systems, University of Haifa, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medlock</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, the Netherlands; Methodology, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alloni</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomeris S.r.l., Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabetta</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomeris S.r.l., Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilk</LastName><ForeName>Szymon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Computing Science, Poznan University of Technology, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Keizer</LastName><ForeName>Nicolette</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, the Netherlands; Methodology, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornet</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Amsterdam UMC location University of Amsterdam, Department of Medical Informatics, Amsterdam, the Netherlands; Methodology, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017432" MajorTopicYN="Y">Unified Medical Language System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062245" MajorTopicYN="Y">RxNorm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ATC</Keyword><Keyword MajorTopicYN="N">Data interoperability</Keyword><Keyword MajorTopicYN="N">OHDSI Standardized Vocabularies</Keyword><Keyword MajorTopicYN="N">RxNorm</Keyword><Keyword MajorTopicYN="N">Terminology mapping</Keyword><Keyword MajorTopicYN="N">UMLS</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>11</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>4</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>3</Day><Hour>18</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39753061</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2024.105777</ArticleId><ArticleId IdType="pii">S1386-5056(24)00440-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39761272</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>ETL: From the German Health Data Lab data formats to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>e0311511</StartPage><MedlinePgn>e0311511</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0311511</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0311511</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The German Health Data Lab is going to provide access to German statutory health insurance claims data ranging from 2009 to the present for research purposes. Due to evolving data formats within the German Health Data Lab, there is a need to standardize this data into a Common Data Model to facilitate collaborative health research and minimize the need for researchers to adapt to multiple data formats. For this purpose we selected transforming the data to the Observational Medical Outcomes Partnership Common Data Model.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed an Extract, Transform, and Load (ETL) pipeline for two distinct German Health Data Lab data formats: Format 1 (2009-2016) and Format 3 (2019 onwards). Due to the identical format structure of Format 1 and Format 2 (2017 -2018), the ETL pipeline of Format 1 can be applied on Format 2 as well. Our ETL process, supported by Observational Health Data Sciences and Informatics tools, includes specification development, SQL skeleton creation, and concept mapping. We detail the process characteristics and present a quality assessment that includes field coverage and concept mapping accuracy using example data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For Format 1, we achieved a field coverage of 92.7%. The Data Quality Dashboard showed 100.0% conformance and 80.6% completeness, although plausibility checks were disabled. The mapping coverage for the Condition domain was low at 18.3% due to invalid codes and missing mappings in the provided example data. For Format 3, the field coverage was 86.2%, with Data Quality Dashboard reporting 99.3% conformance and 75.9% completeness. The Procedure domain had very low mapping coverage (2.2%) due to the use of mocked data and unmapped local concepts The Condition domain results with 99.8% of unique codes mapped. The absence of real data limits the comprehensive assessment of quality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ETL process effectively transforms the data with high field coverage and conformance. It simplifies data utilization for German Health Data Lab users and enhances the use of OHDSI analysis tools. This initiative represents a significant step towards facilitating cross-border research in Europe by providing publicly available, standardized ETL processes (https://github.com/FraunhoferMEVIS/ETLfromHDLtoOMOP) and evaluations of their performance.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Finster et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finster</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-0158-061X</Identifier><AffiliationInfo><Affiliation>Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Bremen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinat</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Erasmus University Medical Center, Rotterdam, South Holland, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taghizadeh</LastName><ForeName>Elham</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5468-0297</Identifier><AffiliationInfo><Affiliation>Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Bremen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="Y">Data Collection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="Y">Insurance Claim Review</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008492" MajorTopicYN="N">Medical Informatics Computing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>7</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>6</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>6</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39761272</ArticleId><ArticleId IdType="pmc">PMC11703056</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0311511</ArticleId><ArticleId IdType="pii">PONE-D-24-28242</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaliyaperumal R and Wilkinson M and Moreno P and Benis N and Cornet R and Vieira B, et al.. Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data. Journal of Biomedical Semantics, 2022. Mar; 13: doi: 10.1186/s13326-022-00264-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13326-022-00264-6</ArticleId><ArticleId IdType="pmc">PMC8922780</ArticleId><ArticleId IdType="pubmed">35292119</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D M, J&#xf3;nsson P, &#xd8;stby T, Hughes N, Rijnbeek P R, Bouvy J C. Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics, 2020; 39: 275&#x2013;285. doi: 10.1007/s40273-020-00981-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg D, Balicer R, Benjamini Y, De-Leon H, Gazit D, Rossman H, et al.. The role of models in the covid-19 pandemic. Israel Journal of Health Policy Research, 2022. Oct; 11: doi: 10.1186/s13584-022-00546-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13584-022-00546-5</ArticleId><ArticleId IdType="pmc">PMC9584247</ArticleId><ArticleId IdType="pubmed">36266704</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid M, Khaled M, Serhani M A. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Computer Methods and Programs in Biomedicine, 2021; 211: 106394. doi: 10.1016/j.cmpb.2021.106394</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnish Social and Health Data Permit Authority. FINDATA. [cited 12 December 2023]. Available from: https://findata.fi/en/.</Citation></Reference><Reference><Citation>Health Data Hub. Health Data Hub. [cited 12 December 2023]. Available from: https://www.health-data-hub.fr/.</Citation></Reference><Reference><Citation>Federal Institute for Drugs and Medical Devices. Health Data Lab. [cited 19 December 2023]. Available from: https://www.healthdatalab.de/.</Citation></Reference><Reference><Citation>EHDEN. European Health Data and Evidence Network. [cited 12 December 2023]. Available from: https://www.ehden.eu/.</Citation></Reference><Reference><Citation>National Association of Statutory Health Insurance Funds. National Association of Statutory Health Insurance Funds. [cited 19 December 2023]. Available from: https://www.gkv-spitzenverband.de/english/english.jsp.</Citation></Reference><Reference><Citation>Henke E, Zoch M, Reinecke I, Spoden M, Ruhnke T, G&#xfc;nster C, et al.. German Claims Data for Real-World Research: Content Coverage Evaluation in OMOP CDM. Studies in Health Technology and Informatics, volume 302, pages 3&#x2013;7, May 2023. 10.3233/SHTI230053</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI230053</ArticleId><ArticleId IdType="pubmed">37203598</ArticleId></ArticleIdList></Reference><Reference><Citation>Semler S C, Wissing F, Heyder R. German Medical Informatics Initiative. Methods Inf Med. 2018. Jul;57(S 01):e50&#x2013;e56. 10.3414/ME18-03-0003. Epub 2018 Jul 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-03-0003</ArticleId><ArticleId IdType="pmc">PMC6178199</ArticleId><ArticleId IdType="pubmed">30016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlocking Real-World Data with AI. [cited 19 January 2024]. Available from: https://www.real4reg.eu/.</Citation></Reference><Reference><Citation>European Health Data Space. [cited 19 January 2024]. Available from: https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en.</Citation></Reference><Reference><Citation>European Medicines Agency. A Common Data Model for Europe?&#x2014;Why? Which? How? Workshop report, European Medicines Agency, 2017 Dec 12.</Citation></Reference><Reference><Citation>Schneeweiss S, Brown J, Bate A, Trifir&#xf2; G, Bartels D. Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. Clinical Pharmacology &amp; Therapeutics, volume 107, 2019. Jul. 10.1002/cpt.1577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1577</ArticleId><ArticleId IdType="pubmed">31330042</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. Journal of Biomedical Informatics, volume 64, pages 333&#x2013;341, 2016. Dec. 10.1016/J.JBI.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JBI.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz J, Chard T, Sa Z, Ritchie A, Jorm L, Gallego B. Extract, Transform, Load Framework for the Conversion of Health Databases to OMOP. PLoS One, 2022. Apr; doi: 10.1371/journal.pone.0266911</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266911</ArticleId><ArticleId IdType="pmc">PMC9000122</ArticleId><ArticleId IdType="pubmed">35404974</ArticleId></ArticleIdList></Reference><Reference><Citation>Health data interoperability: A european challenge for impactful research project. https://www.health-data-hub.fr/health-data-interoperability, 2024 Jan 19.</Citation></Reference><Reference><Citation>CORDIS. CORDIS&#x2014;European Health Data and Evidence Network. [cited 07 December 2023]. Available from: https://cordis.europa.eu/project/id/806968/de.</Citation></Reference><Reference><Citation>Risikostrukturausgleich (RSA). [cited 19 January 2024]. Available from: https://www.bundesgesundheitsministerium.de/risikostrukturausgleich.</Citation></Reference><Reference><Citation>Verordnung zur Umsetzung der Vorschriften &#xfc;ber die Datentransparenz (Datentransparenzverordnung&#x2014;DaTraV) &#xa7; 3 Art und Umfang der zu &#xfc;bermittelnden Daten. [cited 19 June 2020]. Available from: https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen.</Citation></Reference><Reference><Citation>Forschungsdatenzentrum Gesundheit. Datensatzbeschreibung FDZ Gesundheit. [cited 27 May 2024]. Available from: https://github.com/FDZ-Gesundheit/datensatzbeschreibung_fdz_gesundheit.</Citation></Reference><Reference><Citation>Bundesinstitut f&#xfc;r Arzneimittel und Medizinprodukte. Klassifikationen. [cited 27 May 2024]. Available from: https://www.bfarm.de/DE/Kodiersysteme/Klassifikationen/_node.html.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI. [cited 15 January 2023]. Available from: https://ohdsi.github.io/TheBookOfOhdsi/.</Citation></Reference><Reference><Citation>OMOP CDM versions. [cited 15 December 2023]. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html.</Citation></Reference><Reference><Citation>OHDSI. OHDSI Collaborators. [cited 15 December 2023]. Available from: https://www.ohdsi.org/who-we-are/collaborators/.</Citation></Reference><Reference><Citation>Hripcsak G, Ryan P, Duke J, Shah N, Park R W, Huser V, et al.. Characterizing treatment pathways at scale using the OHDSI network. Proceedings of the National Academy of Sciences, 2016. Jun; 113: 201510502. doi: 10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED. [cited 28 December 2023]. Available from: https://www.snomed.org/.</Citation></Reference><Reference><Citation>Athena. [cited 15 December 2023]. Available from: https://athena.ohdsi.org/search-terms/start.</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al.. OHDSI Standardized Vocabularies&#x2014;a large-scale centralized reference ontology for international data harmonization. Journal of the American Medical Informatics Association, 2024. Jan; ocad247. doi: 10.1093/jamia/ocad247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlas. [cited 15 December 2023]. Available from: https://atlas-demo.ohdsi.org/#/home.</Citation></Reference><Reference><Citation>Stang P, Ryan P, Hartzema A G, Madigan D, Overhage J M, Welebob E, et al.. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. Mann&#x2019;s Pharmacovigilance: Third Edition, 2014. Jun; 453&#x2013;461. John Wiley &amp; Sons, Ltd. doi: 10.1002/9781118820186.ch29</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9781118820186.ch29</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan P B, Stang P E, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. Journal of Biomedical Informatics, 2012. Aug; 45(4): 689&#x2013;696. doi: 10.1016/j.jbi.2012.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.05.002</ArticleId><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E A, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al.. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association, 2015. Feb; 22. doi: 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Software Tools. [cited 14 August 2023]. Available from: https://www.ohdsi.org/software-tools/.</Citation></Reference><Reference><Citation>OHDSI. OHDSI White Rabbit. [cited 28 August 2023]. Available from: http://ohdsi.github.io/WhiteRabbit/.</Citation></Reference><Reference><Citation>OHDSI. Rabbit In A Hat. [cited 14 August 2023]. Available from: http://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html.</Citation></Reference><Reference><Citation>Blacketer C, Voss E A, DeFalco F, Hughes N, Schuemie M J, Moinat M, et al.. Using the Data Quality Dashboard to Improve the EHDEN Network. Applied Sciences, 2021; 11(24): 11920. doi: 10.3390/app112411920</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app112411920</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C, DeFalco F J, Ryan P B, Rijnbeek P R. Increasing trust in real-world evidence through evaluation of observational data quality. Journal of the American Medical Informatics Association, 2021. Jul; 28(10): 2251&#x2013;2257. doi: 10.1093/jamia/ocab132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>EHDEN. CDM Inspection. [cited 17 January 2024]. Available from: https://github.com/EHDEN/CdmInspection.</Citation></Reference><Reference><Citation>Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, et al.. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC Medical Research Methodology, 2021. Nov. 21. doi: 10.1186/s12874-021-01434-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>GKV-Spitzenverband. Leistungserbringer. [cited 14 August 2023]. Available from: https://www.gkv-datenaustausch.de/leistungserbringer/leistungserbringer.jsp.</Citation></Reference><Reference><Citation>Kassen&#xe4;rztliche Bundesvereinigung. Einheitlicher Bewertungsmassstab (EBM). [cited 28 May 2024]. Available from: https://www.kbv.de/html/ebm.php.</Citation></Reference><Reference><Citation>Henke E, Zoch M, Kallfelz M, Ruhnke T, Leutner L A, Spoden M, et al.. Assessing the Use of German Claims Data Vocabularies for Research in the Observational Medical Outcomes Partnership Common Data Model: Development and Evaluation Study. JMIR Med Inform, 2023. Nov 7; 11. doi: 10.2196/47959</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/47959</ArticleId><ArticleId IdType="pmc">PMC10653283</ArticleId><ArticleId IdType="pubmed">37942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M, Parrot A, Verloop D, Defebvre M M, et al.. Transforming French Electronic Health Records into the Observational Medical Outcome Partnership&#x2019;s Common Data Model: A Feasibility Study. Applied Clinical Informatics, 2020; 11(1): 13. doi: 10.1055/s-0039-3402754</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A, Rinner C, Sch&#xf6;berl A, Gall W. Feasibility of Mapping Austrian Health Claims Data to the OMOP Common Data Model. Journal of Medical Systems, 2019. October; 43(10): 1&#x2013;5. doi: 10.1007/s10916-019-1436-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, et al.. An evaluation of the THIN database in the OMOP common data model for active drug safety surveillance. Drug Safety, 2013. February; 36(2): 119&#x2013;134. doi: 10.1007/s40264-012-0009-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al.. Towards Implementation of OMOP in a German University Hospital Consortium. Applied Clinical Informatics, 2018. January; 9(1): 54&#x2013;61. doi: 10.1055/s-0037-1617452</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Henke E, Reinecke I, Zoch M, Sedlmayr M, Bathelt F. An ETL-process design for data harmonization to participate in international research with German real-world data based on FHIR and OMOP CDM. International Journal of Medical Informatics, 2023. January; 169(1): 104925. doi: 10.1016/j.ijmedinf.2022.104925</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104925</ArticleId><ArticleId IdType="pubmed">36395615</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Kallfelz M, Sedlmayr M, Siebel J, Bathelt F. Evaluation and Challenges of Medical Procedure Data Harmonization to SNOMED-CT for Observational Research. Studies in health technology and informatics, 2022. May; 294(1): 405&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">35612106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39787902</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>A common data model for oral anticoagulants-related risk of spontaneous intracranial hemorrhage.</ArticleTitle><Pagination><StartPage>111039</StartPage><MedlinePgn>111039</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2025.111039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(25)00011-6</ELocationID><Abstract><AbstractText>Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. sICH occurred in 0.5&#xa0;% of 5,626 patients with warfarin and 0.2&#xa0;% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4&#xa0;&#xb1;&#xa0;373.6 and 124.2&#xa0;&#xb1;&#xa0;135.7&#xa0;days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. NOACs demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Yeh-Hee</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Applied Statistics, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jeong Hyun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea; Naver Corporation, 95 Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi Province, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ha</LastName><ForeName>Eun Jin</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea; Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sung Ho</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kang Min</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyun-Seung</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea. Electronic address: kksoo716@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Won-Sang</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Deparment of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehak-ro Jongno-gu, Seoul 03080, Republic of Korea. Electronic address: nsdrcho@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020300" MajorTopicYN="Y">Intracranial Hemorrhages</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="Y">Warfarin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Non-vitamin K antagonist oral anticoagulants</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Spontaneous intracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">Warfarin</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>9</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39787902</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2025.111039</ArticleId><ArticleId IdType="pii">S0967-5868(25)00011-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39789235</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>09</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Standardized patient profile review using large language models for case adjudication in observational research.</ArticleTitle><Pagination><StartPage>18</StartPage><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-025-01433-4</ELocationID><Abstract><AbstractText>Using administrative claims and electronic health records for observational studies is common but challenging due to data limitations. Researchers rely on phenotype algorithms, requiring labor-intensive chart reviews for validation. This study investigates whether case adjudication using the previously introduced Knowledge-Enhanced Electronic Profile Review (KEEPER) system with large language models (LLMs) is feasible and could serve as a viable alternative to manual chart review. The task involves adjudicating cases identified by a phenotype algorithm, with KEEPER extracting predefined findings such as symptoms, comorbidities, and treatments from structured data. LLMs then evaluate KEEPER outputs to determine whether a patient truly qualifies as a case. We tested four LLMs including GPT-4, hosted locally to ensure privacy. Using zero-shot prompting and iterative prompt optimization, we found LLM performance, across ten diseases, varied by prompt and model, with sensitivities from 78 to 98% and specificities from 48 to 98%, indicating promise for automating phenotype evaluation.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA. schuemie@ohdsi.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, Titusville, NJ, USA. schuemie@ohdsi.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA, Los Angeles, CA, USA. schuemie@ohdsi.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuk</LastName><ForeName>Aleh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korsik</LastName><ForeName>Uladzislau</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: The authors declare no competing interests. MAS receives contracts and grants from the US National Institutes of Health, US Food &amp; Drug Administration, the US Department of Veterans Affairs and Janssen Research &amp; Development, all outside the scope of this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>9</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39789235</ArticleId><ArticleId IdType="pmc">PMC11718233</ArticleId><ArticleId IdType="doi">10.1038/s41746-025-01433-4</ArticleId><ArticleId IdType="pii">10.1038/s41746-025-01433-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FDA. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320939</ArticleId><ArticleId IdType="pubmed">35471704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanes, S., Brown, J. S., Haynes, K., Pollack, M. F. &amp; Walker, A. M. Identifying health outcomes in healthcare databases. Pharmacoepidemiol. Drug Saf.24, 1009&#x2013;1016 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26282185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets, A. et al. Scalable and interpretable alternative to chart review for phenotype evaluation using standardized structured data from electronic health records. J. Am. Med. Inform. Assoc. 31, 119&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746303</ArticleId><ArticleId IdType="pubmed">37847668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilson, A. et al. How does ChatGPT perform on the United States Medical Licensing Examination? The implications of large language models for medical education and knowledge assessment. JMIR Med. Educ.9, e45312 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9947764</ArticleId><ArticleId IdType="pubmed">36753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Li&#xe9;vin, V., Hother, C. E., Motzfeldt, A. G., &amp; Winther, O. Can large language models reason about medical questions? Patterns. 5, https://www.cell.com/patterns/fulltext/S2666-3899(24)00042-4 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10935498</ArticleId><ArticleId IdType="pubmed">38487804</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen, A., M&#xf6;ller, S. &amp; Ryg, J. Use of GPT-4 to Diagnose Complex Clinical Cases. NEJM AI (2023).</Citation></Reference><Reference><Citation>Reich, C. et al. OHDSI Standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. J. Am. Med. Inform. Assoc.31, 583&#x2013;590 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, J. et al. Chain-of-thought prompting elicits reasoning in large language models. Adv. Neural Inf. Process. Syst.35, 24824&#x2013;24837 (2022).</Citation></Reference><Reference><Citation>Zhou, Y. et al. Large Language Models Are Human-Level Prompt Engineers. Preprint at 10.48550/arXiv.2211.01910 (2023).</Citation></Reference><Reference><Citation>Hripcsak, G. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform.216, 574&#x2013;578 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, T. B. et al. Language models are few-shot learners. Proc. of the 34th Int. Conf. on Neural Information Processing Systems. 1877&#x2013;1901. https://dl.acm.org/doi/abs/10.5555/3495724.3495883 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.5555/3495724.3495883</ArticleId></ArticleIdList></Reference><Reference><Citation>Touvron, H. et al. Llama 2: open foundation and fine-tuned chat models. Preprint at 10.48550/arXiv.2307.09288 (2023).</Citation></Reference><Reference><Citation>Mukherjee, S. et al. Orca: progressive learning from complex explanation traces of GPT-4. Preprint at 10.48550/arXiv.2306.02707 (2023).</Citation></Reference><Reference><Citation>Lee, A. N., Hunter, C. J. &amp; Ruiz, N. Platypus: quick, cheap, and powerful refinement of LLMs. Preprint at https://arxiv.org/abs/2308.07317 (2023).</Citation></Reference><Reference><Citation>Open LLM Leaderboard&#x2014;a Hugging Face Space by HuggingFaceH4. https://huggingface.co/spaces/HuggingFaceH4/open_llm_leaderboard.</Citation></Reference><Reference><Citation>Wang, W., Zheng, V. W., Yu, H. &amp; Miao, C. A survey of zero-shot learning: settings, methods, and applications. ACM Trans. Intell. Syst. Technol.10, 1&#x2013;37 (2019).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39789670</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Objective study validity diagnostics: a framework requiring pre-specified, empirical verification to increase trust in the reliability of real-world evidence.</ArticleTitle><Pagination><StartPage>518</StartPage><EndPage>525</EndPage><MedlinePgn>518-525</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocae317</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Propose a framework to empirically evaluate and report validity of findings from observational studies using pre-specified objective diagnostics, increasing trust in real-world evidence (RWE).</AbstractText><AbstractText Label="MATERIALS AND METHODS">The framework employs objective diagnostic measures to assess the appropriateness of study designs, analytic assumptions, and threats to validity in generating reliable evidence addressing causal questions. Diagnostic evaluations should be interpreted before the unblinding of study results or, alternatively, only unblind results from analyses that pass pre-specified thresholds. We provide a conceptual overview of objective diagnostic measures and demonstrate their impact on the validity of RWE from a large-scale comparative new-user study of various antihypertensive medications. We evaluated expected absolute systematic error (EASE) before and after applying diagnostic thresholds, using a large set of negative control outcomes.</AbstractText><AbstractText Label="RESULTS">Applying objective diagnostics reduces bias and improves evidence reliability in observational studies. Among 11&#xa0;716 analyses (EASE&#x2009;=&#x2009;0.38), 13.9% met pre-specified diagnostic thresholds which reduced EASE to zero. Objective diagnostics provide a comprehensive and empirical set of tests that increase confidence when passed and raise doubts when failed.</AbstractText><AbstractText Label="DISCUSSION">The increasing use of real-world data presents a scientific opportunity; however, the complexity of the evidence generation process poses challenges for understanding study validity and trusting RWE. Deploying objective diagnostics is crucial to reducing bias and improving reliability in RWE generation. Under ideal conditions, multiple study designs pass diagnostics and generate consistent results, deepening understanding of causal relationships. Open-source, standardized programs can facilitate implementation of diagnostic analyses.</AbstractText><AbstractText Label="CONCLUSION">Objective diagnostics are a valuable addition to the RWE generation process.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conover</LastName><ForeName>Mitchell M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-5682-3688</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York City, NY 10032, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics (DBEI), The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, UT 20420, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York City, NY 10032, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Science and Informatics, New York City, NY 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL169954</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL167858</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035502" MajorTopicYN="N">Trust</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">causality</Keyword><Keyword MajorTopicYN="N">data interpretation</Keyword><Keyword MajorTopicYN="N">methods</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">research design</Keyword><Keyword MajorTopicYN="N">statistical</Keyword></KeywordList><CoiStatement>Mitchell M. Conover, Patrick B. Ryan, and Martijn J. Schuemie are employees and shareholders of Johnson &amp; Johnson. Marc A. Suchard receives grants and contracts from US Food &amp; Drug Administration, outside the scope of this work, and Johnson &amp; Johnson within the scope of this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>10</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>9</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39789670</ArticleId><ArticleId IdType="pmc">PMC11833483</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocae317</ArticleId><ArticleId IdType="pii">7950905</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. &#xa0;Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018;376:20170356. 10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA. &#xa0;The importance of potential studies that have not existed and registration of observational data sets. JAMA. 2012;308:575-576. 10.1001/jama.2012.8144</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.8144</ArticleId><ArticleId IdType="pubmed">22871867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrank W, Patrick A, Alan Brookhart M. &#xa0;Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26:546-550. 10.1007/s11606-010-1609-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-010-1609-1</ArticleId><ArticleId IdType="pmc">PMC3077477</ArticleId><ArticleId IdType="pubmed">21203857</ArticleId></ArticleIdList></Reference><Reference><Citation>Secemsky EA, Shen C, Yeh RW. &#xa0;Exposure misclassification in observational studies: setting new standards. Circ Cardiovasc Qual Outcomes. 2018;11:e004939. 10.1161/CIRCOUTCOMES.118.004939</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.118.004939</ArticleId><ArticleId IdType="pubmed">29991648</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes DA, Schulz KF. &#xa0;Bias and causal associations in observational research. Lancet. 2002;359:248-252. 10.1016/S0140-6736(02)07451-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)07451-2</ArticleId><ArticleId IdType="pubmed">11812579</ArticleId></ArticleIdList></Reference><Reference><Citation>The European Network of Centres for Pharmacoepidemiology, Pharmacovigilance (ENCePP). 2022. Guide on Methodological Standard in Pharmacoepidemiology.</Citation></Reference><Reference><Citation>Dahabreh IJ, Bibbins-Domingo K. &#xa0;Causal inference about the effects of interventions from observational studies in medical journals. JAMA. 2024;331:1845-1853. 10.1001/jama.2024.7741</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.7741</ArticleId><ArticleId IdType="pubmed">38722735</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagin A, Lewis RJ, Muth CC, Curfman G. &#xa0;What does the proposed causal inference framework for observational studies mean for JAMA and the JAMA network journals? &#xa0;JAMA. 2024;331:1812-1813. 10.1001/jama.2024.8107</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.8107</ArticleId><ArticleId IdType="pubmed">38722708</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. &#xa0;Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND). J Am Med Inform Assoc. 2020;27:1331-1337. 10.1093/jamia/ocaa103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. &#xa0;Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. J Am Med Inform Assoc. 2020;27:1268-1277. 10.1093/jamia/ocaa124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa124</ArticleId><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. &#xa0;Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816-1826. 10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>
Blacketer C, DeFalco F. &#xa0;Measuring Study Potential Through the Use of Data Diagnostics. Observational Health Data Sciences and Informatics; 2023. https://www.ohdsi.org/wp-content/uploads/2023/10/103-Blacketer-BriefReport.pdf. Accessed 2024.</Citation></Reference><Reference><Citation>Rao GA, Shoaibi A, Makadia R, et al. &#xa0;CohortDiagnostics: phenotype evaluation across a network of observational data sources using population-level characterization. medRxiv, 10.1101/2023.06.28.23291982, 2023, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.06.28.23291982</ArticleId><ArticleId IdType="pmc">PMC11737733</ArticleId><ArticleId IdType="pubmed">39820599</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Schuemie M, Murray G, Ryan PB. &#xa0;PheValuator 2.0: methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation. J Biomed Inform. 2022;135:104177. 10.1016/j.jbi.2022.104177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104177</ArticleId><ArticleId IdType="pubmed">35995107</ArticleId></ArticleIdList></Reference><Reference><Citation>Dernie F, Corby G, Robinson A, et al. &#xa0;Standardised and reproducible phenotyping using distributed analytics and tools in the data analysis and real world interrogation network (DARWIN EU). Pharmacoepidemiol Drug Saf. 2024;33:e70042. 10.1002/pds.70042</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.70042</ArticleId><ArticleId IdType="pubmed">39532529</ArticleId></ArticleIdList></Reference><Reference><Citation>Musonda P, Paddy Farrington C, Whitaker HJ. &#xa0;Sample sizes for self-controlled case series studies. Stat Med. 2006;25:2618-2631. 10.1002/sim.2477</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2477</ArticleId><ArticleId IdType="pubmed">16372391</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld DA. &#xa0;Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499-503. 10.2307/2531021</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531021</ArticleId><ArticleId IdType="pubmed">6354290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA. &#xa0;Causal analyses of existing databases: no power calculations required. J Clin Epidemiol. 2022;144:203-205. 10.1016/j.jclinepi.2021.08.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.08.028</ArticleId><ArticleId IdType="pmc">PMC8882204</ArticleId><ArticleId IdType="pubmed">34461211</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansournia MA. &#xa0;Sample size considerations are needed for the causal analyses of existing databases. J Clin Epidemiol. 2022;141:212. 10.1016/j.jclinepi.2021.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.09.024</ArticleId><ArticleId IdType="pubmed">34551318</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris TP, van Smeden M. &#xa0;Causal analyses of existing databases: the importance of understanding what can be achieved with your data before analysis (commentary on Hern&#xe1;n). J Clin Epidemiol. 2022;142:261-263. 10.1016/j.jclinepi.2021.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.09.026</ArticleId><ArticleId IdType="pubmed">34560253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA. &#xa0;Causal analysis of existing databases: no power calculations required. Responses to Campbell, Morris and Mansournia. J Clin Epidemiol. 2022;144:193. 10.1016/j.jclinepi.2021.11.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2021.11.039</ArticleId><ArticleId IdType="pmc">PMC8977232</ArticleId><ArticleId IdType="pubmed">34875379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. &#xa0;Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763. 10.7326/0003-4819-127-8_Part_2-199710151-00064</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-127-8_Part_2-199710151-00064</ArticleId><ArticleId IdType="pubmed">9382394</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster&#x2010;Clark M, St&#xfc;rmer T, Wang T, et al. &#xa0;Using propensity scores to estimate effects of treatment initiation decisions: state of the science. Stat Med. 2021;40:1718-1735. 10.1002/sim.8866</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.8866</ArticleId><ArticleId IdType="pubmed">33377193</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Patrick AR, Lauer MS, et al. &#xa0;A tool for assessing the feasibility of comparative effectiveness research. CER. 2013;2013:11-20. 10.2147/CER.S40357</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CER.S40357</ArticleId></ArticleIdList></Reference><Reference><Citation>Westreich D, Cole SR. &#xa0;Invited commentary: positivity in practice. Am J Epidemiol. 2010;171:674-677. 10.1093/aje/kwp436</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwp436</ArticleId><ArticleId IdType="pmc">PMC2877454</ArticleId><ArticleId IdType="pubmed">20139125</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. &#xa0;Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17:1218-1225. 10.1002/pds.1674</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1674</ArticleId><ArticleId IdType="pubmed">18972455</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. &#xa0;Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107. 10.1002/sim.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand SLT, Landrum MB, Guadagnoli E, et al. &#xa0;Validating recommendations for coronary angiography following acute myocardial infarction in the elderly. J Clin Epidemiol. 2001;54:387-398. 10.1016/S0895-4356(00)00321-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00321-8</ArticleId><ArticleId IdType="pubmed">11297888</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Grootendorst P, Anderson GM. &#xa0;A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734-753. 10.1002/sim.2580</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2580</ArticleId><ArticleId IdType="pubmed">16708349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Zhang L, Li K, Suchard MA, Ryan PB, Schuemie MJ. &#xa0;Assessing covariate balance with small sample sizes. medRxiv, 10.1101/2024.04.23.24306230, 2024; Version 1, preprint: not peer reviewed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.04.23.24306230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipton E. &#xa0;How generalizable is your experiment? An index for comparing experimental samples and populations. J Educ Behav Stat. 2014;39:478-501. 10.3102/1076998614558486</Citation><ArticleIdList><ArticleId IdType="doi">10.3102/1076998614558486</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. &#xa0;Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169-188. 10.1023/A:1020363010465</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1020363010465</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad V, Jena AB. &#xa0;Prespecified falsification end points: can they validate true observational associations? &#xa0;JAMA. 2013;309:241-242. 10.1001/jama.2012.96867</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.96867</ArticleId><ArticleId IdType="pubmed">23321761</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. &#xa0;Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383-388. 10.1097/EDE.0b013e3181d61eeb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofer T, Richardson DB, Colicino E, Schwartz J, Tchetgen Tchetgen EJ. &#xa0;On negative outcome control of unobserved confounding as a generalization of difference-in-differences. Stat Sci. 2016;31:348-361. 10.1214/16-STS558</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/16-STS558</ArticleId><ArticleId IdType="pmc">PMC5322866</ArticleId><ArticleId IdType="pubmed">28239233</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. &#xa0;Interpreting observational studies: why empirical calibration is needed to correct p&#x2010;values. Stat Med. 2014;33:209-218. 10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. &#xa0;Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA. 2018;115:2571-2577. 10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. &#xa0;Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005-2014. 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Reps J, Black A, et al. &#xa0;Health-analytics data to evidence suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966-970. 10.3233/SHTI231108</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI231108</ArticleId><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. &#xa0;Metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33:1685-1699. 10.1002/sim.6058</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6058</ArticleId><ArticleId IdType="pubmed">24323618</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman K. &#xa0;Six persistent research misconceptions. J Gen Intern Med. 2014;29:1060-1064. 10.1007/s11606-013-2755-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-013-2755-z</ArticleId><ArticleId IdType="pmc">PMC4061362</ArticleId><ArticleId IdType="pubmed">24452418</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39797103</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>24</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Impact of Uric Acid Levels on Mortality and Cardiovascular Outcomes in Relation to Kidney Function.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm14010020</ELocationID><Abstract><AbstractText><b>Background</b>: Uric acid levels are linked to cardiovascular outcomes and mortality, especially in chronic kidney disease (CKD). However, their impact across varying kidney function remains unclear. <b>Methods</b>: We conducted a retrospective cohort study using the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) database from a single center. Adult patients with at least one serum uric acid measurement between 2002 and 2021 were included and categorized by estimated glomerular filtration rate (eGFR): normal kidney function (&#x2265;90 mL/min/1.73 m<sup>2</sup>), mild dysfunction (60-89 mL/min/1.73 m<sup>2</sup>), moderate dysfunction (30-59 mL/min/1.73 m<sup>2</sup>), and advanced dysfunction (&lt;30 mL/min/1.73 m<sup>2</sup>). The primary outcome was all-cause mortality with secondary outcomes being myocardial infarction (MI) and heart failure (HF). <b>Results</b>: A total of 242,793 participants were analyzed. Uric acid levels showed a U-shaped association with all-cause mortality in advanced kidney dysfunction, where both low (&lt;3 mg/dL) and high (&gt;10 mg/dL) levels increased mortality risk. In mild kidney dysfunction, lower uric acid levels were linked to better survival. HF risk increased linearly with higher uric acid, particularly in normal kidney function, while no significant association was found between uric acid and MI in any group. <b>Conclusions</b>: Uric acid levels are associated with mortality in a U-shaped pattern for advanced kidney dysfunction, while lower levels appear protective in mild dysfunction. These findings suggest the need for personalized uric acid management in CKD patients based on their kidney function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Young-Eun</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Shin-Young</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-6844-0614</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Gang-Jee</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Young-Joo</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Eun</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K2210741</GrantID><Agency>Korea University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiovascular</Keyword><Keyword MajorTopicYN="N">chronic kidney disease</Keyword><Keyword MajorTopicYN="N">kidney dysfunction</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">uric acid</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>11</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39797103</ArticleId><ArticleId IdType="pmc">PMC11721403</ArticleId><ArticleId IdType="doi">10.3390/jcm14010020</ArticleId><ArticleId IdType="pii">jcm14010020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hassan W., Shrestha P., Sumida K., Thomas F., Sweeney P.L., Potukuchi P.K., Rhee C.M., Streja E., Kalantar-Zadeh K., Kovesdy C.P. Association of Uric Acid-Lowering Therapy with Incident Chronic Kidney Disease. JAMA Netw. Open. 2022;5:e2215878. doi: 10.1001/jamanetworkopen.2022.15878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.15878</ArticleId><ArticleId IdType="pmc">PMC9166229</ArticleId><ArticleId IdType="pubmed">35657621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971&#x2013;1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404&#x2013;2410. doi: 10.1001/jama.283.18.2404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.18.2404</ArticleId><ArticleId IdType="pubmed">10815083</ArticleId></ArticleIdList></Reference><Reference><Citation>Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., Salonen J.T. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch. Intern. Med. 2004;164:1546&#x2013;1551. doi: 10.1001/archinte.164.14.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.14.1546</ArticleId><ArticleId IdType="pubmed">15277287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoieggen A., Alderman M.H., Kjeldsen S.E., Julius S., Devereux R.B., De Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe-Pedersen O., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041&#x2013;1049. doi: 10.1111/j.1523-1755.2004.00484.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00484.x</ArticleId><ArticleId IdType="pubmed">14871425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawada A.M., Carrero J.J., Wolf M., Feuersenger A., Stuard S., Gauly A., Winter A.C., Ramos R., Fouque D., Canaud B. Serum Uric Acid and Mortality Risk Among Hemodialysis Patients. Kidney Int. Rep. 2020;5:1196&#x2013;1206. doi: 10.1016/j.ekir.2020.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.05.021</ArticleId><ArticleId IdType="pmc">PMC7403560</ArticleId><ArticleId IdType="pubmed">32775819</ArticleId></ArticleIdList></Reference><Reference><Citation>Madero M., Sarnak M.J., Wang X., Greene T., Beck G.J., Kusek J.W., Collins A.J., Levey A.S., Menon V. Uric acid and long-term outcomes in CKD. Am. J. Kidney Dis. 2009;53:796&#x2013;803. doi: 10.1053/j.ajkd.2008.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2008.12.021</ArticleId><ArticleId IdType="pmc">PMC2691553</ArticleId><ArticleId IdType="pubmed">19303683</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W.C., Hung C.C., Chen S.C., Yeh S.M., Lin M.Y., Chiu Y.W., Kuo M.C., Chang J.M., Hwang S.J., Chen H.C. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2012;7:541&#x2013;548. doi: 10.2215/CJN.09420911.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.09420911</ArticleId><ArticleId IdType="pubmed">22300737</ArticleId></ArticleIdList></Reference><Reference><Citation>Latif W., Karaboyas A., Tong L., Winchester J.F., Arrington C.J., Pisoni R.L., Marshall M.R., Kleophas W., Levin N.W., Sen A., et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin. J. Am. Soc. Nephrol. 2011;6:2470&#x2013;2477. doi: 10.2215/CJN.00670111.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.00670111</ArticleId><ArticleId IdType="pmc">PMC3359562</ArticleId><ArticleId IdType="pubmed">21868616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y.P., Chang C.C., Yang Y., Wen Y.K., Chiu P.F., Lin C.C. The role of uric acid in chronic kidney disease patients. Nephrology. 2017;22:441&#x2013;448. doi: 10.1111/nep.12679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.12679</ArticleId><ArticleId IdType="pubmed">26610276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong M., Gardner H.L., Dieterle N., Rentko V. Optimization of Electronic Medical Records for Data Mining Using a Common Data Model. Top. Companion Anim. Med. 2019;37:100364. doi: 10.1016/j.tcam.2019.100364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcam.2019.100364</ArticleId><ArticleId IdType="pmc">PMC7874511</ArticleId><ArticleId IdType="pubmed">31837755</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., 3rd, Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009;150:604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg A., Garcia-Arroyo F., Sasai F., Rodriguez-Iturbe B., Sanchez-Lozada L.G., Lanaspa M.A., Johnson R.J. Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease. Am. J. Nephrol. 2021;52:837&#x2013;844. doi: 10.1159/000519491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000519491</ArticleId><ArticleId IdType="pmc">PMC8665019</ArticleId><ArticleId IdType="pubmed">34673651</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein N.R., Zelnick L.R., Anderson A.H., Christenson R.H., deFilippi C.R., Deo R., Go A.S., He J., Ky B., Lash J.P., et al. Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD. Kidney Int. Rep. 2020;5:1052&#x2013;1060. doi: 10.1016/j.ekir.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7335964</ArticleId><ArticleId IdType="pubmed">32647762</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno J.A., Hamza E., Guerrero-Hue M., Rayego-Mateos S., Garcia-Caballero C., Vallejo-Mudarra M., Metzinger L., Metzinger-Le Meuth V. Non-Coding RNAs in Kidney Diseases: The Long and Short of Them. Int. J. Mol. Sci. 2021;22:6077. doi: 10.3390/ijms22116077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22116077</ArticleId><ArticleId IdType="pmc">PMC8200121</ArticleId><ArticleId IdType="pubmed">34199920</ArticleId></ArticleIdList></Reference><Reference><Citation>Suliman M.E., Johnson R.J., Garcia-Lopez E., Qureshi A.R., Molinaei H., Carrero J.J., Heimburger O., Barany P., Axelsson J., Lindholm B., et al. J-shaped mortality relationship for uric acid in CKD. Am. J. Kidney Dis. 2006;48:761&#x2013;771. doi: 10.1053/j.ajkd.2006.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2006.08.019</ArticleId><ArticleId IdType="pubmed">17059995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.M., Lee A.L., Winters T.J., Tam E., Jaleel M., Stenvinkel P., Johnson R.J. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am. J. Nephrol. 2009;29:79&#x2013;85. doi: 10.1159/000151292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000151292</ArticleId><ArticleId IdType="pmc">PMC2786018</ArticleId><ArticleId IdType="pubmed">18689987</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsukuma Y., Masutani K., Tanaka S., Tsuchimoto A., Fujisaki K., Torisu K., Katafuchi R., Hirakata H., Tsuruya K., Kitazono T. A J-shaped association between serum uric acid levels and poor renal survival in female patients with IgA nephropathy. Hypertens. Res. 2017;40:291&#x2013;297. doi: 10.1038/hr.2016.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/hr.2016.134</ArticleId><ArticleId IdType="pubmed">27733763</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A., Kaze A.D., McMullan C.J., Isakova T., Waikar S.S. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am. J. Kidney Dis. 2018;71:362&#x2013;370. doi: 10.1053/j.ajkd.2017.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2017.08.017</ArticleId><ArticleId IdType="pmc">PMC5828916</ArticleId><ArticleId IdType="pubmed">29132945</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., Krotova K., Block E.R., Prabhakar S., Johnson R.J. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739&#x2013;1742. doi: 10.1111/j.1523-1755.2005.00273.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.00273.x</ArticleId><ArticleId IdType="pubmed">15840020</ArticleId></ArticleIdList></Reference><Reference><Citation>Corry D.B., Eslami P., Yamamoto K., Nyby M.D., Makino H., Tuck M.L. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J. Hypertens. 2008;26:269&#x2013;275. doi: 10.1097/HJH.0b013e3282f240bf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0b013e3282f240bf</ArticleId><ArticleId IdType="pubmed">18192841</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrero J.J., Qureshi A.R., Axelsson J., Avesani C.M., Suliman M.E., Kato S., Barany P., Snaedal-Jonsdottir S., Alvestrand A., Heimburger O., et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am. J. Clin. Nutr. 2007;85:695&#x2013;701. doi: 10.1093/ajcn/85.3.695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/85.3.695</ArticleId><ArticleId IdType="pubmed">17344489</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis. 2000;148:131&#x2013;139. doi: 10.1016/S0021-9150(99)00214-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9150(99)00214-2</ArticleId><ArticleId IdType="pubmed">10580179</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki T. Nitrosation of uric acid induced by nitric oxide under aerobic conditions. Nitric Oxide. 2007;16:266&#x2013;273. doi: 10.1016/j.niox.2006.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.niox.2006.10.008</ArticleId><ArticleId IdType="pubmed">17166753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K.J., Kor C.T., Hsieh Y.P. An Inverse Relationship between Hyperuricemia and Mortality in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. J. Clin. Med. 2018;7:416. doi: 10.3390/jcm7110416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7110416</ArticleId><ArticleId IdType="pmc">PMC6262420</ArticleId><ArticleId IdType="pubmed">30400636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuno A., Beloqui O., San Jose G., Moreno M.U., Zalba G., Diez J. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. Kidney Int. 2005;68:S71&#x2013;S75. doi: 10.1111/j.1523-1755.2005.09913.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.09913.x</ArticleId><ArticleId IdType="pubmed">16336581</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner D.E., Tighiouart H., Elsayed E.F., Griffith J.L., Salem D.N., Levey A.S., Sarnak M.J. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am. J. Kidney Dis. 2008;51:212&#x2013;223. doi: 10.1053/j.ajkd.2007.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2007.10.035</ArticleId><ArticleId IdType="pmc">PMC4083633</ArticleId><ArticleId IdType="pubmed">18215699</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarity J.T., Folsom A.R., Iribarren C., Nieto F.J., Rosamond W.D. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann. Epidemiol. 2000;10:136&#x2013;143. doi: 10.1016/S1047-2797(99)00037-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1047-2797(99)00037-X</ArticleId><ArticleId IdType="pubmed">10813506</ArticleId></ArticleIdList></Reference><Reference><Citation>Navaneethan S.D., Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol. Dial. Transplant. 2009;24:1260&#x2013;1266. doi: 10.1093/ndt/gfn621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfn621</ArticleId><ArticleId IdType="pmc">PMC2721426</ArticleId><ArticleId IdType="pubmed">19033255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39805811</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Among Type 2 Diabetes Patients: Replication and Reliability Assessment Across a Research Network.</ArticleTitle><Pagination><StartPage>e70087</StartPage><MedlinePgn>e70087</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70087</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70087</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this study is to use observational methods to evaluate reliability of evidence generated by a study of the effect of glucagon-like peptide 1 receptor agonists (GLP-1RA) on chronic lower respiratory disease (CLRD) outcomes among Type-2 diabetes mellitus (T2DM) patients.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">We independently reproduced a study comparing effects of GLP-1RA versus dipeptidyl peptidase-4 inhibitors (DPP4-i) on CLRD outcomes among patients with T2DM and prior CLRD. We reproduced inputs and outputs using the original study data (national administrative claims) and evaluated the robustness of results in comparison to alternate design/analysis decisions. To evaluate generalizability, we applied an analysis protocol and conducted a meta-analysis across a research network that includes a diverse array of populations and data sources. We also produced additional analyses evaluating individual drugs within the GLP-1RA class and CLRD outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We confirmed alignment of study inputs and outputs and closely reproduced effect estimates and sensitivity analyses. Adjusted effect estimates were robust to empirical calibration. Network meta-analysis confirmed original findings but indicated weaker effects than originally published. Meta-analysis of drugs within the GLP-1RA class against DPP4-i provided evidence that effects vary within the GLP-1RA class, indicating stronger effects for exenatide and weaker effects of dulaglutide.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study supports and establishes the reliability of the original study by (1) producing consistent findings in a range of alternate databases and populations, (2) demonstrating effects for multiple drugs within the GLP-1RA class, and (3) independently confirming the reproducibility of the original study and its findings. This reliability evaluation provides the beginnings of a broader framework for using standardized tools and distributed data networks to systematically interrogate the reliability of findings generated using observational data.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conover</LastName><ForeName>Mitchell M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albogami</LastName><ForeName>Yasser</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2816-6526</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2682-2187</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Analytics, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Observational Health Data Sciences and Informatics (OHDSI) Research Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Observational Health Data Sciences and Informatics (OHDSI) Research Network</Agency><Country/></Grant><Grant><Agency>Janssen Research &amp; Development, a Johnson &amp; Johnson Company</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="Y">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic lower respiratory disease</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">glucagon&#x2010;like peptide 1 receptor agonists</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">real world data</Keyword><Keyword MajorTopicYN="N">real world evidence</Keyword><Keyword MajorTopicYN="N">reliability</Keyword><Keyword MajorTopicYN="N">replicability</Keyword><Keyword MajorTopicYN="N">reproducibility</Keyword><Keyword MajorTopicYN="N">transparency</Keyword></KeywordList><CoiStatement>Sponsors: Observational Health Data Sciences and Informatics (OHDSI) Research Network, Janssen Research &amp; Development, a Johnson &amp; Johnson Company. Four of the co&#x2010;authors for this work (M.M.C., J.H., A.O. and P.B.R.) are employed by Janssen Research &amp; Development LLC, a Johnson &amp; Johnson company, which markets products that are used to treat Type&#x2010;2 diabetes mellitus; however, those products are not evaluated in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>13</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39805811</ArticleId><ArticleId IdType="pmc">PMC11730806</ArticleId><ArticleId IdType="doi">10.1002/pds.70087</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Golder S., Loke Y. K., and Bland M., &#x201c;Meta&#x2010;Analyses of Adverse Effects Data Derived From Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview,&#x201d; PLoS Medicine 8, no. 5 (May 2011): e1001026, 10.1371/journal.pmed.1001026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001026</ArticleId><ArticleId IdType="pmc">PMC3086872</ArticleId><ArticleId IdType="pubmed">21559325</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;Challenges in Irreproducible Research (Special Issue),&#x201d; Nature, 7707 (2018): 557, https://www.nature.com/collections/prbfkwmwvz.</Citation></Reference><Reference><Citation>Begley C. G. and Ioannidis J. P., &#x201c;Reproducibility in Science: Improving the Standard for Basic and Preclinical Research,&#x201d; Circulation Research 116, no. 1 (January 2015): 116&#x2013;126, 10.1161/circresaha.114.303819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.114.303819</ArticleId><ArticleId IdType="pubmed">25552691</ArticleId></ArticleIdList></Reference><Reference><Citation>Coiera E., Ammenwerth E., Georgiou A., and Magrabi F., &#x201c;Does Health Informatics Have a Replication Crisis?,&#x201d; Journal of the American Medical Informatics Association 25, no. 8 (2018): 963&#x2013;968, 10.1093/jamia/ocy028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy028</ArticleId><ArticleId IdType="pmc">PMC6077781</ArticleId><ArticleId IdType="pubmed">29669066</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris J. K., Johnson K. J., Carothers B. J., Combs T. B., Luke D. A., and Wang X., &#x201c;Use of Reproducible Research Practices in Public Health: A Survey of Public Health Analysts,&#x201d; PLoS One 13, no. 9 (2018): e0202447, 10.1371/journal.pone.0202447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0202447</ArticleId><ArticleId IdType="pmc">PMC6135378</ArticleId><ArticleId IdType="pubmed">30208041</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis J. P., &#x201c;Contradicted and Initially Stronger Effects in Highly Cited Clinical Research,&#x201d; JAMA 294, no. 2 (July 2005): 218&#x2013;228, 10.1001/jama.294.2.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.294.2.218</ArticleId><ArticleId IdType="pubmed">16014596</ArticleId></ArticleIdList></Reference><Reference><Citation>Prinz F., Schlange T., and Asadullah K., &#x201c;Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?,&#x201d; Nature Reviews Drug Discovery 10, no. 9 (August 2011): 712, 10.1038/nrd3439-c1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3439-c1</ArticleId><ArticleId IdType="pubmed">21892149</ArticleId></ArticleIdList></Reference><Reference><Citation>Stupple A., Singerman D., and Celi L. A., &#x201c;The Reproducibility Crisis in the Age of Digital Medicine,&#x201d; npj Digital Medicine 2 (2019): 2, 10.1038/s41746-019-0079-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-019-0079-z</ArticleId><ArticleId IdType="pmc">PMC6550262</ArticleId><ArticleId IdType="pubmed">31304352</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedtash A., Blacketer B., et&#xa0;al., The Book of OHDSI: Observational Health Data Sciences and Informatics, 1st ed. (New York: Observational Health Data Science and Informatics, 2020).</Citation></Reference><Reference><Citation>Albogami Y., Cusi K., Daniels M. J., Wei Y. J., and Winterstein A. G., &#x201c;Glucagon&#x2010;Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes,&#x201d; Diabetes Care 44 (April 2021): 1344&#x2013;1352, 10.2337/dc20-1794.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1794</ArticleId><ArticleId IdType="pmc">PMC8247488</ArticleId><ArticleId IdType="pubmed">33875487</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., and Suchard M. A., &#x201c;Robust Empirical Calibration of p&#x2010;Values Using Observational Data,&#x201d; Statistics in Medicine 35, no. 22 (September 2016): 3883&#x2013;3888, 10.1002/sim.6977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Hripcsak G., Ryan P. B., Madigan D., and Suchard M. A., &#x201c;Empirical Confidence Interval Calibration for Population&#x2010;Level Effect Estimation Studies in Observational Healthcare Data,&#x201d; Proceedings of the National Academy of Sciences of the United States of America 115, no. 11 (March 2018): 2571&#x2013;2577, 10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., DuMouchel W., Suchard M. A., and Madigan D., &#x201c;Interpreting Observational Studies: Why Empirical Calibration Is Needed to Correct p&#x2010;Values,&#x201d; Statistics in Medicine 33, no. 2 (January 2014): 209&#x2013;218, 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., Hripcsak G., Madigan D., and Suchard M. A., &#x201c;Improving Reproducibility by Using High&#x2010;Throughput Observational Studies With Empirical Calibration,&#x201d; Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences 376, no. 2128 (September 2018): 20170356, 10.1098/rsta.2017.0356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E. A., Makadia R., Matcho A., et&#xa0;al., &#x201c;Feasibility and Utility of Applications of the Common Data Model to Multiple, Disparate Observational Health Databases,&#x201d; Journal of the American Medical Informatics Association 22, no. 3 (May 2015): 553&#x2013;564, 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K., Solomon D. H., Haneuse S., et&#xa0;al., &#x201c;A Tool for Empirical Equipoise Assessment in Multigroup Comparative Effectiveness Research,&#x201d; Pharmacoepidemiology and Drug Safety 28, no. 7 (July 2019): 934&#x2013;941, 10.1002/pds.4767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4767</ArticleId><ArticleId IdType="pmc">PMC7057252</ArticleId><ArticleId IdType="pubmed">31131965</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A. M., Patrick A. R., Lauer M. S., et&#xa0;al., &#x201c;A Tool for Assessing the Feasibility of Comparative Effectiveness Research,&#x201d; Comparative Effectiveness Research 3 (2013): 11&#x2013;20.</Citation></Reference><Reference><Citation>Austin P. C., &#x201c;Assessing Balance in Measured Baseline Covariates When Using Many&#x2010;To&#x2010;One Matching on the Propensity&#x2010;Score,&#x201d; Pharmacoepidemiology and Drug Safety 17, no. 12 (December 2008): 1218&#x2013;1225, 10.1002/pds.1674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1674</ArticleId><ArticleId IdType="pubmed">18972455</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C., &#x201c;Balance Diagnostics for Comparing the Distribution of Baseline Covariates Between Treatment Groups in Propensity&#x2010;Score Matched Samples,&#x201d; Statistics in Medicine 28, no. 25 (November 2009): 3083&#x2013;3107, 10.1002/sim.3697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C., Grootendorst P., and Anderson G. M., &#x201c;A Comparison of the Ability of Different Propensity Score Models to Balance Measured Variables Between Treated and Untreated Subjects: A Monte Carlo Study,&#x201d; Statistics in Medicine 26, no. 4 (February 2007): 734&#x2013;753, 10.1002/sim.2580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2580</ArticleId><ArticleId IdType="pubmed">16708349</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand S. T., Landrum M. B., Guadagnoli E., et&#xa0;al., &#x201c;Validating Recommendations for Coronary Angiography Following Acute Myocardial Infarction in the Elderly: A Matched Analysis Using Propensity Scores,&#x201d; Journal of Clinical Epidemiology 54, no. 4 (April 2001): 387&#x2013;398, 10.1016/s0895-4356(00)00321-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(00)00321-8</ArticleId><ArticleId IdType="pubmed">11297888</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J. P., Thompson S. G., Deeks J. J., and Altman D. G., &#x201c;Measuring Inconsistency in Meta&#x2010;Analyses,&#x201d; BMJ 327, no. 7414 (September 2003): 557&#x2013;560, 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. V., Verpillat P., Rassen J. A., Patrick A., Garry E. M., and Bartels D. B., &#x201c;Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases,&#x201d; Clinical Pharmacology and Therapeutics 99, no. 3 (March 2016): 325&#x2013;332, 10.1002/cpt.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.329</ArticleId><ArticleId IdType="pmc">PMC7833029</ArticleId><ArticleId IdType="pubmed">26690726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. V., Sreedhara S. K., and Schneeweiss S., &#x201c;Reproducibility of Real&#x2010;World Evidence Studies Using Clinical Practice Data to Inform Regulatory and Coverage Decisions,&#x201d; Nature Communications 13, no. 1 (August 2022): 5126, 10.1038/s41467-022-32310-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32310-3</ArticleId><ArticleId IdType="pmc">PMC9430007</ArticleId><ArticleId IdType="pubmed">36045130</ArticleId></ArticleIdList></Reference><Reference><Citation>White R., &#x201c;Building Trust in Real&#x2010;World Evidence and Comparative Effectiveness Research: The Need for Transparency,&#x201d; Journal of Comparative Effectiveness Research 6, no. 1 (January 2017): 5&#x2013;7, 10.2217/cer-2016-0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/cer-2016-0070</ArticleId><ArticleId IdType="pubmed">27759422</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders W. D., &#x201c;Negative&#x2010;Control Exposures: Adjusting for Unmeasured and Measured Confounders With Bounds for Remaining Bias,&#x201d; Epidemiology 34, no. 6 (November 2023): 850&#x2013;853, 10.1097/ede.0000000000001650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ede.0000000000001650</ArticleId><ArticleId IdType="pmc">PMC10544855</ArticleId><ArticleId IdType="pubmed">37757874</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders W. D., Klein M., Darrow L. A., et&#xa0;al., &#x201c;A Method for Detection of Residual Confounding in Time&#x2010;Series and Other Observational Studies,&#x201d; Epidemiology 22, no. 1 (January 2011): 59&#x2013;67, 10.1097/EDE.0b013e3181fdcabe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181fdcabe</ArticleId><ArticleId IdType="pmc">PMC3743227</ArticleId><ArticleId IdType="pubmed">21068669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M., Tchetgen Tchetgen E., and Cohen T., &#x201c;Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies,&#x201d; Epidemiology 21, no. 3 (May 2010): 383&#x2013;388, 10.1097/EDE.0b013e3181d61eeb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X., Miao W., and Tchetgen E. T., &#x201c;A Selective Review of Negative Control Methods in Epidemiology,&#x201d; Current Epidemiology Reports 7, no. 4 (December 2020): 190&#x2013;202, 10.1007/s40471-020-00243-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-020-00243-4</ArticleId><ArticleId IdType="pmc">PMC8118596</ArticleId><ArticleId IdType="pubmed">33996381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wang Y., Schuemie M. J., Blei D. M., and Hripcsak G., &#x201c;Adjusting for Indirectly Measured Confounding Using Large&#x2010;Scale Propensity Score,&#x201d; Journal of Biomedical Informatics 134 (October 2022): 104204, 10.1016/j.jbi.2022.104204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104204</ArticleId><ArticleId IdType="pmc">PMC9692203</ArticleId><ArticleId IdType="pubmed">36108816</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39810200</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>FHIR PIT: a geospatial and spatiotemporal data integration pipeline to support subject-level clinical research.</ArticleTitle><Pagination><StartPage>24</StartPage><MedlinePgn>24</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-024-02815-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Environmental exposures such as airborne pollutant exposures and socio-economic indicators are increasingly recognized as important to consider when conducting clinical research using electronic health record (EHR) data or other sources of clinical data such as survey data. While numerous public sources of geospatial and spatiotemporal data are available to support such research, the data are challenging to work with due to inconsistencies in file formats and spatiotemporal resolutions, computational challenges with large file sizes, and a lack of tools for patient-&#xa0;or subject-level data integration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We developed FHIR PIT (HL7&#xae; Fast Healthcare Interoperability Resources Patient data Integration Tool) as an open-source, modular, data-integration software pipeline that consumes EHR data in FHIR&#xae; format and integrates the data at the level of the patient or subject with environmental exposures data of varying spatiotemporal resolutions and file formats. We applied FHIR PIT to generate "integrated feature tables" containing patient- or subject-level EHR data integrated with environmental exposures data on two cohorts: one on patients with asthma and related common pulmonary disorders; and a second on patients with primary ciliary dyskinesia and related rare pulmonary disorders. The data were then exposed via the open Integrated Clinical and Environmental Exposures Service, which was then queried to explore relationships between exposures to two representative airborne pollutants (particulate matter and ozone) and annual emergency department or inpatient visits for respiratory issues. We found that hospitalizations for respiratory issues were more common among patients exposed to relatively high levels of particulate matter and ozone and were higher overall among patients with primary ciliary dyskinesia than among patients with asthma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our manuscript describes a major release of FHIR PIT v1.0 and includes a technical demonstration use case and a clinical application on the use of FHIR PIT to support research on environmental exposures and health outcomes related to asthma and primary ciliary dyskinesia. For application of the tool to common data models (CDMs) other than FHIR, we offer open-source conversion tools to map from the PCORnet, i2b2, and OMOP CDMs to FHIR.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fecho</LastName><ForeName>Karamarie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Renaissance Computing Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. kfecho@copperlineprofessionalsolutions.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Copperline Professional Solutions, LLC, Pittsboro, NC, USA. kfecho@copperlineprofessionalsolutions.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Garcia</LastName><ForeName>Juan J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yi</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Renaissance Computing Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roupe</LastName><ForeName>Griffin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Renaissance Computing Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnamurthy</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Renaissance Computing Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>BMC Med Inform Decis Mak. 2025 Feb 25;25(1):102. doi: 10.1186/s12911-025-02940-w.</RefSource><PMID Version="1">40001156</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004781" MajorTopicYN="Y">Environmental Exposure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062211" MajorTopicYN="N">Spatio-Temporal Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Airborne pollutant exposures</Keyword><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">Data integration</Keyword><Keyword MajorTopicYN="N">Environmental exposures</Keyword><Keyword MajorTopicYN="N">HL7&#xae; FHIR&#xae;</Keyword><Keyword MajorTopicYN="N">Hospital visits</Keyword><Keyword MajorTopicYN="N">Primary ciliary dyskinesia</Keyword><Keyword MajorTopicYN="N">Socioeconomic exposures</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The work described in this manuscript was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill (studies #16&#x2013;2978 [asthma] and #21&#x2013;0099 [PCD]). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>15</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>14</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39810200</ArticleId><ArticleId IdType="pmc">PMC11734467</ArticleId><ArticleId IdType="doi">10.1186/s12911-024-02815-6</ArticleId><ArticleId IdType="pii">10.1186/s12911-024-02815-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brokamp C, Wolfe C, Lingren T, Harley J, Ryan P. Decentralized and reproducible geocoding and characterization of community and environmental exposures for multi-site studies. J Am Med Inform Assoc. 2018;25(3):309&#x2013;14. 10.1093/jamia/ocx128. https://degauss.org.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378876</ArticleId><ArticleId IdType="pubmed">29126118</ArticleId></ArticleIdList></Reference><Reference><Citation>CAMP FHIR (Clinical Asset Mapping Program for HL7 Fast Healthcare Interoperability Resources), CAMP FHIR v1.0.4, released August 14, 2023. GitHub repository. https://github.com/NCTraCSIDSci/camp-fhir.</Citation></Reference><Reference><Citation>Choirat C, Braun D, Kioumourtzoglou M-A. Data science in environmental health research. Curr Epidemiol Rep. 2019;6:291&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853613</ArticleId><ArticleId IdType="pubmed">31723546</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LP, Zilber D, Schmitt C, et al. A review of geospatial exposure models and approaches for health data integration. J Expo Sci Environ Epidemiol. Published online September 6, 2024. 10.1038/s41370-024-00712-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12009742</ArticleId><ArticleId IdType="pubmed">39251872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y, Eccles KM, Kwok RK, Joubert BR, Messier KP, Balshaw DM, et al. Integrating multiscale geospatial environmental data into large population health studies: challenges and opportunities. Toxics. 2022;10:403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9316943</ArticleId><ArticleId IdType="pubmed">35878308</ArticleId></ArticleIdList></Reference><Reference><Citation>The Dhall configuration language. https://dhall-lang.org/.</Citation></Reference><Reference><Citation>Environmental Health Language Collaborative (EHLC). Environmental Health Language Collaborative: Harmonizing Data. Connecting Knowledge. Improving Health. December 11, 2023. https://www.niehs.nih.gov/research/programs/ehlc.</Citation></Reference><Reference><Citation>Fecho K,* Ahalt SC, Appold S, Arunachalam S, Pfaff E, Stillwell L, Valencia A, Xu H, Peden D. Development and application of an open tool for sharing and analyzing integrated clinical and environmental exposures data: asthma use case. JMIR Form Res. 2022;6(4):e32357; 10.2196/32357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015759</ArticleId><ArticleId IdType="pubmed">35363149</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecho K,* Ahalt SC, Knowles M, Krishnamurthy A, Leigh M, Morton K, Pfaff E, Wang M, Yi H. Leveraging open electronic health record data and environmental exposures data to derive insights into rare pulmonary disease. Front Artif Intell. 2022;5:918888 (special issue on Biomedical Informatics Applications in Rare Diseases). 10.3389/frai.2022.918888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9274244</ArticleId><ArticleId IdType="pubmed">35837616</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecho K,* Garantziotis S, Krishnamurthy A, Pfaff E, Schmitt C, Schurman S, Shuptrine S, Xu H, Ahalt A. Open integrated analysis of multi-institutional data using ICEES. AMIA 2021 Virtual Annual Informatics Summit, March 2021.</Citation></Reference><Reference><Citation>Fecho K, Pfaff E, Xu H, Champion J, Cox S, Stillwell L, Bizon C, Peden D, Krishnamurthy A, Tropsha A, Ahalt SC. A novel approach for exposing and sharing clinical data: the translator integrated clinical and environmental exposures service. J Am Med Inform Assoc. 2019;26(10):1064&#x2013;73. 10.1093/jamia/ocz042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748811</ArticleId><ArticleId IdType="pubmed">31077269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecho K, Thessen AE, Baranzini SE, et al. Progress toward a universal biomedical data translator [published online ahead of print, 2022 May 25]. Clin Transl Sci. 2022;15(8):1838&#x2013;47. 10.1111/cts.13301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9372428</ArticleId><ArticleId IdType="pubmed">35611543</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR PIT input data, 2024: UNC Health EHR data in FHIR format (https://www.unchealthcare.org/); NIEHS Personalized Environment and Genes Study (PEGS) participant data (formerly known as Environmental Polymorphisms Registry) (https://www.niehs.nih.gov/research/clinical/studies/pegs/index.cfm); US Environmental Protection Agency airborne pollutant exposures data (https://www.epa.gov/hesc/rsig-related-downloadable-data-files); US Department of Transportation, Federal Highway Administration, Highway Performance Monitoring System major roadway/highway exposures data (http://www.fhwa.dot.gov/policyinformation/travel_monitoring/pubs/aadt/); US Census Bureau Topologically Integrated Geographic Encoding and Referencing (TIGER)/Line roadway data (http://www.census.gov/geo/maps-data/data/tiger-line.html); US Census Bureau American Community Survey socio-economic exposures data (https://www.census.gov/programs-surveys/acs/data.html); NC Department of Environmental Quality concentrated animal feeding operations (CAFO) exposures data (https://deq.nc.gov/cafo-map); NC Department of Environmental Quality landfill exposures data (https://www.nconemap.gov/datasets/ncdenr::active-permitted-landfills/about); and National Center for Education Statistics (https://nces.ed.gov/datatools/).</Citation></Reference><Reference><Citation>Garcia JJ, Yi H, Fecho K, Krishnamurthy A. FHIR-PIT: Link FHIR records with environmental exposures. Poster presentation at BioIt World 2023, May 16-18, 2023.</Citation></Reference><Reference><Citation>Goodman S, BenYishay A, Lv Z, Runfola D. GeoQuery: Integrating HPC systems and public web-based geospatial data tools. Comp Geosci. 2019;2019(122):103&#x2013;12.</Citation></Reference><Reference><Citation>Hu H, Liu X, Zheng Y, He X, Hart J, James P, et al. Methodological challenges in spatial and contextual exposome-health studies. Crit Rev Environ Sci Technol. 2023;53:827&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10153069</ArticleId><ArticleId IdType="pubmed">37138645</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan B,* Haaland P, Krishnamurthy A, Peden DB, Schmitt PL, Sharma P, Sinha M, Xu H, Fecho K. Open application of statistical and machine learning models to explore the impact of environmental exposures on health and disease: an asthma use case. Int J Environ Res Public Health 2021;18(21):11398 [published as part of a special issue titled &#x201c;Application of Biostatistical Modelling in Public Health and Epidemiology&#x201d;]; 10.3390/ijerph182111398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8582932</ArticleId><ArticleId IdType="pubmed">34769911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirabelli MC, Vaidyanathan A, Flanders WD, Qin X, Garbe P. Outdoor PM2.5, Ambient air temperature, and asthma symptoms in the past 14 days among adults with active asthma. Environ Health Perspect. 2016;124(12):1882&#x2013;90. 10.1289/EHP92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5132644</ArticleId><ArticleId IdType="pubmed">27385358</ArticleId></ArticleIdList></Reference><Reference><Citation>NumFOCUS, Inc. pandas.cut. 2024. https://pandas.pydata.org/pandas-docs/stable/reference/api/pandas.cut.html.</Citation></Reference><Reference><Citation>NumFOCUS, Inc. pandas.qcut. 2024. https://pandas.pydata.org/pandas-docs/stable/reference/api/pandas.qcut.html.</Citation></Reference><Reference><Citation>US Department of Health and Human Services (US DHHS). Health Insurance Privacy and Accountability Act, Safe Harbor Method for De-identification. October 25, 2022. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html.</Citation></Reference><Reference><Citation>RENCI Environmental Exposures APIs (undated). Socioeconomic Exposures Service, https://bdt-social.renci.org/socio_environmental_exposures_api/v1/ui/; Airborne Pollutant Exposures Service, https://bdt-cmaq.renci.org/cmaq_exposures_api/v1/ui/; Roadway Exposures Service, https://bdt-proximity.renci.org/roadway_proximity_api/v1/ui/.</Citation></Reference><Reference><Citation>Pfaff ER, Champion J, Bradford RL, Clark M, Xu H, Fecho K, Krishnamurthy A, Cox S, Chute CG, Overby Taylor C, Ahalt S. Fast Healthcare Interoperability Resources (FHIR) as a meta model to integrate common data models: development of a tool and quantitative validation study. JMIR Med Inform. 2019;7(4):e15199. 10.2196/15199. https://github.com/NCTraCSIDSci/camp-fhir.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913576</ArticleId><ArticleId IdType="pubmed">31621639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P,* Haaland P, Krishnamurthy A, Lan B, Schmitt PL, Sinha M, Xu H, Fecho K. Evaluating robustness of a generalized linear model when applied to electronic health record data accessed using an openAPI. Health Inform J. 2023;29(2); 10.1177/14604582231170892.</Citation><ArticleIdList><ArticleId IdType="pubmed">37066514</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention (US CDC). (2023). National Environmental Public Health Tracking Network Data Explorer. https://ephtracking.cdc.gov/DataExplorer/.</Citation></Reference><Reference><Citation>US Department of Health and Human Services, Form Approved OMB# 0990&#x2013;0379, Expiration Date 8/31/2023. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html#safeharborguidance.</Citation></Reference><Reference><Citation>US Environmental Protection Agency (EPA). National Ambient Air Quality Standards (NAAQS) for PM. March 6, 2024. https://www.epa.gov/pm-pollution/national-ambient-air-quality-standards-naaqs-pm.</Citation></Reference><Reference><Citation>US NASA Socioeconomic Data and Applications Center (SEDAC). (2023). SEDAC: A data center in NASA's Earth Observing System Data and Information System (EOSDIS)- Hosted by CIESIN at Columbia University. https://sedac.ciesin.columbia.edu.</Citation></Reference><Reference><Citation>Valencia A, Stillwell L, Appold S, Arunachalam S, Cox S, Xu H, Schmitt CP, Schurman SH, Garantziotis S, Xue W, Ahalt SC, Fecho K. Translator Exposure APIs: open access to data on airborne pollutant exposures, roadway exposures, and socio-environmental exposures and use case application. IJERHP. 2020;17(14):5243. 10.3390/ijerph17145243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7400024</ArticleId><ArticleId IdType="pubmed">32708093</ArticleId></ArticleIdList></Reference><Reference><Citation>Vineis P, Robinson O, Chadeau-Hyam M, Dehghan A, Mudway I, Dagnino S. What is new in the exposome? Environ Int. 2020;143:105887. 10.1016/j.envint.2020.105887.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild CP. Complementing the genome with an &#x201c;exposome&#x201d;: the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005;14:1847&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103423</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Cox S, Stillwell L, Pfaff E, Champion J, Ahalt SC, Fecho K. FHIR PIT: an open software application for spatiotemporal integration of clinical data and environmental exposures data. BMC Med Inform Decis Mak. 2020;20:53. 10.21203/rs.2.19633/v1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066811</ArticleId><ArticleId IdType="pubmed">32160884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi H. pcornet-to-fhir mapping tool. 2024. https://github.com/RENCI/tx-pcornet-to-fhir.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39820599</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterization.</ArticleTitle><Pagination><StartPage>e0310634</StartPage><MedlinePgn>e0310634</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0310634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0310634</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This paper introduces a novel framework for evaluating phenotype algorithms (PAs) using the open-source tool, Cohort Diagnostics.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The method is based on several diagnostic criteria to evaluate a patient cohort returned by a PA. Diagnostics include estimates of incidence rate, index date entry code breakdown, and prevalence of all observed clinical events prior to, on, and after index date. We test our framework by evaluating one PA for systemic lupus erythematosus (SLE) and two PAs for Alzheimer's disease (AD) across 10 different observational data sources.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">By utilizing CohortDiagnostics, we found that the population-level characteristics of individuals in the cohort of SLE closely matched the disease's anticipated clinical profile. Specifically, the incidence rate of SLE was consistently higher in occurrence among females. Moreover, expected clinical events like laboratory tests, treatments, and repeated diagnoses were also observed. For AD, although one PA identified considerably fewer patients, absence of notable differences in clinical characteristics between the two cohorts suggested similar specificity.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">We provide a practical and data-driven approach to evaluate PAs, using two clinical diseases as examples, across a network of OMOP data sources. Cohort Diagnostics can ensure the subjects identified by a specific PA align with those intended for inclusion in a research study.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Diagnostics based on large-scale population-level characterization can offer insights into the misclassification errors of PAs.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Rao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-4949-7236</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6976-2594</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2682-2187</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0755-5191</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conover</LastName><ForeName>Mitchell M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0001-8630-5347</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoll</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Nigel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>James P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-2294-3459</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andryc</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinaro</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093983" MajorTopicYN="N">Information Sources</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors were employees of Janssen Research &amp; Development, LLC, and shareholders of Johnson &amp; Johnson (J&amp;J) stock at the time of manuscript conceptualization, drafting, editing, and initial approval for submission. All authors except AM continue to be employees of J&amp;J. Author AM changed affiliation after the initial submission and is currently affiliated with VNS Health. This competing interest does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39820599</ArticleId><ArticleId IdType="pmc">PMC11737733</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0310634</ArticleId><ArticleId IdType="pii">PONE-D-23-23359</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Overby CL, Pathak J, Gottesman O, Haerian K, Perotte A, Murphy S, et al.. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. Journal of the American Medical Informatics Association. 2013;20(e2):e243&#x2013;e52. doi: 10.1136/amiajnl-2013-001930</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-001930</ArticleId><ArticleId IdType="pmc">PMC3861914</ArticleId><ArticleId IdType="pubmed">23837993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. High-fidelity phenotyping: richness and freedom from bias. Journal of the American Medical Informatics Association. 2017;25(3):289&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282504</ArticleId><ArticleId IdType="pubmed">29040596</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver J, Potvien A, Swerdel J, Voss EA, Hester L, Shoaibi A, et al., editors. Best Practices for Creating the Standardized Content of an Entry in the OHDSI Phenotype Library. 5th OHDSI Annual Symposium; 2019.</Citation></Reference><Reference><Citation>Chapman M, Mumtaz S, Rasmussen LV, Karwath A, Gkoutos GV, Gao C, et al.. Desiderata for the development of next-generation electronic health record phenotype libraries. GigaScience. 2021;10(9):giab059. doi: 10.1093/gigascience/giab059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gigascience/giab059</ArticleId><ArticleId IdType="pmc">PMC8434766</ArticleId><ArticleId IdType="pubmed">34508578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuha J, Skinner C, Palmgren J. Misclassification Error. Encyclopedia of Biostatistics2005.</Citation></Reference><Reference><Citation>Xu J, Rasmussen LV, Shaw PL, Jiang G, Kiefer RC, Mo H, et al.. Review and evaluation of electronic health records-driven phenotype algorithm authoring tools for clinical and translational research. Journal of the American Medical Informatics Association. 2015;22(6):1251&#x2013;60. doi: 10.1093/jamia/ocv070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv070</ArticleId><ArticleId IdType="pmc">PMC5009915</ArticleId><ArticleId IdType="pubmed">26224336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, Basford M, Gottesman O, Peissig PL, et al.. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. Journal of the American Medical Informatics Association. 2016;23(6):1046&#x2013;52. doi: 10.1093/jamia/ocv202</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv202</ArticleId><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Boggon R, Van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiology and Drug Safety. 2013;22(2):168&#x2013;75. doi: 10.1002/pds.3374</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3374</ArticleId><ArticleId IdType="pubmed">23239282</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12&#x2013;. doi: 10.3352/jeehp.2013.10.12</Citation><ArticleIdList><ArticleId IdType="doi">10.3352/jeehp.2013.10.12</ArticleId><ArticleId IdType="pmc">PMC3853868</ArticleId><ArticleId IdType="pubmed">24324853</ArticleId></ArticleIdList></Reference><Reference><Citation>Worster A, Haines T. Advanced statistics: understanding medical record review (MRR) studies. Acad Emerg Med. 2004;11(2):187&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">14759964</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas S, Gonzalez-Izquierdo A, Direk K, Fitzpatrick NK, Fatemifar G, Banerjee A, et al.. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. Journal of the American Medical Informatics Association. 2019;26(12):1545&#x2013;59. doi: 10.1093/jamia/ocz105</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz105</ArticleId><ArticleId IdType="pmc">PMC6857510</ArticleId><ArticleId IdType="pubmed">31329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB. PheValuator: development and evaluation of a phenotype algorithm evaluator. Journal of biomedical informatics. 2019;97:103258. doi: 10.1016/j.jbi.2019.103258</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103258</ArticleId><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, Bielinski SJ, Berg RL, Choudhary V, et al.. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. Journal of the American Medical Informatics Association. 2013;20(e1):e147&#x2013;e54. doi: 10.1136/amiajnl-2012-000896</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000896</ArticleId><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Hripcsak G, Knoll C, Ryan P. PHOEBE 2.0: selecting the right concept sets for the right patients using lexical, semantic, and data-driven recommendations.</Citation></Reference><Reference><Citation>Ostropolets A RP, Hripcsak G., editor Phenotyping in distributed data networks: selecting the right codes for the right patients. AMIA Annual Symposium Proceedings; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10148372</ArticleId><ArticleId IdType="pubmed">37128407</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Ramcharran D, Hardin J. Using a data-driven approach for the development and evaluation of phenotype algorithms for systemic lupus erythematosus. PLOS ONE. 2023;18(2):e0281929. doi: 10.1371/journal.pone.0281929</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0281929</ArticleId><ArticleId IdType="pmc">PMC9934349</ArticleId><ArticleId IdType="pubmed">36795690</ArticleId></ArticleIdList></Reference><Reference><Citation>Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison&#x2019;s Manual of Medicine: McGraw-Hill; 2020.</Citation></Reference><Reference><Citation>Taylor DH, Jr., &#xd8;stbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009;17(4):807&#x2013;15. doi: 10.3233/JAD-2009-1099</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1099</ArticleId><ArticleId IdType="pmc">PMC3697480</ArticleId><ArticleId IdType="pubmed">19542620</ArticleId></ArticleIdList></Reference><Reference><Citation>Imfeld P, Bodmer M, Schuerch M, Jick SS, Meier CR. Seizures in patients with Alzheimer&#x2019;s disease or vascular dementia: a population-based nested case-control analysis. Epilepsia. 2013;54(4):700&#x2013;7. doi: 10.1111/epi.12045</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12045</ArticleId><ArticleId IdType="pubmed">23215680</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al.. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association. 2015;22(3):553&#x2013;64. doi: 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al.. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. doi: 10.1038/psp.2013.52</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/psp.2013.52</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C.
ETL-LambdaBuilder
2023.  [Available from: https://ohdsi.github.io/ETL-LambdaBuilder/.</Citation></Reference><Reference><Citation>Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. Increasing trust in real-world evidence through evaluation of observational data quality. Journal of the American Medical Informatics Association. 2021;28(10):2251&#x2013;7. doi: 10.1093/jamia/ocab132</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC. R: A language and environment for statistical computing. 2013.</Citation></Reference><Reference><Citation>Samarati P, Sweeney L. Protecting privacy when disclosing information: k-anonymity and its enforcement through generalization and suppression. 1998.</Citation></Reference><Reference><Citation>Rao G.
Cohort Diagnostics: An R package
2023.  [Available from: https://ohdsi.github.io/CohortDiagnostics.</Citation></Reference><Reference><Citation>Rao G.
Evaluation of Systemic Lupus Erythematous and Alzheimers Disease using Cohort Diagnostics
2023.  [Available from: https://data.ohdsi.org/CohortDiagnostics/.</Citation></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, Shaoibi A, Rao G, Sena AG, et al.. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. Medrxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clinical reviews in allergy &amp; immunology. 2003;25:3&#x2013;11. doi: 10.1385/CRIAI:25:1:3</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/CRIAI:25:1:3</ArticleId><ArticleId IdType="pubmed">12794256</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy EP, Chang CH, Tilton N, Kabeto MU, Langa KM, Bynum JPW. Validation of Claims Algorithms to Identify Alzheimer&#x2019;s Disease and Related Dementias. J Gerontol A Biol Sci Med Sci. 2022;77(6):1261&#x2013;71. doi: 10.1093/gerona/glab373</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glab373</ArticleId><ArticleId IdType="pmc">PMC9159657</ArticleId><ArticleId IdType="pubmed">34919686</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoaibi A, Rao GA, Voss EA, Ostropolets A, Mayer MA, Ram&#xed;rez-Anguita JM, et al.. Phenotype algorithms for the identification and characterization of vaccine-induced thrombotic thrombocytopenia in real world data: a multinational network cohort study. Drug Safety. 2022;45(6):685&#x2013;98. doi: 10.1007/s40264-022-01187-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01187-y</ArticleId><ArticleId IdType="pmc">PMC9160850</ArticleId><ArticleId IdType="pubmed">35653017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostka K, Duarte-Salles T, Prats-Uribe A, Sena AG, Pistillo A, Khalid S, et al.. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. Clinical Epidemiology. 2022:369&#x2013;84. doi: 10.2147/CLEP.S323292</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S323292</ArticleId><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai PM, Ostropolets A, Richter LR, Nieva HR, Spotnitz M, Rodriguez VA, et al.. Phenotype Development and Evaluation of Heart Failure: A Case Study in using Patient Level Prediction to Improve Phenotype Validity.</Citation></Reference><Reference><Citation>Herrera R, Banks V, Caetano C, Janssenswillen C, Moeller C, Su S, et al.. Epidemiology of vasomotor symptoms (VMS) in menopausal women (EpiVaSym): a multi-country, large-scale OHDSI network analytic study.</Citation></Reference><Reference><Citation>Alhambra DP, Dernie F, Corby G, Robinson A, Bezer J, Parry R, et al.. Standardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU&#xae;). Authorea Preprints; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">39532529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A, Albogami Y, Conover M, Banda JM, Baumgartner WA, Jr, Blacketer C, et al.. Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational study. Journal of the American Medical Informatics Association. 2023;30(5):859&#x2013;68. doi: 10.1093/jamia/ocad009</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad009</ArticleId><ArticleId IdType="pmc">PMC10114120</ArticleId><ArticleId IdType="pubmed">36826399</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Schuemie M, Murray G, Ryan PB. PheValuator 2.0: Methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation. Journal of Biomedical Informatics. 2022;135:104177. doi: 10.1016/j.jbi.2022.104177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104177</ArticleId><ArticleId IdType="pubmed">35995107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39824520</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2632-1009</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>16</Day></PubDate></JournalIssue><Title>BMJ health &amp; care informatics</Title><ISOAbbreviation>BMJ Health Care Inform</ISOAbbreviation></Journal><ArticleTitle>Finding a constrained number of predictor phenotypes for multiple outcome prediction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e101227</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjhci-2024-101227</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prognostic models help aid medical decision-making. Various prognostic models are available via websites such as MDCalc, but these models typically predict one outcome, for example, stroke risk. Each model requires individual predictors, for example, age, lab results and comorbidities. There is no clinical tool available to predict multiple outcomes from a list of common medical predictors.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Identify a constrained set of outcome-agnostic predictors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We proposed a novel technique aggregating the standardised mean difference across hundreds of outcomes to learn a constrained set of predictors that appear to be predictive of many outcomes. Model performance was evaluated using the constrained set of predictors across eight prediction tasks. We compared against existing models, models using only age/sex predictors and models without any predictor constraints.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 67 predictors in our constrained set, plus age/sex. Our predictors included illnesses in the following categories: cardiovascular, kidney/liver, mental health, gastrointestinal, infectious and oncologic. Models developed using the constrained set of predictors achieved comparable discrimination compared with models using hundreds or thousands of predictors for five of the eight prediction tasks and slightly lower discrimination for three of the eight tasks. The constrained predictor models performed as good or better than all existing clinical models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is possible to develop models for hundreds or thousands of outcomes that use the same small set of predictors. This makes it feasible to implement many prediction models via a single website form. Our set of predictors can also be used for future models and prognostic model research.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Johnson &amp; Johnson LLC, Raritan, New Jersey, USA jreps@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fridgeirsson</LastName><ForeName>Egill A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Renae R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Spinal Cord Injury/Disorders, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Health Care Inform</MedlineTA><NlmUniqueID>101745500</NlmUniqueID><ISSNLinking>2632-1009</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Science</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Evidence-Based Medicine</Keyword><Keyword MajorTopicYN="N">Medical Informatics</Keyword><Keyword MajorTopicYN="N">Preventive Medicine</Keyword></KeywordList><CoiStatement>Competing interests: JMR and PBR are employees and shareholders of Johnson &amp; Johnson. EAF, LHJ and RDW work for a research group that in the past 3 years has received/received unconditional research grants from Chiesi, UCB, Amgen, Johnson and Johnson, Innovative Medicines Initiative and the European Medicines Agency. None of these grants result in a conflict of interest to the content of this paper. CK has received consultation fees from IQVIA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>18</Day><Hour>15</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>18</Day><Hour>15</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>17</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39824520</ArticleId><ArticleId IdType="pmc">PMC11751890</ArticleId><ArticleId IdType="doi">10.1136/bmjhci-2024-101227</ArticleId><ArticleId IdType="pii">bmjhci-2024-101227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263&#x2013;72. doi: 10.1378/chest.09-1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-1584</ArticleId><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, He W, Guo L, et al. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015;38:555&#x2013;61. doi: 10.1002/clc.22435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22435</ArticleId><ArticleId IdType="pmc">PMC6490831</ArticleId><ArticleId IdType="pubmed">26418409</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015;36:3258&#x2013;64. doi: 10.1093/eurheartj/ehv476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehv476</ArticleId><ArticleId IdType="pmc">PMC4670965</ArticleId><ArticleId IdType="pubmed">26424865</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihatov N, Secemsky EA, Kereiakes DJ, et al. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021;97:569&#x2013;78. doi: 10.1002/ccd.29352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29352</ArticleId><ArticleId IdType="pmc">PMC8620187</ArticleId><ArticleId IdType="pubmed">33111495</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373&#x2013;83. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Akavipat P, Thinkhamrop J, Thinkhamrop B, et al. Acute physiology and chronic health evaluation (Apache) II score &#x2013; the clinical predictor in neurosurgical intensive care unit. Acta Clin Croat. 2019;58:50&#x2013;6. doi: 10.20471/acc.2019.58.01.07.</Citation><ArticleIdList><ArticleId IdType="doi">10.20471/acc.2019.58.01.07</ArticleId><ArticleId IdType="pmc">PMC6629196</ArticleId><ArticleId IdType="pubmed">31363325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang NJ, Rameau P, Julemis M, et al. Automated Pulmonary Embolism Risk Assessment Using the Wells Criteria: Validation Study. JMIR Form Res. 2022;6:e32230. doi: 10.2196/32230.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/32230</ArticleId><ArticleId IdType="pmc">PMC8922138</ArticleId><ArticleId IdType="pubmed">35225812</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet R, de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inform Decis Mak. 2008;8 Suppl 1:1&#x2013;6. doi: 10.1186/1472-6947-8-S1-S2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-8-S1-S2</ArticleId><ArticleId IdType="pmc">PMC2582789</ArticleId><ArticleId IdType="pubmed">19007439</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, et al. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18:441&#x2013;8. doi: 10.1136/amiajnl-2011-000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000116</ArticleId><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Williams RD, You SC, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20:102. doi: 10.1186/s12874-020-00991-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XHD. A pair of new statistical parameters for quality control in RNA interference high-throughput screening assays. Genomics. 2007;89:552&#x2013;61. doi: 10.1016/j.ygeno.2006.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygeno.2006.12.014</ArticleId><ArticleId IdType="pubmed">17276655</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.:574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25:969&#x2013;75. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani Robert. Regression Shrinkage and Selection Via the Lasso. J R Stat Soc Ser B. 1996;58:267&#x2013;88. doi: 10.1111/j.2517-6161.1996.tb02080.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1996.tb02080.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. ACM Trans Model Comput Simul. 2013;23:1&#x2013;17. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JH. Greedy function approximation: A gradient boosting machine. Ann Statist. 2001;29:1189&#x2013;232. doi: 10.1214/aos/1013203451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aos/1013203451</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, Reps JM, Kors JA, et al. Using Iterative Pairwise External Validation to Contextualize Prediction Model Performance: A Use Case Predicting 1-Year Heart Failure Risk in Patients with Diabetes Across Five Data Sources. Drug Saf. 2022;45:563&#x2013;70. doi: 10.1007/s40264-022-01161-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01161-8</ArticleId><ArticleId IdType="pmc">PMC9114056</ArticleId><ArticleId IdType="pubmed">35579818</ArticleId></ArticleIdList></Reference><Reference><Citation>John LH, Kors JA, Reps JM, et al. Logistic regression models for patient-level prediction based on massive observational data: Do we need all data? Int J Med Inform. 2022;163:104762. doi: 10.1016/j.ijmedinf.2022.104762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104762</ArticleId><ArticleId IdType="pubmed">35429722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentes AV, Pineda MD, Venkata KCN. Comprehension of Top 200 Prescribed Drugs in the US as a Resource for Pharmacy Teaching, Training and Practice. Pharmacy (Basel) 2018;6:43. doi: 10.3390/pharmacy6020043.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy6020043</ArticleId><ArticleId IdType="pmc">PMC6025009</ArticleId><ArticleId IdType="pubmed">29757930</ArticleId></ArticleIdList></Reference><Reference><Citation>Finley CR, Chan DS, Garrison S, et al. What are the most common conditions in primary care? Systematic review. Can Fam Physician. 2018;64:832&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234945</ArticleId><ArticleId IdType="pubmed">30429181</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott KW, Roemer M. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs); 2006 Feb&#x2013;. Statistical Brief #277. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021. Most frequent principal diagnoses for inpatient stays in u.s. hospitals, 2018; 34428003</Citation><ArticleIdList><ArticleId IdType="pubmed">34428003</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39837828</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Racial/ethnic differences in post-acute sequelae of SARS-CoV-2 in children and adolescents in the United States.</ArticleTitle><Pagination><StartPage>878</StartPage><MedlinePgn>878</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">878</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-55273-z</ELocationID><Abstract><AbstractText>Racial/ethnic differences are associated with the symptoms and conditions of post-acute sequelae SARS-CoV-2 infection (PASC) in adults. These differences may exist among children and warrant further exploration. We conducted a retrospective cohort study with difference-in-differences analyzes to assess these differences in children and adolescents under the age of 21. The study utilized data from the RECOVER Initiative in the United States, which aims to learn about the long-term effects of COVID-19. The cohort included 225,723 patients with SARS-CoV-2 infection or COVID-19 diagnosis between March 2020 and October 2022. The study compared minority racial/ethnic groups to Non-Hispanic White (NHW) individuals, stratified by severity during the acute phase of COVID-19. Within the severe group, Asian American/Pacific Islanders (AAPI) had a higher prevalence of fever/chills and respiratory&#xa0;signs and symptoms, Hispanic patients showed greater hair loss prevalence in severe COVID-19 cases, while Non-Hispanic Black (NHB) patients had fewer skin symptoms in comparison to NHW patients. Within the non-severe group, AAPI patients had increased POTS/dysautonomia and respiratory symptoms, and NHB patients showed more cognitive symptoms than NHW patients. In conclusion, racial/ethnic differences related to COVID-19 exist among PASC symptoms and conditions in pediatrics, and these differences are associated with the severity of illness during acute COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1431-0785</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5747-1899</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1213-6699</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huiyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chisolm</LastName><ForeName>Deena J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Abigail Wexner Research Institute Nationwide Children's Hospital, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenney</LastName><ForeName>Rachel C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothman</LastName><ForeName>Russell L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Vanderbilt Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornig</LastName><ForeName>Mady</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7572-3092</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linbo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Statistical Sciences, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-8520-6088</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-1252-068X</Identifier><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG077820</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>1R01LM013519</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U01TR003709</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG073435</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>1R01AI130460</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R56AG069880</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R56AG074604</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>ME-2018C3-14899</GrantID><Agency>Patient-Centered Outcomes Research Institute (PCORI)</Agency><Country/></Grant><Grant><GrantID>OT2HL161847-01</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2024 Mar 28:rs.3.rs-4151744. doi: 10.21203/rs.3.rs-4151744/v1.</RefSource><PMID Version="1">38585924</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="Y">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095223" MajorTopicYN="N">White</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: R.J. is a consultant for AstraZeneca, Seqirus, and Dynavax, and receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. S.R. reports prior grant support from GSK and Biofire and is a consultant for Sequiris. All other authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>22</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>21</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39837828</ArticleId><ArticleId IdType="pmc">PMC11751291</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-55273-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-55273-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine38, 101019 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai, T. et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA329, 1934&#x2013;1946 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinicalcase-definition-2023-1 (2023).</Citation></Reference><Reference><Citation>Morello, R. et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. EClinicalMedicine59, 101961 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar, J. et al. Prevalence and characteristics associated With Post&#x2013;COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Netw. Open6, e235763 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Morales, A. J. et al. The global challenges of the long COVID-19 in adults and children. Travel Med. Infect. Dis.54, 102606 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10247301</ArticleId><ArticleId IdType="pubmed">37295581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep.11, 16144 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open4, e2128568 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie, T., Hittle, M. &amp; Goodman, S. N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw. Open4, e2111417 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, S. et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. JAMA Pediatr.176, 1000&#x2013;1009 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig, H. et al. Long-term outcomes of COVID-19 infection in children and young people: a systematic review and meta-analysis. medRxiv 2023&#x2013;2024 (2023).</Citation></Reference><Reference><Citation>Lopez-Leon, S. et al. Long-COVID in children and adolescents: A systematic review and meta-analyses. Sci. Rep.12, 9950 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney, L. L. et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinical Med.55, 101762 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Health Statistics, U.S. Census Bureau &amp; Household Pulse Survey. Long COVID. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm (2022).</Citation></Reference><Reference><Citation>Khullar, D. et al. Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: an EHR-based cohort study from the RECOVER program. J. Gen. Intern Med.38, 1127&#x2013;1136 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933823</ArticleId><ArticleId IdType="pubmed">36795327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford, M. E. &amp; Kelly, P. A. Conceptualizing and categorizing race and ethnicity in health services research. Health Serv. Res.40, 1658&#x2013;1675 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1361221</ArticleId><ArticleId IdType="pubmed">16179001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford, C. L. &amp; Harawa, N. T. A new conceptualization of ethnicity for social epidemiologic and health equity research. Soc. Sci. Med.71, 251&#x2013;258 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908006</ArticleId><ArticleId IdType="pubmed">20488602</ArticleId></ArticleIdList></Reference><Reference><Citation>Saatci, D. et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr.175, 928&#x2013;938 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218232</ArticleId><ArticleId IdType="pubmed">34152371</ArticleId></ArticleIdList></Reference><Reference><Citation>Swann, O. V. et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ370, m3249 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488201</ArticleId><ArticleId IdType="pubmed">32960186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandi, S., Nevid, M. Z. &amp; Mahdavinia, M. African American children are at higher risk of COVID&#x2010;19 infection. Pediatr. Allergy Immunol.31, 861 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283894</ArticleId><ArticleId IdType="pubmed">32469426</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. H. et al. Race/ethnicity among children with COVID-19&#x2013;associated multisystem inflammatory syndrome. JAMA Netw. Open3, e2030280 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705594</ArticleId><ArticleId IdType="pubmed">33252688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisolm, D. J. et al. Associations between area-level health-related social factor indices and risk of acute COVID-19: an EHR-based cohort study from the RECOVER program. medRxiv 2012&#x2013;2022 (2022).</Citation></Reference><Reference><Citation>Razzaghi, H. et al. Vaccine effectiveness against long COVID in children. Pediatrics153, e2023064446 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, C. B. et al. Severity of acute COVID-19 in children&lt;18 years old March 2020 to December 2021. Pediatrics149, e2021055765 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35322270</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, T. D., Haaland, W., Hawley, K., Lambka, K. &amp; Mangione-Smith, R. Development and validation of the pediatric medical complexity algorithm (PMCA) version 3.0. Acad. Pediatr.18, 577&#x2013;580 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivara, F. P., Gonzalez-del-Rey, J. &amp; Forrest, C. B. The pediatric subspecialty physician workforce. JAMA Pediatr.178, 107&#x2013;108 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38109094</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoah, J. et al. Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. Clin. Infect. Dis.71, e497 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713675</ArticleId><ArticleId IdType="pubmed">32069360</ArticleId></ArticleIdList></Reference><Reference><Citation>Asch, D. A. et al. Variation in US hospital mortality rates for patients admitted With COVID-19 during the first 6 months of the pandemic. JAMA Intern Med.181, 471&#x2013;478 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756246</ArticleId><ArticleId IdType="pubmed">33351068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir, M. et al. Using data science and a health equity lens to identify long-COVID sequelae among medically underserved populations. J. Health Care Poor Underserved34, 521&#x2013;534 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37464515</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, R. et al. An empirical study for impacts of measurement errors on EHR based association studies. AMIA Annu. Symp. Proc.2016, 1764 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333313</ArticleId><ArticleId IdType="pubmed">28269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Wang, J., Chubak, J. &amp; Hubbard, R. A. Inflation of type I error rates due to differential misclassification in EHR&#x2010;derived outcomes: empirical illustration using breast cancer recurrence. Pharmacoepidemiol Drug Saf.28, 264&#x2013;268 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716793</ArticleId><ArticleId IdType="pubmed">30375122</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D. &amp; Suchard, M. A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc. Natl Acad. Sci.115, 2571&#x2013;2577 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A. &amp; Madigan, D. Interpreting observational studies: why empirical calibration is needed to correct p&#x2010;values. Stat. Med.33, 209&#x2013;218 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe, C. J., Cole, S. R., Lau, B., Napravnik, S. &amp; Eron, J. J. Jr Selection bias due to loss to follow up in cohort studies. Epidemiology27, 91&#x2013;97 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008911</ArticleId><ArticleId IdType="pubmed">26484424</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland, S., Pearl, J. &amp; Robins, J. M. Confounding and collapsibility in causal inference. Stat. Sci.14, 29&#x2013;46 (1999).</Citation></Reference><Reference><Citation>Whitcomb, B. W. &amp; Naimi, A. I. Defining, quantifying, and interpreting &#x201c;noncollapsibility&#x201d; in epidemiologic studies of measures of &#x201c;effect. Am. J. Epidemiol.190, 697 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530151</ArticleId><ArticleId IdType="pubmed">33305812</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity&#x2010;score matched samples. Stat. Med.28, 3083&#x2013;3107 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl, J. et al. Causality. (Cambridge University Press, 2009).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39857110</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">226</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics15020226</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: Earlier detection of severe immune-related hematological adverse events (irHAEs) in cancer patients treated with a PD-1 or PD-L1 inhibitor is critical to improving treatment outcomes. The study aimed to develop a simple machine learning (ML) model for predicting irHAEs associated with PD-1/PD-L1 inhibitors. <b>Methods</b>: We utilized the Observational Medical Outcomes Partnership-Common Data Model based on electronic medical records from a tertiary (KHMC) and a secondary (KHNMC) hospital in South Korea. Severe irHAEs were defined as Grades 3-5 by the Common Terminology Criteria for Adverse Events (version 5.0). The predictive model was developed using the KHMC dataset, and then cross-validated against an independent cohort (KHNMC). The full ML models were then simplified by selecting critical features based on the feature importance values (FIVs). <b>Results</b>: Overall, 397 and 255 patients were included in the primary (KHMC) and cross-validation (KHNMC) cohort, respectively. Among the tested ML algorithms, random forest achieved the highest accuracy (area under the receiver operating characteristic curve [AUROC] 0.88 for both cohorts). Parsimonious models reduced to 50% FIVs of the full models showed comparable performance to the full models (AUROC 0.83-0.86, <i>p</i> &gt; 0.05). The KHMC and KHNMC parsimonious models shared common predictive features including furosemide, oxygen gas, piperacillin/tazobactam, and acetylcysteine. <b>Conclusions:</b> Considering the simplicity and adequate predictive performance, our simplified ML models might be easily implemented in clinical practice with broad applicability. Our model might enhance early diagnostic screening of irHAEs induced by PD-1/PD-L1 inhibitors, contributing to minimizing the risk of severe irHAEs and improving the effectiveness of cancer immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seok Jun</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0009-0008-7087-4914</Identifier><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Seungwon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suhyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8481-4367</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Sung Hwan</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Taemin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeonji</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Soyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung-Tae</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwack</LastName><ForeName>Won Gun</ForeName><Initials>WG</Initials><Identifier Source="ORCID">0000-0001-9611-4341</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Sung Wook</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yun-Kyoung</ForeName><Initials>YK</Initials><Identifier Source="ORCID">0000-0003-3687-4052</Identifier><AffiliationInfo><Affiliation>College of Pharmacy, The Catholic University of Korea-Sungsim Campus, Bucheon 14662, Gyeonggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jae Myung</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-9403-230X</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0003-0119-5818</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, College of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0001-9200-2799</Identifier><AffiliationInfo><Affiliation>Department of Regulatory Science, College of Pharmacy, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regulatory Innovation Through Science (IRIS), Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23212MFDS228-1</GrantID><Agency>the Ministry of Food and Drug Safety in South Korea</Agency><Country/></Grant><Grant><GrantID>21153MFDS601-1</GrantID><Agency>the Ministry of Food and Drug Safety in South Korea</Agency><Country/></Grant><Grant><GrantID>RS-2024-00331810</GrantID><Agency>the Ministry of Food and Drug Safety in South Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PD-1 inhibitor</Keyword><Keyword MajorTopicYN="N">PD-L1 inhibitor</Keyword><Keyword MajorTopicYN="N">common data model (CDM)</Keyword><Keyword MajorTopicYN="N">immune checkpoint inhibitor</Keyword><Keyword MajorTopicYN="N">immune-related hematological adverse events</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">observational medical outcomes partnership (OMOP)</Keyword><Keyword MajorTopicYN="N">parsimonious model</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">real-world data (RWD)</Keyword><Keyword MajorTopicYN="N">risk prediction</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>13</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>25</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39857110</ArticleId><ArticleId IdType="pmc">PMC11763827</ArticleId><ArticleId IdType="doi">10.3390/diagnostics15020226</ArticleId><ArticleId IdType="pii">diagnostics15020226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wojtukiewicz M.Z., Rek M.M., Karpowicz K., G&#xf3;rska M., Polity&#x144;ska B., Wojtukiewicz A.M., Moniuszko M., Radziwon P., Tucker S.C., Honn K.V. Inhibitors of immune checkpoints&#x2014;PD-1, PD-L1, CTLA-4&#x2014;New opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40:949&#x2013;982. doi: 10.1007/s10555-021-09976-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-021-09976-0</ArticleId><ArticleId IdType="pmc">PMC8556173</ArticleId><ArticleId IdType="pubmed">34236546</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M., Rodr&#xed;guez-Abreu D., Robinson A.G., Hui R., Cs&#x151;szi T., F&#xfc;l&#xf6;p A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375:1823&#x2013;1833. doi: 10.1056/NEJMoa1606774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606774</ArticleId><ArticleId IdType="pubmed">27718847</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert C., Thomas L., Bondarenko I., O&#x2019;Day S., Weber J., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011;364:2517&#x2013;2526. doi: 10.1056/NEJMoa1104621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1104621</ArticleId><ArticleId IdType="pubmed">21639810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggiero R., Fraenza F., Scavone C., di Mauro G., Piscitelli R., Mascolo A., Ferrajolo C., Rafaniello C., Sportiello L., Rossi F., et al. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharma-covigilance Database. Front. Pharmacol. 2020;11:830. doi: 10.3389/fphar.2020.00830.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00830</ArticleId><ArticleId IdType="pmc">PMC7295943</ArticleId><ArticleId IdType="pubmed">32581796</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S., Day D., Nicholls S.J., Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4:579&#x2013;597. doi: 10.1016/j.jaccao.2022.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccao.2022.09.004</ArticleId><ArticleId IdType="pmc">PMC9830229</ArticleId><ArticleId IdType="pubmed">36636451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi T., Takase-Minegishi K., Maeda A., Hamada N., Yoshimi R., Kirino Y., Teranaka H., Kunimoto H., Hagihara M., Matsumoto K., et al. Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis. J. Hematol. 2023;12:66&#x2013;74. doi: 10.14740/jh1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jh1090</ArticleId><ArticleId IdType="pmc">PMC10181326</ArticleId><ArticleId IdType="pubmed">37187501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer R., Zaremba A., Moreira A., Ugurel S., Johnson D.B., Hassel J.C., Salzmann M., Gesierich A., Weppler A., Spain L., et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur. J. Cancer. 2021;147:170&#x2013;181. doi: 10.1016/j.ejca.2021.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2021.01.013</ArticleId><ArticleId IdType="pubmed">33706206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand A., Kostine M., Barnetche T., Truchetet M.E., Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med. 2015;13:211. doi: 10.1186/s12916-015-0455-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0455-8</ArticleId><ArticleId IdType="pmc">PMC4559965</ArticleId><ArticleId IdType="pubmed">26337719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P.F., Chen Y., Song S.Y., Wang T.J., Ji W.J., Li S.W., Liu N., Yan C.X. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front. Pharmacol. 2017;8:730. doi: 10.3389/fphar.2017.00730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00730</ArticleId><ArticleId IdType="pmc">PMC5651530</ArticleId><ArticleId IdType="pubmed">29093678</ArticleId></ArticleIdList></Reference><Reference><Citation>Conroy M., Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat. Commun. 2022;13:392. doi: 10.1038/s41467-022-27960-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-27960-2</ArticleId><ArticleId IdType="pmc">PMC8770784</ArticleId><ArticleId IdType="pubmed">35046403</ArticleId></ArticleIdList></Reference><Reference><Citation>Delanoy N., Michot J.M., Comont T., Kramkimel N., Lazarovici J., Dupont R., Champiat S., Chahine C., Robert C., Herbaux C., et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: A descriptive observational study. Lancet Haematol. 2019;6:e48&#x2013;e57. doi: 10.1016/S2352-3026(18)30175-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(18)30175-3</ArticleId><ArticleId IdType="pubmed">30528137</ArticleId></ArticleIdList></Reference><Reference><Citation>Michot J.M., Lazarovici J., Tieu A., Champiat S., Voisin A.L., Ebbo M., Godeau B., Michel M., Ribrag V., Lambotte O. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur. J. Cancer. 2019;122:72&#x2013;90. doi: 10.1016/j.ejca.2019.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2019.07.014</ArticleId><ArticleId IdType="pubmed">31634647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouvinov K., Nalbandyan K., Kozlov V., Peled N., Yakobson A. Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma. Case Rep. Oncol. 2019;12:29&#x2013;32. doi: 10.1159/000495980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000495980</ArticleId><ArticleId IdType="pmc">PMC6381922</ArticleId><ArticleId IdType="pubmed">30792642</ArticleId></ArticleIdList></Reference><Reference><Citation>Helgadottir H., Kis L., Ljungman P., Larkin J., Kefford R., Ascierto P.A., Hansson J., Masucci G. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. Ann. Oncol. 2017;28:1672&#x2013;1673. doi: 10.1093/annonc/mdx177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx177</ArticleId><ArticleId IdType="pubmed">28407116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroll M.H., Rojas-Hernandez C., Yee C. Hematologic complications of immune checkpoint inhibitors. Blood. 2022;139:3594&#x2013;3604. doi: 10.1182/blood.2020009016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020009016</ArticleId><ArticleId IdType="pmc">PMC9227102</ArticleId><ArticleId IdType="pubmed">34610113</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer J.R., Lacchetti C., Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M., Chau I., Ernstoff M.S., Gardner J.M., Ginex P., et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018;36:1714&#x2013;1768. doi: 10.1200/JCO.2017.77.6385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId><ArticleId IdType="pmc">PMC6481621</ArticleId><ArticleId IdType="pubmed">29442540</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin Y.S., Lee Y.W., Choi Y.H., Park B., Jee Y.K., Choi S.K., Kim E.G., Park J.W., Hong C.S. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Pharmacoepidemiol. Drug Saf. 2009;18:910&#x2013;915. doi: 10.1002/pds.1796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1796</ArticleId><ArticleId IdType="pubmed">19621345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn E.K. A brief introduction to research based on real-world evidence: Considering the Korean National Health Insurance Service database. Integr. Med. Res. 2022;11:100797. doi: 10.1016/j.imr.2021.100797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imr.2021.100797</ArticleId><ArticleId IdType="pmc">PMC8564560</ArticleId><ArticleId IdType="pubmed">34754752</ArticleId></ArticleIdList></Reference><Reference><Citation>Park E.S., Choi H.S., Lee K.S., Kim S.W., Lee J.M. Venous Thromboembolism in Children and Young Adults in Korea: Analysis of the Korean Health Insurance Review and Assessment Service Database. J. Korean Med. Sci. 2019;34:e316. doi: 10.3346/jkms.2019.34.e316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2019.34.e316</ArticleId><ArticleId IdType="pmc">PMC6926097</ArticleId><ArticleId IdType="pubmed">31858756</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung S.J., Qdaisat A., Chaftari P., Lipe D., Merlin J., Rajha E., Wechsler A., Sandoval M., Viets J., Al-Breiki A., et al. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J. Am. Coll. Emerg. Physicians Open. 2020;1:1637&#x2013;1659. doi: 10.1002/emp2.12209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emp2.12209</ArticleId><ArticleId IdType="pmc">PMC7771833</ArticleId><ArticleId IdType="pubmed">33392573</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden D.M., Xu H., Denny J.C., Wilke R.A. Electronic medical records as a tool in clinical pharmacology: Opportunities and challenges. Clin. Pharmacol. Ther. 2012;91:1083&#x2013;1086. doi: 10.1038/clpt.2012.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.42</ArticleId><ArticleId IdType="pmc">PMC3819803</ArticleId><ArticleId IdType="pubmed">22534870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallinan C., Ward R., Hart G., Sullivan C., Pratt N., Ng A., Capurro D., Vegt A., Liaw S.-T., Daly O., et al. Seamless EMR data access: Integrated governance, digital health and the OMOP-CDM. BMJ Health Care Inform. 2024;31:e100953. doi: 10.1136/bmjhci-2023-100953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjhci-2023-100953</ArticleId><ArticleId IdType="pmc">PMC10882353</ArticleId><ArticleId IdType="pubmed">38387992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippenszky L., Mittendorf K.F., Kiss Z., LeNoue-Newton M.L., Napan-Molina P., Rahman P., Ye C., Laczi B., Csernai E., Jain N.M., et al. Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. JCO Clin. Cancer Inform. 2024;8:e2300207. doi: 10.1200/CCI.23.00207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.23.00207</ArticleId><ArticleId IdType="pmc">PMC10919473</ArticleId><ArticleId IdType="pubmed">38427922</ArticleId></ArticleIdList></Reference><Reference><Citation>Giddings R., Joseph A., Callender T., Janes S.M., van der Schaar M., Sheringham J., Navani N. Factors influencing clinician and patient interaction with machine learning-based risk prediction models: A systematic review. Lancet Digit. Health. 2024;6:e131&#x2013;e144. doi: 10.1016/S2589-7500(23)00241-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(23)00241-8</ArticleId><ArticleId IdType="pubmed">38278615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan B., Caffo B., Vedula S.S. A Unified Framework on Generalizability of Clinical Prediction Models. Front. Artif. Intell. 2022;5:872720. doi: 10.3389/frai.2022.872720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/frai.2022.872720</ArticleId><ArticleId IdType="pmc">PMC9100692</ArticleId><ArticleId IdType="pubmed">35573904</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Guideline on Good Pharmacovigilance Practices (GVP): Module VIII&#x2014;Post-Authorisation Safety Studies (Rev 3)  [(accessed on 1 January 2025)];2017 October 9; European Medicines Agency, Heads of Medicines Agencies. Available online:  https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf.</Citation></Reference><Reference><Citation>U.S. National Cancer Institute  Common Terminology Criteria for Adverse Events (CTCAE)  [(accessed on 17 July 2024)]; Available online:  https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_60.</Citation></Reference><Reference><Citation>Srivastava A.K., Safaei N., Khaki S., Lopez G., Zeng W., Ewert F., Gaiser T., Rahimi J. Winter wheat yield prediction using convolutional neural networks from environmental and phenological data. Sci. Rep. 2022;12:3215. doi: 10.1038/s41598-022-06249-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06249-w</ArticleId><ArticleId IdType="pmc">PMC8881605</ArticleId><ArticleId IdType="pubmed">35217689</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen J., Corporan J., Marttila R., Salenius T., Jansen J. Using Machine Learning to Predict Ranking of Webpages in the Gift Industry: Factors for Search-Engine Optimization; Proceedings of the ICIST 2019: 9th International Conference on Information Systems and Technologies; Cairo, Egypt. 24&#x2013;26 March 2019; pp. 1&#x2013;8.</Citation></Reference><Reference><Citation>Addeo A., Banna G.L., Metro G., Di Maio M. Chemotherapy in Combination with Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Front. Oncol. 2019;9:264. doi: 10.3389/fonc.2019.00264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00264</ArticleId><ArticleId IdType="pmc">PMC6478036</ArticleId><ArticleId IdType="pubmed">31058078</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Olio F.G., Maggio I., Massucci M., Mollica V., Fragomeno B., Ardizzoni A. ECOG performance status &#x2265;2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors&#x2014;A systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95&#x2013;104. doi: 10.1016/j.lungcan.2020.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.04.027</ArticleId><ArticleId IdType="pubmed">32417680</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S., Moon J., Oum C., Kim S., Cho S.I., Lim Y., Ock C.-Y., Shin S. Discontinuation risk from adverse events: Immunotherapy alone vs. combined with chemotherapy: A systematic review and network meta-analysis. BMC Cancer. 2024;24:152. doi: 10.1186/s12885-024-11897-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-024-11897-4</ArticleId><ArticleId IdType="pmc">PMC10825980</ArticleId><ArticleId IdType="pubmed">38291376</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto D., Miura S., Yoshimura K., Wakuda K., Oya Y., Haratani K., Itoh S., Uemura T., Morinaga R., Takahama T., et al. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clin. Res. Rep. 2022;3:100265. doi: 10.1016/j.jtocrr.2021.100265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtocrr.2021.100265</ArticleId><ArticleId IdType="pmc">PMC8819387</ArticleId><ArticleId IdType="pubmed">35146460</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan Ali O., Berner F., Bomze D., F&#xe4;ssler M., Diem S., Cozzio A., J&#xf6;rger M., Fr&#xfc;h M., Driessen C., Lenz T.L., et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur. J. Cancer. 2019;107:8&#x2013;14. doi: 10.1016/j.ejca.2018.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2018.11.009</ArticleId><ArticleId IdType="pubmed">30529903</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatouli A.M., Quandt Z., Perdigoto A.L., Clark P.L., Kluger H., Weiss S.A., Gettinger S., Sznol M., Young A., Rushakoff R., et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018;67:1471&#x2013;1480. doi: 10.2337/dbi18-0002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dbi18-0002</ArticleId><ArticleId IdType="pmc">PMC6054443</ArticleId><ArticleId IdType="pubmed">29937434</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano S., Ashida K., Sakamoto R., Sakaguchi C., Ogata M., Maruyama K., Sakamoto S., Ikeda M., Ohe K., Akasu S., et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur. J. Cancer. 2020;130:198&#x2013;203. doi: 10.1016/j.ejca.2020.02.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2020.02.049</ArticleId><ArticleId IdType="pubmed">32229416</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelli L.C., Dorak M.T., Bettinotti M.P., Bingham C.O., Shah A.A. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology. 2019;58:476&#x2013;480. doi: 10.1093/rheumatology/key358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/key358</ArticleId><ArticleId IdType="pmc">PMC6821338</ArticleId><ArticleId IdType="pubmed">30508191</ArticleId></ArticleIdList></Reference><Reference><Citation>Inaba H., Kaido Y., Ito S., Hirobata T., Inoue G., Sugita T., Yamamoto Y., Jinnin M., Kimura H., Kobayashi T., et al. Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors. Endocrinol. Metab. 2022;37:84&#x2013;95. doi: 10.3803/EnM.2021.1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.3803/EnM.2021.1282</ArticleId><ArticleId IdType="pmc">PMC8901959</ArticleId><ArticleId IdType="pubmed">35255603</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahabi V., Berman D., Chasalow S.D., Wang L., Tsuchihashi Z., Hu B., Panting L., Jure-Kunkel M., Ji R.R. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J. Transl. Med. 2013;11:75. doi: 10.1186/1479-5876-11-75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-11-75</ArticleId><ArticleId IdType="pmc">PMC3637501</ArticleId><ArticleId IdType="pubmed">23521917</ArticleId></ArticleIdList></Reference><Reference><Citation>Marschner D., Falk M., Javorniczky N.R., Hanke-M&#xfc;ller K., Rawluk J., Schmitt-Graeff A., Simonetta F., Haring E., Dicks S., Ku M., et al. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI Insight. 2020;5:e135350. doi: 10.1172/jci.insight.132334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.132334</ArticleId><ArticleId IdType="pmc">PMC7213806</ArticleId><ArticleId IdType="pubmed">32125286</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N., Diab A., Yu R.K., Futreal A., Criswell L.A., Tayar J.H., Dadu R., Shannon V., Shete S.S., Suarez-Almazor M.E. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunol. Immunother. 2021;70:1939&#x2013;1949. doi: 10.1007/s00262-020-02797-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-020-02797-0</ArticleId><ArticleId IdType="pmc">PMC10992432</ArticleId><ArticleId IdType="pubmed">33409738</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung C., An J., Lee S., Park J., Lee K.S., Kim I.H., Han J.Y., Park Y.H., Kim J.H., Kang E.J., et al. Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer. Nat. Cancer. 2023;4:844&#x2013;859. doi: 10.1038/s43018-023-00572-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-023-00572-5</ArticleId><ArticleId IdType="pubmed">37308678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chennamadhavuni A., Abushahin L., Jin N., Presley C.J., Manne A. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Front. Immunol. 2022;13:779691. doi: 10.3389/fimmu.2022.779691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.779691</ArticleId><ArticleId IdType="pmc">PMC9086893</ArticleId><ArticleId IdType="pubmed">35558065</ArticleId></ArticleIdList></Reference><Reference><Citation>Tak Y.W., You S.C., Han J.H., Kim S.S., Kim G.T., Lee Y. Perceived Risk of Re-Identification in OMOP-CDM Database: A Cross-Sectional Survey. J. Korean Med. Sci. 2022;37:e205. doi: 10.3346/jkms.2022.37.e205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2022.37.e205</ArticleId><ArticleId IdType="pmc">PMC9259248</ArticleId><ArticleId IdType="pubmed">35790207</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz J.C., Chard T., Sa Z., Ritchie A., Jorm L., Gallego B. Extract, Transform, Load Framework for the Conversion of Health Databases to OMOP. PLoS ONE. 2022;17:e0266911. doi: 10.1371/journal.pone.0266911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266911</ArticleId><ArticleId IdType="pmc">PMC9000122</ArticleId><ArticleId IdType="pubmed">35404974</ArticleId></ArticleIdList></Reference><Reference><Citation>Divas&#xf3;n J., Ceniceros J.F., Sanz-Garcia A., Pernia-Espinoza A., Martinez-de-Pison F.J. PSO-PARSIMONY: A method for finding parsimonious and accurate machine learning models with particle swarm optimization. Application for predicting force&#x2013;displacement curves in T-stub steel connections. Neurocomputing. 2023;548:126414. doi: 10.1016/j.neucom.2023.126414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neucom.2023.126414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39870920</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Extensive benchmarking of a method that estimates external model performance from limited statistical characteristics.</ArticleTitle><Pagination><StartPage>59</StartPage><MedlinePgn>59</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">59</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-024-01414-z</ELocationID><Abstract><AbstractText>Predictive model performance may deteriorate when applied to data sources that were not used for training, thus, external validation is a key step in successful model deployment. As access to patient-level external data sources is typically limited, we recently proposed a method that estimates external model performance using only external summary statistics. Here, we benchmark the proposed method on multiple tasks using five large heterogeneous US data sources, where each, in turn, plays the role of an internal source and the remaining-external. Results showed accurate estimations for all metrics: 95th error percentiles for the area under the receiver operating characteristics (discrimination), calibration-in-the-large (calibration), Brier and scaled Brier scores (overall accuracy) of 0.03, 0.08, 0.0002, and 0.07, respectively. These results demonstrate the feasibility of estimating the transportability of prediction models using an internal cohort and external statistics. It may become an important accelerator of model deployment.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Hay</LastName><ForeName>Tal</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2156-1558</Identifier><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel. talelh@kinstitute.org.il.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanover</LastName><ForeName>Chen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3663-4286</Identifier><AffiliationInfo><Affiliation>KI Research Institute, Kfar Malal, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: J.M.R. is employed by Johnson &amp; Johnson and owns shares in Johnson &amp; Johnson. T.E.H. and C.Y. declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>28</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>28</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39870920</ArticleId><ArticleId IdType="pmc">PMC11772677</ArticleId><ArticleId IdType="doi">10.1038/s41746-024-01414-z</ArticleId><ArticleId IdType="pii">10.1038/s41746-024-01414-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wynants, L. et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ369, m1328 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, G. S. et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ384, e074819 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10772854</ArticleId><ArticleId IdType="pubmed">38191193</ArticleId></ArticleIdList></Reference><Reference><Citation>Balagopalan, A. et al. Machine learning for healthcare that matters: Reorienting from technical novelty to equitable impact. PLoS Digit. Health3, e0000474 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11018283</ArticleId><ArticleId IdType="pubmed">38620047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, A. et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern. Med.181, 1065&#x2013;1070 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218233</ArticleId><ArticleId IdType="pubmed">34152373</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps, J. M. et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med. Res. Methodol.20, 102 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley, R. D. et al. Evaluation of clinical prediction models (part 2): how to undertake an external validation study. BMJ384, e074820 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10788734</ArticleId><ArticleId IdType="pubmed">38224968</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Hay, T. &amp; Yanover, C. Estimating model performance on external samples from their limited statistical characteristics. (eds Flores, G., Chen, G. H., Pollard, T., Ho, J. C. &amp; Naumann, T.) Proceedings of the Conference on Health, Inference, and Learning, Vol. 174 of Proceedings of Machine Learning Research, 48&#x2013;62 (PMLR, 2022). https://proceedings.mlr.press/v174/el-hay22a.html.</Citation></Reference><Reference><Citation>Kostka, K. et al. Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. Clin. Epidemiol.14, 369&#x2013;384 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps, J. M., Williams, R. D., Schuemie, M. J., Ryan, P. B. &amp; Rijnbeek, P. R. Learning patient-level prediction models across multiple healthcare databases: evaluation of ensembles for increasing model transportability. BMC Med. Inform. Decis. Mak.22, 142 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134686</ArticleId><ArticleId IdType="pubmed">35614485</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbaswamy, A., Adams, R. &amp; Saria, S. Evaluating model robustness and stability to dataset shift. In: International Conference on Artificial Intelligence and Statistics, 2611&#x2013;2619 (PMLR, 2021).</Citation></Reference><Reference><Citation>Chen, M. et al. Mandoline: Model evaluation under distribution shift. In: International Conference on Machine Learning, 1617&#x2013;1629 (PMLR, 2021).</Citation></Reference><Reference><Citation>Gashi, S. et al. Modeling multiple sclerosis using mobile and wearable sensor data. NPJ Digit. Med.7, 64 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10928076</ArticleId><ArticleId IdType="pubmed">38467710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon, W. G. et al. How the weather affects the pain of citizen scientists using a smartphone app. NPJ Digit. Med.2, 105 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811599</ArticleId><ArticleId IdType="pubmed">31667359</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger, S. J. et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J. Am. Med. Inform. Assoc.17, 652&#x2013;662 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps, J. M., Schuemie, M. J., Suchard, M. A., Ryan, P. B. &amp; Rijnbeek, P. R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J. Am. Med. Inform. Assoc.25, 969&#x2013;975 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg, E. W. et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology21, 128&#x2013;138 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivinen, J. &amp; Warmuth, M. K. Exponentiated gradient versus gradient descent for linear predictors. Inf. Comput.132, 1&#x2013;63 (1997).</Citation></Reference><Reference><Citation>Hern&#xe1;n, M. &amp; Robins, J. Causal Inference: What if (CRC Press, 2020).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39884366</PMID><DateCompleted><Year>2025</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>375</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Age-related eye diseases and subsequent risk of mental disorders in older adults: A real-world multicenter study.</ArticleTitle><Pagination><StartPage>306</StartPage><EndPage>315</EndPage><MedlinePgn>306-315</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2025.01.128</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(25)00148-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relationship between age-related eye diseases and the subsequent risk of dementia and depressive disorders remains inconsistent. Furthermore, the effects on anxiety disorders and sleep disorders have been underexplored. This study aims to comprehensively examine the impact of age-related eye diseases on common mental disorders in older adults, thereby enhancing our understanding of the mental health implications in these conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The electronic health records of 1,522,036 patients aged over 60 from ten institutions in South Korea were analyzed. Patients with and without age-related eye diseases were identified, and 1:4 propensity score matching (PSM) was implemented. A 10-year longitudinal analysis was conducted using the Cox proportional hazards model to calculate the hazard ratios (HR). A meta-analysis was performed to combine the results from different institutions. Subgroup analyses were conducted to explore the impact of specific age-related eye diseases (cataract, glaucoma, age-related macular degeneration) on mental disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 41,637 patients with age-related eye disease were matched with 134,908 patients without such conditions. Patients with age-related eye disease showed a significantly higher risk of mental disorders (dementia, HR: 1.21 [95&#xa0;% CI: 1.14-1.27]; depressive disorders, HR: 1.28 [95&#xa0;% CI: 1.20-1.36]; anxiety disorders, HR: 1.31 [95&#xa0;% CI: 1.22-1.41]; sleep disorders, HR: 1.29 [95&#xa0;% CI: 1.22-1.37]). In subgroup analyses, each of the three age-related eye diseases was significantly associated with an increased risk of mental disorders. (cataract, HR: 1.25-1.33; glaucoma, HR: 1.15-1.49; age-related macular degeneration, HR: 1.18-1.37).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Age-related eye diseases increase the risk of developing mental disorders in older adults, highlighting the need for a multidisciplinary approach to patient care in these conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Gyubeom</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>So Hee</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>ChulHyoung</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Hyun Woong</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Sang Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea. Electronic address: veritas@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="Y">Eye Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="Y">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002386" MajorTopicYN="N">Cataract</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005901" MajorTopicYN="N">Glaucoma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related eye disease</Keyword><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Cataract</Keyword><Keyword MajorTopicYN="N">Mental disorders</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>31</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>30</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39884366</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2025.01.128</ArticleId><ArticleId IdType="pii">S0165-0327(25)00148-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39888618</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Use of Machine Learning to Assess the Management of Uncomplicated Urinary Tract Infection.</ArticleTitle><Pagination><StartPage>e2456950</StartPage><MedlinePgn>e2456950</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2456950</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.56950</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Uncomplicated urinary tract infection (UTI) is a common indication for outpatient antimicrobial therapy. National guidelines for the management of uncomplicated UTI were published in 2011, but the extent to which they align with current practices, patient diversity, and pathogen biology, all of which have evolved greatly in the time since their publication, is not fully known.</AbstractText><AbstractText Label="OBJECTIVE">To reevaluate the effectiveness and adverse event profile for first-line antibiotics, fluoroquinolones, and oral &#x3b2;-lactams for treating uncomplicated UTI in contemporary clinical practice.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This retrospective, population-based cohort study used a claims dataset from Independence Blue Cross, which contains inpatient, outpatient, laboratory, and pharmacy claims that occurred between 2012 and 2021, formatted into the Observational Medical Outcomes Partnership (OMOP) common data model. Participants were nonpregnant female individuals aged 18 years or older with a diagnosis of uncomplicated, nonrecurrent UTI at an outpatient setting. Patients must also have been treated with first-line (nitrofurantoin or trimethoprim-sulfamethoxazole), fluoroquinolone (ciprofloxacin, levofloxacin, or ofloxacin), or oral &#x3b2;-lactam (amoxicillin-clavulanate, cefadroxil, or cefpodoxime) antibiotics. Data analysis was performed from November 2021 to August 2024.</AbstractText><AbstractText Label="EXPOSURES">Patients exposed to first-line antibiotics were assigned to the treatment group, and those exposed to fluoroquinolone or &#x3b2;-lactam treatments were assigned to control groups.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was a composite end point for treatment failure, defined as outpatient or inpatient revisit within 30 days for UTI, pyelonephritis, or sepsis. Secondary outcomes were the risk of 4 common antibiotic-associated adverse events: gastrointestinal symptoms, rash, kidney injury, and Clostridium difficile infection.</AbstractText><AbstractText Label="RESULTS">There were 57&#x202f;585 episodes of UTI among 49&#x202f;037 female patients (mean [SD] age, 51.7 [20.1]) years), with prescriptions for first-line antibiotics in 35&#x202f;018 episodes (61%), fluoroquinolones in 21&#x202f;140 episodes (37%), and &#x3b2;-lactams in 1427 episodes (2%). After adjustment, receipt of first-line therapies was associated with an absolute risk difference of -1.78% (95% CI, -2.37% to -1.06%) for having a revisit for UTI within 30 days of diagnosis vs fluoroquinolones. First-line therapies were associated with an absolute risk difference of -6.40% (95% CI, -10.14% to -3.24%) for 30-day revisit compared with &#x3b2;-lactam antibiotics. Differences in adverse events were similar between all comparators. Results were identical for models built with an automated OMOP feature extraction package.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this cohort study of patients with uncomplicated UTI derived from a large regional claims dataset, national treatment guidelines published almost 14 years ago continue to recommend optimal treatments. These results also provide proof-of-principle that automated feature extraction methods for OMOP formatted data can emulate manually curated models, thereby promoting reproducibility and generalizability.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>MIT Media Lab, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Ming-Chieh</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healey</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Program in Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Chen Wen</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Operations Research Center, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Advani</LastName><ForeName>Sonali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith-McLallen</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Independence Blue Cross, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Medical Engineering and Sciences, Massachusetts Institute of Technology, Cambridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanjilal</LastName><ForeName>Sanjat</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 DK100024</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 HS027841</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047090">beta-Lactams</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Aug 19:2024.08.18.24312104. doi: 10.1101/2024.08.18.24312104.</RefSource><PMID Version="1">39228716</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014552" MajorTopicYN="Y">Urinary Tract Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024841" MajorTopicYN="N">Fluoroquinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047090" MajorTopicYN="N">beta-Lactams</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Healey reported receiving nonfinancial in-kind support from Optum through research collaboration outside the submitted work. Dr Advani reported receiving grants from the Centers for Disease Control and Prevention, National Institute on Aging/Duke Pepper Center, and Society for Healthcare Epidemiology of America; personal fees from GSK, Locus Biosciences, and Infectious Diseases Society of America; past ownership of IPEC Experts; and being an employee of GSK/ViiV Healthcare as of July 1, 2024, which is over a year after their work on this project. Dr Smith-McLallen reported being an employee of Independence Blue Cross, and this research was conducted as part of his role with the company. Dr Sontag reported receiving personal fees from Layer Health, Inc, outside the submitted work. Dr Kanjilal reported serving on the PhAST Diagnostics scientific advisory board outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>31</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>31</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>31</Day><Hour>11</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39888618</ArticleId><ArticleId IdType="pmc">PMC11786233</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.56950</ArticleId><ArticleId IdType="pii">2829781</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Foxman B, Barlow R, D&#x2019;Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509-515. doi:10.1016/S1047-2797(00)00072-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1047-2797(00)00072-7</ArticleId><ArticleId IdType="pubmed">11118930</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother. 2014;69(1):234-240. doi:10.1093/jac/dkt301</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkt301</ArticleId><ArticleId IdType="pubmed">23887867</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K, Hooton TM, Naber KG, et al. . International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq257</ArticleId><ArticleId IdType="pubmed">21292654</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg Infect Dis. 2005;11(8):1197-1204. doi:10.3201/eid1108.050116</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1108.050116</ArticleId><ArticleId IdType="pmc">PMC3320507</ArticleId><ArticleId IdType="pubmed">16102307</ArticleId></ArticleIdList></Reference><Reference><Citation>Nseir S, Di Pompeo C, Soubrier S, et al. . First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med. 2005;33(2):283-289. doi:10.1097/01.CCM.0000152230.53473.A1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000152230.53473.A1</ArticleId><ArticleId IdType="pubmed">15699829</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Pasupuleti V, Thota P, et al. . Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkt129</ArticleId><ArticleId IdType="pubmed">23620467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA. 2005;293(8):949-955. doi:10.1001/jama.293.8.949</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.293.8.949</ArticleId><ArticleId IdType="pubmed">15728165</ArticleId></ArticleIdList></Reference><Reference><Citation>Arredondo-Garc&#xed;a JL, Figueroa-Dami&#xe1;n R, Rosas A, et al. ; uUTI Latin American Study Group . Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother. 2004;54(4):840-843. doi:10.1093/jac/dkh414</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkh414</ArticleId><ArticleId IdType="pubmed">15347634</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz R, Chazan B, Kennes Y, et al. ; Israeli Urinary Tract Infection Group . Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34(9):1165-1169. doi:10.1086/339812</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/339812</ArticleId><ArticleId IdType="pubmed">11941541</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999;21(11):1864-1872. doi:10.1016/S0149-2918(00)86734-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(00)86734-X</ArticleId><ArticleId IdType="pubmed">10890258</ArticleId></ArticleIdList></Reference><Reference><Citation>Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998;10(1):39-47. doi:10.1016/S0924-8579(98)00021-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(98)00021-1</ArticleId><ArticleId IdType="pubmed">9624542</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. . Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600-606. doi:10.7326/0003-4819-153-9-201011020-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodialam RS, Boiarsky R, Lim J, Dixit N, Sai A, Sontag D. Deep contextual clinical prediction with reverse distillation. arXiv. Preprint posted online December 17, 2020. doi:10.48550/arxiv.2007.05611</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arxiv.2007.05611</ArticleId></ArticleIdList></Reference><Reference><Citation>Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779-788. doi:10.1111/j.0006-341X.2000.00779.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.2000.00779.x</ArticleId><ArticleId IdType="pubmed">10985216</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30):5642-5655. doi:10.1002/sim.7084</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7084</ArticleId><ArticleId IdType="pmc">PMC5157758</ArticleId><ArticleId IdType="pubmed">27549016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg S, Lee SI. A unified approach to interpreting model predictions. arXiv. Preprint posted online November 25, 2017. doi:10.48550/arxiv.1705.07874</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arxiv.1705.07874</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox MA, Villasis-Keever A, Sena AG, Knoll C, Fife D. Evaluation of disability in patients exposed to fluoroquinolones. BMC Pharmacol Toxicol. 2020;21(1):40. doi:10.1186/s40360-020-00415-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-020-00415-4</ArticleId><ArticleId IdType="pmc">PMC7268406</ArticleId><ArticleId IdType="pubmed">32493505</ArticleId></ArticleIdList></Reference><Reference><Citation>Healey E, Jones N. uti-causal-inference. GitHub. Accessed December 23, 2024. https://github.com/clinicalml/uti-causal-inference/</Citation></Reference><Reference><Citation>Pedrotti CHS, Accorsi TAD, De Amicis Lima K, et al. . Antibiotic stewardship in direct-to-consumer telemedicine consultations leads to high adherence to best practice guidelines and a low prescription rate. Int J Infect Dis. 2021;105:130-134. doi:10.1016/j.ijid.2021.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.020</ArticleId><ArticleId IdType="pubmed">33578013</ArticleId></ArticleIdList></Reference><Reference><Citation>Palms DL, Hicks LA, Bartoces M, et al. . Comparison of antibiotic prescribing in retail clinics, urgent care centers, emergency departments, and traditional ambulatory care settings in the United States. JAMA Intern Med. 2018;178(9):1267-1269. doi:10.1001/jamainternmed.2018.1632</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.1632</ArticleId><ArticleId IdType="pmc">PMC6142958</ArticleId><ArticleId IdType="pubmed">30014128</ArticleId></ArticleIdList></Reference><Reference><Citation>Trestioreanu AZ, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev. 2010;34(10):CD007182. doi:10.1002/14651858.CD007182.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007182.pub2</ArticleId><ArticleId IdType="pubmed">20927755</ArticleId></ArticleIdList></Reference><Reference><Citation>Vall&#xe9;e M, Harding C, Hall J, Aldridge PD, Tan A. Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates. J Antimicrob Chemother. 2023;78(2):373-379. doi:10.1093/jac/dkac398</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkac398</ArticleId><ArticleId IdType="pmc">PMC9890214</ArticleId><ArticleId IdType="pubmed">36480295</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira Rodrigues A, Roque F, Falc&#xe3;o A, Figueiras A, Herdeiro MT. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents. 2013;41(3):203-212. doi:10.1016/j.ijantimicag.2012.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2012.09.003</ArticleId><ArticleId IdType="pubmed">23127482</ArticleId></ArticleIdList></Reference><Reference><Citation>Livorsi D, Comer A, Matthias MS, Perencevich EN, Bair MJ. Factors influencing antibiotic-prescribing decisions among inpatient physicians: a qualitative investigation. Infect Control Hosp Epidemiol. 2015;36(9):1065-1072. doi:10.1017/ice.2015.136</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2015.136</ArticleId><ArticleId IdType="pmc">PMC4797059</ArticleId><ArticleId IdType="pubmed">26078017</ArticleId></ArticleIdList></Reference><Reference><Citation>Krockow EM, Colman AM, Chattoe-Brown E, et al. . Balancing the risks to individual and society: a systematic review and synthesis of qualitative research on antibiotic prescribing behaviour in hospitals. J Hosp Infect. 2019;101(4):428-439. doi:10.1016/j.jhin.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2018.08.007</ArticleId><ArticleId IdType="pubmed">30099092</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SV, Schneeweiss S, Franklin JM, et al. ; RCT-DUPLICATE Initiative . Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376-1385. doi:10.1001/jama.2023.4221</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.4221</ArticleId><ArticleId IdType="pmc">PMC10130954</ArticleId><ArticleId IdType="pubmed">37097356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel MC, Trautner BW, Grigoryan L. The five Ds of outpatient antibiotic stewardship for urinary tract infections. Clin Microbiol Rev. 2021;34(4):e0000320. doi:10.1128/CMR.00003-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00003-20</ArticleId><ArticleId IdType="pmc">PMC8404614</ArticleId><ArticleId IdType="pubmed">34431702</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcelin JR, Chung P, Van Schooneveld TC. Antimicrobial stewardship in the outpatient setting: a review and proposed framework. Infect Control Hosp Epidemiol. 2020;41(7):833-840. doi:10.1017/ice.2020.94</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.94</ArticleId><ArticleId IdType="pubmed">32342826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nys CL, Fischer K, Funaro J, et al. . Impact of education and data feedback on antibiotic prescribing for urinary tract infections in the emergency department: an interrupted time-series analysis. Clin Infect Dis. 2022;75(7):1194-1200. doi:10.1093/cid/ciac073</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac073</ArticleId><ArticleId IdType="pubmed">35100621</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39896425</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>Implementing a Common Data Model in Ophthalmology: Mapping Structured Electronic Health Record Ophthalmic Examination Data to Standard Vocabularies.</ArticleTitle><Pagination><StartPage>100666</StartPage><MedlinePgn>100666</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100666</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2024.100666</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To identify and characterize concept coverage gaps of ophthalmology examination data elements within the Cerner Millennium electronic health record (EHR) implementations by the Observational Health Data Sciences and Informatics Observational Medical Outcomes Partnership (OMOP) common data model (CDM).</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Analysis of data elements in EHRs.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="UNASSIGNED">Not applicable.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Source eye examination data elements from the default Cerner Model Experience EHR and a local implementation of the Cerner Millennium EHR were extracted, classified into one of 8 subject categories, and mapped to the semantically closest standard concept in the OMOP CDM. Mappings were categorized as exact, if the data element and OMOP concept represented equivalent information, wider, if the OMOP concept was missing conceptual granularity, narrower, if the OMOP concept introduced excess information, and unmatched, if no standard concept adequately represented the data element. Descriptive statistics and qualitative analysis were used to describe the concept coverage for each subject category.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">Concept coverage gaps in 8 ophthalmology subject categories of data elements by the OMOP CDM.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 409 and 947 ophthalmology data elements in the default and local Cerner modules, respectively. Of the 409 mappings in the default Cerner module, 25% (n&#xa0;=&#xa0;102) were exact, 53% (n&#xa0;=&#xa0;217) were wider, 3% (n&#xa0;=&#xa0;11) were narrower, and 19% (n&#xa0;=&#xa0;79) were unmatched. In the local Cerner module, 18% (n&#xa0;=&#xa0;173) of mappings were exact, 54% (n&#xa0;=&#xa0;514) were wider, 1% (n&#xa0;=&#xa0;10) were narrower, and 26% (n&#xa0;=&#xa0;250) were <i>unmatched</i>. The largest coverage gaps were seen in the local Cerner module under the visual acuity, sensorimotor testing, and refraction categories, with 95%, 95%, and 81% of data elements in each respective category having mappings that were not exact. Concept coverage gaps spanned all 8 categories in both EHR implementations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Considerable coverage gaps by the OMOP CDM exist in all areas of the ophthalmology examination, which should be addressed to improve the OMOP CDM's effectiveness in ophthalmic research. We identify specific subject categories that may benefit from increased granularity in the OMOP CDM and provide suggestions for facilitating consistency of standard concepts, with the goal of improving data standards in ophthalmology.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Academy of Ophthalmology&#xe9;.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quon</LastName><ForeName>Justin C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halfpenny</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Southern California Clinical and Translational Science Institute, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Cindy X</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Sally L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daketi</LastName><ForeName>Vamsi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Information Technology, Keck Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Information Technology, Keck Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahroos</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Southern California Clinical and Translational Science Institute, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Benjamin Y</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toy</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 EY032985</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 EY033440</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 EY029220</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM011271</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Data standards</Keyword><Keyword MajorTopicYN="N">Electronic health record</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39896425</ArticleId><ArticleId IdType="pmc">PMC11783105</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2024.100666</ArticleId><ArticleId IdType="pii">S2666-9145(24)00202-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boland M.V., Chiang M.F., Lim M.C., et al. Adoption of electronic health records and preparations for demonstrating meaningful use: an American Academy of Ophthalmology survey. Ophthalmology. 2013;120:1702&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">23806425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.B., Shahid H. Distribution and extent of electronic medical record utilisation in eye units across the United Kingdom: a cross-sectional study of the current landscape. BMJ Open. 2017;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5541331</ArticleId><ArticleId IdType="pubmed">28515180</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M.C., Boland M.V., McCannel C.A., et al. Adoption of electronic health records and perceptions of financial and clinical outcomes among ophthalmologists in the United States. JAMA Ophthalmol. 2018;136:164&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5838599</ArticleId><ArticleId IdType="pubmed">29285542</ArticleId></ArticleIdList></Reference><Reference><Citation>Li E., Clarke J., Ashrafian H., et al. The impact of electronic health record interoperability on safety and quality of care in high-income countries: systematic review. J&#xa0;Med Internet Res. 2022;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9523524</ArticleId><ArticleId IdType="pubmed">36107486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstam E.V., Warner J.L., Krauss J.C., et al. Quantitating and assessing interoperability between electronic health records. J&#xa0;Am Med Inform Assoc. 2022;29:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006690</ArticleId><ArticleId IdType="pubmed">35015861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang M.F., Boland M.V., Brewer A., et al. Special requirements for electronic health record systems in ophthalmology. Ophthalmology. 2011;118:1681&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">21680023</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfpenny W., Baxter S.L. Towards effective data sharing in ophthalmology: data standardization and data privacy. Curr Opin Ophthalmol. 2022;33:418&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357189</ArticleId><ArticleId IdType="pubmed">35819893</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter S.L., Reed A.A., Maa A., et al. Ocular health and national data standards: a case for including visual acuity in the United States Core Data for Interoperability. Ophthalmol Sci. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767820</ArticleId><ArticleId IdType="pubmed">36570621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan J., Hirschfeld S., Foster E., et al. Improving the value of clinical research through the use of Common Data Elements. Clin Trials. 2016;13:671&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133155</ArticleId><ArticleId IdType="pubmed">27311638</ArticleId></ArticleIdList></Reference><Reference><Citation>Son N., Kim B., Chung S., Han S. Korean pharmacovigilance system based on EHR-CDM. Stud Health Technol Inf. 2019;264:1592&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H., Kim S., Yi S., et al. Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J&#xa0;Biomed Inf. 2020;107</Citation><ArticleIdList><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N., Peng Y., Wolfien M., et al. OMOP CDM can facilitate data-driven studies for cancer prediction: a systematic review. Int J Mol Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R., Gurley M., Dymshyts D., et al. Standardized observational cancer research using the OMOP CDM oncology module. Stud Health Technol Inf. 2019;264:1831&#x2013;1832.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438365</ArticleId></ArticleIdList></Reference><Reference><Citation>Long C.P., Tai-Seale M., El-Kareh R., et al. Electronic health record use among ophthalmology residents while on call. J&#xa0;Acad Ophthalmol (2017) 2020;12:e143&#x2013;e150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7710324</ArticleId><ArticleId IdType="pubmed">33274310</ArticleId></ArticleIdList></Reference><Reference><Citation>Read-Brown S., Hribar M.R., Reznick L.G., et al. Time requirements for electronic health record use in an academic ophthalmology center. JAMA Ophthalmol. 2017;135:1250&#x2013;1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710390</ArticleId><ArticleId IdType="pubmed">29049512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gali H.E., Baxter S.L., Lander L., et al. Impact of electronic health record implementation on ophthalmology trainee time expenditures. J&#xa0;Acad Ophthalmol (2017) 2019;11:e65&#x2013;e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095731</ArticleId><ArticleId IdType="pubmed">33954272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Duke J.D., Shah N.H., et al. Observational health data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inf. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP common data model. GitHub. https://ohdsi.github.io/CommonDataModel/</Citation></Reference><Reference><Citation>Quiroz J.C., Chard T., Sa Z., et al. Extract, transform, load framework for the conversion of health databases to OMOP. PLoS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000122</ArticleId><ArticleId IdType="pubmed">35404974</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F., Resnic F.S., Robbins S.L., et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inf. 2015;6:536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Henke E., Sedlmayr M., Bathelt F. Towards ETL processes to OMOP CDM using metadata and modularization. Stud Health Technol Inf. 2023;302:751&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">37203486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima D.M., Rodrigues-Jr J.F., Traina A.J.M., et al. Transforming two decades of ePR data to OMOP CDM for clinical research. Stud Health Technol Inf. 2019;264:233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437920</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann P., Ong R., Davydov A., et al. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC Med Res Methodol. 2021;21:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsch F., Hussein R., Korntheuer R., Duftschmid G. Converting HL7 CDA based nationwide Austrian medication data to OMOP CDM. Stud Health Technol Inf. 2023;302:899&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">37203528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang M.F., Casper D.S., Cimino J.J., Starren J. Representation of ophthalmology concepts by electronic systems: adequacy of controlled medical terminologies. Ophthalmology. 2005;112:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15691548</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskins Jr., H.D., Hildebrand P.L., Lum F. The American Academy of Ophthalmology adopts SNOMED CT as its official clinical terminology. Ophthalmology. 2008;115:225&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">18243903</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C.X., Halfpenny W., Boland M.V., et al. Advancing toward a common data model in ophthalmology: gap analysis of general eye examination concepts to standard observational medical outcomes partnership (OMOP) concepts. Ophthalmol Sci. 2023;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10630664</ArticleId><ArticleId IdType="pubmed">38025162</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub - OHDSI/Athena  Web application for distributing and browsing the Standardized Vocabularies for all instances of an OMOP CDM. GitHub. https://github.com/OHDSI/Athena</Citation></Reference><Reference><Citation>USAGI for vocabulary mapping  OHDSI observational health data Sciences and Informatics. https://www.ohdsi.org/analytic-tools/usagi/</Citation></Reference><Reference><Citation>HL7 FHIR  Resource concept map &#x2013; content. https://www.hl7.org/fhir/conceptmap.html</Citation></Reference><Reference><Citation>Mi&#xf1;arro-Gim&#xe9;nez J.A., Mart&#xed;nez-Costa C., L&#xf3;pez-Garc&#xed;a P., Schulz S. Building SNOMED CT post-coordinated expressions from annotation groups. Stud Health Technol Inf. 2017;235:446&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">28423832</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson D., Nystr&#xf6;m M., Cornet R. Does SNOMED CT post-coordination scale? Stud Health Technol Inf. 2014;205:1048&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">25160348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ophthalmology Content ETL Dashboard  OHDSI eye care and vision WG github. https://ohdsi.github.io/EyeCareVisionWG/Approach.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39904407</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>163</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Bias, type I error and statistical power of the prior Knowledge-Guided integrated likelihood estimation (PIE) for bias reduction in EHR based association studies.</ArticleTitle><Pagination><StartPage>104787</StartPage><MedlinePgn>104787</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2025.104787</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(25)00016-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Binary outcomes in electronic health records (EHR) derived using automated phenotype algorithms may suffer from phenotyping error, resulting in bias in association estimation. Huang et al. [1] proposed the Prior Knowledge-Guided Integrated Likelihood Estimation (PIE) method to mitigate the estimation bias, however, their investigation focused on point estimation without statistical inference, and the evaluation of PIE therein using simulation was a proof-of-concept with only a limited scope of scenarios. This study aims to comprehensively assess PIE's performance including (1) how well PIE performs under a wide spectrum of operating characteristics of phenotyping algorithms under real-world scenarios (e.&#xa0;g., low prevalence, low sensitivity, high specificity); (2) beyond point estimation, how much variation of the PIE estimator was introduced by the prior distribution; and (3) from a hypothesis testing point of view, if PIE improves type I error and statistical power relative to the na&#xef;ve method (i.e., ignoring the phenotyping error).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Synthetic data and use-case analysis were utilized to evaluate PIE. The synthetic data were generated under diverse outcome prevalence, phenotyping algorithm sensitivity, and association effect sizes. Simulation studies compared PIE under different prior distributions with the na&#xef;ve method, assessing bias, variance, type I error, and power. Use-case analysis compared the performance of PIE and the na&#xef;ve method in estimating the association of multiple predictors with COVID-19 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PIE exhibited reduced bias compared to the na&#xef;ve method across varied simulation settings, with comparable type I error and power. As the effect size became larger, the bias reduced by PIE was larger. PIE has superior performance when prior distributions aligned closely with true phenotyping algorithm characteristics. Impact of prior quality was minor for low-prevalence outcomes but large for common outcomes. In use-case analysis, PIE maintains a relatively accurate estimation across different scenarios, particularly outperforming the na&#xef;ve approach under large effect sizes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PIE effectively mitigates estimation bias in a wide spectrum of real-world settings, particularly with accurate prior information. Its main benefit lies in bias reduction rather than hypothesis testing. The impact of the prior is small for low-prevalence outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Naimin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA; Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA; Leonard Davis Institute of Health Economics, Philadelphia, PA, USA; Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. Electronic address: ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Association study</Keyword><Keyword MajorTopicYN="N">Bias reduction</Keyword><Keyword MajorTopicYN="N">Electronic health record</Keyword><Keyword MajorTopicYN="N">Phenotyping error</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>3</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>5</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>4</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39904407</ArticleId><ArticleId IdType="mid">NIHMS2087400</ArticleId><ArticleId IdType="pmc">PMC12180398</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2025.104787</ArticleId><ArticleId IdType="pii">S1532-0464(25)00016-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang J, Duan R, Hubbard RA, Wu Y, Moore JH, Xu H, Chen Y, PIE: A prior knowledge guided integrated likelihood estimation method for bias reduction in association studies using electronic health records data, J. Am. Med. Inform. Assoc 25 (3) (2018) 345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378882</ArticleId><ArticleId IdType="pubmed">29206922</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB, PheValuator: development and evaluation of a phenotype algorithm evaluator, J. Biomed. Inform 97 (2019) 103258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuhaus JM (1999). Bias and efficiency loss due to misclassified responses in binary regression. Biometrika, 86(4), 843&#x2013;855.</Citation></Reference><Reference><Citation>Swerdel JN, Hripcsak G, &amp; Ryan PB (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, Cao M, Wu Y, Huang J, Denny JC, Xu H, &amp; Chen Y (2016). An empirical study for impacts of measurement errors on EHR based association studies. In AMIA Annual Symposium Proceedings (Vol. 2016, p. 1764). American Medical Informatics Association.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333313</ArticleId><ArticleId IdType="pubmed">28269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger JO, Liseo B, Wolpert RL, Integrated likelihood methods for eliminating nuisance parameters, Stat. Sci 14 (1) (1999) 1&#x2013;28.</Citation></Reference><Reference><Citation>Severini TA, Integrated likelihood functions for non-Bayesian inference, Biometrika 94 (3) (2007) 529&#x2013;542.</Citation></Reference><Reference><Citation>Koehler E, Brown E, Haneuse SJP, On the assessment of Monte Carlo error in simulation-based statistical analyses, Am. Stat 63 (2) (2009) 155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3337209</ArticleId><ArticleId IdType="pubmed">22544972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorman V, Rao S, Jhaveri R, Case A, Mejias A, Pajor NM, Patel P, Thacker D, Bose-Brill S, Block J, Hanley PC, Prahalad P, Chen Y, Forrest CB, Bailey LC, Lee GM, Razzaghi H, Understanding pediatric long COVID using a tree-based scan statistic approach: an EHR-based cohort study from the RECOVER Program, JAMIA Open 6 (1) (2023) ooad016, 10.1093/jamiaopen/ooad016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad016</ArticleId><ArticleId IdType="pmc">PMC10013630</ArticleId><ArticleId IdType="pubmed">36926600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA, Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data, Proc. Natl. Acad. Sci 115 (11) (2018) 2571&#x2013;2577, 10.1073/pnas.1708282114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang J, Chubak J, Hubbard RA, Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: empirical illustration using breast cancer recurrence, Pharmacoepidemiology and Drug Safety 28 (2) (2019) 264&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716793</ArticleId><ArticleId IdType="pubmed">30375122</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Tong J, Zhang B, Zhang D, Chen J, Lei Y, Chen Y, Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents, Ann. Intern. Med (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Further reading</Title><Reference><Citation>Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, et al. , PEDSnet: a national pediatric learning health system, J. Am. Med. Inform. Assoc. 21 (4) (2014. Jul 1) 602&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>https://github.com/PEDSnet/Data_Models_Public/tree/master/PEDSnet.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39913942</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1741-2811</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Health informatics journal</Title><ISOAbbreviation>Health Informatics J</ISOAbbreviation></Journal><ArticleTitle>Project Victoria: A pragmatic data model to automate RWE generation from the national French claims database.</ArticleTitle><Pagination><StartPage>14604582251318250</StartPage><MedlinePgn>14604582251318250</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/14604582251318250</ELocationID><Abstract><AbstractText><b>Objective:</b> This paper describes Victoria, an empirically built data pipeline for SNDS to: - Build an automated, scalable pipeline supporting changes to the data model inherent to the use of large databases, - Deliver a documented pipeline with clear processes, enabling scientific, epidemiological researches, - Ease access to SNDS data in compliance with regulatory requirements. <b>Methods:</b> This paper describes the 2-steps process of the Victoria pipeline and its final output. The initial cleaning step consists in formatting, deleting empty, error or duplicate records and renaming variables without changing their values, accordingly with the official SNDS documentation. The second step consists in creating 2 linearised data models: every line of each table is an event, and each table is indexed with a unique patient identifier, without the need for a central patient or identifier table. These 2 models are: - the epidemiological model, used for answering most of the research questions requiring population phenotyping (demography, diagnosis, procedures characteristics). - the medico-economic model is used for costs and healthcare consumption analyses. It contains more complex information about reimbursements rates and the data quality assessment is focused on costs rather than medico-administrative information. <b>Results:</b> The pipeline was executed on 2 different datasets representing &#x223c;85 000 and &#x223c;870 000 beneficiaries with the following configuration: one master with 4 cores and 16Go of RAM and respectively 4 and 6 workers. The total execution time for the smaller dataset was 25&#xa0;h and 96&#xa0;h for the larger one. The longest part of those times is represented by the format conversion to parquet. The cleaning step took only 4&#xa0;h in both cases. The epidemiological model took 344&#xa0;min for the smaller dataset and 1934&#xa0;min for the larger one. The medico-economic model took the longest time with 704&#xa0;min and 2145&#xa0;min, respectively. <b>Conclusion:</b> Victoria pipeline is a successfully implemented SNDS pipeline. Compared to previous pipelines, reviewability is part of its design as unit tests and quality assessments can natively be developed to ensure data and analysis quality. The pipeline has been used for 2 published studies. The recent work toward OMOP conversion will be integrated in upcoming versions and, as Victoria is set to run on a CD platform, the potential evolution if SNDS format can be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ouazzani</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2321-141X</Identifier><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansolabehere</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0007-4619-265X</Identifier><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Journeau</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaubourg</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doublet</LastName><ForeName>Maxime</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0005-3301-2862</Identifier><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thollot</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0007-9902-9784</Identifier><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabre</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-1408-1638</Identifier><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glatt</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinityx, Boulogne-Billancourt, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Informatics J</MedlineTA><NlmUniqueID>100883604</NlmUniqueID><ISSNLinking>1460-4582</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="Y">Insurance Claim Review</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DCIR</Keyword><Keyword MajorTopicYN="N">PMSI</Keyword><Keyword MajorTopicYN="N">RWE</Keyword><Keyword MajorTopicYN="N">SNDS</Keyword><Keyword MajorTopicYN="N">Victoria</Keyword><Keyword MajorTopicYN="N">claims</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">pipeline</Keyword><Keyword MajorTopicYN="N">real world evidence</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39913942</ArticleId><ArticleId IdType="doi">10.1177/14604582251318250</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39949611</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2673-253X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in digital health</Title><ISOAbbreviation>Front Digit Health</ISOAbbreviation></Journal><ArticleTitle>Harmonizing population health data into OMOP common data model: a demonstration using COVID-19 sero-surveillance data from Nairobi Urban Health and Demographic Surveillance System.</ArticleTitle><Pagination><StartPage>1423621</StartPage><MedlinePgn>1423621</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1423621</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fdgth.2025.1423621</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Observational health data are collected in different formats and structures, making it challenging to analyze with common tools. The Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) is a standardized data model that can harmonize observational health data.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This paper demonstrates the use of the OMOP CDM to harmonize COVID-19 sero-surveillance data from the Nairobi Urban Health and Demographic Surveillance System (HDSS).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, we extracted data from the Nairobi Urban HDSS COVID-19 sero-surveillance database and mapped it to the OMOP CDM. We used open-source Observational Health Data Sciences and Informatics (OHDSI) tools like WhiteRabbit, RabbitInAHat, and USAGI. The steps included data profiling (scanning), mapping the vocabularies using the offline USAGI and online ATHENA, and designing the extract, transform, and load (ETL) process using RabbitInAHat. The ETL process was implemented using Pentaho Data Integration community edition software and structured query language (SQL). The target OMOP CDM can now be used to analyze the prevalence of COVID-19 antibodies in the Nairobi Urban HDSS population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We successfully mapped the Nairobi Urban HDSS COVID-19 sero-surveillance data to the OMOP CDM. The standardized dataset included information on demographics, COVID-19 symptoms, vaccination, and COVID-19 antibody test results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The OMOP CDM is a valuable tool for harmonizing observational health data. Using the OMOP CDM facilitates the sharing and analysis of observational health data, leading to a better understanding of disease conditions and trends and improving evidence-based population health strategies.</AbstractText><CopyrightInformation>&#xa9; 2025 Ochola, Kiwuwa-Muyingo, Bhattacharjee, Amadi, Ng&#x2019;etich, Kadengye, Owoko, Igumba, Greenfield, Todd and Kiragga.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ochola</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiwuwa-Muyingo</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharjee</LastName><ForeName>Tathagata</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng'etich</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadengye</LastName><ForeName>Damazo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owoko</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igumba</LastName><ForeName>Boniface</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Machine Learning (AI and ML), Committee on Data of the International Science Council (CODATA), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Population Health, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiragga</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data Science Program, African Population and Health Research Center (APHRC), Nairobi, Kenya.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Implementation Network for Sharing Population Information from Research Entities (INSPIRE Network), Nairobi, Kenya.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Digit Health</MedlineTA><NlmUniqueID>101771889</NlmUniqueID><ISSNLinking>2673-253X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Africa</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">Nairobi Urban HDSS</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">observational health data</Keyword><Keyword MajorTopicYN="N">population health data</Keyword><Keyword MajorTopicYN="N">sero-surveillance</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39949611</ArticleId><ArticleId IdType="pmc">PMC11822943</ArticleId><ArticleId IdType="doi">10.3389/fdgth.2025.1423621</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reimer AP, Milinovich A, Madigan EA. Data quality assessment framework to assess electronic medical record data for use in research. Int J Med Inform. (2016) 90:40&#x2013;7. 10.1016/j.ijmedinf.2016.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2016.03.006</ArticleId><ArticleId IdType="pmc">PMC4845906</ArticleId><ArticleId IdType="pubmed">27103196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace M, Ettelt S, Mays N, Nolte E. Assessing quality in cross-country comparisons of health systems and policies: towards a set of generic quality criteria. Health Policy. (2013) 112(1&#x2013;2):156&#x2013;62. 10.1016/j.healthpol.2013.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2013.03.020</ArticleId><ArticleId IdType="pubmed">23628482</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, Rasmussen LV, Liu C, Benoit B, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform. (2019) 96:2&#x2013;3. 10.1016/j.jbi.2019.103253</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103253</ArticleId><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://ohdsi.org/ (accessed September 14, 2023)</Citation></Reference><Reference><Citation>Lynch KE, Deppen S, Duvall S, Viernes B, Cao A, Park D, et al. Dynamic-ETL: a hybrid approach for health data extraction, transformation and loading. Appl Clin Inform. (2017) 17(5):1&#x2013;12. 10.1186/s12911-017-0532-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-017-0532-3</ArticleId><ArticleId IdType="pmc">PMC5598056</ArticleId><ArticleId IdType="pubmed">28903729</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Schuemie MJ, Lu Y, Ostropolets A, Chen R, Hripcsak G, et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open. (2022) 12(6):e057977&#x2013;16. 10.1136/bmjopen-2021-057977</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057977</ArticleId><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. The Book of OHDSI. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html#person (accessed August 30, 2023)</Citation></Reference><Reference><Citation>APHRC. APHRC Online Microdata Library. African Population and Health Research Center (APHRC). Available online at:
https://microdataportal.aphrc.org (accessed August 30, 2023)</Citation></Reference><Reference><Citation>Kagucia EW, Ziraba AK, Nyagwange J, Kutima B, Kimani M, Akech D, et al. SARS-CoV-2 seroprevalence and implications for population immunity: evidence from two health and demographic surveillance system sites in Kenya, February&#x2013;June 2022. medRXiv [Preprint]. (2022):6&#x2013;8. 10.1101/2022.10.10.22280824</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.10.22280824</ArticleId><ArticleId IdType="pmc">PMC10522478</ArticleId><ArticleId IdType="pubmed">37752065</ArticleId></ArticleIdList></Reference><Reference><Citation>Etyang AO, Adetifa I, Omore R, Misore T, Ziraba AK, Ng'oda MA, et al. SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020&#x2013;May 2021. PLOS Global Public Health. (2022) 2(8):e0000883. 10.1371/journal.pgph.0000883</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0000883</ArticleId><ArticleId IdType="pmc">PMC10021917</ArticleId><ArticleId IdType="pubmed">36962821</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. WhiteRabbit for ETL Design. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://www.ohdsi.org/analytic-tools/whiterabbit-for-etl-design/ (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. Athena. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://athena.ohdsi.org/search-terms/start (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. Usagi. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://www.ohdsi.org/analytic-tools/usagi/ (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. Rabbit in a Hat. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. OMOP CDM v6.0. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://ohdsi.github.io/CommonDataModel/cdm60.html (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. OHDSI/CommonDataModel. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://github.com/OHDSI/CommonDataModel/tree/v5.4.0/inst/ddl/5.4 (accessed August 30, 2023)</Citation></Reference><Reference><Citation>Kiwuwa-Muyingo S, Todd J, Bhattacharjee T, Taylor A, Greenfield J. Enabling data sharing and utilization for African population health data using OHDSI tools with an OMOP-common data model. Front Public Health. (2023) 11:2&#x2013;4. 10.3389/fpubh.2023.1116682</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1116682</ArticleId><ArticleId IdType="pmc">PMC10287979</ArticleId><ArticleId IdType="pubmed">37361151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Zong N, Wen A, Liu S, Stone DJ, Knaack D, et al. Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration. J Biomed Inform. (2022) 127:104002. 10.1016/j.jbi.2022.104002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104002</ArticleId><ArticleId IdType="pmc">PMC8791245</ArticleId><ArticleId IdType="pubmed">35077901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimwe A, Ruranga C, Musanabaganwa C, Mugeni R, Semakula M, Nzabanita J, et al. Leveraging artificial intelligence and data science techniques in harmonizing, sharing, accessing and analyzing SARS-COV-2/COVID-19 data in Rwanda (LAISDAR project): study design and rationale. BMC Med Inform Decis Mak. (2022) 22(1):2&#x2013;5. 10.1186/s12911-022-01965-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-022-01965-9</ArticleId><ArticleId IdType="pmc">PMC9372951</ArticleId><ArticleId IdType="pubmed">35962355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitachi. Pentaho Data Integration. Hitachi Vantara LLC. Available online at:
https://www.hitachivantara.com/en-us/products/pentaho-platform/data-integration-analytics.html (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. OHDSI/CommonDataModel. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://github.com/OHDSI/CommonDataModel (accessed August 30, 2023)</Citation></Reference><Reference><Citation>OHDSI. Standardized Data: The OMOP Common Data Model. Observational Health Data Sciences and Informatics (OHDSI). Available online at:
https://www.ohdsi.org/data-standardization/ (accessed June 30, 2023)</Citation></Reference><Reference><Citation>Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, et al. Standardizing registry data to the OMOP common data model: experience from three pulmonary hypertension databases. BMC Med Res Methodol. (2021) 21(1):3&#x2013;7. 10.1186/s12874-021-01434-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C, Voss E, Defalco F, Hughes N, Schuemie M, Moinat M, et al. Using the data quality dashboard to improve the ehden network. Appl Sci. (2021) 11(24):6&#x2013;8. 10.3390/app112411920</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app112411920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Callahan T, Barnard J, Bauck A, Brown J, Davidson B, et al. A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. eGEMs. (2017) 4(1):18. 10.13063/2327-9214.1244</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1244</ArticleId><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, Gitonga J, et al. Seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 among healthcare workers in Kenya. Clin Infect Dis. (2022) 74(2):288&#x2013;93. 10.1093/cid/ciab346</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab346</ArticleId><ArticleId IdType="pmc">PMC8135298</ArticleId><ArticleId IdType="pubmed">33893491</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. (2018) 9(1):54&#x2013;61. 10.1055/s-0037-1617452</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39950235</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Expanding the OMOP Common Data Model to Support Perinatal Research in Network Studies.</ArticleTitle><Pagination><StartPage>e70106</StartPage><MedlinePgn>e70106</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70106</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70106</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The Observational Medical Outcomes Partnership common data model (OMOP-CDM) is a useful tool for large-scale network analysis but currently lacks a structured approach to pregnancy episodes. We aimed to develop and implement a perinatal expansion for the OMOP-CDM to facilitate perinatal network research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collaboratively developed a perinatal expansion with input from domain experts and stakeholders to reach consensus. The structure and vocabularies followed the OMOP-CDM ontological framework principles. We tested the expansion using SIDIAP and Norwegian databases. We developed a diagnostics package for quality control assessment and conducted a descriptive analysis on the captured perinatal data mapped to the OMOP-CDM.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The perinatal expansion consists of a pregnancy table and an infant table, each with required and optional variables incorporated into standardized vocabularies. Quality assessment of the perinatal expansion table in SIDIAP and Norwegian databases demonstrated accurate capture of perinatal characteristics. Descriptive analysis measured the number of pregnancies (SIDIAP: 646&#x2009;530; Norway: 746&#x2009;671), pregnancy outcomes (e.g., 0.5% stillbirths in SIDIAP and 0.4% in Norway), gestational length (median [IQR] in days, SIDIAP: 273 [56-280]; Norway: 280 [273-286]), number of infants (Norway: 758&#x2009;806), and birth weight (median [IQR] in grams, Norway: 3520 [3175-3860)], among other relevant variables.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="CONCLUSIONS">We developed and implemented a perinatal expansion that captures important variables for perinatal research and allows interoperability with existing tables in the OMOP-CDM, which is expected to facilitate future network studies. The publicly available diagnostics package enables testing the implementation of the extension table and the quality and completeness of available data on pregnancy and pregnancy-related outcomes in databases mapped to the OMOP CDM.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abellan</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6552-6060</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung T H</ForeName><Initials>NTH</Initials><Identifier Source="ORCID">0000-0003-2794-5322</Identifier><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkard</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1313-4473</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5163-380X</Identifier><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Bertol&#xed;n</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>Eimir</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segundo</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M E Nordeng</LastName><ForeName>Hedvig</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6361-2918</Identifier><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari Per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Health Data and Evidence Network</Agency><Country/></Grant><Grant><Agency>European Union's Horizon 2020</Agency><Country/></Grant><Grant><Agency>European Federation of Pharmaceutical Industries and Associations</Agency><Country/></Grant><Grant><GrantID>806968</GrantID><Agency>Innovative Medicines Initiative 2 Joint Undertaking</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018743" MajorTopicYN="Y">Perinatal Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="Y">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">medical ontologies</Keyword><Keyword MajorTopicYN="N">perinatal epidemiology</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39950235</ArticleId><ArticleId IdType="pmc">PMC11826376</ArticleId><ArticleId IdType="doi">10.1002/pds.70106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barker D. J. P., &#x201c;The Origins of the Developmental Origins Theory,&#x201d; Journal of Internal Medicine 261 (2007): 412&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">17444880</ArticleId></ArticleIdList></Reference><Reference><Citation>Huybrechts K. F., Bateman B. T., and Hern&#xe1;ndez&#x2010;D&#xed;az S., &#x201c;Use of Real&#x2010;World Evidence From Healthcare Utilization Data to Evaluate Drug Safety During Pregnancy,&#x201d; Pharmacoepidemiology and Drug Safety 28 (2019): 906&#x2013;922, 10.1002/PDS.4789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.4789</ArticleId><ArticleId IdType="pmc">PMC6823105</ArticleId><ArticleId IdType="pubmed">31074570</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J., Soto Conti C. P., Gunier R. B., et&#xa0;al., &#x201c;Pregnancy Outcomes and Vaccine Effectiveness During the Period of Omicron as the Variant of Concern, INTERCOVID&#x2010;2022: A Multinational, Observational Study,&#x201d; Lancet 401 (2023): 447&#x2013;457, 10.1016/S0140-6736(22)02467-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02467-9</ArticleId><ArticleId IdType="pmc">PMC9910845</ArticleId><ArticleId IdType="pubmed">36669520</ArticleId></ArticleIdList></Reference><Reference><Citation>Favre G., Maisonneuve E., Pomar L., et&#xa0;al., &#x201c;Maternal and Perinatal Outcomes Following Pre&#x2010;Delta, Delta, and Omicron SARS&#x2010;CoV&#x2010;2 Variants Infection Among Unvaccinated Pregnant Women in France and Switzerland: A Prospective Cohort Study Using the COVI&#x2010;PREG Registry,&#x201d; Lancet Regional Health Europe 26 (2023): 26, 10.1016/J.LANEPE.2022.100569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.LANEPE.2022.100569</ArticleId><ArticleId IdType="pmc">PMC9815480</ArticleId><ArticleId IdType="pubmed">36628358</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth M. L., Schofield R., Ayoubkhani D., et&#xa0;al., &#x201c;Vaccine Effectiveness for Prevention of Covid&#x2010;19 Related Hospital Admission During Pregnancy in England During the Alpha and Delta Variant Dominant Periods of the SARS&#x2010;CoV&#x2010;2 Pandemic: Population Based Cohort Study,&#x201d; BMJ Medicine 2 (2023): e000403, 10.1136/BMJMED-2022-000403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJMED-2022-000403</ArticleId><ArticleId IdType="pmc">PMC10410807</ArticleId><ArticleId IdType="pubmed">37564827</ArticleId></ArticleIdList></Reference><Reference><Citation>Piekos S. N., Hwang Y. M., Roper R. T., et&#xa0;al., &#x201c;Effect of COVID&#x2010;19 Vaccination and Booster on Maternal&#x2010;Fetal Outcomes: A Retrospective Cohort Study,&#x201d; Lancet Digit Health 5 (2023): e594&#x2013;e606, 10.1016/S2589-7500(23)00093-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(23)00093-6</ArticleId><ArticleId IdType="pmc">PMC10473855</ArticleId><ArticleId IdType="pubmed">37537121</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;OHDSI&#x2014;Observational Health Data Sciences and Informatics,&#x201d; accessed July 6, 2023, https://www.ohdsi.org/.</Citation></Reference><Reference><Citation>
Hripcsak G., &#x201c;OHDSI Global Symposium 2024,&#x201d; State of the OHDSI Community. accessed November 29, 2024, https://www.ohdsi.org/wp&#x2010;content/uploads/2024/10/1&#x2010;OHDSI2024&#x2010;Hripcsak&#x2010;State&#x2010;of&#x2010;Community.pdf?_gl=1*81m2fh*_ga*MjcyOTEyNDE2LjE3MzIwMDc5MTM.*_ga_PNYYSZVRVX*MTczMjc4NDIzNi41LjEuMTczMjc4NDI0Mi4wLjAuMA.</Citation></Reference><Reference><Citation>Blacketer C., Defalco F. J., Ryan P. B., and Rijnbeek P. R., &#x201c;Increasing Trust in Real&#x2010;World Evidence Through Evaluation of Observational Data Quality,&#x201d; Journal of the American Medical Informatics Association 28 (2021): 2251&#x2013;2257, 10.1093/JAMIA/OCAB132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/JAMIA/OCAB132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A., Ryan P., Fife D., Gifkins D., Knoll C., and Friedman A., &#x201c;Inferring Pregnancy Episodes and Outcomes Within a Network of Observational Databases,&#x201d; PLoS One 13 (2018): e0192033, 10.1371/JOURNAL.PONE.0192033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0192033</ArticleId><ArticleId IdType="pmc">PMC5794136</ArticleId><ArticleId IdType="pubmed">29389968</ArticleId></ArticleIdList></Reference><Reference><Citation>Margulis A. V. and Huybrechts K., &#x201c;Identification of Pregnancies in Healthcare Data: A Changing Landscape,&#x201d; Pharmacoepidemiology and Drug Safety 32 (2022): 84&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">35976191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu T., Liang C., Liu J., et&#xa0;al., &#x201c;Temporal Events Detector for Pregnancy Care (TED&#x2010;PC): A Rule&#x2010;Based Algorithm to Infer Gestational Age and Delivery Date From Electronic Health Records of Pregnant Women With and Without COVID&#x2010;19,&#x201d; PLoS One 17 (2022): 17, 10.1371/JOURNAL.PONE.0276923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0276923</ArticleId><ArticleId IdType="pmc">PMC9621451</ArticleId><ArticleId IdType="pubmed">36315520</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;OHDSI: OHDSI Vocabulary Principles,&#x201d; accessed July 6, 2023, https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:principles.</Citation></Reference><Reference><Citation>Bellas L., Camacho&#x2010;Arteaga L., Giner&#x2010;Soriano M., et&#xa0;al., &#x201c;Women's Health in Focus: Real&#x2010;World Data on Valproate Prescriptions During Pregnancy &#x2010; a Cohort Study in Catalonia (Spain),&#x201d; BMJ Open 14 (2024): e085167, 10.1136/BMJOPEN-2024-085167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJOPEN-2024-085167</ArticleId><ArticleId IdType="pmc">PMC11337672</ArticleId><ArticleId IdType="pubmed">39134441</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gelder M. M. H. J. and Nordeng H., &#x201c;Antiemetic Prescription Fills in Pregnancy: A Drug Utilization Study Among 762,437 Pregnancies in Norway,&#x201d; Clinical Epidemiology 13 (2021): 161&#x2013;174, 10.2147/CLEP.S287892.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S287892</ArticleId><ArticleId IdType="pmc">PMC7924249</ArticleId><ArticleId IdType="pubmed">33664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M., Rodr&#xed;guez C., Burn E., et&#xa0;al., &#x201c;Data Resource Profile: The Information System for Research in Primary Care (SIDIAP),&#x201d; International Journal of Epidemiology 51 (2022): e324&#x2013;e336, 10.1093/IJE/DYAC068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/IJE/DYAC068</ArticleId><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E., Fern&#xe1;ndez&#x2010;Bertol&#xed;n S., Voss E. A., et&#xa0;al., &#x201c;Establishing and Characterising Large COVID&#x2010;19 Cohorts After Mapping the Information System for Research in Primary Care in Catalonia to the OMOP Common Data Model,&#x201d; medRxiv, (2021), 10.1101/2021.11.23.21266734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.23.21266734</ArticleId></ArticleIdList></Reference><Reference><Citation>
&#x201c;Data Sources in Norway,&#x201d; accessed July 6, 2023, https://helsedata.no/en/data&#x2010;sources/?page=1&amp;sort=0.</Citation></Reference><Reference><Citation>
&#x201c;Norwegian Prescription Database (NorPD)&#x2014;NIPH,&#x201d; accessed July 6, 2023, https://www.fhi.no/en/he/norpd/.</Citation></Reference><Reference><Citation>
&#x201c;Norwegian Immunisation Registry SYSVAK&#x2014;NIPH,&#x201d; accessed July 6, 2023, https://www.fhi.no/en/va/norwegian&#x2010;immunisation&#x2010;registry&#x2010;sysvak/.</Citation></Reference><Reference><Citation>
&#x201c;Norwegian Surveillance System for Communicable Diseases (MSIS)&#x2014;NIPH,&#x201d; accessed July 6, 2023, https://www.fhi.no/en/ou/msis/.</Citation></Reference><Reference><Citation>
&#x201c;Norwegian Patient Registry (NPR),&#x201d; accessed July 6, 2023, https://helsedata.no/en/forvaltere/norwegian&#x2010;directorate&#x2010;of&#x2010;health/norwegian&#x2010;patient&#x2010;registry&#x2010;npr/.</Citation></Reference><Reference><Citation>
&#x201c;Medical Birth Registry of Norway&#x2014;NIPH,&#x201d; accessed July 6, 2023, https://www.fhi.no/en/ch/medical&#x2010;birth&#x2010;registry&#x2010;of&#x2010;norway/.</Citation></Reference><Reference><Citation>
Blacketer C. and Voss E., &#x201c;The Book of OHDSI. Chapter&#xa0;6 Extract Transform Load,&#x201d; accessed October 26, 2024, https://ohdsi.github.io/TheBookOfOhdsi/ExtractTransformLoad.html.</Citation></Reference><Reference><Citation>
&#x201c;PET Diagnostics Package,&#x201d; accessed July 6, 2023, https://github.com/oxford&#x2010;pharmacoepi/PETDiagnostics.</Citation></Reference><Reference><Citation>
&#x201c;Tasa de Natalidad Por Comunidad Aut&#xf3;noma,&#x201d; Instituto Nacional de Estad&#xed;stica. accessed July 6, 2023, https://www.ine.es/jaxiT3/Datos.htm?t=1433.</Citation></Reference><Reference><Citation>
Folkehelseinstitutet
, &#x201c;Medisinsk F&#xf8;dselsregister (MFR),&#x201d;
https://statistikkbank.fhi.no/mfr/.</Citation></Reference><Reference><Citation>
&#x201c;Fertility Decline in Norway&#x2014;NIPH,&#x201d; accessed July 17, 2023, https://www.fhi.no/en/publ/2020/fertility&#x2010;decline&#x2010;in&#x2010;norway/.</Citation></Reference><Reference><Citation>
&#x201c;European Health Data Evidence Network&#x2014;ehden.eu,&#x201d; accessed July 6, 2023, https://www.ehden.eu/.</Citation></Reference><Reference><Citation>Jones S., Bradwell K. R., Chan L. E., et&#xa0;al., &#x201c;Who Is Pregnant? Defining Real&#x2010;World Data&#x2010;Based Pregnancy Episodes in the National COVID Cohort Collaborative (N3C),&#x201d; medRxiv, (2022), 10.1101/2022.08.04.22278439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.04.22278439</ArticleId><ArticleId IdType="pmc">PMC10432357</ArticleId><ArticleId IdType="pubmed">37600074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornbrook M. C., Whitlock E. P., Berg C. J., et&#xa0;al., &#x201c;Development of an Algorithm to Identify Pregnancy Episodes in an Integrated Health Care Delivery System,&#x201d; Health Services Research 42 (2007): 908&#x2013;927, 10.1111/J.1475-6773.2006.00635.X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.1475-6773.2006.00635.X</ArticleId><ArticleId IdType="pmc">PMC1955367</ArticleId><ArticleId IdType="pubmed">17362224</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade S. E., Raebel M. A., Morse A. N., et&#xa0;al., &#x201c;Use of Prescription Medications With a Potential for Fetal Harm Among Pregnant Women,&#x201d; Pharmacoepidemiology and Drug Safety 15 (2006): 546&#x2013;554, 10.1002/PDS.1235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.1235</ArticleId><ArticleId IdType="pubmed">16586470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J. R., Holford T. R., Hall G. C., and Bracken M. B., &#x201c;Strategies for Identifying Pregnancies in the Automated Medical Records of the General Practice Research Database,&#x201d; Pharmacoepidemiology and Drug Safety 13 (2004): 749&#x2013;759, 10.1002/PDS.935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.935</ArticleId><ArticleId IdType="pubmed">15386720</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine S., West S., Andrews E., et&#xa0;al., &#x201c;The Identification of Pregnancies Within the General Practice Research Database,&#x201d; Pharmacoepidemiology and Drug Safety 19 (2010): 45&#x2013;50, 10.1002/PDS.1862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.1862</ArticleId><ArticleId IdType="pubmed">19823973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cea&#x2010;Soriano L., Garc&#xed;a Rodr&#xed;guez L. A., Fern&#xe1;ndez Cantero O., and Hern&#xe1;ndez&#x2010;D&#xed;az S., &#x201c;Challenges of Using Primary Care Electronic Medical Records in the UK to Study Medications in Pregnancy,&#x201d; Pharmacoepidemiology and Drug Safety 22 (2013): 977&#x2013;985, 10.1002/PDS.3472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.3472</ArticleId><ArticleId IdType="pubmed">23813653</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Andrade S. E., Cooper W. O., et&#xa0;al., &#x201c;Validation of an Algorithm to Estimate Gestational Age in Electronic Health Plan Databases,&#x201d; Pharmacoepidemiology and Drug Safety 22 (2013): 524&#x2013;532, 10.1002/PDS.3407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.3407</ArticleId><ArticleId IdType="pmc">PMC3644383</ArticleId><ArticleId IdType="pubmed">23335117</ArticleId></ArticleIdList></Reference><Reference><Citation>Margulis A. V., Setoguchi S., Mittleman M. A., Glynn R. J., Dormuth C. R., and Hern&#xe1;ndez&#x2010;D&#xed;az S., &#x201c;Algorithms to Estimate the Beginning of Pregnancy in Administrative Databases,&#x201d; Pharmacoepidemiology and Drug Safety 22 (2013): 16&#x2013;24, 10.1002/PDS.3284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PDS.3284</ArticleId><ArticleId IdType="pmc">PMC3437228</ArticleId><ArticleId IdType="pubmed">22550030</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency
, &#x201c;Data Analysis and Real World Interrogation Network (DARWIN EU),&#x201d; accessed October 19, 2023, https://www.ema.europa.eu/en/about&#x2010;us/how&#x2010;we&#x2010;work/big&#x2010;data/data&#x2010;analysis&#x2010;real&#x2010;world&#x2010;interrogation&#x2010;network&#x2010;darwin&#x2010;eu.</Citation></Reference><Reference><Citation>Kostka K., Duarte&#x2010;Salles T., Prats&#x2010;Uribe A., et&#xa0;al., &#x201c;Unraveling COVID&#x2010;19: A Large&#x2010;Scale Characterization of 4.5 Million COVID&#x2010;19 Cases Using CHARYBDIS,&#x201d; Clinical Epidemiology 14 (2022): 369&#x2013;384, 10.2147/CLEP.S323292.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S323292</ArticleId><ArticleId IdType="pmc">PMC8957305</ArticleId><ArticleId IdType="pubmed">35345821</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver J., Hardin J. H., Blacketer C., et&#xa0;al., &#x201c;Development and Evaluation of an Algorithm to Link Mothers and Infants in Two US Commercial Healthcare Claims Databases for Pharmacoepidemiology Research,&#x201d; medRxiv, (2022), 10.1101/2022.12.13.22283418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.13.22283418</ArticleId><ArticleId IdType="pmc">PMC10590518</ArticleId><ArticleId IdType="pubmed">37865728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39962485</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>De-identification of clinical notes with pseudo-labeling using regular expression rules and pre-trained BERT.</ArticleTitle><Pagination><StartPage>82</StartPage><MedlinePgn>82</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">82</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-025-02913-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">De-identification of clinical notes is essential to utilize the rich information in unstructured text data in medical research. However, only limited work has been done in removing personal information from clinical notes in Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our study utilized a comprehensive dataset stored in the Note table of the OMOP Common Data Model at Seoul National University Bundang Hospital. This dataset includes 11,181,617 radiology and 9,282,477 notes from various other departments (non-radiology reports). From this, 0.1% of the reports (11,182) were randomly selected for training and validation purposes. We used two de-identification strategies to improve performance with limited and few annotated data. First, a rule-based approach is used to construct regular expressions on the 1,112 notes annotated by domain experts. Second, by using the regular expressions as label-er, we applied a semi-supervised approach to fine-tune a pre-trained Korean BERT model with pseudo-labeled notes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Validation was conducted using 342 radiology and 12 non-radiology notes labeled at the token level. Our rule-based approach achieved 97.2% precision, 93.7% recall, and 96.2% F1 score from the department of radiology notes. For machine learning approach, KoBERT-NER that is fine-tuned with 32,000 automatically pseudo-labeled notes achieved 96.5% precision, 97.6% recall, and 97.1% F1 score.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">By combining a rule-based approach and machine learning in a semi-supervised way, our results show that the performance of de-identification can be improved.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>An</LastName><ForeName>Jiyong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Graduate School of Data Science, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Jiyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Graduate School of Data Science, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunwoo</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Hyunyoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea. yoosoo0@snubh.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seunggeun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Graduate School of Data Science, Seoul National University, Seoul, South Korea. lee7801@snu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RS-2023-00222663</GrantID><Agency>Korea Government</Agency><Country/></Grant><Grant><GrantID>2020H1D3A2A03100666</GrantID><Agency>Ministry of Science and ICT</Agency><Country/></Grant><Grant><GrantID>HI22C0471</GrantID><Agency>Ministry of Health and Welfare,South Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068240" MajorTopicYN="Y">Data Anonymization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003219" MajorTopicYN="Y">Confidentiality</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical documentation and communications</Keyword><Keyword MajorTopicYN="N">De-identification</Keyword><Keyword MajorTopicYN="N">Electronic health records and systems</Keyword><Keyword MajorTopicYN="N">Natural language processing</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was performed in accordance with the relevant guidelines and regulations of SNUBH Institutional Review Board. It was approved by the Institutional Review Board of SNUBH with wavier of informed consent (IRB No.: B-2206-761-002). Consent for publication: This study does not contain any individual person&#x2019;s data in any form (including any individual details, images, or videos). No consent is required for publication. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>18</Day><Hour>0</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39962485</ArticleId><ArticleId IdType="pmc">PMC11831849</ArticleId><ArticleId IdType="doi">10.1186/s12911-025-02913-z</ArticleId><ArticleId IdType="pii">10.1186/s12911-025-02913-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Williams C, Mostashari F, Mertz K, Hogin E, Atwal P. From the office of the national coordinator: the strategy for advancing the exchange of health information. Health Aff. 2012;31(3):527&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22392663</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuad A, Hsu CY. High rate EHR adoption in Korea and health IT rise in Asia. 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22632820</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Chang B-C, Kang SW, Bae H, Park RW. Adoption of electronic health records in Korean tertiary teaching and general hospitals. Int J Med Inf. 2012;81(3):196&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">22206619</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgeot B, Muenzen K, Peterson TA, et al. Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. NPJ Digit Med. 2020;3(1):57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156708</ArticleId><ArticleId IdType="pubmed">32337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Gaizauskas R, Roberts I, Demetriou G, Hepple M. Identifying personal health information using support vector machines. Paper presented at: i2b2 workshop on challenges in natural language processing for clinical data. 2006. p. 10&#x2013;11.</Citation></Reference><Reference><Citation>Uzuner &#xd6;, Luo Y, Szolovits P. Evaluating the state-of-the-art in automatic de-identification. J Am Med Inform Assoc. 2007;14(5):550&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1975792</ArticleId><ArticleId IdType="pubmed">17600094</ArticleId></ArticleIdList></Reference><Reference><Citation>Khin K, Burckhardt P, Padman R. A deep learning architecture for de-identification of patient notes: Implementation and evaluation. arXiv preprint arXiv:1810.01570. 2018.</Citation></Reference><Reference><Citation>Lee J, Yoon W, Kim S, et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics. 2020;36(4):1234&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703786</ArticleId><ArticleId IdType="pubmed">31501885</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsentzer E, Murphy JR, Boag W, Weng WH, Jin D, Naumann T, McDermott M. Publicly available clinical BERT embeddings. arXiv preprint arXiv:1904.03323. 2019.</Citation></Reference><Reference><Citation>Meaney C, Hakimpour W, Kalia S, Moineddin R. A Comparative Evaluation Of Transformer Models For De-Identification Of Clinical Text Data. arXiv preprint arXiv:2204.07056. 2022.</Citation></Reference><Reference><Citation>Yang X, Lyu T, Li Q, Lee CY, Bian J, Hogan WR, Wu Y. A study of deep learning methods for de-identification of clinical notes in cross-institute settings. BMC Med Inf Decis Mak. 2019;19:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894104</ArticleId><ArticleId IdType="pubmed">31801524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman T, Howell MD, Dean J, Hoory S, Slyper R, Laish I, Gilon O, Vainstein D, Corrado G, Chou K, Po MJ. Customization scenarios for de-identification of clinical notes. BMC Med Inf Decis Mak. 2020;20:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993314</ArticleId><ArticleId IdType="pubmed">32000770</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AE, Bulgarelli L, Pollard TJ. Deidentification of free-text medical records using pre-trained bidirectional transformers. Proc ACM Conf Health Inference Learn. 2020;2020:214&#x2013;22115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330601</ArticleId><ArticleId IdType="pubmed">34350426</ArticleId></ArticleIdList></Reference><Reference><Citation>Grouin C, N&#xe9;v&#xe9;ol A. De-identification of clinical notes in French: towards a protocol for reference corpus development. J Biomed Inform. 2014;50:151&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24380818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Li Y, Yang L, Li S, Li L, Zhao Z, Long S, Wang F, Wang H, Li Y, Wang C. An efficient method for deidentifying protected health information in Chinese electronic health records: algorithm development and validation. JMIR Med Inf. 2022;10(8):e38154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472063</ArticleId><ArticleId IdType="pubmed">36040774</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin SY, Park YR, Shin Y, Choi HJ, Park J, Lyu Y, Lee MS, Choi CM, Kim WS, Lee JH. A de-identification method for bilingual clinical texts of various note types. J Korean Med Sci. 2015;30(1): 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4278030</ArticleId><ArticleId IdType="pubmed">25552878</ArticleId></ArticleIdList></Reference><Reference><Citation>SKTBrain S. Korean BERT pre-trained cased (KoBERT). 2019. Available at:&#xa0;https://github.com/SKTBrain/KoBERT.</Citation></Reference><Reference><Citation>Park J. KoBERT-NER. 2020. Available at:&#xa0;https://github.com/monologg/KoBERT-NER.</Citation></Reference><Reference><Citation>Naver. Naver NLP. challenge. 2018. Available at: https://github.com/naver/nlp-challenge.</Citation></Reference><Reference><Citation>Beltagy I, Lo K, Cohan A. SciBERT: A pretrained language model for scientific text. arXiv preprint arXiv:1903.10676. 2019.</Citation></Reference><Reference><Citation>Tai W, Kung HT, Dong XL, Comiter M, Kuo CF. exBERT: Extending pre-trained models with domain-specific vocabulary under constrained training resources. Findings of the Association for Computational Linguistics: EMNLP 2020. 2020;1433&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39973032</PMID><DateRevised><Year>2025</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Utility of Treatment Pattern Analysis Using a Common Data Model: A Scoping Review.</ArticleTitle><Pagination><StartPage>4</StartPage><EndPage>15</EndPage><MedlinePgn>4-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2025.31.1.4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to derive observational research evidence on treatment patterns through a scoping review of common data model (CDM)-based publications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched the medical literature databases PubMed and EMBASE, as well as the Observational Health Data Sciences and Informatics (OHDSI) website, for papers published between January 1, 2010 and August 21, 2023 to identify research papers relevant to our topic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen articles satisfied the inclusion criteria for this scoping review. We summarized study characteristics such as phenotypes, patient numbers, data periods, countries, Observational Medical Outcomes Partnership (OMOP) CDM databases, and definitions of index date and target cohort. Type 2 diabetes mellitus emerged as the most frequently studied disease, covered in five articles, followed by hypertension and depression, each addressed in four articles. Biguanides, with metformin as the primary drug, were the most commonly prescribed first-line treatments for type 2 diabetes mellitus. Most studies utilized sunburst plots to visualize treatment patterns, whereas two studies used Sankey plots. Various software tools were employed for treatment pattern analysis, including JavaScript, the open-source ATLAS by OHDSI, R code, and the R package "TreatmentPatterns."</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides a comprehensive overview of research on treatment patterns using the CDM, highlighting the growing importance of OMOP CDM in enabling multinational observational network studies and advancing collaborative research in this field.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Eun-Gee</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Jung</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Kichul</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Borim</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Korea Health Information Service</Agency><Country/></Grant><Grant><Agency>Ministry of Health and Welfare</Agency><Country/></Grant><Grant><GrantID>RE-2023-00241887</GrantID><Agency>National Research Foundation of Korea</Agency><Country/></Grant><Grant><Agency>Ministry of Science and ICT</Agency><Country/></Grant><Grant><GrantID>3720230025</GrantID><Agency>NAVER Corporation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cohort Studies</Keyword><Keyword MajorTopicYN="N">Common Data Elements</Keyword><Keyword MajorTopicYN="N">Drug Utilization</Keyword><Keyword MajorTopicYN="N">Epidemiologic Methods</Keyword><Keyword MajorTopicYN="N">Scoping Review</Keyword></KeywordList><CoiStatement>
<b>Conflict of Interest</b>
. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>1</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39973032</ArticleId><ArticleId IdType="pmc">PMC11854637</ArticleId><ArticleId IdType="doi">10.4258/hir.2025.31.1.4</ArticleId><ArticleId IdType="pii">hir.2025.31.1.4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Observational Health Data Sciences and Informatics  . The book of OHDSI [Internet] New York (NY): Observational Health Data Sciences and Informatics; 2021.  [cited at 2024 Jan 9]. Available from:  https://ohdsi.github.io/TheBookOfOhdsi/OhdsiCommunity.html.</Citation></Reference><Reference><Citation>Sentinel Sentinel Common Data Model [Internet] Silver Springer (MD): Sentinel Initiative; 2024.  [cited at 2024 Jan 9]. Available from:  https://www.sentinelinitiative.org/sentinel/data/distributed-database-common-data-model.</Citation></Reference><Reference><Citation>PCORnet  . PCORnet Common Data Model (CDM) [Internet] Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2024.  [cited at 2024 Jan 9]. Available from:  https://pcornet.org/news/resources-pcornet-common-data-model/</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600&#x2013;6. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. doi: 10.1136/amia-jnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amia-jnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(1):54&#x2013;8. doi: 10.4258/hir.2016.22.1.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2016.22.1.54</ArticleId><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi IY. Present and future of utilizing healthcare data. Healthc Inform Res. 2023;29(1):1&#x2013;3. doi: 10.4258/hir.2023.29.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2023.29.1.1</ArticleId><ArticleId IdType="pmc">PMC9932309</ArticleId><ArticleId IdType="pubmed">36792095</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  . About OHDSI [Internet] New York (NY): Observational Health Data Sciences and Informatics; c2024.  [cited at 2024 Jan 9]. Available from:  https://www.ohdsi.org/</Citation></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;36. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Markus AF, Verhamme KM, Kors JA, Rijnbeek PR. TreatmentPatterns: an R package to facilitate the standardized development and analysis of treatment patterns across disease domains. Comput Methods Programs Biomed. 2022;225:107081. doi: 10.1016/j.cmpb.2022.107081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2022.107081</ArticleId><ArticleId IdType="pubmed">36084453</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas A, Lubarsky S, Durning SJ, Young ME. Knowledge syntheses in medical education: demystifying scoping reviews. Acad Med. 2017;92(2):161&#x2013;6. doi: 10.1097/ACM.0000000000001452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACM.0000000000001452</ArticleId><ArticleId IdType="pubmed">27782918</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio LA, Larsen K, Thomas A, Costello JA, Artino AR., Jr Scoping reviews in medical education: a scoping review. Med Educ. 2021;55(6):689&#x2013;700. doi: 10.1111/medu.14431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/medu.14431</ArticleId><ArticleId IdType="pmc">PMC8247025</ArticleId><ArticleId IdType="pubmed">33300124</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MD, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119&#x2013;26. doi: 10.11124/JBIES-20-00167.</Citation><ArticleIdList><ArticleId IdType="doi">10.11124/JBIES-20-00167</ArticleId><ArticleId IdType="pubmed">33038124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastner M, Tricco AC, Soobiah C, Lillie E, Perrier L, Horsley T, et al. What is the most appropriate knowledge synthesis method to conduct a review?: protocol for a scoping review. BMC Med Res Methodol. 2012;12:114. doi: 10.1186/1471-2288-12-114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-12-114</ArticleId><ArticleId IdType="pmc">PMC3477082</ArticleId><ArticleId IdType="pubmed">22862833</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco AC, Lillie E, Zarin W, O&#x2019;Brien K, Colquhoun H, Kastner M, et al. A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16:15. doi: 10.1186/s12874-016-0116-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0116-4</ArticleId><ArticleId IdType="pmc">PMC4746911</ArticleId><ArticleId IdType="pubmed">26857112</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C, Sedlmayr M, Bathelt F. The usage of OHDSI OMOP: a scoping review. Stud Health Technol Inform. 2021;283:95&#x2013;103. doi: 10.3233/SHTI210546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210546</ArticleId><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Zoch M, Kelbert P, Noll R, Schaaf J, Wolfien M, et al. Methods used in the development of common data models for health data: scoping review. JMIR Med Inform. 2023;11:e45116. doi: 10.2196/45116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/45116</ArticleId><ArticleId IdType="pmc">PMC10436118</ArticleId><ArticleId IdType="pubmed">37535410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A, Yuan Y, Eccles L, Chitkara A, Dalen J, Varol N. Treatment patterns for advanced non-small cell lung cancer in the US: a systematic review of observational studies. Cancer Treat Res Commun. 2022;33:100648. doi: 10.1016/j.ctarc.2022.100648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctarc.2022.100648</ArticleId><ArticleId IdType="pubmed">36270164</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, Bessonova L, Hughes R, Doane MJ, O&#x2019;Sullivan AK, Snook K, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. Adv Ther. 2022;39(9):3933&#x2013;56. doi: 10.1007/s12325-022-02232-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-022-02232-z</ArticleId><ArticleId IdType="pmc">PMC9402774</ArticleId><ArticleId IdType="pubmed">35844007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco AC, Lillie E, Zarin W, O&#x2019;Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467&#x2013;73. doi: 10.7326/M18-0850.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0850</ArticleId><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang L, Miao S, Xu H, Yin Y, Zhu Y, et al. Analysis of treatment pathways for three chronic diseases using OMOP CDM. J Med Syst. 2018;42(12):260. doi: 10.1007/s10916-018-1076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-018-1076-5</ArticleId><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Ryan P, Natarajan K, Falconer T, Crew KD, Reich CG, et al. Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network. JCO Clin Cancer Inform. 2020;4:171&#x2013;83. doi: 10.1200/CCI.19.00107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.19.00107</ArticleId><ArticleId IdType="pmc">PMC7113074</ArticleId><ArticleId IdType="pubmed">32134687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern DM, Cepeda MS, Defalco F, Etropolski M. Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019. BMC Psychiatry. 2020;20(1):4. doi: 10.1186/s12888-019-2418-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-019-2418-7</ArticleId><ArticleId IdType="pmc">PMC6942399</ArticleId><ArticleId IdType="pubmed">31900133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern DM, Cepeda MS. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurol. 2020;20(1):296. doi: 10.1186/s12883-020-01882-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-020-01882-2</ArticleId><ArticleId IdType="pmc">PMC7418327</ArticleId><ArticleId IdType="pubmed">32781983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Yoo S, Jeon Y, Yi S, Kim S, Choi SA, et al. Characterization of anti-seizure medication treatment pathways in pediatric epilepsy using the electronic health record-based common data model. Front Neurol. 2020;11:409. doi: 10.3389/fneur.2020.00409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00409</ArticleId><ArticleId IdType="pmc">PMC7235379</ArticleId><ArticleId IdType="pubmed">32477256</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Son M, Choi B, Park C, Shin DH, Jung JH, et al. Characterization of medication trends for chronic kidney disease: mineral and bone disorder treatment using electronic health record-based common data model. Biomed Res Int. 2021;2021:5504873. doi: 10.1155/2021/5504873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5504873</ArticleId><ArticleId IdType="pmc">PMC8629641</ArticleId><ArticleId IdType="pubmed">34853790</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon H, You SC, Kang SY, Seo SI, Warner JL, Belenkaya R, et al. Characterizing the anticancer treatment trajectory and pattern in patients receiving chemotherapy for cancer using harmonized observational databases: retrospective study. JMIR Med Inform. 2021;9(4):e25035. doi: 10.2196/25035.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/25035</ArticleId><ArticleId IdType="pmc">PMC8058693</ArticleId><ArticleId IdType="pubmed">33720842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KA, Jin HY, Kim YJ, Im YJ, Kim EY, Park TS. Treatment patterns of type 2 diabetes assessed using a common data model based on electronic health records of 2000&#x2013;2019. J Korean Med Sci. 2021;36(36):e230. doi: 10.3346/jkms.2021.36.e230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e230</ArticleId><ArticleId IdType="pmc">PMC8438187</ArticleId><ArticleId IdType="pubmed">34519186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan SM, Jeon YS, Dang TK, Lim SC, Shao YM, Tai ES, et al. Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM dataset. Appl Clin Inform. 2021;12(4):757&#x2013;67. doi: 10.1055/s-0041-1732301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1732301</ArticleId><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Byun J, Lee DY, Jeong CW, Kim Y, Rhee HY, Moon KW, et al. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer&#x2019;s dementia using OMOP CDM. Sci Rep. 2022;12(1):4451. doi: 10.1038/s41598-022-08595-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08595-1</ArticleId><ArticleId IdType="pmc">PMC8924152</ArticleId><ArticleId IdType="pubmed">35292697</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung TK, Jeon Y, Hong Y, Hong S, Moon JS, Lee H. Factors affecting the changes in antihypertensive medications in patients with hypertension. Front Cardiovasc Med. 2022;9:999548. doi: 10.3389/fcvm.2022.999548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.999548</ArticleId><ArticleId IdType="pmc">PMC9561640</ArticleId><ArticleId IdType="pubmed">36247446</ArticleId></ArticleIdList></Reference><Reference><Citation>Mun Y, Park C, Lee DY, Kim TM, Jin KW, Kim S, et al. Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology. Sci Rep. 2022;12(1):10162. doi: 10.1038/s41598-022-14386-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-14386-5</ArticleId><ArticleId IdType="pmc">PMC9205933</ArticleId><ArticleId IdType="pubmed">35715561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo SI, Kim TJ, Choi YJ, Bang CS, Lee YK, Lee MW, et al. Clinical characteristics and treatment pathway of patients treated with Helicobacter pylori infection: a single center cohort study using common data model. Korean J Helicobacter Up Gastrointest Res. 2022;22(3):214&#x2013;21. doi: 10.7704/kjhugr.2022.0010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7704/kjhugr.2022.0010</ArticleId></ArticleIdList></Reference><Reference><Citation>Spotnitz M, Ostropolets A, Castano VG, Natarajan K, Waldman GJ, Argenziano M, et al. Patient characteristics and antiseizure medication pathways in newly diagnosed epilepsy: feasibility and pilot results using the common data model in a single-center electronic medical record database. Epilepsy Behav. 2022;129:108630. doi: 10.1016/j.yebeh.2022.108630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2022.108630</ArticleId><ArticleId IdType="pubmed">35276502</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora P, Morgan Stewart H, Russell B, Asiimwe A, Brobert G. Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States. Int J Clin Pract. 2022;2022:6707985. doi: 10.1155/2022/6707985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6707985</ArticleId><ArticleId IdType="pmc">PMC9159118</ArticleId><ArticleId IdType="pubmed">35685531</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui MH, Lee DY, Park SJ, Park KH. Real-world treatment intensity and patterns in patients with myopic choroidal neovascularization: common data model in ophthalmology. J Korean Med Sci. 2023;38(23):e174. doi: 10.3346/jkms.2023.38.e174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e174</ArticleId><ArticleId IdType="pmc">PMC10261705</ArticleId><ArticleId IdType="pubmed">37309694</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023;47(5):575&#x2013;94. doi: 10.4093/dmj.2023.0282.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2023.0282</ArticleId><ArticleId IdType="pmc">PMC10555541</ArticleId><ArticleId IdType="pubmed">37793979</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association  Standards of care in diabetes&#x2013;2023. Diabetes Care. 2023;46(Suppl 1):S1&#x2013;S291. 
 https://diabetesjournals.org/care/issue/46/Supplement_1.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20. doi: 10.1186/s40885-019-0124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0124-x</ArticleId><ArticleId IdType="pmc">PMC6670135</ArticleId><ArticleId IdType="pubmed">31388453</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence  . Depression in adults: treatment and management [Internet] Manchester, UK: National Institute for Health and Care Excellence; 2022.  [cited at 2024 Jan 9]. Available from:  https://www.nice.org.uk/guidance/ng222.</Citation><ArticleIdList><ArticleId IdType="pubmed">35977056</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo JS, Bahk WM, Woo YS, Park YM, Kim W, Jeong JH, et al. Korean medication algorithm for depressive disorder 2021, fourth revision: an executive summary. Clin Psychopharmacol Neurosci. 2021;19(4):751&#x2013;72. doi: 10.9758/cpn.2021.19.4.751.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2021.19.4.751</ArticleId><ArticleId IdType="pmc">PMC8553538</ArticleId><ArticleId IdType="pubmed">34690130</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GH, Park J, Kim J, Kim Y, Choi B, Park RW, et al. Feasibility study of federated learning on the distributed research network of OMOP common data model. Healthc Inform Res. 2023;29(2):168&#x2013;73. doi: 10.4258/hir.2023.29.2.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2023.29.2.168</ArticleId><ArticleId IdType="pmc">PMC10209729</ArticleId><ArticleId IdType="pubmed">37190741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39975698</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study.</ArticleTitle><Pagination><StartPage>103096</StartPage><MedlinePgn>103096</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103096</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2025.103096</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Fluoroquinolones (FQs) are commonly used to treat urinary tract infections (UTIs), but some studies have suggested they may increase the risk of aortic aneurysm or dissection (AA/AD). However, no large-scale international study has thoroughly assessed this risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A retrospective cohort study was conducted using a large, distributed network analysis across 14 databases from 5 countries (United States, South Korea, Japan, Taiwan, and Australia). The study included 13,588,837 patients aged 35 or older who initiated systemic fluoroquinolones (FQs) or comparable antibiotics (trimethoprim with or without sulfamethoxazole [TMP] or cephalosporins [CPHs]) for UTI treatment in the outpatient setting between JAN 01, 2010 and DEC 31, 2019. Patients were included if at the index date they had at least 365 days of prior observation and were not hospitalised for any reason on or within 7 days prior to the index date. The primary outcome was AA/AD occurrence within 60 days of exposure, with secondary outcomes examining AA and AD separately. Cox proportional hazards models with 1:1 propensity score (PS) matching were used to estimate the risk, with results calibrated using negative control outcomes. Analyses were subjected to pre-defined study diagnostics, and only those passing all diagnostics were reported. Hazard ratios (HRs) were pooled using Bayesian random-effects meta-analysis.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Among analyses that passed diagnostics there were 1,954,798 and 1,195,962 propensity-matched pairs for the FQ versus TMP and FQ versus CPH comparisons respectively. For the 60-day follow-up there was no difference in risk of AA/AD between FQ and TMP (absolute rate difference [ARD], 0.21 per 1000 person-year; calibrated HR, 0.91 [95% CI 0.73-1.10]). There was no significant difference in risk for FQ versus CPH (ARD, 0.11 per 1000 person-year; calibrated HR, 1.01 [95% CI 0.82-1.25]).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">This large-scale study used a rigorous design with objective diagnostics to address bias and confounding. There was no increased risk of AA/AD associated with FQ compared to TMP or CPH in patients treated for UTI in the outpatient setting. As we only examined FQ used to treat UTIs in the outpatient setting, the results may not be generalisable to other indications with different severity.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">Yonsei University College of Medicine, Government-wide R&amp;D Fund project for infectious disease research (GFID), Republic of Korea, National Health and Medical Research Council (NHMRC) Australian Government. Department of Veterans Affairs (VA) Informatics and Computing Infrastructure (VINCI), Department of Veterans Affairs, the United States Government.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janetzki</LastName><ForeName>Jack L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Clinical and Health Sciences, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung Ho</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung Ah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Pharmacy Practice Research Unit, Faculty of Pharmacy, Jazan University, Jazan, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, United States Department of Veterans Affairs, Salt Lake City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seonji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Thanh-Phuc</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>International Ph.D. Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phung-Anh</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Clinical Data Center, Office of Data Science, Taipei Medical University, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Min-Huei</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jason C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Clinical Data Center, Office of Data Science, Taipei Medical University, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>James P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology, Johnson &amp; Johnson, Titusville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology, Johnson &amp; Johnson, Titusville, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical and Health Sciences, Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan You</LastName><ForeName>Seng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aortic aneurysm</Keyword><Keyword MajorTopicYN="N">Aortic dissection</Keyword><Keyword MajorTopicYN="N">Fluoroquinolone</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword></KeywordList><CoiStatement>All authors have completed the International Committee of Medical Journal Editors disclosure of interest form and declare the following disclosures. EM discloses previous consulting relationships with Janssen and Orpyx Medical Technologies, in areas unrelated to this work. DRM was supported by a Wellcome Trust Clinical Research Fellowship. RK received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under award K23HL153775) and the Doris Duke Charitable Foundation (under award, 2022060). He also receives research support, through Yale, from BridgeBio, Bristol-Myers Squibb, and Novo Nordisk. He is a coinventor of U.S. Provisional Patent Applications 63/562,355, 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315, 63/606,203, and 18/813,882, unrelated to current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. SLD reports grants from Alnylam Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP, Biodesix, Inc, Celgene Corporation, Cerner Enviza, GSK PLC, IQVIA Janssen Pharmaceuticals, Inc., Novartis International AG, Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. KKCM reported receiving grants from the Hong Kong Research Grant Council, the CW Maplethorpe Fellowship, UK, National Institute for Health and Care Research, European Commission Framework Horizon 2020, Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, and personal fees from IQVIA Ltd outside the submitted work. SS and MVZ are employees of IQVIA. JPG, PBR and MJS are employees and shareholders of Johnson &amp; Johnson. MAS receives grants and contracts from the US National Institutes of Health, US Food &amp; Drug Administration and Johnson &amp; Johnson outside the scope of this work. MEM received grants from NIH NHLBI and VA ORD and has a patent pending for an AI algorithm related to surveillance. KKCM received grants from the CW Maplethorpe Fellowship, IQVIA, the European Union Horizon 2020, the UK National Institute of Health Research, the Hong Kong Research Grant Council, and the Hong Kong Innovation and Technology Commission. NP received a grant from NHMRC (GNT 1196900). SCY reports being a chief technology officer of PHI Digital Healthcare; and grants from Daiichi Sankyo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39975698</ArticleId><ArticleId IdType="pmc">PMC11836508</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2025.103096</ArticleId><ArticleId IdType="pii">S2589-5370(25)00028-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dai X.-C., Yang X.-X., Ma L., Tang G.-M., Pan Y.-Y., Hu H.-L. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies. BMC Cardiovasc Disord. 2020;20(1):49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6998374</ArticleId><ArticleId IdType="pubmed">32013928</ArticleId></ArticleIdList></Reference><Reference><Citation>Koba A., Yamagishi K., Sairenchi T., et al. Risk factors for mortality from aortic aneurysm and dissection: results from a 26-year follow-up of a community-based population. J&#xa0;Am Heart Assoc. 2023;12(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10227264</ArticleId><ArticleId IdType="pubmed">37042285</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2017. https://www.fda.gov/media/119532/download</Citation></Reference><Reference><Citation>Administration AGDoHaACTG  Medication Safety Update Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection. 12 April 2019 2024. https://www.tga.gov.au/news/safety-updates/fluoroquinolone-antibiotics-and-risk-aortic-aneurysmdissection</Citation></Reference><Reference><Citation>Agency E.M. Quinolone- and fluoroquinolone-containing medicinal products - referral. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-and-fluoroquinolone-containing-medicinal-products</Citation></Reference><Reference><Citation>Buehrle D.J., Wagener M.M., Clancy C.J. Outpatient fluoroquinolone prescription fills in the United States, 2014 to 2020: assessing the impact of Food and drug administration safety warnings. Antimicrob Agents Chemother. 2021;65(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218674</ArticleId><ArticleId IdType="pubmed">33875430</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. Fluoroquinolone antibiotics: prescribe only as last resort, says UK regulator. BMJ. 2024;384:q183.</Citation><ArticleIdList><ArticleId IdType="pubmed">38267066</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y.-H., Chang C.-H., Wang J.-L., Wu L.-C., Lin J.-W., Toh S. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180(12):1587&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489369</ArticleId><ArticleId IdType="pubmed">32897358</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan C., Bykov K., Fischer M.A., Connolly J.G., Gagne J.J., Fralick M. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180(12):1596&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489402</ArticleId><ArticleId IdType="pubmed">32897307</ArticleId></ArticleIdList></Reference><Reference><Citation>Vouga Ribeiro N., Gouveia Melo R., Guerra N.C., et al. Fluoroquinolones are associated with increased risk of aortic aneurysm or dissection: systematic review and meta-analysis. Semin Thorac Cardiovasc Surg. 2021;33(4):907&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">33181305</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., Ryan P.B., Pratt N., et al. Principles of large-scale evidence generation and evaluation across a network of databases (LEGEND) J&#xa0;Am Med Inform Assoc. 2020;27(8):1331&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Duke J.D., Shah N.H., et al. Observational health data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang C.I., Kim J., Park D.W., et al. Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infect Chemother. 2018;50(1):67&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5895837</ArticleId><ArticleId IdType="pubmed">29637759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K., Hooton T.M., Naber K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103&#x2013;e120.</Citation><ArticleIdList><ArticleId IdType="pubmed">21292654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.-C., Lee M.-T.G., Chen Y.-S., et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175(11):1839&#x2013;1847.</Citation><ArticleIdList><ArticleId IdType="pubmed">26436523</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak B., Inghammar M., Svanstr&#xf6;m H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5842359</ArticleId><ArticleId IdType="pubmed">29519881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.-C., Lee M.-T.G., Hsieh R., et al. Oral fluoroquinolone and the risk of aortic dissection. J&#xa0;Am Coll Cardiol. 2018;72(12):1369&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pubmed">30213330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.P., Wing K., Leyrat C., et al. Association between fluoroquinolone use and hospitalization with aortic aneurysm or aortic dissection. JAMA Cardiol. 2023;8(9):865&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10433140</ArticleId><ArticleId IdType="pubmed">37585175</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Schuemie M.J., Suchard M.A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., Hripcsak G., Ryan P.B., Madigan D., Suchard M.A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115(11):2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M.J., Chen Y., Madigan D., Suchard M.A. Combining cox regressions across a heterogeneous distributed research network facing small and zero counts. Stat Methods Med Res. 2022;31(3):438&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">34841975</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A., Patrick A., Lauer M., et al. A&#xa0;tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res (Auckl) 2013;11</Citation></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMaire S.A., Zhang L., Luo W., et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 2018;153(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233654</ArticleId><ArticleId IdType="pubmed">30046809</ArticleId></ArticleIdList></Reference><Reference><Citation>Daneman N., Lu H., Redelmeier D.A. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654346</ArticleId><ArticleId IdType="pubmed">26582407</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K., Kang M., Jung J. Lack of association between fluoroquinolone and aortic aneurysm or dissection. Eur Heart J. 2023;44(42):4476&#x2013;4484. doi: 10.1093/eurheartj/ehad627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad627</ArticleId><ArticleId IdType="pubmed">37724037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Cho K.H., Lee S.W., et al. vol. 12. 2017. pp. 28&#x2013;34. (Recent antimicrobial susceptibilities for uropathogenic Escherichia coli in patients with community acquired urinary tract infections: a multicenter study).</Citation></Reference><Reference><Citation>Schuemie M., Reps J., Black A., et al. Health-analytics data to evidence suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcaccio C.L., Schermerhorn M.L. Epidemiology of abdominal aortic aneurysms. Semin Vasc Surg. 2021;34(1):29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">33757632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39976940</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6173</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA ophthalmology</Title><ISOAbbreviation>JAMA Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.</ArticleTitle><Pagination><StartPage>304</StartPage><EndPage>314</EndPage><MedlinePgn>304-314</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaophthalmol.2024.6555</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non-GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals' risks during exposure and nonexposure periods for each drug. The cohort design used propensity score-adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">GLP-1RA and non-GLP-1RAs.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The study included 37.1 million individuals with T2D, including 810&#x202f;390 new semaglutide users. Of the 43&#x202f;620 new users of semaglutide in the Optum's deidentified Clinformatics Data Mart Database, 24&#x202f;473 (56%) were aged 50 to 69 years, and 26&#x202f;699 (61%) were female. The incidence rate of NAION was 14.5 per 100&#x202f;000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non-GLP-1RAs using the sensitive NAION definition-empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P&#x2009;=&#x2009;.12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P&#x2009;=&#x2009;.27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P&#x2009;=&#x2009;.25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P&#x2009;=&#x2009;.02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Cindy X</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hribar</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Eye Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Casey Eye Institute, Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Kerry</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Eye Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Swarup S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flowers</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vanderbilt Eye Institute, Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Eye Institute, Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Eric N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Vanderbilt Eye Institute, Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toy</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Aiyin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Casey Eye Institute, Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karalis Johnson Retina Center, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Theodore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrlich</LastName><ForeName>Joshua R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkmeier</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armbrust</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Mass Eye and Ear and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyce</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Practice, Faculty of Pharmacy, Jazan University, Jazan, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacy Practice Research Unit, Faculty of Pharmacy, Jazan University, Jazan, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA School of Public Health, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA School of Public Health, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Informatics, Data Science and Biostatistics, Department of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westlund</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathioudakis</LastName><ForeName>Nestoras</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Ruochong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Informatics, Data Science and Biostatistics, Department of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocking</LastName><ForeName>Jacqueline C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of California Davis, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takkouche</LastName><ForeName>Sahar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Diabetes and Endocrinology, Vanderbilt University, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Lok Hin</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yangyiran</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humes</LastName><ForeName>Izabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCoy</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adibuzzaman</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areaux</LastName><ForeName>Raymond G</ForeName><Initials>RG</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas-Carabali</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brash</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiskopf</LastName><ForeName>Nicole G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawn</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Rupesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tan Tock Seng Hospital, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan-Cooper</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine and Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine and Stanford Health Care, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Horsham, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL169954</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 EY033440</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM011271</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013990</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 HL168222</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG060942</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Ophthalmol</MedlineTA><NlmUniqueID>101589539</NlmUniqueID><ISSNLinking>2168-6165</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>62340-29-8</RegistryNumber><NameOfSubstance UI="D004763">Glucagon-Like Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>53AXN4NNHX</RegistryNumber><NameOfSubstance UI="C000591245">semaglutide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Ophthalmol. 2025 Apr 1;143(4):315-316. doi: 10.1001/jamaophthalmol.2025.0005.</RefSource><PMID Version="1">39976950</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004763" MajorTopicYN="Y">Glucagon-Like Peptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018917" MajorTopicYN="Y">Optic Neuropathy, Ischemic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Cai reported receiving grants from Regeneron Pharmaceuticals outside the submitted work. Dr Baxter reported receiving grants from National Institutes of Health (NIH) and Research to Prevent Blindess, personal fees from Topcon, and nonfinancial support from Optomed outside the submitted work. Dr Swaminathan reported receiving personal fees from AbbVie, Elios Vision, and Lumata Health and grants from Heidelberg Engineering outside the submitted work. Dr Toy reported receiving advisory board fees from Alimera Sciences, Bausch &amp; Lomb, and Regeneron outside the submitted work. Dr C. Lee reported receiving grants from NIH, Centers for Disease Control and Prevention, and the Alzheimer&#x2019;s Disease Drug Foundation outside the submitted work. Dr Leng reported receiving grants from Astellas and personal fees from Topcon, Astellas, Alcon, Boehringer Ingelheim, Iridex, Nanoscope, Regeneron, Genentech/Roche, Virtual Field, Aptitude Medical, Protagonist Therapeutics, Apellis, and Graybug outside the submitted work. Dr Boland reported receiving personal fees from Carl Zeiss Meditec, Topcon Healthcare, Allergan, and Janssen during the conduct of the study. Dr Swerdel reported being an employee and shareholder of Johnson &amp; Johnson outside the submitted work. Dr Suchard reported receiving grants from NIH, US Department of Veterans Affairs, and the US Food and Drug Administration and personal fees from Johnson &amp; Johnson outside the submitted work. Drs Schuemie and Sena reported being and employee and shareholder of Johnson &amp; Johnson outside the submitted work. Dr DuVall reported receiving grants from Alnylam Pharmaceuticals, Astellas Pharma, AstraZeneca, Biodesix, Celgene Corp, Cerner Enviza, GSK, IQVIA, Janssen Pharmaceuticals, Moderna, Novartis International AG, and Parexel International Corp outside the submitted work. Dr Lai reported being a shareholder of Johnson &amp; Johnson outside the submitted work. Dr Brash reported being employed by IQVIA outside the submitted work. Dr Mawn reported receiving grants from Research to Prevent Blindness and consultant fees from Amgen and Genentech. Dr Ryan reported being an employee and shareholder of Johnson &amp; Johnson. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>17</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>20</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39976940</ArticleId><ArticleId IdType="pmc">PMC11843465</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2024.6555</ArticleId><ArticleId IdType="pii">2830475</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009;28(1):34-62. doi:10.1016/j.preteyeres.2008.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.11.002</ArticleId><ArticleId IdType="pubmed">19063989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115(2):298-305.e2. doi:10.1016/j.ophtha.2007.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2007.05.027</ArticleId><ArticleId IdType="pmc">PMC2782939</ArticleId><ArticleId IdType="pubmed">17698200</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ischemic Optic Neuropathy Decompression Trial Research Group . Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273(8):625-632. doi:10.1001/jama.1995.03520320035038</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1995.03520320035038</ArticleId><ArticleId IdType="pubmed">7844872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hathaway JT, Shah MP, Hathaway DB, et al. . Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2024.2296</ArticleId><ArticleId IdType="pmc">PMC11223051</ArticleId><ArticleId IdType="pubmed">38958939</ArticleId></ArticleIdList></Reference><Reference><Citation>Klonoff DC, Hui G, Gombar S. Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. J Diabetes Sci Technol. 2024;18(6):1517-1518. doi:10.1177/19322968241268050</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19322968241268050</ArticleId><ArticleId IdType="pmc">PMC11529103</ArticleId><ArticleId IdType="pubmed">39080859</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee . 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes&#x2014;2024. Diabetes Care. 2024;47(suppl 1):S158-S178. doi:10.2337/dc24-S009</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Schuemie MJ, Lu Y, et al. . Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open. 2022;12(6):e057977. doi:10.1136/bmjopen-2021-057977</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057977</ArticleId><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Aminorroaya A, Dhingra LS, et al. . Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes: a large-scale, multinational, federated analysis of the LEGEND-T2DM study. medRxiv. Preprint posted online February 8, 2024. doi:10.1101/2024.02.05.24302354</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.05.24302354</ArticleId><ArticleId IdType="pubmed">39197980</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, et al. ; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Tuttle KR, Rossing P, et al. ; FLOW Trial Committees and Investigators . Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403347</ArticleId><ArticleId IdType="pubmed">38785209</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Aminorroaya A, Dhingra LS, et al. . Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes: a multinational, federated analysis of LEGEND-T2DM. J Am Coll Cardiol. 2024;84(10):904-917. doi:10.1016/j.jacc.2024.05.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.05.069</ArticleId><ArticleId IdType="pubmed">39197980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai CX, Nishimura A, Bowring MG, et al. . Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an Observational Health Data Sciences and Informatics network study. Ophthalmol Retina. 2024;8(8):733-743. doi:10.1016/j.oret.2024.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2024.03.014</ArticleId><ArticleId IdType="pmc">PMC11298306</ArticleId><ArticleId IdType="pubmed">38519026</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816-1826. doi:10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54-60. doi:10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . OHDSI studies/semaglutide naion. Accessed August 17, 2024. https://github.com/ohdsi-studies/SemaglutideNaion</Citation></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Stunkel L, Kung NH, Wilson B, McClelland CM, Van Stavern GP. Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol. 2018;136(1):76-81. doi:10.1001/jamaophthalmol.2017.5470</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2017.5470</ArticleId><ArticleId IdType="pmc">PMC5833602</ArticleId><ArticleId IdType="pubmed">29222573</ArticleId></ArticleIdList></Reference><Reference><Citation>Stunkel L, Newman NJ, Biousse V. Diagnostic error and neuro-ophthalmology. Curr Opin Neurol. 2019;32(1):62-67. doi:10.1097/WCO.0000000000000635</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000635</ArticleId><ArticleId IdType="pmc">PMC6310060</ArticleId><ArticleId IdType="pubmed">30516641</ArticleId></ArticleIdList></Reference><Reference><Citation>Stunkel L, Sharma RA, Mackay DD, et al. . Patient harm due to diagnostic error of neuro-ophthalmologic conditions. Ophthalmology. 2021;128(9):1356-1362. doi:10.1016/j.ophtha.2021.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2021.03.008</ArticleId><ArticleId IdType="pubmed">33713783</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Schuemie M, Murray G, Ryan PB. PheValuator 2.0: methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation. J Biomed Inform. 2022;135:104177. doi:10.1016/j.jbi.2022.104177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104177</ArticleId><ArticleId IdType="pubmed">35995107</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI . Research protocol. Accessed August 17, 2024. https://ohdsi-studies.github.io/SemaglutideNaion/protocol.html</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct P values. Stat Med. 2014;33(2):209-218. doi:10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115(11):2571-2577. doi:10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . OHDSI/strategus. Accessed August 17, 2024. https://github.com/OHDSI/Strategus</Citation></Reference><Reference><Citation>Schuemie M, Reps J, Black A, et al. . Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966-970. doi:10.3233/SHTI231108</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI231108</ArticleId><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI Evidence Sharing . OHDSI analysis viewer. Accessed September 5, 2024. https://results.ohdsi.org/app/20_Semanaion_Char</Citation></Reference><Reference><Citation>GitHub . OHDSI/characterization. Accessed August 17, 2024. https://github.com/OHDSI/Characterization</Citation></Reference><Reference><Citation>Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)&#x2014;update and ICD-10 translation. J Diabetes Complications. 2017;31(6):1007-1013. doi:10.1016/j.jdiacomp.2017.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2017.02.018</ArticleId><ArticleId IdType="pubmed">28416120</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079. doi:10.1016/0895-4356(93)90103-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(93)90103-8</ArticleId><ArticleId IdType="pubmed">8410092</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . OHDSI/cohort incidence. Accessed August 17, 2024. https://github.com/OHDSI/CohortIncidence</Citation></Reference><Reference><Citation>GitHub . OHDSI/cohort method. Accessed August 17, 2024. https://github.com/OHDSI/CohortMethod</Citation></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005-2014. doi:10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wang Y, Schuemie MJ, Blei DM, Hripcsak G. Adjusting for indirectly measured confounding using large-scale propensity score. J Biomed Inform. 2022;134:104204. doi:10.1016/j.jbi.2022.104204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104204</ArticleId><ArticleId IdType="pmc">PMC9692203</ArticleId><ArticleId IdType="pubmed">36108816</ArticleId></ArticleIdList></Reference><Reference><Citation>Novo Nordisk . Q1 2023 presentation. Accessed August 18, 2024. https://investor.novonordisk.com/q1-2023-presentation/?page=15</Citation></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, et al. . How confident are we about observational findings in health care: a benchmark study. Harv Data Sci Rev. 2020;2(1). doi:10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . OHDSI/self-controlled case series. Accessed August 17, 2024. https://github.com/OHDSI/SelfControlledCaseSeries</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ. Evaluating performance of risk identification methods through a large-scale simulation of observational data. Drug Saf. 2013;36(suppl 1):S171-S180. doi:10.1007/s40264-013-0110-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0110-2</ArticleId><ArticleId IdType="pubmed">24166233</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, Stang PE, Berlin JA, et al. . A systematic statistical approach to evaluating evidence from observational studies [abstract]. Annu Rev Stat Appl. 2014;1(1):11-39. doi:10.1146/annurev-statistics-022513-115645</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-statistics-022513-115645</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768-1797. doi:10.1002/sim.2302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2302</ArticleId><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen I, Douglas I, Whitaker H. Self-controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515. doi:10.1136/bmj.i4515</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4515</ArticleId><ArticleId IdType="pubmed">27618829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018;376(2128):20170356. doi:10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of P values using observational data. Stat Med. 2016;35(22):3883-3888. doi:10.1002/sim.6977</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6977</ArticleId><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Chen Y, Madigan D, Suchard MA. Combining cox regressions across a heterogeneous distributed research network facing small and zero counts. Stat Methods Med Res. 2022;31(3):438-450. doi:10.1177/09622802211060518</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09622802211060518</ArticleId><ArticleId IdType="pubmed">34841975</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub . OHDSI/evidence synthesis. Accessed August 17, 2024. https://github.com/OHDSI/EvidenceSynthesis</Citation></Reference><Reference><Citation>Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy: population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol. 1994;14(1):38-44. doi:10.1097/00041327-199403000-00011</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041327-199403000-00011</ArticleId><ArticleId IdType="pubmed">8032479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(1):103-107. doi:10.1016/S0002-9394(14)70999-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9394(14)70999-7</ArticleId><ArticleId IdType="pubmed">9186104</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster RC, Bhatti MT, Crum OM, Lesser ER, Hodge DO, Chen JJ. Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester epidemiology project study. J Neuroophthalmol. 2024;44(3):337-341. doi:10.1097/WNO.0000000000002102</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000002102</ArticleId><ArticleId IdType="pubmed">38358828</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Park KA, Oh SY. Prevalence and incidence of nonarteritic anterior ischemic optic neuropathy in South Korea: a nationwide population-based study. Br J Ophthalmol. 2018;102(7):936-941. doi:10.1136/bjophthalmol-2017-311140</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2017-311140</ArticleId><ArticleId IdType="pubmed">28972024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosci&#x107; V, Boji&#x107; L, Marovi&#x107; T. The incidence of nonarteritic ischemic optic neuropathy in the Split-Dalmatia County. Article in Croatian. Acta Med Croatica. 2009;63(2):169-172.</Citation><ArticleIdList><ArticleId IdType="pubmed">19580225</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Wang Y, Jonas JB. Incidence of nonarteritic anterior ischemic optic neuropathy in adult Chinese: the Beijing Eye Study. Eur J Ophthalmol. 2007;17(3):459-460. doi:10.1177/112067210701700335</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/112067210701700335</ArticleId><ArticleId IdType="pubmed">17534837</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Grossman D, Arnold AC, Sloan FA. Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients. Ophthalmology. 2011;118(5):959-963. doi:10.1016/j.ophtha.2011.01.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2011.01.054</ArticleId><ArticleId IdType="pmc">PMC3087834</ArticleId><ArticleId IdType="pubmed">21439645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamedani AG, Kim DS, Chaitanuwong P, Gonzalez LA, Moss HE, DeLott LB. Validity of administrative coding for nonarteritic ischemic optic neuropathy. J Neuroophthalmol. 2024;44(3):342-345. doi:10.1097/WNO.0000000000002163</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000002163</ArticleId><ArticleId IdType="pmc">PMC11338734</ArticleId><ArticleId IdType="pubmed">38706093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamedani AG, De Lott LB, Deveney T, Moss HE. Validity of international classification of diseases codes for identifying neuro-ophthalmic disease in large data sets: a systematic review. J Neuroophthalmol. 2020;40(4):514-519. doi:10.1097/WNO.0000000000000971</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000000971</ArticleId><ArticleId IdType="pmc">PMC7678809</ArticleId><ArticleId IdType="pubmed">33197163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform. 2021;30(1):283-289. doi:10.1055/s-0041-1726481</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich N, H&#xf6;lscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer and Parkinson disease: an in-depth review. Front Neurosci. 2022;16:970925. doi:10.3389/fnins.2022.970925</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.970925</ArticleId><ArticleId IdType="pmc">PMC9475012</ArticleId><ArticleId IdType="pubmed">36117625</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Qiang Q, Li N, Feng P, Wei W, H&#xf6;lscher C. Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research. Front Neurol. 2022;13:844697. doi:10.3389/fneur.2022.844697</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.844697</ArticleId><ArticleId IdType="pmc">PMC8964641</ArticleId><ArticleId IdType="pubmed">35370875</ArticleId></ArticleIdList></Reference><Reference><Citation>Niazi S, Gnesin F, Thein AS, et al. . Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes. Ophthalmology. 2024;131(9):1056-1063. doi:10.1016/j.ophtha.2024.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2024.03.004</ArticleId><ArticleId IdType="pubmed">38490274</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio LL, Ussher JR, McLean BA, et al. . The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6(11):1339-1349. doi:10.1016/j.molmet.2017.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2017.08.010</ArticleId><ArticleId IdType="pmc">PMC5681270</ArticleId><ArticleId IdType="pubmed">29107282</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705. doi:10.1016/S0140-6736(06)69705-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69705-5</ArticleId><ArticleId IdType="pubmed">17098089</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupersmith MJ, Fraser CL, Morgenstern R, Miller NR, Levin LA, Jette N; Quark207 NAION Study Group . Ophthalmic and systemic factors of acute nonarteritic anterior ischemic optic neuropathy in the Quark207 Treatment Trial. Ophthalmology. 2024;131(7):790-802. doi:10.1016/j.ophtha.2024.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2024.01.011</ArticleId><ArticleId IdType="pubmed">38211825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai CX, Halfpenny W, Boland MV, et al. . Advancing toward a common data model in ophthalmology: gap analysis of general eye examination concepts to Standard Observational Medical Outcomes Partnership (OMOP) concepts. Ophthalmol Sci. 2023;3(4):100391. doi:10.1016/j.xops.2023.100391</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2023.100391</ArticleId><ArticleId IdType="pmc">PMC10630664</ArticleId><ArticleId IdType="pubmed">38025162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hribar M, Baxter SL, OHDSI Eye Care and Vision Workgroup, Goetz KE. Data standardization in the OHDSI Eye Care and Vision Research workgroup [abstract]. Invest Ophthalmol Vis Sci. 2024;65(7):2420.</Citation></Reference><Reference><Citation>Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12:645617. doi:10.3389/fendo.2021.645617</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.645617</ArticleId><ArticleId IdType="pmc">PMC8269445</ArticleId><ArticleId IdType="pubmed">34248838</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Yu Y, Liu W, Deng T, Xiang D. Risk factors for nonarteritic anterior ischemic optic neuropathy: a large scale meta-analysis. Front Med (Lausanne). 2021;8:618353. doi:10.3389/fmed.2021.618353</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.618353</ArticleId><ArticleId IdType="pmc">PMC8520961</ArticleId><ArticleId IdType="pubmed">34671609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39983051</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2291-9694</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2025</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Analysis of Retinal Thickness in Patients With Chronic Diseases Using Standardized Optical Coherence Tomography Data: Database Study Based on the Radiology Common Data Model.</ArticleTitle><Pagination><StartPage>e64422</StartPage><MedlinePgn>e64422</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e64422</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/64422</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The Observational Medical Outcome Partners-Common Data Model (OMOP-CDM) is an international standard for harmonizing electronic medical record (EMR) data. However, since it does not standardize unstructured data, such as medical imaging, using this data in multi-institutional collaborative research becomes challenging. To overcome this limitation, extensions such as the Radiology Common Data Model (R-CDM) have emerged to include and standardize these data types.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This work aims to demonstrate that by standardizing optical coherence tomography (OCT) data into an R-CDM format, multi-institutional collaborative studies analyzing changes in retinal thickness in patients with long-standing chronic diseases can be performed efficiently.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We standardized OCT images collected from two tertiary hospitals for research purposes using the R-CDM. As a proof of concept, we conducted a comparative analysis of retinal thickness between patients who have chronic diseases and those who have not. Patients diagnosed or treated for retinal and choroidal diseases, which could affect retinal thickness, were excluded from the analysis. Using the existing OMOP-CDM at each institution, we extracted cohorts of patients with chronic diseases and control groups, performing large-scale 1:2 propensity score matching (PSM). Subsequently, we linked the OMOP-CDM and R-CDM to extract the OCT image data of these cohorts and analyzed central macular thickness (CMT) and retinal nerve fiber layer (RNFL) thickness using a linear mixed model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">OCT data of 261,874 images from Ajou University Medical Center (AUMC) and 475,626 images from Seoul National University Bundang Hospital (SNUBH) were standardized in the R-CDM format. The R-CDM databases established at each institution were linked with the OMOP-CDM database. Following 1:2 PSM, the type 2 diabetes mellitus (T2DM) cohort included 957 patients, and the control cohort had 1603 patients. During the follow-up period, significant reductions in CMT were observed in the T2DM cohorts at AUMC (P=.04) and SNUBH (P=.007), without significant changes in RNFL thickness (AUMC: P=.56; SNUBH: P=.39). Notably, a significant reduction in CMT during the follow-up was observed only at AUMC in the hypertension cohort, compared to the control group (P=.04); no other significant differences in retinal thickness were found in the remaining analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The significance of our study lies in demonstrating the efficiency of multi-institutional collaborative research that simultaneously uses clinical data and medical imaging data by leveraging the OMOP-CDM for standardizing EMR data and the R-CDM for standardizing medical imaging data.</AbstractText><CopyrightInformation>&#xa9; ChulHyoung Park, So Hee Lee, Da Yun Lee, Seoyoon Choi, Seng Chan You, Ja Young Jeon, Sang Jun Park, Rae Woong Park. Originally published in JMIR Medical Informatics (https://medinform.jmir.org).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>ChulHyoung</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0531-9144</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 206, Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea, 82 31-219-4471.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lee</LastName><ForeName>So Hee</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0009-0007-5030-9320</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Da Yun</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-9604-8337</Identifier><AffiliationInfo><Affiliation>Department of Scientific Solutions, CMIC Korea Co, Ltd, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Seoyoon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-0621-6412</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Ja Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-3877-0479</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sang Jun</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-0542-2758</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, 206, Worldcup-ro, Yeongtong-gu, Suwon, 16499, Republic of Korea, 82 31-219-4471.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID><ISSNLinking>2291-9694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="Y">Retina</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data standardization</Keyword><Keyword MajorTopicYN="N">ophthalmology</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword><Keyword MajorTopicYN="N">radiology</Keyword><Keyword MajorTopicYN="N">retinal thickness</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>18</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>21</Day><Hour>15</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39983051</ArticleId><ArticleId IdType="pmc">PMC11870599</ArticleId><ArticleId IdType="doi">10.2196/64422</ArticleId><ArticleId IdType="pii">v13i1e64422</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578. Medline.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics; 2023.  [24-01-2025]. 2023 &#x201c;our journey&#x201d; annual report.https://www.ohdsi.org/wp-content/uploads/2023/11/OHDSI-Book2023.pdf URL. Accessed.</Citation></Reference><Reference><Citation>Shin SJ, You SC, Park YR, et al. Genomic common data model for seamless interoperation of biomedical data in clinical practice: retrospective study. J Med Internet Res. 2019 Mar 26;21(3):e13249. doi: 10.2196/13249. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13249</ArticleId><ArticleId IdType="pmc">PMC6454347</ArticleId><ArticleId IdType="pubmed">30912749</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley MJ, Golozar A, et al. Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin Cancer Inform. 2021 Jan;5:12&#x2013;20. doi: 10.1200/CCI.20.00079. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.20.00079</ArticleId><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C, You SC, Jeon H, Jeong CW, Choi JW, Park RW. Development and validation of the Radiology Common Data Model (R-CDM) for the international standardization of medical imaging data. Yonsei Med J. 2022 Jan;63(Suppl):S74&#x2013;S83. doi: 10.3349/ymj.2022.63.S74. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2022.63.S74</ArticleId><ArticleId IdType="pmc">PMC8790584</ArticleId><ArticleId IdType="pubmed">35040608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieves-Moreno M, Mart&#xed;nez-de-la-Casa JM, Morales-Fern&#xe1;ndez L, S&#xe1;nchez-Jean R, S&#xe1;enz-Franc&#xe9;s F, Garc&#xed;a-Feijo&#xf3; J. Impacts of age and sex on retinal layer thicknesses measured by spectral domain optical coherence tomography with Spectralis. PLoS ONE. 2018;13(3):e0194169. doi: 10.1371/journal.pone.0194169. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194169</ArticleId><ArticleId IdType="pmc">PMC5844598</ArticleId><ArticleId IdType="pubmed">29522565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lee WH, Lim HB, Jo YJ, Kim JY. Thicknesses of central macular, retinal nerve fiber, and ganglion cell inner plexiform layers in patients with hypertension. Retina (Philadelphia, Pa) 2019 Sep;39(9):1810&#x2013;1818. doi: 10.1097/IAE.0000000000002216. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000002216</ArticleId><ArticleId IdType="pubmed">29757807</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Liu Y, Chen Y, et al. Analysis of changes in retinal thickness in type 2 diabetes without diabetic retinopathy. J Diabetes Res. 2018;2018:3082893. doi: 10.1155/2018/3082893. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3082893</ArticleId><ArticleId IdType="pmc">PMC5845508</ArticleId><ArticleId IdType="pubmed">29682578</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014 Dec;12(12):1495&#x2013;1499. doi: 10.1016/j.ijsu.2014.07.013. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.07.013</ArticleId><ArticleId IdType="pubmed">25046131</ArticleId></ArticleIdList></Reference><Reference><Citation>Mun Y, Kim J, Noh KJ, et al. An innovative strategy for standardized, structured, and interoperable results in ophthalmic examinations. BMC Med Inform Decis Mak. 2021 Jan 6;21(1):9. doi: 10.1186/s12911-020-01370-0. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01370-0</ArticleId><ArticleId IdType="pmc">PMC7789748</ArticleId><ArticleId IdType="pubmed">33407448</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150&#x2013;161. doi: 10.1002/pst.433. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.433</ArticleId><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima DM, Rodrigues-Jr JF, Traina AJM, Pires FA, Gutierrez MA. Transforming two decades of ePR data to OMOP CDM for clinical research. Stud Health Technol Inform. 2019 Aug 21;264:233&#x2013;237. doi: 10.3233/SHTI190218. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI190218</ArticleId><ArticleId IdType="pubmed">31437920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, et al. Development of web-based management system and dataset for radiology-common data model (R-CDM) and its clinical application in liver cirrhosis. The 2020 Intelligent Systems Conference (IntelliSys); Sep 3-4, 2020; pp. 687&#x2013;695. Presented at. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-55190-2_54</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DY, Kim N, Park C, et al. Explainable multimodal prediction of treatment-resistance in patients with depression leveraging brain morphometry and natural language processing. Psychiatry Res. 2024 Apr;334:115817. doi: 10.1016/j.psychres.2024.115817. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2024.115817</ArticleId><ArticleId IdType="pubmed">38430816</ArticleId></ArticleIdList></Reference><Reference><Citation>Praeta J, Houghtaling J, Jung F, De Backer S, Pinxten J, Smeets D.  Observational Health Data Sciences and Informatics; Jul 31, 2023.  [24-01-2025]. Application of the R-CDM extension to capture metadata and features extracted from quantitative brain MRI and CT data.https://ohdsi-europe.org/images/symposium-2023/posters/praet_rcdmposter_2023_V3_-_Jared_Houghtaling.pdf URL. Accessed.</Citation></Reference><Reference><Citation>Rubin DL, Kahn CE., Jr Common data elements in radiology. Radiology. 2017 Jun;283(3):837&#x2013;844. doi: 10.1148/radiol.2016161553. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016161553</ArticleId><ArticleId IdType="pubmed">27831831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalokyri V, Kondylakis H, Sfakianakis S, et al. MI-Common Data Model: extending Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) for registering medical imaging metadata and subsequent curation processes. JCO Clin Cancer Inform. 2023 Sep;7:e2300101. doi: 10.1200/CCI.23.00101. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.23.00101</ArticleId><ArticleId IdType="pmc">PMC10715775</ArticleId><ArticleId IdType="pubmed">38061012</ArticleId></ArticleIdList></Reference><Reference><Citation>Park WY, Jeon K, Schmidt TS, et al. Development of medical imaging data standardization for imaging-based observational research: OMOP Common Data Model extension. J Imaging Inform Med. 2024 Apr;37(2):899&#x2013;908. doi: 10.1007/s10278-024-00982-6. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-024-00982-6</ArticleId><ArticleId IdType="pmc">PMC11031512</ArticleId><ArticleId IdType="pubmed">38315345</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshitari T, Hanawa K, Adachi-Usami E. Changes of macular and RNFL thicknesses measured by Stratus OCT in patients with early stage diabetes. Eye (Lond) 2009 Apr;23(4):884&#x2013;889. doi: 10.1038/eye.2008.119. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2008.119</ArticleId><ArticleId IdType="pubmed">18437178</ArticleId></ArticleIdList></Reference><Reference><Citation>Asefzadeh B, Fisch BM, Parenteau CE, Cavallerano AA. Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy. Clin Exp Ophthalmol. 2008 Jul;36(5):455&#x2013;463. doi: 10.1111/j.1442-9071.2008.01769.x. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1442-9071.2008.01769.x</ArticleId><ArticleId IdType="pubmed">18925914</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3; R, Hern&#xe1;ndez C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014 Jan;25(1):23&#x2013;33. doi: 10.1016/j.tem.2013.09.005. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2013.09.005</ArticleId><ArticleId IdType="pubmed">24183659</ArticleId></ArticleIdList></Reference><Reference><Citation>Akay F, G&#xfc;ndo&#x11f;an FC, Yolcu U, Toyran S, Tun&#xe7; E, Uzun S. Retinal structural changes in systemic arterial hypertension: an OCT study. Eur J Ophthalmol. 2016 Aug 4;26(5):436&#x2013;441. doi: 10.5301/ejo.5000740. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/ejo.5000740</ArticleId><ArticleId IdType="pubmed">26951532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong M, Kwun Y, Sung J, Ham DI, Song YM. Association between systemic hypertension and macular thickness measured by optical coherence tomography. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2144&#x2013;2150. doi: 10.1167/iovs.14-16080. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-16080</ArticleId><ArticleId IdType="pubmed">25736785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursali &#xd6;, Altinta&#x15f; &#xd6;, A&#x11f;ir A, Y&#xfc;ksel N, &#xd6;zkan B. Optical coherence tomography measurements in patients with systemic hypertension. Scott Med J. 2021 Aug;66(3):115&#x2013;121. doi: 10.1177/00369330211011175. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00369330211011175</ArticleId><ArticleId IdType="pubmed">33947281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayreh SS. Ischemic optic neuropathy. Prog Retin Eye Res. 2009 Jan;28(1):34&#x2013;62. doi: 10.1016/j.preteyeres.2008.11.002. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.11.002</ArticleId><ArticleId IdType="pubmed">19063989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TY, Klein R, Klein BE, Tielsch JM, Hubbard L, Nieto FJ. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol. 2001;46(1):59&#x2013;80. doi: 10.1016/s0039-6257(01)00234-x. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0039-6257(01)00234-x</ArticleId><ArticleId IdType="pubmed">11525792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong TY, Shankar A, Klein R, Klein BEK, Hubbard LD. Prospective cohort study of retinal vessel diameters and risk of hypertension. BMJ. 2004 Jul 10;329(7457):79. doi: 10.1136/bmj.38124.682523.55. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38124.682523.55</ArticleId><ArticleId IdType="pmc">PMC449809</ArticleId><ArticleId IdType="pubmed">15175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018 Dec 1;47(6):2005&#x2013;2014. doi: 10.1093/ije/dyy120. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong ACM, Chan CWN, Hui SP. Relationship of gender, body mass index, and axial length with central retinal thickness using optical coherence tomography. Eye (Lond) 2005 Mar;19(3):292&#x2013;297. doi: 10.1038/sj.eye.6701466. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6701466</ArticleId><ArticleId IdType="pubmed">15258609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelty PJ, Payne JF, Trivedi RH, Kelty J, Bowie EM, Burger BM. Macular thickness assessment in healthy eyes based on ethnicity using Stratus OCT optical coherence tomography. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2668&#x2013;2672. doi: 10.1167/iovs.07-1000. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.07-1000</ArticleId><ArticleId IdType="pubmed">18515595</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson U, Alm A. Macular thickness decreases with age in normal eyes: a study on the macular thickness map protocol in the Stratus OCT. Br J Ophthalmol. 2009 Nov;93(11):1448&#x2013;1452. doi: 10.1136/bjo.2007.131094. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.2007.131094</ArticleId><ArticleId IdType="pubmed">19019921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39993315</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-3704</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of internal medicine</Title><ISOAbbreviation>Ann Intern Med</ISOAbbreviation></Journal><ArticleTitle>Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.</ArticleTitle><Pagination><StartPage>315</StartPage><EndPage>326</EndPage><MedlinePgn>315-326</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7326/ANNALS-24-01347</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To compare the risk for depression in older adults with type 2 diabetes (T2D) initiating treatment with GLP-1RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is).</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Target trial emulation study.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">U.S. National Medicare administrative data from January 2014 to December 2020.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="UNASSIGNED">Adults aged 66 years or older with T2D initiating treatment with a GLP-1RA were matched 1:1 on propensity score with those initiating treatment with either an SGLT2i or a DPP4i.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="UNASSIGNED">The primary end point was incident depression. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) with 95% CI within matched groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 14&#x2009;665 matched pairs of older adults were included in the cohort for GLP-1RAs versus SGLT2is; the rate difference of depression between GLP-1RA users and SGLT2i users was 3.48 (95% CI, -0.81 to 7.78) per 1000 person-years, with an HR of 1.07 (CI, 0.98 to 1.18). In the cohort for GLP-1RAs versus DPP4is (13&#x2009;711 matched pairs), the rate difference was -5.78 (CI, -10.49 to -1.07) per 1000 person-years, with an HR of 0.90 (CI, 0.82 to 0.98).</AbstractText><AbstractText Label="LIMITATION" NlmCategory="UNASSIGNED">Unmeasured confounders (such as hemoglobin A<sub>1c</sub> levels and body mass index), outcome misclassification, and limited generalizability to all GLP-1RA users (for example, younger populations or those without T2D receiving the drug for obesity treatment).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Among older adults with T2D, the incidence of depression was relatively low. Use of GLP-1RAs was associated with a modestly lower risk for depression compared with use of DPP4is, but not SGLT2is.</AbstractText><AbstractText Label="PRIMARY FUNDING SOURCE" NlmCategory="UNASSIGNED">National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Huilin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5814-6657</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida (H.T., Y.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida (H.T., Y.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donahoo</LastName><ForeName>William T</ForeName><Initials>WT</Initials><Identifier Source="ORCID">0000-0002-2126-860X</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes and Metabolism, College of Medicine, University of Florida, Gainesville, Florida (W.T.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westen</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0001-9891-4529</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida (S.C.W.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence, University of Pennsylvania; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine; Leonard Davis Institute of Health Economics; Penn Medicine Center for Evidence-based Practice; and Penn Institute for Biomedical Informatics, Philadelphia, Pennsylvania, and Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida (Y.C.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2238-5429</Identifier><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida (J.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jingchuan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9799-2592</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, and Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida (J.G.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK133465</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Intern Med</MedlineTA><NlmUniqueID>0372351</NlmUniqueID><ISSNLinking>0003-4819</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="Y">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="Y">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosures:</b> Disclosure forms are available with the article online.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>25</Day><Hour>12</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>24</Day><Hour>23</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>24</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39993315</ArticleId><ArticleId IdType="mid">NIHMS2082136</ArticleId><ArticleId IdType="pmc">PMC12132804</ArticleId><ArticleId IdType="doi">10.7326/ANNALS-24-01347</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crawford AL, Laiteerapong N. Type 2 diabetes. Ann Intern Med. 2024;177:ITC81&#x2013;ITC96. doi: 10.7326/AITC202406180</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202406180</ArticleId><ArticleId IdType="pubmed">38857502</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes &#x2013; global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107&#x2013;111. doi: 10.2991/jegh.k.191028.001</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/jegh.k.191028.001</ArticleId><ArticleId IdType="pmc">PMC7310804</ArticleId><ArticleId IdType="pubmed">32175717</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 15
May
2024. Accessed at www.cdc.gov/diabetes/php/data-research/index.html on 7 June 2024.</Citation></Reference><Reference><Citation>Farmaki P, Damaskos C, Garmpis N, et al. Complications of the type 2 diabetes mellitus. Curr Cardiol Rev. 2020;16:249&#x2013;251. doi: 10.2174/1573403X1604201229115531</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403X1604201229115531</ArticleId><ArticleId IdType="pmc">PMC7903505</ArticleId><ArticleId IdType="pubmed">33407062</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canto E, Ceriello A, Ryd&#xe9;n L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25&#x2013;32. doi: 10.1177/2047487319878371</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487319878371</ArticleId><ArticleId IdType="pubmed">31722562</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzoubi A, Abunaser R, Khassawneh A, et al. The bidirectional relationship between diabetes and depression: a literature review. Korean J Fam Med. 2018;39:137&#x2013;146. doi: 10.4082/kjfm.2018.39.3.137</Citation><ArticleIdList><ArticleId IdType="doi">10.4082/kjfm.2018.39.3.137</ArticleId><ArticleId IdType="pmc">PMC5975983</ArticleId><ArticleId IdType="pubmed">29788701</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#x103;descu SV, T&#x103;taru C, Kobylinska L, et al. The association between diabetes mellitus and depression. J Med Life. 2016;9:120&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4863499</ArticleId><ArticleId IdType="pubmed">27453739</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31:2383&#x2013;2390. doi: 10.2337/dc08-0985</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc08-0985</ArticleId><ArticleId IdType="pmc">PMC2584200</ArticleId><ArticleId IdType="pubmed">19033418</ArticleId></ArticleIdList></Reference><Reference><Citation>Naicker K, Johnson JA, Skogen JC, et al. Type 2 diabetes and comorbid symptoms of depression and anxiety: longitudinal associations with mortality risk. Diabetes Care. 2017;40:352&#x2013;358. doi: 10.2337/dc16-2018</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-2018</ArticleId><ArticleId IdType="pubmed">28077458</ArticleId></ArticleIdList></Reference><Reference><Citation>Michos ED, Lopez-Jimenez F, Gulati M. Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. J Am Heart Assoc. 2023;12:e029282. doi: 10.1161/JAHA.122.029282</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.122.029282</ArticleId><ArticleId IdType="pmc">PMC10381974</ArticleId><ArticleId IdType="pubmed">37278394</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini S, Favacchio G, Panico C, et al. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovasc Diabetol. 2023;22:69. doi: 10.1186/s12933-023-01800-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01800-z</ArticleId><ArticleId IdType="pmc">PMC10039680</ArticleId><ArticleId IdType="pubmed">36966321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ard J, Fitch A, Fruh S, et al. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38:2821&#x2013;2839. doi: 10.1007/s12325-021-01710-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-021-01710-0</ArticleId><ArticleId IdType="pmc">PMC8189979</ArticleId><ArticleId IdType="pubmed">33977495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brierley DI, Holt MK, Singh A, et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021;3:258&#x2013;273. doi: 10.1038/s42255-021-00344-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00344-4</ArticleId><ArticleId IdType="pmc">PMC7116821</ArticleId><ArticleId IdType="pubmed">33589843</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. 11
July
2023. Accessed at www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists on 11 September 2024.</Citation></Reference><Reference><Citation>Chen X, Zhao P, Wang W, et al. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2024;32:117&#x2013;127. doi: 10.1016/j.jagp.2023.08.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2023.08.010</ArticleId><ArticleId IdType="pubmed">37684186</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YK, Kim OY, Song J. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function. Front Pharmacol. 2020;11:1270. doi: 10.3389/fphar.2020.01270</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01270</ArticleId><ArticleId IdType="pmc">PMC7456867</ArticleId><ArticleId IdType="pubmed">32922295</ArticleId></ArticleIdList></Reference><Reference><Citation>Detka J, G&#x142;ombik K. Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacol Rep. 2021;73:1020&#x2013;1032. doi: 10.1007/s43440-021-00274-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00274-8</ArticleId><ArticleId IdType="pmc">PMC8413152</ArticleId><ArticleId IdType="pubmed">34003475</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DH, Ramachandra R, Ceban F, et al. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review. J Psychiatr Res. 2023;164:80&#x2013;89. doi: 10.1016/j.jpsychires.2023.05.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2023.05.041</ArticleId><ArticleId IdType="pubmed">37331261</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WH, Sung FC, Chiu LT, et al. Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population-based cohort study. Front Pharmacol. 2022;13:765446. doi: 10.3389/fphar.2022.765446</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.765446</ArticleId><ArticleId IdType="pmc">PMC8904427</ArticleId><ArticleId IdType="pubmed">35281896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wium-Andersen IK, Osler M, J&#xf8;rgensen MB, et al. Diabetes, antidiabetic medications and risk of depression &#x2013; a population-based cohort and nested case-control study. Psychoneuroendocrinology. 2022;140:105715. doi: 10.1016/j.psyneuen.2022.105715</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2022.105715</ArticleId><ArticleId IdType="pubmed">35338947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamble JM, Chibrikov E, Midodzi WK, et al. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink. BMJ Open. 2018;8:e023830. doi: 10.1136/bmjopen-2018-023830</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-023830</ArticleId><ArticleId IdType="pmc">PMC6194463</ArticleId><ArticleId IdType="pubmed">30297350</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessing LV, Rytgaard HC, Ekstr&#xf8;m CT, et al. Antidiabetes agents and incident depression: a nationwide population-based study. Diabetes Care. 2020;43:3050&#x2013;3060. doi: 10.2337/dc20-1561</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1561</ArticleId><ArticleId IdType="pubmed">32978179</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund JL, Richardson DB, St&#xfc;rmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221&#x2013;228. doi: 10.1007/s40471-015-0053-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-015-0053-5</ArticleId><ArticleId IdType="pmc">PMC4778958</ArticleId><ArticleId IdType="pubmed">26954351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendor R, St&#xfc;rmer T. Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31:261&#x2013;269. doi: 10.1002/pds.5407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5407</ArticleId><ArticleId IdType="pmc">PMC9121653</ArticleId><ArticleId IdType="pubmed">35019190</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes&#x2014;2024. Diabetes Care. 2024;47:S158&#x2013;S178. doi: 10.2337/dc24-S009</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925&#x2013;1966. doi: 10.1007/s00125-022-05787-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05787-2</ArticleId><ArticleId IdType="pmc">PMC9510507</ArticleId><ArticleId IdType="pubmed">36151309</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck M Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203&#x2013;216. doi: 10.1111/dom.12591</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12591</ArticleId><ArticleId IdType="pmc">PMC4785614</ArticleId><ArticleId IdType="pubmed">26489970</ArticleId></ArticleIdList></Reference><Reference><Citation>Khokhar B, Jette N, Metcalfe A, et al. Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations. BMJ Open. 2016;6:e009952. doi: 10.1136/bmjopen-2015-009952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-009952</ArticleId><ArticleId IdType="pmc">PMC4985868</ArticleId><ArticleId IdType="pubmed">27496226</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy CE. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18:1075&#x2013;1078. doi: 10.5811/westjem.2017.8.35985</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/westjem.2017.8.35985</ArticleId><ArticleId IdType="pmc">PMC5654877</ArticleId><ArticleId IdType="pubmed">29085540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripollone JE, Huybrechts KF, Rothman KJ, et al. Implications of the propensity score matching paradox in pharmacoepidemiology. Am J Epidemiol. 2018;187:1951&#x2013;1961. doi: 10.1093/aje/kwy078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy078</ArticleId><ArticleId IdType="pmc">PMC6118075</ArticleId><ArticleId IdType="pubmed">29750409</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Kim HJ, Lonjon G, et al. ; written on behalf of AME Big-Data Clinical Trial Collaborative Group. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16. doi: 10.21037/atm.2018.12.10</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.12.10</ArticleId><ArticleId IdType="pmc">PMC6351359</ArticleId><ArticleId IdType="pubmed">30788363</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>Arillotta D, Floresta G, Guirguis A, et al. GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach. Brain Sci. 2023;13:1503. doi: 10.3390/brainsci13111503</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci13111503</ArticleId><ArticleId IdType="pmc">PMC10669484</ArticleId><ArticleId IdType="pubmed">38002464</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderberg RH, Richard JE, Hansson C, et al. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54&#x2013;66. doi: 10.1016/j.psyneuen.2015.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.11.021</ArticleId><ArticleId IdType="pubmed">26724568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30:168&#x2013;176. doi: 10.1038/s41591-023-02672-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02672-2</ArticleId><ArticleId IdType="pmc">PMC11034947</ArticleId><ArticleId IdType="pubmed">38182782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Lu Y, Donahoo WT, et al. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes. A target trial emulation study. Ann Intern Med. 2024;177:1004&#x2013;1015. doi: 10.7326/M24-0329</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M24-0329</ArticleId><ArticleId IdType="pmc">PMC12132802</ArticleId><ArticleId IdType="pubmed">39008852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda P, S&#xf6;derling J, Wintzell V, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184:1301&#x2013;1312. doi: 10.1001/jamainternmed.2024.4369</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2024.4369</ArticleId><ArticleId IdType="pmc">PMC11372654</ArticleId><ArticleId IdType="pubmed">39226030</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Update on FDA&#x2019;s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. 11
January
2024. Accessed at www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type on 12 January 2024.</Citation></Reference><Reference><Citation>Tang H, Lu Y, Kotecha P, et al. CO180 newer glucose-lowering drugs and risk of depression: a meta-analysis of randomized outcome trials [Abstract]. Value Health. 2024;27(suppl):S51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11410519</ArticleId><ArticleId IdType="pubmed">39075921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mui JV, Li L, Chou OHI, et al. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong. Acta Diabetol. 2023;60:917&#x2013;927. doi: 10.1007/s00592-023-02063-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-023-02063-6</ArticleId><ArticleId IdType="pmc">PMC10198893</ArticleId><ArticleId IdType="pubmed">37000300</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad RN, Ahmed LA, Abdul Salam RM, et al. Crosstalk among NLRP3 inflammasome, ETBR signaling, and miRNAs in stress-induced depression-like behavior: a modulatory role for SGLT2 inhibitors. Neurotherapeutics. 2021;18:2664&#x2013;2681. doi: 10.1007/s13311-021-01140-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01140-4</ArticleId><ArticleId IdType="pmc">PMC8804152</ArticleId><ArticleId IdType="pubmed">34664178</ArticleId></ArticleIdList></Reference><Reference><Citation>Essmat N, Soliman E, Mahmoud MF, et al. Antidepressant activity of anti-hyperglycemic agents in experimental models: a review. Diabetes Metab Syndr. 2020;14:1179&#x2013;1186. doi: 10.1016/j.dsx.2020.06.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.06.021</ArticleId><ArticleId IdType="pubmed">32673838</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong D, Liu X, Ma L, et al. Dapagliflozin inhibits the activity of lateral habenula to alleviate diabetes mellitus-induced depressive-like behavior. Exp Neurol. 2023;366:114448. doi: 10.1016/j.expneurol.2023.114448</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2023.114448</ArticleId><ArticleId IdType="pubmed">37211324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar AK, Barton DA. Depression and the link with cardiovascular disease. Front Psychiatry. 2016;7:33. doi: 10.3389/fpsyt.2016.00033</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2016.00033</ArticleId><ArticleId IdType="pmc">PMC4800172</ArticleId><ArticleId IdType="pubmed">27047396</ArticleId></ArticleIdList></Reference><Reference><Citation>Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018;20:974&#x2013;984. doi: 10.1111/dom.13184</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13184</ArticleId><ArticleId IdType="pmc">PMC6207375</ArticleId><ArticleId IdType="pubmed">29206336</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40012646</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-1152</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of the American College of Emergency Physicians open</Title><ISOAbbreviation>J Am Coll Emerg Physicians Open</ISOAbbreviation></Journal><ArticleTitle>Mapping Emergency Medicine Data to the Observational Medical Outcomes Partnership Common Data Model: A Gap Analysis of the American College of Emergency Physicians Clinical&#xa0;Emergency Data Registry.</ArticleTitle><Pagination><StartPage>100016</StartPage><MedlinePgn>100016</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.acepjo.2024.100016</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study aims to conduct a gap analysis to determine the feasibility of mapping electronic health record data from the Clinical Emergency Data Registry (CEDR) to the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We employed a structured approach using a custom-built comparison matrix. This matrix facilitated the alignment of CEDR data fields with the corresponding elements in the OMOP-CDM schema. Each field was evaluated for compatibility, with categorization into 3 distinct types: direct matches, fields requiring transformation, and fields with no OMOP-CDM equivalent. The mapping process was informed by consultations with the Observational Health Data Sciences and Informatics community forums and was guided by existing documentation and best practices in data harmonization. We performed descriptive analyses, quantifying the extent of direct matches and identifying the specific transformations needed for each CEDR-CDM field to ensure compliance with the OMOP-CDM model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Our analysis indicates a high degree of compatibility between CEDR and OMOP, with over 90% (244/269) of CEDR fields being successfully mapped. Specifically, 173 fields had direct matches, whereas 71 required transformations. Challenges identified include addressing fields unique to CEDR with no OMOP-CDM equivalent and managing the transformations required for proper alignment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The OMOP-CDM presents a promising framework for standardizing emergency medicine data, thereby enhancing future query automation, analytics, and cross-institutional collaboration. Despite the potential challenges in capturing unique CEDR fields and addressing necessary transformations, most emergency department data can be standardized within the OMOP-CDM, fostering broader insights and applications in research and public health.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Inessa</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program of Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diao</LastName><ForeName>Zihan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Pawan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>American College of Emergency Physicians, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Aarti</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>American College of Emergency Physicians, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawk</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malcom</LastName><ForeName>Bill</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>American College of Emergency Physicians, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malicki</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Dhruv</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>American College of Emergency Physicians, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>American College of Emergency Physicians, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Scott G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>R Andrew</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section for Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33 DA059169</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R61 DA059169</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Emerg Physicians Open</MedlineTA><NlmUniqueID>101764779</NlmUniqueID><ISSNLinking>2688-1152</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">databases</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">emergency service</Keyword><Keyword MajorTopicYN="N">informatics</Keyword><Keyword MajorTopicYN="N">opioid/adverse effects</Keyword><Keyword MajorTopicYN="N">quality of health care</Keyword><Keyword MajorTopicYN="N">registries</Keyword></KeywordList><CoiStatement>RAT receives grant funding from Beckman Coulter for unrelated work pertaining to artificial intelligence development around emergency department triage. The authors otherwise declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. PG, DS, AKV, KH, and SW also report receiving support from the Elevance Foundation for Opioid Response Efforts to support a national ED-based quality improvement network directed at opioid use disorder.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>27</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40012646</ArticleId><ArticleId IdType="pmc">PMC11853007</ArticleId><ArticleId IdType="doi">10.1016/j.acepjo.2024.100016</ArticleId><ArticleId IdType="pii">S2688-1152(24)01330-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lin M.P., Sharma D., Venkatesh A., et al. The clinical emergency data registry: structure, use, and limitations for research. Ann Emerg Med. 2024;83(5):467&#x2013;476. doi: 10.1016/j.annemergmed.2023.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2023.12.014</ArticleId><ArticleId IdType="pmc">PMC11627304</ArticleId><ArticleId IdType="pubmed">38276937</ArticleId></ArticleIdList></Reference><Reference><Citation>EMDI Transition &amp; PA Consulting. https://www.acep.org/cedr/newsroom/spring-2022/emdi-transition--pa-consulting</Citation></Reference><Reference><Citation>Taylor T.B., Plance C., Hotard M., Malcom B., Smit C. Clinical Emergency Data Registry Emergency Medicine Data Institute Transition ACEP Webinar. https://www.youtube.com/watch?v=nKDS7Xxpsjw&amp;t=8s</Citation></Reference><Reference><Citation>OMOP Common Data Model. https://ohdsi.github.io/CommonDataModel/</Citation></Reference><Reference><Citation>Adam A. OHDSI RWE revolution: igniting data modernization with harmonized standards for cutting-edge health research (EMA Data Analytics and Methods Task Force) https://www.ohdsi.org/wp-content/uploads/2023/11/AMIA2023-Workshop.pdf</Citation></Reference><Reference><Citation>Haendel M.A., Chute C.G., Bennett T.D., et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J&#xa0;Am Med Inform Assoc. 2021;28(3):427&#x2013;443. doi: 10.1093/jamia/ocaa196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallfelz M, Tsvetkova A, Pollard T, et&#xa0;al (2021). MIMIC-IV demo data in the OMOP Common Data Model (version 0.9). PhysioNet. https://doi.org/10.13026/p1f5-7x35</Citation><ArticleIdList><ArticleId IdType="doi">10.13026/p1f5-7x35</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberger A.L., Amaral L.A., Glass L., et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circulation. 2000;101(23):E215&#x2013;E220. doi: 10.1161/01.cir.101.23.e215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.101.23.e215</ArticleId><ArticleId IdType="pubmed">10851218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez A.H., Sulieman L., Schlueter D.J., et al. The All of Us research program: data quality, utility, and diversity. Patterns (N Y) 2022;3(8) doi: 10.1016/j.patter.2022.100570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.patter.2022.100570</ArticleId><ArticleId IdType="pmc">PMC9403360</ArticleId><ArticleId IdType="pubmed">36033590</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Henke E., Reinecke I., Zoch M., Sedlmayr M., Bathelt F. An ETL-process design for data harmonization to participate in international research with German real-world data based on FHIR and OMOP CDM. Int J Med Inform. 2023;169 doi: 10.1016/j.ijmedinf.2022.104925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104925</ArticleId><ArticleId IdType="pubmed">36395615</ArticleId></ArticleIdList></Reference><Reference><Citation>Oja M., Tamm S., Mooses K., et al. Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) common data model: lessons learned. JAMIA Open. 2023;6(4) doi: 10.1093/jamiaopen/ooad100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad100</ArticleId><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C.X., Halfpenny W., Boland M.V., et al. Advancing toward a common data model in ophthalmology: gap analysis of general eye examination concepts to standard observational medical outcomes partnership (OMOP) concepts. Ophthalmol Sci. 2023;3(4) doi: 10.1016/j.xops.2023.100391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2023.100391</ArticleId><ArticleId IdType="pmc">PMC10630664</ArticleId><ArticleId IdType="pubmed">38025162</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Zong N., Wen A., Liu S., et al. Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration. J&#xa0;Biomed Inform. 2022;127 doi: 10.1016/j.jbi.2022.104002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104002</ArticleId><ArticleId IdType="pmc">PMC8791245</ArticleId><ArticleId IdType="pubmed">35077901</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathappan S.M.K., Jeon Y.S., Dang T.K., et al. Transformation of electronic health records and questionnaire data to OMOP CDM: a feasibility study using SG_T2DM dataset. Appl Clin Inform. 2021;12(4):757&#x2013;767. doi: 10.1055/s-0041-1732301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1732301</ArticleId><ArticleId IdType="pmc">PMC8357458</ArticleId><ArticleId IdType="pubmed">34380168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A., Abou-Arab O., Bourgeois A., et al. Transforming anesthesia data into the observational medical outcomes partnership common data model: development and usability study. J&#xa0;Med Internet Res. 2021;23(10) doi: 10.2196/29259.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/29259</ArticleId><ArticleId IdType="pmc">PMC8590192</ArticleId><ArticleId IdType="pubmed">34714250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A., Depas N., Doutreligne M., et al.  Transforming French electronic health records into the observational medical outcome partnership's common data model: a feasibility study. Appl Clin Inform. 2020;11(1):13&#x2013;22. doi: 10.1055/s-0039-3402754. https://doi.org/10.1055/s-0040-1702166 Erratum in: Appl Clin Inform. 2020;11(1):e1. </Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1702166</ArticleId><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson A., Rinner C., Sch&#xf6;berl A., Gall W. Feasibility of mapping Austrian health claims data to the OMOP common data model. J&#xa0;Med Syst. 2019;43(10):314. doi: 10.1007/s10916-019-1436-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C., Lang L., Storf H., et al. Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F., Resnic F.S., Robbins S.L., et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(3):536&#x2013;547. doi: 10.4338/ACI-2014-12-CR-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI Forums  OHDSI Forums. https://forums.ohdsi.org/</Citation></Reference><Reference><Citation>Athena. https://athena.ohdsi.org/search-terms/start</Citation></Reference><Reference><Citation>Xu Z., Zhou B., Yang Z., Yuan X., Zhang Y., Lu Q. NeatSankey: Sankey diagrams with improved readability based on node positioning and edge bundling. Comput Graph. 2023;113:10&#x2013;20. doi: 10.1016/j.cag.2023.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cag.2023.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Ryan P.B., Duke J.D., et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;7336. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40034827</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-5778</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>AJOG global reports</Title><ISOAbbreviation>AJOG Glob Rep</ISOAbbreviation></Journal><ArticleTitle>Characterization of severity of hemolytic disease of the fetus and newborn due to Rhesus antigen alloimmunization.</ArticleTitle><Pagination><StartPage>100439</StartPage><MedlinePgn>100439</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100439</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xagr.2024.100439</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical manifestations of hemolytic disease of the fetus and newborn include anemia, hyperbilirubinemia, hydrops fetalis, kernicterus, and fetal or neonatal demise. More than 50 antibodies are linked to hemolytic disease of the fetus and newborn, with Rhesus (including D and c) and Kell antigens carrying the highest risk of disease. To date, a multicenter, comprehensive evaluation of hemolytic disease of the fetus and newborn due to Rhesus antigen alloantibodies in the United States has not been undertaken.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to implement a novel severity index to characterize the real-world disease spectrum of hemolytic disease of the fetus and newborn due to alloantibodies from the Rhesus class.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">This retrospective cohort study was conducted in neonates with commercial insurance available through Optum's deidentified Clinformatics&#xae; Data Mart Database (Clinformatics&#xae;) and Merative MarketScan&#xae; Commercial Claims and Encounters (CCAE) Database from 2000 to 2022. Neonatal and maternal records were linked algorithmically by shared family identifier. A hierarchical severity index was developed for neonates with a Rhesus antigen hemolytic disease of the fetus and newborn diagnosis code in the first 30 days of life, using antenatal and neonatal diagnoses and treatments: <i>Severe</i> (neonatal death, hydrops fetalis, intrauterine transfusion); <i>Moderate</i> (neonatal exchange transfusion); <i>Mild</i> (neonatal simple transfusion); <i>Minimal</i> (neonatal phototherapy or hyperbilirubinemia). Maternal, antenatal, and perinatal demographic and clinical characteristics were summarized descriptively by severity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In Clinformatics&#xae; and Commercial Claims and Encounters Database, respectively, 1927 and 1268 neonates met the inclusion criteria. Most (93.1% Clinformatics&#xae;; 93.5% CCAE Database) displayed minimal severity, although in both databases nearly 40% of these neonates still required phototherapy. More neonates were mildly affected (3.3% Clinformatics&#xae;; 2.2% Commercial Claims and Encounters Database) than moderately (1.0% Clinformatics&#xae;; 1.1% Commercial Claims and Encounters Database). In Clinformatics&#xae; and Commercial Claims and Encounters Database, respectively, severe hemolytic disease of the fetus and newborn affected 2.6% and 3.2% of neonates, 54% and 46% of whom received exchange or simple transfusions. Severely affected neonates were more commonly delivered by cesarean delivery and at a lower gestational age (34.1 weeks Clinformatics&#xae;; 35.4 weeks Commercial Claims and Encounters Database) than those minimally affected (38.5 weeks Clinformatics&#xae;; 38.4 weeks Commercial Claims and Encounters Database).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results across 2 real-world US databases found that although most neonates affected by hemolytic disease of the fetus and newborn due to Rhesus antigen alloantibodies did not require intervention beyond phototherapy, nearly 7% experienced disease severity requiring invasive intervention or resulting in neonatal mortality. More severely affected neonates had lower gestational age at birth, higher rates of cesarean delivery and neonatal intensive care unit admission, and longer length of hospital stay at birth compared with minimally affected neonates. The HDFN Severity Index is a useful tool to characterize hemolytic disease of the fetus and newborn and may be valuable alongside guideline-driven care in subsequent pregnancies.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krumme</LastName><ForeName>Alexis A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Global Epidemiology, Janssen Research &amp; Development, Titusville, NJ (Krumme, Suruki, Blacketer, Hardin, and Swerdel).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suruki</LastName><ForeName>Robert Y</ForeName><Initials>RY</Initials><AffiliationInfo><Affiliation>Global Epidemiology, Janssen Research &amp; Development, Titusville, NJ (Krumme, Suruki, Blacketer, Hardin, and Swerdel).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Global Epidemiology, Janssen Research &amp; Development, Titusville, NJ (Krumme, Suruki, Blacketer, Hardin, and Swerdel).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Epidemiology, Janssen Research &amp; Development, Titusville, NJ (Krumme, Suruki, Blacketer, Hardin, and Swerdel).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Global Epidemiology, Janssen Research &amp; Development, Titusville, NJ (Krumme, Suruki, Blacketer, Hardin, and Swerdel).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjoa</LastName><ForeName>May Lee</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Cambridge, MA (Tjoa).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markham</LastName><ForeName>Kara B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Cincinnati, Cincinnati, OH (Markham).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AJOG Glob Rep</MedlineTA><NlmUniqueID>101777907</NlmUniqueID><ISSNLinking>2666-5778</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Rhesus</Keyword><Keyword MajorTopicYN="N">Rhesus D antigen</Keyword><Keyword MajorTopicYN="N">alloantibodies</Keyword><Keyword MajorTopicYN="N">alloimmunization</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">hemolytic disease of the fetus and newborn</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>4</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40034827</ArticleId><ArticleId IdType="pmc">PMC11872512</ArticleId><ArticleId IdType="doi">10.1016/j.xagr.2024.100439</ArticleId><ArticleId IdType="pii">S2666-5778(24)00133-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the fetus and newborn. Vox Sang. 2015;109:99&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">25899660</ArticleId></ArticleIdList></Reference><Reference><Citation>Moise KJ, Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol. 2012;120:1132&#x2013;1139.</Citation><ArticleIdList><ArticleId IdType="pubmed">23090532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ree IMC, Smits-Wintjens VEHJ, van der Bom JG, van Klink JMM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10:607&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">28503958</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopriore E, Rath MEA, Liley H, Smits-Wintjens VEHJ. Improving the management and outcome in haemolytic disease of the foetus and newborn. Blood Transfus. 2013;11:484&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3827389</ArticleId><ArticleId IdType="pubmed">24120585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Ajne G, Wikman A, Lindqvist C, Reilly M, Tiblad E. Management and clinical consequences of red blood cell antibodies in pregnancy: a population-based cohort study. Acta Obstet Gynecol Scand. 2021;100:2216&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">34476807</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugrue RP, Moise KJ, Federspiel JJ, et al. Maternal red blood cell alloimmunization prevalence in the United States. Blood Adv. 2024;8:4311&#x2013;4319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11372799</ArticleId><ArticleId IdType="pubmed">38662646</ArticleId></ArticleIdList></Reference><Reference><Citation>Moinuddin I, Fletcher C, Millward P. Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women &#x2013; a study from a tertiary care hospital in Southeast Michigan. J Blood Med. 2019;10:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708388</ArticleId><ArticleId IdType="pubmed">31692490</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology. 2013;29:127&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">24689681</ArticleId></ArticleIdList></Reference><Reference><Citation>Markham KB, Rossi KQ, Nagaraja HN, O'Shaughnessy RW. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol. 2015;213:68.e1&#x2013;68.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25644438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D, Ling LE, Krumme AA, Tjoa ML, Moise KJ. Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010. AJOG Glob Rep. 2023;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205505</ArticleId><ArticleId IdType="pubmed">37229151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr TM, Tweddell SM, Zalla JM, et al. Neonatal and obstetrical outcomes of pregnancies complicated by alloimmunization. Pediatrics. 2024;153</Citation><ArticleIdList><ArticleId IdType="pubmed">38784990</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794136</ArticleId><ArticleId IdType="pubmed">29389968</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver J, Hardin JH, Blacketer C, Krumme AA, Jacobson MH, Ryan PB. Development and evaluation of an algorithm to link mothers and infants in two US commercial healthcare claims databases for pharmacoepidemiology research. BMC Med Res Methodol. 2023;23:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10590518</ArticleId><ArticleId IdType="pubmed">37865728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitsommart R, Janes M, Mahajan V, et al. Outcomes of late-preterm infants: a retrospective, single-center, Canadian study. Clin Pediatr (Phila) 2009;48:844&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pubmed">19596865</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinonen K, Eriksson JG, Lahti J, et al. Late preterm birth and neurocognitive performance in late adulthood: a birth cohort study. Pediatrics. 2015;135:e818&#x2013;e825.</Citation><ArticleIdList><ArticleId IdType="pubmed">25733746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150</Citation><ArticleIdList><ArticleId IdType="pubmed">35927462</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver J, Hardin JH, Blacketer C, Krumme AA, Jacobson MH, Ryan PB. Development and evaluation of an algorithm to link mothers and infants in two US commercial healthcare claims databases for pharmacoepidemiology research. BMC Med Res Methodol 2023;23:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10590518</ArticleId><ArticleId IdType="pubmed">37865728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JW, Booth GS, Moise KJ, et al. Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States. Transfusion. 2024;64:1870&#x2013;1880. doi: 10.1111/trf.18011. Epub 2024 Sep 9. PMID: 39248602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.18011</ArticleId><ArticleId IdType="pubmed">39248602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachodimitropoulou E, Garbowski M, Anne Solomon S, et al. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion. Br J Haematol. 2022;196:1096&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">34862601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40036958</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Effect of intra-articular corticosteroid injections for osteoarthritis on the subsequent use of pain medications: a UK CPRD cohort study.</ArticleTitle><Pagination><StartPage>3832</StartPage><EndPage>3841</EndPage><MedlinePgn>3832-3841</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keaf126</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate the effect of intra-articular corticosteroid injection (IACI) for osteoarthritis on longer-term incidence of pain medications.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a cohort study of patients registered in the UK Clinical Practice Research Datalink (CPRD) GOLD primary care database with an incident diagnosis of knee, hip, hand or shoulder osteoarthritis between 2005 and 2019. Exposure of interest was single or repeated use of IACI (analysed separately). Main outcome measures were five-year incidence of uncombined opioids, opioid-nonopioid analgesic combinations, oral corticosteroids, paracetamol, oral non-steroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs. Instrumental variable (IV) analysis was used, given this methodology can account for strong and unmeasured confounding. Secondary analyses used propensity-score matching and Cox regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Amongst 74&#x2009;527 knee osteoarthritis patients, IACI use was associated with lower subsequent prescribing of most pain medications studied, including opioid-nonopioid analgesic combinations following single IACI [number needed to treat (NNT)&#x2009;=&#x2009;5 (95% CI: 5-6), P&#x2009;&lt;&#x2009;0.001] and uncombined opioids following repeat IACI [NNT&#x2009;=&#x2009;12 (8-546), P&#x2009;=&#x2009;0.049]. Amongst 15&#x2009;092 hand osteoarthritis patients, single IACI was associated with reduced use of opioid-nonopioid combinations, paracetamol and oral NSAIDs. Secondary analyses confirmed lower incidence rates of opioid-nonopioid combinations after single IACI for knee [hazard ratio (HR)&#x2009;=&#x2009;0.88 (0.81-0.96)], hip [HR&#x2009;=&#x2009;0.76 (0.62-0.92)], hand [HR&#x2009;=&#x2009;0.77 (0.61-0.98)] or shoulder [HR&#x2009;=&#x2009;0.72 (0.53-0.99)] osteoarthritis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IACI for knee or hand osteoarthritis showed lower incidence of several pain medications over the longer-term relative to no IACI use. Secondary findings suggest IACI may be effective in reducing longer-term use of opioid-nonopioid analgesic combinations for patients with knee, hip, hand or shoulder osteoarthritis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawley</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7034-6168</Identifier><AffiliationInfo><Affiliation>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Learning &amp; Research Building Level 1, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matharu</LastName><ForeName>Gulraj S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Learning &amp; Research Building Level 1, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judge</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3015-0432</Identifier><AffiliationInfo><Affiliation>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Learning &amp; Research Building Level 1, Bristol, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR), Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Learning &amp; Research Building Level 1, Bristol, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR), Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIHR129011</GrantID><Agency>National Institute for Health and Care Research</Agency><Country/></Grant><Grant><Agency>European Medicines Agency</Agency><Country/></Grant><Grant><Acronym>AMS_</Acronym><Agency>Academy of Medical Sciences</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>European Medicines Agency, Innovative Medicines Initiative</Agency><Country/></Grant><Grant><Agency>AstraZeneca</Agency><Country/></Grant><Grant><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Healthcare Quality Improvement Partnership</Agency><Country/></Grant><Grant><Agency>Royal College of Physicians and Tommy's Health Foundation</Agency><Country/></Grant><Grant><Agency>Healthcare Quality Improvement Partnership and Ceramtec</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007270" MajorTopicYN="N">Injections, Intra-Articular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010003" MajorTopicYN="Y">Osteoarthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="Y">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020370" MajorTopicYN="N">Osteoarthritis, Knee</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015207" MajorTopicYN="N">Osteoarthritis, Hip</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="Y">Analgesics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">osteoarthritis</Keyword><Keyword MajorTopicYN="N">pain management</Keyword><Keyword MajorTopicYN="N">pharmaco-epidemiology</Keyword><Keyword MajorTopicYN="N">prescribing</Keyword><Keyword MajorTopicYN="N">steroid injection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>5</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40036958</ArticleId><ArticleId IdType="pmc">PMC12107031</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaf126</ArticleId><ArticleId IdType="pii">8046668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cross M, Smith E, Hoy D &#xa0;et al. &#xa0;The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis &#xa0;2014;73:1323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24553908</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwic A, Edwards MH, Dennison EM, Cooper C. &#xa0;Epidemiology and burden of osteoarthritis. Br Med Bull &#xa0;2013;105:185&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690438</ArticleId><ArticleId IdType="pubmed">23337796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevilacqua G, Laskou F, Patel HP &#xa0;et al. &#xa0;What impact does osteoarthritis have on ability to self-care and receipt of care in older adults? Findings from the Hertfordshire Cohort Study. Osteoarthr Cartil Open &#xa0;2022;4:100310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9718070</ArticleId><ArticleId IdType="pubmed">36474798</ArticleId></ArticleIdList></Reference><Reference><Citation>Swain S, Sarmanova A, Mallen C &#xa0;et al. &#xa0;Trends in incidence and prevalence of osteoarthritis in the United Kingdom: findings from the Clinical Practice Research Datalink (CPRD). Osteoarthritis Cartilage &#xa0;2020;28:792&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">32184134</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T, Lim SS, Abbafati C &#xa0;et al. &#xa0;Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet &#xa0;2020;396:1204&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567026</ArticleId><ArticleId IdType="pubmed">33069326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitton R. &#xa0;The economic burden of osteoarthritis. Am J Manag Care &#xa0;2009;15:S230&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19817509</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkiewicz A, Petersson IF, Bj&#xf6;rk J &#xa0;et al. &#xa0;Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthritis Cartilage &#xa0;2014;22:1826&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">25084132</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Nuki G, Moskowitz RW &#xa0;et al. &#xa0;OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage &#xa0;2010;18:476&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">20170770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Moskowitz RW, Nuki G &#xa0;et al. &#xa0;OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage &#xa0;2008;16:137&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">18279766</ArticleId></ArticleIdList></Reference><Reference><Citation>Juni P, Hari R, Rutjes AW &#xa0;et al. &#xa0;Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev &#xa0;2015;2015:CD005328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884338</ArticleId><ArticleId IdType="pubmed">26490760</ArticleId></ArticleIdList></Reference><Reference><Citation>
NICE. NICE guideline [NG226]: Osteoarthritis in over 16s: diagnosis and management. 2022. https://www.nice.org.uk/guidance/ng226 (6 September 2024, date last accessed).</Citation></Reference><Reference><Citation>Najm A, Alunno A, Gwinnutt JM, Weill C, Berenbaum F. &#xa0;Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Joint Bone Spine &#xa0;2021;88:105198.</Citation><ArticleIdList><ArticleId IdType="pubmed">33901659</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan RL, Edwards TA, Judge A &#xa0;et al. &#xa0;Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables. Osteoarthritis Cartilage &#xa0;2022;30:1658&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">36108937</ArticleId></ArticleIdList></Reference><Reference><Citation>Orchard JW. &#xa0;Is there a place for intra-articular corticosteroid injections in the treatment of knee osteoarthritis? &#xa0;BMJ &#xa0;2020; 368: l6923.</Citation><ArticleIdList><ArticleId IdType="pubmed">31941647</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. NG266 Recommendations for research. https://www.nice.org.uk/guidance/ng226/chapter/recommendations-for-research#11-intra-articular-injections (6 September 2024, date last accessed).</Citation></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K &#xa0;et al. &#xa0;Data Resource Profile: clinical Practice Research Datalink (CPRD). Int J Epidemiol &#xa0;2015;44:827&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmestri A, Prieto-Alhambra D. &#xa0;CPRD GOLD and linked ONS mortality records: reconciling guidelines. Int J Med Inform &#xa0;2020;136:104038.</Citation><ArticleIdList><ArticleId IdType="pubmed">32078979</ArticleId></ArticleIdList></Reference><Reference><Citation>Delmestri A, Prieto-Alhambra D. &#xa0;Curator&#x2014;A data curation tool for clinical real-world evidence. Inform Med Unlocked &#xa0;2023;40:101291.</Citation></Reference><Reference><Citation>Pergolizzi J, Varrassi G, LeQuang JAK, Breve F, Magnusson P. &#xa0;Fixed dose versus loose dose: analgesic combinations. Cureus &#xa0;2023;15:e33320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894647</ArticleId><ArticleId IdType="pubmed">36741676</ArticleId></ArticleIdList></Reference><Reference><Citation>
Department for Communities and Local Government. The English indices of deprivation 2015: research report. 2015. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/464597/English_Indices_of_Deprivation_2015_-_Research_Report.pdf</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. &#xa0;A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis &#xa0;1987;40:373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Rassen JA, Schneeweiss S. &#xa0;Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf &#xa0;2010;19:537&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886161</ArticleId><ArticleId IdType="pubmed">20354968</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;rnighausen T, Oldenburg C, Tugwell P &#xa0;et al. &#xa0;Quasi-experimental study designs series-paper 7: assessing the assumptions. J Clin Epidemiol &#xa0;2017;89:53&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">28365306</ArticleId></ArticleIdList></Reference><Reference><Citation>Prats-Uribe A, Kolovos S, Berencsi K &#xa0;et al. &#xa0;Unicompartmental compared with total knee replacement for patients with multimorbidities: a cohort study using propensity score stratification and inverse probability weighting. Health Technol Assess &#xa0;2021;25:1&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">34812138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MS, Uddin MJ, Groenwold RHH &#xa0;et al. &#xa0;Quantitative falsification of instrumental variables assumption using balance measures. Epidemiology &#xa0;2014;25:770&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">25076152</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. &#xa0;Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simulat Comput &#xa0;2009;38.</Citation></Reference><Reference><Citation>Palmer TM, Sterne JAC, Harbord RM &#xa0;et al. &#xa0;Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am J Epidemiol &#xa0;2011;173:1392&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555716</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook RJ, Sackett DL. &#xa0;The number needed to treat: a clinically useful measure of treatment effect. BMJ &#xa0;1995;310:452&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2548824</ArticleId><ArticleId IdType="pubmed">7873954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MS, Prieto-Alhambra D, Lopes LC &#xa0;et al. &#xa0;Propensity score methods in health technology assessment: principles, extended applications, and recent advances. Front Pharmacol &#xa0;2019;10:973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6760465</ArticleId><ArticleId IdType="pubmed">31619986</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. &#xa0;Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat &#xa0;2011;10:150&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. &#xa0;Multiple imputation after 18+ years. J Am Stat Assoc 1996;91:473&#x2013;89.</Citation></Reference><Reference><Citation>
Carpenter J, Kenward MG. Missing data in randomised controlled trials&#x2014;a practical guide. 2007. https://researchonline.lshtm.ac.uk/id/eprint/4018500 (6 September 2024, date last accessed).</Citation></Reference><Reference><Citation>Lund LC, St&#xf8;vring H, Potteg&#xe5;rd A, Andersen M, Hallas J. &#xa0;Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness &amp; safety. J Clin Epidemiol &#xa0;2023;156:127&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933854</ArticleId><ArticleId IdType="pubmed">36806733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Doherty M, Leeb BF &#xa0;et al. &#xa0;EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis &#xa0;2007;66:377&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1856004</ArticleId><ArticleId IdType="pubmed">17046965</ArticleId></ArticleIdList></Reference><Reference><Citation>Arden NK, Perry TA, Bannuru RR &#xa0;et al. &#xa0;Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol &#xa0;2021;17:59&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">33116279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolasinski SL, Neogi T, Hochberg MC &#xa0;et al. &#xa0;2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol &#xa0;2020;72:220&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10518852</ArticleId><ArticleId IdType="pubmed">31908163</ArticleId></ArticleIdList></Reference><Reference><Citation>Paskins Z, Bromley K, Lewis M &#xa0;et al. &#xa0;Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial. BMJ &#xa0;2022;377:e068446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984871</ArticleId><ArticleId IdType="pubmed">35387783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigozi J, Oppong R, Paskins Z &#xa0;et al. &#xa0;The cost-effectiveness of adding an ultrasound corticosteroid and local anaesthetic injection to advice and education for hip osteoarthritis. Rheumatology (Oxford) &#xa0;2025;64:165&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11701301</ArticleId><ArticleId IdType="pubmed">38085178</ArticleId></ArticleIdList></Reference><Reference><Citation>Spolidoro Paschoal NdO, Natour J, Machado FS, de Oliveira HAV, Furtado RNV. &#xa0;Effectiveness of triamcinolone hexacetonide intraarticular injection in interphalangeal joints: a 12-week randomized controlled trial in patients with hand osteoarthritis. J Rheumatol &#xa0;2015;42:1869&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">26233501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kloppenburg M, Kroon FP, Blanco FJ &#xa0;et al. &#xa0;2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis &#xa0;2019;78:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30154087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuggle N, Bere N, Bruy&#xe8;re O &#xa0;et al. &#xa0;Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach. Aging Clin Exp Res &#xa0;2022;34:1985&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9464159</ArticleId><ArticleId IdType="pubmed">35864304</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlindon TE, LaValley MP, Harvey WF &#xa0;et al. &#xa0;Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. JAMA &#xa0;2017;317:1967&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815012</ArticleId><ArticleId IdType="pubmed">28510679</ArticleId></ArticleIdList></Reference><Reference><Citation>Maricar N, Parkes MJ, Callaghan MJ &#xa0;et al. &#xa0;Structural predictors of response to intra-articular steroid injection in symptomatic knee osteoarthritis. Arthritis Res Ther &#xa0;2017;19:88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423020</ArticleId><ArticleId IdType="pubmed">28482926</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. &#xa0;Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology &#xa0;2006;17:268&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715942</ArticleId><ArticleId IdType="pubmed">16617275</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou R, Turner JA, Devine EB &#xa0;et al. &#xa0;The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med &#xa0;2015;162:276&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">25581257</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Jenkins DA, Peek N, Dixon WG, Jani M. &#xa0;High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time. Ann Rheum Dis &#xa0;2023;82:1116&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">37193609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannuru RR, Osani MC, Vaysbrot EE &#xa0;et al. &#xa0;OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage &#xa0;2019;27:1578&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31278997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wylde V, Moore AJ, Anderson E &#xa0;et al. &#xa0;Research priorities for intra-articular corticosteroid injections for osteoarthritis: a Delphi study. Osteoarthr Cartil Open &#xa0;2022;4:100291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613692</ArticleId><ArticleId IdType="pubmed">36221289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson RJ, Prieto-Alhambra D, Walker C &#xa0;et al. &#xa0;Validation of hip osteoarthritis diagnosis recording in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf &#xa0;2019;28:187&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30375101</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40055683</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Psychiatric and neuropsychiatric sequelae of COVID-19 within 2&#xa0;years: a multinational cohort study.</ArticleTitle><Pagination><StartPage>144</StartPage><MedlinePgn>144</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-025-03952-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The long-term psychiatric and neuropsychiatric sequelae of COVID-19 across diverse populations remain not fully understood. This cohort study aims to investigate the short-, medium-, and long-term risks of psychiatric and neuropsychiatric disorders following COVID-19 infection in five countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This population-based multinational network study used electronic medical records from France, Italy, Germany, and the UK and claims data from the USA. The initial target and comparator cohorts were identified using an exact matching approach based on age and sex. Individuals diagnosed with COVID-19 or those with a positive SARS-CoV-2 screening test between December 1, 2019, and December 1, 2020, were included as targets. Up to ten comparators without COVID-19 for each target were selected using the propensity score matching approach. All individuals were followed from the index date until the end of continuous enrolment or the last healthcare encounter. Cox proportional hazard regression models were fitted to estimate the risk of incident diagnosis of depression, anxiety disorders, alcohol misuse or dependence, substance misuse or dependence, bipolar disorders, psychoses, personality disorders, self-harm and suicide, sleep disorders, dementia, and neurodevelopmental disorders within the first 6&#xa0;months (short-term), 6&#xa0;months to 1&#xa0;year (medium-term), and 1 to 2&#xa0;years (long-term) post-infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 303,251 individuals&#xa0;with COVID-19 and 22,108,925 individuals without COVID-19 from five countries were originally included. Within the first 6&#xa0;months, individuals with COVID-19 had a significantly higher risk of any studied disorders in all databases, with Hazard Ratios (HRs) ranging from 1.14 (95% CI, 1.07-1.22) in Germany to 1.89 (1.64-2.17) in Italy. Increased risks were consistently observed for depression, anxiety disorders, and sleep disorders across almost all countries. During the medium- and long-term periods, higher risks were observed only for depression (medium-term: 1.29, 1.18-1.41; long-term: 1.36, 1.25-1.47), anxiety disorders (medium-term: 1.29, 1.20-1.38; long-term: 1.37, 1.29-1.47), and sleep disorders (medium-term: 1.10, 1.01-1.21; long-term: 1.14, 1.05-1.24) in France, and dementia (medium-term: 1.65, 1.28-2.10) in the UK.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study suggests that increased risks of psychiatric and neuropsychiatric outcomes were consistently observed only within, and not after, the 6-month observation period across all databases, except for certain conditions in specific countries.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chai</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Hong Kong Jockey Club Centre for Suicide Research and Prevention, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lam</LastName><ForeName>Ivan C H</ForeName><Initials>ICH</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Division of Psychiatry, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Camden and Islington NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Eric Y F</ForeName><Initials>EYF</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chui</LastName><ForeName>Celine S L</ForeName><Initials>CSL</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wallis C Y</ForeName><Initials>WCY</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real-World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Esther W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24h), Hong Kong Science Park, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian C K</ForeName><Initials>ICK</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aston Pharmacy School, Aston University, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health Sciences, University of Waterloo, Waterloo, ON, Canada. hao.luo1@uwaterloo.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C7154-20GF</GrantID><Agency>University Grants Committee</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Neuropsychiatric disorders</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Psychiatric disorders</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The data partners have obtained institutional review board exemption for their participation in this study. Informed consent was waived because the study used deidentified data, and no patients were contacted. Consent for publication: Not applicable. Competing interests: Kenneth K.C. Man reports grants from the CW Maplethorpe Fellowship, National Institute of Health Research, UK, Hong Kong Research Grant Council and the European Commission Horizon 2020 Framework, personal fees from IQVIA and grants from Amgen and GlaxoSmithKline, outside the submitted work; Joseph F. Hayes reports grants from UKRI, NIHR UCLH Biomedical Research Centre, and Wellcome Trust and Consultancy Fees from Wellcome Trust and juli Health, outside the submitted work; Xue Li reports grants from the Hong Kong Health and Medical Research Fund (HMRF, HMRF Fellowship Scheme, HKSAR), Research Grants Council Early Career Scheme (RGC/ECS, HKSAR), Janssen, and Pfizer, internal funding from the University of Hong Kong; and consultancy fees from Merck Sharp &amp; Dohme and Pfizer, outside the submitted work; Eric Y.F. Wan reports grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region and the Hong Kong Research Grants Council, outside the submitted work; Celine S.L. Chui reports grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen and personal fees from PrimeVigilance, outside the submitted work; Wallis C.Y. Lau reports receiving grants from AIR@InnoHK administered by the Innovation and Technology Commission of Hong Kong, outside the submitted work; Esther W. Chan reports grants from Research Grants Council of Hong Kong, Research Fund Secretariat of the Food and Health Bureau of Hong Kong, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda and Narcotics Division of the Security Bureau of Hong Kong; honorarium from Hospital Authority, outside the submitted work; Ian C.K. Wong reports grants from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK and Novartis, the Hong Kong RGC, and the Hong Kong Health and Medical Research Fund in Hong Kong, National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, consulting fees from IQVIA, payment for expert testimony and is an independent non-executive director of Jacobson Medical in Hong Kong, outside of the submitted work; no other relationships or activities that could appear to have influenced the submitted work. Hao Luo reports grants from the Research Grants Council of Hong Kong, outside the submitted work; All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>9</Day><Hour>15</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>7</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40055683</ArticleId><ArticleId IdType="pmc">PMC11887073</ArticleId><ArticleId IdType="doi">10.1186/s12916-025-03952-z</ArticleId><ArticleId IdType="pii">10.1186/s12916-025-03952-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsamakis K, Tsiptsios D, Ouranidis A, Mueller C, Schizas D, Terniotis C, et al. COVID-19 and its consequences on mental health (Review). Exp Ther Med. 2021;21(3):244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851613</ArticleId><ArticleId IdType="pubmed">33603852</ArticleId></ArticleIdList></Reference><Reference><Citation>Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19 &#x2013; a systematic review. Brain Behav Immun. 2021;97:328&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363196</ArticleId><ArticleId IdType="pubmed">34339806</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. BMJ. 2022;376:e068993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Psychiatry. COVID-19 and mental health. Lancet Psychiatry. 2021;8(2):87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7825966</ArticleId><ArticleId IdType="pubmed">33485416</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldrini M, Canoll PD, Klein RS. How COVID-19 affects the brain. JAMA Psychiat. 2021;78(6):682&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894299</ArticleId><ArticleId IdType="pubmed">33769431</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninx B. Psychiatric symptoms and cognitive impairment in &#x201c;Long COVID&#x201d;: the relevance of immunopsychiatry. World Psychiatry. 2021;20(3):357&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8429338</ArticleId><ArticleId IdType="pubmed">34505378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn&#xfa;sd&#xf3;ttir I, Lovik A, Unnarsd&#xf3;ttir AB, McCartney D, Ask H, K&#xf5;iv K, et al. Acute COVID-19 severity and mental health morbidity trajectories in patient populations of six nations: an observational study. Lancet Public Health. 2022;7(5):e406&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920517</ArticleId><ArticleId IdType="pubmed">35298894</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020;7(9):813&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7365642</ArticleId><ArticleId IdType="pubmed">32682460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kola L, Kohrt BA, Hanlon C, Naslund JA, Sikander S, Balaji M, et al. COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health. Lancet Psychiatry. 2021;8(6):535&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9764935</ArticleId><ArticleId IdType="pubmed">33639109</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Su B, Xie J, Garcia-Rizo C, Prieto-Alhambra D. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. Nat Hum Behav. 2024;8(6):1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11199144</ArticleId><ArticleId IdType="pubmed">38514769</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1284437 patients. Lancet Psychiatry. 2022;9(10):815&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, et al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10173760</ArticleId><ArticleId IdType="pubmed">37197226</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninx BWJH, Benros ME, Klein RS, Vinkers CH. How COVID-19 shaped mental health: from infection to pandemic effects. Nat Med. 2022;28(10):2027&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711928</ArticleId><ArticleId IdType="pubmed">36192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Lau WCY, Chai Y, Torre CO, Howard R, Liu KY, et al. Rates of antipsychotic drug prescribing among people living with dementia during the COVID-19 pandemic. JAMA Psychiat. 2023;80(3):211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878427</ArticleId><ArticleId IdType="pubmed">36696128</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai Y, Man KKC, Luo H, Torre CO, Wing YK, Hayes JF, et al. Incidence of mental health diagnoses during the COVID-19 pandemic: a multinational network study. Epidemiol Psychiatr Sci. 2024;33:e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10940053</ArticleId><ArticleId IdType="pubmed">38433286</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H, Chai Y, Li S, Lau WCY, Torre CO, Hayes J, et al. Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study. Lancet Psychiatry. 2024;11(10):807&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">39241791</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau WCY, Torre CO, Man KKC, Stewart HM, Seager S, Van Zandt M, et al. Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation&#x202f;: a multinational population-based cohort study. Ann Intern Med. 2022;175(11):1515&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">36315950</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180(4):542&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2024 [cited 2024 May 15]. Available from: https://www.R-project.org/</Citation></Reference><Reference><Citation>Schuemie M, Suchard M, Ryan P. CohortMethod: New-User Cohort Method with Large Scale Propensity and Outcome Models [online]. 2024 [cited 2024 May 15]. Available from: https://ohdsi.github.io/CohortMethod/</Citation></Reference><Reference><Citation>Schuemie M, Reps J, Black A, Defalco F, Evans L, Fridgeirsson E, et al. Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>Elm Ev, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2022;4(1):fcab297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Ed&#xe9;n A, Grahn A, Bremell D, Aghvanyan A, Bathala P, Fuchs D, et al. Viral antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms. JAMA Netw Open. 2022;5(5):e2213253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127556</ArticleId><ArticleId IdType="pubmed">35604688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagst M, Pottk&#xe4;mper L, G&#xf6;mer A, Pitarokoili K, Steinmann E. Neuroinvasion and neurotropism of severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Microbiol. 2024;79:102474.</Citation><ArticleIdList><ArticleId IdType="pubmed">38615394</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375(6578):267&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Shi L, Que J, Lu Q, Liu L, Lu Z, et al. The impact of quarantine on mental health status among general population in China during the COVID-19 pandemic. Mol Psychiatry. 2021;26(9):4813&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821451</ArticleId><ArticleId IdType="pubmed">33483692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao R, Wu W. Mental disorders associated with COVID-19 related unemployment. Appl Res Qual Life. 2022;17(2):949&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096626</ArticleId><ArticleId IdType="pubmed">33968280</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimoradi Z, Ohayon MM, Griffiths MD, Lin CY, Pakpour AH. Fear of COVID-19 and its association with mental health-related factors: systematic review and meta-analysis. BJPsych Open. 2022;8(2):e73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8943231</ArticleId><ArticleId IdType="pubmed">35307051</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes KM, Pratt C, Galea S, McLaughlin KA, Koenen KC, Shear MK. The burden of loss: unexpected death of a loved one and psychiatric disorders across the life course in a national study. Am J Psychiatry. 2014;171(8):864&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4119479</ArticleId><ArticleId IdType="pubmed">24832609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau ST, Makelarski JA, Boyd K, Doyle KE, Haider S, Kumar S, et al. Change in health-related socioeconomic risk factors and mental health during the early phase of the COVID-19 pandemic: a national survey of U.S. women. J Womens Health. 2021;30(4):502&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064961</ArticleId><ArticleId IdType="pubmed">33818123</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X, Guan Y, Liao Q, Ma Z, Zhang L, Dong J, et al. Long-term sequelae of different COVID-19 variants: the original strain versus the Omicron variant. Glob Health Med. 2022;4(6):322&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9773225</ArticleId><ArticleId IdType="pubmed">36589219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M. COVID-19-related stigma and its impact on psychological distress: a cross-sectional study in Wuhan, China. Health Sci Rep. 2022;5(5):e758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358535</ArticleId><ArticleId IdType="pubmed">35949673</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz U, Bierbauer W, L&#xfc;scher J. Social stigma, mental health, stress, and health-related quality of life in people with long COVID. Int J Environ Res Public Health. 2023;20(5):3927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10001775</ArticleId><ArticleId IdType="pubmed">36900938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nat Commun. 2024;15(1):1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10894867</ArticleId><ArticleId IdType="pubmed">38403654</ArticleId></ArticleIdList></Reference><Reference><Citation>Servier C, Porcher R, Pane I, Ravaud P, Tran V-T. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset. Int J Infect Dis. 2023;133:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176960</ArticleId><ArticleId IdType="pubmed">37182548</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly M, Robinson E. Psychological distress and adaptation to the COVID-19 crisis in the United States. J Psychiatr Res. 2021;136:603&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588823</ArticleId><ArticleId IdType="pubmed">33138985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahara M, Mashizume Y, Takahashi K. Coping mechanisms: exploring strategies utilized by Japanese healthcare workers to reduce stress and improve mental health during the COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(1):131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7795636</ArticleId><ArticleId IdType="pubmed">33375444</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022;379:e071594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597610</ArticleId><ArticleId IdType="pubmed">36288813</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40102084</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2171-8695</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</Title><ISOAbbreviation>Farm Hosp</ISOAbbreviation></Journal><ArticleTitle>Real-world evidence for regulatory purposes: The example of DARWIN EU&#xae;.</ArticleTitle><Pagination><StartPage>62</StartPage><EndPage>64</EndPage><MedlinePgn>62-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.farma.2025.02.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1130-6343(25)00018-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raventos</LastName><ForeName>Berta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands; Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom. Electronic address: Daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Farm Hosp</MedlineTA><NlmUniqueID>9440679</NlmUniqueID><ISSNLinking>1130-6343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>18</Day><Hour>23</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40102084</ArticleId><ArticleId IdType="doi">10.1016/j.farma.2025.02.011</ArticleId><ArticleId IdType="pii">S1130-6343(25)00018-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40107446</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0849</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of medical genetics</Title><ISOAbbreviation>Eur J Med Genet</ISOAbbreviation></Journal><ArticleTitle>Identifying patients with neurofibromatosis type 1 related optic pathway glioma using the OMOP CDM.</ArticleTitle><Pagination><StartPage>105011</StartPage><MedlinePgn>105011</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmg.2025.105011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1769-7212(25)00018-7</ELocationID><Abstract><AbstractText>Neurofibromatosis type 1 (NF1) is a rare tumour predisposition syndrome. Optic pathway gliomas (NF1-related OPG) are a well-characterised tumour type. There is great need for tools that can efficiently identify patients with NF1-related OPG at hospitals. Computable phenotypes algorithms can be used to find patients with certain clinical features in an electronic database. We developed computable phenotype algorithms using the Observational Medical Outcome Partnership (OMOP) Common Data Model. We subsequently assessed if these algorithms could identify patients with NF1-related OPG in an electronic health records (EHR) derived database. We created phenotype algorithms based on diagnosis codes, visits, and radiologic procedures. These phenotypes were applied to the EHR-derived database of an academic hospital. To assess the performance of the phenotypes, we calculated the precision, recall, and F2 score against a list of known cases (n&#xa0;=&#xa0;61), provided by a clinician. To evaluate the ability of the phenotypes to identify additional cases, we manually reviewed the predicted positives of each phenotype algorithm. The phenotype algorithm based on the diagnosis codes 'Neurofibromatosis syndrome' and 'Neoplasm of optic nerve' performed best (precision&#xa0;=&#xa0;1.000, recall&#xa0;=&#xa0;0.614, F2-score&#xa0;=&#xa0;0.665). The phenotype 'Neurofibromatosis syndrome and three or more Ophthalmology visits and one or more MRI of brain' performed best of the phenotypes based on visits and radiologic procedures (precision&#xa0;=&#xa0;0.489, recall&#xa0;=&#xa0;0.511, F2-score&#xa0;=&#xa0;0.507). Generally, increased precision came at the cost of a decrease in recall. Following review of the predicted positives of each phenotype, 27 additional cases were identified. OMOP computable phenotype algorithms successfully identified NF1-related OPG patients in an EHR-derived database. They provided swift insight into the number of NF1-related OPG cases and were able to identify additional cases, which were not included in the original list of known cases. Phenotype algorithms created with OMOP could be an invaluable tool to facilitate patient screening, especially in multi-centric trials for rare diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhaenens</LastName><ForeName>Britt A E</ForeName><Initials>BAE</Initials><AffiliationInfo><Affiliation>Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands; The ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, the Netherlands. Electronic address: B.dhaenens@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinat</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didden</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd., a Janssen company of Johson&amp;Johnson, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ammour</LastName><ForeName>Nadir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Science &amp; Operations, Global Development, Sanofi R&amp;D, Chilly-Mazarin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oostenbrink</LastName><ForeName>Rianne</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands; The ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Med Genet</MedlineTA><NlmUniqueID>101247089</NlmUniqueID><ISSNLinking>1769-7212</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009456" MajorTopicYN="Y">Neurofibromatosis 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020339" MajorTopicYN="Y">Optic Nerve Glioma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Computable phenotype algorithm</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Neurofibromatosis type 1</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Optic pathway glioma</Keyword><Keyword MajorTopicYN="N">Patient identification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>8</Day><Hour>3</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>20</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>19</Day><Hour>20</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40107446</ArticleId><ArticleId IdType="doi">10.1016/j.ejmg.2025.105011</ArticleId><ArticleId IdType="pii">S1769-7212(25)00018-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40121766</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>199</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>LinkR: An open source, low-code and collaborative data science platform for healthcare data analysis and visualization.</ArticleTitle><Pagination><StartPage>105876</StartPage><MedlinePgn>105876</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2025.105876</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(25)00093-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The development of Clinical Data Warehouses (CDWs) has greatly increased access to big data in medical research. However, the lack of standardization among different data models hampers interoperability and, consequently, the research potential of these vast data resources. Moreover, data manipulation and analysis require advanced programming skills, a skill set that healthcare professionals often lack.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To address these issues, we created an open source, low-code and collaborative data science platform for manipulating, visualizing and analyzing healthcare data using graphical tools alongside an advanced programming interface. The software is based on the OMOP Common Data Model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">LinkR enables users to generate studies using data imported from multiple sources. The software organizes the studies into two main sections: individual and population data sections. In the individual data section, user-friendly graphical tools allow users to customize data presentation, recreating the equivalent of a medical record, according to the needs of their study. The population data section is designed for conducting statistical analyses through both graphical and programming interfaces. The application also integrates a Git module, streamlining collaboration and facilitating shared data analysis across research centers. The platform was tested with datasets including the OMOP database (46,520 patients and over 36 million rows in the measurement table) during the InterHop datathon with 12 concurrent users. Usability testing yielded a median System Usability Scale (SUS) score of 75 [63.8-85.6], indicating high user satisfaction.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">LinkR is a low-code data science platform that democratizes access, manipulation, and analysis of data from clinical data warehouses and facilitates collaborative work on healthcare data, using an open science approach.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delange</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>InterHop, Saint-Malo, France; LTSI, INSERM UMR 1099, University of Rennes 1, F-35042 Rennes, France. Electronic address: boris.delange@univ-rennes.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popoff</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>InterHop, Saint-Malo, France; CHU Rouen, Department of Anesthesiology and Critical Care, F-76000 Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe9;it&#xe9;</LastName><ForeName>Thibault</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>CH Saint-Brieuc, Department of Anesthesiology, 22000 Saint-Brieuc, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>InterHop, Saint-Malo, France; Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, Lille, France; F&#xe9;d&#xe9;ration R&#xe9;gionale de Recherche en Psychiatrie et Sant&#xe9; Mentale (F2RSM Psy), Hauts-de-France, Saint-Andr&#xe9;-lez-Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>InterHop, Saint-Malo, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="Y">Data Science</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="Y">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="Y">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003299" MajorTopicYN="N">Cooperative Behavior</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical data warehouse</Keyword><Keyword MajorTopicYN="N">Data analysis</Keyword><Keyword MajorTopicYN="N">Data visualization</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">Low-code data analysis</Keyword><Keyword MajorTopicYN="N">Open science</Keyword><Keyword MajorTopicYN="N">Web application</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>23</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40121766</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2025.105876</ArticleId><ArticleId IdType="pii">S1386-5056(25)00093-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40124300</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2352-3409</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Data in brief</Title><ISOAbbreviation>Data Brief</ISOAbbreviation></Journal><ArticleTitle>A dataset for mapping the Japanese drugs to RxNorm standard concepts.</ArticleTitle><Pagination><StartPage>111418</StartPage><MedlinePgn>111418</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111418</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dib.2025.111418</ELocationID><Abstract><AbstractText>Observational Health Data Sciences and Informatics (OHDSI) is an international research community dedicated to large-scale observational studies using real-world healthcare data. Participation in OHDSI requires mapping local terminology systems to the OHDSI Standard Vocabulary (OSV) and transforming healthcare data into the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), a standardized database schema. Adherence to the OSV and CDM enables the integration of datasets from different countries and regions, facilitating international cross-sectional analyses and supporting the discovery of large-scale evidence and new medical knowledge. Despite the globally recognized healthcare technology and systems excellence in Japan, Japanese real-world data (RWD) remain underutilized in international research. This is primarily due to reliance on domestically managed controlled terminologies in Japan that are not aligned with international controlled terminologies such as SNOMED CT, making mapping Japanese RWD to the CDM challenging. In addition, the wide variety of pharmaceutical products in Japan has hindered the establishment of mappings to RxNorm, the standardized drug terminology used in OHDSI. Previously, we used a Large Language Model (LLM) to map Japanese pharmaceutical data to RxNorm. A sampling-based evaluation confirmed that the LLM could accurately identify mapping candidates. Pharmacists and a medical informatics researcher validated these mappings, resulting in an ingredient-based mapping of Japanese pharmaceutical terms to RxNorm. Researchers interested in pharmacoepidemiology, pharmacoeconomics, and drug-related clinical decision support systems integrated with Japanese RWD can benefit significantly from this dataset. It also contains information about the target drugs, their translated names, LLM-generated suggestions, and reference data, making it suitable for developing and validating natural language processing and machine learning techniques for terminology mapping.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Eizen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Medical School of Ehime University, Toon, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Yukinobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Medical School of Ehime University, Toon, Ehime, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Yuimedi Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okajima</LastName><ForeName>Ai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yuimedi Inc., Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Data Brief</MedlineTA><NlmUniqueID>101654995</NlmUniqueID><ISSNLinking>2352-3409</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Controlled terminology</Keyword><Keyword MajorTopicYN="N">Drug database</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">RxNorm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40124300</ArticleId><ArticleId IdType="pmc">PMC11926709</ArticleId><ArticleId IdType="doi">10.1016/j.dib.2025.111418</ArticleId><ArticleId IdType="pii">S2352-3409(25)00150-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G., Duke J.D., Shah N.H., Reich C.G., Huser V., Schuemie M.J., Suchard M.A., Park R.W., Wong I.C.K., Rijnbeek P.R. MEDINFO 2015: Ehealth-Enabled Health. IOS Press; 2015. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers; pp. 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang P.E., Ryan P.B., Racoosin J.A., Overhage J.M., Hartzema A.G., Reich C., Welebob E., Scarnecchia T., Woodcock J. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann. Intern. Med. 2010;153:600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C., Ostropolets A., Ryan P., Rijnbeek P., Schuemie M., Davydov A., Dymshyts D., Hripcsak G. OHDSI standardized vocabularies&#x2014;a large-scale centralized reference ontology for international data harmonization. J. Am. Med. Inform. Assoc. 2024;31:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson S.J., Zeng K., Kilbourne J., Powell T., Moore R. Normalized names for clinical drugs: rxNorm at 6 years. J. Am. Med. Inform. Assoc. 2011;18:441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhang Y., Jiang M., Wang J., Dong J., Liu Y., Tao C., Jiang G., Zhou Y., Xu H. Toward a normalized clinical drug knowledge base in China&#x2014;Applying the RxNorm model to Chinese clinical drugs. J. Am. Med. Inform. Assoc. 2018;25:809&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647010</ArticleId><ArticleId IdType="pubmed">29635469</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke E., Zoch M., Kallfelz M., Ruhnke T., Leutner L.A., Spoden M., G&#xfc;nster C., Sedlmayr M., Bathelt F. Assessing the use of German claims data vocabularies for research in the observational medical outcomes partnership common data model: development and evaluation study. JMIR Med. Inform. 2023;11:e47959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10653283</ArticleId><ArticleId IdType="pubmed">37942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C., Lang L., Storf H., Vormstein P., Bieber R., Bernarding J., Herrmann T., Haverkamp C., Horki P., Laufer J. Towards implementation of OMOP in a German university hospital consortium. Appl. Clin. Inform. 2018;9:054&#x2013;061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura E., Kawakami Y., Inoue S., Okajima A. Mapping drug terms via integration of a retrieval-augmented generation algorithm with a large language model. Healthc. Inform. Res. 2024;30:355&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11570653</ArticleId><ArticleId IdType="pubmed">39551922</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunstall L S.P., Sanseviero O., Cuenca P., Dehaene O., von Werra L., et al. Hugging Face; Brooklyn (NY): 2023. Welcome Mixtral: a SOTA Mixture of Experts on Hugging Face.</Citation></Reference><Reference><Citation>Zeng K., Bodenreider O., Kilbourne J., Nelson S.J. AMIA Annual Symposium Proceedings. American Medical Informatics Association; 2006. RxNav: a web service for standard drug information; p. 1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839335</ArticleId><ArticleId IdType="pubmed">17238775</ArticleId></ArticleIdList></Reference><Reference><Citation>Odysseus Data Services, ATHENA: OHDSI Vocabularies Repository, in, 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>